PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	EFTHIMIOU, J; PITCHER, M; ORMEROD, O; HARPER, F; WESTABY, S; GRAHAMESMITH, D				EFTHIMIOU, J; PITCHER, M; ORMEROD, O; HARPER, F; WESTABY, S; GRAHAMESMITH, D			SEVERE SILENT MITRAL REGURGITATION AFTER MYOCARDIAL-INFARCTION - A CLINICAL CONUNDRUM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAPILLARY-MUSCLE RUPTURE; TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; DIAGNOSIS				EFTHIMIOU, J (corresponding author), JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND.							BURCH GE, 1968, AM HEART J, V75, P399, DOI 10.1016/0002-8703(68)90097-5; GIBSON DG, 1989, OXFORD TXB MED, V2, P288; GOLDMAN AP, 1991, ANN THORAC SURG, V52, P296, DOI 10.1016/0003-4975(91)91357-2; KOENIG K, 1987, AM J CARDIOL, V59, P362, DOI 10.1016/0002-9149(87)90816-2; NISHIMURA RA, 1983, AM J CARDIOL, V51, P373, DOI 10.1016/S0002-9149(83)80067-8; NISHIMURA RA, 1982, BRIT HEART J, V48, P598; PATEL AM, 1989, AM HEART J, V118, P1330, DOI 10.1016/0002-8703(89)90026-4; SANDERS RJ, 1957, DIS CHEST, V31, P316, DOI 10.1378/chest.31.3.316; STODDARD MF, 1990, AM HEART J, V120, P690, DOI 10.1016/0002-8703(90)90029-W; WEI JY, 1979, ANN INTERN MED, V90, P149, DOI 10.7326/0003-4819-90-2-149	10	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	1992	305	6845					105	106		10.1136/bmj.305.6845.105	http://dx.doi.org/10.1136/bmj.305.6845.105			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638225	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JD85000031
J	DRICKAMER, K				DRICKAMER, K			CLEARING UP GLYCOPROTEIN HORMONES	CELL			English	Review							RECEPTOR; BINDING; LIVER				DRICKAMER, K (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BOURBONNAIS Y, 1985, J BIOL CHEM, V260, P5832; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; KNUTSON VP, 1991, FASEB J, V5, P2130, DOI 10.1096/fasebj.5.8.2022311; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Parekh RB, 1991, CURR OPIN STRUC BIOL, V1, P750, DOI 10.1016/0959-440X(91)90174-R; RICE KG, 1990, J BIOL CHEM, V265, P18429; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X	13	92	95	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1029	1032		10.1016/0092-8674(91)90278-7	http://dx.doi.org/10.1016/0092-8674(91)90278-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662115				2022-12-28	WOS:A1991GX16400001
J	SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N				SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N			TARGETING OF THE MASTER RECEPTOR MOM19 TO MITOCHONDRIA	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; PRECURSOR PROTEINS; IMPORT RECEPTOR; MATRIX; INSERTION; CARRIER; SITE	The targeting of proteins to mitochondria involves the recognition of the precursor proteins by receptors on the mitochondrial surface followed by insertion of the precursors into the outer membrane at the general insertion site GIP. Most mitochondrial proteins analyzed so far use a mitochondrial outer membrane protein of 19 kilodaltons (MOM19) as an import receptor. The gene encoding MOM19 has now been isolated. The deduced amino acid sequence predicts that MOM19 is anchored in the outer membrane by an NH2-terminal hydrophobic sequence, while the rest of the protein forms a hydrophilic domain exposed to the cytosol. MOM19 was targeted to the mitochondria via a pathway that is independent of protease-accessible surface receptors and controlled by direct assembly of the MOM19 precursor with GIP.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Munich; Max Planck Society	PFANNER, N (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY.		Pfanner, Nikolaus/AAV-7878-2021					BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, UNPUB; STEGER HF, 1990, J CELL BIOL, V111, P2355; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1991, J BIOL CHEM, V266, P6416; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	29	101	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1659	1662		10.1126/science.1661031	http://dx.doi.org/10.1126/science.1661031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661031	Green Submitted			2022-12-28	WOS:A1991GV07300050
J	LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV				LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV			FOODBORNE DISEASE OUTBREAKS IN NURSING-HOMES, 1975 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; ROTAVIRUS INFECTION; SALMONELLA; GASTROENTERITIS; TRANSMISSION; SURVEILLANCE; FACILITIES; HOSPITALS; GUIDELINE	Objective. - To describe the epidemiology of foodborne disease outbreaks in nursing homes and to identify where preventive efforts might be focused. Data Sources. - Reports by state and local health departments of foodborne disease outbreaks occurring from January 1, 1975, through December 31, 1987. Study Selection. - Foodborne disease outbreaks reported to the Centers for Disease Control, Atlanta, Ga, on standard investigation forms. Data Extraction. - Each foodborne disease outbreak report was examined by an epidemiologist or statistician. Outbreaks were considered to have a known pathogen if confirmed by laboratory tests, and a known vehicle when an epidemiologic investigation implicated a specific food item. Data Synthesis. - From 1975 through 1987, 26 states reported 115 outbreaks of foodborne disease in nursing homes, causing illness in 4944 persons and death in 51. These outbreaks represented 2% of all reported foodborne disease outbreaks and 19% of outbreak-associated deaths in this period. Of 52 outbreaks with a known cause, Salmonella was the most frequently reported pathogen, accounting for 52% of outbreaks and 81% of deaths. Salmonella enteritidis outbreaks accounted for 56% of the Salmonella-associated deaths since 1981. The implicated food vehicles in S enteritidis outbreaks were made with eggs or prepared with equipment contaminated with eggs. Staphylococcal foodborne disease was the next most commonly identified cause, accounting for 23% of outbreaks. Conclusions. - Since the elderly are at high risk for serious morbidity from foodborne disease, nursing homes should practice careful food handling, preparation, and storage procedures; provide education for food handlers; and have active infection control programs to rapidly detect and control outbreaks of foodborne disease.	US FDA, CTR FOOD SAFETY & APPL NUTR, DIV MICROBIOL, WASHINGTON, DC 20204 USA	US Food & Drug Administration (FDA)	LEVINE, WC (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ENTER DIS BRANCH, ATLANTA, GA 30333 USA.							ASERKOFF B, 1969, NEW ENGL J MED, V281, P636, DOI 10.1056/NEJM196909182811202; AVORN J, 1981, NEW ENGL J MED, V305, P759, DOI 10.1056/NEJM198109243051309; BAINE WB, 1973, J INFECT DIS, V128, P357, DOI 10.1093/infdis/128.3.357; BARTLETT PC, 1982, PUBLIC HEALTH REP, V97, P258; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P864, DOI 10.1056/NEJM196004282621706; BLACK PH, 1960, NEW ENGL J MED, V262, P811, DOI 10.1056/NEJM196004212621606; BLASER MJ, 1981, J INFECT DIS, V143, P743, DOI 10.1093/infdis/143.5.743; BRYAN FL, 1968, J MILK FOOD TECHNOL, V31, P110, DOI 10.4315/0022-2747-31.4.110; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CROSSLEY KB, 1985, JAMA-J AM MED ASSOC, V254, P2918, DOI 10.1001/jama.254.20.2918; CUBITT WD, 1981, J CLIN PATHOL, V34, P924, DOI 10.1136/jcp.34.8.924; CUBITT WD, 1980, J CLIN PATHOL, V33, P306, DOI 10.1136/jcp.33.3.306; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GIANNELLA RA, 1971, AM J DIG DIS, V16, P1000, DOI 10.1007/BF02235012; GORDON SM, 1990, AM J EPIDEMIOL, V131, P702, DOI 10.1093/oxfordjournals.aje.a115554; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; HOLMBERG SD, 1984, JAMA-J AM MED ASSOC, V251, P487, DOI 10.1001/jama.251.4.487; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; HONISH A, 1986, ALBERTA SOC SERV COM, V10, P363; JOSEPH CA, 1989, BRIT MED J, V298, P1161, DOI 10.1136/bmj.298.6681.1161; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; LEVINE WC, 1991, J INFECT DIS, V164, P81, DOI 10.1093/infdis/164.1.81; MARRIE TJ, 1982, ARCH INTERN MED, V142, P313, DOI 10.1001/archinte.142.2.313; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; NICOLLE LE, 1984, J AM GERIATR SOC, V32, P513, DOI 10.1111/j.1532-5415.1984.tb02236.x; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255; REID JA, 1988, LANCET, V2, P321; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SCHROEDER SA, 1968, NEW ENGL J MED, V279, P674, DOI 10.1056/NEJM196809262791303; SMITH PW, 1987, AM J INFECT CONTROL, V15, P97, DOI 10.1016/0196-6553(87)90162-3; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAUXE RV, 1988, J INFECT DIS, V157, P370, DOI 10.1093/infdis/157.2.370; VLAHOV D, 1987, AM J INFECT CONTROL, V15, P47, DOI 10.1016/0196-6553(87)90001-0; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; WHITE KE, 1989, J INFECT DIS, V160, P298, DOI 10.1093/infdis/160.2.298; WILLIAMS WW, 1983, INFECT CONT HOSP EP, V4, P326; 1989, VITAL HLTH STAT 14, V33; 1990, MMWR, V38, P877; 1983, CAN DISEASE WEEKLY R, V9, P29	45	95	98	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2105	2109		10.1001/jama.266.15.2105	http://dx.doi.org/10.1001/jama.266.15.2105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1656108				2022-12-28	WOS:A1991GJ47400031
J	DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ				DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ			SUPPRESSION OF TUMORIGENICITY IN WILMS-TUMOR BY THE P15.5-P14 REGION OF CHROMOSOME-11	SCIENCE			English	Article							SHORT ARM; DELETION; ALLELES; CELLS; 11P13; GENES; LOCUS; DNA; HETEROZYGOSITY; CANCER	Wilms tumor has been associated with genomic alterations at both the 11p13 and 11p15 regions. To differentiate between the involvement of these two loci, a chromosome 11 was constructed that had one or the other region deleted, and this chromosome was introduced into the tumorigenic Wilms tumor cell line G401. When assayed for tumor-forming activity in nude mice, the 11p13-deleted, but not the 11p15.5-p14.1-deleted chromosome, retained its ability to suppress tumor formation. These results provide in vivo functional evidence for the existence of a second genetic locus (WT2) involved in suppressing the tumorigenic phenotype of Wilms tumor.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA19104, CA44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BECKWITH JB, 1983, HUM PATHOL, V14, P481, DOI 10.1016/S0046-8177(83)80003-3; BEST LG, 1981, AM J MED GENET, V9, P291, DOI 10.1002/ajmg.1320090405; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAVIS LM, 1988, GENOMICS, V3, P264, DOI 10.1016/0888-7543(88)90087-0; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DOWDY SF, UNPUB; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LITTLE MH, 1988, HUM GENET, V79, P186, DOI 10.1007/BF00280564; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUNAGA E, 1981, HUM GENET, V57, P231; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P984; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PLRITCHARDJONES K, 1990, NATURE, V364, P194; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROONEY CW, 1986, HUMAN CYTOGENETICS P; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	41	136	136	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					293	295		10.1126/science.1656527	http://dx.doi.org/10.1126/science.1656527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1656527				2022-12-28	WOS:A1991GJ64200042
J	GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR				GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR			CELL-CYCLE REGULATION OF HISTONE-H1 KINASE-ACTIVITY ASSOCIATED WITH THE ADENOVIRAL PROTEIN-E1A	SCIENCE			English	Article							CONTROL GENE CDC2+; FISSION YEAST; E1A PROTEINS; DIVISION CYCLE; DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; TRANSFORMATION; GROWTH; EXPRESSION	Several cellular proteins form stable complexes with the proteins encoded by the adenovirus early region 1A (E1A) gene in extracts derived from adenovirus infected or transformed cells. Two of the cellular proteins that bind to E1A have been identified; one, a 105-kilodalton protein (pRb), is the product of the retinoblastoma gene, and the other, a 60-kilodalton protein, is a human cyclin A. Two other proteins that bind E1A have now been shown to be related to p34cdc2. This E1A complex displayed histone H1-specific kinase activity; the kinase activity was modulated during the cell division cycle, and association of pRb with E1A apparently was not required for this activity.	COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, UNPUB; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; STEPHENS C, 1986, CANCER CELL, V4, P429; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	53	93	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1271	1275		10.1126/science.1653969	http://dx.doi.org/10.1126/science.1653969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1653969				2022-12-28	WOS:A1991GE68900038
J	SAMPEDRO, J; GUERRERO, I				SAMPEDRO, J; GUERRERO, I			UNRESTRICTED EXPRESSION OF THE DROSOPHILA GENE PATCHED ALLOWS A NORMAL SEGMENT POLARITY	NATURE			English	Article							PATTERN-FORMATION; BODY PATTERN; EMBRYOS; REQUIREMENTS; WINGLESS; PROTEIN; CUTICLE; LARVAL	IN the Drosophila embryo, mutations in the segment polarity gene patched (ptc) cause the replacement of the middle region of each segment by a mirror-image duplication of the remaining structures, including the parasegmental border 1-3. This gene, which encodes a transmembrane protein, is initially expressed in a generalized way at blastoderm, but later stops being transcribed in cells expressing the engrailed gene, and even later in cells in the middle of the parasegment 2-4. The genes engrailed (en) and wingless (wg) are also segment-polarity genes, and they are expressed in adjacent stripes flanking the parasegment borders in the embryo 5; in ptc mutants wg expression extends anteriorly and an ectopic stripe of en expression is induced 6,7. The suggestion has been made that ptc must be transcribed in a specific subset of cells to prevent en expression anterior to the wg-expressing stripe 4. Here we report that unrestricted expression of ptc from a heat-shock promoter has no adverse effect on development of Drosophila embryos. The heat-shock construct can also rescue ptc mutants, restoring wg expression to its normal narrow stripe. The ectopic en stripe fails to appear, but the normal one remains unaffected. The results imply that, despite its localized requirement, the restricted expression of ptc does not itself allocate positional information.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Guerrero, Isabel/K-2518-2014	Guerrero, Isabel/0000-0001-6761-1218				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	19	31	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					187	190		10.1038/353187a0	http://dx.doi.org/10.1038/353187a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653907				2022-12-28	WOS:A1991GE73100060
J	GAILANI, D; BROZE, GJ				GAILANI, D; BROZE, GJ			FACTOR-XI ACTIVATION IN A REVISED MODEL OF BLOOD-COAGULATION	SCIENCE			English	Article							MOLECULAR-WEIGHT KININOGEN; PLASMA THROMBOPLASTIN ANTECEDENT; HAGEMAN-FACTOR; CONTACT ACTIVATION; DEXTRAN SULFATE; MECHANISM; THROMBIN; ASSAY; THROMBOMODULIN; PREKALLIKREIN	Coagulation factor XI is activated in vitro by factor XIIa in the presence of high molecular weight kininogen (HMWK) and a negatively charged surface. Factor XII deficiency is not associated with bleeding, which suggests that another mechanism for factor XI activation exists in vivo. A revised model of coagulation is proposed in which factor XI is activated by thrombin. In the absence of cofactors, thrombin is more effective (k(cat)/K(m) = 1.6 X 10(5)) than factor XIIa (1.7 X 10(4)) in activating factor XI. Dextran sulfate enhances activation of factor XI by thrombin 2000-fold; part of this effect is due to autoactivation of factor XI by activated factor XI.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)								BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; ESMON CT, 1982, J BIOL CHEM, V257, P7944; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; HULTIN MB, 1978, BLOOD, V52, P928; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAGNI MV, 1985, BLOOD, V65, P719; RATNOFF OD, 1979, P NATL ACAD SCI USA, V76, P958, DOI 10.1073/pnas.76.2.958; REVAK SD, 1977, J CLIN INVEST, V59, P1167, DOI 10.1172/JCI108741; SCOTT CF, 1984, BLOOD, V63, P42; TANKERSLEY DL, 1983, BLOOD, V62, P448; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1982, BLOOD, V59, P1225	27	638	662	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1991	253	5022					909	912		10.1126/science.1652157	http://dx.doi.org/10.1126/science.1652157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1652157				2022-12-28	WOS:A1991GC15200047
J	RECHSTEINER, M				RECHSTEINER, M			NATURAL SUBSTRATES OF THE UBIQUITIN PROTEOLYTIC PATHWAY	CELL			English	Review							SHORT-LIVED PROTEIN; ORNITHINE DECARBOXYLASE; PHYTOCHROME DEGRADATION; ABNORMAL PROTEINS; HELA-CELLS; ENZYME; BREAKDOWN; INDUCTION				RECHSTEINER, M (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84112, USA.							BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DOHMEN RJ, 1991, IN PRESS P NATL ACAD; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS A, 1990, J BIOL CHEM, V265, P21664; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1984, P NATL ACAD SCI-BIOL, V81, P90, DOI 10.1073/pnas.81.1.90; JABBEN M, 1989, J BIOL CHEM, V264, P4998; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; REICHSTEINER M, 1988, UBIQUITIN; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	30	246	254	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					615	618		10.1016/0092-8674(91)90104-7	http://dx.doi.org/10.1016/0092-8674(91)90104-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652366				2022-12-28	WOS:A1991GC74500001
J	SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK				SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK			FOSCARNET THERAPY IN 5 PATIENTS WITH AIDS AND ACYCLOVIR-RESISTANT VARICELLA-ZOSTER VIRUS-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						VARICELLA ZOSTER VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; FOSCARNET; ACYCLOVIR; HUMAN IMMUNODEFICIENCY VIRUS	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HERPES-ZOSTER	Objective: To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS). Design: Open-label study. Setting. Three university medical centers. Patients: Five patients with AIDS who were infected with thymidine-kinase-deficient or -altered strains of varicella-zoster virus. Intervention: Foscarnet, 40 mg/kg body weight every 8 hours in 1-hour infusions for 10 or more days. Main Results: Four patients had healing in response to foscarnet therapy, and each of four tested patients became culture negative for virus during foscarnet therapy. Results of fluorescent antigen testing remained positive during therapy in two patients; one of these patients had concomitant clinical failure but the other patient healed fully. One patient had complete healing despite the emergence of resistance to foscarnet in serial specimens obtained during foscarnet therapy. Conclusion: Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94110 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	University of California System; University of California San Francisco; Burroughs Wellcome Fund								BABA M, 1986, TOHOKU J EXP MED, V148, P275, DOI 10.1620/tjem.148.275; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; GILSON IH, 1989, J AM ACAD DERMATOL, V20, P637, DOI 10.1016/S0190-9622(89)70076-1; HOPPENJANS WB, 1990, ARCH DERMATOL, V126, P1048, DOI 10.1001/archderm.126.8.1048; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; JANIER M, 1988, J AM ACAD DERMATOL, V18, P584, DOI 10.1016/S0190-9622(88)80295-0; LINNEMANN CC, 1990, AIDS, V4, P577, DOI 10.1097/00002030-199006000-00014; PAHWA S, 1988, JAMA-J AM MED ASSOC, V260, P2879, DOI 10.1001/jama.260.19.2879; SAFRIN S, 1990, J INFECT DIS, V161, P1078, DOI 10.1093/infdis/161.6.1078; WEIGLE KA, 1983, J INFECT DIS, V148, P630, DOI 10.1093/infdis/148.4.630	10	165	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					19	21		10.7326/0003-4819-115-1-19	http://dx.doi.org/10.7326/0003-4819-115-1-19			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1646585				2022-12-28	WOS:A1991FT93700004
J	INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J				INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J			REDUCED BINDING OF TFIID TO TRANSCRIPTIONALLY COMPROMISED MUTANTS OF VP16	NATURE			English	Article							FUNCTIONAL DISSECTION; ACTIVATION DOMAIN; MAMMALIAN-CELLS; RNA-POLYMERASE; PROTEINS; EXPRESSION; YEAST; GENE	ACTIVATOR proteins that control transcription initiation by RNA polymerase II 1,2 usually have two domains: one binds to DNA, and the other activates transcription 3,4. A particularly potent acidic 5,6 activation domain at the C terminus of the herpes simplex virus protein VP16 7-9 binds directly and selectively to the human and yeast TATA box-binding factor TFIID 10. We have now investigated the biological significance of this in vitro interaction by using mutant forms of VP16 11. For changes at the critical phenylalanine residue at position 442 of VP16 there was a good correlation between transactivation activity in vivo and the binding of VP16 to TFIID in vitro. In contrast, mutants with reduced negative charge were more defective for binding than for activation.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	INGLES, CJ (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.			Triezenberg, Steven/0000-0003-4184-5221				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	17	292	297	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					588	590		10.1038/351588a0	http://dx.doi.org/10.1038/351588a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646402				2022-12-28	WOS:A1991FR03400066
J	TAYLOR, DR; SEARS, MR				TAYLOR, DR; SEARS, MR			BETA-2-AGONISTS	LANCET			English	Letter									MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA; ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8N 4A6,ONTARIO,CANADA	McMaster University; McGill University; McMaster University	TAYLOR, DR (corresponding author), UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND.							AYRES, 1991, LANCET, V337, P300; 1990, LANCET, V336, P1391; 1991, LANCET, V37, P43	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					426	427		10.1016/0140-6736(91)91200-E	http://dx.doi.org/10.1016/0140-6736(91)91200-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671442				2022-12-28	WOS:A1991EX60500029
J	PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS				PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS			EXPRESSION OF EPSTEIN-BARR-VIRUS LATENT GENE-PRODUCTS IN TUMOR-CELLS OF HODGKINS-DISEASE	LANCET			English	Article							ESTABLISHED RODENT CELLS; MEMBRANE-PROTEIN; NASOPHARYNGEAL CARCINOMA; MALIGNANT-LYMPHOMAS; INFECTION; TRANSFORMATION; PATTERNS; TAMARINS; TISSUES; GENOMES	The Epstein-Barr virus (EBV)-encoded latent gene products, latent membrane protein (LMP) and EBV nuclear antigen 2 (EBNA 2), seem to have important roles in EBV-induced cell transformation in vitro, and have been implicated as important effector molecules in EBV-associated lymphomagenesis. Because up to 35% of Hodgkin's disease (HD) samples have been reported to contain EBV genomes, the expression of LMP and EBNA 2 in these tumours was investigated. 84 cases of HD were studied with monoclonal antibodies and immunohistochemical labelling of acetone-fixed cryostat sections. LMP, but not EBNA 2 was demonstrated in Reed-Sternberg (RS) cells of 40 cases (48%); the two proteins were easily detected in transformed lymphocytes of positive control acute infectious mononucleosis tonsils. LMP expression in RS cells varied according to the histological subtype of HD (1/10 cases [10%] of lymphocyte predominance subtype, 16/50 cases [32%] of nodular sclerosis, 23/24 [96%] cases of mixed cellularity type). That the LMP antibodies showed no substantial cross-reactivity with negative control tissues shows that they are useful probes for the diagnosis of latent EBV infection in tissue sections. The finding suggest that EBV is associated with more cases of HD than was previously recognised, that in positive cases RS cells express a latent infection protein phenotype (LMP +, EBNA 2-) which differs from that of other EBV-associated lymphomas, and the LMP expression is related to histologically aggressive subtypes of HD.	UNIV BIRMINGHAM,DEPT CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	PALLESEN, G (corresponding author), AARHUS UNIV,AARHUS KOMMUNE HOSP,INST PATHOL,IMMUNOHISTOL LAB,FINSENSGADE 12,DK-8000 AARHUS,DENMARK.		Rowe, Martin/B-2880-2009; Dutoit, Stephen Hamilton/E-1815-2013; Young, Lawrence S/B-7213-2009	Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; Hamilton-Dutoit, Stephen/0000-0003-2158-3885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; CLEARY ML, 1985, SCIENCE, V228, P722, DOI 10.1126/science.2986287; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; EPSTEIN MA, 1986, LANCET, V1, P1425; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; JOHANSSO.B, 1970, INT J CANCER, V6, P450, DOI 10.1002/ijc.2910060316; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEVINE PH, 1971, CANCER-AM CANCER SOC, V27, P416, DOI 10.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-W; MASIH A, 1990, LAB INVEST, V62, pA64; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; PALLESEN G, 1990, ORD M EUR ASS HAEM W, P1; PALLESEN G, 1990, 3RD M EUR ASS HAEM W, P1; POPPEMA S, 1985, AM J CLIN PATHOL, V84, P385, DOI 10.1093/ajcp/84.3.385; ROSDAHL N, 1974, BMJ-BRIT MED J, V2, P253, DOI 10.1136/bmj.2.5913.253; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STAAL SP, 1989, AM J CLIN PATHOL, V91, P1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1987, AM J PATHOL, V129, P86; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WOLF BC, 1990, AM J PATHOL, V136, P717; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1989, J VIROL, V63, P1967, DOI 10.1128/JVI.63.5.1967-1974.1989	30	658	663	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					320	322		10.1016/0140-6736(91)90943-J	http://dx.doi.org/10.1016/0140-6736(91)90943-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671232				2022-12-28	WOS:A1991EX36200003
J	MITCHELL, H; MEDLEY, G				MITCHELL, H; MEDLEY, G			LONGITUDINAL-STUDY OF WOMEN WITH NEGATIVE CERVICAL SMEARS ACCORDING TO ENDOCERVICAL STATUS	LANCET			English	Article							CYTOLOGY; CANCER; SAMPLE	A longitudinal study of 20 222 women who received negative cervical smear reports in 1987 showed that the incidence of definite or equivocal cervical intraepithelial neoplasia (CIN) was not significantly different between those whose first smear lacked an endocervical component and those whose smear included an endocervical component. The incidence of definite cytological evidence of CIN was significantly lower in women whose first smear did not include an endocervical component. It is concluded that women whose smears are reported as negative but lack an endocervical component should not be rescreened any earlier than women with negative smears that include an endocervical component.			MITCHELL, H (corresponding author), VICTORIAN CYTOL SERV, POB 253B, MELBOURNE 3001, AUSTRALIA.							BLAND M, 1987, INTRO MED STATISTICS, P302; ELIAS A, 1983, ACTA CYTOL, V27, P225; Frost J K, 1969, Obstet Gynecol Surv, V24, P893, DOI 10.1097/00006254-196907001-00019; KIVLAHAN C, 1986, ACTA CYTOL, V30, P258; LAVERTY CR, 1989, MED J AUSTRALIA, V150, P432, DOI 10.5694/j.1326-5377.1989.tb136563.x; MAUNEY M, 1990, DIAGN CYTOPATHOL, V6, P18, DOI 10.1002/dc.2840060106; MITCHELL H, 1990, BRIT MED J, V300, P1622, DOI 10.1136/bmj.300.6740.1622; MORELL ND, 1982, OBSTET GYNECOL, V60, P41; PATERSON MEL, 1984, BRIT MED J, V289, P896, DOI 10.1136/bmj.289.6449.896; SOLOMON D, 1989, ACTA CYTOL, V33, P567; VOOIJS GP, 1986, ACTA CYTOL, V30, P251; VOOIJS PG, 1985, ACTA CYTOL, V29, P323; WOODMAN CBJ, 1989, LANCET, V2, P88; 1988, ACTA CYTOL, V32, P913	14	68	70	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	1991	337	8736					265	267		10.1016/0140-6736(91)90870-U	http://dx.doi.org/10.1016/0140-6736(91)90870-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671112				2022-12-28	WOS:A1991EV71900004
J	ROUSE, F				ROUSE, F			THE CRUZAN CASE	LANCET			English	Editorial Material																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					105	106		10.1016/0140-6736(91)90757-G	http://dx.doi.org/10.1016/0140-6736(91)90757-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670690				2022-12-28	WOS:A1991ER47700019
J	EPHRUSSI, A; LEHMANN, R				EPHRUSSI, A; LEHMANN, R			INDUCTION OF GERM-CELL FORMATION BY OSKAR	NATURE			English	Article							POSTERIOR DETERMINANT NANOS; SEGMENTATION GENE HUNCHBACK; DROSOPHILA POLAR GRANULES; MATERNAL GENE; ANTERIOR PATTERN; MESSENGER-RNA; LOCALIZATION; PROTEIN; EMBRYO; PLASM	The oskar gene directs germ plasm assembly and controls the number of germ cell precursors formed at the posterior pole of the Drosophila embryo. Mislocalization of oskar RNA to the anterior pole leads to induction of germ cells at the anterior. Of the eight genes necessary for germ cell formation at the posterior, only three, oskar, vasa and tudor, are essential at an ectopic site.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Ephrussi, Anne/AAG-4075-2020; Ephrussi, Anne/ABD-4393-2021	Ephrussi, Anne/0000-0002-5061-4620; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEHMANN R, IN PRESS CURR OPIN G; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1986, NATURE, V324, P672; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1985, COLD SPRING HARB SYM, V50, P105, DOI 10.1101/SQB.1985.050.01.015; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Rabinowitz M, 1941, J MORPHOL, V69, P1, DOI 10.1002/jmor.1050690102; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SPRADLING AC, 1960, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	41	514	522	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					387	392		10.1038/358387a0	http://dx.doi.org/10.1038/358387a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641021				2022-12-28	WOS:A1992JF85300046
J	THEOLOGIS, A				THEOLOGIS, A			ONE ROTTEN APPLE SPOILS THE WHOLE BUSHEL - THE ROLE OF ETHYLENE IN FRUIT RIPENING	CELL			English	Review							ENCODING 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; ANTISENSE RNA; POLYGALACTURONASE; BIOSYNTHESIS; CLONING; PLANTS; TOMATO; GENE; ARABIDOPSIS; EXPRESSION				THEOLOGIS, A (corresponding author), PLANT GENE EXPRESS CTR, ALBANY, CA 94710 USA.							Abeles F.B, 1973, ETHYLENE PLANT BIOL; BOTELLA JR, 1992, IN PRESS PLANT MOL B; BREDT DS, 1992, SCI AM, V266, P68; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; BURG SP, 1962, ANNU REV PLANT PHYS, V13, P265, DOI 10.1146/annurev.pp.13.060162.001405; GRAY J, 1992, PLANT MOL BIOL, V19, P69, DOI 10.1007/BF00015607; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HUANG PL, 1991, P NATL ACAD SCI USA, V88, P7021, DOI 10.1073/pnas.88.16.7021; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; KIM WT, 1992, PLANT PHYSIOL, V98, P465, DOI 10.1104/pp.98.2.465; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LIANG XW, 1992, IN PRESS P NATL ACAD, V89; MCGARVEY DJ, 1992, PLANT PHYSIOL, V98, P554, DOI 10.1104/pp.98.2.554; NAKAGAWA N, 1991, PLANT CELL PHYSIOL, V32, P1153; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; OLSON DC, 1991, P NATL ACAD SCI USA, V88, P5340, DOI 10.1073/pnas.88.12.5340; PARK KY, 1992, PLANT MOL BIOL, V18, P377, DOI 10.1007/BF00034964; PELEMAN J, 1989, PLANT CELL, V1, P81, DOI 10.1105/tpc.1.1.81; PENARRUBIA L, 1992, PLANT CELL, V4, P681, DOI 10.1105/tpc.4.6.681; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SHEEHY RE, 1988, P NATL ACAD SCI USA, V85, P8805, DOI 10.1073/pnas.85.23.8805; SLATER A, 1985, PLANT MOL BIOL, V5, P137, DOI 10.1007/BF00015677; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SPANU P, 1991, EMBO J, V10, P2007, DOI 10.1002/j.1460-2075.1991.tb07730.x; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; YIP WK, 1992, P NATL ACAD SCI USA, V89, P2475, DOI 10.1073/pnas.89.6.2475; ZAREMBINSKI T, 1992, IN PRESS P NATL ACAD, V89	33	232	262	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					181	184		10.1016/0092-8674(92)90093-R	http://dx.doi.org/10.1016/0092-8674(92)90093-R			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638627				2022-12-28	WOS:A1992JE75700002
J	ANDERSON, DJ; FLANNELLY, GM; KITCHENER, HC; FISHER, PM; MANN, EM; CAMPBELL, MK; TEMPLETON, A				ANDERSON, DJ; FLANNELLY, GM; KITCHENER, HC; FISHER, PM; MANN, EM; CAMPBELL, MK; TEMPLETON, A			MILD AND MODERATE DYSKARYOSIS - CAN WOMEN BE SELECTED FOR COLPOSCOPY ON THE BASIS OF SOCIAL CRITERIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CERVICAL-CANCER; ATYPIA; SMEAR; RISK; INFECTION; SMOKING; RATES	Objective-To describe the distribution of cervical intraepithelial neoplasia grades among women with mild and moderate dyskaryosis after a single cervical smear and to determine whether social criteria could help identify women who are at increased risk of grade II or III disease. Design-Cross sectional analysis within a randomised prospective study. Subjects had a repeat smear, a colposcopic examination, and an excision biopsy of the transformation zone. In addition, women were asked to complete a social questionnaire. Setting-Colposcopy clinic, Aberdeen. Subjects-228 women with a single smear test showing mild or moderate dyskaryosis. Main outcome measures-Histology, age, sexual and contraceptive history, cigarette smoking. Results-159 (70%) women had cervical intraepithelial neoplasia grades II or III. Among current smokers the prevalence of grade II and III disease was higher in women who smoked greater-than-or-equal-to 20 cigarettes a day (84%) than among those who smoked less (66%; p<0.04). Women with more than one sexual partner also had a higher prevalence (75%) than women with only one partner (50%; p=0.0028). Use of oral contraceptives and younger age were not significantly associated. The prevalence of grade II or III disease was up to 66% in the lower risk groups. Conclusions-Because of the high prevalence of cervical intraepithelial neoplasia grades II and III in both the high and the low risk groups social factors are not useful for selecting women with mild or moderate dyskaryosis for either early referral to colposcopy or cytological surveillance.	ABERDEEN ROYAL INFIRM, HARRIS BIRTHRIGHT RES CTR, FORESTER HILL, ABERDEEN AB9 2ZB, SCOTLAND	University of Aberdeen			Campbell, Marion/ABB-7063-2020					BRINTON LA, 1986, INT J CANCER, V38, P339, DOI 10.1002/ijc.2910380307; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; CLARKE EA, 1985, AM J OBSTET GYNECOL, V151, P612, DOI 10.1016/0002-9378(85)90149-8; CUZICK J, 1990, EUR J CANCER, V26, P684, DOI 10.1016/0277-5379(90)90117-C; DONNAN SPB, 1989, INT J EPIDEMIOL, V18, P32, DOI 10.1093/ije/18.1.32; JONES RW, 1988, NEW ZEAL MED J, V101, P132; KITCHENER HC, 1991, BRIT J OBSTET GYNAEC, V98, P1112, DOI 10.1111/j.1471-0528.1991.tb15363.x; KITCHENER HC, 1987, BRIT MED J, V294, P1313, DOI 10.1136/bmj.294.6583.1313; RAFFLE AE, 1990, BMJ-BRIT MED J, V301, P907, DOI 10.1136/bmj.301.6757.907; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SOUTTER WP, 1990, BRIT MED J, V301, P1335, DOI 10.1136/bmj.301.6764.1335-c; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; VESSEY MP, 1983, LANCET, V2, P930; WALKER EM, 1986, LANCET, V2, P672; WINKELSTEIN W, 1984, AM J EPIDEMIOL, V119, P1	17	22	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	1992	305	6845					84	87		10.1136/bmj.305.6845.84	http://dx.doi.org/10.1136/bmj.305.6845.84			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638252	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JD85000021
J	TEANBY, D				TEANBY, D			UNDERREPORTING OF PEDESTRIAN ROAD ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Road accidents to pedestrians caused 1706 deaths and 58 374 injuries in Great Britain during 1989.(1) These figures and other data used for road planning and safety campaigns are derived from accident data supplied by the police. I assessed the completeness of police recording by comparing their figures on accidents to pedestrians with data from a regional database of trauma care.			TEANBY, D (corresponding author), WARRINGTON GEN HOSP,MERSEY REG TRAUMA SURVEY,WARRINGTON WA5 1QG,ENGLAND.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; 1990, ROAD ACCIDENTS GREAT, P47	2	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					422	422		10.1136/bmj.304.6824.422	http://dx.doi.org/10.1136/bmj.304.6824.422			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1637379	Green Published, Bronze			2022-12-28	WOS:A1992HE38900021
J	VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M				VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M			EFFECTS OF THERAPY IN X-LINKED HYPOPHOSPHATEMIC RICKETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D-RESISTANT RICKETS; VITAMIN-D; PRETERM INFANTS; PHOSPHATE; NEPHROCALCINOSIS; HEIGHT; CALCITRIOL; GROWTH	Background. Patients with X-linked hypophosphatemic rickets, which is clinically manifested by growth failure and bowing of the legs, are usually treated with phosphate and a vitamin D preparation. However, the efficacy of this treatment has been disputed, and nephrocalcinosis is a recognized complication of therapy. Methods. We studied 24 patients with X-linked hypophosphatemic rickets (9 boys and 15 girls) ranging in age from 1 to 16 years (median, 5.3). The duration of combination therapy ranged from 0.3 to 11.8 years (median, 3.0). We measured height as a standard-deviation (SD) score (the number of SDs from the mean height for chronologic age). Measurements made before the age of two years or after the onset of puberty were excluded. We compared the results with those reported in 1971 for 16 untreated prepubertal Australian patients. We also determined the severity of nephrocalcinosis (on a scale of 0 to 4, with 0 indicating no abnormalities and 4 stone formation) with renal ultrasonography and whether it could be related to the dosage of phosphate or vitamin D or to other factors. Results. Patients treated for at least two years before the onset of puberty (n = 19) had a mean height SD score of -1.08, as compared with -2.05 in the untreated historical controls. The 13 patients who had been treated with calcitriol and phosphate for at least two years had an increase in the mean height SD score of 0.33, from -1.58 to -1.25 (95 percent confidence interval, 0 to 0.67; P = 0.05). Nineteen of the 24 patients (79 percent) had nephrocalcinosis detected on renal ultrasonography. The grade of nephrocalcinosis was significantly correlated with the mean phosphate dose (r = 0.60, P = 0.002), but not with the dose of vitamin D or the duration of therapy. All patients had normal serum creatinine concentrations. Conclusions. Therapy with calcitriol and phosphate may increase the growth of children with X-linked hypophosphatemic rickets. Nephrocalcinosis in these children represents a complication of therapy and is associated with the dose of phosphate received.	CHILDRENS HOSP, RAY WILLIAMS INST PAEDIAT ENDOCRINOL DIABET & META, SYDNEY, AUSTRALIA; CHILDRENS HOSP, DEPT RADIOL, SYDNEY, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								ALON U, 1985, PEDIATRICS, V75, P754; BALSAN S, 1990, J PEDIATR-US, V116, P365, DOI 10.1016/S0022-3476(05)82822-7; CHAN JCM, 1985, J PEDIATR-US, V106, P533, DOI 10.1016/S0022-3476(85)80068-8; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GLORIEUX FH, 1972, NEW ENGL J MED, V287, P481, DOI 10.1056/NEJM197209072871003; GOODYER PR, 1987, J PEDIATR-US, V111, P700, DOI 10.1016/S0022-3476(87)80245-7; HAASE P, 1975, J ANAT, V119, P19; HITCHCOCK NE, 1986, MED J AUSTRALIA, V145, P373, DOI 10.5694/j.1326-5377.1986.tb112388.x; HOWARD CP, 1979, PEDIATR RES, V13, P380; HUFNAGLE KG, 1982, PEDIATRICS, V70, P360; KLEEREKOPER M, 1974, CLIN CHEM, V20, P369; PAK CYC, 1969, J CLIN INVEST, V48, P1914, DOI 10.1172/JCI106158; PATRIQUIN H, 1986, AM J ROENTGENOL, V146, P1253, DOI 10.2214/ajr.146.6.1253; POLISSON RP, 1985, NEW ENGL J MED, V313, P1, DOI 10.1056/NEJM198507043130101; RASMUSSEN H, 1981, J PEDIATR-US, V99, P16, DOI 10.1016/S0022-3476(81)80951-1; REUSZ GS, 1990, LANCET, V335, P1240, DOI 10.1016/0140-6736(90)91304-S; REUSZ GS, 1990, ARCH DIS CHILD, V65, P1125, DOI 10.1136/adc.65.10.1125; STEENDIJK R, 1971, HELV PAEDIATR ACTA, V26, P179; STICKLER GB, 1989, LANCET, V2, P902; STICKLER GB, 1988, AM J DIS CHILD, V142, P14, DOI 10.1001/archpedi.1988.02150010020009; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TSURU N, 1987, AM J DIS CHILD, V141, P108, DOI 10.1001/archpedi.1987.04460010108039; WOOLFIELD N, 1988, ARCH DIS CHILD, V63, P86, DOI 10.1136/adc.63.1.86; 1976, PHS HRA761120 PUBL	24	169	176	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1991	325	26					1843	1848		10.1056/NEJM199112263252604	http://dx.doi.org/10.1056/NEJM199112263252604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW528	1660098				2022-12-28	WOS:A1991GW52800004
J	SABBAGH, R; SHIELDS, CL; SHIELDS, JA; EHYA, H; FINEGAN, JT				SABBAGH, R; SHIELDS, CL; SHIELDS, JA; EHYA, H; FINEGAN, JT			SPONTANEOUS HYPHEMA - INITIAL MANIFESTATION OF LUNG-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIAGNOSIS; CANCER		WARREN HOSP,PHILIPSBURG,PA; THOMAS JEFFERSON UNIV,CYTOPATHOL LAB,PHILADELPHIA,PA 19107	Jefferson University	SABBAGH, R (corresponding author), WILLS EYE HOSP & RES INST,OCULAR ONCOL SERV,PHILADELPHIA,PA 19107, USA.							AUGSBURGER JJ, 1985, OPHTHALMOLOGY, V92, P39; FERRY AP, 1974, ARCH OPHTHALMOL-CHIC, V92, P276, DOI 10.1001/archopht.1974.01010010286003; LIEB WE, 1990, BRIT J OPHTHALMOL, V74, P373, DOI 10.1136/bjo.74.6.373; SHIELDS JA, 1991, INTRAOCULAR TUMORS T; SHIELDS JA, 1989, DUANES CLIN OPHTHALM, P1; STEPHENS RF, 1979, OPHTHALMOLOGY, V86, P1336	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1991	266	22					3194	3194		10.1001/jama.266.22.3194	http://dx.doi.org/10.1001/jama.266.22.3194			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT654	1659642				2022-12-28	WOS:A1991GT65400035
J	WOOD, SA; PARK, JE; BROWN, WJ				WOOD, SA; PARK, JE; BROWN, WJ			BREFELDIN-A CAUSES A MICROTUBULE-MEDIATED FUSION OF THE TRANS-GOLGI NETWORK AND EARLY ENDOSOMES	CELL			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; I-CELL DISEASE; MHC CLASS-II; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; COATED VESICLES; BETA-GLUCURONIDASE; SECRETORY PROTEINS; HUMAN-FIBROBLASTS	Brefeldin A (BFA) is a fungal metabolite that causes a redistribution of the stacked cisternae of the Golgi complex into the endoplasmic reticulum by inhibiting anterograde transport. We report that BFA also causes membrane tubules derived from the trans-Golgi network (TGN) to fuse with early endosomes. In the presence of BFA, a mannose-6-phosphate receptor (M6PR)-enriched tubular network rapidly forms from the TGN, not from the prelysosomal compartment, and can be labeled with endocytic tracers after only 5 min of uptake at either 20-degrees-C or 37-degrees-C, indicating that it is also functionally an early endosome. Formation of the TGN-early endosome network is microtubule dependent and may involve modification of membrane processes affected by microtubule-associated motor activity. Concomitant with the formation of the fused TGN-early endosome network, there is a > 5-fold increase in cell surface M6PRs. The data suggest that BFA has revealed a membrane transport cycle between the TGN and early endosomes, perhaps used for the secretion or delivery of molecules to the cell surface.			WOOD, SA (corresponding author), CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA.		Brown, William/GXN-2777-2022		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R23AM037249] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 37249] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER EG, 1987, EXP CELL RES, V173, P267, DOI 10.1016/0014-4827(87)90352-1; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; BROWN WJ, 1990, EUR J CELL BIOL, V51, P201; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; CAMPBELL CH, 1983, J BIOL CHEM, V258, P3347; CAMPBELL CH, 1983, J BIOL CHEM, V258, P2628; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GONATAS NK, 1983, MOL CELL BIOL, V3, P91, DOI 10.1128/MCB.3.1.91; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMANSKY P, 1987, J CELL BIOL, V104, P1743, DOI 10.1083/jcb.104.6.1743; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1990, J CELL BIOL, V111, P1383, DOI 10.1083/jcb.111.4.1383; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; PARK JE, 1991, J CELL BIOL, V112, P245, DOI 10.1083/jcb.112.2.245; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SCHULZELOHOFF E, 1985, J CELL BIOL, V101, P824, DOI 10.1083/jcb.101.3.824; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	68	379	380	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					591	600		10.1016/0092-8674(91)90533-5	http://dx.doi.org/10.1016/0092-8674(91)90533-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657400	hybrid			2022-12-28	WOS:A1991GN66400015
J	GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH				GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH			THE RETINOBLASTOMA GENE-PRODUCT REGULATES PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE	CELL			English	Article							LARGE-T-ANTIGEN; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; EXPRESSION; TUMORIGENICITY; IDENTIFICATION	The RB gene product is a nuclear phosphoprotein that undergoes cell cycle-dependent changes in its phosphorylation status. To test whether RB regulates cell cycle progression, purified RB proteins, either full-length or a truncated form containing the T antigen-binding region, were injected into cells. Injection of either protein early in G1 inhibits progression into S phase. Co-injection of anti-RB antibodies antagonizes this effect. Injection of RB into cells arrested at G1/S or late in G1 has no effect on BrdU incorporation, suggesting that RB does not inhibit DNA synthesis in S phase. These results indicate that RB regulates cell proliferation by restricting cell cycle progression at a specific point in G1 and establish a biological assay for RB activity. Neither co-injection of RB with a T antigen peptide nor injection into cells expressing T antigen prevents cells from progressing into S phase, which supports the hypothesis that T antigen binding has functional consequences for RB.			GOODRICH, DW (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,SAN ANTONIO,TX 78284, USA.							ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMEL P, 1990, MOL CELL BIOL, V12, P6585; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HENSEL CH, 1990, CANCER RES, V50, P3067; HONG F, 1991, IN PRESS BIOSCI REP; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudson A. G., 1973, ADV CANCER RES, V17, P317; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOR SUPPRESSOR GEN, V20, P159; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maniatis T., 1982, MOL CLONING; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	62	725	736	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					293	302		10.1016/0092-8674(91)90181-W	http://dx.doi.org/10.1016/0092-8674(91)90181-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655277				2022-12-28	WOS:A1991GL47000009
J	STRANG, J; DONMALL, M; WEBSTER, A; TANTAM, D				STRANG, J; DONMALL, M; WEBSTER, A; TANTAM, D			COMPARISON BETWEEN COMMUNITY DRUG TEAMS WITH AND WITHOUT INBUILT MEDICAL-SERVICES	BRITISH MEDICAL JOURNAL			English	Article									PRESTWICH HOSP,DRUG RES UNIT,MANCHESTER M25 7BL,ENGLAND; WALSGRAVE GEN HOSP,PSYCHOTHERAPY,COVENTRY CV2 2DX,ENGLAND		STRANG, J (corresponding author), BETHLEM ROYAL & MAUDSLEY HOSP,DRUG DEPENDENCE CLIN RES & TREATMENT UNIT,BECKENHAM BR3 3BX,KENT,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Donmall, Michael/0000-0001-7022-7372				DONMALL MC, 1990, INTRO COMMUNITY BASE; STRANG J, 1990, CHALLENGE POLICY PRA; 1988, PREVENTION SPREAD HI; 1988, AIDS DRUG MISUSE R 1; 1989, AIDS DRUG MISUSE R 2	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1991	303	6807					897	897		10.1136/bmj.303.6807.897	http://dx.doi.org/10.1136/bmj.303.6807.897			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK221	1657260	Green Published, Bronze			2022-12-28	WOS:A1991GK22100023
J	BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT				BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT			AN OUTBREAK OF HERPES-GLADIATORUM AT A HIGH-SCHOOL WRESTLING CAMP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1	Background and Methods. Herpes simplex virus type 1 (HSV-1) has been identified as a cause of cutaneous or ocular infection among athletes involved in contact sports; in this context it is known as herpes gladiatorum. In July 1989, we investigated an outbreak among 175 high-school wrestlers attending a four-week intensive-training camp. Cases of infection were identified by review of medical records, interview and examination of the wrestlers, and culture of skin lesions. Oropharyngeal swabs were obtained for HSV-1 culture, and serum samples for HSV-1 serologic studies. HSV-1 isolates were compared by restriction-endonuclease analysis. Results. HSV-1 infection was diagnosed in 60 wrestlers (34 percent). The lesions were on the head in 73 percent of the wrestlers, the extremities in 42 percent, and the trunk in 28 percent. HSV-1 was isolated from 21 wrestlers (35 percent), and in 39 (65 percent) infection was identified by clinical criteria. Five had conjunctivitis or blepharitis; none had keratitis. Constitutional symptoms were common, including fever (25 percent), chills (27 percent), sore throat (40 percent), and headache (22 percent). The attack rate varied significantly among the three practice groups, ranging from 25 percent for practice group 1 (lightweights) to 67 percent for group 3 (heavyweights). Restriction-endonuclease analysis identified four strains of HSV-1 among the 21 isolates. All 10 isolates from practice group 3 were identical (strain A), and 5 of 7 isolates from practice group 2 (middleweights) were identical (strain B), which suggested concurrent transmission of different strains within different groups. HSV-1 was not isolated from any oropharyngeal swabs. Conclusions. Herpes gladiatorum may cause substantial morbidity among wrestlers, and it is primarily transmitted by direct skin-to-skin contact. Prompt identification and exclusion of wrestlers with skin lesions may reduce transmission.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 SE DELAWARE ST,BOX 9441,MINNEAPOLIS,MN 55440; CTR DIS CONTROL,DIV FIELD SERV,ATLANTA,GA 30333; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital				Belongia, Edward/0000-0001-7478-0415				BECKER TM, 1988, AM J SPORT MED, V16, P665, DOI 10.1177/036354658801600620; DYKE LM, 1965, J AMER MED ASSOC, V194, P1001, DOI 10.1001/jama.194.9.1001; GOODMAN JL, 1986, VIRUS RES, V5, P191, DOI 10.1016/0168-1702(86)90017-1; LIESEGANG TJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1160, DOI 10.1001/archopht.1989.01070020226030; PORTER PS, 1965, J AMER MED ASSOC, V194, P998, DOI 10.1001/jama.194.9.998; SELLING B, 1964, NEW ENGL J MED, V270, P979, DOI 10.1056/NEJM196405072701903; SOSIN DM, 1989, AM J SPORT MED, V17, P828, DOI 10.1177/036354658901700618; WALBOOMERS JMM, 1976, VIROLOGY, V74, P256, DOI 10.1016/0042-6822(76)90151-3; WHEELER CE, 1965, J AMER MED ASSOC, V194, P993; WHITE WB, 1984, JAMA-J AM MED ASSOC, V252, P533	10	90	91	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					906	910		10.1056/NEJM199109263251302	http://dx.doi.org/10.1056/NEJM199109263251302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1652687				2022-12-28	WOS:A1991GF85600002
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS			TRANSMISSION OF HEPATITIS-C VIRUS BY ORGAN-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; LIVER-DISEASE; RENAL-TRANSPLANTATION; HEPATOCELLULAR-CARCINOMA; HEMODIALYSIS-PATIENTS; CYTOMEGALO-VIRUS; VIRAL-HEPATITIS; ANTIBODIES; RECIPIENTS	Background. Liver disease is a frequent and major complication after organ transplantation. We sought to determine whether hepatitis C virus (HCV) is transmitted by organ transplantation and whether it causes post-transplantation liver disease. Methods. Serum samples from all cadaver organ donors to the New England Organ Bank between 1986 and 1990 were screened retrospectively for antibodies to HCV (anti-HCV) by enzyme-linked immunosorbent assay (ELISA). We reviewed the hospital records of all recipients of organs from anti-HCV-positive donors for evidence of liver disease. Serum samples from recipients obtained before transplantation and during follow-up were analyzed for anti-HCV. Results. Of 716 organ donors, 13 (1.8 percent) were positive for anti-HCV. Their organs (19 kidneys, 6 hearts, and 4 livers) went to 29 recipients. Non-A, non-B hepatitis developed after transplantation in 14 of the 29 (48 percent), for a prevalence 7.4 times the 6.5 percent prevalence after transplantation from untested donors that was previously reported by two institutions in the organ bank (P < 0.0001). The liver disease began a mean of 3.8 months after transplantation and became chronic in 12 patients; the other 2 had subfulminant hepatic failure. Liver disease was more frequent in the patients who had received antilymphocyte preparations (P = 0.04). HCV was the cause of the post-transplantation liver disease in 12 of the 13 recipients (92 percent) for whom serum samples were available. Anti-HCV was detected by ELISA in eight and enzyme immunoassay in one; in three others, HCV RNA was detected by polymerase chain reaction in serum samples obtained after transplantation. Conclusions. Organ transplantation can transmit hepatitis C. This raises serious questions about the continued acceptance of organs from donors positive for anti-HCV.	NEW ENGLAND ORGAN BANK INC,138 HARVARD ST,BROOKLINE,MA 02146									ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ANDRES A, 1990, J AM SOC NEPHROL, V1, P754; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BOYCE NW, 1988, AM J KIDNEY DIS, V11, P307, DOI 10.1016/S0272-6386(88)80135-5; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; BRUIX J, 1989, LANCET, V2, P1004; CHEESEMAN SH, 1979, NEW ENGL J MED, V300, P1345, DOI 10.1056/NEJM197906143002401; CHEESEMAN SH, 1980, ANN INTERN MED, V93, P39, DOI 10.7326/0003-4819-93-1-39; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTABAN JI, 1989, LANCET, V2, P294; FERNANDEZ JA, 1990, J AM SOC NEPHROL, V1, P757; GILLI P, 1990, LANCET, V336, P243, DOI 10.1016/0140-6736(90)91766-4; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HARNETT JD, 1987, TRANSPLANTATION, V44, P369, DOI 10.1097/00007890-198709000-00009; HESS G, 1989, LANCET, V2, P987; JEFFERS LJ, 1990, KIDNEY INT, V38, P320, DOI 10.1038/ki.1990.203; KIDD S, 1990, 8TH INT C VIR BERL; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; MASIH AS, 1988, AM J SURG PATHOL, V12, P362, DOI 10.1097/00000478-198805000-00004; MONDELLI MU, 1990, LANCET, V336, P244; MORTIMER PP, 1989, LANCET, V2, P798; PAR A, 1990, LANCET, V336, P123, DOI 10.1016/0140-6736(90)91644-P; PARFREY PS, 1985, TRANSPLANTATION, V39, P610, DOI 10.1097/00007890-198506000-00007; PARKER RL, 1946, JAMA-J AM MED ASSOC, V131, P95, DOI 10.1001/jama.1946.02870190019005; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROGGENDORF M, 1989, LANCET, V2, P324; RUBIN RH, 1989, TRANSPL P, V21, P1440; SCHLIPKOTER U, 1990, LANCET, V335, P1409, DOI 10.1016/0140-6736(90)91296-M; SHERLOCK S, 1989, DISEASES LIVER BILIA, V32, P339; SOPKO J, 1978, AM J MED, V64, P139, DOI 10.1016/0002-9343(78)90190-0; TREPO C, 1990, 8TH INT C VIR BERL; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; YAMAGUCHI K, 1990, LANCET, V335, P1409; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	45	355	355	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					454	460		10.1056/NEJM199108153250702	http://dx.doi.org/10.1056/NEJM199108153250702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649402				2022-12-28	WOS:A1991GA76300002
J	GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD				GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD			TRKB MEDIATES BDNF/NT-3-DEPENDENT SURVIVAL AND PROLIFERATION IN FIBROBLASTS LACKING THE LOW AFFINITY NGF RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; GENE-TRANSFER; FACTOR FAMILY; PC12 CELLS; MAMMALIAN-CELLS; EXPRESSION; BRAIN; DIFFERENTIATION	The neurotrophins (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], neurotrophin-3 [NT-3], and neurotrophin-4 [NT-4]) have been defined by their ability to support neuronal survival. These factors utilize the Trk family of receptor tyrosine kinases, perhaps in conjunction with a second component known as the low affinity NGF receptor (LNGFR). Here we demonstrate that TrkB mediates survival and proliferation in response to both BDNF and NT-3 when expressed in a particular strain of NIH 3T3 fibroblasts, with BDNF the more potent ligand. Furthermore, the BDNF dose dependency displayed by these TrkB-expressing fibroblasts is similar to that required to support the survival of primary neurons. The LNGFR is not expressed in our fibroblast system, implying that this receptor is not essential for responses to physiological concentrations of the neurotrophins. We discuss our findings in the context of neurotrophin signaling pathways and mechanisms of neuronal cell death.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Regeneron	GLASS, DJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; HOSANG M, 1985, J BIOL CHEM, V260, P655; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LINDSAY RM, 1985, DEV BIOL, V112, P30, DOI 10.1016/0012-1606(85)90116-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MURPHY AJM, 1987, P NATL ACAD SCI USA, V84, P8277, DOI 10.1073/pnas.84.23.8277; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	46	280	293	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					405	413		10.1016/0092-8674(91)90629-D	http://dx.doi.org/10.1016/0092-8674(91)90629-D			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649703				2022-12-28	WOS:A1991FY71200020
J	THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B				THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B			SEQUENCE-SPECIFIC TRANSACTIVATION OF THE DROSOPHILA TWIST GENE BY THE DORSAL GENE-PRODUCT	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VENTRAL POLARITY; BICOID PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; REL ONCOGENE; EMBRYO; CELLS; EXPRESSION	The maternal gene dorsal encodes a nuclear protein acting as a morphogen that determines the size and fate of regions along the dorsal-ventral axis of the Drosophila embryo. From previous genetic and biochemical studies it was hypothesized that dorsal might be responsible for the activation of the zygotic gene twist. In this report, regulatory sequences required for correct spatial and quantitative expression of twist are defined, by using phenotypic rescue and studying twist-beta-galactosidase expression. In addition, by transient cotransfection assays, we show that the dorsal protein specifically activates expression from the twist promoter. We demonstrate that dorsal is a sequence-specific DNA-binding protein that recognizes a motif similar to that recognized by the mammalian transcriptional activator NF-kappa-B.			THISSE, C (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.			THISSE, Christine/0000-0002-8684-1681				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELMESSAL M, 1987, THESIS U L PASTEUR S; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IP YT, 1991, CELL, V64, P439; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARTIN M, 1988, J INSECT PHYSIOL, V34, P691, DOI 10.1016/0022-1910(88)90079-0; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIMPSON P, 1983, GENETICS, V105, P615; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1984, NATURE, V311, P262, DOI 10.1038/311262a0; STEWARD R, 1985, COLD SPRING HARB SYM, V50, P223, DOI 10.1101/SQB.1985.050.01.028; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; VAUGHN JL, 1986, TCA MANUAL, V3, P527; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9	55	214	215	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1191	1201		10.1016/0092-8674(91)90014-P	http://dx.doi.org/10.1016/0092-8674(91)90014-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648449				2022-12-28	WOS:A1991FU89900011
J	HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE				HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE			CORRELATION BETWEEN ANTIBODIES TO TYPE-II COLLAGEN AND TREATMENT OUTCOME IN BILATERAL PROGRESSIVE SENSORINEURAL HEARING-LOSS	LANCET			English	Article							INNER-EAR DISEASE; RELAPSING POLYCHONDRITIS; RHEUMATOID-ARTHRITIS; SERUM ANTIBODIES; AUTOIMMUNITY	Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Meniere's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres - significantly (p < 0.005) more than in any other group (one Meniere's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2.02[SEM 0.62] vs 0.17 [0.17]) Meniere's disease, 0.44 [0.32] otosclerosis, 0 all others; p < 0.005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3.46 [0.88] vs 0.59 [0.59] for the nine non-responsive patients; p < 0.04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.	MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS EYE & EAR HOSP,DIV OTORHINOLARYNGOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HELFGOTT, SM (corresponding author), BETH ISRAEL HOSP,DEPT MED,RES E,ROOM 319,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P211; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ARNOLD W, 1985, ACTA OTO-LARYNGOL, V99, P437, DOI 10.3109/00016488509108935; BOWMAN CA, 1987, LARYNGOSCOPE, V97, P7; CLAGUE RB, 1983, ANN RHEUM DIS, V42, P537, DOI 10.1136/ard.42.5.537; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; HARRIS JP, 1986, ANN OTO RHINOL LARYN, V95, P176, DOI 10.1177/000348948609500214; HUGHES GB, 1986, LARYNGOSCOPE, V96, P502, DOI 10.1288/00005537-198605000-00006; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; KAKANI RS, 1990, J OTOLARYNGOL, V19, P100; LEUTJE CM, 1989, LARYNGOSCOPE, V99, P1137; MARKUSSE HM, 1988, ANN RHEUM DIS, V47, P600, DOI 10.1136/ard.47.7.600; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MOLONEY JR, 1978, J LARYNGOL OTOL, V92, P9, DOI 10.1017/S0022215100084875; MOSCICKI R, 1990, Journal of Allergy and Clinical Immunology, V85, P149; PLESTER D, 1989, AM J OTOL, V10, P188; TRENTHAM DE, 1983, J IMMUNOL, V130, P2684; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YOO TJ, 1985, AM J OTOLARYNG, V6, P209, DOI 10.1016/S0196-0709(85)80087-9; YOO TJ, 1983, SCIENCE, V222, P65, DOI 10.1126/science.6623056; YOO TJ, 1982, SCIENCE, V217, P1153, DOI 10.1126/science.7112122; YOO TJ, 1984, J LARYNGOL OTOL, V9, P220; YOO TJ, 1985, AM J OTOL, V6, P95	23	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					387	389		10.1016/0140-6736(91)91165-Q	http://dx.doi.org/10.1016/0140-6736(91)91165-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671423				2022-12-28	WOS:A1991EX60500003
J	AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M				AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M			RAPID DIAGNOSIS OF HERPES-SIMPLEX ENCEPHALITIS BY NESTED POLYMERASE CHAIN-REACTION ASSAY OF CEREBROSPINAL-FLUID	LANCET			English	Article							LINKED IMMUNOSORBENT-ASSAY; ENZYMATIC AMPLIFICATION; VIRUS ENCEPHALITIS; SERODIAGNOSIS; VIDARABINE; ACYCLOVIR; THERAPY; DNA	With the aim of improving early diagnosis of herpes simplex encephalitis a polymerase chain reaction (PCR) assay with two "nested" primer pairs was developed for the amplification of herpes simplex virus DNA in cerebrospinal fluid (CSF). Southern blotting was used to confirm the specificity of the amplification. The assay was applied to 151 CSF samples from 43 consecutive patients with herpes simplex encephalitis verified by the finding of herpes simplex virus/viral antigen in a brain biopsy sample or at necropsy (13) and/or intrathecal production of IgG antibody to the virus (40). As controls, 87 CSF samples from 60 patients with acute febrile focal encephalopathy (initially suspected to be herpes simplex encephalitis but excluded by the absence of intrathecal antibody synthesis) were tested. PCR detected herpes simplex virus DNA in 42 of the 43 patients with proven herpes simplex encephalitis; all but 1 were positive in the first CSF sample taken. The 1 PCR-negative patient had been treated with acyclovir from 20 h after the onset of symptoms. All the control subjects were PCR negative, as were 270 internal contamination controls. The PCR result remained positive in samples drawn up to 27 days after the onset of neurological symptoms. This method is a rapid and non-invasive means to diagnose herpes simplex encephalitis; it is highly sensitive and specific.	CENT MICROBIOL LAB,DEPT VIROL,STOCKHOLM,SWEDEN		AURELIUS, E (corresponding author), KAROLINSKA INST,DANDERYD HOSP,DEPT INFECT DIS,S-18288 DANDERYD,SWEDEN.							ANDERSON N E, 1989, Australian and New Zealand Journal of Medicine, V19, P635; AURELIUS E, 1989, SERODIAG IMMUN INF D, V3, P249, DOI 10.1016/0888-0786(89)90005-X; BOERMAN RH, 1989, J VIROL METHODS, V25, P189, DOI 10.1016/0166-0934(89)90032-3; BOS CA, 1987, J MED VIROL, V21, P169, DOI 10.1002/jmv.1890210209; FORSGREN M, 1989, SERODIAG IMMUN INF D, V3, P259, DOI 10.1016/0888-0786(89)90006-1; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HIGUCHI R, 1989, AMPLIFICATIONS; JOHNSON RT, 1968, ARCH NEUROL-CHICAGO, V18, P260, DOI 10.1001/archneur.1968.00470330050004; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAKEMAN FD, 1987, J INFECT DIS, V155, P1172, DOI 10.1093/infdis/155.6.1172; LEVINE DP, 1978, JAMA-J AM MED ASSOC, V240, P356, DOI 10.1001/jama.240.4.356; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PORTERJORDAN K, 1990, J MED VIROL, V30, P85, DOI 10.1002/jmv.1890300202; POWELL KF, 1990, LANCET, V335, P357, DOI 10.1016/0140-6736(90)90648-O; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303	21	476	483	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					189	192		10.1016/0140-6736(91)92155-U	http://dx.doi.org/10.1016/0140-6736(91)92155-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670839				2022-12-28	WOS:A1991EU92400001
J	GRANT, JM				GRANT, JM			THE FETAL HEART-RATE TRACE IS NORMAL, ISNT IT - OBSERVER AGREEMENT OF CATEGORICAL ASSESSMENTS	LANCET			English	Article							TRIAL	The limitations of the kappa statistic method to measure inter-observer variation of categorical assessments are shown by means of a hypothetical example. Another method for assessing the inter-observer variation of categorical variables, the proportion of agreement, is used for the same example, and reasons why it is preferable to the kappa statistic are given. Since this method allows measurement of the inherent difficulty of carrying out a particular assessment, it has wide applicability in the introduction of new technology. If a proportion of agreement study shows poor inter-observer agreement for a new method, the technology must either be improved or abandoned.			GRANT, JM (corresponding author), BELLSHILL MATERN HOSP,N RD,BELLSHILL ML4 3JN,LANARK,SCOTLAND.							BAILEY SM, 1989, BRIT J OBSTET GYNAEC, V96, P1266, DOI 10.1111/j.1471-0528.1989.tb03223.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; FENGER C, 1990, J CLIN PATHOL, V43, P320, DOI 10.1136/jcp.43.4.320; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; GRANT A, 1989, LANCET, V2, P1233; LANGLEY R, 1979, PRACTICAL STATISTICS, P318; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MURPHY KW, 1990, BRIT J OBSTET GYNAEC, V97, P470, DOI 10.1111/j.1471-0528.1990.tb02515.x; ROBERTS MM, 1990, LANCET, V335, P241; ROBERTSON AJ, 1990, J CLIN PATHOL, V43, P17, DOI 10.1136/jcp.43.1.17; 1985, J CLIN PATHOL, V38, P1358	12	123	124	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					215	218		10.1016/0140-6736(91)92169-3	http://dx.doi.org/10.1016/0140-6736(91)92169-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670851				2022-12-28	WOS:A1991EU92400014
J	KLINE, RL; BROTHERS, T; HALSEY, N; BOULOS, R; LAIRMORE, MD; QUINN, TC				KLINE, RL; BROTHERS, T; HALSEY, N; BOULOS, R; LAIRMORE, MD; QUINN, TC			EVALUATION OF ENZYME IMMUNOASSAYS FOR ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUSES TYPE-I/II	LANCET			English	Article							CELL LEUKEMIA-VIRUS; CHRONIC PROGRESSIVE MYELOPATHY; HTLV-I; LYMPHOMA VIRUS; BLOOD; TRANSMISSION; INFECTION; ANTIGEN	To evaluate the sensitivity and specificity of HTLV-I/II assays, serum from 1100 pregnant Haitian women was tested with seven commercially available HTLV I/II assays. Serum that was found to be reactive in any assay was analysed by western blot and all indeterminate samples were further characterised by radioimmunoprecipitation assays (RIPA). 59 (5.4%) samples were HTLVI/II antibody positive by western blot and/or RIPA. The sensitivity of these seven assays ranged from 93.2% to 100%, with the 'Recombinant HTLV-I' (Cambridge Bioscience) and 'Serodia' HTLV-I' (Fujirebio) assays having the highest sensitivity (100%). The specificity of these assays ranged from 98.4% to 100%, with the Abbott assay having the highest specificity (99.5%), 100%) according to two different methods of evaluation. Whether the antigens used in any assay were whole disrupted virus or recombinant gene products made no difference. The low positive predictive values of some of these assays (71.8-91.7%), even in a high prevalence population, and the need for RIPA to test indeterminate sera, indicate that for routine screening of blood donors there is still room for improvement both in screening and confirmatory assays for HTLV-I/II.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; CTR DEV & HLTH,PORT AU PRINCE,HAITI; CTR DIS CONTROL,RETROVIRUS DIS BRANCH,ATLANTA,GA 30333	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA					PHS HHS [R0IA126521] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON DW, 1989, BLOOD, V74, P2585; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BLATTNER WA, 1983, J INFECT DIS, V147, P406, DOI 10.1093/infdis/147.3.406; BOULOS R, 1990, J ACQ IMMUN DEF SYND, V3, P721; BREW BJ, 1988, NEW ENGL J MED, V318, P1195, DOI 10.1056/NEJM198805053181809; CATOVSKY D, 1982, LANCET, V1, P639; CLARK J, 1985, INT J CANCER, V36, P37, DOI 10.1002/ijc.2910360107; GESSAIN A, 1985, LANCET, V2, P407; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P646, DOI 10.1128/JCM.28.4.646-650.1990; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; KHABBAZ RF, IN PRESS J INFECT DI; KHABBAZ RF, IN PRESS AM J PUBLIC; LAIRMORE MD, IN PRESS P NATL ACAD; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MINAMOTO GY, 1988, NEW ENGL J MED, V318, P219, DOI 10.1056/NEJM198801283180405; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUINN TC, 1989, MEDICINE, V68, P189, DOI 10.1097/00005792-198907000-00001; ROSENBLATT JD, 1987, LEUKEMIA, V1, P397; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; WILLIAMS AE, 1988, SCIENCE, V36, P37; 1988, MMWR, V37, P736	25	27	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					30	33		10.1016/0140-6736(91)93343-8	http://dx.doi.org/10.1016/0140-6736(91)93343-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670658				2022-12-28	WOS:A1991EQ60400017
J	BARBEE, RA				BARBEE, RA			BRONCHIAL REACTIVITY - HYPORESPONSIVENESS VS HYPERRESPONSIVENESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							POPULATION; RESPONSIVENESS; METHACHOLINE				BARBEE, RA (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					802	802						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640589				2022-12-28	WOS:A1992JG66600041
J	BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL				BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL			A ROLE FOR ADP-RIBOSYLATION FACTOR IN NUCLEAR VESICLE DYNAMICS	NATURE			English	Article							GTP-BINDING PROTEINS; BREFELDIN-A; MEMBRANE-VESICLES; FORMATION INVITRO; GOLGI-APPARATUS; ENVELOPE; COMPONENTS; TRANSPORT; TARGETS; EGGS	Two distinct steps in nuclear envelope assembly can be assayed in vitro1-3: the protein-mediated binding4 of nuclear-specific vesicles to chromatin, and the subsequent fusion5 of these vesicles to enclose the chromatin within a double nuclear membrane. Nuclear vesicle fusion, like fusion in the secretory pathway6,7, requires ATP8,9 and cytosol1,3,5 and is inhibited by nonhydrolysable GTP analogues1,2. The sensitivity of nuclear vesicle fusion to GTP-gamma-S requires a GTP-dependent soluble factor, the properties of which are strikingly similar to a GTP-dependent Golgi binding factor (GCBF) that inhibits Golgi vesicle fusion in the presence of GTP-gamma-S and belongs to the ADP-ribosylation factor (ARF) family of small GTPases10,11. In the presence of GTP-gamma-S, ARF proteins and alpha-, beta-, gamma-, delta-COP ('coatomer') subunits are associated with Golgi transport vesicles 6,12,13, but the exact roles of ARF proteins in secretion are not vet understood. We report here that purified ARF1 and GGBF have GTP-dependent soluble factor activity in the nuclear vesicle fusion assay. Our results show that the function of ARF is not limited to the Golgi apparatus, and indicate that there may be a link between the formation of nuclear vesicles during mitosis and proteins involved in secretion.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Johns Hopkins University; University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DONALDSON JG, IN PRESS P NATN ACAD; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4637; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57	30	104	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					512	514		10.1038/358512a0	http://dx.doi.org/10.1038/358512a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641041				2022-12-28	WOS:A1992JG73900053
J	KLAGSBRUN, M; BAIRD, A				KLAGSBRUN, M; BAIRD, A			A DUAL RECEPTOR SYSTEM IS REQUIRED FOR BASIC FIBROBLAST GROWTH-FACTOR ACTIVITY	CELL			English	Review							PROTEOGLYCAN; CLONING		CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOLEC PHARMACOL, BOSTON, MA 02115 USA; SCRIPPS RES INST, WHITTIER INST, DEPT MOLEC & CELLULAR GROWTH BIOL, LA JOLLA, CA 92037 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute	KLAGSBRUN, M (corresponding author), HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA.			Baird, Andrew/0000-0003-0027-9905				BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIEFER MC, 1991, IN PRESS GROWTH FACT; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	15	555	568	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					229	231		10.1016/0092-8674(91)90173-V	http://dx.doi.org/10.1016/0092-8674(91)90173-V			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655276				2022-12-28	WOS:A1991GL47000002
J	STEIN, C; COMISEL, K; HAIMERL, E; YASSOURIDIS, A; LEHRBERGER, K; HERZ, A; PETER, K				STEIN, C; COMISEL, K; HAIMERL, E; YASSOURIDIS, A; LEHRBERGER, K; HERZ, A; PETER, K			ANALGESIC EFFECT OF INTRAARTICULAR MORPHINE AFTER ARTHROSCOPIC KNEE SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCGILL PAIN QUESTIONNAIRE; OPIOID RECEPTORS; INFLAMMATION; ANTINOCICEPTION; NOCICEPTION	Background. Opioids can produce potent antinociceptive effects by interacting with local opioid receptors in inflamed peripheral tissue. In this study we examined the analgesic effects of the intraarticular, as compared with intravenous, administration of morphine after arthroscopic knee surgery. Methods. In a double-blind, randomized trial, we studied 52 patients who had received one of four injections at the end of surgery. The patients in group 1 (n = 18) received 1 mg of morphine intraarticularly and saline intravenously; those in group 2 (n = 15), saline intraarticularly and 1 mg of morphine intravenously; those in group 3 (n = 10), 0.5 m of morphine intraarticularly and saline intravenously; and those in group 4 (n = 9), 1 mg of morphine and 0.1 mg of naloxone intraarticularly and saline intravenously. The volume of the intraarticular injections was 40 ml, and that of the intravenous injections was 1 ml. After 1, 2, 3, 4, 6, and 24 hours, postoperative pain was assessed with a visual-analogue scale, a numerical-rating scale, and the McGill pain questionnaire. The need for supplemental analgesic agents, the patients' vital signs, and the occurrence of side effects were monitored. Results. All pain scores were lower in group 1 than in group 2 at all times. The differences were significant (P < 0.05) at three, four, and six hours (mean [+/- SD] visual-analogue score at six hours, 9 +/- 13 mm vs. 37 +/- 31 mm). The mean (+/- SD) consumption of supplemental analgesic medication per 24 hours was significantly lower in group 1 (36 +/- 51 mg of diclofenac and 1.2 +/- 3.4 mg of meperidine) than in group 2 (75 +/- 42 mg of diclofenac and 14 +/- 18 mg of meperidine, P < 0.05). The visual-analogue scores in group 3 were slightly but not significantly higher than those in group 1 at all times except 6 and 24 hours after injection. The visual-analogue scores were significantly higher in group 4 than in group 1 one to four hours after injection (P < 0.05), indicating that the analgesic effect of intraarticular morphine was reversible by naloxone. Conclusions. Low doses of intraarticular morphine can significantly reduce pain after knee surgery through an action specific to local opioid receptors that reaches its maximal effect three to six hours after injection.	UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT ORTHOPED,W-8000 MUNICH 70,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT NEUROPHARMACOL,W-8033 MARTINSRIED,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT BIOSTAT,W-8033 MARTINSRIED,GERMANY	University of Munich; Max Planck Society; Max Planck Society	STEIN, C (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT ANESTHESIOL,W-8000 MUNICH 70,GERMANY.			Stein, Christoph/0000-0001-5240-6836				BARTHO L, 1990, N-S ARCH PHARMACOL, V342, P666, DOI 10.1007/BF00175710; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; de Castro J, 1979, Acta Anaesthesiol Belg, V30, P5; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P191, DOI 10.1016/0090-6980(79)90104-7; JAFFE JH, 1985, GOODMAN GILMANS PHAR, P491; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; STEIN C, 1988, EUR J PHARMACOL, V155, P255, DOI 10.1016/0014-2999(88)90511-0; STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7	15	427	449	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1123	1126		10.1056/NEJM199110173251602	http://dx.doi.org/10.1056/NEJM199110173251602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1653901				2022-12-28	WOS:A1991GK53800002
J	ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J				ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J			HIGH-RATE OF INFECTIVITY AND LIVER-DISEASE IN BLOOD-DONORS WITH ANTIBODIES TO HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, CHRONIC ACTIVE; HEPATITIS-C VIRUS; LIVER CIRRHOSIS; BLOOD DONORS; HEPATITIS ANTIBODIES	NON-B-HEPATITIS; NON-A-HEPATITIS; HEPATOCELLULAR-CARCINOMA; VIRAL SEQUENCES; FRACTIONATION; PLASMA	Objective: To determine the epidemiologic, clinical, serologic, and histologic importance of antibodies to hepatitis C virus (anti-HCV) in blood donors. Design: Cross-sectional identification and prospective evaluation of seropositive donors; retrospective assessment of infectivity; and nested case-control study for risk factors. Setting: Liver unit of a referral-based university hospital. Subjects: Of 30 231 consecutive donors, 368 (1.2%) were found to be anti-HCV-reactive by enzyme-linked immunosorbent assay (ELISA). Two hundred and fifty-four of these 368 donors were evaluated for risk factors by comparison with 284 age- and sex-matched controls. Eighty-six spouses of seropositive donors were also evaluated. Measurements and Main Results: Twenty-four percent of the seropositive donors had a history of percutaneous exposure to blood. This rate increased to 45% when only those donors confirmed to be anti-HCV positive by a second-generation recombinant immunoblot assay (RIBA-2) were considered. A family history of liver disease (odds ratio, 2.8; 95% Cl, 1.6 to 4.8), previous blood transfusion (odds ratio, 6.1; 95% Cl, 3 to 12.5), and a history of tattooing or intravenous drug abuse (odds ratio, 8.4; 95% Cl, 2.3 to 31) were associated with anti-HCV seropositivity. An elevated alanine aminotransferase (ALT) level was found in 58% of the seropositive donors. Of the 150 donors tested, 104 (69%; Cl, 62% to 77%) were confirmed by RIBA-2 to be anti-HCV positive. Of the 105 donors who had a biopsy, 16% had normal histologic findings, 11% had minimal changes, 21% had chronic persistent hepatitis, 45% had chronic active hepatitis, and 7% had active cirrhosis. All 77 donors with RIBA-2-confirmed seropositivity had histologic abnormalities. Of 43 donors evaluated in an infectivity study, 82% were implicated in previous HCV transmission. Only 2.3% of the spouses were anti-HCV positive. The ELISA, RIBA-2, and ALT results correlated with infectivity and abnormal histologic findings. Conclusions: In our geographic area, almost 70% of donors who are anti-HCV positive by ELISA are confirmed to be positive by RIBA-2; most of these donors appear to be chronic carriers of HCV and have substantial liver disease.	HOSP SANTA CRUZ & SAN PABLO, BLOOD BANK, E-08025 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, INST CATALA SALUT, BLOOD BANK, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT PATHOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT CLIN PHARMACOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT MED, HEMATOL HEMOTHERAPY SERV, E-08035 BARCELONA, SPAIN	Fundacio Banc Sang Teixits de les Illes Balears; Fundacio Banc Sang Teixits de les Illes Balears; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	ESTEBAN, JI (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, LIVER UNIT, PASSEIG VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Vidal, Xavier/I-5958-2019; Genesca, Joan/H-7467-2019	Vidal, Xavier/0000-0001-6705-4298; Genesca, Joan/0000-0002-0831-8422; Viladomiu, Lluis/0000-0002-3434-9847; esteban, rafael/0000-0001-5280-392X				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FINLAYSON JS, 1990, LANCET, V335, P1274, DOI 10.1016/0140-6736(90)91335-8; FORTUNY C, 1991, VIRAL HEPATITIS LIVE; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HABIBI B, 1990, LANCET, V335, P855, DOI 10.1016/0140-6736(90)90968-B; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; QUAN S, 1990, 2ND P INT S HCV LOS; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; [No title captured]; 1989, 1ST P INT S HEP C VI, P25; 1989, 1ST P INT S HEP C VI, P9	18	314	316	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					443	449		10.7326/0003-4819-115-6-443	http://dx.doi.org/10.7326/0003-4819-115-6-443			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651674				2022-12-28	WOS:A1991GE81000005
J	MCCRACKEN, S; GREENBLATT, J				MCCRACKEN, S; GREENBLATT, J			RELATED RNA-POLYMERASE BINDING REGIONS IN HUMAN RAP30/74 AND ESCHERICHIA-COLI SIGMA-70	SCIENCE			English	Article							TRANSCRIPTION INITIATION-FACTOR; LARGEST SUBUNIT; FACTOR-IIF; TATA BOX; GENE; PURIFICATION; PROTEINS; SPECIFICITY; CLONING; DNA	RAP30/74 is a heteromeric general transcription initiation factor that binds to mammalian RNA polymerase II. The RAP30 subunit contains a region that is similar in amino acid sequence to the RNA polymerase-binding domain of the Escherichia coli transcription initiation factor sigma 70 (sigma-70). Mammalian RNA polymerase II specifically protected a serine residue in the sigma-70-related region of RAP30 from phosphorylation in vitro. In addition, human RAP30/74 bound to Escherichia coli RNA polymerase and was displaced by sigma-70. These results suggest that RAP30 and sigma-70 have functionally related RNA polymerase-binding regions.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gros E., 1967, METHOD ENZYMOL, V11, P238; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; MCCRACKEN S, UNPUB; MEMET S, 1988, J BIOL CHEM, V263, P2830; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WU FYH, 1976, BIOCHEMISTRY-US, V15, P3254, DOI 10.1021/bi00660a014	37	92	92	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					900	902		10.1126/science.1652156	http://dx.doi.org/10.1126/science.1652156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1652156				2022-12-28	WOS:A1991GC15200044
J	ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J				ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J			NEGATIVE AND POSITIVE SELECTION OF ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES-T AFFECTED BY THE ALPHA-3 DOMAIN OF MHC-I MOLECULES	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; CELLS; CD8; EXPRESSION; HLA-A2	THE alpha-1 and alpha-2 domains of major histocompatibility complex (MHC) class I molecules function in the binding and presentation of foreign peptides to the T-cell antigen receptor and control both negative and positive selection of the T-cell repertoire 1-3. Although the alpha-3 domain of class I is not involved in peptide binding, it does interact with the T-cell accessory molecule, CD8 (refs 4, 5). CD8 is important in the selection of T cells as anti-CD8 antibody injected into perinatal mice interferes with this process 6. We previously used a hybrid class I molecule with the alpha-1/alpha-2 domains from L(d) and the alpha-3 domain from Q7b and showed that this molecule binds an L(d)-restricted peptide but does not interact with CD8-dependent cytotoxic T lymphocytes 7. Expression of this molecule in transgenic mice fails to negatively select a subpopulation of anti-L(d) cytotoxic T lymphocytes. In addition, positive selection of virus-specific L(d)-restricted cytotoxic T lymphocytes does not occur. We conclude that besides the alpha-1/alpha-2 domains of class I, the alpha-3 domain plays an important part in both positive and negative selection of antigen-specific cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV ULM,VIROL ABT,W-7900 ULM,GERMANY; CALTECH,DEPT BIOL,PASADENA,CA 91125	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Ulm University; California Institute of Technology	ALDRICH, CJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551				ALDRICH CJ, 1991, J IMMUNOL, V146, P3082; ALDRICH CJ, 1986, J IMMUNOL, V136, P383; ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BUDD RC, 1987, J IMMUNOL, V138, P1009; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; KOSZINOWSKI UH, 1987, J EXP MED, V166, P289, DOI 10.1084/jem.166.1.289; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	24	84	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					718	721		10.1038/352718a0	http://dx.doi.org/10.1038/352718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652099	Green Submitted			2022-12-28	WOS:A1991GC06400059
J	WOODS, DF; BRYANT, PJ				WOODS, DF; BRYANT, PJ			THE DISKS-LARGE TUMOR SUPPRESSOR GENE OF DROSOPHILA ENCODES A GUANYLATE KINASE HOMOLOG LOCALIZED AT SEPTATE JUNCTIONS	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; AFFECTING IMAGINAL DISKS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; RECESSIVE ONCOGENE; MEMBRANE-PROTEINS; EPITHELIAL-CELLS	Mutations of the lethal(1)discs large-1 (dlg) tumor suppressor gene of Drosophila cause neoplastic overgrowth of the imaginal discs. Sequencing of a near full-length cDNA predicts a protein containing a domain homologous to yeast guanylate kinase and a region homologous to SH3, a putative regulatory motif in nonreceptor protein tyrosine kinases and other signal transduction proteins. Immunofluorescence analysis using antibodies directed against fusion peptides shows that the dlg gene product is localized in an apical belt of the lateral cell membrane, at the position of the septate junction. The results suggest that a signal transduction process involving guanine nucleotides occurs at the septate junction and is necessary for cell proliferation control in Drosophila epithelia.			WOODS, DF (corresponding author), UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717, USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOS JL, 1989, CANCER RES, V49, P4682; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; BRYANT PJ, 1971, DEV BIOL, V24, P233, DOI 10.1016/0012-1606(71)90097-2; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEQUIN R, 1984, DEV BIOL, V104, P37, DOI 10.1016/0012-1606(84)90034-4; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EICHENBERGERGLINZ S, 1979, ROUX ARCH DEV BIOL, V186, P333, DOI 10.1007/BF00848457; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GATEFF E, 1974, ROUXS ARCH, V176, P23; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Goebel S.J., 1990, VIROLOGY, V179, P517; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HANRATTY WP, 1984, ROUX ARCH DEV BIOL, V193, P98, DOI 10.1007/BF00848637; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JURSNICH VA, 1990, DEV BIOL, V140, P413, DOI 10.1016/0012-1606(90)90090-6; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN P, 1977, DEV BIOL, V55, P213, DOI 10.1016/0012-1606(77)90168-3; MARTIN PF, 1982, J EXP ZOOL, V222, P97, DOI 10.1002/jez.1402220113; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY C, 1974, DEV BIOL, V39, P23, DOI 10.1016/S0012-1606(74)80005-9; Noirot-Timothee C., 1980, International Review of Cytology, V63, P97, DOI 10.1016/S0074-7696(08)61758-1; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; PISAM M, 1976, J CELL BIOL, V71, P907, DOI 10.1083/jcb.71.3.907; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POODRY CA, 1990, ROUX ARCH DEV BIOL, V199, P219, DOI 10.1007/BF01682081; Potts W M, 1988, Oncogene Res, V3, P343; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WEINER J, 1990, J CELL BIOL, V22, P587; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZIOMEK CA, 1980, J CELL BIOL, V86, P849, DOI 10.1083/jcb.86.3.849	75	781	793	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					451	464		10.1016/0092-8674(81)90009-X	http://dx.doi.org/10.1016/0092-8674(81)90009-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651169				2022-12-28	WOS:A1991GA94100007
J	BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J				BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J			MECHANISM OF ASSEMBLY OF THE TYROSYL RADICAL DINUCLEAR IRON CLUSTER COFACTOR OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Article							ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; HYDROGEN-PEROXIDE; SMALL SUBUNIT; MOSSBAUER; SPECTROSCOPY; PROTEIN-B2; ACTIVATION; RESONANCE; ENZYME	Incubation of the apoB2 subunit of Escherichia coli ribonucleotide reductase with Fe2+ and O2 produces native B2, which contains the tyrosyl radical-dinuclear iron cluster cofactor required for nucleotide reduction. The chemical mechanism of this reconstitution reaction was investigated by stopped-flow absorption spectroscopy and by rapid freeze-quench EPR (electron paramagnetic resonance) spectroscopy. Two novel intermediates have been detected in the reaction. The first exhibits a broad absorption band centered at 565 nanometers. Based on known model chemistry, this intermediate is proposed to be a mu-peroxodiferric complex. The second intermediate exhibits a broad absorption band centered at 360 nanometers and a sharp, isotropic EPR signal with g = 2.00. When the reaction is carried out with Fe-57(2+), this EPR signal is broadened, demonstrating that the intermediate is an iron-coupled radical. Variation of the ratio of Fe2+ to B2 in the reaction and comparison of the rates of formation and decay of the intermediates to the rate of formation of the tyrosyl radical (.Y122) suggest that both intermediates can generate .Y122. This conclusion is supported by the fact that both intermediates exhibit an increased lifetime in a mutant B2 subunit (B2-Y122F) lacking the oxidizable Y122. Based on these kinetic and spectroscopic data, a mechanism for the reaction is proposed. Unlike reactions catalyzed by heme-iron peroxidases, oxygenases, and model complexes, the reconstitution reaction appears not to involve high-valent iron intermediates.	EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Emory University; Emory University; Colorado State University	BOLLINGER, JM (corresponding author), MIT,DEPT CHEM & BIOL,CAMBRIDGE,MA 02139, USA.		Bollinger, Joseph/C-1425-2016; Filley, Jon/AAI-6208-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029595, R01GM029595, R01GM029433, R01GM032187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29433, GM32187, GM29595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BALLOU DP, 1974, ANAL CHEM, V46, P1248, DOI 10.1021/ac60345a034; BOLLINGER JM, IN PRESS J AM CHEM S; BUNKER G, 1987, BIOCHEMISTRY-US, V26, P4708, DOI 10.1021/bi00389a017; CHIN DH, 1980, J AM CHEM SOC, V102, P4344, DOI 10.1021/ja00533a009; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P17698; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MCCORMICK JM, IN PRESS NEW J CHEM; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; QUE L, 1990, PROG INORG CHEM, V38, P97; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; SANDERSLOEHR J, 1988, OXIDASES RELATED RED, P193; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1985, FEBS LETT, V183, P99, DOI 10.1016/0014-5793(85)80962-5; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004	36	342	343	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					292	298		10.1126/science.1650033	http://dx.doi.org/10.1126/science.1650033			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1650033				2022-12-28	WOS:A1991FX22400033
J	GOODWIN, FK				GOODWIN, FK			BLUNTED GROWTH-HORMONE PANICS PREREQUISITE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,ROCKVILLE,MD 20857									IN PRESS NEUROPSYCHO	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					323	323						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1647468				2022-12-28	WOS:A1991FV96000006
J	HORVITZ, HR; STERNBERG, PW				HORVITZ, HR; STERNBERG, PW			MULTIPLE INTERCELLULAR SIGNALING SYSTEMS CONTROL THE DEVELOPMENT OF THE CAENORHABDITIS-ELEGANS VULVA	NATURE			English	Article							SPECIFIES CELL FATES; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; C-ELEGANS; EMBRYONIC-DEVELOPMENT; LATERAL INHIBITION; DROSOPHILA-NOTCH; GENETIC PATHWAY; TYROSINE KINASE; NERVOUS-SYSTEM	Developmental, genetic and molecular studies indicate that multiple intercellular signalling systems interact to specify the types and spatial patterns of cells generated during the formation of the vulva of the nematode Caenorhabditis elegans. Two classes of evolutionarily conserved transmembrane receptors and a Ras protein function in these signalling systems. The biology of vulval development provides a framework for understanding how cell interactions control the development of animals as diverse as nematodes, insects and mammals.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute	HORVITZ, HR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sternberg, Paul/0000-0002-7699-0173				ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; Barbacid M., 1987, REV BIOCH, V56, P779; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1989, TRENDS GENET, V5, P237, DOI 10.1016/0168-9525(89)90094-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1980, GENETICS, V96, P435; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LEWIS J, 1977, J THEOR BIOL, V65, P575; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NISHIDA H, 1989, DEV BIOL, V132, P355, DOI 10.1016/0012-1606(89)90232-7; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RABBITTS T, 1990, NATURE, V348, P418; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANKLAND M, 1987, TRENDS GENET, V3, P314, DOI 10.1016/0168-9525(87)90279-4; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1991, J NIH RES, V3, P45; WHITE J, 1988, NEMATODE CAENORHABDI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	229	245	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					535	541		10.1038/351535a0	http://dx.doi.org/10.1038/351535a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646401				2022-12-28	WOS:A1991FR03400048
J	BAILEY, DG; SPENCE, JD; MUNOZ, C; ARNOLD, JMO				BAILEY, DG; SPENCE, JD; MUNOZ, C; ARNOLD, JMO			INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE	LANCET			English	Note							PYRIDINE	Six men with borderline hypertension took felodipine 5 mg with water, grapefruit juice, or orange juice. The mean felodipine bioavailability with grapefruit juice was 284 (range 164-469)% of that with water. The dehydrofelodipine/felodipine AUC ratio was lower, diastolic blood pressure lower, and heart rate higher with grapefruit juice than with water. Vasodilatation-related side-effects were more frequent. Orange juice had no such effects. Six healthy men took nifedipine 10 mg with water or grapefruit juice; the bioavailability with grapefruit juice was 134 (108-169)% of that with water.			BAILEY, DG (corresponding author), UNIV WESTERN ONTARIO,VICTORIA HOSP,DEPT MED,375 S ST,LONDON N6A 4G5,ONTARIO,CANADA.		Spence, J. David/K-6396-2013; Arnold, Malcolm/G-2869-2011	Spence, J. David/0000-0001-7478-1098; 				ANHOFF M, 1984, J PHARM BIOMED ANAL, V2, P519; BAARNHIELM C, 1984, XENOBIOTICA, V14, P719; BAILEY DG, 1989, CLIN INVEST MED, V12, P357; BUENING MK, 1981, CANCER RES, V41, P67; EDGAR B, 1987, DRUGS, V34, P16, DOI 10.2165/00003495-198700343-00005; EDGAR B, 1990, CLIN PHARMACOL THER, V47, P181; EDGAR B, 1985, DRUGS, V29, P9, DOI 10.2165/00003495-198500292-00004; EDGAR B, 1985, CLIN PHARMACOL THER, V38, P205, DOI 10.1038/clpt.1985.160; FUNAKI T, 1989, BIOCHEM PHARMACOL, V38, P4213, DOI 10.1016/0006-2952(89)90517-0; SVENSSON CK, 1983, CLIN PHARMACOL THER, V34, P316, DOI 10.1038/clpt.1983.174	10	513	526	1	46	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					268	269		10.1016/0140-6736(91)90872-M	http://dx.doi.org/10.1016/0140-6736(91)90872-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671113				2022-12-28	WOS:A1991EV71900005
J	HUMPHREY, M; MOSCA, J; BAKER, JR; DRABICK, JJ; CARR, FE; BURKE, DS; WARTOFSKY, L; DJUH, YY; BURMAN, KD				HUMPHREY, M; MOSCA, J; BAKER, JR; DRABICK, JJ; CARR, FE; BURKE, DS; WARTOFSKY, L; DJUH, YY; BURMAN, KD			ABSENCE OF RETROVIRAL SEQUENCES IN GRAVES-DISEASE	LANCET			English	Note							THYROID EPITHELIAL-CELLS; SARCOMA-VIRUS	An earlier report of HIB-1 gene sequences in thyroid cell genomic DNA from patients with Graves' disease prompted use of the polymerase chain reaction technique to identify such sequences in Graves' disease thyroid tissue and in white blood-cells from these patients. We were unable to confirm the existence of HIV-1-related DNA sequences in Graves' specimens.	WALTER REED ARMY MED CTR,DEPT MED & CLIN INVEST,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV RETROVIROL DIS,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV BACTERIAL DIS,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	HUMPHREY, M (corresponding author), WALTER REED ARMY MED CTR,KYLE METAB UNIT,ENDOCRINE METAB SERV,WASHINGTON,DC 20307, USA.			/0000-0002-5704-8094				CIAMPOLILLO A, 1989, LANCET, V1, P1096; CORK LC, 1980, LAB INVEST, V42, P596; DRABICK JJ, IN PRESS MIL MED; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; PORTELLA G, 1989, ONCOGENE, V4, P181; STANCEK D, 1974, ACTA VIROL, V18, P365; TOMINAGA T, 1991, 10TH INT THYR C; WERNER J, 1979, LANCET, V2, P258	9	38	38	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					17	18		10.1016/0140-6736(91)93335-7	http://dx.doi.org/10.1016/0140-6736(91)93335-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670652				2022-12-28	WOS:A1991EQ60400009
J	JACKSON, LG; ZACHARY, JM; FOWLER, SE; DESNICK, RJ; GOLBUS, MS; LEDBETTER, DH; MAHONEY, MJ; PERGAMENT, E; SIMPSON, JL; BLACK, S; WAPNER, RJ				JACKSON, LG; ZACHARY, JM; FOWLER, SE; DESNICK, RJ; GOLBUS, MS; LEDBETTER, DH; MAHONEY, MJ; PERGAMENT, E; SIMPSON, JL; BLACK, S; WAPNER, RJ			A RANDOMIZED COMPARISON OF TRANSCERVICAL AND TRANSABDOMINAL CHORIONIC-VILLUS SAMPLING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUCCESS; SAFETY; BIOPSY	Background. Chorionic-villus sampling is done in early pregnancy to obtain fetal cells for the prenatal diagnosis of genetic and chromosomal defects. Transcervical chorionic-villus sampling has been shown to be safe and effective in national trials. Recently, an alternative transabdominal technique has been suggested as potentially easier and safer. Methods. From April 1987 through September 1989, we prospectively compared transcervical and transabdominal chorionic-villus sampling in 3999 women with singleton pregnancies in whom the risk of a genetically abnormal fetus was increased. Women between 7 and 12 weeks of gestation underwent ultrasonographic evaluation of placental and uterine position. Those with active vaginal infections, active bleeding, or cervical polyps were excluded. If the obstetrician thought either sampling procedure was acceptable, the woman was asked to consent to random assignment to one of the two procedures. Both groups were followed to determine the outcome of pregnancy and the rate of spontaneous fetal loss after chorionic-villus sampling. Results. Among the 3999 women who entered the study, sampling was attempted in 3873 (97 percent), 1944 of whom had been assigned to undergo transcervical sampling and 1929 to undergo transabdominal sampling. Of these 3873 women, sampling was eventually successful in 3863. Sampling was successful after a single insertion of the sampling instrument in 94 percent of the transabdominal procedures and 90 percent of the transcervical procedures. Among the women with cytogenetically normal pregnancies who had sampling because of maternal age, the rate of spontaneous fetal loss through 28 weeks of pregnancy was 2.5 percent in the transcervical-sampling group and 2.3 percent in the transabdominal-sampling group (difference, 0.26 percent; 95 percent confidence interval, -0.5 to 1.0 percent). Conclusions. Transabdominal and transcervical chorionic-villus sampling appear to be equally safe procedures for first-trimester diagnosis of fetal abnormalities.	GEORGE WASHINGTON UNIV,CTR BIOSTAT,WASHINGTON,DC 20052; GENET & INVITRO FERTILIZAT INST,FAIRFAX,VA; YALE UNIV,NEW HAVEN,CT 06520; UNIV TENNESSEE CTR HLTH SCI,MEMPHIS,TN 38163; BAYLOR COLL MED,HOUSTON,TX 77030; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; ILLINOIS MASONIC MED CTR,CHICAGO,IL 60657	George Washington University; Yale University; University of Tennessee System; University of Tennessee Health Science Center; Baylor College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco	JACKSON, LG (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV MED GENET,1100 WALNUT ST,4TH FLOOR,PHILADELPHIA,PA 19107, USA.							[Anonymous], 1991, LANCET, V337, P1491; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; JACKSON LG, 1986, LANCET, V1, P674; JACKSON LG, 1990, HUMAN PRENATAL DIAGN, P37; LEDBETTER DH, 1990, AM J OBSTET GYNECOL, V162, P495, DOI 10.1016/0002-9378(90)90419-8; LEDBETTER DH, 1992, PRENATAL DIAG, V12, P317, DOI 10.1002/pd.1970120503; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SMIDTJENSEN S, 1984, PRENATAL DIAG, V4, P163, DOI 10.1002/pd.1970040302; SMIDTJENSEN S, 1991, ULTRASOUND OBST GYN, V1, P86, DOI 10.1046/j.1469-0705.1991.01020086.x	9	137	142	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					594	598		10.1056/NEJM199208273270903	http://dx.doi.org/10.1056/NEJM199208273270903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640952				2022-12-28	WOS:A1992JK20400003
J	BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF				BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF			PERFORMANCE OF 45 LABORATORIES PARTICIPATING IN A PROFICIENCY TESTING PROGRAM FOR LYME-DISEASE SEROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; ANTIBODY; SERODIAGNOSIS	Objective.-We show that significant interlaboratory and intralaboratory variations exist in Lyme disease proficiency testing. Design.-Six case-defined Lyme serum samples and three serum samples from individuals with no history of Lyme disease were randomized in four shipments and distributed to 45 participating laboratories. Results.-Interlaboratory and intralaboratory performances were highly variable. Approximately 4% to 21% of laboratories failed to identify correctly positive serum samples with titers of 512 or more using polyvalent serum or immunoglobulin G conjugates. With lower levels of anti-Borrelia burgdorferi antibody in the serum sample, approximately 55% of participating laboratories did not identify a case-defined serum. There was also a striking inability of many laboratories to reproduce their results on split samples from the same individual. In addition, 2% to 7% of laboratories identified serum samples from individuals with no known exposure to B burgdorferi as positive using polyvalent serum. The false positivity rate increased to 27% with the use of immunoglobulin G conjugate. Conclusions.-Our results indicate that there is an urgent need for standardization of current testing methodologies. Until a national commitment is made, serological testing for Lyme disease will be of questionable value for the diagnosis of the disease.	UNIV WISCONSIN,WISCONSIN STATE LAB HYG,465 HENRY MALL,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED MICROBIOL & IMMUNOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; GUNDERSON MED FDN,LA CROSSE,WI; LUTHERAN HOSP,LA CROSSE,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Gundersen Lutheran Medical Center								AFZELIUS A, 1990, ARCH DERAMTOL SYPH, V101, P405; BERGSTROM S, 1991, EUR J CLIN MICROBIOL, V10, P422, DOI 10.1007/BF01968022; CALLISTER SM, 1988, J CLIN MICROBIOL, V26, P2632, DOI 10.1128/JCM.26.12.2632-2636.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; LANE RS, 1990, J CLIN MICROBIOL, V28, P1774, DOI 10.1128/JCM.28.8.1774-1779.1990; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; QUAN TJ, 1991, 1ST P NAT C LYM DIS, P61; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SCRIMENTI RJ, 1970, ARCH DERMATOL, V102, P104, DOI 10.1001/archderm.102.1.104; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; 1991, MMWR, V40, P417	17	119	119	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					891	895		10.1001/jama.268.7.891	http://dx.doi.org/10.1001/jama.268.7.891			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640618				2022-12-28	WOS:A1992JH58800040
J	CNATTINGIUS, S; FORMAN, MR; BERENDES, HW; ISOTALO, L				CNATTINGIUS, S; FORMAN, MR; BERENDES, HW; ISOTALO, L			DELAYED CHILDBEARING AND RISK OF ADVERSE PERINATAL OUTCOME - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; MATERNAL AGE; PREGNANCY; OLDER	Objective.-To investigate the effect of advancing maternal age on pregnancy outcome among healthy nulliparous women, after adjustment for demographic characteristics, smoking, history of infertility, and other medical conditions. Design.-A population-based cohort study was conducted with prospectively collected data from the Swedish Medical Birth Register. Patients.-Nulliparous Nordic women (N=173715), aged 20 years and above, who delivered single births at Swedish hospitals from 1983 through 1987. Outcome Measures.-Late fetal and early neonatal death rates; rates of very low birth weight (VLBW, <1500 g), moderately low birth weight (MLBW, 1500 through 2499 g), very preterm delivery (less-than-or-equal-to 32 weeks), moderately preterm delivery (33 through 36 weeks), and small-for-gestational-age (SGA) infants (<-2 SDs). Results.-Compared with women aged 20 to 24 years, women aged 30 to 34 years had significantly higher adjusted odds ratios (ORs) of late fetal deaths (OR=1.4); VLBW (OR=1.2); MLBW (OR=1.4); very preterm birth (OR=1.2); and SGA infants (OR=1.4). Among women aged 35 to 39 years, the adjusted OR was significantly higher for VLBW (OR=1.9); MLBW (OR=1.7); very preterm birth (OR=1.7); moderately preterm birth (OR=1.2); and SGA infants (OR=1.7). Among women 40 years old and older, the adjusted OR was significantly higher for VLBW (OR=1.8); MLBW (OR=2.0); very preterm birth (OR=1.9); moderately preterm birth (OR=1.5); and SGA infants (OR=1.4). Conclusions.-Delayed childbearing is associated with an increased risk of poor pregnancy outcomes after adjustment for maternal complications and other risk factors.	NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,BETHESDA,MD 20892; NCI,CANC PREVENT STUDIES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS MM, 1982, JAMA-J AM MED ASSOC, V247, P493, DOI 10.1001/jama.247.4.493; BALDWIN WH, 1984, POPUL B, V39, P14; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P69, DOI 10.1111/j.1651-2227.1984.tb09900.x; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; GRIMES DA, 1981, OBSTET GYNECOL, V58, P614; Hansen J P, 1986, Obstet Gynecol Surv, V41, P726, DOI 10.1097/00006254-198611000-00024; KANE SH, 1967, OBSTET GYNECOL, V29, P409; KIELY JL, 1986, AM J EPIDEMIOL, V123, P444, DOI 10.1093/oxfordjournals.aje.a114259; KIRTZ DS, 1985, AM J OBSTET GYNECOL, V152, P7; LIN CC, 1991, AM J OBSTET GYNECOL, V164, P1535, DOI 10.1016/0002-9378(91)91433-W; Lindmark G, 1991, Acta Obstet Gynecol Scand, V70, P105, DOI 10.3109/00016349109006190; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Schlesselman J., 1982, CASE CONTROL STUDIES, P354; STEVENSSIMON C, 1990, J ADOLESCENT HEALTH, V11, P432, DOI 10.1016/0197-0070(90)90091-F; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Tzoumaka-Bakoula C, 1989, Paediatr Perinat Epidemiol, V3, P41, DOI 10.1111/j.1365-3016.1989.tb00368.x; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; VENTURA SJ, 1984, PUBLIC HEALTH REP, V99, P138; VENTURA SJ, 1989, VITAL HLTH STAT 21, V47; WILLIAMS MA, 1991, FERTIL STERIL, V56, P668; 1989, SAS USERS GUIDE STAT; 1990, SAS P200 SAS I INC S; 1992, POPULATION CHANGES 1, V3; 1988, SWEDISH STANDARD CLA, V1, P4	29	197	206	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					886	890						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640617				2022-12-28	WOS:A1992JH58800039
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - APPENDICITIS	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND.			Jones, David/0000-0001-5743-8562					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					44	47		10.1136/bmj.305.6844.44	http://dx.doi.org/10.1136/bmj.305.6844.44			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638204	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JC79900036
J	OREILLY, SE; CONNORS, JM				OREILLY, SE; CONNORS, JM			CURRENT ISSUES IN CANCER .9. NON-HODGKINS-LYMPHOMA .2. MANAGEMENT PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							THERAPY; ADULTS				OREILLY, SE (corresponding author), BRITISH COLUMBIA CANC AGCY,VANCOUVER V5Z 4E6,BC,CANADA.		Connors, Joseph/AAF-5284-2019	Connors, Joseph/0000-0002-1361-7531				CABANILLAS F, 1982, BLOOD, V60, P693; CABANILLAS F, 1991, ANN ONCOL, V1, P31; COLEMAN CN, 1986, J CLIN ONCOL, V4, P1628, DOI 10.1200/JCO.1986.4.11.1628; JACOBS C, 1985, INT J RADIAT ONCOL, V11, P357, DOI 10.1016/0360-3016(85)90158-0; KOHN EC, 1990, J CLIN ONCOL, V8, P155, DOI 10.1200/JCO.1990.8.1.155; MAGRATH IT, 1984, BLOOD, V63, P1102; OREILLY SE, 1991, J CLIN ONCOL, V9, P741, DOI 10.1200/JCO.1991.9.5.741; OREILLY SE, 1992, BRIT MED J, V304, P1682, DOI 10.1136/bmj.304.6843.1682; OREILLY SE, 1992, P AM SOC CLIN ONCOL, V11, P326; PHILIP T, 1987, NEW ENGL J MED, V24, P316; ROSENFELT F, 1980, CANCER, V45, P2188, DOI 10.1002/1097-0142(19800415)45:8<2188::AID-CNCR2820450830>3.0.CO;2-E; STARZL TE, 1984, LANCET, V1, P53; VELASQUEZ WS, 1988, BLOOD, V71, P117; VOSE JM, 1988, J CLIN ONCOL, V6, P1838, DOI 10.1200/JCO.1988.6.12.1838; WEISENBURGER DD, 1987, BLOOD, V69, P1617	15	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					39	42		10.1136/bmj.305.6844.39	http://dx.doi.org/10.1136/bmj.305.6844.39			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638201	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JC79900034
J	ADAM, SA; GERACE, L				ADAM, SA; GERACE, L			CYTOSOLIC PROTEINS THAT SPECIFICALLY BIND NUCLEAR LOCATION SIGNALS ARE RECEPTORS FOR NUCLEAR IMPORT	CELL			English	Article							LARGE-T-ANTIGEN; RAT-LIVER NUCLEI; ASP-GLU-ASP; PORE COMPLEX; SEQUENCE REQUIREMENTS; TRANSPORT SIGNALS; MAMMALIAN-CELLS; LOCALIZATION; TRANSLOCATION; ENVELOPE	We have purified two major polypeptides of 54 and 56 kd from bovine erythrocytes that specifically bind the nuclear location sequence (NLS) of the SV40 large T antigen. When added to a permeabilized cell system for nuclear import, the purified proteins increase by 2- to 3-fold the nuclear accumulation of a fluorescent protein containing the large T antigen NLS. The import stimulation is saturable and dependent upon the presence of cytosol. Nuclear protein accumulation in vitro is sensitive to inactivation by N-ethylmaleimide (NEM). NEM inactivation can be overcome by addition of the purified NLS-binding proteins to the import system. NEM treatment of the purified proteins abolishes their ability to stimulate import but does not affect NLS binding. Our results indicate that the NLS-binding proteins are NEM-sensitive receptors for nuclear import. At least one other NEM-sensitive cytosolic activity and an NEM-insensitive cytosolic activity are also necessary for protein import in vitro.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	ADAM, SA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.			Adam, Stephen/0000-0003-3444-7655				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MANDELL RB, 1990, J CELL BIOL, V111, P1175; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MEHLIN H, 1988, CELL BIOL INT REP, V12, P729, DOI 10.1016/0309-1651(88)90086-0; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TOGNON M, 1981, J VIROL, V40, P870, DOI 10.1128/JVI.40.3.870-880.1981; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WHITE EM, 1989, J CELL BIOL, V109, P1983, DOI 10.1083/jcb.109.5.1983; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3	61	370	378	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					837	847		10.1016/0092-8674(91)90431-W	http://dx.doi.org/10.1016/0092-8674(91)90431-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653647				2022-12-28	WOS:A1991GE46000004
J	HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG				HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG			POSSIBLE HORIZONTAL TRANSFER OF DROSOPHILA GENES BY THE MITE PROCTOLAELAPS-REGALIS	SCIENCE			English	Article							SCAPTOMYZA-PALLIDA DROSOPHILIDAE; P-TRANSPOSABLE ELEMENTS; SALTANS SPECIES GROUPS; HYBRID DYSGENESIS; ENZYMATIC AMPLIFICATION; HOMOLOGOUS SEQUENCES; MELANOGASTER GENOME; OBSCURA GROUP; DNA; POPULATIONS	There is strong inferential evidence for recent horizontal gene transfer of the P (mobile) element to Drosophila melanogaster from a species of the Drosophila willistoni group. One potential vector of this transfer is a semiparasitic mite, Proctolaelaps regalis DeLeon, whose morphology, behavior, and co-occurrence with Drosophila are consistent with the properties necessary for such a vector. Southern blot hybridization, polymerase chain reaction (PCR) amplification, and DNA sequencing showed that samples of P. regalis associated with a P strain of D. melanogaster carried P element sequences. Similarly, Drosophila ribosomal DNA sequences were identified in P. regalis samples that had been associated with Drosophila cultures. These result, have potentially important evolutionary implications, not only for understanding the mechanisms by which genes may be transferred between reproductively isolated species, but also for improved detection of some host-parasite and predator-prey relationships.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV ARIZONA,DEPT ECOL & EVOLUT BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					PHS HHS [36715] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; ANXOLABEHERE D, 1985, GENET SEL EVOL, V17, P579, DOI 10.1186/1297-9686-17-4-579; APPENZELLER T, 1990, SCIENCE, V247, P1030, DOI 10.1126/science.2309117; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BROOKFIELD JFY, 1984, NATURE, V310, P330, DOI 10.1038/310330a0; Cantelo WW, 1973, DROSOPHILA INF SERV, V50, P163; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; DANIELS SB, 1987, GENETICS, V115, P711; DANIELS SB, 1986, J MOL EVOL, V23, P138, DOI 10.1007/BF02099908; DANIELS SB, 1990, GENETICS, V129, P399; DELEON D, FLA ENTOMOL, V196; Ehrman L., 1982, Genetics and Biology of Drosophila, V3b, P193; Engels W.R, 1989, MOBILE DNA, P437; Evans G. O, 1961, TERRESTRIAL ACARI BR, V1; GOOD AG, 1989, GENETICS, V122, P387; HAGEMANN S, 1990, J MOL EVOL, V31, P478, DOI 10.1007/BF02102074; Hammen L, 1964, ZOOLOGISCHE VERHANDE, V71; IWANO M, 1984, JPN J GENET, V59, P403, DOI 10.1266/jjg.59.403; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KIYASU PK, 1984, GENET RES, V44, P251, DOI 10.1017/S0016672300026495; KONDO S, 1985, P NATL ACAD SCI USA, V82, P6236; Krantz G.W, 1978, MANUAL ACAROLOGY, Vsecond; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Woolley TA, 1988, ACAROLOGY MITES HUMA	32	202	208	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1125	1129		10.1126/science.1653453	http://dx.doi.org/10.1126/science.1653453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653453				2022-12-28	WOS:A1991GD80800028
J	GOODWIN, FK				GOODWIN, FK			DIAZEPAM AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J DRUG ALCOHOL AB, V17, P129	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-28	WOS:A1991GB97500006
J	RAPRAEGER, AC; KRUFKA, A; OLWIN, BB				RAPRAEGER, AC; KRUFKA, A; OLWIN, BB			REQUIREMENT OF HEPARAN-SULFATE FOR BFGF-MEDIATED FIBROBLAST GROWTH AND MYOBLAST DIFFERENTIATION	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; SKELETAL-MUSCLE MYOBLASTS; PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; SWISS-3T3 CELLS; FACTOR RECEPTOR; AFFINITY; BINDING; CLONING; IDENTIFICATION	Basic fibroblast growth factor (bFGF) binds to heparan sulfate proteoglycans at the cell surface and to receptors with tyrosine kinase activity. Prevention of binding between cell surface heparan sulfate and bFGF (i) substantially reduces binding of fibroblast growth factor to its cell-surface receptors, (ii) blocks the ability of bFGF to support the growth of Swiss 3T3 fibroblasts, and (iii) induces terminal differentiation of MM14 skeletal muscle cells, which is normally repressed by fibroblast growth factor. These results indicate that cell surface heparan sulfate is directly involved in bFGF cell signaling.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	RAPRAEGER, AC (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014	Krufka, Alison/0000-0002-8921-6291	NIAMS NIH HHS [AR39467, R01 AR039467] Funding Source: Medline; NICHD NIH HHS [HD21881] Funding Source: Medline; PHS HHS [5T32H007118] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039467, R01AR039467] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HUANG SS, 1986, BIOCHEM BIOPH RES CO, V139, P619, DOI 10.1016/S0006-291X(86)80035-3; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KRUFKA A, 1990, Journal of Cell Biology, V111, p223A; KRUFKA A, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LORIES V, 1989, J BIOL CHEM, V264, P7009; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, UNPUB; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, UNPUB; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	1420	1462	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1705	1708		10.1126/science.1646484	http://dx.doi.org/10.1126/science.1646484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1646484				2022-12-28	WOS:A1991FT11400046
J	HOUAMED, KM; KUIJPER, JL; GILBERT, TL; HALDEMAN, BA; OHARA, PJ; MULVIHILL, ER; ALMERS, W; HAGEN, FS				HOUAMED, KM; KUIJPER, JL; GILBERT, TL; HALDEMAN, BA; OHARA, PJ; MULVIHILL, ER; ALMERS, W; HAGEN, FS			CLONING, EXPRESSION, AND GENE STRUCTURE OF A G-PROTEIN-COUPLED GLUTAMATE RECEPTOR FROM RAT-BRAIN	SCIENCE			English	Article							AMINO-ACID RECEPTORS; INOSITOL PHOSPHOLIPID-METABOLISM; CENTRAL NERVOUS-SYSTEM; XENOPUS OOCYTES; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; FUNCTIONAL EXPRESSION; INTRACELLULAR CALCIUM; ENDOGENOUS CHANNELS; MOLECULAR-CLONING	A complementary DNA encoding a G protein-coupled glutamate receptor from rat brain, Glu(G)R, was cloned by functional expression in Xenopus oocytes. The complementary DNA encodes a protein of 1199 amino acids containing a seven-transmembrane motif, flanked by large amino- and carboxyl-terminal domains. This receptor lacks any amino acid sequence similarity with other G protein-coupled receptors, suggesting that it may be a member of a new subfamily. The presence of two introns flanking the central core suggests that Glu(G)R may have evolved by exon shuffling. Expressed in oocytes, Glu(G)R is activated by quisqualate > glutamate > ibotenate > trans-1-aminocyclopentyl-1,3-dicarboxylate, and it is inhibited by 2-amino-3-phosphonopropionate. Activation is blocked by Bordella pertussis toxin. These properties are typical of some metabotropic glutamate receptors.	ZYMOGENET, DEPT MOLEC & CELLULAR BIOL, 4225 ROOSEVELT WAY NE, SEATTLE, WA 98105 USA; UNIV WASHINGTON, SCH MED, DEPT PHYSIOL & BIOPHYS, SEATTLE, WA 98195 USA; ZYMOGENET, DEPT DNA CHEM, SEATTLE, WA 98105 USA	Zymogenet Inc.; University of Washington; University of Washington Seattle; Zymogenet Inc.					NIAMS NIH HHS [AR 17803] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017803, R01AR017803] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLACKSTONE CD, 1989, P NATL ACAD SCI USA, V86, P4316, DOI 10.1073/pnas.86.11.4316; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; FONG TM, 1988, SYNAPSE, V2, P657, DOI 10.1002/syn.890020613; FURUYA S, 1989, J PHYSIOL-LONDON, V414, P539, DOI 10.1113/jphysiol.1989.sp017702; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KYTE J, 1982, J MOL BIOL, V157, P132; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI O, 1990, MOL PHARMACOL, V38, P1; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULVIHILL E, UNPUB; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; NICOLETTI F, 1988, NEUROPHARMACOLOGY, V27, P551, DOI 10.1016/0028-3908(88)90174-8; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OOSAWA Y, 1989, J PHYSIOL-LONDON, V408, P223, DOI 10.1113/jphysiol.1989.sp017456; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1989, J NEUROCHEM, V53, P273, DOI 10.1111/j.1471-4159.1989.tb07324.x; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; STRATTON KR, 1989, EUR J PHARMACOL, V173, P235, DOI 10.1016/0014-2999(89)90529-3; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; SUGIYAMA H, 1989, NEURON, V3, P129, DOI 10.1016/0896-6273(89)90121-9; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; THORPE DS, 1989, J BIOL CHEM, V264, P6454; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATSON GB, 1990, EUR J PHARMACOL, V179, P479, DOI 10.1016/0014-2999(90)90194-B	45	512	554	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1318	1321		10.1126/science.1656524	http://dx.doi.org/10.1126/science.1656524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1656524				2022-12-28	WOS:A1991FN85700044
J	SCHATTEN, C; PATEISKY, N; VAVRA, N; EHRENBOCK, P; ANGELBERGER, P; SIVOLAPENKO, G; EPENETOS, A				SCHATTEN, C; PATEISKY, N; VAVRA, N; EHRENBOCK, P; ANGELBERGER, P; SIVOLAPENKO, G; EPENETOS, A			LYMPHOSCINTIGRAPHY WITH I-123 LABELED EPIDERMAL GROWTH-FACTOR	LANCET			English	Note							RADIOLABELED MONOCLONAL-ANTIBODIES; FACTOR RECEPTOR; LOCALIZATION; CANCER	We have used I-123-labelled epidermal growth factor (EGF) scans to study 14 patients with advanced cervical cancer. Abnormal lymph node imaging was seen most clearly 6-8 h after the injection and revealed abnormal uptake by pelvic lymph nodes in 11 patients. 4 of these 11 had abnormal computerised tomographic and ultrasound scans; in the other 7 conventional radiology did not confirm the presence of disease.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON W12 0HS,ENGLAND; UNIV VIENNA,DEPT OBSTET & GYNAECOL 1,A-1010 VIENNA,AUSTRIA; AUSTRIAN RES CTR,DEPT RADIOPHARM,SEIBERSDORF,AUSTRIA	Cancer Research UK; Imperial College London; University of Vienna; Austrian Institute of Technology (AIT)				Sivolapenko, Gregory/0000-0003-2388-362X				DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EPENETOS AA, 1986, CANCER RES, V46, P3183; EPENETOS AA, 1985, BRIT MED J, V290, P1463, DOI 10.1136/bmj.290.6480.1463; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P49; GITSCH E, 1984, J NUCL MED, V25, P486; KALOFONOS HP, 1989, J NUCL MED, V30, P1636; KRENNING EP, 1989, LANCET, V1, P242; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; SANTON JB, 1986, CANCER RES, V46, P4701	9	35	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					395	396		10.1016/0140-6736(91)91169-U	http://dx.doi.org/10.1016/0140-6736(91)91169-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671427				2022-12-28	WOS:A1991EX60500007
J	CRAWFORD, CL; HOBBS, MJ				CRAWFORD, CL; HOBBS, MJ			INFANTILE PARALYSIS IN DEVELOPING-COUNTRIES - IS IT POLIOMYELITIS OR DIPLEGIA	LANCET			English	Editorial Material							SERIOUS PROBLEM				CRAWFORD, CL (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND.							ALLBROOK D, 1960, LANCET, V1, P459; BANNISTER R, 1985, BRAINS CLIN NEUROLOG, P328; BAZIN M, 1980, NATURE, V285, P7; BURNETT M, 1962, NATURAL HIST INFECTI, P91; CRAWFORD C L, 1968, Leprosy Review, V39, P9; HARRIES JR, 1973, TROPICAL NEUROLOGY, P213; HUCKSTEP RL, 1975, POLIOMYELITIS, P6; LAFORCE FM, 1980, B WORLD HEALTH ORGAN, V58, P609; MIMS CA, 1976, PATHOGENESIS INFECTI, P202; MODLIN JF, 1990, PRINCIPLES PRACTICE, P1359; NICHOLAS DD, 1977, BRIT MED J, V1, P1009, DOI 10.1136/bmj.1.6067.1009; OFOSUAMAAH S, 1977, BRIT MED J, V1, P1012, DOI 10.1136/bmj.1.6067.1012; POSKANZER DC, 1963, LANCET, V2, P917; SHARRARD WJW, 1955, J BONE JOINT SURG BR, V37, P540, DOI 10.1302/0301-620X.37B4.540; WALKER A J, 1956, East Afr Med J, V33, P169; WILSON SAK, 1954, NEUROLOGY, V2, P891; 1990, B WORLD HEALTH ORGAN, V68, P115	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					284	286		10.1016/0140-6736(91)90883-Q	http://dx.doi.org/10.1016/0140-6736(91)90883-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671124				2022-12-28	WOS:A1991EV71900016
J	BARKER, JNWN; MITRA, RS; GRIFFITHS, CEM; DIXIT, VM; NICKOLOFF, BJ				BARKER, JNWN; MITRA, RS; GRIFFITHS, CEM; DIXIT, VM; NICKOLOFF, BJ			KERATINOCYTES AS INITIATORS OF INFLAMMATION	LANCET			English	Review							INTERCELLULAR-ADHESION MOLECULE-1; RECOMBINANT GAMMA-INTERFERON; CULTURED HUMAN KERATINOCYTES; HLA-DR EXPRESSION; IRRADIATION; INHIBITION; INVITRO; ICAM-1; CELLS; SKIN	Environmental stimuli responsible for inducing cutaneous inflammation include contact allergens and ultraviolet light. We postulate that these diverse stimuli trigger a cutaneous inflammatory response by directly inducing epidermal keratinocytes to elaborate specific pro-inflammatory cytokines and adhesion molecules. The consequences are activation of dermal microvascular endothelial cells and selective accumulation of specific monocuclear cells in the dermis and epidermis. Thus, keratinocytes may act as "signal transducers", capable of converting exogenous stimuli into the production of cytokines, adhesion molecules, and chemotactic factors (acting in an autocrine and paracrine fashion) responsible for initiation of "antigen-independent" cutaneous inflammation. The initiation phase may facilitate or promote an amplification phase with additional production of tumour-necrosis factor alpha and interferon gamma via an "antigen-dependent" pathway, and keratinocyte/T cell/antigen-presenting dendritic cellular associations. The direct activation of keratinocytes, with their ability to produce the complete repertoire of pro-inflammatory cytokines, can profoundly influence endogenous and recruited immunocompetent cells, thereby providing the critical trigger responsible for the swift and clinically dramatic alterations that occur following contact between the epidermis and a host of "noxious" agents.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE ST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT DERMATOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Griffiths, Christopher E.M./P-5448-2014; dixit, vishva m/A-4496-2012	Griffiths, Christopher E.M./0000-0001-5371-4427; dixit, vishva m/0000-0001-6983-0326; Barker, Jonathan/0000-0002-9030-183X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040065, F32AR008123] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR31857, AR40065, AR08123] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANSEL JC, 1983, J INVEST DERMATOL, V81, P519, DOI 10.1111/1523-1747.ep12522862; AUBOCK J, 1986, BRIT J DERMATOL, V114, P467; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; BARKER JNWN, 1989, BRIT J DERMATOL, V120, P613, DOI 10.1111/j.1365-2133.1989.tb01345.x; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; BARKER JNWN, 1991, J IMMUNOL, V146, P1192; BASHAM TY, 1984, J INVEST DERMATOL, V83, P88, DOI 10.1111/1523-1747.ep12262597; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; FISHER GJ, IN PRESS J INVEST DE; GRANSTEIN RD, 1987, LYMPHOKINE RES, V6, P187; GRIFFITHS CEM, 1989, AM J PATHOL, V135, P1045; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; GRIFFITHS CEM, 1990, BRIT J DERMATOL, V122, P333, DOI 10.1111/j.1365-2133.1990.tb08281.x; GRIFFITHS CEM, IN PRESS BR J DERMAT; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; KIRNBAUER R, 1989, J IMMUNOL, V142, P1922; KOCK A, 1989, J INVEST DERMATOL, V92, pA462; KRUEGER G, 1990, J INVEST DERMATOL, V94, P545; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LUGER TA, 1981, J IMMUNOL, V127, P1493; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; NICKOLOFF BJ, 1990, AM J PATHOL, V136, P261; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; NICKOLOFF BJ, 1988, ARCH DERMATOL, V124, P1835, DOI 10.1001/archderm.124.12.1835; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V95, P355; NORRIS DA, 1990, CLIN RES, V38, P285; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICARDO M, 1990, BRIT J DERMATOL, V122, P729, DOI 10.1111/j.1365-2133.1990.tb06259.x; SIMON JC, 1990, CLIN RES, V38, P285; SPORN SA, 1990, J IMMUNOL, V144, P4434; STINGL G, 1989, IMMUNE MECHANISMS CU, P3; URBANSKI A, 1990, J INVEST DERMATOL, V94, P808, DOI 10.1111/1523-1747.ep12874666; WEISSMANN G, 1986, P NATL ACAD SCI USA, V83, P2914, DOI 10.1073/pnas.83.9.2914	36	620	631	2	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					211	214		10.1016/0140-6736(91)92168-2	http://dx.doi.org/10.1016/0140-6736(91)92168-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670850	Green Submitted			2022-12-28	WOS:A1991EU92400013
J	PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F				PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F			LEISHMANIA-DONOVANI-CHAGASI - NEW CLINICAL VARIANT OF CUTANEOUS LEISHMANIASIS IN HONDURAS	LANCET			English	Article							INFANTUM SENSU-LATO; MONOCLONAL-ANTIBODIES; IDENTIFICATION	During surveillance for endemic visceral leishmaniasis on an island off the Pacific coast of Honduras, an unusual form of cutaneous leishmaniasis was encountered. By clinical and laboratory criteria, 17 cases were identified over 5 months; children aged 4 to 15 years were primarily affected. Lesions were generally few in number, small, always papular, and non-ulcerative, even when present for several years. Patients with skin lesions seemed otherwise healthy and were well nourished. Montenegro skin tests with Leishmania mexicana and L major antigens were positive in 10 of 17 patients tested, and lesions from 9 patients were positive by culture. Since the summer of 1988, cases of atypical cutaneous leishmaniasis continue to occur on the island (8) as well as on the mainland of southern Honduras (23). A total of 9 parasite isolates from skin lesions, 4 from bone marrow of patients with kala-azar, and 2 from sandflies were identified as L donovani chagasi and were indistinguishable from one another by isoenzyme analysis.	NIAID, PARASIT DIS LAB, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA; YALE UNIV, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YOUNGSTOWN STATE UNIV, DEPT BIOL, YOUNGSTOWN, OH 44555 USA; HOSP ESCUELA TEGUCIGALPA, TEGUCIGALPA, HONDURAS; MINIST HLTH, CENT LAB, TEGUCIGAL, HONDURAS	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; University System of Ohio; Youngstown State University				Morrison, Amy/0000-0001-6224-5984				BELAZZOUG S, 1985, ANN PARASIT HUM COMP, V60, P1; CAHILL KM, 1964, AM J TROP MED HYG, V13, P794, DOI 10.4269/ajtmh.1964.13.794; GRAMICCIA M, 1989, T ROY SOC TROP MED H, V83, P76, DOI 10.1016/0035-9203(89)90713-X; GRAMICCIA M, 1987, T ROY SOC TROP MED H, V81, P235, DOI 10.1016/0035-9203(87)90225-2; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; JAFFE CL, 1984, J IMMUNOL, V133, P440; KILLICKKENDRICK R, 1980, ANN TROP MED PARASIT, V74, P563, DOI 10.1080/00034983.1980.11687385; KREUTZER RD, 1980, AM J TROP MED HYG, V29, P199, DOI 10.4269/ajtmh.1980.29.199; KREUTZER RD, 1983, AM J TROP MED HYG, V32, P703, DOI 10.4269/ajtmh.1983.32.703; KUMAR PV, 1989, AM J TROP MED HYG, V40, P150, DOI 10.4269/ajtmh.1989.40.150; LAINSON R, 1979, BIOL KINETOPLASTIDA, V2, P68; MANSONBAHR PEC, 1955, NATURE, V175, P433, DOI 10.1038/175433b0; NAVIN TR, 1987, AM J TROP MED HYG, V35, P1069; NETO MPO, 1986, ANN TROP MED PARASIT, V80, P587, DOI 10.1080/00034983.1986.11812072; NETO MPO, 1986, MEM I O CRUZ, V81, P303; PRATA A., 1956, Hospital (Rio de Janeiro, Brazil), V49, P481; REES PH, 1987, LEISHMANIASES BIOL M, V2, P605; ZELEDON R, 1989, T ROY SOC TROP MED H, V83, P786, DOI 10.1016/0035-9203(89)90328-3	18	85	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	1991	337	8733					67	70		10.1016/0140-6736(91)90734-7	http://dx.doi.org/10.1016/0140-6736(91)90734-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670724				2022-12-28	WOS:A1991ER47700002
J	JOHNSON, E				JOHNSON, E			NEUROPSYCHOLOGICAL IMPAIRMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, AM J DRUG ALCOHOL AB, V192, P131	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640596				2022-12-28	WOS:A1992JH58800009
J	STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH				STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH			A PROSPECTIVE-STUDY OF PLASMA HOMOCYST(E)INE AND RISK OF MYOCARDIAL-INFARCTION IN UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BETA-SYNTHASE DEFICIENCY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ENDOTHELIAL-CELL INJURY; VASCULAR-DISEASE; HOMOCYSTEINE; HOMOCYSTINURIA; HYPERHOMOCYST(E)INEMIA; PREVALENCE; CAROTENE	Objective.-To assess prospectively the risk of coronary heart disease associated with elevated plasma levels of homocyst(e)ine. Design.-Nested case-control study using prospectively collected blood samples. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 14916 male physicians, aged 40 to 84 years, with no prior myocardial infarction (MI) or stroke provided plasma samples at baseline and were followed up for 5 years. Samples from 271 men who subsequently developed MI were analyzed for homocyst(e)ine levels together with paired controls, matched by age and smoking. Main Outcome Measure.-Acute MI or death due to coronary disease. Results.-Levels of homocyst(e)ine were higher in cases than in controls (11.1+/-4.0 [SD] vs 10.5+/-2.8 nmol/mL; P=.03). The difference was attributable to an excess of high values among men who later had MIs. The relative risk for the highest 5% vs the bottom 90% of homocyst(e)ine levels was 3.1 (95% confidence interval, 1.4 to 6.9; P=.005). After additional adjustment for diabetes, hypertension, aspirin assignment, Quetelet's Index, and total/high-density lipoprotein cholesterol, this relative risk was 3.4 (95% confidence interval, 1.3 to 8.8) (P=.01). Thirteen controls and 31 cases (11%) had values above the 95th percentile of the controls. Conclusions.- Moderately high levels of plasma homocyst(e)ine are associated with subsequent risk of MI independent of other coronary risk factors. Because high levels can often be easily treated with vitamin supplements, homocyst(e)ine may be an independent, modifiable risk factor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT COMMUNITY & PREVENT MED,PORTLAND,OR 97201; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Harvard University; Harvard Medical School	STAMPFER, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA42182] Funding Source: Medline; NHLBI NIH HHS [HL26490, HL34595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KATRANGI N, 1984, J LIPID RES, V25, P400; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MALINOW MR, 1992, NUTR METAB CARDIOVAS, V1, P166; MANORE MM, 1989, AM J CLIN NUTR, V50, P339, DOI 10.1093/ajcn/50.2.339; MEREAURICHARD C, 1991, CLIN CHEM, V37, P126; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; Polansky M. M., 1985, METHODS VITAMIN ASSA, P417; REED T, 1991, CLIN GENET, V39, P425; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; SMOLIN LA, 1981, J PEDIATR-US, V99, P467, DOI 10.1016/S0022-3476(81)80352-6; SMOLIN LA, 1988, ANAL BIOCHEM, V168, P374, DOI 10.1016/0003-2697(88)90332-6; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1985, METABOLISM, V34, P1115, DOI 10.1016/0026-0495(85)90156-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; 1971, 5TH WORK GROUP COP	36	1391	1455	2	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					877	881		10.1001/jama.268.7.877	http://dx.doi.org/10.1001/jama.268.7.877			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640615				2022-12-28	WOS:A1992JH58800037
J	RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A				RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A			THE SMALL GTP-BINDING PROTEIN RAC REGULATES GROWTH-FACTOR INDUCED MEMBRANE RUFFLING	CELL			English	Article								The function of rac, a ras-related GTP-binding protein, was investigated in fibroblasts by microinjection. In confluent serum-starved Swiss 3T3 cells, rac1 rapidly stimulated actin filament accumulation at the plasma membrane, forming membrane ruffles. Several growth factors and activated H-ras also induced membrane ruffling, and this response was prevented by a dominant inhibitory mutant rac protein, N17rac1. This suggests that endogenous rac proteins are required for growth factor-induced membrane ruffling. In addition to membrane ruffling, a later response to both rac1 microinjection and some growth factors was the formation of actin stress fibers, a process requiring endogenous rho proteins. Using N17rac1 we have shown that these growth factors act through rac to stimulate this rho-dependent response. We propose that rac and rho are essential components of signal transduction pathways linking growth factors to the organization of polymerized actin.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST, INST CANC RES, FULHAM RD, LONDON SW3 6JB, ENGLAND.			Tapon, Dagmar/0000-0003-3837-4764; Ridley, Anne/0000-0001-8186-5708				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BARSAGI D, 1987, J CELL PHYSIOL, P69; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KELLER HU, 1990, J CELL SCI, V96, P99; KELLER HU, 1990, J CELL PHYSIOL, V145, P465, DOI 10.1002/jcp.1041450311; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOLL J, 1991, ONCOGENE, V6, P863; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; ROZENGURT E, 1989, BRIT MED BULL, V45, P515, DOI 10.1093/oxfordjournals.bmb.a072339; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBUE K, 1988, P NATL ACAD SCI USA, V85, P482, DOI 10.1073/pnas.85.2.482; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	45	3172	3239	2	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					401	410		10.1016/0092-8674(92)90164-8	http://dx.doi.org/10.1016/0092-8674(92)90164-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643658	Bronze			2022-12-28	WOS:A1992JH12400005
J	HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA				HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA			PHYSIOLOGICAL AND BEHAVIORAL THERMOREGULATION IN BIGEYE TUNA (THUNNUS-OBESUS)	NATURE			English	Article							FISH; MOVEMENTS	TUNA are unique among teleost fishes in being thermoconserving. Vascular counter-current heat exchangers maintain body temperatures above ambient water temperature, thereby improving locomotor muscle efficiency, especially at burst speeds and when pursuing prey below the thermocline1-6. Because tuna also occasionally swim rapidly in warm surface waters, it has been hypothesized that tuna thermoregulate to accommodate changing activity levels or ambient temperatures7. But previous field experiments have been unable to demonstrate definitively short-latency, mammalian-type physiological thermoregulation8,9. Here we show using telemetered data that free-ranging bigeye tuna (Thunnus obesus) can rapidly alter whole-body thermal conductivity by two orders of magnitude. The heat exchangers are disengaged to allow rapid warming as the tuna ascend from cold water into warmer surface waters, and are reactivated to conserve heat when they return into the depths. Combining physiological and behavioural thermoregulation expands the foraging space of bigeye tuna into otherwise prohibitively cold, deep water.	NATL MARINE FISHERIES SERV,HONOLULU LAB,HONOLULU,HI 96822; OTTER RES LTD,NANAIMO,BC,CANADA	National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA	HOLLAND, KN (corresponding author), HAWAII INST MARINE BIOL,POB 1346,COCONUT ISL,KANEOHE,HI 96744, USA.		Holland, Kim/ABH-1490-2021					[Anonymous], 1978, FISH PHYSL; AXELSSON M, 1986, J EXP BIOL, V126, P225; CAREY FG, 1973, SCI AM, V228, P36, DOI 10.1038/scientificamerican0273-36; CAREY FG, 1973, COMP BIOCHEM PHYSIOL, V44, P375, DOI 10.1016/0300-9629(73)90490-8; CAREY FG, 1987, PHYSIOL ZOOL, V60, P138, DOI 10.1086/physzool.60.1.30158635; CAREY FG, 1990, MAR BIOL, V106, P329, DOI 10.1007/BF01344309; Carey FG, 1990, PLANNING FUTURE BILL, P103; DIZON AE, 1979, AM ZOOL, V19, P249; DIZON AE, 1976, J THERM BIOL, V1, P18; Graham J.B., 1978, P113; Graham J.B., 1983, P248; GRAHAM JB, 1975, FISH B-NOAA, V73, P219; GRAHAM JB, 1981, PHYSIOL ZOOL, V54, P470, DOI 10.1086/physzool.54.4.30155840; GREIWANK A, 1991, AUTOMATIC DIFFERENTI; HOLLAND K, 1985, MAR FISH REV, V47, P26; HOLLAND KN, 1990, FISH B-NOAA, V88, P493; NEILL W H, 1976, Environmental Biology of Fishes, V1, P61, DOI 10.1007/BF00761729; NEILL WS, 1974, SCIENCE, V184, P8; STEFFEL S, 1976, T AM FISH SOC, V105, P558; STEVENS ED, 1974, J EXP BIOL, V61, P145; 1991, AUTODIF A C PLUS PLU	21	180	190	5	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					410	412		10.1038/358410a0	http://dx.doi.org/10.1038/358410a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641023				2022-12-28	WOS:A1992JF85300054
J	WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA				WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA			A PHOSPHORYLATION SITE IN THE NA+ CHANNEL REQUIRED FOR MODULATION BY PROTEIN-KINASE-C	SCIENCE			English	Article							SODIUM-CHANNEL; RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; SKELETAL-MUSCLE; MESSENGER-RNAS; EXPRESSION; INACTIVATION; ACTIVATION; SEQUENCE	Voltage-gated sodium channels are responsible for generation of action potentials in excitable cells. Activation of protein kinase C slows inactivation of sodium channels and reduces peak sodium currents. Phosphorylation of a single residue, serine 1506, that is located in the conserved intracellular loop between domains III and IV and is involved in inactivation of the sodium channel, is required for both modulatory effects. Mutant sodium channels lacking this phosphorylation site have normal functional properties in unstimulated cells but do not respond to activation of protein kinase C. Phosphorylation of this conserved site in sodium channel alpha-subunits may regulate electrical activity in a wide range of excitable cells.			WEST, JW (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751, R01NS025704] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEGG C, 1977, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B, 1984, IONIC CHANNELS EXCIT; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SARAO R, IN PRESS NUCLEIC ACI; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	29	237	241	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					866	868		10.1126/science.1658937	http://dx.doi.org/10.1126/science.1658937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658937				2022-12-28	WOS:A1991GN83300048
J	SHINDO, M; DIBISCEGLIE, AM; CHEUNG, L; SHIH, JWK; CRISTIANO, K; FEINSTONE, SM; HOOFNAGLE, JH				SHINDO, M; DIBISCEGLIE, AM; CHEUNG, L; SHIH, JWK; CRISTIANO, K; FEINSTONE, SM; HOOFNAGLE, JH			DECREASE IN SERUM HEPATITIS-C VIRAL-RNA DURING ALPHA-INTERFERON THERAPY FOR CHRONIC HEPATITIS-C	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; POLYMERASE CHAIN-REACTION; NON-A; CONTROLLED TRIAL; BLOOD-DONORS; VIRUS; ANTIBODIES; SEQUENCES; GENOME; ALFA	Objective: To assess the effect of alpha-interferon therapy on hepatitis C viral RNA in serum of patients with chronic hepatitis C. Design: Retrospective testing for hepatitis C viral (HCV) RNA and antibody to the hepatitis C virus (anti-HCV) of stored serum samples from a randomized, double-blind, placebo-controlled trial of alpha-interferon therapy. Setting: Warren Grant Magnuson Clinical Center of the National Institutes of Health, a tertiary referral center. Patients: Forty-one patients with chronic non-A, non-B hepatitis were entered in this trial. Interventions: Twenty-one patients were treated with alpha-interferon, and 20 patients were treated with placebo for 6 months. Seventeen placebo recipients were then treated with alpha-interferon for up to 1 year. Methods: Samples were tested for anti-HCV by enzyme-linked immunosorbent assay. Hepatitis C viral RNA was detected in serum using the polymerase chain reaction. Titers of both antibody and RNA were determined by serial end-point dilution. Main Results: At entry into the trial, 37 (90%) of 41 patients had anti-HCV and 39 (95%) had HCV RNA in serum. Anti-HCV titers decreased slightly with treatment. Serum levels of HCV RNA decreased in all patients who responded to alpha-interferon therapy with improvements in serum aminotransferases; in 17 of 21 responders (81%; 95% CI, 58% to 95%) HCV RNA became undetectable. In contrast, in only 2 of 16 (12%; CI, 2% to 38%) patients who did not respond to treatment did HCV RNA become undetectable. In 19 patients treated during the preliminary 6-month period with placebo, HCV RNA remained detectable. Finally, in the 11 patients who relapsed when treatment was stopped, HCV RNA reappeared in the serum, but in 4 of 7 patients with a sustained improvement in serum aminotransferases, HCV RNA remained undetectable. Conclusions: These results indicate that the clinical and serum biochemical response to alpha-interferon in chronic hepatitis C is associated with a loss of detectable HCV genome from serum.	US FDA, ROCKVILLE, MD 20857 USA	US Food & Drug Administration (FDA)	SHINDO, M (corresponding author), NIH, LIVER DIS SECT, BLD 10, ROOM 4D52, BETHESDA, MD 20892 USA.		Yang, Chen/G-1379-2010					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CRISTIANO K, 1991, IN PRESS VIRAL HEPAT; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; ESTEBAN JI, 1989, LANCET, V2, P294; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KANAI K, 1990, LANCET, V336, P245, DOI 10.1016/0140-6736(90)91768-6; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KUHNL P, 1989, LANCET, V2, P324; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; ROGGENDORF M, 1989, LANCET, V2, P324; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q	19	395	401	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					700	704		10.7326/0003-4819-115-9-700	http://dx.doi.org/10.7326/0003-4819-115-9-700			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1656828				2022-12-28	WOS:A1991GL69700006
J	PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D				PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D			GERMLINE MUTATIONS IN THE WILMS-TUMOR SUPPRESSOR GENE ARE ASSOCIATED WITH ABNORMAL UROGENITAL DEVELOPMENT IN DENYS-DRASH SYNDROME	CELL			English	Article							ZINC FINGER PROTEIN; P53 GENE; CHROMOSOME-11; DELETION; CANCER; LOCUS; DNA; PSEUDOHERMAPHRODITISM; BINDING; SRY	Denys-Drash syndrome is a rare human condition in which severe urogenital aberrations result in renal failure, pseudohermaphroditism, and Wilms' tumor (nephroblastoma). To investigate its possible role, we have analyzed the coding exons of the Wilms' tumor suppressor gene (WT1) for germline mutations. In ten independent cases of Denys-Drash syndrome, point mutations in the zinc finger domains of one WT1 gene copy were found. Nine of these mutations are found within exon 9 (zinc finger III); the remaining mutation is in exon 8 (zinc finger II). These mutations directly affect DNA sequence recognition. In two families analyzed, the mutations were shown to arise de novo. Wilms' tumors from three individuals and one juvenile granulosa cell tumor demonstrate reduction to homozygosity for the mutated WT1 allele. Our results provide evidence of a direct role for WT1 in Denys-Drash syndrome and thus urogenital system development.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV MINNESOTA,SCH MED,DEPT PEDIAT NEPHROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; HOP NECKER ENFANTS MALAD,INSERM,U73,F-75730 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U192,F-75730 PARIS 15,FRANCE; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; SUNY STONY BROOK,DEPT PEDIAT,STONY BROOK,NY 11794; CHILDRENS MEM HOSP,DIV PEDIAT ENDOCRINOL,CHICAGO,IL 60614; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114	McGill University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Oregon Health & Science University; Oregon Health & Science University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Ann & Robert H. Lurie Children's Hospital of Chicago; Harvard University; Harvard Medical School; Massachusetts General Hospital	PELLETIER, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [1K08CA 01356] Funding Source: Medline; NHGRI NIH HHS [HG00299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001356] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKWITH JB, 1989, PEDIATR PATHOL, V10, P1; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOND JV, 1975, LANCET, V2, P482; BRESLOW N, 1988, CANCER RES, V48, P1653; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FRASIER SD, 1964, J PEDIATR-US, V64, P740, DOI 10.1016/S0022-3476(64)80622-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLADE PR, 1976, PROG MED GENET, V1, P1; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, IN PRESS P NATL ACAD; HABIB R, 1985, CLIN NEPHROL, V24, P269; HUFF V, 1991, AM J HUM GENET, V48, P997; JADRESIC L, 1991, HUM GENET, V86, P497; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, IN PRESS MOL BASIS H; PELLETIER J, 1991, IN PRESS NATURE; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZUNIN C, 1964, ANN PAEDIATR-BASEL, V203, P29	50	783	803	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					437	447		10.1016/0092-8674(91)90194-4	http://dx.doi.org/10.1016/0092-8674(91)90194-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655284				2022-12-28	WOS:A1991GL47000022
J	MACEJAK, DG; SARNOW, P				MACEJAK, DG; SARNOW, P			INTERNAL INITIATION OF TRANSLATION MEDIATED BY THE 5' LEADER OF A CELLULAR MESSENGER-RNA	NATURE			English	Article							CAP-BINDING-PROTEIN; SECONDARY STRUCTURE; NONCODING REGION; POLIOVIRUS; VIRUS; CELLS; GENE; CONSERVATION; INVOLVEMENT; ADENOVIRUS	A RIBOSOME-SCANNING model has been proposed to explain the initiation of eukaryotic messenger RNAs 1 in which binding of the 43S ternary ribosomal subunit near or at the 5' end of the mRNA is facilitated by an interaction between the methylated cap-structure at the end of the mRNA and the cap-binding protein complex eIF-4F (refs 2, 3). But picornaviral mRNAs do not have a 5' terminal cap structure and are translated by internal ribosome binding 4-7. A cellular mRNA, encoding the immunoglobulin heavy-chain binding protein, can be translated in poliovirus-infected cells at a time when cap-dependent translation of host cell mRNAs is inhibited 8. We report here that the 5' leader of the binding protein mRNA can directly confer internal ribosome binding to an mRNA in mammalian cells, indicating that translation initiation by an internal ribosome-binding mechanism is used by eukaryotic mRNAs.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MACEJAK, DG (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,MOLEC BIOL PROGRAM,DENVER,CO 80262, USA.			Sarnow, Peter/0000-0002-2043-2770				Ausubel FM, 1988, MOL REPROD DEV; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BENERJEE AK, 1980, MICROBIOL REV, V44, P175; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275	24	462	711	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					90	94		10.1038/353090a0	http://dx.doi.org/10.1038/353090a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1652694				2022-12-28	WOS:A1991GD80500067
J	GOODWIN, FK				GOODWIN, FK			COCAINE WITHDRAWAL AND THE BRAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J PSYCHIAT, V148, P621	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-28	WOS:A1991GB97500007
J	DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A				DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A			THE PML-RAR-ALPHA FUSION MESSENGER-RNA GENERATED BY THE T(15-17) TRANSLOCATION IN ACUTE PROMYELOCYTIC LEUKEMIA ENCODES A FUNCTIONALLY ALTERED RAR	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; V-ERBA; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL EXPRESSION; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; GENE-EXPRESSION; VIRUS TYPE-1; ZINC FINGER	We have previously shown that the t(15; 17) translocation specifically associated with acute promyelocytic leukemia (APL) fuses the retinoic acid receptor-alpha (RAR-alpha) locus to an as yet unknown gene, initially called myl and now renamed PML. We report here that this gene product contains a novel zinc finger motif common to several DNA-binding proteins. The PML-RAR-alpha mRNA encodes a predicted 106 kd chimeric protein containing most of the PML sequences fused to a large part of RAR-alpha, including its DNA- and hormone-binding domains. In transient expression assays, the hybrid protein exhibits altered transactivating properties if compared with the wild-type RAR-alpha progenitor. Identical PML-RAR-alpha fusion points are found in several patients. These observations suggest that in APL, the t(15;17) translocation generates an RAR mutant that could contribute to leukemogenesis through interference with promyelocytic differentiation.	UNIV PARIS 07,BIOL CELLULAIRE HEMATOPOET LAB,F-75221 PARIS 05,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV MED NUCL,F-75010 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	DETHE, H (corresponding author), INST PASTEUR,INSERM,U163,UNITE RECOMBINAISON & EXPRESS GENET,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Dejean, Anne/L-5145-2018; Lavau, Catherine/Q-2928-2019	Lavau, Catherine/0000-0003-4800-1320; CHOMIENNE, Christine/0000-0001-5513-5752				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOEFFLER HP, 1985, CHRONIC ACUTE LEUKEM, P27; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	62	1245	1264	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					675	684		10.1016/0092-8674(91)90113-D	http://dx.doi.org/10.1016/0092-8674(91)90113-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652369				2022-12-28	WOS:A1991GC74500008
J	MCMANUS, IC				MCMANUS, IC			MEMBERSHIP EXAMINATIONS AND ROYAL-COLLEGE FINANCES	LANCET			English	Editorial Material											MCMANUS, IC (corresponding author), IMPERIAL COLL SCI TECHNOL MED,ST MARYS HOSP,SCH MED,PRAED ST,LONDON W2 1NY,ENGLAND.			McManus, Ian/0000-0003-3510-4814				[Anonymous], 1990, LANCET, V335, P443; BIRLEY JLT, 1990, LANCET, V335, P730; FLEMING PR, 1990, LANCET, V335, P1040, DOI 10.1016/0140-6736(90)91107-L; MARSTON A, 1990, LANCET, V335, P1594, DOI 10.1016/0140-6736(90)91425-A; MCMANUS IC, 1990, SEP ANN M ASS STUD M; SILVERSTONE PH, 1990, LANCET, V335, P730, DOI 10.1016/0140-6736(90)90849-Z; 1990, NATURE, V348, P2	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					414	415		10.1016/0140-6736(91)91178-W	http://dx.doi.org/10.1016/0140-6736(91)91178-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671436				2022-12-28	WOS:A1991EX60500016
J	MURPHY, SB; COHN, SL; CRAFT, AW; WOODS, WG; SAWADA, T; CASTLEBERRY, RP; LEVY, HL; PROROK, PC; HAMMOND, GD				MURPHY, SB; COHN, SL; CRAFT, AW; WOODS, WG; SAWADA, T; CASTLEBERRY, RP; LEVY, HL; PROROK, PC; HAMMOND, GD			DO CHILDREN BENEFIT FROM MASS-SCREENING FOR NEUROBLASTOMA - CONSENSUS STATEMENT FROM THE AMERICAN-CANCER-SOCIETY WORKSHOP ON NEUROBLASTOMA SCREENING	LANCET			English	Editorial Material							NEURO-BLASTOMA; PROGNOSIS		UNIV MINNESOTA,MINNEAPOLIS,MN 55455; KYOTO PREFECTURAL UNIV MED,KYOTO 602,JAPAN; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV ALABAMA,UNIVERSITY,AL 35486; NCI,BETHESDA,MD 20892; UNIV SO CALIF,LOS ANGELES,CA 90089	University of Minnesota System; University of Minnesota Twin Cities; Kyoto Prefectural University of Medicine; Northwestern University; Newcastle University - UK; University of Alabama System; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650				BRODEUR GM, 1987, CANCER RES, V47, P4248; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HAYASHI Y, 1988, J PEDIATR-US, V112, P567, DOI 10.1016/S0022-3476(88)80168-9; ISHIMOTO K, 1990, J PEDIATR SURG, V25, P398, DOI 10.1016/0022-3468(90)90379-N; KANEKO Y, 1987, CANCER RES, V47, P311; KANEKO Y, 1990, J CLIN ONCOL, V8, P2005, DOI 10.1200/JCO.1990.8.12.2005; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, IN PRESS J CLIN ONCO; MCGILL AC, 1988, ANN CLIN BIOCH S, V25, P1325; NAITO H, 1990, J PEDIATR SURG, V25, P245, DOI 10.1016/0022-3468(90)90410-B; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; NISHI M, 1989, PEDIATR RES, V26, P603, DOI 10.1203/00006450-198912000-00018; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TUCHMAN M, 1990, PEDIATRICS, V86, P765	17	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					344	346		10.1016/0140-6736(91)90957-Q	http://dx.doi.org/10.1016/0140-6736(91)90957-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671243				2022-12-28	WOS:A1991EX36200015
J	ROSOVE, MH; BREWER, PMC				ROSOVE, MH; BREWER, PMC			ANTIPHOSPHOLIPID THROMBOSIS - CLINICAL COURSE AFTER THE 1ST THROMBOTIC EVENT IN 70 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						FIBRINOLYTIC AGENTS; THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; LUPUS ERYTHEMATOSUS, SYSTEMIC PURPURA, THROMBOCYTOPENIC, IDIOPATHIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-CARDIOLIPIN ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CIRCULATING ANTICOAGULANT; HABITUAL ABORTION; FETAL LOSSES; PREVALENCE; ASSOCIATION; WOMEN; PREDNISONE	Objective: To determine the clinical course and influence of antithrombotic therapy in patients with lupus anticoagulant or anticardiolipin antibodies, or both, after the first thromboembolic event. Design: Retrospective survey of consecutive patients treated according to their physician's best judgment. Setting: Secondary and tertiary referral practice. Patients: Seventy patients (48 women [69%]) with a mean age (+/-SD) of 45.5 +/- 17.3 years. The antiphospholipid syndrome was primary in 51 patients (73%) and secondary to systemic lupus erythematosus in 14 patients (20%) and to chronic idiopathic thrombocytopenic purpura in 5 patients (7%). Measurements: Site of initial and recurrent thrombotic events (venous or arterial), as well as kind (aspiring, heparin, or warfarin) and intensity of anticoagulation. Results: Total follow-up after the first thrombotic event was 361.0 patient-years (mean [+/-SD], 5.2 +/- 5.6 years per patient). Thirty-seven patients (53%) had 54 recurrent events, with 2 patients experiencing fatal events. Arterial events were followed by arterial events, and venous events by venous events, in 49 of 54 instances (91%). Recurrence rates during "no treatment;" aspirin therapy; or low-, intermediate-, or high-intensity warfarin therapy (international normalized ratios [INRs] less-than-or-equal-to 1.9, 2.0 to 2.9, and greater-than-or-equal-to 3.0, respectively, or rabbit brain thromboplastin prothrombin time ratios of approximately <1.3, 1.3 to 1.5, and >1.5, respectively) were 0.19, 0.32, 0.57, 0.07 (P = 0.12), and 0.00 (P < 0.001) per patient-year. The follow-up periods for the five types of therapy were 161.2, 37.8, 11.3, 40.9, and 110.2 patient-years, respectively. The highest INR coincident with thrombosis was 2.6. Five warfarin-treated patients had five significant bleeding events (0.031 per patient-year). Conclusions: Recurrent thrombosis is a potentially serious problem for patients with lupus anticoagulant or anticardiolipin antibodies or both. The site of the first event (arterial or venous) tended to predict the site of subsequent events. Intermediate- to high-intensity warfarin therapy may confer better antithrombotic protection than low- to intermediate-intensity warfarin therapy or aspirin therapy. Further studies are needed to define more precisely the rethrombosis rate and optimal type, intensity, and duration of antithrombotic therapy.			ROSOVE, MH (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, 100 UCLA MED PLAZA, SUITE 550, LOS ANGELES, CA 90024 USA.							ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; BOEY ML, 1983, BMJ-BRIT MED J, V287, P1021, DOI 10.1136/bmj.287.6398.1021; BRANCH DW, 1985, NEW ENGL J MED, V313, P1322, DOI 10.1056/NEJM198511213132104; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408; CARRERAS LO, 1982, THROMB HAEMOSTASIS, V48, P38; CERVERA R, 1990, ANN RHEUM DIS, V49, P109, DOI 10.1136/ard.49.2.109; COWCHOCK S, 1986, AM J OBSTET GYNECOL, V155, P1002, DOI 10.1016/0002-9378(86)90335-2; DERKSEN RHWM, 1986, ARTHRITIS RHEUM, V29, P1295, DOI 10.1002/art.1780291021; EDELMAN P, 1986, HUM REPROD, V1, P295, DOI 10.1093/oxfordjournals.humrep.a136408; ELDRUPJORGENSEN J, 1989, J VASC SURG, V9, P334, DOI 10.1067/mva.1989.vs0090334; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FEINSTEIN DI, 1985, NEW ENGL J MED, V313, P1348, DOI 10.1056/NEJM198511213132109; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1983, LANCET, V2, P1211; ISHII Y, 1990, ANN RHEUM DIS, V49, P387, DOI 10.1136/ard.49.6.387; KALUNIAN KC, 1988, AM J MED, V85, P602; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; LEUNG WH, 1990, AM J MED, V89, P411, DOI 10.1016/0002-9343(90)90368-N; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LUBBE WF, 1983, LANCET, V1, P1361; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NILSSON IM, 1975, ACTA MED SCAND, V197, P153; PALARETI G, 1991, THROMB HAEMOSTASIS, V65, P452; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; ROSOVE MH, 1986, BLOOD, V68, P472; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; ROSOVE MH, 1989, AM J HEMATOL, V32, P148, DOI 10.1002/ajh.2830320215; SANTIAGO MB, 1989, CLIN RHEUMATOL, V8, P23, DOI 10.1007/BF02031064; SHAPIRO SS, 1982, PROG HEMOST THROMB, V6, P263; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; STEGNAR M, 1991, THROMB RES, V63, P433, DOI 10.1016/0049-3848(91)90230-T; STIMMLER MM, 1989, ARCH INTERN MED, V149, P1833, DOI 10.1001/archinte.149.8.1833; TAYLOR M, 1990, AM J REPROD IMMUNOL, V23, P33, DOI 10.1111/j.1600-0897.1990.tb00666.x; UNANDER AM, 1987, AM J OBSTET GYNECOL, V156, P114, DOI 10.1016/0002-9378(87)90218-3; WANG Y, 1990, RHEUMATOL INT, V10, P75, DOI 10.1007/BF02274787	41	579	586	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					303	308		10.7326/0003-4819-117-4-303	http://dx.doi.org/10.7326/0003-4819-117-4-303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637025				2022-12-28	WOS:A1992JH46400006
J	CROSBY, WH				CROSBY, WH			OLD-AGE AND HEMOCHROMATOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					802	802						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640590				2022-12-28	WOS:A1992JG66600042
J	SALTMAN, RB				SALTMAN, RB			SINGLE-SOURCE FINANCING SYSTEMS - A SOLUTION FOR THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNIVERSAL HEALTH-INSURANCE; COST-CONTAINMENT; CARE SYSTEM; PROMOTE QUALITY; WEST-GERMANY; COMPETITION; ECONOMY; PAYMENT; POLICY; 1990S	Although tax-based and social insurance-based forms of single-source financing differ in how they raise funds, they share a common set of structural characteristics. In particular, they both enable publicly accountable authorities to control aggregate expenditure levels by creating a countervailing power to pressures for increased expenditures from providers. While major reform initiatives are under way in European single-source financing systems, these initiatives have so far sought to improve the efficiency, effectiveness, and/or responsiveness to patterns of service delivery without reducing their commitment to universal access to necessary care. The article concludes with a review of the advantages and disadvantages that could accompany the introduction of a single-source financing system in the United States.	EMORY UNIV, SCH PUBL HLTH, DIV HLTH POLICY & MANAGEMENT, 1599 CLIFTON RD NE, ATLANTA, GA 30329 USA	Emory University								ABELSMITH B, 1983, MILBANK Q, V63, P1; Brown Brandon, 2011, PERSIANS AESCHYLUS; ELSINGA E, 1989, HEALTH POLICY, V11, P243, DOI 10.1016/0168-8510(89)90005-5; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; Enthoven AC, 1980, HLTH PLAN ONLY PRACT; EVANS RG, 1990, J HEALTH POLIT POLIC, V15, P101, DOI 10.1215/03616878-15-1-101; EVANS RG, 1986, J HEALTH POLIT POLIC, V11, P585, DOI 10.1215/03616878-11-4-585; FUCHS VR, 1988, HEALTH AFFAIR, V7, P5, DOI 10.1377/hlthaff.7.3.5; GLASER WA, 1990, AM J PUBLIC HEALTH, V80, P804, DOI 10.2105/AJPH.80.7.804; GLASER WA, 1987, PAYING HOSPITAL; HAM C, 1990, HLTH CHECK HLTH CARE; Henke K.-D., 1991, STATSWISSENSCHAFTEN, V2, P170; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; KIRKMANLIFF BL, 1990, J HEALTH POLIT POLIC, V15, P69, DOI 10.1215/03616878-15-1-69; LUFT HS, 1988, HEALTH AFFAIR, V7, P97, DOI 10.1377/hlthaff.7.3.97; MORONE JA, 1990, J HEALTH POLIT POLIC, V15, P129, DOI 10.1215/03616878-15-1-129; Rodwin V G, 1987, Med Care Rev, V44, P119, DOI 10.1177/107755878704400106; ROSENTHAL MM, 1988, DEALING MED MALPRACT; SALKEVER DS, 1976, MILBANK FUND Q, V54, P185, DOI 10.2307/3349587; SALTMAN RB, 1985, J HEALTH POLIT POLIC, V9, P563, DOI 10.1215/03616878-9-4-563; SALTMAN RB, 1989, J HEALTH POLIT POLIC, V14, P773, DOI 10.1215/03616878-14-4-773; SALTMAN RB, 1988, J HEALTH POLIT POLIC, V13, P27, DOI 10.1215/03616878-13-1-27; SALTMAN RB, 1992, PLANNED MARKERTS PUB; SAPOLSKY HM, 1986, J HEALTH POLIT POLIC, V11, P633, DOI 10.1215/03616878-11-4-633; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; TAYLOR M, 1990, INSURING NATIONAL HL; VANDEVEN WPMM, 1987, HEALTH POLICY, V7, P253, DOI 10.1016/0168-8510(87)90036-4; VANDEVEN WPMM, 1991, EUR ECON REV, V35, P430, DOI 10.1016/0014-2921(91)90144-8; WYSONG JA, 1990, MILBANK Q, V68, P527, DOI 10.2307/3350193; [No title captured]; 1992, HLTH CARE REFORMS 7	33	10	10	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					774	779		10.1001/jama.268.6.774	http://dx.doi.org/10.1001/jama.268.6.774			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640579				2022-12-28	WOS:A1992JG66600021
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1-PERCENT HYDROCORTISONE PRODUCTS TO BE AVAILABLE OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-28	WOS:A1991GU96400005
J	DALAKAS, MC				DALAKAS, MC			POLYMYOSITIS, DERMATOMYOSITIS, AND INCLUSION-BODY MYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTERSTITIAL LUNG-DISEASE; TRANSFER RNA-SYNTHETASE; IDIOPATHIC INFLAMMATORY MYOPATHY; MONOCLONAL-ANTIBODY ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; PULMONARY HISTOPATHOLOGIC FINDINGS; MEDIATED CYTO-TOXICITY; MONONUCLEAR-CELLS; DIFFERENTIAL-DIAGNOSIS; NEUROMUSCULAR DISEASES				DALAKAS, MC (corresponding author), NINCDS,NEUROMUSCULAR DIS SECT,BLDG 10,RM 4N248,BETHESDA,MD 20892, USA.							ALJANADI M, 1989, J RHEUMATOL, V16, P1592; ANSELL BM, 1984, CLIN RHEUM DIS, V10, P1; ARAHATA K, 1988, ANN NEUROL, V23, P493, DOI 10.1002/ana.410230511; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; ARNETT FC, 1981, J RHEUMATOL, V8, P925; ARNETT FC, 1986, HOSP PRACT, V21, P89; ASKARI AD, 1984, CLIN RHEUM DIS, V10, P31; ATLAS E, 1988, ANN INTERN MED, V109, P245, DOI 10.7326/0003-4819-109-3-245; BANKER BQ, 1986, MYOLOGY, P1385; BANKER BQ, 1986, MYOLOGY, P1467; BARKHAUS PE, 1990, MUSCLE NERVE, V13, P247, DOI 10.1002/mus.880130312; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BERNSTEIN RM, 1984, BRIT MED J, V289, P151, DOI 10.1136/bmj.289.6438.151; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; BOMBARDIERI S, 1989, LANCET, V1, P1138; BOWLES NE, 1987, LANCET, V1, P1004; BUNCH TW, 1981, ARTHRITIS RHEUM, V24, P45, DOI 10.1002/art.1780240107; BUNCH TW, 1980, ANN INTERN MED, V92, P365, DOI 10.7326/0003-4819-92-3-365; BUNCH TW, 1988, MT SINAI J MED, V55, P483; BUNCH TW, 1990, MAYO CLIN PROC, V65, P1480, DOI 10.1016/S0025-6196(12)62170-3; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; CALLEN JP, 1982, J AM ACAD DERMATOL, V6, P253, DOI 10.1016/S0190-9622(82)70018-0; CALLEN JP, 1988, CLIN DERMATOL, V2, P55; CARO I, 1989, MED CLIN N AM, V73, P1181; CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8; Carpenter S, 1981, Pathol Annu, V16, P205; CARPENTER S, 1988, POLYMYOSITIS DERMATO, P195; CHERIN P, 1990, LANCET, V336, P116, DOI 10.1016/0140-6736(90)91630-S; CHOU SM, 1986, HUM PATHOL, V17, P765, DOI 10.1016/S0046-8177(86)80197-6; COLE AJ, 1988, BRAIN, V111, P1025, DOI 10.1093/brain/111.5.1025; CRONIN ME, 1989, J RHEUMATOL, V16, P1225; DALAKAS M, 1989, Current Opinion in Rheumatology, V1, P443; DALAKAS M, 1990, CURR OPIN NEUROL NEU, V3, P689; DALAKAS M, 1990, NEUROL CLIN, V8, P93, DOI 10.1016/S0733-8619(18)30375-X; DALAKAS M, 1991, Neurology, V41, P375; DALAKAS M, 1991, PEDIATRIC AIDS CHALL, P420; Dalakas M., 1988, POLYMYOSITIS DERMATO, P281; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; DALAKAS MC, 1988, ANN NEUROL, V23, pS38, DOI 10.1002/ana.410230713; DALAKAS MC, 1987, P SOC EXP BIOL MED, V185, P368, DOI 10.3181/00379727-185-42556; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALAKAS MC, 1988, POLYMYOSITIS DERMATO, P1; DALAKAS MC, 1988, POLYMYOSITIS DERMATO; DALAKAS MC, 1988, POLYMYOSITIS DERMATO, P235; DAU PC, 1981, ARCH NEUROL-CHICAGO, V38, P544, DOI 10.1001/archneur.1981.00510090038003; DEMERIEUX P, 1983, ARTHRITIS RHEUM, V26, P961; DENBOW CE, 1979, ARTHRITIS RHEUM, V22, P1088, DOI 10.1002/art.1780221007; DENMAN AM, 1988, POLYMYOSITIS DERMATO, P97; DIETZ F, 1980, ARTHRITIS RHEUM, V23, P491, DOI 10.1002/art.1780230412; DOYLE DR, 1983, ANN INTERN MED, V98, P327, DOI 10.7326/0003-4819-98-3-327; EISEN A, 1983, NEUROLOGY, V33, P1109, DOI 10.1212/WNL.33.9.1109; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0; ENGEL AG, 1984, ANN NEUROL, V16, P209, DOI 10.1002/ana.410160207; ENGEL AG, 1989, CURR OPIN NEUROL NEU, V2, P695; ENGEL WK, 1981, LANCET, V1, P658; ENGEL WK, 1982, THERAPY NEUROLOGIC D, P51; Franks AG, 1988, J MUSCULOSKELETAL ME, V5, P39; GAUT P, 1988, ARCH INTERN MED, V148, P1608, DOI 10.1001/archinte.148.7.1608; GENTH E, 1990, ARTHRITIS RHEUM-US, V33, P657, DOI 10.1002/art.1780330508; HAUPT HM, 1982, AM J CARDIOL, V50, P998, DOI 10.1016/0002-9149(82)90408-8; HAYS AP, 1986, MYOLOGY, P1439; HECKMATT J, 1989, LANCET, V1, P1063, DOI 10.1016/S0140-6736(89)92456-2; HENRIKSSON KG, 1982, ACTA NEUROL SCAND, V65, P280, DOI 10.1111/j.1600-0404.1982.tb03087.x; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HOCHBERG MC, 1986, SEMIN ARTHRITIS RHEU, V15, P168, DOI 10.1016/0049-0172(86)90014-4; HOCHBERG MC, 1984, J RHEUMATOL, V11, P663; HOHLFELD R, 1991, ANN NEUROL, V29, P498, DOI 10.1002/ana.410290509; HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303; HUBBARD WN, 1982, BRIT MED J, V284, P1915, DOI 10.1136/bmj.284.6333.1915; HUDGSON P, 1975, J PATHOL, V116, P139, DOI 10.1002/path.1711160303; ILLA I, 1991, ANN NEUROL, V29, P474, DOI 10.1002/ana.410290505; JAN S, 1990, NEUROLOGY S1, V40, P120; JONES DW, 1987, ARTHRITIS RHEUM, V30, P959, DOI 10.1002/art.1780300825; KAGEN LJ, 1987, ARTHRITIS RHEUM, V30, P213, DOI 10.1002/art.1780300212; KAGEN LJ, 1977, JAMA-J AM MED ASSOC, V237, P1448, DOI 10.1001/jama.1977.03270410048019; KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111; KARPATI G, 1988, CURR OPIN NEUROL NEU, V1, P806; KELLY JJ, 1986, NEUROLOGY, V36, P1264, DOI 10.1212/WNL.36.9.1264; KELLY JJ, 1988, MUSCLE NERVE, V11, P120, DOI 10.1002/mus.880110206; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; KISSEL JT, 1991, ARCH NEUROL-CHICAGO, V48, P26, DOI 10.1001/archneur.1991.00530130034016; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; LAKHANPAL S, 1987, ANN RHEUM DIS, V46, P23, DOI 10.1136/ard.46.1.23; LAMPERTH L, 1991, Neurology, V41, P211; LAMPERTH L, 1990, Neurology, V40, P121; LEON-MONZON M E L, 1991, Neurology, V41, P376; LOTZ BP, 1989, BRAIN, V112, P727, DOI 10.1093/brain/112.3.727; MANCHUL LA, 1985, ARCH INTERN MED, V145, P1835, DOI 10.1001/archinte.145.10.1835; MASSA R, 1991, ARCH NEUROL-CHICAGO, V48, P519, DOI 10.1001/archneur.1991.00530170083024; MASTAGLIA FL, 1985, ANN NEUROL, V17, P215, DOI 10.1002/ana.410170302; MASTAGLIA FL, 1982, DRUGS, V24, P304, DOI 10.2165/00003495-198224040-00003; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; METZGER AL, 1974, ANN INTERN MED, V81, P182, DOI 10.7326/0003-4819-81-2-182; MIKOL J, 1986, MYOLOGY, P1423; MIMORI T, 1987, INT J DERMATOL, V26, P419, DOI 10.1111/j.1365-4362.1987.tb00580.x; MORGAN OS, 1989, LANCET, V2, P1184; MUNSAT TL, 1972, NEUROLOGY, V22, P335, DOI 10.1212/WNL.22.4.335; NIAKAN E, 1980, NEUROLOGY, V30, P286, DOI 10.1212/WNL.30.3.286; NISHINO H, 1989, ANN NEUROL, V25, P260, DOI 10.1002/ana.410250309; ODDIS CV, 1988, J RHEUMATOL, V15, P807; PEARSON CM, 1977, MED CLIN N AM, V61, P439, DOI 10.1016/S0025-7125(16)31343-8; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; RICHARDSON JB, 1989, MED CLIN N AM, V73, P1211, DOI 10.1016/S0025-7125(16)30629-0; RINGEL SP, 1986, ARCH NEUROL-CHICAGO, V43, P1004, DOI 10.1001/archneur.1986.00520100026010; ROBINSON LR, 1991, MUSCLE NERVE, V14, P310, DOI 10.1002/mus.880140404; ROIFMAN CM, 1987, JAMA-J AM MED ASSOC, V258, P513, DOI 10.1001/jama.1987.03400040111034; ROSENBERG NL, 1989, ANN NEUROL, V26, P204, DOI 10.1002/ana.410260204; ROSENBERG NL, 1988, POLYMYOSITIS DERMATO, P37; Rowland L P, 1977, Adv Neurol, V17, P63; ROWLAND LP, 1989, MERRITTS TXB NEUROLO, P733; RUCHETON M, 1985, VIROLOGY, V144, P468, DOI 10.1016/0042-6822(85)90287-9; RUFF RL, 1989, VIRAL DISEASE, V56, P193; SALMERON G, 1981, ARCH INTERN MED, V141, P1005, DOI 10.1001/archinte.141.8.1005; SHARP GC, 1991, HARRISONS PRINCIPLES, V2, P1448; SHEPHERD JJ, 1983, LANCET, V2, P1240; SHEVELL M, 1990, NEUROLOGY, V40, P1111, DOI 10.1212/WNL.40.7.1111; SIMPSON DM, 1988, ANN NEUROL, V24, P79, DOI 10.1002/ana.410240114; STAHL NI, 1979, ANN INTERN MED, V91, P577, DOI 10.7326/0003-4819-91-4-577; TARGOFF I N, 1989, Current Opinion in Rheumatology, V1, P432; TARGOFF I N, 1990, Current Opinion in Rheumatology, V2, P882; TARGOFF IN, 1990, AM J MED, V88, P241, DOI 10.1016/0002-9343(90)90149-8; TARGOFF IN, 1989, J CLIN INVEST, V84, P162, DOI 10.1172/JCI114136; TAZELAAR HD, 1990, AM REV RESPIR DIS, V141, P727, DOI 10.1164/ajrccm/141.3.727; TYMMS KE, 1985, J RHEUMATOL, V12, P1140; UCHINO M, 1985, J NEUROL, V232, P175, DOI 10.1007/BF00313897; UNCINI A, 1990, MUSCLE NERVE, V13, P263, DOI 10.1002/mus.880130315; WALKER EJ, 1988, MED HYPOTHESES, V25, P21, DOI 10.1016/0306-9877(88)90041-2; WALLACE DJ, 1985, ARTHRITIS RHEUM, V28, P590, DOI 10.1002/art.1780280523; WALTON J, 1991, J NEUROL NEUROSUR PS, V54, P285, DOI 10.1136/jnnp.54.4.285; WARNER CL, 1991, NEUROLOGY, V141, P750; WHITAKER JN, 1982, MUSCLE NERVE, V5, P573, DOI 10.1002/mus.880050802; WHITAKER JN, 1972, NEW ENGL J MED, V286, P333, DOI 10.1056/NEJM197202172860701; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; WULFF JD, 1982, ANN NEUROL, V12, P398, DOI 10.1002/ana.410120415; YOUSEF GE, 1990, ANN RHEUM DIS, V49, P310, DOI 10.1136/ard.49.5.310	143	825	849	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1487	1498		10.1056/NEJM199111213252107	http://dx.doi.org/10.1056/NEJM199111213252107			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1658649				2022-12-28	WOS:A1991GQ40600007
J	EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ				EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ			HETEROSEXUAL COTRANSMISSION OF HEPATITIS-C VIRUS (HCV) AND HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; HEPATOCELLULAR-CARCINOMA; III ANTIBODIES; LIVER-DISEASE; BELLE-GLADE; HEMOPHILIACS; PREVALENCE; AIDS; FLORIDA	Objectives: To determine the prevalence of antibodies to hepatitis C virus (HCV) in female sexual partners of multitransfused men with hemophilia and to compare the frequency of transmission of HCV and human immunodeficiency virus (HIV). Study Design: Cross-sectional measurement of HCV and HIV antibodies. Setting: Ten hemophilia treatment centers. Patients: A total of 234 female sexual partners of 231 multitransfused men with hemophilia. Measurements and Main Results: The prevalence of antibodies to HCV (anti-HCV) among female sexual partners of HCV-Positive men was 5 of 194 (2.6%). Anti-HIV prevalence among female sexual partners of HIV-positive men was 25 of 196 (12.8%). Five (3%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HCV compared with none of the 30 female sexual partners of HIV-negative/HCV-positive men. Twenty-one (13%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HIV compared with 4 (13%) of 32 female sexual partners of HIV-positive/HCV-indeterminate men. The co-infected men were five times more likely to transmit both viruses than would be expected by chance (P = 0.01). When a single virus was transmitted to a female sexual partner, it was more often HIV than HCV (18 of 164 compared with 2 of 164, P = 0.001; odds ratio, 8.5; 95% Cl, 2.2 to 33.1). Conclusions: The higher prevalence of HCV in female sexual partners of men with hemophilia than in blood donor and other low-risk groups suggests that there is a low level of sexual transmission. Male to female sexual transmission of HCV is less efficient than that of HIV. The frequency of HCV transmission to sexual partners is five times higher when HIV is also transmitted, suggesting that HIV may be a cofactor for the sexual transmission of HCV.			EYSTER, ME (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, BOX 850, HERSHEY, PA 17033 USA.			, M. Elaine Eyster/0000-0001-8248-6793	NCI NIH HHS [N01-CP-85649] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		ALEDORT LM, 1985, BLOOD, V66, P367; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, IN PRESS 1990 INT S; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BIANCHI L, 1987, SEMIN LIVER DIS, V7, P203, DOI 10.1055/s-2008-1040577; BRUIX J, 1989, LANCET, V2, P1004; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1985, JAMA-J AM MED ASSOC, V253, P2219, DOI 10.1001/jama.253.15.2219; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOEDERT JJ, 1988, 4 INT C AIDS STOCKH, P264; KITCHEN LW, 1984, NATURE, V312, P367, DOI 10.1038/312367a0; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; RAGNI MV, 1986, BLOOD, V67, P592; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; SCHRAMM W, 1989, BLUT, V59, P390, DOI 10.1007/BF00321210; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, 51 US DEP HLTH HUM S, P19; 1989, 1ST P INT S HEP C VI, P31	32	281	287	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					764	768		10.7326/0003-4819-115-10-764	http://dx.doi.org/10.7326/0003-4819-115-10-764			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1656825				2022-12-28	WOS:A1991GP80000003
J	HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN				HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN			DIARRHEAL DISEASE DURING OPERATION-DESERT-SHIELD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOXIGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; NORWALK VIRUS; SOUTH-KOREA; TRIMETHOPRIM; SHIGELLA; ANTIGEN; SULFAMETHOXAZOLE; GASTROENTERITIS; CHILDREN	Background. Under combat conditions infectious disease can become a major threat to military forces. During Operation Desert Shield, there were numerous outbreaks of diarrhea among the U.S. forces. To evaluate the causes of and risk factors for diarrheal disease, we collected clinical and epidemiologic data from U.S. troops stationed in northeastern Saudi Arabia. Methods. Between September and December 1990, stool cultures for enteric pathogens were obtained from 432 military personnel who presented with diarrhea, cramps, vomiting, or hematochezia. In addition, a questionnaire was administered to 2022 soldiers in U.S. military units located in various regions of Saudi Arabia. Results. A bacterial enteric pathogen was identified in 49.5 percent of the troops with gastroenteritis. Enterotoxigenic Escherichia coli and Shigella sonnei were the most common bacterial pathogens. Of 125 E. coli infections, 39 percent were resistant to trimethoprim-sulfamethoxazole, 63 percent to tetracycline, and 48 percent to ampicillin. Of 113 shigella infections, 85 percent were resistant to trimethoprim-sulfamethoxazole, 68 percent to tetracycline, and 21 percent to ampicillin. All bacterial isolates were sensitive to norfloxacin and ciprofloxacin. After an average of two months in Saudi Arabia, 57 percent of the surveyed troops had at least one episode of diarrhea, and 20 percent reported that they were temporarily unable to carry out their duties because of diarrheal symptoms. Vomiting was infrequently reported as a primary symptom, but of 11 military personnel in whom vomiting was a major symptom, 9 (82 percent) had serologic evidence of infection with the Norwalk virus. Conclusions. Gastroenteritis caused by enterotoxigenic E coli and shigella resistant to a number of drugs was a major problem that frequently interfered with the duties of U.S. troops during Operation Desert Shield.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; NIH,INFECT DIS LAB,BETHESDA,MD 20892; USN,MED RES & DEV COMMAND,BETHESDA,MD 20814; USN,MED RES INST DETACHMENT,LIMA,PERU; USN,ENVIRONM & PREVENT MED UNIT 7,NAPLES,ITALY; USA,MED DEPT ACT,PREVENT MED SERV,FT CAMPBELL,KY; USN,MED RES UNIT 3,DIV EPIDEMIOL,CAIRO,EGYPT; WILLIAM BEAUMONT ARMY MED CTR,DEPT PEDIAT,EL PASO,TX 79920	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); National Institutes of Health (NIH) - USA; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); United States Department of Defense; United States Navy; William Beaumont Army Medical Center	HYAMS, KC (corresponding author), USN,MED RES INST,DIV EPIDEMIOL,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.							AUGUST MJ, 1987, J CLIN MICROBIOL, V25, P2233, DOI 10.1128/JCM.25.11.2233-2235.1987; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHATKAEOMORAKOT A, 1987, PEDIATR INFECT DIS J, V6, P735, DOI 10.1097/00006454-198708000-00008; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; COHEN D, 1991, LANCET, P993; DANIELL FD, 1985, MIL MED, V150, P171, DOI 10.1093/milmed/150.4.171; DAVIS H, 1988, AM J EPIDEMIOL, V128, P1312, DOI 10.1093/oxfordjournals.aje.a115084; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; ECHEVERRIA P, 1979, AM J EPIDEMIOL, V109, P493, DOI 10.1093/oxfordjournals.aje.a112706; ECHEVERRIA P, 1979, J INFECT DIS, V139, P215, DOI 10.1093/infdis/139.2.215; ECHEVERRIA P, 1978, AM J EPIDEMIOL, V108, P68; ECHEVERRIA P, 1990, GENE PROBES BACTERIA, P95; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; GARY GW, 1987, J CLIN MICROBIOL, V25, P2001, DOI 10.1128/JCM.25.10.2001-2003.1987; GASSER RA, 1991, NEW ENGL J MED, V324, P859, DOI 10.1056/NEJM199103213241229; GOLDFIELD EC, 1991, REV INFECT DIS S3, V13, pS197; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; HABERBERGER RL, 1991, MIL MED, V156, P27, DOI 10.1093/milmed/156.1.27; HEGGERS JP, 1978, MIL MED, V143, P390; Kapikian AZ, 1990, VIROLOGY, P1353; KAPIKIAN AZ, 1975, PERSPECT VIROL, V9, P9; KAPIKIAN AZ, 1990, VIROLOGY, V1, P671; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; MARTIN DL, 1986, AM J EPIDEMIOL, V124, P299, DOI 10.1093/oxfordjournals.aje.a114388; MELDMAN IJ, 1978, BACTERIOLOGY ANAL MA; MIDTHUN K, 1989, J CLIN MICROBIOL, V27, P2799, DOI 10.1128/JCM.27.12.2799-2804.1989; MIKHAIL IA, 1990, J CLIN MICROBIOL, V28, P956, DOI 10.1128/JCM.28.5.956-961.1990; Morris G. K., 1985, MANUAL CLIN MICROBIO, P302; MURRAY BE, 1986, REV INFECT DIS, V8, pS172; OLDFIELD EC, 1987, AM J TROP MED HYG, V37, P616, DOI 10.4269/ajtmh.1987.37.616; OPRANDY JJ, 1988, J CLIN MICROBIOL, V26, P92, DOI 10.1128/JCM.26.1.92-95.1988; PAZZAGLIA G, 1982, MIL MED, V147, P27, DOI 10.1093/milmed/147.1.27; QUIN NE, 1982, MIL MED, V147, P728, DOI 10.1093/milmed/147.9.728; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SCOTT DA, 1990, AM J TROP MED HYG, V42, P160, DOI 10.4269/ajtmh.1990.42.160; SERENY B, 1955, Acta Microbiol Acad Sci Hung, V2, P293; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; TAYLOR WR, 1982, NEW ENGL J MED, V306, P1093, DOI 10.1056/NEJM198205063061807; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YOLKEN RH, 1986, MANUAL CLIN LABORATO, P573; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52	47	218	226	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1423	1428		10.1056/NEJM199111143252006	http://dx.doi.org/10.1056/NEJM199111143252006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1656260				2022-12-28	WOS:A1991GP52400006
J	SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A				SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A			DEPENDENCE OF KIDNEY MORPHOGENESIS ON THE EXPRESSION OF NERVE GROWTH-FACTOR RECEPTOR	SCIENCE			English	Article							NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR BINDING; MESSENGER-RNA; HIGH-AFFINITY; BRAIN; CELLS; PROTEIN; DIFFERENTIATION; TISSUES	Nerve growth factor receptor (NGFR) serves as the binding site for the neurotrophic growth factors. Although NGFR has been found in several embryonic tissues outside the nervous system, the function of NGFR in embryogenesis of non-neuronal organs remains unknown. NGFR is transiently synthesized by embryonic rat kidney and disappears from nephrons upon their terminal differentiation. Anti-sense oligonucleotide inhibition of NGFR expression inhibits kidney morphogenesis. Therefore, NGFR is required not only for development of the nervous system, but also for differentiation of the kidney tubules.	ACAD SCI ESSSR, INST CHEM PHYS & BIOPHYS, 200103 TALLINN, ESTONIA, USSR; UNIV HELSINKI, INST PEDODONT & ORTHODONT, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, SF-00100 HELSINKI 10, FINLAND	National Institute of Chemical Physics & Biophysics (NICPB); University of Helsinki; University of Helsinki; University of Helsinki	SARIOLA, H (corresponding author), UNIV HELSINKI, CHILDRENS HOSP, DEPT PAEDIAT PATHOL, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND.		Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENGTSTROM M, IN PRESS NUCLEIC ACI; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CHESA PG, 1988, J HISTOCHEM CYTOCHEM, V36, P383, DOI 10.1177/36.4.2831267; COSTRINI NV, 1979, P NATL ACAD SCI USA, V76, P3242, DOI 10.1073/pnas.76.7.3242; ENFORS P, 1990, NEURON, V5, P511; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1991, INT J DEV NEUROSCI, V9, P57, DOI 10.1016/0736-5748(91)90073-U; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GROB PM, 1985, J BIOL CHEM, V260, P8044; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HEMSTEAD BL, 1991, NATURE, V350, P678; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARAVANOV AA, 1983, EXPERIENTIA, V39, P1015, DOI 10.1007/BF01989779; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Maniatis T., 1982, MOL CLONING; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; SARIOLA H, UNPUB; Saxen L., 1987, ORGANOGENESIS KIDNEY; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; YAN Q, 1988, J NEUROSCI, V8, P3481	41	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					571	573		10.1126/science.1658930	http://dx.doi.org/10.1126/science.1658930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1658930				2022-12-28	WOS:A1991GL79900049
J	DERR, LK; STRATHERN, JN; GARFINKEL, DJ				DERR, LK; STRATHERN, JN; GARFINKEL, DJ			RNA-MEDIATED RECOMBINATION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST RETROTRANSPOSON TY; LONG TERMINAL REPEATS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; ELEMENT TRANSPOSITION; EUKARYOTIC GENOME; GENE-EXPRESSION; CDNA GENES; SPT3 GENE	The existence of pseudogenes and the observation of intron loss suggest that RNA can serve as an intermediate in recombination. We used a HIS3 reporter gene to show that RNA-mediated recombination occurs in yeast. His3+ prototroph formation required transcription and expression of the retrotransposon Ty. Two RNA-mediated recombination events were detected: homologous recombination between the cDNA and plasmid his3 sequences, resulting in intron loss, and insertion of the cDNA into the chromosome in the absence of HIS3 homology. The chromosomal His3+ prototrophs showed many hallmarks of naturally occurring pseudogenes. They integrated at novel sites in the chromosome, lacked introns, and possessed poly(A) tracts. Additionally, their 5' ends corresponded with the site of initiation of the GAL1 transcript.			DERR, LK (corresponding author), NCI, FREDERICK CANC RES FACIL, EUKARYOT GENE EXPRESS LAB, FREDERICK, MD 21701 USA.				PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1988, MOL CELL BIOL, V8, P1431; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; COLICELLI J, 1988, J VIROL, V62, P633, DOI 10.1128/JVI.62.2.633-636.1988; CURCIO MJ, 1990, MOL GEN GENET, V220, P213; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNBURG R, 1990, J VIROL, V64, P886, DOI 10.1128/JVI.64.2.886-889.1990; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; DORNBURG R, 1990, MOL CELL BIOL, V10, P68, DOI 10.1128/MCB.10.1.68; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LEVINE KL, 1990, MOL CELL BIOL, V10, P1891, DOI 10.1128/MCB.10.5.1891; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; LINIAL M, 1987, CELL, V49, P93, DOI 10.1016/0092-8674(87)90759-8; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; PAQUIN CE, 1984, SCIENCE, V226, P53, DOI 10.1126/science.226.4670.53; SHERMAN F, 1986, LABORATORY COURSE MA; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WEINSTOCK KG, 1990, MOL CELL BIOL, V10, P2882, DOI 10.1128/MCB.10.6.2882; WILKE CM, 1989, GENETICS, V123, P655; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; YOSHIMATSU T, 1989, SCIENCE, V244, P1346, DOI 10.1126/science.2544026	36	115	119	2	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					355	364		10.1016/0092-8674(91)90187-4	http://dx.doi.org/10.1016/0092-8674(91)90187-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655280				2022-12-28	WOS:A1991GL47000015
J	GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B				GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B			POLY(A) POLYMERASE AND A DISSOCIABLE POLYADENYLATION STIMULATORY FACTOR ENCODED BY VACCINIA VIRUS	CELL			English	Article							THYMIDINE KINASE GENE; EARLY TRANSCRIPTION FACTOR; RNA-CAPPING ENZYME; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BINDING-PROTEIN; FOWLPOX VIRUS; ACID; DNA	mRNA made in eukaryotic cells typically has a 3' poly(A) tail that is added posttranscriptionally. To investigate mechanisms by which 3' poly(A) is formed, we identified the genes for the two vaccinia virus-encoded polypeptides, VP55 and VP39. Primer-dependent polyadenylation activity was associated exclusively with purified VP55-VP39 heterodimer, which, although stable to column chromatography and glycerol gradient sedimentation, was readily dissociated by antibody to an N-terminal peptide of VP55. Poly(A) polymerase activity was associated with immunopurified VP55, but not with immunopurified or chromatographically purified VP39. VP39 was, however, required for the formation of long poly(A) molecules, in conjunction with either purified VP55 or low concentrations of the heterodimer, and was shown to bind free poly(A). Thus, a catalytic polypeptide and a dissociable poly(A)-binding stimulatory factor each contribute to poly(A) tail formation. No prokaryotic or eukaryotic homologs of either polypeptide were detected in sequence data bases, consistent with the absence of previously reported poly(A) polymerase genes from any source.	NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GERSHON, PD (corresponding author), NIAID,VIRAL DIS LAB,BETHESDA,MD 20892, USA.			Moss, Bernard/0000-0002-2154-8564				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BINNS MM, 1988, J GEN VIROL, V69, P1275, DOI 10.1099/0022-1317-69-6-1275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRILLIEN R, 1987, VIROLOGY, V160, P203, DOI 10.1016/0042-6822(87)90061-4; EDMONDS M, 1990, METHOD ENZYMOL, V181, P161; GERSHON PD, 1989, J GEN VIROL, V70, P525, DOI 10.1099/0022-1317-70-3-525; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOB ST, 1983, ENZYMES NUCLEIC ACID, P135; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NEVINS JR, 1975, VIROLOGY, V63, P1, DOI 10.1016/0042-6822(75)90365-7; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUCIENNICZAK A, 1985, NUCLEIC ACIDS RES, V13, P985, DOI 10.1093/nar/13.3.985; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENBERG AH, 1987, GENE, V59, P191, DOI 10.1016/0378-1119(87)90327-1; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P521, DOI 10.1093/nar/12.1Part2.521; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	50	111	116	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1269	1278		10.1016/0092-8674(91)90048-4	http://dx.doi.org/10.1016/0092-8674(91)90048-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1670500				2022-12-28	WOS:A1991GG55200020
J	BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P				BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P			ELEVATED BRAIN CONCENTRATIONS OF 1,4-BENZODIAZEPINES IN FULMINANT HEPATIC-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BENZODIAZEPINE RECEPTOR LIGANDS; GAMMA-AMINOBUTYRIC-ACID; ANIMAL-MODEL; RABBIT MODEL; ANTAGONIST FLUMAZENIL; ENCEPHALOPATHY; COMPLEX; REVERSAL; DIAZEPAM; POTATO	Background. Increased gamma-aminobutyric acid (GABA) neurotransmission has been implicated in the pathogenesis of hepatic encephalopathy. The mechanism by which GABA-ergic activity is increased in hepatic failure is unclear, but recent studies in animals with encephalopathy due to fulminant hepatic failure suggest that GABA-ergic neurotransmission may be increased by the presence of elevated concentrations of benzodiazepine agonists such as diazepam and N-desmethyldiazepam. Methods and Results. Samples of frontal cortex were obtained at autopsy from 11 patients with hepatic encephalopathy who died of acetaminophen-induced fulminant hepatic failure and 8 patients who died of cardiovascular disease or trauma. None of the 19 patients had received benzodiazepines while hospitalized. Chromatographic analyses of extracts of these samples revealed 4 to 19 peaks representing substances that inhibited the binding of a radiolabeled imidazobenzodiazepine ([H-3]flumazenil) to its receptors. Several of these peaks had retention times corresponding to those of known 1,4-benzodiazepines. Ultraviolet- and mass-spectroscopic analysis confirmed that two of these peaks represented diazepam and N-desmethyldiazepam. The patients who died of fulminant hepatic failure could be divided into two groups: six who had had significantly elevated brain concentrations (2-fold to 10-fold higher than normal) of substances inhibiting the binding of [H-3]flumazenil and five who had normal concentrations. Conclusions. Brain concentrations of substances inhibiting the binding of [H-3]flumazenil to its receptors are increased in some patients with hepatic encephalopathy due to fulminant hepatic failure. The origin of these substances is unknown, but these findings provide a rational basis for trials of benzodiazepine-receptor antagonists in the management of this disorder.	NIDDKD,DIGEST DIS BRANCH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,LIVER DIS SECT,BETHESDA,MD 20892; UNIV LONDON KINGS COLL,SCH MED & DENT,LIVER UNIT,LONDON WC2R 2LS,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London	BASILE, AS (corresponding author), NIDDKD,DIGEST DIS BRANCH,NEUROSCI LAB,BLDG 8,RM 111,BETHESDA,MD 20892, USA.		Harrison, Phillip M/D-5374-2009	opoku, anita/0000-0001-7243-8157				BANSKY G, 1989, GASTROENTEROLOGY, V97, P744, DOI 10.1016/0016-5085(89)90647-1; BASILE AS, 1989, J NEUROCHEM, V53, P1057, DOI 10.1111/j.1471-4159.1989.tb07395.x; BASILE AS, 1990, NEUROPSYCHOPHARMACOL, V3, P61; BASILE AS, 1991, SYNAPSE, V7, P141, DOI 10.1002/syn.890070208; BASILE AS, 1988, J NEUROSCI, V8, P2414; BASILE AS, 1990, P NATL ACAD SCI USA, V87, P5263, DOI 10.1073/pnas.87.14.5263; BASILE AS, 1991, PHARMACOL REV, V43, P28; BASSETT ML, 1987, GASTROENTEROLOGY, V93, P1069, DOI 10.1016/0016-5085(87)90571-3; BASSETT ML, 1990, GASTROENTEROLOGY, V98, P747, DOI 10.1016/0016-5085(90)90298-F; Conn HO, 1978, HEPATIC COMA SYNDROM; FERENCI P, 1989, GASTROENTEROLOGY, V96, P240, DOI 10.1016/0016-5085(89)90787-7; FOERSTER EH, 1978, J ANAL TOXICOL, V2, P50, DOI 10.1093/jat/2.2.50; GAMMAL SH, 1990, HEPATOLOGY, V11, P371, DOI 10.1002/hep.1840110307; Greenblatt DJ, 1987, PSYCHOPHARMACOLOGY 3, P1377; GRIMM G, 1988, LANCET, V2, P1392; JONES EA, 1988, LIVER BIOL PATHOBIOL, P985; LUCKNER M., 1984, SECONDARY METABOLISM, DOI DOI 10.1007/978-3-662-09838-7; MEDINA JH, 1988, BIOCHEM BIOPH RES CO, V152, P534, DOI 10.1016/S0006-291X(88)80070-6; MENNINI T, 1983, BENZODIAZEPINE RECOG, P189; MULLEN KD, 1989, METAB BRAIN DIS, V4, P253, DOI 10.1007/BF00999771; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; OLASMAA M, 1989, LANCET, V1, P491; OSSELTON MD, 1977, J FORENSIC SCI SOC, V17, P189, DOI 10.1016/S0015-7368(77)71147-8; SANGAMESWARAN L, 1986, P NATL ACAD SCI USA, V83, P9236, DOI 10.1073/pnas.83.23.9236; SCHAFER DF, 1982, LANCET, V1, P18, DOI 10.1016/S0140-6736(82)92559-4; SCHENKER S, 1988, HEPATIC ENCEPHALOPAT, P15; SCOLLOLAVIZZARI G, 1985, LANCET, V1, P1324; SKOLNICK P, 1988, ISI ATLAS-PHARMACOL, V2, P19; STEINDL P, 1990, Gastroenterology, V98, pA636; UNSELD E, 1990, BIOCHEM PHARMACOL, V39, P210, DOI 10.1016/0006-2952(90)90668-B; WILDMANN J, 1987, J NEURAL TRANSM, V70, P383, DOI 10.1007/BF01253613; WILDMANN J, 1988, BIOCHEM PHARMACOL, V37, P3549, DOI 10.1016/0006-2952(88)90384-X; WILDMANN J, 1988, BIOCHEM BIOPH RES CO, V157, P1436, DOI 10.1016/S0006-291X(88)81036-2; 1985, DISEASES LIVER BILIA, P91	35	144	145	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					473	478		10.1056/NEJM199108153250705	http://dx.doi.org/10.1056/NEJM199108153250705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649403	Bronze			2022-12-28	WOS:A1991GA76300005
J	FENTIMAN, IS; MANSEL, RE				FENTIMAN, IS; MANSEL, RE			THE AXILLA - NOT A NO-GO ZONE	LANCET			English	Editorial Material							EARLY BREAST-CANCER; CLINICAL-TRIAL; SIMPLE MASTECTOMY; MANAGEMENT; DISSECTION; BIOPSY; NODES	Many surgeons, particularly in the UK, give inadequate primary treatment to patients with operable breast cancer. For spurious reasons they regard axillary clearance as unnecessarily extensive surgery and rely instead upon total mastectomy or tumour excision and node sampling, with or without postoperative radiotherapy. But it is now clear that relapse-free and overall survival can be improved by appropriate adjuvant therapy. Thus inadequate exploration of the axilla is doubly unjustified. Not only is there the obvious risk of failure to remove nodes that contain metastases-so that some patients are deprived of cure by primary treatment-but the extent of tumour spread will be inadequately assessed in many more patients, with the risk that they may not received appropriate adjuvant treatment.	WITHINGTON HOSP,DEPT SURG,MANCHESTER M20 8LE,ENGLAND		FENTIMAN, IS (corresponding author), GUYS & ST THOMAS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND.		Fentiman, Ian S/I-7644-2019; Fentiman, Ian/AAB-9886-2020					ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; BARNES DM, 1989, LANCET, V1, P1126; BENSON EA, 1986, EUR J SURG ONCOL, V12, P267; BRUNETON JN, 1986, RADIOLOGY, V158, P325, DOI 10.1148/radiology.158.2.3510440; CANT ELM, 1975, LANCET, V1, P995; DAVIS GC, 1980, ANN SURG, V192, P145; FENTIMAN IS, 1984, BRIT MED J, V289, P1108, DOI 10.1136/bmj.289.6452.1108; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FORREST APM, 1982, ANN SURG, V196, P371, DOI 10.1097/00000658-198209000-00017; HARRIS JR, 1985, BREAST CANCER RES TR, V5, P17, DOI 10.1007/BF01807645; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; KISSIN MW, 1982, LANCET, V1, P1210; KJAERGAARD J, 1985, BRIT J SURG, V72, P365, DOI 10.1002/bjs.1800720511; LESLIE MD, 1990, BRIT MED J, V300, P749, DOI 10.1136/bmj.300.6726.749-d; MATTHEIEM W, 1989, EUR J SURG ONCOL, V15, P490; MCLEAN RG, 1986, J NUCL MED, V27, P1116; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; RICHARDS MA, IN PRESS J CLIN ONCO; SACRE RA, 1986, EUR J SURG ONCOL, V12, P169; VANDERSCHUEREN E, 1988, EUR J CANCER CLIN ON, V24, P89, DOI 10.1016/0277-5379(88)90182-4; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; WALLACE IWJ, 1972, LANCET, V1, P217; YEOH EK, 1986, ACTA ONCOL, V25, P105, DOI 10.3109/02841868609136386; 1980, LANCET, V2, P55; 1988, NEW ENGL J MED, V319, P1681	27	118	118	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					221	223		10.1016/0140-6736(91)92172-X	http://dx.doi.org/10.1016/0140-6736(91)92172-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670853				2022-12-28	WOS:A1991EU92400016
J	JENCKS, SF; WILENSKY, GR				JENCKS, SF; WILENSKY, GR			THE HEALTH-CARE QUALITY IMPROVEMENT INITIATIVE - A NEW APPROACH TO QUALITY ASSURANCE IN MEDICARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; CONSENSUS; CRITERIA; SURGERY				JENCKS, SF (corresponding author), HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.							Berwick D. M, 1990, CURING HLTH CARE NEW; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Deming E.W., 1982, OUT CRISIS; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Juran J.M., 1988, JURAN PLANNING QUALI; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KELLER RB, 1990, J BONE JOINT SURG AM, V72A, P1286, DOI 10.2106/00004623-199072090-00002; KELLIE SE, 1991, JAMA-J AM MED ASSOC, V265, P1265, DOI 10.1001/jama.265.10.1265; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; KRAKAUER H, IN PRESS HLTH SERV R; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; 1992, MEDICARE HOSPITAL IN; 1992, AMH ACCREDITATION MA; 1988, 03281 US DEP HLTH HU; 1990, MEDICARE STRATEGY QU; 1990, HLTH CARE FINANCING	27	247	248	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					900	903		10.1001/jama.268.7.900	http://dx.doi.org/10.1001/jama.268.7.900			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640620				2022-12-28	WOS:A1992JH58800042
J	HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M				HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M			IDENTIFICATION OF A NEURAL ALPHA-CATENIN AS A KEY REGULATOR OF CADHERIN FUNCTION AND MULTICELLULAR ORGANIZATION	CELL			English	Article							CELL-ADHESION MOLECULE; CYTOPLASMIC DOMAIN; EXPRESSION; UVOMORULIN; CDNA; EMBRYOS; REGION	The function of cadherin cell adhesion molecules is thought to be regulated by a group of cytoplasmic proteins, including alpha-catenin. We identified a subtype of alpha-catenin, termed alpha-catenin, which is associated with N-cadherin and expressed mainly in the nervous system. cDNA transfection experiments showed that alpha-N-catenin can also bind with E-cadherin. To investigate the role of alpha-N-catenin, we transfected lung carcinoma PC9 cells, which express E-cadherin and beta-catenin but neither alpha- nor alpha-N-catenin, with alpha-N-catenin cDNA. While parental PC9 grew as isolated cells, the transfectant lines formed aggregates in which cells were tightly adhered to each other, showing epithelial arrangements, and they occasionally gave rise to cystic spheres. These results suggest that alpha-N-catenin is crucial not only for cadherin function but also for organization of multicellular structures.	NATL CANC CTR, RES INST, DIV PATHOL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan	HIRANO, S (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KINJO M, 1979, BRIT J CANCER, V39, P15, DOI 10.1038/bjc.1979.3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, IN PRESS J CELL BIOL; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x	33	530	539	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					293	301		10.1016/0092-8674(92)90103-J	http://dx.doi.org/10.1016/0092-8674(92)90103-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638632				2022-12-28	WOS:A1992JE75700012
J	LOFTIN, C; MCDOWALL, D; WIERSEMA, B; COTTEY, TJ				LOFTIN, C; MCDOWALL, D; WIERSEMA, B; COTTEY, TJ			EFFECTS OF RESTRICTIVE LICENSING OF HANDGUNS ON HOMICIDE AND SUICIDE IN THE DISTRICT-OF-COLUMBIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGULATIONS; GUNS	Background. Whether restricting access to handguns will reduce firearm-related homicides and suicides is currently a matter of intense debate. In 1976 the District of Columbia adopted a law that banned the purchase, sale, transfer, or possession of handguns by civilians. We evaluated the effect of implementing this law on the frequency of homicides and suicides. Methods. Homicides and suicides committed from 1968 through 1987 were classified according to place of occurrence (within the District of Columbia or in adjacent metropolitan areas where the law did not apply), cause (homicide or suicide), mechanism of death (firearms or other means), and time of occurrence (before or after the implementation of the law). The number of suicides and homicides was calculated for each month during the study period, and differences between the mean monthly totals before and after the law went into effect were estimated. Results. In Washington, D.C., the adoption of the gun-licensing law coincided with an abrupt decline in homicides by firearms (a reduction of 3.3 per month, or 25 percent) and suicides by firearms (reduction, 0.6 per month, or 23 percent). No similar reductions were observed in the number of homicides or suicides committed by other means, nor were there similar reductions in the adjacent metropolitan areas in Maryland and Virginia. There were also no increases in homicides or suicides by other methods, as would be expected if equally lethal means were substituted for handguns. Conclusions. Restrictive licensing of handguns was associated with a prompt decline in homicides and suicides by firearms in the District of Columbia. No such decline was observed for homicides or suicides in which guns were not used, and no decline was seen in adjacent metropolitan areas where restrictive licensing did not apply. Our data suggest that restrictions on access to guns in the District of Columbia prevented an average of 47 deaths each year after the law was implemented.			LOFTIN, C (corresponding author), UNIV MARYLAND, INST CRIMINAL JUSTICE & CRIMINOL, VIOLENCE RES GRP, 2220 LEFRAK HALL, COLLEGE PK, MD 20742 USA.		Wiersema, Brian/E-5305-2012	Wiersema, Brian/0000-0003-4026-7888				[Anonymous], 1976, TIME SERIES ANAL; [Anonymous], 1968, U CHICAGO LAW REV; BAKER SP, 1985, AM J PUBLIC HEALTH, V75, P587, DOI 10.2105/AJPH.75.6.587; BOX GEP, 1975, J AM STAT ASSOC, V70, P70, DOI 10.2307/2285379; Cochran WG, 1983, PLANNING ANAL OBSERV; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; Daly, 1983, GUN WEAPONS CRIME VI; JONES ED, 1981, ANN AM ACAD POLIT SS, V455, P138, DOI 10.1177/000271628145500112; LIU LM, 1986, SCA STATISTICAL SYST; McDowall D., 1980, INTERRUPTED TIME SER; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; MORIN R, 1989, WASH POST       0908, pA1; NICHOLSON R, 1980, ANAL FIREARMS CONTRO; RICH CL, 1990, AM J PSYCHIAT, V147, P342; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; VALENTINE PW, 1980, WASHINGTON POST 0629, pB1; WENTWORTH E, 1977, WASHINGTON POST 0205, pB1; ZIMRING FE, 1981, ANN AM ACAD POLIT SS, V455, P1, DOI 10.1177/000271628145500102; 1976, BUREAU CENSUS CU P26, V7820; 1973, CENSUS POPULATION 10, V1; 1990, VITAL STATISTICS U A, V2; 1969, BUREAU CENSUS CU P25, V537; 1967, PHS PUBLICATION, V1693; 1976, BUREAU CENSUS CU P26, V7546; 1969, BUREAU CENSUS CU P25, V688; 1989, DHHS PHS891260 PUBL; 1976, BUREAU CENSUS CU P26, V7646; 1976, BUREAU CENSUS CU P26, V7746; 1969, BUREAU CENSUS CU P25, V629; 1988, HOMICIDE DISTRICT CO; 1990, MORTALITY DETAIL FIL; 1988, CRIME US 1987; 1967, STANDARD METROPOLITA; 1969, BUREAU CENSUS CU P25, V432; 1976, BUREAU CENSUS CU P26, V7720; 1969, BUREAU CENSUS CU P25, V517; 1976, BUREAU CENSUS CU P26, V7620; 1976, BUREAU CENSUS CU P26, V7846; 1969, BUREAU CENSUS CU P25, V694	40	268	270	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1615	1620		10.1056/NEJM199112053252305	http://dx.doi.org/10.1056/NEJM199112053252305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1669841	Bronze			2022-12-28	WOS:A1991GR77000005
J	HAMMERTON, RW; KRZEMINSKI, KA; MAYS, RW; RYAN, TA; WOLLNER, DA; NELSON, WJ				HAMMERTON, RW; KRZEMINSKI, KA; MAYS, RW; RYAN, TA; WOLLNER, DA; NELSON, WJ			MECHANISM FOR REGULATING CELL-SURFACE DISTRIBUTION OF NA+, K+-ATPASE IN POLARIZED EPITHELIAL-CELLS	SCIENCE			English	Article							CANINE KIDNEY-CELLS; MEMBRANE CYTOSKELETAL COMPLEX; ADHESION MOLECULE UVOMORULIN; MDCK CELLS; ALPHA-SUBUNIT; NA,K-ATPASE; PROTEIN; ANKYRIN; PLASMA; FODRIN	Restriction of sodium, potassium adenosine triphosphatase (Na+, K+-ATPase) to either the apical or basal-lateral membrane domain of polarized epithelial cells is fundamental to vectorial ion and solute transport in many tissues and organs. A restricted membrane distribution of Na+, K+-ATPase in Madin-Darby canine kidney (MDCK) epithelial cells was found experimentally to be generated by preferential retention of active enzyme in the basal-lateral membrane domain and selective inactivation and loss from the apical membrane domain, rather than by vectorial targeting of newly synthesized protein from the Golgi complex to the basal-lateral membrane domain. These results show how different distributions of the same subunits of Na+, K+-ATPase may be generated in normal polarized epithelia and in disease states.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University			Ryan, Timothy/AAO-8286-2020	Ryan, Timothy/0000-0003-2533-9548	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R37GM035527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVNER E, UNPUB; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; CAPLAN M, 1989, MODERN CELL BIOL, V8, P71; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; COHEN SM, 1983, J BIOL CHEM, V258, P2621; CONTRERAS RG, 1989, AM J PHYSIOL, V257, pC896, DOI 10.1152/ajpcell.1989.257.5.C896; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; GHOSH S, 1990, J BIOL CHEM, V265, P2935; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, UNPUB; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KELLY RA, 1986, J BIOL CHEM, V261, P1704; KOOB R, 1987, European Journal of Cell Biology, V45, P230; MARRS JA, 1990, J AM SOC NEPHROL, V1, P711; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MOLITORIS BA, 1988, J MEMBRANE BIOL, V106, P233, DOI 10.1007/BF01872161; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STAHL WL, 1986, NEUROCHEM INT, V8, P449, DOI 10.1016/0197-0186(86)90179-8; SUTHERLAND E, 1988, P NATL ACAD SCI USA, V85, P8673, DOI 10.1073/pnas.85.22.8673; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WOLLNER D, UNPUB; WRIGHT EM, 1972, J PHYSIOL-LONDON, V226, P545, DOI 10.1113/jphysiol.1972.sp009997; ZHENG B, 1990, CANCER RES, V50, P3025	39	281	284	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					847	850		10.1126/science.1658934	http://dx.doi.org/10.1126/science.1658934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658934				2022-12-28	WOS:A1991GN83300042
J	ZOMERDIJK, JCBM; KIEFT, R; BORST, P				ZOMERDIJK, JCBM; KIEFT, R; BORST, P			EFFICIENT PRODUCTION OF FUNCTIONAL MESSENGER-RNA MEDIATED BY RNA POLYMERASE-I IN TRYPANOSOMA-BRUCEI	NATURE			English	Article							TRANSCRIPTION UNIT; GENE; EXPRESSION; PROMOTER; TRANS; IDENTIFICATION; PROVIDES; TUBULIN; CELLS; RDNA	THE unicellular eukaryote Trypanosoma brucei evades the immune defence of its mammalian host by antigenic variation 1. The genes for variant-specific surface glycoproteins (VSGs) are expressed within large multicistronic transcription units 2. Mature messenger RNAs are produced by trans-splicing and polyadenylation 3-5. A remarkable feature of the transcription of VSG genes is its insensitivity to the RNA polymerase II inhibitor alpha-amanitin 6. This has led to the speculation that RNA polymerase I, normally only involved in the transcription of ribosomal RNA genes, also mediates expression of these surface antigen genes. In higher eukaryotes, however, transcripts produced by RNA polymerase I were found to be poor substrates for processing into mature mRNAs 7-9. In contrast, we show here that the RNA polymerase I of T. brucei can mediate the efficient production of functional mRNA for neomycin phosphotransferase. The exceptional ability may be related to the unusual way in which pre-mRNAs are capped in trypanosomes. In most eukaryotes, mRNAs are modified at their 5' end by a capping activity associated with RNA polymerase II10; in trypanosomes, mRNAs acquire their 5'-cap from capped mini-exon donor RNA by trans-splicing 3-5, a process that could be independent of the RNA polymerase producing the pre-mRNA.			ZOMERDIJK, JCBM (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Zomerdijk, Joost/A-5142-2008	Zomerdijk, Joost/0000-0003-1865-729X				CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; GRIMALDI G, 1986, NUCLEIC ACIDS RES, V14, P6417, DOI 10.1093/nar/14.16.6417; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; IMBODEN M, 1986, J MOL BIOL, V166, P393; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; JOVE R, 1982, P NATL ACAD SCI-BIOL, V79, P5842, DOI 10.1073/pnas.79.19.5842; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LOPATA MA, 1986, P NATL ACAD SCI USA, V83, P6677, DOI 10.1073/pnas.83.18.6677; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; SATHER S, 1985, P NATL ACAD SCI USA, V82, P5695, DOI 10.1073/pnas.82.17.5695; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	24	83	84	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					772	775		10.1038/353772a0	http://dx.doi.org/10.1038/353772a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1658658				2022-12-28	WOS:A1991GL69600074
J	NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P				NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P			CHARACTERIZATION OF THE ROUGH ENDOPLASMIC-RETICULUM RIBOSOME-BINDING ACTIVITY	NATURE			English	Article							MICROSOMAL-MEMBRANES; IDENTIFICATION; TRANSLOCATION; PROTEINS	THE rough endoplasmic reticulum membranes of mammalian cells contain specific ribosome-binding sites 1. A purification to apparent homogeneity of a negatively charged protein (ERpl80) of relative molecular mass 180,000 (180 K) was reported which was proposed to function as a rough endoplasmic reticulum ribosome receptor 2 We report here that ribosome-binding site activity quantitatively solubilized from rough endoplasmic reticulum membranes does not cofractionate with ERpl80. By contrast, ribosome-binding site activity fractionates as a much smaller, positively charged protein.			NUNNARI, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; COLLINS PG, IN PRESS J CELL BIOL; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WALTER P, 1983, METHOD ENZYMOL, V96, P682; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	8	31	31	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					638	640		10.1038/352638a0	http://dx.doi.org/10.1038/352638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650916				2022-12-28	WOS:A1991GB21100061
J	GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION AND CHARACTERIZATION OF THE FAMILIAL ADENOMATOUS POLYPOSIS-COLI GENE	CELL			English	Article							COLORECTAL CANCERS; POINT MUTATIONS; HUMAN DNA; POLYMORPHISMS; CHROMOSOME-5; INHERITANCE; DELETION	DNA from 61 unrelated patients with adenomatous polyposis coli (APC) was examined for mutations in three genes (DP1, SRP19, and DP2.5) located within a 100 kb region deleted in two of the patients. The intron-exon boundary sequences were defined for each of these genes, and single-strand conformation polymorphism analysis of exons from DP2.5 identified four mutations specific to APC patients. Each of two aberrant alleles contained a base substitution changing an amino acid to a stop codon in the predicted peptide; the other mutations were small deletions leading to frameshifts. Analysis of DNA from parents of one of these patients showed that his 2 bp deletion is a new mutation; furthermore, the mutation was transmitted to two of his children. These data have established that DP2.5 is the APC gene.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	GRODEN, J (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		Pillay, Nischalan/F-9536-2012; McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; Maniatis T., 1982, MOL CLONING; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIVERA H, 1990, J MED GENET, V27, P267, DOI 10.1136/jmg.27.4.267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X	28	2345	2415	2	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					589	600		10.1016/0092-8674(81)90021-0	http://dx.doi.org/10.1016/0092-8674(81)90021-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651174				2022-12-28	WOS:A1991GA94100019
J	HOYT, MA; TOTIS, L; ROBERTS, BT				HOYT, MA; TOTIS, L; ROBERTS, BT			SACCHAROMYCES-CEREVISIAE GENES REQUIRED FOR CELL-CYCLE ARREST IN RESPONSE TO LOSS OF MICROTUBULE FUNCTION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DIVISION CYCLE; YEAST; KINASE; DNA; MUTATIONS; MUTANTS	We have identified mutant strains of S. cerevisiae that fail to properly arrest their cell cycles at mitosis in response to the loss of microtubule function. New bud emergence and DNA replication (but not cytokinesis) occur with high efficiency in the mutants under conditions that inhibit these events in wild-type cells. The inability to halt cell cycle progression is specific for impaired microtubule function; the mutants respond normally to other cell cycle-blocking treatments. Under microtubule-disrupting conditions, the mutants neither achieve nor maintain the high level of histone H-1 kinase activity characteristic of wild-type cells. Our studies have defined three genes required for normal cell cycle arrest. These findings are consistent with the existence of a surveillance system that halts the cell cycle in response to microtubule perturbation.			HOYT, MA (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.				NCRR NIH HHS [S07RR07041] Funding Source: Medline; NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Dustin P., 1984, MICROTUBULES; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGE P, 1980, MOL GEN GENET, V180, P605, DOI 10.1007/BF00268067; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	36	951	978	2	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					507	517		10.1016/0092-8674(81)90014-3	http://dx.doi.org/10.1016/0092-8674(81)90014-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651171	hybrid			2022-12-28	WOS:A1991GA94100012
J	FERRARI, MD				FERRARI, MD			TREATMENT OF MIGRAINE ATTACKS WITH SUMATRIPTAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							5-HT1-LIKE RECEPTOR AGONIST; GR43175; HEADACHE	Background. The headache in migraine attacks may be caused by dilatation of certain cranial arteries or arteriovenous anastomoses, by neurogenic dural plasma extravasation, or by both of these mechanisms. Sumatriptan, a novel selective agonist of 5-hydroxytryptamine-like receptors, blocks these phenomena. We investigated its efficacy in migraine. Methods. We studied 639 patients with migraine attacks in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. We assessed the effect of subcutaneous injections of 6 or 8 mg of sumatriptan or placebo on the severity of headache and associated migraine symptoms 30, 60, and 120 minutes after treatment. Patients who were not free of pain after 60 minutes subsequently received placebo if they had initially received placebo or 8 mg of sumatriptan, and 6 mg of sumatriptan or placebo if they had initially received 6 mg of sumatriptan. Results. After 60 minutes, the severity of headache was decreased in 72 percent (95 percent confidence interval, 68 to 76 percent) of the 422 patients given 6 mg of sumatriptan, 79 percent (95 percent confidence interval, 71 to 87 percent) of the 109 patients given 8 mg of sumatriptan, and 25 percent (95 percent confidence interval, 17 to 33 percent) of the 105 patients given placebo (data on 3 patients could not be evaluated). As compared with the placebo group, 47 percent (95 percent confidence interval, 38 to 57 percent) more patients who had received 6 mg of sumatriptan and 54 percent (95 percent confidence interval, 43 to 65 percent) more patients who had received 8 mg of sumatriptan had a decrease in the severity of headache (P < 0.001 for both comparisons). After 120 minutes, 86 to 92 percent of the 511 patients treated with sumatriptan (202 assigned to 6 mg plus placebo, 203 to 6 mg plus 6 mg, and 106 to 8 mg plus placebo) had improvement in the severity of headache, as compared with only 37 percent of the 104 patients who received placebo once or twice (P < 0.001 for all comparisons). Twenty-one patients were excluded from the analysis because of missing data (19) or protocol violations (2). The response rates did not differ significantly among the sumatriptan regimens. Adverse events were minor and transient in all groups. Conclusions. We conclude that a single 6-mg dose of sumatriptan given subcutaneously is a highly effective, rapid-acting, and well-tolerated treatment for migraine attacks. The administration of a second dose 60 minutes later to patients not responding well to an initial dose affords little additional benefit.			FERRARI, MD (corresponding author), UNIV HOSP LEIDEN,DEPT NEUROL,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Ferrari, Michel D./ABE-3758-2021	Ferrari, Michel D./0000-0001-9691-9449				BABORIER D, 1985, Journal de Medecine de Strasbourg, V16, P589; Blau JN, 1987, MIGRAINE CLIN THERAP, P3; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; BYER J, 1989, CEPHALALGIA S10, V9, P349; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; COOK NR, 1989, ARCH NEUROL-CHICAGO, V46, P1338, DOI 10.1001/archneur.1989.00520480082024; DOENICKE A, 1988, LANCET, V1, P1309; FERRARI M, 1989, CEPHALALGIA S10, V9, P348; FERRARI MD, 1989, NEUROLOGY, V39, P1239, DOI 10.1212/WNL.39.9.1239; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HUMPHREY PPA, 1989, CEPHALALGIA, V9, P23; LANCE JW, 1966, ARCH NEUROL-CHICAGO, V15, P356, DOI 10.1001/archneur.1966.00470160022003; LANCE JW, 1989, CEPHALALGIA, V9, P7; LEONSOTOMAYOR LA, 1974, ANGIOLOGY, V25, P161, DOI 10.1177/000331977402500301; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LINET MS, 1987, MIGRAINE CLIN THERAP, P451; Moskowitz M., 1988, BASIC MECH HEADACHE, P429; PEATFIELD RC, 1986, HDB CLIN NEUROLOGY, V4, P173; PERERA GA, 1971, J AMER MED ASSOC, V215, P488, DOI 10.1001/jama.1971.03180160084040; PERREN MJ, 1989, CEPHALALGIA, V9, P41; PERRIN VL, 1989, CEPHALALGIA, V9, P63; PERRIN VL, 1985, CLIN PHARMACOKINET, V10, P334, DOI 10.2165/00003088-198510040-00004; SAXENA PR, 1989, TRENDS PHARMACOL SCI, V10, P200, DOI 10.1016/0165-6147(89)90238-1; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; THRUSH D, 1984, DILEMMAS MANAGEMENT, P106; ZIEGLER DK, 1986, HDB CLIN NEUROLOGY, V48, P13	26	362	370	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1991	325	5					316	321						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY715	1647495				2022-12-28	WOS:A1991FY71500004
J	IMANISHIKARI, T				IMANISHIKARI, T			IMANISHI-KARI RIPOSTE	NATURE			English	Editorial Material																		OTOOLE M, 1991, NATURE, V351, P180, DOI 10.1038/351180a0	1	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					691	692		10.1038/351691a0	http://dx.doi.org/10.1038/351691a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648173				2022-12-28	WOS:A1991FU20100030
J	SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF				SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF			THE NEUROTROPHIC FACTORS BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 ARE LIGANDS FOR THE TRKB TYROSINE KINASE RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; PDGF BETA-RECEPTOR; MOLECULAR-CLONING; FACTOR FAMILY; SIGNALING COMPLEX; MESSENGER-RNA; GENE-TRANSFER; EXPRESSION; ONCOGENE; CELLS	Neurotrophic factors are essential for neuronal survival and function. Recent data have demonstrated that the product of the tyrosine kinase trk protooncogene binds NGF and is a component of the high affinity NGF receptor. Analysis of the trkB gene product, gp145trkB, in NIH 3T3 cells indicates that this tyrosine kinase receptor is rapidly phosphorylated on tyrosine residues upon exposure to the NGF-related neurotrophic factors BDNF and NT-3. Furthermore, gp145trkB specifically binds BDNF and NT-3 in NIH 3T3 cells and in hippocampal cells,but does not bind NGF. Thus, the trk family of receptors are likely to be important signal transducers of NGF-related trophic signals in the formation and maintenance of neuronal circuits.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA 94080; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Roche Holding; Genentech; Salk Institute	SOPPET, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC EMBRYOL SECT,FREDERICK,MD 21702, USA.		Parada, luis F/B-9400-2014		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Black I.B., 1990, Current Topics in Developmental Biology, V24, P161; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHAO MV, 1990, HDB EXPT PHARM, P135; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HIGASHIYAMA S, 1991, SCIENCE, V251, P72; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MARTINZANCA D, 1990, AVIAN MODEL IN DEVELOPMENT BIOLOGY : FROM ORGANISM TO GENES, P291; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Ramon y Cajal S., 1909, HISTOLOGIE SYSTEME N, DOI [DOI 10.5962/BHL.TITLE.48637, 10.5962/bhl.title.48637]; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSENTHAL A, 1991, IN PRESS ENDOCRINOLO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SUTTER A, 1979, J BIOL CHEM, V254, P5972; VETTER ML, 1991, IN PRESS P NATL ACAD	56	716	744	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					895	903		10.1016/0092-8674(91)90396-G	http://dx.doi.org/10.1016/0092-8674(91)90396-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645620				2022-12-28	WOS:A1991FP51600019
J	PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA				PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA			SERIAL LYMPHOCYTE-CD4 COUNTS AND DEVELOPMENT OF AIDS	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; NATURAL-HISTORY; HOMOSEXUAL MEN; HIV INFECTION; LYMPHADENOPATHY; SUBSETS; FOLLOW; COHORT	Low CD4 lymphocyte counts are associated with increased risk of progression to AIDS in human immunodeficiency virus (HIV) infection. We investigated the extent to which the timing of progression to AIDS can be explained solely in terms of decline of the CD4 lymphocyte count in 111 haemophiliacs followed for up to 11 years since infection with HIV. A median of 10 CD4 lymphocyte counts were made per patient. By applying a simple linear model for the decline in CD4 lymphocyte counts over time, we estimated the date of development of AIDs in 96 patients who had at least 5 determinations. 84% (81 of 96) of patients were correctly classified as to development of AIDS before Jan 1, 1990 (p < 0.0001), with this model. The results suggest that differences in the time at which patients with HIV will progress to AIDS can largely be explained by differences in rates of decline of CD4 lymphocyte counts.	ROYAL FREE HOSP, SCH MED, CTR HAEMOPHILIA, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT IMMUNOL, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH & PRIMARY CARE, ROWLAND HILL ST, LONDON NW3 2PF, ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				CAMPANA D, 1987, J IMMUNOL, V138, P648; CROWE S, 1990, 6 INT C AIDS SAN FRA; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FABIO G, 1990, BRIT J HAEMATOL, V75, P531, DOI 10.1111/j.1365-2141.1990.tb07794.x; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GARDENER MJ, 1989, STATISTICS CONFIDENC; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, BRIT J HAEMATOL, V75, P623, DOI 10.1111/j.1365-2141.1990.tb07813.x; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1990, 6 INT C AIDS SAN FRA; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VISSCHER B, 1990, 6 INT C AIDS SAN FRA; WAYNE WF, 1988, CYTOMETRY, V3, P23; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017	28	319	322	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	1991	337	8738					389	392						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671424				2022-12-28	WOS:A1991EX60500004
J	SAVIC, I; WIDEN, L; STONEELANDER, S				SAVIC, I; WIDEN, L; STONEELANDER, S			FEASIBILITY OF REVERSING BENZODIAZEPINE TOLERANCE WITH FLUMAZENIL	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; RO 15-1788; ANTAGONIST; RO-15-1788; INVIVO; MICE; BINDING; BRAIN	To examine whether the benzodiazepine antagonist flumazenil can reverse tolerance to benzodiazepines but without precipitating withdrawal seizures, the antiepileptic effect of flumazenil itself and its ability to reverse tolerance at a dose that would leave sufficient receptors free for the binding of benzodiazepines were investigated. Electroencephalographic studies in 6 patients with partial and 6 with generalised seizures showed that flumazenil had a short (20 min) non-dose-dependent suppressant effect on epileptic discharges in those with partial seizures. Receptor occupancy studies in 12 patients showed that 1.5 mg flumazenil given intravenously occupied 55% receptors, whereas 15 mg occupied nearly all receptors. When 3 patients with partial seizures who had become tolerant to clonazepam were given 1.5 mg flumazenil, they were seizure-free for 6-21 days after the injection. The value of intermittent therapy with a benzodiazepine antagonist for preventing or reversing tolerance to benzodiazepine agonists ought to be investigated further.	KAROLINSKA PHARM,STOCKHOLM,SWEDEN	Karolinska Institutet	SAVIC, I (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROPHYSIOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN.							BORMANN J, 1988, CHLORIDE CHANNELS TH, P47; ERIKSSON L, 1988, IEEE T NUCL SCI, V35, P703, DOI 10.1109/23.12815; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GASTAUT H, 1985, J CLIN NEUROPHYSIOL, V2, P313, DOI 10.1097/00004691-198510000-00001; GELLER E, 1985, ANESTHESIOLOGY, V63, pA157; GLOOR P, 1982, H GASTAUT MARSEILLES, P45; GONSALVES SF, 1987, BRAIN RES, V405, P94, DOI 10.1016/0006-8993(87)90993-0; GONSALVES SF, 1985, EUR J PHARMACOL, V110, P163, DOI 10.1016/0014-2999(85)90208-0; GRECKSCH G, 1983, LIFE SCI, V32, P2579, DOI 10.1016/0024-3205(83)90241-2; Haefley W, 1988, CHLORIDE CHANNELS TH, P275; HAIGH JRM, 1988, TRENDS PHARMACOL SCI, V9, P361, DOI 10.1016/0165-6147(88)90255-6; HALLDIN C, 1988, APPL RADIAT ISOTOPES, V39, P993; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; JENSEN LH, 1983, LIFE SCI, V33, P393, DOI 10.1016/S0024-3205(83)80014-9; LUKAS SE, 1982, SCIENCE, V217, P1161, DOI 10.1126/science.6287579; MENNINI T, 1982, LIFE SCI, V31, P2025, DOI 10.1016/0024-3205(82)90094-7; MILLER LG, 1987, J PHARMACOL EXP THER, V240, P516; NUTT DJ, 1988, LIFE SCI, V43, P1045, DOI 10.1016/0024-3205(88)90199-3; PERSSON A, 1989, Human Psychopharmacology, V4, P215, DOI 10.1002/hup.470040307; POTIER MC, 1988, LIFE SCI, V43, P1287, DOI 10.1016/0024-3205(88)90583-8; ROBERTSON HA, 1983, BRAIN RES, V270, P380, DOI 10.1016/0006-8993(83)90619-4; SAVIC I, 1988, LANCET, V2, P863, DOI 10.1016/S0140-6736(88)92468-3; SAVIC I, IN PRESS EPILEPSIA; SCOLLOLAVIZZARI G, 1984, EUR NEUROL, V23, P1, DOI 10.1159/000115669; SHINOTOH H, 1989, PSYCHOPHARMACOLOGY, V99, P202, DOI 10.1007/BF00442808; SWAHN C-G, 1989, Human Psychopharmacology, V4, P297, DOI 10.1002/hup.470040410; THEODORSSON E, 1988, COMPUT METH PROG BIO, V26, P207, DOI 10.1016/0169-2607(88)90046-6	27	82	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					133	137		10.1016/0140-6736(91)90799-U	http://dx.doi.org/10.1016/0140-6736(91)90799-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670787				2022-12-28	WOS:A1991ET67900003
J	MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H				MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H			MATERNAL HEAT EXPOSURE AND NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-PREGNANCY; HYPERTHERMIA; SAUNA; TERATOGEN; FEVER; ABNORMALITIES; EMBRYOS; WOMEN	Objective.-To determine if exposure to hot tub, sauna, fever, or electric blanket during early pregnancy was associated with an increased risk for neural tube defects (NTDs). Design.-Prospective follow-up study. Setting.-Mostly private obstetric practices, primarily in New England. Participants.-A cohort of 23491 women having serum alpha-fetoprotein screening or an amniocentesis were identified. Complete exposure and outcome information was available for 97% of these women. Outcome Measures.-Relative risks (RRs) were used to compare incidence of NTD in those exposed to heat with those who were not exposed to any heat. Crude RRs were calculated directly from the data. Unconfounded RRs were calculated using logistic regression. Results.-Women reporting any heat exposure (sauna, hot tub, fever, or electric blanket) in early pregnancy had a crude risk of their fetuses developing NTD of 1.6 (95% CI [confidence interval], 0.9 to 2.9). Women reporting exposure to sauna, hot tub, or fever in early pregnancy had a crude risk of their fetuses developing NTD 2.2 times that of women without heat exposure (95% CI, 1.2 to 4.1). For hot tub use, the crude RR was 2.9 (95% CI, 1.4 to 6.3); for sauna, 2.6 (95% CI, 0.7 to 10.1); for fever, 1.9 (95% CI, 0.8 to 4.1); and for electric blanket, 1.2 (95% CI, 0.5 to 2.6). Multivariate adjusted RRs for individual heat sources, after controlling for maternal age, folic acid supplements, family history of NTD, and exposure to other heat sources, were for hot tub use, 2.8 (95% CI, 1.2 to 6.5); sauna, 1.8 (95% CI, 0.4 to 7.9); fever, 1.8 (95% CI, 0.8 to 4.1); and electric blanket, 1.2 (95% CI, 0.5 to 2.6). When only hot tub, sauna, and fever were considered and the women's exposure to each tallied, compared with no heat exposure, the RR for NTDs increased from 1.9 (95% CI, 0.9 to 3.7) after one type of heat exposure to 6.2 (95% CI, 2.2 to 17.2) after two types of heat exposure. Conclusions.-Exposure to heat in the form of hot tub, sauna, or fever in the first trimester of pregnancy was associated with an increased risk for NTDs. Hot tub exposure appeared to have the strongest effect of any single heat exposure. Exposure to electric blanket was not materially associated with increased risk for NTDs.	BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED & EPIDEMIOL,BOSTON,MA 02118; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	MILUNSKY, A (corresponding author), BOSTON UNIV,SCH MED,CTR HUMAN GENET,80 E CONCORD ST,BOSTON,MA 02118, USA.			Rothman, Kenneth/0000-0003-2398-1705; Milunsky, Aubrey/0000-0003-2114-4823; Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992	NINDS NIH HHS [NS 19561] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019561] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARORA KL, 1979, TERATOLOGY, V19, P251, DOI 10.1002/tera.1420190216; BRINSMADE A B, 1957, Beitr Pathol Anat, V117, P154; CHANCE PF, 1978, LANCET, V1, P769; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; EDWARDS MJ, 1972, LANCET, V1, P320; EDWARDS MJ, 1974, J EMBRYOL EXP MORPH, V32, P593; EDWARDS MJ, 1967, ARCH PATHOL, V84, P42; EDWARDS MJ, 1986, TERATOGEN CARCIN MUT, V6, P563, DOI 10.1002/tcm.1770060610; FISHER NL, 1981, PEDIATRICS, V68, P480; FRASER FC, 1978, LANCET, V2, P634; GERMAN J, 1984, AM J MED, V76, P293, DOI 10.1016/0002-9343(84)90788-5; GRAHAM JM, 1988, TERATOLOGY, V37, P461; HARTLEY WJ, 1974, TERATOLOGY, V9, P299, DOI 10.1002/tera.1420090309; HARVEY MAS, 1981, CAN MED ASSOC J, V125, P50; HENDRICKX AG, 1979, TERATOLOGY, V19, P177, DOI 10.1002/tera.1420190208; HUNTER AGW, 1984, AM J MED GENET, V19, P45, DOI 10.1002/ajmg.1320190108; KILHAM L, 1976, TERATOLOGY, V14, P323, DOI 10.1002/tera.1420140307; KLEINEBRECHT J, 1979, LANCET, V1, P1403; LAYDE PM, 1980, TERATOLOGY, V21, P105, DOI 10.1002/tera.1420210114; LIPSON A, 1988, AM J MED GENET, V29, P117, DOI 10.1002/ajmg.1320290114; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILLER P, 1978, LANCET, V1, P519; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; NILSEN NO, 1984, TERATOLOGY, V30, P237, DOI 10.1002/tera.1420300211; PLEET H, 1981, PEDIATRICS, V67, P785; SAXEN L, 1982, TERATOLOGY, V25, P309, DOI 10.1002/tera.1420250307; SHIOTA K, 1982, AM J MED GENET, V12, P281, DOI 10.1002/ajmg.1320120306; SMITH DW, 1978, J PEDIATR-US, V92, P878, DOI 10.1016/S0022-3476(78)80352-7; SOHAR E, 1976, ISRAEL J MED SCI, V12, P1275; SPRAGGETT K, 1982, TERATOLOGY, V25, pA78; SUPERNEAU DW, 1985, AM J MED GENET, V21, P575, DOI 10.1002/ajmg.1320210319; UHARI M, 1979, BRIT MED J, V1, P1216, DOI 10.1136/bmj.1.6172.1216; UMPIERRE CC, 1978, TERATOLOGY, V16, P155; WANNER RA, 1976, J PATHOL, V118, P235, DOI 10.1002/path.1711180406; WARKANY J, 1986, TERATOLOGY, V33, P365, DOI 10.1002/tera.1420330316; WEBSTER WS, 1984, TERATOLOGY, V29, P417, DOI 10.1002/tera.1420290313; 1978, BMJ, V2, P1586; 1978, LANCET, V2, P560	38	188	194	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					882	885		10.1001/jama.268.7.882	http://dx.doi.org/10.1001/jama.268.7.882			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640616				2022-12-28	WOS:A1992JH58800038
J	NADELMAN, RB; LUGER, SW; FRANK, E; WISNIEWSKI, M; COLLINS, JJ; WORMSER, GP				NADELMAN, RB; LUGER, SW; FRANK, E; WISNIEWSKI, M; COLLINS, JJ; WORMSER, GP			COMPARISON OF CEFUROXIME AXETIL AND DOXYCYCLINE IN THE TREATMENT OF EARLY LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CEFUROXIME; DOXYCYCLINE; LYME DISEASE; ERYTHEMA CHRONICUM MIGRANS	BORRELIA-BURGDORFERI; INVIVO SUSCEPTIBILITY; ANTIMICROBIAL AGENTS; PENICILLIN; CEFTRIAXONE; INVITRO; MANIFESTATIONS; SPIROCHETE; THERAPY	Objective: To compare the efficacy of cefuroxime axetil and doxycycline in the treatment of patients with Lyme disease associated with erythema migrans. Design: Randomized, multicenter, investigator-blinded clinical trial with clinical evaluations during treatment (8 to 12 days) and at 1 to 5 days and 1, 3, 6, 9, and 12 months post-treatment. Setting: Three university referral centers and one private practice. Patients: A total of 123 patients with physician-documented erythema migrans. Intervention: Patients were treated orally for 20 days with either cefuroxime axetil, 500 mg twice daily (63 patients), or doxycycline, 100 mg three times daily (60 patients). Measurements: Resolution of erythema migrans and of signs and symptoms related to early Lyme disease as well as prevention of late Lyme disease. Results: A satisfactory clinical outcome (success or improvement) was achieved in 51 of 55 (93%) evaluable patients treated with cefuroxime axetil and in 45 of 51 (88%) patients treated with doxycycline (difference, 5%; 95% Cl, - 5% to 14%). The only complication at 1 month post-treatment was Lyme arthritis in one patient who received doxycycline. Of the patients with satisfactory outcomes at 1 month post-treatment who were evaluable at 1 year post-treatment, a satisfactory outcome was achieved in 43 of 48 (90%) and in 35 of 38 (92%) patients treated with cefuroxime axetil and doxycycline, respectively (difference, - 2%; Cl, - 12% to 7%). Lyme arthritis did not develop in any patient after 1 month post-treatment, whereas peripheral neuropathy was suspected in one patient treated with cefuroxime axetil. Thirty percent of patients treated with cefuroxime axetil and 32% of those treated with doxycycline had one or more drug-related adverse events. Doxycycline was associated with more photosensitivity reactions (15% compared with 0%; P = 0.001) and cefuroxime axetil with more diarrhea (21% compared with 7%; P = 0.035) and Jarisch-Herxheimer reactions (29% compared with 8%; P = 0.005). Conclusions: Cefuroxime axetil is well tolerated and appears to be equally as effective as doxycycline in the treating of early Lyme disease and in preventing the subsequent development of late Lyme disease.	OLD LYME FAMILY PRACTICE PC, OLD LYME, CT 06371 USA; JERSEY SHORE MED CTR, DEPT MED, NEPTUNE, NJ 07753 USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	Jersey Shore University Medical Center; GlaxoSmithKline	NADELMAN, RB (corresponding author), NEW YORK MED COLL, WESTCHESTER CTY MED CTR, DIV INFECT DIS, MACY PAVIL 209 SE, VALHALLA, NY 10595 USA.							BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1987, ARTHRITIS RHEUM, V30, P448, DOI 10.1002/art.1780300414; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DATTWYLER RJ, 1987, J INFECT DIS, V155, P1322, DOI 10.1093/infdis/155.6.1322; DONOWITZ GR, 1990, PRINCIPLES PRACTICE, P246; EMMERSON AM, 1988, J ANTIMICROB CHEMOTH, V22, P101, DOI 10.1093/jac/22.2.101; FINN A, 1987, BIOPHARM DRUG DISPOS, V8, P519, DOI 10.1002/bdd.2510080604; FROST P, 1972, ARCH DERMATOL, V105, P681, DOI 10.1001/archderm.105.5.681; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; HASSLER D, 1990, INFECTION MUNICH, V18, P24; HOLLSTROM E, 1951, Acta Derm Venereol, V31, P235; JAMES NC, 1991, ANTIMICROB AGENTS CH, V35, P1860, DOI 10.1128/AAC.35.9.1860; JOHNSON RC, 1987, ANTIMICROB AGENTS CH, V31, P164, DOI 10.1128/AAC.31.2.164; JOHNSON RC, 1990, ANTIMICROB AGENTS CH, V34, P2133, DOI 10.1128/AAC.34.11.2133; KENDALL MG, 1979, ADV THEORY STATISTIC, V2; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LUFT BJ, 1989, REV INFECT DIS, V11, pS1518; LUFT BJ, 1988, ANN NY ACAD SCI, V539, P93; MANDELL GL, 1990, GOODMAN GILMANS PHAR, P1081; MARX MA, 1988, DRUG INTEL CLIN PHAR, V22, P651, DOI 10.1177/106002808802200901; MURSIC VP, 1987, EUR J CLIN MICROBIOL, V6, P424, DOI 10.1007/BF02013102; NEU HC, 1988, ANN NY ACAD SCI, V539, P314, DOI 10.1111/j.1749-6632.1988.tb31865.x; PFISTER HW, 1989, ARCH NEUROL-CHICAGO, V46, P1190, DOI 10.1001/archneur.1989.00520470044025; RUBIN DA, 1990, PACE, V13, P1367, DOI 10.1111/j.1540-8159.1990.tb04009.x; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; Standiford H. C., 1990, PRINCIPLES PRACTICE, P284; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; 1991, DOXYCYCLINE HYCLATE; 1989, MED LETT, V31, P57; 1991, MEDISPAN PRESCRIPTIO	39	155	156	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					273	280		10.7326/0003-4819-117-4-273	http://dx.doi.org/10.7326/0003-4819-117-4-273			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637021				2022-12-28	WOS:A1992JH46400001
J	DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK				DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK			HIP-FRACTURES AND FLUORIDATION IN UTAH ELDERLY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WATER FLUORIDATION; BONE; COMMUNITIES; WOMEN; OSTEOPOROSIS; DENSITY; OLDER	Objective.-To test the effect of water fluoridated to 1 ppm on the incidence of hip fractures in the elderly. Design.-Ecological cohort. Setting.-The incidence of femoral neck fractures in patients 65 years of age or older was compared in three communities in Utah, one with and two without water fluoridated to 1 ppm. Patients.-All patients with hip fractures who were 65 years of age and older over a 7-year period in the three communities, excluding (1) those with revisions of hip fractures, (2) those in whom the hip fracture was anything but a first diagnosis, (3) those in whom metastatic disease was present, or (4) those in whom the fracture was a second fracture (n=246). Outcome Measure.-Rate of hospital discharge for hip fracture. Results.-The relative risk for hip fracture for women in the fluoridated area was 1.27 (95% confidence interval [Cl]=1.08 to 1.46) and for men was 1.41 (95% Cl=1.00 to 1.81) relative to the nonfluoridated areas. Conclusions.-We found a small but significant increase in the risk of hip fracture in both men and women exposed to artificial fluoridation at 1 ppm, suggesting that low levels of fluoride may increase the risk of hip fracture in the elderly.			DANIELSON, C (corresponding author), UNIV UTAH,DEPT FAMILY & PREVENT MED,50 N MED DR,SALT LAKE CITY,UT 84132, USA.							ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ANSEL BM, 1965, ANN RHEUM DIS, V25, P67; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P433; BERNSTEI.DS, 1966, J AMER MED ASSOC, V198, P499, DOI 10.1001/jama.198.5.499; Chiang C, 1961, VITAL STAT SPEC REP, P47; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; EVANS FG, 1976, ACTA ORTHOP SCAND, V47, P489, DOI 10.3109/17453677608988726; ISKRANT AP, 1968, AM J PUBLIC HEALTH N, V58, P485, DOI 10.2105/AJPH.58.3.485; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; KENDALL MG, 1977, ADV THEORY STATISTIC, V1; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LEONE NC, 1955, AMER J ROENTGENOL RA, V74, P874; Lindsay R, 1988, Clin Geriatr Med, V4, P411; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; PHIPPS KR, 1990, J DENT RES, V69, P1256, DOI 10.1177/00220345900690060601; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SAVILLE PD, 1966, JAMA-J AM MED ASSOC, V199, P105; SIMONEN O, 1985, LANCET, V2, P432; SOWERS MR, 1991, AM J EPIDEMIOL, V133, P649, DOI 10.1093/oxfordjournals.aje.a115940; 1989, CDC898411 US DEP HLT, P76	23	78	79	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					746	748						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640574				2022-12-28	WOS:A1992JG66600015
J	DUANE, PD; MAGEE, TM; ALEXANDER, MS; HEATLEY, RV; LOSOWSKY, MS				DUANE, PD; MAGEE, TM; ALEXANDER, MS; HEATLEY, RV; LOSOWSKY, MS			ESOPHAGEAL ACHALASIA IN ADOLESCENT WOMEN MISTAKEN FOR ANOREXIA-NERVOSA	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES UNIV HOSP,DEPT PSYCHIAT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; HIGH ROYDS HOSP,MENSTON,W YORKSHIRE,ENGLAND	Saint James's University Hospital; University of Leeds	DUANE, PD (corresponding author), ST JAMES UNIV HOSP,DEPT MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							CLOUSE RE, 1983, NEW ENGL J MED, V309, P1337, DOI 10.1056/NEJM198312013092201; KENNEY RD, 1984, J ADOLESCENT HEALTH, V5, P283, DOI 10.1016/S0197-0070(84)80134-5; MAYBERRY JF, 1985, Q J MED, V56, P451; ROSENZWEIG S, 1989, J CLIN GASTROENTEROL, V11, P147, DOI 10.1097/00004836-198904000-00007; STACHER G, 1986, GUT, V27, P1120, DOI 10.1136/gut.27.10.1120; STACHER G, 1990, Dysphagia, V5, P216, DOI 10.1007/BF02412690	6	21	20	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					43	43		10.1136/bmj.305.6844.43	http://dx.doi.org/10.1136/bmj.305.6844.43			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638203	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JC79900035
J	LOPEZCASILLAS, F; CHEIFETZ, S; DOODY, J; ANDRES, JL; LANE, WS; MASSAGUE, J				LOPEZCASILLAS, F; CHEIFETZ, S; DOODY, J; ANDRES, JL; LANE, WS; MASSAGUE, J			STRUCTURE AND EXPRESSION OF THE MEMBRANE PROTEOGLYCAN BETAGLYCAN, A COMPONENT OF THE TGF-BETA RECEPTOR SYSTEM	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; GLYCOSAMINOGLYCAN CHAINS; CONDITIONED MEDIUM; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; LIGAND-BINDING; FACTOR-ALPHA; PROTEINS	We describe the primary structure of rat betaglycan, a polymorphic membrane-anchored proteoglycan with high affinity for transforming growth factor-beta (TGF-beta). As deduced from its cDNA sequence, the 853 amino acid core protein of betaglycan has an extracellular domain with clustered sites for potential attachment of glycosaminoglycan chains. These chains are dispensable for TGF-beta binding to the core protein. The transmembrane region and the short cytoplasmic tail of betaglycan are very similar to these regions in human endoglin, an endothelial cell membrane glycoprotein involved in intercellular recognition. The ectodomain of betaglycan can be released as a soluble proteoglycan; a potential cleavage site near the transmembrane region is identical to the highly regulated cleavage site of the membrane-anchored transforming growth factor-alpha precursor. The unique features of betaglycan suggest important roles in cell interaction with TGF-beta.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Harvard University	LOPEZCASILLAS, F (corresponding author), MEM SLOAN KETTERING CANC CTR, PROGRAM CELL BIOL & GENET, NEW YORK, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ANDRES JL, 1991, IN PRESS J BIOL CHEM, V266; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERENT S L, 1985, Biotechniques, V3, P208; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHEIFETZ S, 1991, IN PRESS J BIOL CHEM, V266; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	75	595	627	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					785	795		10.1016/0092-8674(91)90073-8	http://dx.doi.org/10.1016/0092-8674(91)90073-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657406				2022-12-28	WOS:A1991GQ40700015
J	WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA				WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA			EXPRESSION CLONING AND CHARACTERIZATION OF THE TGF-BETA TYPE-III RECEPTOR	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MEMBRANE PROTEOGLYCAN; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN CHAINS; EXTRACELLULAR-MATRIX; CELL PROLIFERATION; DOMAIN-STRUCTURE; LIGAND-BINDING; 2 FORMS; INHIBITION	The rat TGF-beta type III receptor cDNA has been cloned by overexpression in COS cells. The encoded receptor is an 853 amino acid protein with a large N-terminal extracellular domain containing at least one site for glycosaminoglycan addition, a single hydrophobic transmembrane domain, and a 41 amino acid cytoplasmic tail with no obvious signaling motif. Introduction of the cDNA into COS cells and L6 myoblasts induces expression of a heterogenously glycosylated 280-330 kd protein characteristic of the type III receptor that binds TGF-beta-1 specifically. In L6 myoblasts lacking the endogenous type III receptor, expression of the recombinant receptor leads to an increase in the amount of ligand bound and cross-linked to surface type II TGF-beta receptors. This indicates that the type III receptor may regulate the ligand-binding ability or surface expression of the type II receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WANG, XF (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.			Downward, Julian/0000-0002-2331-4729	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA39826] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIGMS NIH HHS [T 32 GM07287-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNFIELD M, 1991, IN PRESS ANN NY ACAD; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CARR BI, 1986, CANCER RES, V46, P2330; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P1699; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIN HY, 1991, IN PRESS SCIENCE; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1985, CANCER CELL, V3, P65; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	66	588	619	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					797	805		10.1016/0092-8674(91)90074-9	http://dx.doi.org/10.1016/0092-8674(91)90074-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657407				2022-12-28	WOS:A1991GQ40700016
J	CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R				CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R			INVIVO AND INVITRO SODIUM-PUMP ACTIVITY IN SUBJECTS WITH THYROTOXIC PERIODIC PARALYSIS	BRITISH MEDICAL JOURNAL			English	Article							OUABAIN-BINDING-SITES; NA+,K+-ATPASE ACTIVITY; RUBIDIUM CHLORIDE; CATION-TRANSPORT; SKELETAL-MUSCLE; THYROID-HORMONE; ATPASE ACTIVITY; GRAVES-DISEASE; POTASSIUM PUMP; HYPERTHYROIDISM	Objective - To examine whether sodium pump activity plays a part in the pathogenesis of thyrotoxic periodic paralysis. Design - Measurement of platelet sodium-potassium ATPase and in vivo sodium pump activities in healthy subjects and thyrotoxic subjects with and without paralysis. Setting - University hospital in Hong Kong. Subjects - 21 healthy subjects, 23 untreated thyrotoxic subjects, 13 untreated men with periodic paralysis, seven treated thyrotoxic subjects, and six treated men with periodic paralysis. Main outcome measures - Platelet Na+, K+-ATPase activity and plasma rubidium concentration after oral loading. Results - Median (range) platelet Na+, K+-ATPase activity in thyrotoxic subjects was 253 (169-821) mu-mol inorganic phosphate/h/g protein-significantly higher than that in healthy subjects (134 (81-180) mu-mol/h/g protein; p < 0.001). Na+, K+-ATPase activity in those with periodic paralysis was 374 (195-11%) mu-mol/h/g protein, again significantly higher than that in healthy subjects (p < 0.001) and that in other thyrotoxic subjects (p < 0.01) despite similar degrees of hyperthyroidism. Activities in treated thyrotoxic subjects with and without periodic paralysis were 148 (110-234) and 131 (86-173) mu-mol/h/g protein respectively. Mean (95% confidence interval) plasma rubidium concentration five hours after oral administration in thyrotoxic subjects (7.0 (6.6 to 7.5) mu-mol/l) was significantly lower than in healthy subjects (10.2 (9.5 to 10.9) mu-mol/l; p < 0.001) and higher than in those with periodic paralysis (6.0 (5.7 to 6.3) mu-mol/l; p < 0.01). Conclusions - Sodium pump activity in untreated subjects with periodic paralysis is higher than in other thyrotoxic subjects, and this may be responsible for the hypokalaemia.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT CHEM PATHOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital								ARNOTT RD, 1982, J CLIN ENDOCR METAB, V54, P1150, DOI 10.1210/jcem-54-6-1150; ARUMANAYAGAM M, 1990, J CLIN ENDOCR METAB, V71, P260, DOI 10.1210/jcem-71-1-260; ARUMANAYAGAM M, 1990, METABOLISM, V39, P952, DOI 10.1016/0026-0495(90)90307-X; ASANO Y, 1976, J CLIN INVEST, V57, P368, DOI 10.1172/JCI108288; BARON DN, 1985, CLIN SCI, V68, P143, DOI 10.1042/cs0680143; BERNSTEIN JC, 1970, J PHARMACOL EXP THER, V174, P323; BOON NA, 1984, CLIN SCI, V66, P569, DOI 10.1042/cs0660569; DALY JA, 1972, CLIN CHEM, V18, P263; ENGEL AG, 1972, MAYO CLIN PROC, V47, P919; FEELY J, 1981, POSTGRAD MED J, V57, P238, DOI 10.1136/pgmj.57.666.238; FIEVE RR, 1971, PSYCHOPHARMACOLOGIA, V20, P307, DOI 10.1007/BF00403562; HABER RS, 1984, ENDOCRINOLOGY, V115, P291, DOI 10.1210/endo-115-1-291; HALLIS KF, 1985, CLIN CHEM, V31, P274; HAWKINS BR, 1985, CLIN ENDOCRINOL, V23, P245, DOI 10.1111/j.1365-2265.1985.tb00220.x; ISMAILBEIGI F, 1988, AM ZOOL, V28, P363; KHAN FA, 1987, CLIN SCI, V72, P171, DOI 10.1042/cs0720171; KJELDSEN K, 1984, LANCET, V2, P8; LAM KSL, 1989, AUST NZ J MED, V19, P6, DOI 10.1111/j.1445-5994.1989.tb01664.x; LIN MH, 1978, J BIOL CHEM, V253, P723; MARX A, 1989, MUSCLE NERVE, V12, P810, DOI 10.1002/mus.880121005; MCFADZEAN AJ, 1967, BMJ-BRIT MED J, V1, P451, DOI 10.1136/bmj.1.5538.451; OH VMS, 1990, CLIN SCI, V78, P199, DOI 10.1042/cs0780199; OKINAKA S, 1957, J CLIN ENDOCR METAB, V17, P1454, DOI 10.1210/jcem-17-12-1454; RUBYTHON EJ, 1983, CLIN SCI, V64, P441, DOI 10.1042/cs0640441; SCHIZUME K, 1966, METABOLISM, V15, P138; TURAIHI K, 1989, METABOLISM, V38, P773, DOI 10.1016/0026-0495(89)90065-6; YEO PPB, 1978, BRIT MED J, V2, P930, DOI 10.1136/bmj.2.6142.930; YEUNG RTT, 1974, AM J MED, V57, P584, DOI 10.1016/0002-9343(74)90010-2; YEUNG RTT, 1987, OXFORD TXB MED, V10, P48	29	127	134	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1096	1099		10.1136/bmj.303.6810.1096	http://dx.doi.org/10.1136/bmj.303.6810.1096			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1660744	Green Published, Bronze			2022-12-28	WOS:A1991GN20900020
J	CATTERALL, WA				CATTERALL, WA			FUNCTIONAL SUBUNIT STRUCTURE OF VOLTAGE-GATED CALCIUM CHANNELS	SCIENCE			English	Editorial Material							RABBIT SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MAMMALIAN BRAIN; SPINAL-CORD; EXPRESSION; ALPHA-1-SUBUNIT; LOCALIZATION; RETINA				CATTERALL, WA (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.		Tuluc, Petronel/C-2527-2011					AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; AHLIJANIAN MK, IN PRESS J BIOL CHEM; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; Catterall W A, 1991, Curr Opin Neurobiol, V1, P5, DOI 10.1016/0959-4388(91)90004-Q; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HOFMANN F, 1988, J CARDIOVASC PHARM, V12, pS25, DOI 10.1097/00005344-198806121-00005; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEUNG AT, 1988, J BIOL CHEM, V263, P994; MacKinnon R, 1991, Curr Opin Neurobiol, V1, P14, DOI 10.1016/0959-4388(91)90005-R; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PRAGNELL M, 1991, Biophysical Journal, V59, p390A; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI X, IN PRESS J BIOL CHEM	32	149	153	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1499	1500		10.1126/science.1654596	http://dx.doi.org/10.1126/science.1654596			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1654596				2022-12-28	WOS:A1991GG65100031
J	MICHELSON, HB; WONG, RKS				MICHELSON, HB; WONG, RKS			EXCITATORY SYNAPTIC RESPONSES MEDIATED BY GABA(A) RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							SOMATOSTATIN-LIKE IMMUNOREACTIVITY; CENTRAL-NERVOUS-SYSTEM; PYRAMIDAL CELLS; GABAERGIC NEURONS; RAT; INTERNEURONS; ANTAGONISTS; SUBTYPES; SLICES; ACID	Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the cortex. Activation of postsynaptic GABA(A) receptors hyperpolarizes cells and inhibits neuronal activity. Synaptic responses mediated by GABA(A) receptors also strongly excited hippocampal neurons. This excitatory response was recorded in morphologically identified interneurons in the presence of 4-aminopyridine or after elevation of extracellular potassium concentrations. The synaptic excitation sustained by GABA(A) receptors synchronized the activity of inhibitory interneurons. This synchronized discharge of interneurons in turn elicited large-amplitude inhibitory postsynaptic potentials in pyramidal and granule cells. Excitatory synaptic responses mediated by GABA(A) receptors may thus provide a mechanism for the recruitment of GABAergic interneurons through their recurrent connections.			MICHELSON, HB (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203, USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; ARAM J, 1989, BRIT J PHARMACOL, V96, P82; ARAM JA, 1991, J NEUROPHYSIOL, V65, P1034, DOI 10.1152/jn.1991.65.5.1034; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KNOWLES WD, 1981, J NEUROSCI, V1, P318; KOSAKA T, 1988, EXP BRAIN RES, V71, P388; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; Lux H D, 1986, Adv Neurol, V44, P619; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1990, J PHYSIOL-LONDON, V423, P95; MULLER W, 1990, J NEUROPHYSIOL, V64, P46, DOI 10.1152/jn.1990.64.1.46; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; PERREAULT P, 1989, Society for Neuroscience Abstracts, V15, P1213; SLOVITER RS, 1987, J COMP NEUROL, V256, P42, DOI 10.1002/cne.902560105; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; STEWART WW, 1981, NATURE, V292, P17, DOI 10.1038/292017a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; WONG RKS, 1982, SCIENCE, V216, P745	25	271	271	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1420	1423		10.1126/science.1654594	http://dx.doi.org/10.1126/science.1654594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654594				2022-12-28	WOS:A1991GF85100042
J	OSTERGAARD, HL; TROWBRIDGE, IS				OSTERGAARD, HL; TROWBRIDGE, IS			NEGATIVE REGULATION OF CD45 PROTEIN TYROSINE PHOSPHATASE-ACTIVITY BY IONOMYCIN IN T-CELLS	SCIENCE			English	Article							LEUKOCYTE-COMMON ANTIGEN; ACTIVATION; PHOSPHORYLATION; CALCIUM; KINASE; EXPRESSION; FLUORESCENCE; RESPONSES; MEMBRANE; ALTERS	CD45 is a leukocyte-specific, transmembrane protein tyrosine phosphatase (PTPase) required for T cell responsiveness. How the activity of PTPases is regulated in vivo is unclear. Treatment of murine thymocytes and a variety of murine T cell lines with the calcium ionophore ionomycin decreased CD45 PTPase activity. Ionomycin treatment also led to a decreased phosphorylation of serine residues in CD45. These results indicate that increased intracellular calcium modulates CD45 PTPase activity, demonstrating regulation of CD45 PTPase activity in vivo, and also implicate serine dephosphorylation as a possible mechanism.	SALK INST,DEPT CANC BIOL,SAN DIEGO,CA 92186	Salk Institute					NATIONAL CANCER INSTITUTE [R01CA017733, R37CA017733] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT PR, 1985, J BIOL CHEM, V260, P8746; ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OSTERGAARD H, 1987, J IMMUNOL, V139, P3573; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, UNPUB; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1991, ADV PROT PHOSPHATASE, V6, P227; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806	30	109	110	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1423	1425		10.1126/science.1654595	http://dx.doi.org/10.1126/science.1654595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654595				2022-12-28	WOS:A1991GF85100043
J	FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R				FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R			INHIBITION OF NEOINTIMAL SMOOTH-MUSCLE ACCUMULATION AFTER ANGIOPLASTY BY AN ANTIBODY TO PDGF	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN ATHEROSCLEROTIC PLAQUES; CORONARY ANGIOPLASTY; CELL-PROLIFERATION; DIFFERENT ISOFORMS; LESION FORMATION; GENE-EXPRESSION; ARTERIAL INJURY; PLATELET; RAT	Approximately 30 to 40 percent of atherosclerotic coronary arteries treated by angioplasty or by bypass surgery occlude as a result of restenosis. This restenosis is due principally to the accumulation of neointimal smooth muscle cells, which is also a prominent feature of the advanced lesions of atherosclerosis. The factors responsible for the accumulation of intimal smooth muscle cells have not been identified. Platelet-derived growth factor (PDGF) is a potent smooth muscle chemoattractant and mitogen. It is present in platelets and can be formed by endothelium, smooth muscle, and monocyte-derived macrophages. The development of an intimal lesion in the carotid artery of athymic nude rats induced by intraarterial balloon catheter deendothelialization was inhibited by a polyclonal antibody to PDGF. These data demonstrate that endogenous PDGF is involved in the accumulation of neointimal smooth muscle cells associated with balloon injury and may be involved in restenosis after angioplasty, and perhaps in atherogenesis as well.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND; ZYMOGENET INC,SEATTLE,WA 98105	University of London; Queen Mary University London; Zymogenet Inc.			Ghayour-Mobarhan, Majid/AAY-5963-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03174, HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMGART.HR, 1966, PATHOL MICROBIOL, V29, P393, DOI 10.1159/000161922; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; FELLSTROM B, 1989, TRANSPLANT P, V21, P3689; FERNS GAA, UNPUB; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FESTING MFW, 1978, NATURE, V274, P365, DOI 10.1038/274365a0; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRENS GAA, 1991, AM J PATHOL, V138, P1045; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JAWIEN A, 1991, FASEB J, V55, pA1246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LINDNER V, 1991, CIRC RES, V68, P103; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; RAINES E, UNPUB; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REIDY MA, 1985, LAB INVEST, V53, P513; REIDY MA, 1981, LAB INVEST, V44, P301; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; VAESSEN LMB, 1986, SCAND J IMMUNOL, V24, P223, DOI 10.1111/j.1365-3083.1986.tb02089.x; WIJNS W, 1985, AM J CARDIOL, V55, P357, DOI 10.1016/0002-9149(85)90375-3; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	40	1012	1107	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1129	1132		10.1126/science.1653454	http://dx.doi.org/10.1126/science.1653454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653454				2022-12-28	WOS:A1991GD80800029
J	KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B				KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B			NAPTS, A MUTATION AFFECTING SODIUM-CHANNEL ACTIVITY IN DROSOPHILA, IS AN ALLELE OF MLE, A REGULATOR OF X-CHROMOSOME TRANSCRIPTION	CELL			English	Article							SENSITIVE PARALYTIC MUTANTS; DOSAGE COMPENSATION; MEMBRANE EXCITABILITY; NERVOUS-SYSTEM; MELANOGASTER; BINDING; GENE; RNA; DNA; CONDUCTION	nap(ts) is a recessive mutation that affects the level of sodium channel activity and, at high temperature, causes paralysis associated with a loss of action potentials. We show, by genetic complementation tests, germline transformation, and analysis of mutations, that nap(ts) is a gain-of-function mutation of mle, a gene required for X chromosome dosage compensation and male viability. Molecular analyses of nap and mle mutations indicate that mle+, nap+, and nap(ts) activities are encoded by the same open reading frame and suggest that nap(ts) is due to a single amino acid substitution. Although nap(ts) is known to act via para+, an X-linked sodium channel structural gene, its effect is not due to a simple defect in para+ dosage compensation.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94306	University of Wisconsin System; University of Wisconsin Madison; Stanford University	KERNAN, MJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.			Kernan, Maurice/0000-0002-1546-6159	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHILLER D, 1986, DEV BIOL, V118, P379, DOI 10.1016/0012-1606(86)90007-2; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; COLQUHOUN D, 1972, J PHYSIOL-LONDON, V221, P533, DOI 10.1113/jphysiol.1972.sp009766; COMPANY M, 1991, NATURE, V349, P497; ELKINS T, 1990, J NEUROGENET, V6, P207, DOI 10.3109/01677069009107111; FUKUNAGA A, 1975, GENETICS, V81, P135; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GANETZKY B, 1984, GENETICS, V108, P897; GANETZKY B, 1982, GENETICS, V100, P597; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KAUVAR LM, 1982, MOL GEN GENET, V187, P172, DOI 10.1007/BF00384402; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LOUGHNEY K, 1989, MOL BIOL NEURORECEPT, P201; LOVERRE A, 1980, DROS INF SERV, V55, P88; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; ODOWD DK, 1988, J NEUROSCI, V8, P3633; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN M, 1990, GENETICS, V124, P133; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; WU CF, 1983, J NEUROSCI, V3, P1888; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047	40	104	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					949	959		10.1016/0092-8674(91)90440-A	http://dx.doi.org/10.1016/0092-8674(91)90440-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653649				2022-12-28	WOS:A1991GE46000013
J	GOLDSCHMIDTCLERMONT, PJ; JANMEY, PA				GOLDSCHMIDTCLERMONT, PJ; JANMEY, PA			PROFILIN, A WEAK CAP FOR ACTIN AND RAS	CELL			English	Review							BINDING PROTEINS; PHOSPHOLIPASE-C		HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	GOLDSCHMIDTCLERMONT, PJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205, USA.							CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	23	78	81	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					419	421		10.1016/0092-8674(81)90002-7	http://dx.doi.org/10.1016/0092-8674(81)90002-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651167	hybrid			2022-12-28	WOS:A1991GA94100002
J	BLACKLOW, NR; GREENBERG, HB				BLACKLOW, NR; GREENBERG, HB			MEDICAL PROGRESS - VIRAL GASTROENTERITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INFECTIOUS NONBACTERIAL GASTROENTERITIS; IMMUNE ELECTRON-MICROSCOPY; NON-BACTERIAL GASTROENTERITIS; HUMAN ROTAVIRUS SEROTYPES; ASTROVIRUS-ASSOCIATED GASTROENTERITIS; SEVERE COMBINED IMMUNODEFICIENCY; ENTERIC ADENOVIRUS INFECTION; LINKED IMMUNOSORBENT-ASSAY; CORONAVIRUS-LIKE PARTICLES; 3 CLINICAL SETTINGS		STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT IMMUNOL, STANFORD, CA 94305 USA; VET AFFAIRS MED CTR, PALO ALTO, CA USA	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BLACKLOW, NR (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.			greenberg, harry/0000-0002-2128-9080				ANDREW ME, 1990, J VIROL, V64, P4776, DOI 10.1128/JVI.64.10.4776-4783.1990; ASHLEY CR, 1978, J CLIN PATHOL, V31, P939, DOI 10.1136/jcp.31.10.939; BEARDS GM, 1989, J CLIN MICROBIOL, V27, P2827, DOI 10.1128/JCM.27.12.2827-2833.1989; BERNSTEIN DI, 1990, J INFECT DIS, V162, P1055, DOI 10.1093/infdis/162.5.1055; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; BISHOP RF, 1973, LANCET, V2, P1281, DOI 10.1016/s0140-6736(73)92867-5; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; BLACK RE, 1982, J INFECT DIS, V145, P483, DOI 10.1093/infdis/145.4.483; BLACKLOW NR, 1979, J CLIN MICROBIOL, V10, P903, DOI 10.1128/JCM.10.6.903-909.1979; BLACKLOW NR, 1972, ANN INTERN MED, V76, P993, DOI 10.7326/0003-4819-76-6-993; BOTH GW, 1983, P NATL ACAD SCI-BIOL, V80, P3091, DOI 10.1073/pnas.80.10.3091; BRANDT CD, 1984, J CLIN MICROBIOL, V20, P1008, DOI 10.1128/JCM.20.5.1008-1009.1984; BRANDT CD, 1983, J CLIN MICROBIOL, V18, P71, DOI 10.1128/JCM.18.1.71-78.1983; BRANDT CD, 1985, J INFECT DIS, V151, P437, DOI 10.1093/infdis/151.3.437; BROWN DWG, 1987, J CLIN MICROBIOL, V25, P637, DOI 10.1128/JCM.25.4.637-640.1987; BRUSSOW H, 1988, J INFECT DIS, V158, P588, DOI 10.1093/infdis/158.3.588; BUITENWERF J, 1985, J VIROL METHODS, V10, P39, DOI 10.1016/0166-0934(85)90086-2; CAUL E O, 1988, P139; CAUL EO, 1982, J MED VIROL, V9, P257, DOI 10.1002/jmv.1890090403; CHEN GM, 1990, VIROLOGY, V178, P311, DOI 10.1016/0042-6822(90)90411-J; CHIBA S, 1986, LANCET, V2, P417; CHIBA S, 1983, LANCET, V2, P954; CLARK HF, 1990, J INFECT DIS, V161, P1099, DOI 10.1093/infdis/161.6.1099; COLLINS J, 1988, J PEDIATR GASTR NUTR, V7, P264, DOI 10.1097/00005176-198803000-00017; COOK SM, 1990, B WORLD HEALTH ORGAN, V68, P171; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; CRUZ JR, 1990, J CLIN MICROBIOL, V28, P1780, DOI 10.1128/JCM.28.8.1780-1784.1990; CUBITT WD, 1987, CIBA F SYMP, V128, P126; CUBITT WD, 1987, J INFECT DIS, V156, P806, DOI 10.1093/infdis/156.5.806; CUBITT WD, 1981, LANCET, V2, P975; CUBITT WD, 1987, J MED VIROL, V21, P361, DOI 10.1002/jmv.1890210408; CUBITT WD, 1981, J CLIN PATHOL, V34, P924, DOI 10.1136/jcp.34.8.924; CUKOR G, 1980, INFECT IMMUN, V29, P822; DAVIDSON GP, 1989, LANCET, V2, P709, DOI 10.1016/S0140-6736(89)90771-X; DEJONG JC, 1983, J MED VIROL, V11, P215, DOI 10.1002/jmv.1890110305; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; DHARAKUL T, 1990, J VIROL, V64, P4375, DOI 10.1128/JVI.64.9.4375-4382.1990; DINGLE JH, 1953, AM J HYG, V58, P16, DOI 10.1093/oxfordjournals.aje.a119587; DOLIN R, 1982, J INFECT DIS, V146, P184, DOI 10.1093/infdis/146.2.184; DUPONT HL, 1980, INFECTIONS GASTROINT, P195; DYALLSMITH ML, 1986, P NATL ACAD SCI USA, V83, P3465, DOI 10.1073/pnas.83.10.3465; ELLIS ME, 1984, ARCH DIS CHILD, V59, P848, DOI 10.1136/adc.59.9.848; ERDMAN DD, 1989, J VIROL METHODS, V24, P57, DOI 10.1016/0166-0934(89)90007-4; ERICSON BL, 1983, VIROLOGY, V127, P320, DOI 10.1016/0042-6822(83)90147-2; ESTES MK, 1987, J VIROL, V61, P1488, DOI 10.1128/JVI.61.5.1488-1494.1987; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FLEWETT TH, 1973, LANCET, V2, P1497; FLORES J, 1987, LANCET, V1, P882; FLORES J, 1990, LANCET, V336, P330, DOI 10.1016/0140-6736(90)91876-C; FOX JP, 1977, AM J EPIDEMIOL, V105, P362, DOI 10.1093/oxfordjournals.aje.a112394; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; GERNA G, 1990, J INFECT DIS, V161, P1105, DOI 10.1093/infdis/161.6.1105; GERNA G, 1985, J INFECT DIS, V151, P796, DOI 10.1093/infdis/151.5.796; GLASS RI, 1986, ACTA PAEDIATR SCAND, V75, P713, DOI 10.1111/j.1651-2227.1986.tb10279.x; GOMBOLD JL, 1987, VIROLOGY, V161, P463, DOI 10.1016/0042-6822(87)90140-1; GORZIGLIA M, 1988, J VIROL, V62, P2978, DOI 10.1128/JVI.62.8.2978-2984.1988; GORZIGLIA M, 1990, P NATL ACAD SCI USA, V87, P7155, DOI 10.1073/pnas.87.18.7155; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRAHAM DY, 1984, DIGEST DIS SCI, V29, P1028, DOI 10.1007/BF01311255; GREENBERG HB, 1981, J VIROL, V37, P994, DOI 10.1128/JVI.37.3.994-999.1981; GREENBERG HB, 1983, J GEN VIROL, V64, P313, DOI 10.1099/0022-1317-64-2-313; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; GREENBERG HB, 1978, J MED VIROL, V2, P97, DOI 10.1002/jmv.1890020204; GREENBERG HB, 1981, P NATL ACAD SCI-BIOL, V78, P420, DOI 10.1073/pnas.78.1.420; GREENBERG HB, 1979, INFECT IMMUN, V26, P270, DOI 10.1128/IAI.26.1.270-273.1979; GREENBERG HB, 1981, PERSPECT VIROL, V11, P163; GRUNOW JE, 1985, J PEDIATR-US, V106, P73, DOI 10.1016/S0022-3476(85)80470-4; GUERRANT RL, IN PRESS N ENGL J ME; HAMMOND G, 1987, J CLIN MICROBIOL, V25, P1881, DOI 10.1128/JCM.25.10.1881-1885.1987; HAYASHI Y, 1989, J CLIN MICROBIOL, V27, P1728, DOI 10.1128/JCM.27.8.1728-1733.1989; HERRMANN JE, 1991, NEW ENGL J MED, V324, P1757, DOI 10.1056/NEJM199106203242501; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HERRMANN JE, 1988, J INFECT DIS, V158, P182, DOI 10.1093/infdis/158.1.182; HERRMANN JE, 1988, J CLIN MICROBIOL, V26, P1783, DOI 10.1128/JCM.26.9.1783-1786.1988; HERRMANN JE, 1985, J MED VIROL, V17, P127, DOI 10.1002/jmv.1890170205; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; HO MS, 1989, LANCET, V2, P961; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; HOPKINS RS, 1984, AM J PUBLIC HEALTH, V74, P263, DOI 10.2105/AJPH.74.3.263; HOSHINO Y, 1984, J INFECT DIS, V149, P694, DOI 10.1093/infdis/149.5.694; HOSHINO Y, 1988, J VIROL, V62, P744, DOI 10.1128/JVI.62.3.744-748.1988; HRDY DB, 1987, REV INFECT DIS, V9, P461; HUNDLEY F, 1987, J VIROL, V61, P3365, DOI 10.1128/JVI.61.11.3365-3372.1987; ISOLAURI E, 1989, ACTA PAEDIATR SCAND, V78, P685, DOI 10.1111/j.1651-2227.1989.tb11127.x; JIANG X, 1990, Science (Washington D C), V250, P1580; JOHNSON PC, 1990, J INFECT DIS, V161, P18, DOI 10.1093/infdis/161.1.18; KALJOT KT, 1988, J VIROL, V62, P1136, DOI 10.1128/JVI.62.4.1136-1144.1988; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KAPIKIAN AZ, 1983, J INFECT DIS, V147, P95, DOI 10.1093/infdis/147.1.95; KAPIKIAN AZ, 1989, REV INFECT DIS, V11, pS539; Kapikian AZ, 1990, VIROLOGY, P1353; KAPIKIAN AZ, 1990, VIROLOGY, V1, P671; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KIDD AH, 1989, J MED VIROL, V27, P164, DOI 10.1002/jmv.1890270219; KIM KH, 1990, J CLIN MICROBIOL, V28, P2279, DOI 10.1128/JCM.28.10.2279-2284.1990; KOGASAKA R, 1981, J MED VIROL, V8, P187, DOI 10.1002/jmv.1890080305; KONNO T, 1982, J MED VIROL, V9, P11, DOI 10.1002/jmv.1890090103; KONNO T, 1984, J INFECT DIS, V149, P683, DOI 10.1093/infdis/149.5.683; KOOPMAN JS, 1989, AM J EPIDEMIOL, V130, P750, DOI 10.1093/oxfordjournals.aje.a115396; KOOPMAN JS, 1984, AM J EPIDEMIOL, V119, P114, DOI 10.1093/oxfordjournals.aje.a113712; KOTLOFF KL, 1989, PEDIATRICS, V84, P219; KOTLOFF KL, 1988, PEDIATR INFECT DIS J, V7, P753, DOI 10.1097/00006454-198811000-00002; KURTZ J, 1978, MED MICROBIOL IMMUN, V166, P227, DOI 10.1007/BF02121154; KURTZ JB, 1987, CIBA F SYMP, V128, P92; KURTZ JB, 1977, J CLIN PATHOL, V30, P948, DOI 10.1136/jcp.30.10.948; KURTZ JB, 1979, J MED VIROL, V3, P221, DOI 10.1002/jmv.1890030308; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; LEE TW, 1981, J GEN VIROL, V57, P421, DOI 10.1099/0022-1317-57-2-421; LINHARES AC, 1981, AM J EPIDEMIOL, V113, P703; LOPEZ S, 1985, VIROLOGY, V144, P11, DOI 10.1016/0042-6822(85)90300-9; LOSONSKY GA, 1985, J CLIN INVEST, V76, P2362, DOI 10.1172/JCI112248; MACKOW ER, 1989, J VIROL, V63, P1661, DOI 10.1128/JVI.63.4.1661-1668.1989; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; MACKOW ER, 1990, J VIROL, V64, P1698, DOI 10.1128/JVI.64.4.1698-1703.1990; MADELEY CR, 1979, J CLIN PATHOL, V32, P1, DOI 10.1136/jcp.32.1.1; MADELEY CR, 1979, J INFECT DIS, V139, P519, DOI 10.1093/infdis/139.5.519; MADORE HP, 1986, J VIROL, V58, P487, DOI 10.1128/JVI.58.2.487-492.1986; MADORE HP, 1990, J MED VIROL, V32, P96, DOI 10.1002/jmv.1890320206; MANSELL EA, 1990, J VIROL, V64, P4988, DOI 10.1128/JVI.64.10.4988-4996.1990; MARRIE TJ, 1982, ARCH INTERN MED, V142, P313, DOI 10.1001/archinte.142.2.313; MARSHALL JA, 1989, J MED VIROL, V29, P238, DOI 10.1002/jmv.1890290404; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; MATSON DO, 1989, J INFECT DIS, V159, P71, DOI 10.1093/infdis/159.1.71; MATSUI SM, 1989, ADV VIRUS RES, V36, P181; MATSUI SM, 1989, J CLIN MICROBIOL, V27, P780, DOI 10.1128/JCM.27.4.780-782.1989; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MATSUNO S, 1987, VIRUS RES, V7, P273; MEEROFF JC, 1980, ANN INTERN MED, V92, P370, DOI 10.7326/0003-4819-92-3-370; MONROE SS, 1991, J VIROL, V65, P641, DOI 10.1128/JVI.65.2.641-648.1991; MONTO AS, 1983, J INFECT DIS, V148, P284, DOI 10.1093/infdis/148.2.284; NAKAGOMI O, 1990, J CLIN MICROBIOL, V28, P1198, DOI 10.1128/JCM.28.6.1198-1203.1990; NAKATA S, 1985, J INFECT DIS, V152, P274, DOI 10.1093/infdis/152.2.274; NAKATA S, 1988, J CLIN MICROBIOL, V26, P2001, DOI 10.1128/JCM.26.10.2001-2005.1988; NAKATA S, 1983, J CLIN MICROBIOL, V17, P198, DOI 10.1128/JCM.17.2.198-201.1983; NAKATA S, 1985, J CLIN MICROBIOL, V22, P519, DOI 10.1128/JCM.22.4.519-521.1985; NIEL C, 1986, J CLIN MICROBIOL, V24, P785, DOI 10.1128/JCM.24.5.785-789.1986; NOONE C, 1986, EUR J CLIN INVEST, V16, P217, DOI 10.1111/j.1365-2362.1986.tb01332.x; OFFIT PA, 1986, J VIROL, V57, P46, DOI 10.1128/JVI.57.1.46-49.1986; OFFIT PA, 1986, J VIROL, V60, P491, DOI 10.1128/JVI.60.2.491-496.1986; OFFIT PA, 1988, J VIROL, V62, P127, DOI 10.1128/JVI.62.1.127-131.1988; OKADA S, 1990, J CLIN MICROBIOL, V28, P1244, DOI 10.1128/JCM.28.6.1244-1248.1990; OSHIRO LS, 1981, J INFECT DIS, V143, P791, DOI 10.1093/infdis/143.6.791; PARRINO TA, 1977, NEW ENGL J MED, V297, P86, DOI 10.1056/NEJM197707142970204; PENARANDA ME, 1989, J CLIN MICROBIOL, V27, P2180, DOI 10.1128/JCM.27.10.2180-2183.1989; PEREIRA HG, 1988, LANCET, V2, P103; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; REID JA, 1988, LANCET, V2, P321; RENNELS MB, 1990, AM J DIS CHILD, V144, P601, DOI 10.1001/archpedi.1990.02150290095037; RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091; RICHARDSON SC, 1990, J CLIN MICROBIOL, V28, P1891, DOI 10.1128/JCM.28.9.1891-1897.1990; RICHMOND SJ, 1979, LANCET, V1, P1178; RIEPENHOFFTALTY M, 1987, J VIROL, V61, P3345, DOI 10.1128/JVI.61.10.3345-3348.1987; RODRIGUEZ WJ, 1985, J PEDIATR-US, V107, P514, DOI 10.1016/S0022-3476(85)80007-X; RODRIGUEZ WJ, 1980, AM J DIS CHILD, V134, P777, DOI 10.1001/archpedi.1980.02130200047015; RODRIGUEZ WJ, 1987, PEDIATR INFECT DIS J, V6, P170, DOI 10.1097/00006454-198702000-00006; RUGGERI FM, 1989, J CLIN MICROBIOL, V27, P1522, DOI 10.1128/JCM.27.7.1522-1526.1989; RYDER RW, 1981, J INFECT DIS, V144, P442, DOI 10.1093/infdis/144.5.442; SABARA M, 1987, J GEN VIROL, V68, P123, DOI 10.1099/0022-1317-68-1-123; SANDINO AM, 1986, J VIROL, V60, P797, DOI 10.1128/JVI.60.2.797-802.1986; SANTOSHAM M, 1985, PEDIATRICS, V76, P159; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; SCHREIBER DS, 1977, GASTROENTEROLOGY, V73, P174; SCHREIBER DS, 1973, NEW ENGL J MED, V288, P1318, DOI 10.1056/NEJM197306212882503; SCOTTTAYLOR T, 1990, J CLIN MICROBIOL, V28, P2797, DOI 10.1128/JCM.28.12.2797-2801.1990; SINGHNAZ N, 1988, J CLIN MICROBIOL, V26, P297, DOI 10.1128/JCM.26.2.297-300.1988; SNODGRASS DR, 1984, J CLIN MICROBIOL, V20, P342, DOI 10.1128/JCM.20.3.342-346.1984; SUZUKI H, 1979, J MED VIROL, V4, P321, DOI 10.1002/jmv.1890040410; TAKIFF HE, 1985, J MED VIROL, V16, P107, DOI 10.1002/jmv.1890160203; TANIGUCHI K, 1988, J VIROL, V62, P1870, DOI 10.1128/JVI.62.6.1870-1874.1988; THOMAS EE, 1988, J CLIN MICROBIOL, V26, P1189, DOI 10.1128/JCM.26.6.1189-1193.1988; THORNHILL TS, 1977, J INFECT DIS, V135, P20, DOI 10.1093/infdis/135.1.20; TUFVESSON B, 1986, ACTA PAEDIATR SCAND, V75, P211, DOI 10.1111/j.1651-2227.1986.tb10186.x; UHNOO I, 1986, J INFECTION, V13, P73, DOI 10.1016/S0163-4453(86)92348-0; UHNOO I, 1984, J CLIN MICROBIOL, V20, P365, DOI 10.1128/JCM.20.3.365-372.1984; URASAWA S, 1989, J INFECT DIS, V160, P44, DOI 10.1093/infdis/160.1.44; VESIKARI T, 1984, LANCET, V1, P977; VIAL PA, 1988, J INFECT DIS, V157, P668, DOI 10.1093/infdis/157.4.668; VONBONSDORFF CH, 1988, SCAND J INFECT DIS, V20, P475, DOI 10.3109/00365548809032493; WADELL G, 1987, CIBA F SYMP, V128, P63; WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871; WARD RL, 1990, J INFECT DIS, V161, P440, DOI 10.1093/infdis/161.3.440; WELCH SKW, 1989, J VIROL, V63, P3974, DOI 10.1128/JVI.63.9.3974-3982.1989; WENMAN WM, 1979, NEW ENGL J MED, V301, P303, DOI 10.1056/NEJM197908093010604; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; WILLCOCKS MM, 1990, ARCH VIROL, V113, P73, DOI 10.1007/BF01318354; WOOD DJ, 1989, J CLIN MICROBIOL, V27, P1155, DOI 10.1128/JCM.27.6.1155-1158.1989; WYATT RG, 1974, J INFECT DIS, V129, P709, DOI 10.1093/infdis/129.6.709; YEAGER M, 1990, J CELL BIOL, V110, P2133, DOI 10.1083/jcb.110.6.2133; YOLKEN R, 1989, LANCET, V1, P517; YOLKEN RH, 1982, J PEDIATR-US, V101, P21, DOI 10.1016/S0022-3476(82)80173-X; ZHENG BJ, 1989, J CLIN MICROBIOL, V27, P2083, DOI 10.1128/JCM.27.9.2083-2090.1989; 1985, I MED NEW VACCINE DE, V1, P410; 1990, MMWR, V39, P1	196	188	200	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					252	264		10.1056/NEJM199107253250406	http://dx.doi.org/10.1056/NEJM199107253250406			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	1647494				2022-12-28	WOS:A1991FX62700006
J	BRANTHWAITE, JP; NICHOLLS, A				BRANTHWAITE, JP; NICHOLLS, A			CYCLOSPORINE AND DICLOFENAC INTERACTION IN RHEUMATOID-ARTHRITIS	LANCET			English	Letter									W SUFFOLK HOSP,BURY ST EDMUNDS,SUFFOLK,ENGLAND		BRANTHWAITE, JP (corresponding author), SANDOZ PHARMACEUT,FRIMLEY BUSINESS PK,CAMBERLEY GU16 5SG,SURREY,ENGLAND.							Mihatsch M J, 1988, Adv Nephrol Necker Hosp, V17, P303; NEILD G, 1988, ESSENT FATTY ACIDS, V33, P207; TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495-198835030-00004	3	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					252	252		10.1016/0140-6736(91)92230-Y	http://dx.doi.org/10.1016/0140-6736(91)92230-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670893				2022-12-28	WOS:A1991EU92400070
J	HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N				HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N			EXPERIMENTAL REDUCTION OF PORTAL-HYPERTENSION BY MECHANICAL INCREASE OF LIVER PORTAL FLOW	LANCET			English	Note								Studies on the isolated perfused rat liver demonstrated that an increase in portal pressure is associated with an increase in the portal blood flow in normal and in cirrhotic livers. In two pigs with portal hypertension mesenteric portal pressure was lowered by mechanically increasing the liver portal blood flow by means of a balloon pump around the portal vein.	HAMMERSMITH HOSP,DEPT SURG,LONDON W12 0HS,ENGLAND; HOP COCHIN,SURG RES LAB,F-75674 PARIS 14,FRANCE; ECOLE NATL SUPER ARTS & METIERS,ANGERS,FRANCE	Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Arts et Metiers Institute of Technology	HABIB, N (corresponding author), ROYAL FREE HOSP,DEPT SURG,HEPATOBILIARY & LIVER TRANSPLANTAT UNIT,LONDON NW3 2QG,ENGLAND.								0	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					16	17		10.1016/0140-6736(91)93334-6	http://dx.doi.org/10.1016/0140-6736(91)93334-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670651				2022-12-28	WOS:A1991EQ60400008
J	HEALY, B				HEALY, B			ON GENE PATENTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; 1991, OTABA494 OFF TECHN A; 1991, REPORT NATIONAL BIOT; 1992, IBA POSITION PAPER R	5	29	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					664	668		10.1056/NEJM199208273270930	http://dx.doi.org/10.1056/NEJM199208273270930			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640972	Bronze			2022-12-28	WOS:A1992JK20400034
J	BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L				BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L			GENETIC ISOLATION OF ADA2 - A POTENTIAL TRANSCRIPTIONAL ADAPTER REQUIRED FOR FUNCTION OF CERTAIN ACIDIC ACTIVATION DOMAINS	CELL			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ACCURATE INITIATION; REGULATORY PROTEIN; S-CEREVISIAE; YEAST GENE; BOX FACTOR; CYC1 GENE; DNA	We have devised a genetic strategy to isolate the target of acidic activation domains of transcriptional activators based on toxicity in yeast cells of the chimeric activator, GAL4-VP16. Toxicity required the integrity of both the VP16 acidic activation domain and the GAL4 DNA-binding domain, suggesting that inhibition resulted from trapping of general transcription factors at genomic sites. Mutations that break the interaction between GAL4-VP16 and general factors would alleviate toxicity and identify transcriptional adaptors, if adaptors bridged the interaction between activators and general factors. We thus identified ADA1, ADA2, and ADA3. Mutations in ADA2 reduced the activity of GAL4-VP16 and GCN4 in vivo. ada2 mutant extracts exhibited normal basal transcription, but were defective in responding to GAL4-VP16, GCN4, or the dA:dT activator. Strikingly, the mutant extract responded like wild type to GAL4-HAP4. We conclude that ADA2 potentiates the activity of one class of acidic activation domain but not a second class.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, GENET PROGRAM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University	BERGER, SL (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Piña, Benjamin/A-1671-2011	Piña, Benjamin/0000-0001-9216-2768; Silverman, Neal/0000-0002-4259-456X; Triezenberg, Steven/0000-0003-4184-5221; Berger, Shelley/0000-0001-5398-4400	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27323] Funding Source: Medline; NIGMS NIH HHS [GM 30454-10] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEZELEE S, 1989, EMBO J, V8, P3437, DOI 10.1002/j.1460-2075.1989.tb08508.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FASSLER JS, 1988, GENETICS, V118, P203; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WINSTON F, 1984, GENETICS, V107, P179; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	83	389	409	2	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					251	265		10.1016/0092-8674(92)90100-Q	http://dx.doi.org/10.1016/0092-8674(92)90100-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638630				2022-12-28	WOS:A1992JE75700009
J	HAUSEN, HZ				HAUSEN, HZ			VIRUSES IN HUMAN CANCERS	SCIENCE			English	Article							HEPATITIS-B-VIRUS; T-CELL LEUKEMIA; EPSTEIN-BARR-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; HERPES-SIMPLEX VIRUS; PRIMARY HUMAN KERATINOCYTES; HUMAN GENITAL CANCER; OPEN READING FRAMES; C-MYC EXPRESSION; HEPATOCELLULAR-CARCINOMA	Viruses may contribute to the development of human tumors by different mechanisms: indirectly by inducing immunosuppression or by modifying the host cell genome without persistence of viral DNA; directly by inducing oncoproteins or by altering the expression of host cell proteins at the site of viral DNA integration. Human cancers associated with papillomavirus, hepatitis B virus, Epstein-Barr virus, and human T cell leukemia-lymphoma virus infections are responsible for approximately 15 percent of the worldwide cancer incidence. Cancer of the cervix and hepatocellular carcinoma account for about 80 percent of virus-linked cancers. Because experimental and epidemiologic data imply a causative role for viruses, particularly in cervical and liver cancer, viruses must be thought of as the second most important risk factor for cancer development in humans, exceeded only by tobacco consumption.			HAUSEN, HZ (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BEASLEY RP, 1981, LANCET, V2, P1129; BLATTNER WA, 1983, J INFECT DIS, V147, P406, DOI 10.1093/infdis/147.3.406; BOIOCCHI M, 1989, TUMORI, V75, P345, DOI 10.1177/030089168907500409; BOSCH FX, 1989, FALK SYMP, V51, P3; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRAUN L, 1990, CANCER RES, V50, P7324; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CAPUTO A, 1983, J MED VIROL, V12, P37, DOI 10.1002/jmv.1890120105; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CRUM CP, 1985, J CELL BIOCHEM, V9, P70; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; CUTURI MC, 1987, J EXP MED, V165, P1581, DOI 10.1084/jem.165.6.1581; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DEVILLIERS EM, COMMUNICATION; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DUFF R, 1971, J VIROL, V8, P469, DOI 10.1128/JVI.8.4.469-477.1971; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1991, J VIROL, V65, P796; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1973, INT J CANCER, V12, P309, DOI 10.1002/ijc.2910120202; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; ERNBERG I, 1986, INT J CANCER, V38, P729, DOI 10.1002/ijc.2910380517; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; FU YS, 1981, GYNECOL ONCOL, V12, pS220, DOI 10.1016/0090-8258(81)90076-7; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GURTSEVITCH VE, 1988, INT J CANCER, V41, P87, DOI 10.1002/ijc.2910410117; HALL AJ, 1985, LANCET, V1, P91; HAUSEN HD, UNPUB; HAUSEN HZ, 1983, INT REV EXP PATHOL, V25, P307; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HAUSEN HZ, 1970, NATURE, V227, P245, DOI 10.1038/227245a0; HAUSEN HZ, 1986, LANCET, V2, P489; HAUSEN HZ, 1975, BIOCHIM BIOPHYS ACTA, V417, P25, DOI 10.1016/0304-419X(75)90007-4; HAUSEN HZ, 1977, BEHRING I MITT, V61, P23; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HENLE W, 1973, NATL CANCER I MONOGR, P79; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; HENLE W, 1977, INT J CANCER, V20, P663, DOI 10.1002/ijc.2910200504; HESSE J, 1977, INT J CANCER, V19, P49, DOI 10.1002/ijc.2910190108; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOTCHIN NA, 1990, INT J CANCER, V45, P566, DOI 10.1002/ijc.2910450332; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUMORO A, 1983, LANCET, V2, P240; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MAEDA Y, 1984, INT J CANCER, V33, P717, DOI 10.1002/ijc.2910330602; MARION PL, 1980, P NATL ACAD SCI-BIOL, V77, P2941, DOI 10.1073/pnas.77.5.2941; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MASON WS, 1980, J VIROL, V36, P829, DOI 10.1128/JVI.36.3.829-836.1980; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MUNGER K, 1989, J VIROL, V63, P4417; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NAHMIAS AJ, 1970, AM J EPIDEMIOL, V91, P547, DOI 10.1093/oxfordjournals.aje.a121166; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; ORTH G, 1987, PAPOVAVIRIDAE, V2, P199; PAGNANI M, 1986, J VIROL, V59, P500, DOI 10.1128/JVI.59.2.500-505.1986; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PECORARO G, 1991, AM J PATHOL, V138, P1; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; POPOVIC M, 1982, NATURE, V300, P63, DOI 10.1038/300063a0; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; PRINCE AM, 1975, INT J CANCER, V16, P376, DOI 10.1002/ijc.2910160304; RAWLS WE, 1973, CANCER RES, V33, P1511; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROBERTGUROFF M, 1983, J EXP MED, V157, P248, DOI 10.1084/jem.157.1.248; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1989, MOL CARCINOGEN, V2, P72, DOI 10.1002/mc.2940020205; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANADA I, 1985, BLOOD, V65, P649; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHLEHOFER JR, 1983, INT J CANCER, V32, P591, DOI 10.1002/ijc.2910320512; SCHLEHOFER JR, 1983, INT J CANCER, V32, P99, DOI 10.1002/ijc.2910320116; SCHMUCKLER EA, 1984, VIRAL HEPATITIS LIVE, P201; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SHOPE T, 1973, P NATL ACAD SCI USA, V70, P2487, DOI 10.1073/pnas.70.9.2487; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; SPRENGEL R, 1988, J VIROL, V62, P3832, DOI 10.1128/JVI.62.10.3832-3839.1988; SPRENGEL R, 1987, VIRUS DISEASE LABORA, P363; STAAL SP, 1989, AM J CLIN PATHOL, V91, P1; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; SUNDBERG JP, 1987, CONTRIB ONCOL, V24, P11; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; Takatsuki K, 1990, RETROVIRUS BIOL HUMA, P147; TAKEMOTO KK, 1974, JNCI-J NATL CANCER I, V53, P1205, DOI 10.1093/jnci/53.5.1205; TRICHOPOULOS D, 1976, BRIT J CANCER, V34, P83, DOI 10.1038/bjc.1976.125; UESHIMA Y, 1981, BLOOD, V58, P420; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; VONKNEBELDOEBER.M, 1989, EMBO J, V8, P513; VONLORINGHOVEN AF, 1985, EMBO J, V4, P249, DOI 10.1002/j.1460-2075.1985.tb02343.x; WALDMANN TA, 1984, J CLIN INVEST, V73, P1711, DOI 10.1172/JCI111379; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WEISS LM, 1987, AM J PATHOL, V129, P86; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; WOLF J, 1990, CANCER RES, V50, P3095; WOLF J, 1991, INT J CANCER, V47, P99, DOI 10.1002/ijc.2910470118; Wolf J., UNPUB; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WOODWORTH CD, 1990, J VIROL, V64, P4767, DOI 10.1128/JVI.64.10.4767-4775.1990; WOODWORTH CD, 1990, CANCER RES, V50, P3709; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; YEE C, 1985, AM J PATHOL, V119, P361; YOKOSUKA O, 1985, P NATL ACAD SCI USA, V82, P5180, DOI 10.1073/pnas.82.15.5180; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAHM P, 1988, ONCOGENE, V3, P169; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0; ZURHAUSEN H, 1976, CANCER RES, V36, P794	153	650	665	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	1991	254	5035					1167	1173		10.1126/science.1659743	http://dx.doi.org/10.1126/science.1659743			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1659743				2022-12-28	WOS:A1991GQ83400036
J	ALTER, HJ				ALTER, HJ			DESCARTES BEFORE THE HORSE - I CLONE, THEREFORE I AM - THE HEPATITIS-C VIRUS IN CURRENT PERSPECTIVE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; CLONING, MOLECULES; HEPATITIS ANTIBODIES; HEPATITIS, VIRAL, NON-A, NON-B; BLOOD TRANSFUSION	NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; CIRCULATING ANTIBODIES; PREVALENCE; INFECTION; RISK; HCV	In an unprecedented approach to viral discovery, the hepatitis C virus (HCV) was cloned before it was established by conventional methods of viral detection or by genomic characterization. Hepatitis C virus is a small (10-kb), single-stranded RNA virus with a genomic organization that places it in the family Flaviviridae. The virus is global in distribution, with a prevalence between 0.3% and 1.5%. The same agent causes parenterally acquired and sporadic non-A, non-B hepatitis. Nonparenteral modes of spread are poorly defined, but low-level sexual transmission is probable. There is a strong association between the presence of antibody to HCV (anti-HCV) and hepatocellular carcinoma; a causal role for HCV is suspected but has not been proved. Hepatitis C virus accounts for at least 85% of the cases of transfusion-associated hepatitis; an anti-HCV-reactive donor was retrospectively identified in nearly 90% of cases. Among donors confirmed by recombinant immunoblot assay (RIBA) to be anti-HCV positive, 80% to 90% are infectious. Hepatitis C virus RNA can be detected within 1 to 2 weeks of exposure and persists throughout the course of infection. Generally, the presence of anti-HCV cannot be confirmed until 9 to 20 weeks after exposure, creating a window period of seronegativity and potential infectivity. It is anticipated that the anti-HCV assay will reduce the number of cases of transfusion-associated hepatitis by 50% in the United States; a 70% reduction has been documented in Spain.	NIH, DEPT TRANSFUS MED, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	ALTER, HJ (corresponding author), NIH, IMMUNOL SECT, 9000 ROCKVILLE PIKE, BLDG 10, ROOM 1C711, BETHESDA, MD 20892 USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1990, J GASTROEN HEPATOL, V5, P78, DOI 10.1111/j.1440-1746.1990.tb01783.x; ALTER HJ, 1982, VIRAL HEPATITIS, P279; ALTER HJ, 1991, IN PRESS 1990 INT S; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BLANCHETTE VS, 1991, IN PRESS BLOOD; BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254; BRETTLER DB, 1990, BLOOD, V76, P254; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLOMBO M, 1989, LANCET, V2, P1006; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1990, BLOOD, V76, pA398; FARCI P, 1990, HEPATOLOGY, V12, P904; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; KRAULEDAT PB, 1989, 4ST P INT S HEP C VI; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; TEGGER A, 1990, IN PRESS 1990 INT S; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B	29	105	109	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					644	649		10.7326/0003-4819-115-8-644	http://dx.doi.org/10.7326/0003-4819-115-8-644			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1654040				2022-12-28	WOS:A1991GJ90200010
J	INGHAM, PW; TAYLOR, AM; NAKANO, Y				INGHAM, PW; TAYLOR, AM; NAKANO, Y			ROLE OF THE DROSOPHILA PATCHED GENE IN POSITIONAL SIGNALING	NATURE			English	Article							SEGMENT POLARITY GENE; SPATIAL-DISTRIBUTION; EMBRYONIC PATTERN; FUSHI-TARAZU; PROTEIN; EXPRESSION; WINGLESS; BLASTODERM; REGION	AFTER cellularization of the Drosophila embryo, positional differences within each primordial segment are maintained and elaborated by processes that require cell interactions. The best-documented examples 1,2 of such intercellular signalling are the mutual interactions between neighbouring cells expressing the homeodomain protein engrailed 3 and the secreted glycoprotein encoded by wingless 4, the Drosophila homologue of the murine Wnt-1 gene 5. Little is known about the molecular basis of these signalling mechanisms but the activities of several other genes, notably patched and hedgehog, have been implicated in the process 1,2. Here we show that the role of patched in positional signalling is permissive rather than instructive, its activity being required to suppress wingless transcription in cells predisposed to express the latter. According to this view, expression of wingless is normally maintained only in those cells receiving an extrinsic signal, encoded by hedgehog, that antagonizes the repressive activity of patched. We suggest that the patched protein may itself be the receptor for this signal, implying that this is an unusual mechanism of ligand-dependent receptor inactivation.			INGHAM, PW (corresponding author), IMPERIAL CANC RES FUND, DEPT ZOOL, DEV BIOL UNIT, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip W/G-9903-2011; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958; 				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	381	399	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					184	187		10.1038/353184a0	http://dx.doi.org/10.1038/353184a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653906				2022-12-28	WOS:A1991GE73100059
J	LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA				LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA			THE TRK PROTOONCOGENE RESCUES NGF RESPONSIVENESS IN MUTANT NGF-NONRESPONSIVE PC12 CELL-LINES	CELL			English	Article							NERVE GROWTH-FACTOR; FACTOR RECEPTOR; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; DIFFERENTIATION; SURVIVAL; AFFINITY; RESPOND	The trk tyrosine kinase proto-oncogene product gp140prototrk binds nerve growth factor (NGF) and is rapidly and selectively activated by this neurotrophic factor. To determine whether gp140prototrk is involved in transducing a functional NGF signal, PC12 cell mutants (PC12nnr) deficient in high affinity NGF binding and unresponsive to NGF were used. Northern analysis revealed that these mutant cells have greatly reduced levels of trk expression. PC12nnr cultures were transiently transfected with expression vectors encoding the full-length rat trk cDNA and assessed for responsiveness to NGF. Expression of exogenous trk rescued the capacity for NGF-promoted neurite outgrowth, cellular hypertrophy, and serum-free survival by these cells. These results indicate that gp140prototrk is necessary for functional NGF signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	LOEB, DM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744	NINDS NIH HHS [NS 27680, NS 21072, NS 16036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016036, P50NS027680, R01NS021072, P01NS027680] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1991, IN PRESS CULTURING N; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANIATIS T, 1982, MOL CLONING LABORATO, P383; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RUIT KG, 1990, J NEUROSCI, V10, P2412; RUKENSTEIN A, 1991, IN PRESS J NEUROSCI; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; Volonte C, 1990, GROWTH FACTORS, V2, P321; YAN Q, 1988, J NEUROSCI, V8, P3481	41	242	243	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					961	966		10.1016/0092-8674(91)90441-Z	http://dx.doi.org/10.1016/0092-8674(91)90441-Z			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653650				2022-12-28	WOS:A1991GE46000014
J	HALLETT, M				HALLETT, M			CLASSIFICATION AND TREATMENT OF TREMOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							PRIMARY WRITING TREMOR; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; PRIMIDONE				HALLETT, M (corresponding author), NINCDS,MED NEUROL BRANCH,HUMAN MOTOR CONTROL SECT,BLDG 10,ROOM 5N-226,BETHESDA,MD 20892, USA.							ANDREW J, 1982, J NEUROL NEUROSUR PS, V45, P815, DOI 10.1136/jnnp.45.9.815; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; Cohen L G, 1987, Mov Disord, V2, P109, DOI 10.1002/mds.870020205; COOK D, 1990, NEUROLOGY, V40, P212, DOI 10.1212/WNL.40.2.212; DALAKAS MC, 1984, ARCH NEUROL-CHICAGO, V41, P711, DOI 10.1001/archneur.1984.04050180033012; ELBLE RJ, 1990, MOVEMENT DISORD, V5, P118, DOI 10.1002/mds.870050205; FINDLEY LJ, 1985, J NEUROL NEUROSUR PS, V48, P192, DOI 10.1136/jnnp.48.2.192; GERAGHTY JJ, 1985, ANN NEUROL, V17, P329, DOI 10.1002/ana.410170404; HALLETT M, 1985, NEUROLOGY, V35, P1374, DOI 10.1212/WNL.35.9.1374; HALLETT M, 1987, HDB CLIN NEUROLOGY, V5, P583; HEILMAN KM, 1984, ARCH NEUROL-CHICAGO, V41, P880, DOI 10.1001/archneur.1984.04050190086020; HUBBLE JP, 1989, CLIN NEUROPHARMACOL, V12, P453, DOI 10.1097/00002826-198912000-00001; KACHI T, 1985, J NEUROL NEUROSUR PS, V48, P545, DOI 10.1136/jnnp.48.6.545; KLAWANS HL, 1982, NEUROLOGY, V32, P203, DOI 10.1212/WNL.32.2.203; KOLLER WC, 1989, NEUROLOGY, V39, P1587, DOI 10.1212/WNL.39.12.1587; Lefebre-DAmour M, 1978, PROG CLIN NEUROPHYS, V5, P160; NARABAYASHI H, 1982, MOVEMENT DISORDERS B, V2, P292; RAVITS J, 1985, NEUROLOGY, V35, P1387, DOI 10.1212/WNL.35.9.1387; ROTHWELL JC, 1979, J NEUROL NEUROSUR PS, V42, P1106, DOI 10.1136/jnnp.42.12.1106; SABRA AF, 1984, NEUROLOGY, V34, P151, DOI 10.1212/WNL.34.2.151; SASSO E, 1990, CLIN NEUROPHARMACOL, V13, P67, DOI 10.1097/00002826-199002000-00007; SECHI GP, 1989, J NEUROL, V236, P461, DOI 10.1007/BF00328507; Smith IS, 1984, MOVEMENT DISORDERS T, P399; SPEELMAN JD, 1984, J NEUROL NEUROSUR PS, V47, P596, DOI 10.1136/jnnp.47.6.596; YOUNG RR, 1987, HDB CLIN NEUROLOGY, V5, P565	25	55	57	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1115	1117		10.1001/jama.266.8.1115	http://dx.doi.org/10.1001/jama.266.8.1115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1650852				2022-12-28	WOS:A1991GB97500036
J	FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH				FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH			A LONG-TERM STUDY OF HEPATITIS-C VIRUS-REPLICATION IN NON-A, NON-B HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODIES; GENOME; BLOOD; CDNA; CHIMPANZEES; SEQUENCE; ANTIGEN; RNA; PCR	Background. Although antibodies to the hepatitis C virus (HCV) are known to be associated with non-A, non-B hepatitis, little is known about the pattern of HCV replication, its relation to antibody levels, and the clinical course of non-A, non-B hepatitis. Methods. We measured HCV RNA in serial serum samples from five patients with post-transfusion non-A, non-B hepatitis who were followed for 1 0 to 14 years after transfusion. We also studied four chimpanzees that were experimentally infected with serum from four of these patients. Serum HCV RNA was detected by a "nested" polymerase-chain-reaction (PCR) assay that used two sets of primers derived from the third (NS3) and fourth (NS4) nonstructural gene regions of the HCV genome. Results. HCV sequences were detected by PCR in only two of the five patients and two of the four chimpanzees with the set of primers corresponding to the NS3 region, but in all five patients (and in all four chimpanzees) with the primers from the NS4 region. Serum HCV RNA was first detected within three weeks of transfusion in all five patients and within one week in three patients. The viremia lasted less than 4 months in the patient (and two chimpanzees) with acute, self-limited hepatitis, whereas it persisted for 10 to 14 years in the four patients (and for 1 and 3 years in two chimpanzees) with chronic non-A, non-B hepatitis. Antibodies to HCV were first detected at week 12 to 14; they disappeared after nine years in the patient with self-limited disease and became borderline after five years in one of the patients with chronic disease. Conclusions. During the early phase of primary HCV infection, there is a period of several months of seronegativity during which HCV RNA is the only diagnostic marker of infection. The disappearance of HCV RNA from serum appears to correlate with the resolution of non-A, non-B hepatitis, whereas viremia persists in patients whose disease progresses to chronic hepatitis. In contrast, antibody levels do not necessarily remain elevated in patients with chronic disease.	NIH,BIOMED ENGN & INSTRUMENTAT BRANCH,WARREN G MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BLDG 7,RM 202,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Jett, Betsy/AAT-5154-2021					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HOUGHTON M, 1988, Patent No. 883109225; KANEKO S, 1990, LANCET, V335, P976, DOI 10.1016/0140-6736(90)91042-9; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MIYAMURA T, 1990, P NATL ACAD SCI USA, V87, P983, DOI 10.1073/pnas.87.3.983; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	25	494	511	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					98	104		10.1056/NEJM199107113250205	http://dx.doi.org/10.1056/NEJM199107113250205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	1646962				2022-12-28	WOS:A1991FV52200005
J	EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S				EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S			CLONING OF A CDNA FOR A GLUTAMATE RECEPTOR SUBUNIT ACTIVATED BY KAINATE BUT NOT AMPA	NATURE			English	Article							AMINO-ACID RECEPTORS; FUNCTIONAL EXPRESSION; XENOPUS-OOCYTES; KAINIC ACID; NERVOUS-SYSTEM; BINDING-SITES; PHARMACOLOGY; QUISQUALATE; FAMILY; SEQUENCE	FAST excitatory transmission in the vertebrate central nervous system is mediated mainly by L-glutamate. On the basis of pharmacological, physiological and agonist binding properties, the ionotropic glutamate receptors are classified into NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) and kainate subtypes 1. Sequence homology between complementary DNA clones encoding non-NMDA glutamate receptor subunits reveals at least two subunit classes: the GluR1 to GluR4 class 2-6 and the GluR5 class 7. Here we report the cloning and expression of a functional rat glutamate receptor subunit cDNA, GluR6, which has a very different pharmacology from that of the GluR1-GluR4 class. Receptors generated from the GluR1-GluR4 class have a higher apparent affinity for AMPA than for kainate 3-6. When expressed in Xenopus oocytes the homomeric GluR6 receptor is activated by kainate, quisqualate and L-glutamate but not by AMPA, and the apparent affinity for kainate is higher than for receptors from the GluR1-GluR4 class. Desensitization of the receptor was observed with continuous application of agonist. The homomeric GluR6 glutamate receptor exhibits an outwardly rectifying current-voltage relationship. In situ hybridizations reveal a pattern of GluR6 gene expression reminiscent of the binding pattern obtained with [H-3]kainate.			EGEBJERG, J (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.		bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207				BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MEYER ML, 1989, P NATL ACAD SCI USA, V86, P1411; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1989, MOL PHARMACOL, V35, P360; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0	22	581	593	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					745	748		10.1038/351745a0	http://dx.doi.org/10.1038/351745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648177				2022-12-28	WOS:A1991FU20100064
J	GOODWIN, FK				GOODWIN, FK			PEER-REARED MONKEYS ALCOHOL-PRONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							HIGHLEY JD, IN PRESS P NATL ACAD	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1646339				2022-12-28	WOS:A1991FR83500007
J	BOWIE, C; BOWIE, SHU				BOWIE, C; BOWIE, SHU			RADON AND HEALTH	LANCET			English	Review							LUNG-CANCER MORTALITY; URANIUM MINERS; INDOOR RADON; EXPOSURE; RADIATION; DAUGHTERS; WOMEN	Radon and its daughter decay products are thought to be the cause of 5% of lung cancer in the UK. This assessment has been made by the National Radiological Protection Board (NRPB) after a national survey of radon levels in homes, when more houses than anticipated were found to have high levels, and after a reappraisal upwards of the effectiveness of radon and its daughter products in causing lung cancer. A review of the scientific evidence reveals no direct evidence to incriminate radon or its decay products at the levels found in our homes in lung cell carcinogenesis. The issue involves different scientific disciplines and is highly complex. Debate between scientists is required and more epidemiological studies of lung cancer and low radon exposure are necessary. Meanwhile the indirect evidence linking low levels of radon exposure to lung cancer is insufficient to warrant the remedial action proposed by the NRPB and accepted by the UK government.	TANYARD FARM CLAPTON,CREWKERNE TA18 8PS,SOMERSET,ENGLAND		BOWIE, C (corresponding author), SOMERSET HLTH AUTHOR,TAUNTON TA2 7PQ,SOMERSET,ENGLAND.			Bowie, Cam/0000-0002-6956-3691				[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1988, RADON ITS DECAY PROD; AXELSON O, 1988, SCAND J WORK ENV HEA, V14, P286, DOI 10.5271/sjweh.1918; AXELSON O, 1979, SCAND J WORK ENV HEA, V5, P10, DOI 10.5271/sjweh.2671; BLOT WJ, 1990, J NATL CANCER I, V82, P1025, DOI 10.1093/jnci/82.12.1025; BOWIE C, 1990, RADON HLTH FACTS; BOWIE SHU, 1958, 2ND P INT C PEAC US; BRECKON G, 1990, LANCET, V335, P656, DOI 10.1016/0140-6736(90)90439-C; CLARKE RH, 1989, NATURE, V338, P197, DOI 10.1038/338197a0; COHEN BL, 1990, ENV RADON OCCURRENCE; DAMBER LA, 1987, ACTA ONCOL, V26, P211, DOI 10.3109/02841868709091434; DARBY SC, 1990, NATURE, V344, P824, DOI 10.1038/344824a0; EDLING C, 1984, SCAND J WORK ENV HEA, V10, P25, DOI 10.5271/sjweh.2366; Falk R., 1984, Radiation Protection Dosimetry, V7, P377; FORASTIERE F, 1985, SCI TOTAL ENVIRON, V45, P519, DOI 10.1016/0048-9697(85)90257-8; FREMLIN JH, 1987, NUCLEAR RAD FRIEND F; GEORGE AC, 1967, HEALTH PHYS, V13, P375, DOI 10.1097/00004032-196704000-00005; GOTTLIEB LS, 1982, CHEST, V81, P449, DOI 10.1378/chest.81.4.449; HAYNES RM, 1988, RADIAT PROT DOSIM, V25, P93, DOI 10.1093/oxfordjournals.rpd.a080357; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; LEES REM, 1987, INT J EPIDEMIOL, V16, P7, DOI 10.1093/ije/16.1.7; LUBIN JH, 1990, CANCER RES, V50, P174; LUBIN JH, 1990, AM J EPIDEMIOL, V131, P552, DOI 10.1093/oxfordjournals.aje.a115530; LYKKEN GI, 1989, HEALTH PHYS, V57, P161; NUSSBAUM E, 1957, SCIENCE, V125, P552, DOI 10.1126/science.125.3247.552; PETO J, 1990, NATURE, V345, P389, DOI 10.1038/345389a0; POHL E, 1964, RADIOLOGICAL HLTH SA; ROSCOE RJ, 1989, JAMA-J AM MED ASSOC, V262, P629, DOI 10.1001/jama.262.5.629; SACCOMANNO G., 1964, HEALTH PHYS, V10, P1195, DOI 10.1097/00004032-196412000-00040; SAMET JM, 1989, J NATL CANCER I, V81, P745, DOI 10.1007/s00484-020-01860-w; SAMUELSSON C, 1988, NATURE, V334, P338, DOI 10.1038/334338a0; SCHOENBERG JB, 1990, MMWR, V38, P715; STOCKWELL HG, 1988, RADIAT PROT DOSIM, V24, P475; SVENSSON C, 1989, CANCER RES, V49, P1861; SVENSSON C, 1987, INT ARCH OCC ENV HEA, V59, P123, DOI 10.1007/BF00378490; WRIXON AD, 1988, NRPBR190 HM STAT OFF; 1987, AM CRP, V17, P1; 1990, RADIOL PROTECTION B, V110, P5; 1988, HLTH RISKS RADON OTH; 1990, HOUSEHOLDERS GUIDE R; 1990, DOCUMENTS NRPB, V1	41	43	44	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					409	413		10.1016/0140-6736(91)91177-V	http://dx.doi.org/10.1016/0140-6736(91)91177-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671435				2022-12-28	WOS:A1991EX60500015
J	RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			TREATABLE COMPLICATIONS IN UNDIAGNOSED CASES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							INTRACRANIAL ANEURYSMS; BLOOD-PRESSURE; PROGRESSION; DIAGNOSIS; ONSET	In a study to determine the proportion of unrecognised cases and the prevalence of treatable complications of autosomal dominant polycystic kidney disease (ADPKD), 46 probands were identified through genetics and renal clinics in Melbourne, Australia. 321 offspring of the probands who were older than 15 years and had not been previously diagnosed as having ADPKD were identified. 68 (21%) had ultrasound evidence of polycystic kidney disease. Of this previously undiagnosed group, 25 (37%) had one or more treatable complications at the time of diagnosis. The complications included 20 cases of hypertension (diastolic blood pressure 95 mm Hg or above), 7 cases of impaired renal function (serum creatinine 0.12 mmol/l or above), and 4 cases of bacterial urinary tract infection. 8 people had several complications. ADPKD has an important treatable component which is not being treated in a substantial proportion of affected individuals, because the disease is not being diagnosed despite the presence of a positive family history.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT RADIOL,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT NEPHROL,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	RAVINE, D (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA.		Ravine, David/A-6797-2008					BALDWIN DS, 1985, HYPERTENSION KIDNEY, pA57; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; CHURCHILL DN, 1984, KIDNEY INT, V26, P190, DOI 10.1038/ki.1984.154; COLEMAN AJ, 1966, J CLIN INVEST, V45, P1116, DOI 10.1172/JCI105418; DALGAARD O. Z., 1957, ACTA MED SCAND SUPPL, V158, P1; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GARDNER KD, 1984, KIDNEY INT, V25, P244; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KANNEL WB, 1976, STROKE, V7, P327, DOI 10.1161/01.STR.7.4.327; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MCNAMARA JJ, 1965, AM J SURG, V109, P178; MILUTINOVIC J, 1980, AM J CLIN PATHOL, V73, P740; REEDERS ST, 1989, CLIN CHEM, V35, pB13; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RYU SJ, 1990, STROKE, V21, P291, DOI 10.1161/01.STR.21.2.291; SIMON HB, 1955, JAMA-J AM MED ASSOC, V159, P657, DOI 10.1001/jama.1955.02960240023006; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488; WERDER AA, 1984, J LAB CLIN MED, V103, P399; ZEIER M, 1988, NEPHRON, V49, P177, DOI 10.1159/000185052	22	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					127	129		10.1016/0140-6736(91)90797-S	http://dx.doi.org/10.1016/0140-6736(91)90797-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670785				2022-12-28	WOS:A1991ET67900001
J	SHANKAR, P; MANJUNATH, N; MOHAN, KK; PRASAD, K; BEHARI, M; SHRINIWAS; AHUJA, GK				SHANKAR, P; MANJUNATH, N; MOHAN, KK; PRASAD, K; BEHARI, M; SHRINIWAS; AHUJA, GK			RAPID DIAGNOSIS OF TUBERCULOUS MENINGITIS BY POLYMERASE CHAIN-REACTION	LANCET			English	Article							MYCOBACTERIUM-BOVIS BCG; MPB64	The polymerase chain reaction (PCR) in cerebrospinal fluid was compared with conventional bacteriology and an enzyme-linked immunosorbent assay (ELISA) for cerebrospinal fluid antibodies in the diagnosis of tuberculous meningitis (TBM). PCR was the most sensitive technique; it detected 15 (75%) of 20 cases of highly probably TBM (based on clinical features), 4 (57%) of 7 probable cases, and 3 (43%) of 7 possible cases. ELISA detected 11 (55%) of the highly probable cases and 2 each of the probable and possible cases. Culture was positive in only 4 of the highly probable cases. Among the controls (14 pyogenic meningitis, 3 aseptic meningitis, 34 other neurological disorders), 6 subjects tested early in the study (2 pyogenic meningitis, 4 other disorders) were PCR positive. Second DNA preparations from their stored cerebrospinal fluid samples were all PCR negative, suggesting that the false-positive results were due to cross-contamination. 18 PCR-positive TBM samples retested were all still PCR positive. The antibody ELISA was positive in 3 controls despite the use of a high cutoff value.	ALL INDIA INST MED SCI,DEPT MICROBIOL,ANSARI NAGAR,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROL,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi								Behari M, 1989, J Assoc Physicians India, V37, P499; BHARADWAJ OP, 1984, INDIAN J MED MICROBI, V2, P39; CHANDRAMUKI A, 1985, J MED MICROBIOL, V20, P239, DOI 10.1099/00222615-20-2-239; DANIEL TM, 1989, REV INFECT DIS, V11, pS471; DANIEL TM, 1987, J INFECT DIS, V155, P599, DOI 10.1093/infdis/155.4.599; GRANGE JM, 1989, TUBERCLE, V70, P1, DOI 10.1016/0041-3879(89)90059-7; HARBOE M, 1986, INFECT IMMUN, V52, P293, DOI 10.1128/IAI.52.1.293-302.1986; LO YMD, 1988, LANCET, V2, P679; Maniatis T., 1982, MOL CLONING; MOLAVI A, 1985, MED CLIN N AM, V69, P315; SHANKAR P, 1990, LANCET, V335, P423, DOI 10.1016/0140-6736(90)90268-A; Tandon PN, 1978, HDB CLIN NEUROLOGY I, V33, P195; YAMAGUCHI R, 1989, INFECT IMMUN, V57, P283, DOI 10.1128/IAI.57.1.283-288.1989	13	210	223	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					5	7		10.1016/0140-6736(91)93328-7	http://dx.doi.org/10.1016/0140-6736(91)93328-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670668				2022-12-28	WOS:A1991EQ60400002
J	ANNAS, GJ				ANNAS, GJ			THE SUPREME-COURT, LIBERTY, AND ABORTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1991, NEW ENGL J MED, V325, P362, DOI 10.1056/NEJM199108013250519; ANNAS GJ, 1989, NEW ENGL J MED, V321, P1200, DOI 10.1056/NEJM198910263211720	2	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					651	654		10.1056/NEJM199208273270920	http://dx.doi.org/10.1056/NEJM199208273270920			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK204	1640971	Green Published			2022-12-28	WOS:A1992JK20400033
J	JOHNSON, E				JOHNSON, E			ELEVATED VASOPRESSIN AND BULIMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, J CLIN ENDOCRINOLOGY, V74, P1277	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-28	WOS:A1992JH58800011
J	RUMSEY, JM				RUMSEY, JM			THE BIOLOGY OF DEVELOPMENTAL DYSLEXIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEARNING-DISABILITIES; READING-DISABILITY; BRAIN MORPHOLOGY; PREVALENCE; DISORDERS; SKILLS				RUMSEY, JM (corresponding author), NIMH,CHILD PSYCHIAT BRANCH,BLDG 10,ROOM 6N240,BETHESDA,MD 20892, USA.							ANNETT M, 1990, J CHILD PSYCHOL PSYC, V31, P511, DOI 10.1111/j.1469-7610.1990.tb00795.x; DEFRIES JC, 1991, READING BRAIN BIOL B, P53; DENCKLA MB, 1992, DIS NERV SYST, P636; DUARA R, 1991, ARCH NEUROL-CHICAGO, V48, P410, DOI 10.1001/archneur.1991.00530160078018; FINUCCI JM, 1984, DEV MED CHILD NEUROL, V24, P143; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; GESCHWIND N, 1987, CEREBRAL LATERALIZAT, P58; HENDERSON VW, 1986, BRAIN LANG, V29, P119, DOI 10.1016/0093-934X(86)90037-4; HINSHELWOOD J, 1917, CONGENTIAL WORD BLIN; HUMPHREYS P, 1990, ANN NEUROL, V28, P727, DOI 10.1002/ana.410280602; HYND GW, 1989, PSYCHOL BULL, V106, P447, DOI 10.1037/0033-2909.106.3.447; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; LAMBERT NM, 1980, J ABNORM CHILD PSYCH, V8, P33, DOI 10.1007/BF00918160; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; MANN VA, 1988, J CONSULT CLIN PSYCH, V56, P811; Morgan W P, 1896, Br Med J, V2, P1378; OLSON R, 1989, J LEARN DISABIL, V22, P339, DOI 10.1177/002221948902200604; Orton ST., 1937, READING WRITING SPEE; PENNINGTON BF, 1987, ARCH NEUROL-CHICAGO, V44, P634, DOI 10.1001/archneur.1987.00520180054016; PENNINGTON BF, 1988, J CONSULT CLIN PSYCH, V56, P817, DOI 10.1037/0022-006X.56.6.817; REYNOLDS CR, 1981, J SCHOOL PSYCHOL, V19, P350, DOI 10.1016/0022-4405(81)90029-7; RUMSEY JM, 1992, ARCH NEUROL-CHICAGO, V49, P527, DOI 10.1001/archneur.1992.00530290115020; RUTTER M, 1978, DYSLEXIA APPRAISAL C, P3; Satz P., 1981, NEUROPSYCHOLOGICAL C, P109; SCARBOROUGH HS, 1984, BRIT J PSYCHOL, V75, P329, DOI 10.1111/j.2044-8295.1984.tb01904.x; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SMITH SD, 1990, J AM ACAD CHILD PSY, V29, P204, DOI 10.1097/00004583-199003000-00008; VELLUTINO FR, 1987, SCI AM, V256, P34, DOI 10.1038/scientificamerican0387-34; WAGNER RK, 1987, PSYCHOL BULL, V101, P192, DOI 10.1037/0033-2909.101.2.192; 1987, DIAGNOSTIC STATISTIC	30	22	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					912	915		10.1001/jama.268.7.912	http://dx.doi.org/10.1001/jama.268.7.912			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640623				2022-12-28	WOS:A1992JH58800045
J	BERGMAN, B; BRISMAR, B; NORDIN, C				BERGMAN, B; BRISMAR, B; NORDIN, C			UTILIZATION OF MEDICAL-CARE BY ABUSED WOMEN	BRITISH MEDICAL JOURNAL			English	Article									HUDDINGE HOSP,DEPT SURG,S-14186 HUDDINGE,SWEDEN		BERGMAN, B (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,DEPT PSYCHIAT,S-14186 HUDDINGE,SWEDEN.							APPLETON W, 1980, ANN EMERG MED, V9, P84, DOI 10.1016/S0196-0644(80)80336-2; GAYFORD JJ, 1975, BRIT MED J, V1, P194, DOI 10.1136/bmj.1.5951.194; GAYFORD JJ, 1979, MED SCI LAW, V15, P237; JAFFE P, 1986, CAN J PSYCHIAT, V31, P625, DOI 10.1177/070674378603100705; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY	5	56	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					27	28		10.1136/bmj.305.6844.27	http://dx.doi.org/10.1136/bmj.305.6844.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC799	1638194	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JC79900026
J	LIDDINGTON, RC; YAN, Y; MOULAI, J; SAHLI, R; BENJAMIN, TL; HARRISON, SC				LIDDINGTON, RC; YAN, Y; MOULAI, J; SAHLI, R; BENJAMIN, TL; HARRISON, SC			STRUCTURE OF SIMIAN VIRUS-40 AT 3.8-A RESOLUTION	NATURE			English	Article							BUSHY STUNT VIRUS; SIMPLE SPHERICAL VIRUSES; MAJOR CAPSID PROTEIN; COMMON COLD VIRUS; POLYOMA-VIRUS; SUBUNIT ASSOCIATION; MULTIPLE-MODES; INVITRO; CELLS; VP1	The crystallographically determined structure of simian virus 40 shows that the 72 pentamers of viral protein VP1, which form the outer shell, have identical conformations except for the C-terminal arms of their subunits. Five arms emerge from each pentamer and insert into neighbouring pentamers. This tying together of standard building blocks allows for the required variability in packing geometry without sacrificing specificity.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University; Harvard Medical School			Sahli, Roland/K-6479-2017	Sahli, Roland/0000-0001-7513-1142				ARGOS P, 1976, ACTA CRYSTALLOGR B, V32, P2975, DOI 10.1107/S0567740876009394; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BAKER TS, 1983, NATURE, V303, P446, DOI 10.1038/303446a0; BLASQUEZ V, 1983, J BIOL CHEM, V258, P8477; BRADY JN, 1977, J VIROL, V23, P717, DOI 10.1128/JVI.23.3.717-724.1977; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHRISTIANSEN G, 1977, J VIROL, V21, P1079, DOI 10.1128/JVI.21.3.1079-1084.1977; CRAWFORD JL, 1977, THESIS HARVARD U; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; ELLIS RJ, 1991, REV BIOCH, V60, P321; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1991, J VIROL, V65, P350, DOI 10.1128/JVI.65.1.350-355.1991; FRIED H, 1981, VIROLOGY, V109, P188, DOI 10.1016/0042-6822(81)90485-2; GARCEA RL, 1983, P NATL ACAD SCI-BIOL, V80, P3613, DOI 10.1073/pnas.80.12.3613; GARCEA RL, 1987, NATURE, V329, P86, DOI 10.1038/329086a0; HARRISON SC, 1985, METHOD ENZYMOL, V114, P211; HARRISON SC, 1991, HARVEY LECT, V85, P127; HARRISON SC, 1980, BIOPHYS J, V32, P139, DOI 10.1016/S0006-3495(80)84930-7; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HOGLE J, 1983, J MOL BIOL, V171, P95, DOI 10.1016/S0022-2836(83)80315-5; KISELEV NA, 1969, J MOL BIOL, V40, P155, DOI 10.1016/0022-2836(69)90465-3; KLUG A, 1965, J MOL BIOL, V11, P424, DOI 10.1016/S0022-2836(65)80067-5; LATTMAN EE, 1980, SCIENCE, V208, P1048, DOI 10.1126/science.6246579; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; MORELAND RB, 1991, J VIROL, V65, P1168, DOI 10.1128/JVI.65.3.1168-1176.1991; MORELAND RB, IN PRESS VIROLOGY; OFARRELL PZ, 1976, CELL, V9, P289, DOI 10.1016/0092-8674(76)90119-7; OLSON AJ, 1983, J MOL BIOL, V171, P61, DOI 10.1016/S0022-2836(83)80314-3; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; ROSSMAN MG, 1963, ACTA CRYSTALLOGR, V16, P39, DOI 10.1107/S0365110X63000062; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; SIMPSON PG, 1965, ACTA CRYSTALLOGR, V18, P169, DOI 10.1107/S0365110X65000427; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Tooze J, 1980, DNA TUMOR VIRUSES; WALTER G, 1974, COLD SPRING HARB SYM, V39, P255, DOI 10.1101/SQB.1974.039.01.033	42	575	590	1	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					278	284		10.1038/354278a0	http://dx.doi.org/10.1038/354278a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659663				2022-12-28	WOS:A1991GT20400038
J	AARONSON, SA				AARONSON, SA			GROWTH-FACTORS AND CANCER	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C-GAMMA; RETINOBLASTOMA SUSCEPTIBILITY GENE; THYROID PAPILLARY CARCINOMAS; PC12 PHEOCHROMOCYTOMA CELLS; FACTOR RECEPTOR GENES; SIMIAN SARCOMA-VIRUS; PDGF BETA-RECEPTOR; FACTOR-I RECEPTOR	Signaling pathways that mediate the normal functions of growth factors are commonly subverted in cancer. Oncogenes identified by a variety of approaches have been shown to function at critical steps in mitogenic signaling. Progression through the cell cycle requires the coordinated actions of members of two complementary classes of growth factors, and oncogenes appear to replace the actions of one set of these growth factors. Growth factors can also influence normal cell differentiation, and constitutive activation of growth-promoting pathways in cancer cells can modulate the cell phenotype as well. Paracrine actions of growth factors and cytokines may also influence the stepwise series of genetic events that lead to malignancy. New approaches for cancer therapy are being developed that intervene at various steps in growth factor signaling pathways.			AARONSON, SA (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							AARONSON SA, 1991, CANCER MED; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AYIVERX J, 1991, CELL, V64, P983; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENEDICT WF, 1990, CANCER INVEST, V8, P535, DOI 10.3109/07357909009012078; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BESNARD F, 1989, INT J DEV NEUROSCI, V7, P401, DOI 10.1016/0736-5748(89)90061-0; BIGNAMI M, 1988, ONCOGENE, V2, P509; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOS JL, 1989, CANCER RES, V49, P4682; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOURNE HR, 1989, ONCOGENES MOL ORIGIN, P97; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANT J, 1991, CELL, V65, P1231; COBURN RJ, 1976, CANC SKIN, V2, P939; COHEN S, 1986, BIOSCIENCE REP, V6, P1017, DOI 10.1007/BF01141022; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P4242; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DERYNCK R, 1987, CANCER RES, V47, P707; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1989, ONCOGENE, V4, P831; Donjacour A A, 1991, Cancer Treat Res, V53, P335; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DRINKWATER NR, 1990, CANCER CELL-MON REV, V2, P8; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FALCO JP, 1988, ONCOGENE, V2, P573; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FORCE T, 1991, J BIOL CHEM, V266, P6650; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUNG YK, 1987, SCIENCE, V236, P1547; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HELDIN CH, 1989, BRIT MED BULL, V45, P453, DOI 10.1093/oxfordjournals.bmb.a072334; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISFORT R, 1988, J BIOL CHEM, V263, P19203; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAGAN J, 1991, ANN ONCOL, V2, P9, DOI 10.1093/annonc/2.suppl_2.9; KANAKURA Y, 1990, BLOOD, V76, P706; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMBERTS SWJ, 1987, ACTA ENDOCRINOL-COP, V116, P54; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LEOF EB, 1983, EXP CELL RES, V147, P202, DOI 10.1016/0014-4827(83)90285-9; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LILL MCC, 1990, BLOOD REV, V4, P238, DOI 10.1016/0268-960X(90)90003-B; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIPPMAN ME, 1989, J STEROID BIOCHEM, V34, P107, DOI 10.1016/0022-4731(89)90071-X; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSES HL, 1991, CIBA F SYMP, V157, P66; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Mule J J, 1989, Important Adv Oncol, P99; MULSHINE JL, 1988, ANN NY ACAD SCI, V547, P360, DOI 10.1111/j.1749-6632.1988.tb23903.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, ONCOGENE, V6, P501; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISTER M, 1988, CANCER RES, V48, P3910; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEREZ CA, 1989, CANCER PRINCIPLES PR, P1023; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PONZETTO C, 1991, ONCOGENE, V6, P553; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAMACHANDRAN J, 1989, BIOESSAYS, V10, P54, DOI 10.1002/bies.950100205; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1988, ONCOGENE, V3, P9; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHALLY AV, 1984, P SOC EXP BIOL MED, V175, P259; SCHALLY AV, 1988, CANCER RES, V48, P6977; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SELL S, 1990, CLIN LAB MED, V10, P1; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHATTIL SJ, IN PRESS CURR OPIN C; SHEPHERD JJ, 1986, LANCET, V2, P574; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VONRUDEN T, 1988, EMBO J, V7, P2749, DOI 10.1002/j.1460-2075.1988.tb03129.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; WEXLER D, UNPUB; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMAMOTO T, 1986, CANCER RES, V46, P414; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YOKOTA J, 1986, LANCET, V1, P765; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHENG BK, 1990, NATURE, V346, P754; 1987, EUR J CLIN INVEST, V17, P281	254	1231	1304	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	1991	254	5035					1146	1153		10.1126/science.1659742	http://dx.doi.org/10.1126/science.1659742			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1659742				2022-12-28	WOS:A1991GQ83400033
J	LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR				LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR			EXPRESSION CLONING OF AN ADENYLATE-CYCLASE COUPLED CALCITONIN RECEPTOR	SCIENCE			English	Article							G-PROTEINS	A calcitonin receptor complementary DNA (cDNA) was cloned by expression of a cDNA library from a porcine kidney epithelial cell line in COS cells. The 482-amino acid receptor has high affinity for salmon calcitonin (dissociation constant K(d) almost-equal-to 6 nM) and is functionally coupled to increases in intracellular cyclic adenosine monophosphate (cAMP). The receptor shows no sequence similarity to other reported G protein-coupled receptors but is homologous to the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor, indicating that the receptors for these hormones, which regulate calcium homeostasis, represent a new family of G protein-coupled receptors.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MED SERV, ARTHRIT UNIT, BOSTON, MA 02114 USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIADDK NIH HHS [AM 03564] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM003564] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOWALSKI LF, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LOREAU N, 1978, J ENDOCRINOL, V76, P533, DOI 10.1677/joe.0.0760533; MURAD F, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P446, DOI 10.1073/pnas.65.2.446; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	19	433	469	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1022	1024		10.1126/science.1658940	http://dx.doi.org/10.1126/science.1658940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658940				2022-12-28	WOS:A1991GP88300050
J	RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA			SEQUENCE-ANALYSIS OF PEPTIDES BOUND TO MHC CLASS-II MOLECULES	NATURE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY MOLECULES; MONOCLONAL-ANTIBODIES; IA; SPECIFICITY; COMPLEX; CLONES; CHAIN; RESTRICTION	CD4 T cells recognize peptide fragments of foreign proteins bound to self class II molecules of the major histocompatibility complex (MHC). Naturally processed peptide fragments bound to MHC class II molecules are peptides of 13-17 amino acids which appear to be precessively truncated from the carboxy terminus, perhaps after binding to the MHC class II molecule. The finding of predominant self peptides has interesting implications for antigen processing and self-non-self discrimination.	YALE UNIV,SCH MED,PSYCHOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENOIST C, 1991, Current Biology, V1, P143, DOI 10.1016/0960-9822(91)90213-G; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Briner T. J., 1987, T CELL RECEPTORS, P309; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEASE KB, 1986, J EXP MED, V164, P1779, DOI 10.1084/jem.164.5.1779; CRESSWELL P, 1989, COLD SH Q B, V54, P309; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; M/ller G., 1988, IMMUNOL REV, V98, P1; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; Stone K. L., 1988, MACROMOLECULAR SEQUE, P7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	49	1016	1062	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					622	627		10.1038/353622a0	http://dx.doi.org/10.1038/353622a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656276				2022-12-28	WOS:A1991GK67200057
J	RUTALA, WA; WEBER, DJ				RUTALA, WA; WEBER, DJ			INFECTIOUS WASTE - MISMATCH BETWEEN SCIENCE AND POLICY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MICROBIAL-CONTAMINATION; HOSPITAL INCINERATOR; HOUSEHOLD REFUSE; UNITED-STATES; MANAGEMENT; EMISSION; BACTERIA; HIV-1				RUTALA, WA (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.							ALLEN RJ, 1989, JAPCA J AIR WASTE MA, V39, P164, DOI 10.1080/08940630.1989.10466516; ALTHAUS H, 1983, ZBL BAKT MIK HYG B, V178, P1; BARBA PD, 1987, NOV MID AIR POLL CON; BECK M, 1989, NEWSWEEK        1127, P75; Beck Melinda, 1989, NEWSWEEK, P66; BLENKHARN JI, 1989, J HOSP INFECT, V14, P73, DOI 10.1016/0195-6701(89)90137-0; COOPER RC, 1975, WATER RES, V9, P733, DOI 10.1016/0043-1354(75)90065-2; DONNELLY JA, 1984, EPA600824119 MUN ENV; DRIVER JH, 1989, 1989 P INT C U CAL I; ENGELBRECHT RS, 1974, VIRUS SURVIVAL WATER, P201; GARNER JS, 1985, INFECTIVE WASTE GUID; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAGER E, 1989, ZBL HYG UMWELTMED, V188, P343; KALNOWSKI G, 1983, ZBL BAKT MIK HYG B, V178, P364; KARPIAK J, 1991, AM J INFECT CONTROL, V19, P8, DOI 10.1016/0196-6553(91)90155-6; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; MARCHESE JT, 1990, 3RD INT C NOS INF AT; MOSE JR, 1985, ZBL BAKT MIK HYG B, V181, P98; OHARA K, 1989, TRASH AM BEACHES NAT; PAHREN HR, 1987, CRC CRIT R ENVIRON, V7, P187; RESNICK L, 1986, JAMA-J AM MED ASSOC, V255, P1887, DOI 10.1001/jama.255.14.1887; RICHARDSON JH, 1988, HHS NIH888395 DEP HL; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; RUTALA WA, 1983, INFECT CONT HOSP EP, V4, P198, DOI 10.1017/S0195941700058227; RUTALA WA, 1987, ASEPSIS, V9, P2; RUTALA WA, 1987, CLIN CRITICAL CARE M, V12, P131; SLADE JS, 1989, WATER SCI TECHNOL, V21, P55, DOI 10.2166/wst.1989.0078; SLAVIK N, 1988, HLTH FACILITIES  SEP, P22; SOBSEY MD, 1978, AM J PUBLIC HEALTH, V68, P858, DOI 10.2105/AJPH.68.9.858; SOBSEY MD, 1975, APPL MICROBIOL, V30, P565, DOI 10.1128/AEM.30.4.565-574.1975; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; 1990, PUBLIC HLTH IMPLICAT; 1988, STATE INFECTIOUS WAS; 1990, OTA0459 OFF TECHN AS; 1989, INVENTORY MED WASTE; 1986, EPA530SW86014 REP; 1989, FED REGISTER, V54, P12326; 1990, EPA530SW90087A INT R; 1990, EPA530SW90051A INT R; 1987, MMWR S2S, V36, P3; 1988, INVESTIGATION SOURCE; 1989, SUMMARY POTENTIAL RI	42	24	24	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					578	582		10.1056/NEJM199108223250811	http://dx.doi.org/10.1056/NEJM199108223250811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1649972	Green Submitted			2022-12-28	WOS:A1991GB44700011
J	SHEN, SH; BASTIEN, L; POSNER, BI; CHRETIEN, P				SHEN, SH; BASTIEN, L; POSNER, BI; CHRETIEN, P			A PROTEIN-TYROSINE PHOSPHATASE WITH SEQUENCE SIMILARITY TO THE SH2 DOMAIN OF THE PROTEIN-TYROSINE KINASES	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; PHOSPHOLIPASE-C; SRC GENE; FAMILY; ONCOGENE; MEMBER; TRANSDUCTION; EXPRESSION; REGION	THE phosphorylation of proteins at tyrosine residues is critical in cellular signal transduction, neoplastic transformation and control of the mitotic cycle 1. These mechanisms are regulated by the activities of both protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPases) 2. As in the PTKs, there are two classes of PTPases: membrane associated, receptor-like enzymes 3-5 and soluble proteins 3,6,7. Here we report the isolation of a complementary DNA clone encoding a new form of soluble PTPase, PTPIC. The enzyme possesses a large noncatalytic region at the N terminus which unexpectedly contains two adjacent copies of the Src homology region 2 (the SH2 domain) found in various nonreceptor PTKs 8 and other cytoplasmic signalling proteins 9-11. As with other SH2 sequences, the SH2 domains of PTPIC formed high-affinity complexes with the activated epidermal growth factor receptor and other phosphotyrosine-containing proteins. These results suggest that the SH2 regions in PTPIC may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. PTPase activity may thus directly link growth factor receptors and other signalling proteins through protein-tyrosine phosphorylation.	MCGILL UNIV,MONTREAL H3A 2B2,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DEPT MED,POLYPEPTIDE HORMONE LAB,MONTREAL H3A 2B2,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital	SHEN, SH (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MOLEC GENET SECT,6100 ROYALMOUNT AVE,MONTREAL H4P 2R2,QUEBEC,CANADA.		Posner, Barry/B-6733-2008					CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COOKE M P, 1989, New Biologist, V1, P66; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; ENGEL LW, 1978, CANCER RES, V38, P3352; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; GERYK J, 1989, J VIROL, V63, P481, DOI 10.1128/JVI.63.2.481-492.1989; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATINA CV, 1988, GENE, V74, P365; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	30	423	447	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					736	739		10.1038/352736a0	http://dx.doi.org/10.1038/352736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652101				2022-12-28	WOS:A1991GC06400066
J	STROM, M; MADSEN, S; NORLANDER, B				STROM, M; MADSEN, S; NORLANDER, B			INTRAGASTRIC PH RISE WITH EFFERVESCENT CITRATE-CIMETIDINE	LANCET			English	Letter							24-HOUR		LINKOPING UNIV HOSP,DEPT CLIN PHARMACOL,S-58185 LINKOPING,SWEDEN	Linkoping University	STROM, M (corresponding author), LINKOPING UNIV HOSP,GASTROENTEROL UNIT,S-58185 LINKOPING,SWEDEN.							ANDERSEN J, 1988, SCAND J GASTROENTERO, V23, P375, DOI 10.3109/00365528809093882; ARMSTRONG D, 1989, EUR J GASTROEN HEPAT, V1, P167; BURLAND WL, 1975, BRIT J CLIN PHARMACO, V2, P481, DOI 10.1111/j.1365-2125.1975.tb00564.x; DEGARA CJ, 1987, AM J GASTROENTEROL, V82, P36	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					433	433		10.1016/0140-6736(91)91215-G	http://dx.doi.org/10.1016/0140-6736(91)91215-G			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671456				2022-12-28	WOS:A1991EX60500050
J	WOLFF, K; HONIGSMANN, H				WOLFF, K; HONIGSMANN, H			GENITAL CARCINOMAS IN PSORIASIS PATIENTS TREATED WITH PHOTOCHEMOTHERAPY	LANCET			English	Letter							LONG-TERM PHOTOCHEMOTHERAPY; FOLLOW-UP; PUVA TREATMENT; EUROPEAN PUVA; SKIN-CANCER; TUMORS				WOLFF, K (corresponding author), UNIV VIENNA,SCH MED,DEPT DERMATOL 1,A-1090 VIENNA,AUSTRIA.		Hoenigsmann, Herbert/H-9045-2019; Hoenigsmann, Herbert/H-9540-2019	Honigsmann, Herbert/0000-0001-6401-6966				GIBBS NK, 1986, LANCET, V1, P150; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; HONIGSMANN H, 1980, J AM ACAD DERMATOL, V3, P406, DOI 10.1016/S0190-9622(80)80336-7; LASSUS A, 1981, ACTA DERM-VENEREOL, V61, P141; LINDSKOV R, 1983, ACTA DERM-VENEREOL, V63, P223; PERKINS, 1990, LANCET, V336, P1248; ROS AM, 1983, ACTA DERM-VENEREOL, V63, P215; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; TANEW A, 1986, J AM ACAD DERMATOL, V15, P980	11	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					439	439		10.1016/0140-6736(91)91226-K	http://dx.doi.org/10.1016/0140-6736(91)91226-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671465				2022-12-28	WOS:A1991EX60500065
J	FRICK, TW; FRYD, DS; GOODALE, RL; SIMMONS, RL; SUTHERLAND, DER; NAJARIAN, JS				FRICK, TW; FRYD, DS; GOODALE, RL; SIMMONS, RL; SUTHERLAND, DER; NAJARIAN, JS			LACK OF ASSOCIATION BETWEEN AZATHIOPRINE AND ACUTE-PANCREATITIS IN RENAL-TRANSPLANTATION PATIENTS	LANCET			English	Letter							DRUG-INDUCED PANCREATITIS; CYCLOSPORINE; RECIPIENTS		UNIV MINNEAPOLIS,DEPT SURG,MINNEAPOLIS,MN		FRICK, TW (corresponding author), UNIV ZURICH,DEPT SURG,CH-8091 ZURICH,SWITZERLAND.							BANERJEE AK, 1989, MED TOXICOL ADV DRUG, V4, P186, DOI 10.1007/BF03259996; DOBRILLA G, 1986, DEUT MED WOCHENSCHR, V111, P868, DOI 10.1055/s-2008-1068548; MALLORY A, 1988, BAILLIERE CLIN GASTR, V2, P293, DOI 10.1016/0950-3528(88)90005-X; MALLORY A, 1980, GASTROENTEROLOGY, V78, P813, DOI 10.1016/0016-5085(80)90689-7; NAJARIAN JS, 1985, ANN SURG, V201, P142, DOI 10.1097/00000658-198502000-00003; SCARPELLI DG, 1989, TOXICOL APPL PHARM, V101, P534; YOSHIMURA N, 1988, AM J KIDNEY DIS, V12, P11, DOI 10.1016/S0272-6386(88)80065-9	7	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					251	252		10.1016/0140-6736(91)92229-U	http://dx.doi.org/10.1016/0140-6736(91)92229-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670892				2022-12-28	WOS:A1991EU92400069
J	[Anonymous]				[Anonymous]			ENDOTHELINS	LANCET			English	Editorial Material							VASOCONSTRICTOR PEPTIDE; PLASMA ENDOTHELIN; RAT; RELEASE; FAMILY; ARTERY; CELLS; BRAIN											ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; CRAWFORD MLA, 1990, N-S ARCH PHARMACOL, V341, P268; DAVENPORT AP, 1990, CLIN SCI, V78, P261, DOI 10.1042/cs0780261; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; HOFFMAN A, 1989, LANCET, V2, P1519; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIDA N, 1989, FEBS LETT, V247, P337, DOI 10.1016/0014-5793(89)81365-1; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; JONES CR, 1989, NEUROSCI LETT, V97, P276, DOI 10.1016/0304-3940(89)90610-1; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOYAMA H, 1989, LANCET, V1, P991; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LIU JJ, 1990, J CARDIOVASC PHARM, V15, P436, DOI 10.1097/00005344-199003000-00014; MACLEAN MR, 1990, EUR J PHARMACOL, V190, P263, DOI 10.1016/0014-2999(90)94137-M; MASAOKA H, 1989, LANCET, V2, P1402; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; PERNOW J, 1990, ACTA PHYSIOL SCAND, V140, P311, DOI 10.1111/j.1748-1716.1990.tb09005.x; RAKUGI H, 1990, BIOCHEM BIOPH RES CO, V169, P973, DOI 10.1016/0006-291X(90)91989-6; RANDALL MD, 1989, BRIT J PHARMACOL, V98, P685, DOI 10.1111/j.1476-5381.1989.tb12644.x; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SALMINEN K, 1989, LANCET, V2, P747; SUMPIO BE, 1990, SURGERY, V108, P277; TAKAGI M, 1988, BIOCHEM BIOPH RES CO, V157, P1164, DOI 10.1016/S0006-291X(88)80996-3; TOMITA K, 1989, NEW ENGL J MED, V321, P1127; TURNER NC, 1989, BRIT J PHARMACOL, V98, P361, DOI 10.1111/j.1476-5381.1989.tb12605.x; WIKLUND NP, 1988, ACTA PHYSIOL SCAND, V134, P311, DOI 10.1111/j.1748-1716.1988.tb08495.x; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B	32	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	1991	337	8733					79	81						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670729				2022-12-28	WOS:A1991ER47700007
J	MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ				MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ			PRESYMPTOMATIC SCREENING FOR MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A WITH LINKED DNA MARKERS	LANCET			English	Article							MEDULLARY-THYROID CARCINOMA; GENETIC-LINKAGE MAP; CHROMOSOME 10; POLYMORPHISM; FAMILIES; LOCUS	Seven DNA markers from the pericentromeric region of chromosome 10 were tested for linkage to MEN 2A in a panel of 17 families. Four of the markers proved to be tightly linked and therefore suitable for predictive testing. The markers were used to estimate carrier risks for individuals who had a negative biochemical screening test for thyroid C-cell hyperplasia. The analysis substantially altered the carrier risks of most of these individuals, which suggests that typing with DNA markers should be introduced into the screening programme of MEN 2A families. Accurate prenatal diagnosis for this disorder is also now possible.	UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CTR,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Cambridge; University of London; Institute of Cancer Research - UK; Japanese Foundation for Cancer Research			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016684] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01 RR00054] Funding Source: Medline; NIADDK NIH HHS [5T32 AM0703910] Funding Source: Medline; NIDDK NIH HHS [5R37 DK16684] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CARTER C, 1987, CYTOGENET CELL GENET, V45, P33, DOI 10.1159/000132422; CHIN KS, 1988, NUCLEIC ACIDS RES, V16, P1645, DOI 10.1093/nar/16.4.1645; EASTON DF, 1989, AM J HUM GENET, V44, P208; EMERY AEH, 1976, METHODOLOGY MED GENE; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GAGEL RF, 1982, J PEDIATR-US, V101, P941, DOI 10.1016/S0022-3476(82)80014-0; KAPLAN MM, 1989, 64TH M AM THYR ASS S; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MATHEW CGP, 1990, ANN HUM GENET, V54, P121, DOI 10.1111/j.1469-1809.1990.tb00368.x; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P374, DOI 10.1093/nar/16.1.374; NAKAMURA Y, 1988, GENOMICS, V3, P389, DOI 10.1016/0888-7543(88)90133-4; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SOBOL H, 1988, LANCET, V1, P62; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; TELENIUSBERG M, 1977, EUR J CLIN INVEST, V7, P7, DOI 10.1111/j.1365-2362.1977.tb01563.x; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; WU JS, 1989, HUM GENET, V83, P383, DOI 10.1007/BF00291386; YAMAMOTO M, 1989, HUM GENET, V82, P287, DOI 10.1007/BF00291173	26	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					7	11		10.1016/0140-6736(91)93329-8	http://dx.doi.org/10.1016/0140-6736(91)93329-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670689				2022-12-28	WOS:A1991EQ60400003
J	JAGADEESH, B; GRAY, CM; FERSTER, D				JAGADEESH, B; GRAY, CM; FERSTER, D			VISUALLY EVOKED OSCILLATIONS OF MEMBRANE-POTENTIAL IN CELLS OF CAT VISUAL-CORTEX	SCIENCE			English	Article							DEPENDENT NEURONAL OSCILLATIONS; RESPONSES; MODEL	In response to visual stimulation, cells of the cat visual cortex fire rhythmically at frequencies between 30 and 60 hertz. This rhythmic firing can be synchronized among cells in widespread areas of the visual cortex. The visual stimulus conditions under which this process occurs suggest that the synchronization may contribute to the integration of information across broadly displaced parts of the visual field. An intricate mechanism must control the regularity of firing and its synchronization. In vivo whole-cell patch recordings from cells in area 17 have now shown that robust oscillations of membrane potential underlie the regularity of firing seen extracellularly. In the cells studied, the characteristics of the oscillations of membrane potential suggest that such oscillations are produced by rhythmic activity in synaptic inputs. These rhythmic synaptic inputs form the most likely mechanism for the synchronization of activity in neighboring cortical cells.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	Salk Institute	JAGADEESH, B (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208, USA.				NATIONAL EYE INSTITUTE [R29EY008686, R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY04726, R29 EY08686] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; ARIEL M, 1983, VISION RES, V23, P1485, DOI 10.1016/0042-6989(83)90160-8; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FERSTER D, 1990, VISUAL NEUROSCI, V4, P115, DOI 10.1017/S0952523800002285; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; FERSTER D, 1992, J NEUROSCI, V12, P1262; Freeman WJ, 1975, MASS ACTION NERVOUS; FUSTER JOAQUIN M., 1965, Z VER GLEICHENDE PHYSIOL, V49, P605, DOI 10.1007/BF00367161; GHOSE GM, 1990, SOC NEUR ABSTR, V16, P523; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRAY CM, 1992, INDUCED RHYTHMS BRAI, P29; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAGADEESH B, UNPUB; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VANDERMALSBURG C, 1985, BER BUNSEN PHYS CHEM, V89, P703; VANDERMALSBURG C, 1981, CORRELATION THEORY B; VANDERMALSBURG C, 1986, BRAIN THEORY, P161; WILSON HR, 1972, BIOPHYS J, V12, P1, DOI 10.1016/S0006-3495(72)86068-5	31	128	131	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					552	554		10.1126/science.1636094	http://dx.doi.org/10.1126/science.1636094			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636094				2022-12-28	WOS:A1992JE75500036
J	WAKEFORD, R; FAROOQI, A; RASHID, A; SOUTHGATE, L				WAKEFORD, R; FAROOQI, A; RASHID, A; SOUTHGATE, L			DOES THE MRCGP EXAMINATION DISCRIMINATE AGAINST ASIAN DOCTORS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To ascertain whether the membership examination for the Royal College of General Practitioners (MRCGP) discriminates against doctors of Indian subcontinent ethnic origin ("Asian doctors"). Design-Retrospective analysis of data from five administrations of the MRCGP examination (December 1988-December 1990). Setting-United Kingdom national examination body. Subjects-3686 doctors taking the examination for the first time, 244 of whom were classified as Asian, the remainder as non-Asian. Main outcome measures-Comparison of performance in each of the written and oral components of the examination between Asian doctors, identified by their names and classified into subgroups by countries of birth and primary medical training from data provided at registration, and non-Asian doctors. Results-On written components of the examination (multiple choice paper mean score Asians versus non-Asians 42.3 v 48.6, modified essay paper 40.9 v 48.9, practice topic/critical reading paper 41.5 v 48.7, all p<0.001 by t testing). But analysis by countries of birth and primary training showed that these differences were due largely to poor performance by certain groups of Asian doctors, especially those born and trained in the Indian subcontinent or elsewhere outside the United Kingdom. Asian doctors born and trained in the United Kingdom and those born in Africa or the West Indies and trained in the United Kingdom performed similarly to the non-Asian doctors. Conclusions-The examination does not systematically discriminate against Asian doctors, but the poor performance of the two subgroups of Asians is cause for serious concern and requires investigation.	UPPINGHAM RD HLTH CTR,LEICESTER LE5 4BP,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN SCH OFF,CAMBRIDGE CB2 2QQ,ENGLAND; HLTH CTR COUNTESTHORPE,LEICESTER LE8 3QJ,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON EC1M 6BQ,ENGLAND; ROYAL LONDON HOSP,COLL MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON EC1M 6BQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital			Farooqi, Ammad Ahmad/AAF-5325-2021; Farooqi, Ammad A/H-1610-2016					Anwar M., 1987, OVERSEAS DOCTORS EXP; DONALDSON LJ, 1986, BRIT MED J, V293, P1079, DOI 10.1136/bmj.293.6554.1079; JOLLY BC, 1988, 27TH P ANN C ASS AM, P234; LOCKIE C, 1990, EXAMINATION MEMBERSH; MCAVOY BR, 1988, HLTH TRENDS, V20, P11; MCMANUS IC, 1990, STUD HIGH EDUC, V15, P57, DOI 10.1080/03075079012331377591; RASHID A, 1990, HLTH CARE ASIANS, P46; 1986, CENSUS SURVEY MED MA	8	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					92	94		10.1136/bmj.305.6845.92	http://dx.doi.org/10.1136/bmj.305.6845.92			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638253	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JD85000025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOSCARNET APPROVED FOR AIDS PATIENTS WITH CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-28	WOS:A1991GU96400004
J	DESMET, MD; NUSSENBATT, RB				DESMET, MD; NUSSENBATT, RB			OCULAR MANIFESTATIONS OF AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE-DEFICIENCY SYNDROME; CYTOMEGALO-VIRUS RETINITIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; GANCICLOVIR; RETINOPATHY; FOSCARNET; DISEASE				DESMET, MD (corresponding author), NEI,IMMUNOL LAB,BLDG 10,ROOM 10N202,BETHESDA,MD 20892, USA.		De Smet, Marc D./E-2451-2013	De Smet, Marc D./0000-0002-9217-5603				BIEMER JJ, 1990, ANN CLIN LAB SCI, V20, P175; BLOOM JN, 1988, ANN INTERN MED, V109, P963, DOI 10.7326/0003-4819-109-12-963; BREZIN A, 1990, INT OPHTHALMOL, V14, P37, DOI 10.1007/BF00131167; CACOUB P, 1988, CLIN NEPHROL, V29, P315; COLE EL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1027; DAVIS JL, 1989, AM J OPHTHALMOL, V107, P613, DOI 10.1016/0002-9394(89)90258-4; ENGSTROM RE, 1990, AM J OPHTHALMOL, V109, P153, DOI 10.1016/S0002-9394(14)75980-X; FREEMAN WR, 1989, ARCH OPHTHALMOL-CHIC, V107, P863, DOI 10.1001/archopht.1989.01070010885036; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HOLLAND GN, 1989, ARCH OPHTHALMOL-CHIC, V107, P1759, DOI 10.1001/archopht.1989.01070020841024; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; KHADEM M, 1984, ARCH OPHTHALMOL-CHIC, V102, P201; LEHOANG P, 1989, OPHTHALMOLOGY, V96, P865; MCLEISH WM, 1990, OPHTHALMOLOGY, V97, P196; NEWSOME DA, 1988, OPHTHALMOL CLIN N AM, V1, P73; PALESTINE A G, 1990, Investigative Ophthalmology and Visual Science, V31, P366; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; POLIS M, 1989, 5 INT C AIDS SCI SOC, P243; SHIELDS W, 1988, OPHTHALMOL CLIN N AM, V1, P81; SHULER JD, 1989, INT OPHTHALMOL CLIN, V29, P98, DOI 10.1097/00004397-198902920-00007; SHUMAN JS, 1987, SURV OPHTHALMOL, V31, P384; YOUNG TL, 1989, OPHTHALMOLOGY, V96, P1476	24	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3019	3022		10.1001/jama.266.21.3019	http://dx.doi.org/10.1001/jama.266.21.3019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668177				2022-12-28	WOS:A1991GR77500036
J	GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR				GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR			TARGETED GENE REPLACEMENT IN DROSOPHILA VIA P-ELEMENT-INDUCED GAP REPAIR	SCIENCE			English	Article							HYBRID DYSGENESIS; TRANSPOSABLE ELEMENT; MOLECULAR ANALYSIS; GERM-LINE; RECOMBINATION; MELANOGASTER; DNA; MUTAGENESIS; LOCUS; CHROMOSOMES	Transposable elements of the P family in Drosophila are thought to transpose by a cut-and-paste process that leaves a double-strand gap. The repair of such gaps resulted in the transfer of up to several kilobase pairs of information from a homologous template sequence to the site of P element excision by a process similar to gene conversion. The template was an in vitro-modified sequence that was tested at various genomic positions. Characterization of 123 conversion tracts provided a detailed description of their length and distribution. Most events were continuous conversion tracts that overlapped the P insertion site without concomitant conversion of the template. The average conversion tract was 1379 base pairs, and the distribution of tract lengths fit a simple model of gap enlargement. The conversion events occurred at sufficiently high frequencies to form the basis of an efficient means of directed gene replacement.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	GLOOR, GB (corresponding author), MEM UNIV NEWFOUNDLAND,FAC MED,ST JOHNS A1C 5S7,NEWFOUNDLAND,CANADA.		Gloor, Greg B/D-1671-2013	Gloor, Gregory/0000-0001-5803-3380	NIGMS NIH HHS [GM30948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM030948, R01GM030948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA JW, 1989, MOBILE DNA, P939; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; BERG DE, 1989, MOBILE DNA, pCH6; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BORTS RH, 1989, GENETICS, V123, P69; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; COEN ES, 1989, MOBILE DNA, P413; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CURTIS D, 1991, GENETICS, V127, P739; CURTIS D, 1989, GENETICS, V122, P653; DANIELS SB, 1990, GENETICS, V124, P339; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; ENGELS WR, 1986, FOCUS, V8, P6; FELLER W, 1950, INTRO PROBABILITY TH, V1; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P6455, DOI 10.1073/pnas.85.17.6455; GLOOR GB, IN PRESS DROS INFORM; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KASSIS JA, COMMUNICATION; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; LEVERE G, 1976, GENETICS BIOL DROS A, V1, P32; LIM JK, 1988, P NATL ACAD SCI USA, V85, P9153, DOI 10.1073/pnas.85.23.9153; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SALZ HK, 1987, GENETICS, V117, P221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SVED JA, 1990, GENETICS, V124, P331; SVED JA, 1991, MOL GEN GENET, V225, P443, DOI 10.1007/BF00261685; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILLIAMS JA, 1988, MOL CELL BIOL, V8, P1489, DOI 10.1128/MCB.8.4.1489; [No title captured]	51	318	334	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1110	1117		10.1126/science.1653452	http://dx.doi.org/10.1126/science.1653452			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653452				2022-12-28	WOS:A1991GD80800024
J	SAFRIN, S; CRUMPACKER, C; CHATIS, P; DAVIS, R; HAFNER, R; RUSH, J; KESSLER, HA; LANDRY, B; MILLS, J				SAFRIN, S; CRUMPACKER, C; CHATIS, P; DAVIS, R; HAFNER, R; RUSH, J; KESSLER, HA; LANDRY, B; MILLS, J			A CONTROLLED TRIAL COMPARING FOSCARNET WITH VIDARABINE FOR ACYCLOVIR-RESISTANT MUCOCUTANEOUS HERPES-SIMPLEX IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADENINE-ARABINOSIDE THERAPY; VIRUS-INFECTIONS; DNA-POLYMERASE; IMMUNOCOMPROMISED PATIENT; AIDS; TYPE-2; THYMIDINE; TOXICITY; KINASE; HUMANS	Background and Methods. Most strains of herpes simplex virus that are resistant to acyclovir are susceptible in vitro to both foscarnet and vidarabine. We conducted a randomized trial to compare foscarnet with vidarabine in 14 patients with the acquired immunodeficiency syndrome (AIDS) and mucocutaneous herpetic lesions that had been unresponsive to intravenous therapy with acyclovir for a minimum of 10 days. The patients were randomly assigned to receive either foscarnet (40 mg per kilogram of body weight intravenously every 8 hours) or vidarabine (15 mg per kilogram per day intravenously) for 10 to 42 days. In the isolates of herpes simplex virus we documented in vitro resistance to acyclovir and susceptibility to foscarnet and vidarabine. Results. The lesions in all eight patients assigned to foscarnet healed completely after 10 to 24 days of therapy. In contrast, vidarabine was discontinued because of failure in all six patients assigned to receive it. The time to complete healing (P = 0.01), time to 50 percent reductions in the size of the lesions (P = 0.01) and the pain score (P = 0.004), and time to the end of viral shedding (P = 0.006) were all significantly shorter in the patients assigned to foscarnet. Three patients had new neurologic abnormalities while receiving vidarabine. No patient discontinued foscarnet because of toxicity. Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42.5 days (range, 14 to 191) after foscarnet was discontinued. Conclusions. For the treatment of acyclovir-resistant herpes simplex infection in patients with AIDS, foscarnet has superior efficacy and less frequent serious toxicity than vidarabine. Once the treatment is stopped, however, there is a high frequency of relapse.	NIAID,DIV AIDS,BETHESDA,MD 20892; RUSH MED COLL,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612; HARVARD UNIV,SCH PUBL HLTH,CTR STAT & DATA ANAL,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rush University; Rush University; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center								BIRCH CJ, 1990, J INFECT DIS, V162, P731, DOI 10.1093/infdis/162.3.731; BURDGE DR, 1985, CAN MED ASSOC J, V132, P392; CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; CHIEN LT, 1976, J INFECT DIS, V133, pA184; COLLINS P, 1989, J GEN VIROL, V70, P375, DOI 10.1099/0022-1317-70-2-375; DREW WL, 1985, MANUAL CLIN MICROBIO, P705; ELLIS MN, 1987, ANTIMICROB AGENTS CH, V31, P1117, DOI 10.1128/AAC.31.7.1117; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FELDMAN S, 1986, J INFECT DIS, V154, P889, DOI 10.1093/infdis/154.5.889; GATELEY A, 1990, J INFECT DIS, V161, P711, DOI 10.1093/infdis/161.4.711; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JAMIESON AT, 1974, J GEN VIROL, V24, P465, DOI 10.1099/0022-1317-24-3-465; LAUTER CB, 1976, J INFECT DIS, V134, P75, DOI 10.1093/infdis/134.1.75; MARKER SC, 1980, ARCH INTERN MED, V140, P1441, DOI 10.1001/archinte.140.11.1441; MARKS GL, 1989, REV INFECT DIS, V11, P474; NORRIS SA, 1988, J INFECT DIS, V157, P209, DOI 10.1093/infdis/157.1.209; PARKER AC, 1987, LANCET, V2, P1461; ROSS AH, 1976, J INFECT DIS, V133, pA192, DOI 10.1093/infdis/133.Supplement_2.A192; SACKS SL, 1982, ANTIMICROB AGENTS CH, V21, P93, DOI 10.1128/AAC.21.1.93; SACKS SL, 1979, JAMA-J AM MED ASSOC, V241, P28, DOI 10.1001/jama.1979.03290270020010; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SAFRIN S, 1990, J INFECT DIS, V161, P1078, DOI 10.1093/infdis/161.6.1078; VANETTA L, 1981, JAMA-J AM MED ASSOC, V246, P1703, DOI 10.1001/jama.246.15.1703; VINCKIER F, 1987, J ORAL MAXIL SURG, V45, P723, DOI 10.1016/0278-2391(87)90320-X; WHITLEY RJ, 1980, ANTIMICROB AGENTS CH, V18, P709, DOI 10.1128/AAC.18.5.709; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1984, J INFECT DIS, V149, P1, DOI 10.1093/infdis/149.1.1; WHITLEY RJ, 1980, PEDIATRICS, V66, P495; YOULE MM, 1988, LANCET, V2, P341	30	281	292	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					551	555		10.1056/NEJM199108223250805	http://dx.doi.org/10.1056/NEJM199108223250805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1649971				2022-12-28	WOS:A1991GB44700005
J	LI, R; MURRAY, AW				LI, R; MURRAY, AW			FEEDBACK-CONTROL OF MITOSIS IN BUDDING YEAST	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DNA-REPLICATION; CHROMATIN CONDENSATION; MAMMALIAN-CELLS; TUBULIN GENES; PROTEIN; MUTANTS; CALCIUM	We have investigated the feedback control that prevents cells with incompletely assembled spindles from leaving mitosis. We isolated budding yeast mutants sensitive to the anti-microtubule drug benomyl. Mitotic arrest-deficient (mad) mutants are the subclass of benomyl-sensitive mutants in which the completion of mitosis is not delayed in the presence of benomyl and that die as a consequence of their premature exit from mitosis. A number of properties of the mad mutants indicate that they are defective in the feedback control over the exit from mitosis: their killing by benomyl requires passage through mitosis; their benomyl sensitivity can be suppressed by an independent method for delaying the exit from mitosis; they have normal microtubules; and they have increased frequencies of chromosome loss. We cloned MAD2, which encodes a putative calcium-binding protein whose disruption is lethal. We discuss the role of feedback controls in coordinating events in the cell cycle.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, R (corresponding author), UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDENIN DA, 1990, YEAST, V7, P37; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JOHNSTON GC, 1983, EXP CELL RES, V149, P1, DOI 10.1016/0014-4827(83)90375-0; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIRAS P, 1978, GENETICS, V88, P651; MCCUSKER JH, 1981, GENETICS, V99, P383; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PALMER RE, 1990, GENETICS, V125, P763; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHLEGEL R, 1987, J CELL PHYSIOL, V131, P85, DOI 10.1002/jcp.1041310113; Sherman F., 1974, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1990, GENETICS, V124, P237; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	50	987	1012	0	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					519	531		10.1016/0092-8674(81)90015-5	http://dx.doi.org/10.1016/0092-8674(81)90015-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651172				2022-12-28	WOS:A1991GA94100013
J	KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M				KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRKB TYROSINE PROTEIN-KINASE IS A RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3	CELL			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; CHOLINERGIC NEURONS; MESSENGER-RNA; EXPRESSION; GENE; BDNF; IDENTIFICATION; SURVIVAL	trkB is a tyrosine protein kinase gene highly related to trk, a proto-oncogene that encodes a receptor for nerve growth factor (NGF) and neurotrophin-3 (NT-3). trkB expression is confined to structures of the central and peripheral nervous systems, suggesting it also encodes a receptor for neurotrophic factors. Here we show that brain-derived neurotrophic factor (BDNF) and NT-3, but not NGF, can induce rapid phosphorylation on tyrosine of gp145trkB, one of the receptors encoded by trkB. BDNF and NT-3 can induce DNA synthesis in quiescent NIH 3T3 cells that express gp145trkB. Cotransfection of plasmids encoding gp145trkB and BDNF or NT-3 leads to transformation of recipient NIH 3T3 cells. In these assays, BDNF elicits a response at least two orders of magnitude higher than NT-3. Finally, I-125-NT-3 binds to NIH 3T3 cells expressing gp145trkB; binding can be competed by NT-3 and BDNF but not by NGF. These findings indicate that gp145trkB may function as a neurotrophic receptor for BDNF and NT-3.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017; Klein, Ruediger/C-6147-2008	Lamballe, Fabienne/0000-0001-7631-942X; Klein, Ruediger/0000-0002-3109-0163; JONES, KEVIN/0000-0002-3802-7562	NINDS NIH HHS [P01 NS016033, P01 NS016033-230014] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARBACID M, 1991, IN PRESS BIOCH BIOPH; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0	38	819	849	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					395	403		10.1016/0092-8674(91)90628-C	http://dx.doi.org/10.1016/0092-8674(91)90628-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649702	Green Accepted			2022-12-28	WOS:A1991FY71200019
J	MIZUUCHI, K; ADZUMA, K				MIZUUCHI, K; ADZUMA, K			INVERSION OF THE PHOSPHATE CHIRALITY AT THE TARGET SITE OF MU-DNA STRAND TRANSFER - EVIDENCE FOR A ONE-STEP TRANSESTERIFICATION MECHANISM	CELL			English	Article							DIASTEREOMERIC PHOSPHOROTHIOATE ANALOGS; BACTERIOPHAGE-MU; DEOXYADENOSINE TRIPHOSPHATE; POLYMERASE-I; TRANSPOSITION; PROTEIN; RECOMBINATION; CLEAVAGE; GENE; PURIFICATION	Central to transposition of phage Mu are two reactions mediated by the MuA protein. First, MuA introduces single-stranded cuts at the ends of the Mu DNA to generate 3'OH termini. In the subsequent strand-transfer step, the MuA-Mu DNA end complex cuts a target DNA and joins the Mu 3 'ends to the 5' ends of the target. DNA containing chiral phosphorothioates was used to demonstrate inversion of the chirality during the course of strand transfer. This result strongly supports a one-step transesterification mechanism in which the 3'OH of the cleaved donor DNA is the attacking nucleophile. Furthermore, this donor 3'OH group was essential for target DNA cleavage. In contrast, during lambda-integration the phosphate chirality was retained, as expected for a two-step transesterification involving a covalent protein-DNA intermediate.			MIZUUCHI, K (corresponding author), NIADDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							BAKER TA, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg DE, 1989, MOBILE DNA; BUCHWALD SL, 1982, METHOD ENZYMOL, V87, P279; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HANIFORD DB, 1991, CELL, V64, P171; HERSCHLAG D, 1991, IN PRESS BIOCHEMISTR, V30; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229	32	139	141	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					129	140		10.1016/0092-8674(91)90145-O	http://dx.doi.org/10.1016/0092-8674(91)90145-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649006				2022-12-28	WOS:A1991FW91300015
J	UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM				UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM			DIRECT REPEATS AS SELECTIVE RESPONSE ELEMENTS FOR THE THYROID-HORMONE, RETINOIC ACID, AND VITAMIN-D3 RECEPTORS	CELL			English	Article							DNA-BINDING DOMAIN; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; NEGATIVE REGULATION; PROMOTER ELEMENTS; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; NUCLEAR-PROTEIN; AMINO-ACIDS	We report here the identification of thyroid hormone response elements (TREs) that consist of a direct repeat, not a palindrome, of the half-sites. Unlike palindromic TREs, direct repeat TREs do not confer a retinoic acid response. The tandem TRE can be converted into a retinoic acid response element by increasing the spacing between the half-sites by 1 nucleotide, and the resulting retinoic acid response element is no longer a TRE. Decreasing the half-site spacing by 1 nucleotide converts the TRE to a vitamin D3 response element, while eliminating response to T3. These results correlate well with DNA-binding affinities of the thyroid hormone, retinoic acid, and vitamin D3 receptors. This study points to the general importance of tandem repeat hormone response elements and suggests a simple physiologic code exists in which half-site spacing plays a critical role in achieving selective hormonal response.			UMESONO, K (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,POB 85800,SAN DIEGO,CA 92186, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V249, P157; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OZONO K, 1991, IN PRESS J BIOL CHEM; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRASK RV, 1988, J BIOL CHEM, V263, P17142; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINBERGER C, 1990, ANNU REV PHYSIOL, V52, P823; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	72	1614	1655	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1255	1266		10.1016/0092-8674(91)90020-Y	http://dx.doi.org/10.1016/0092-8674(91)90020-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648450	Green Accepted			2022-12-28	WOS:A1991FU89900017
J	WERNER, P; VOIGT, M; KEINANEN, K; WISDEN, W; SEEBURG, PH				WERNER, P; VOIGT, M; KEINANEN, K; WISDEN, W; SEEBURG, PH			CLONING OF A PUTATIVE HIGH-AFFINITY KAINATE RECEPTOR EXPRESSED PREDOMINANTLY IN HIPPOCAMPAL CA3 CELLS	NATURE			English	Article							ACID BINDING-SITES; KAINIC ACID; GLUTAMATE RECEPTOR; NERVOUS-SYSTEM; RAT FOREBRAIN; LOCALIZATION; SUBUNIT; BRAIN; SEQUENCE; FAMILY	KAINIC acid is a potent neurotoxin for certain neurons 1. Its neurotoxicity is thought to be mediated by an excitatory amino-acid-gated ion channel (ionotropic receptor) possessing nanomolar affinity for kainate 2. Here we describe a new member of the rat excitatory amino-acid receptor gene family, KA-1, that has a 30% sequence similarity with the previously characterized alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor subunits GluR-A to -D 3-5. The pharmacological profile of expressed recombinant KA-1 determined in binding experiments with [H-3]kainate is different from that of the cloned AMPA receptors and similar to the mammalian high-affinity kainate receptor (kainate > quisqualate > glutamate >> AMPA) with a dissociation constant of about 5 nM for kainate 2,6. The selectively high expression of KA-1 messenger RNA in the CA3 region of the hippocampus closely corresponds to autoradiographically located high-affinity kainate binding sites 7-9. This correlation, as well as the particular in vivo pattern of neurodegeneration observed on kainate-induced neurotoxicity 1,2, suggests that KA participates in receptors mediating the kainate sensitivity of neurons in the central nervous system.	UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Keinanen, Kari/E-9122-2010; Wisden, William/A-4071-2011	Wisden, William/0000-0003-4743-0334				BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COYLE JT, 1983, J NEUROCHEM, V41, P1; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; FOSTER AC, 1981, NATURE, V289, P73, DOI 10.1038/289073a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HAMPSON DR, 1987, J NEUROCHEM, V49, P1209, DOI 10.1111/j.1471-4159.1987.tb10012.x; HENLEY J M, 1989, New Biologist, V1, P153; HENLEY JM, 1991, J NEUROCHEM, V56, P702, DOI 10.1111/j.1471-4159.1991.tb08206.x; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MILLER LP, 1990, NEUROSCIENCE, V35, P45, DOI 10.1016/0306-4522(90)90118-N; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; NADLER VJ, 1978, NATURE, V271, P766; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Paxinos G, 1990, ATLAS DEV RAT BRAIN; REPRESA A, 1987, NEUROSCIENCE, V20, P739, DOI 10.1016/0306-4522(87)90237-5; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; UNNERSTALL JR, 1983, EUR J PHARMACOL, V86, P361, DOI 10.1016/0014-2999(83)90185-1; VERDOORN TA, IN PRESS SCIENCE; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, V2, P205; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I	30	438	451	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					742	744		10.1038/351742a0	http://dx.doi.org/10.1038/351742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648176				2022-12-28	WOS:A1991FU20100063
J	BRAHAMS, D				BRAHAMS, D			COMPULSION IN DNA PATERNITY TESTS	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					169	169		10.1016/0140-6736(91)90822-7	http://dx.doi.org/10.1016/0140-6736(91)90822-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670802				2022-12-28	WOS:A1991ET67900019
J	MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J				MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J			SURGICAL STANDBY FOR CORONARY BALLOON ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-SURGERY; TASK-FORCE; COMPLICATIONS; OCCLUSION; GUIDELINES; CARDIOLOGY; HEART	Objective.-To assess the predictability of need for emergency surgery after coronary balloon angioplasty. Design.-Nonrandomized intervention study. Setting.-Nonprofit university hospital. Patients.-Prior to balloon angioplasty, 1000 consecutive patients were assigned to either the "standby" group (189 patients [19%]) or the "no-standby" group (811 patients [81%]). Patients in the standby group (intervention coordinated with cardiac surgery) included all operable patients undergoing angioplasty of their largest coronary arteries that were not currently or previously totally occluded or collateralized; the no-standby group consisted of the remainder of patients. Intervention.-Allocation to coronary angioplasty with or without surgical standby. Main Outcome Measures.-Need for bypass surgery, occurrence of myocardial infarction, and mortality from complications of angioplasty. Results.-Bypass surgery immediately after angioplasty was done in one patient in each group (standby, 0.5%, vs no-standby, 0.1%). The frequency of infarction was 5% vs 4%, respectively. All eight deaths occurred in the no-standby group (1.0%), but none of them were consequences of a lack of surgical standby. They occurred in situations in which bypass surgery would not have changed the outcome (two cardiac failures late after technically successful angioplasty for postinfarct cardiogenic shock, one in-laboratory rupture of an unrecognized ventricular pseudoaneurysm, and one protamine reaction), secondary to acute problems late after successful angioplasty (two sudden deaths and one vessel occlusion in an inoperable patient), or despite surgery (one patient with left main stem dissection). Conclusions.-Performing roughly 80% of coronary angioplasties without surgical standby did not increase patient risk. Coronary angioplasty without surgical backup, albeit not an ideal setting, appears ethically feasible in selected patients if dictated by logistic considerations.			MEIER, B (corresponding author), UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND.							BOURASSA M G, 1988, European Heart Journal, V9, P1034; CAMERON DE, 1990, ANN THORAC SURG, V50, P35, DOI 10.1016/0003-4975(90)90078-K; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; Deutsche Gessellschaft fur Herz- und Kreislaufforschung, 1987, Z KARDIOL, V76, P382; GRUENTZIG AR, 1979, NEW ENGL J MED, V301, P61; MEIER B, 1991, J AM COLL CARDIOL, V17, pB50; MEIER B, 1987, CORONARY ANGIOPLASTY, P146; REIFART N, 1990, Z KARDIOL, V79, P446; RENNER U, 1991, HERZ KREISLAUF, V23, P409; RICHARDSON SG, 1990, BRIT MED J, V300, P355, DOI 10.1136/bmj.300.6721.355; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; RYAN TJ, 1990, J AM COLL CARDIOL, V15, P1469, DOI 10.1016/0735-1097(90)92812-G; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1988, CIRCULATION, V78, P1121, DOI 10.1161/01.CIR.78.5.1121; STEFFENINO G, 1988, BRIT HEART J, V59, P151; STEWART JT, 1990, BRIT HEART J, V63, P74; ULLYOT DJ, 1987, CIRCULATION, V76, P149; WEAVER WF, 1985, CATHETER CARDIO DIAG, V11, P109, DOI 10.1002/ccd.1810110117; 1988, CATHET CARDIOVASC DI, V15, P136	20	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					741	745		10.1001/jama.268.6.741	http://dx.doi.org/10.1001/jama.268.6.741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640573				2022-12-28	WOS:A1992JG66600014
J	HILL, RJ; STERNBERG, PW				HILL, RJ; STERNBERG, PW			THE GENE LIN-3 ENCODES AN INDUCTIVE SIGNAL FOR VULVAR DEVELOPMENT IN C-ELEGANS	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; NEMATODE CAENORHABDITIS-ELEGANS; SPECIFIES CELL FATES; FACTOR-ALPHA; TYROSINE KINASE; MYXOMA VIRUS; SEQUENCE; EGF; EXPRESSION; LINEAGES	The lin-3 gene is necessary for induction of the Caenorhabditis elegans vulva by the anchor cell. It encodes a molecule similar to epidermal growth factor and to transforming growth factor-alpha and acts through the epidermal growth factor receptor homologue let-23. Expression of lin-3 in the anchor cell stimulates vulval induction; lin-3 may encode the vulval inducing signal.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HILL, RJ (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CLARK DV, 1988, GENETICS, V119, P345; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DAVIS C G, 1990, New Biologist, V2, P410; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; OCHMAN H, 1988, GENETICS, V120, P621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENZWEIG B, 1983, NUCLEIC ACIDS RES, V11, P4201, DOI 10.1093/nar/11.12.4201; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	58	321	339	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					470	476		10.1038/358470a0	http://dx.doi.org/10.1038/358470a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641037				2022-12-28	WOS:A1992JG73900039
J	CUNLIFFE, V; SMITH, JC				CUNLIFFE, V; SMITH, JC			ECTOPIC MESODERM FORMATION IN XENOPUS EMBRYOS CAUSED BY WIDESPREAD EXPRESSION OF A BRACHYURY HOMOLOG	NATURE			English	Article							EARLY AMPHIBIAN EMBRYO; PATTERN; LAEVIS; CELLS; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEIN; MUSCLE; GENES	THE Brachyury (T) gene is required cell-autonomously for mesoderm formation in the posterior of the mouse embryo1,2, and both its complementary DNA sequence and expression pattern3 closely resemble those of a Xenopus homologue (Xbra)4, suggesting that these genes have an evolutionarily conserved function in vertebrate development. Strong expression of Xbra messenger RNA is found in the ring of involuting mesoderm during Xenopus gastrulation 4, and the expression of Xbra is an immediate-early response of animal pole blastomeres to mesoderm-inducing factors4. To assess the role of Xbra in mesoderm formation, we increased its domain of expression in the embryo by microinjection of Xbra transcripts into the animal pole of Xenopus embryos at the one-cell stage. We show that expression of Xbra by cells of the early embryo is sufficient to direct their development into differentiated mesodermal tissues. At the molecular level this response shows a sharp threshold of sensitivity to the dose of Xbra RNA delivered, and we suggest that Xbra may act as a genetic switch initiating posterior mesodermal specification during embryogenesis.			CUNLIFFE, V (corresponding author), NATL INST MED RES, DEV BIOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Cunliffe, Vincent/E-6170-2010	Cunliffe, Vincent/0000-0001-7483-7610; Smith, Jim/0000-0003-2413-9392				ALTABA ARI, 1989, DEVELOPMENT, V106, P173; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1979, J EMBRYOL EXP MORPH, V51, P165; DALE L, 1992, DEVELOPMENT, V115, P573; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; RASHBASS P, 1991, NATURE, V353, P348, DOI 10.1038/353348a0; RUIZ IA, 1989, CELL, V57, P317; SARGENT MG, 1990, DEVELOPMENT, V109, P967; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; [No title captured]	25	216	216	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					427	430		10.1038/358427a0	http://dx.doi.org/10.1038/358427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641026				2022-12-28	WOS:A1992JF85300060
J	STONER, GR; ALBRIGHT, TD				STONER, GR; ALBRIGHT, TD			NEURAL CORRELATES OF PERCEPTUAL MOTION COHERENCE	NATURE			English	Article								THE motions of overlapping contours in a visual scene may arise from the physical motion(s) of either a single or multiple surface(s). A central problem facing the visual motion system is that of assigning the most likely interpretation. The rules underlying this perceptual decision can be explored using a visual stimulus formed by superimposing two moving gratings. The resultant percept is either that of a single coherently moving 'plaid pattern' (coherent motion) or of the two component gratings sliding noncoherently across one another (noncoherent motion)1,2. When plaid patterns are configured to mimic one transparent grating overlying another, the percept of noncoherent motion dominates3. We now report that neurons in the visual cortex of rhesus monkeys exhibit changes in direction tuning that parallel this perceptual phenomenon: sensitivity to the motions of the component gratings is enhanced under conditions that favour the perception of noncoherent motion. These results challenge models of cortical visual processing that fail to take into account the contribution of figural image segmentation cues to the analysis of visual motion.			STONER, GR (corresponding author), SALK INST BIOL STUDIES,VIS CTR LAB,LA JOLLA,CA 92037, USA.							ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1984, J OPT SOC AM A, V1, P1266; BECK J, 1986, HUMAN MACHINE VISION, V2, P1; KOOI FL, IN PRESS PERCEPTION; KRAUSKOPF J, 1990, NATURE, V348, P328, DOI 10.1038/348328a0; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; MOVSHON JA, 1985, STUDY GROUP PATTERN; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; STONER GR, 1992, INVEST OPHTH VIS SCI, V33, P1050; VALLORTIGARA G, 1992, VISION RES, V31, P1967	11	147	147	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					412	414		10.1038/358412a0	http://dx.doi.org/10.1038/358412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641024				2022-12-28	WOS:A1992JF85300055
J	KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK				KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK			EXPRESSION CLONING OF A CDNA-ENCODING A RETINOBLASTOMA-BINDING PROTEIN WITH E2F-LIKE PROPERTIES	CELL			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; SV40 LARGE-T; DNA-BINDING; REGULATORY ELEMENT; IMMUNE INTERFERON; MESSENGER-RNA; RB GENE; CELLS	An expression vector was modified to permit the rapid synthesis of purified, P-32-labeled, glutathione S-transferase (GST)-retinoblastoma (RB) fusion proteins. The products were used to screen lambda-gt11 expression libraries, from which we cloned a cDNA encoding a polypeptide (RBAP-1) capable of binding directly to a putative functional domain (the pocket) of the retinoblastoma gene product (RB). The RB "pocket" is known to bind, directly or indirectly, to the cellular transcription factor, E2F, implicated in cell growth control. We have found that RBAP-1 copurifies with E2F, interacts specifically with the adenovirus E4 ORF 6/7 protein, binds specifically and directly to a known E2F DNA recognition sequence, and contains a functional transactivation domain. Therefore, RBAP-1 is a species of E2F and can bind specifically to the RB pocket.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV CALIF SAN FRANCISCO,SCH MED,HORMONE RES INST,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.			Farnham, Peggy/0000-0003-4469-7914				ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PRIMIG M, 1992, IN PRESS NATURE; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	73	845	890	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					351	364		10.1016/0092-8674(92)90108-O	http://dx.doi.org/10.1016/0092-8674(92)90108-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638635				2022-12-28	WOS:A1992JE75700017
J	GOREVIC, PD; MUNOZ, PC; GORGONE, G; PURCELL, JJ; RODRIGUES, M; GHISO, J; LEVY, E; HALTIA, M; FRANGIONE, B				GOREVIC, PD; MUNOZ, PC; GORGONE, G; PURCELL, JJ; RODRIGUES, M; GHISO, J; LEVY, E; HALTIA, M; FRANGIONE, B			AMYLOIDOSIS DUE TO A MUTATION OF THE GELSOLIN GENE IN AN AMERICAN FAMILY WITH LATTICE CORNEAL-DYSTROPHY TYPE-II	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							FINNISH HEREDITARY AMYLOIDOSIS; CRANIAL NEUROPATHY; VITREOUS AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; PLASMA GELSOLIN; PROTEIN; TRANSTHYRETIN; PREALBUMIN; SEQUENCE; FIBRIL		ST LOUIS UNIV, ST MARYS HLTH CTR, SCH MED, DEPT OPHTHALMOL, ST LOUIS, MO 63103 USA; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA; UNIV MARYLAND, DEPT OPHTHALMOL, BALTIMORE, MD 21201 USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10003 USA	Saint Louis University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University System of Maryland; University of Maryland Baltimore; New York University	GOREVIC, PD (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, HSC-16T-040, STONY BROOK, NY 11794 USA.				NIAMS NIH HHS [AR02594] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR002594, R37AR002594] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOYSEN G, 1979, J NEUROL NEUROSUR PS, V42, P1020, DOI 10.1136/jnnp.42.11.1020; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BROWNSTEIN M H, 1970, American Journal of Ophthalmology, V69, P423; CASTANO EM, 1988, LAB INVEST, V58, P122; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COHEN AS, 1991, B RHEUM DIS, V40, P1; DARRAS BT, 1986, NEUROLOGY, V36, P432, DOI 10.1212/WNL.36.3.432; GHISO J, 1990, BIOCHEM J, V272, P827, DOI 10.1042/bj2720827; GOREVIC PD, 1987, OPHTHALMOLOGY, V94, P792; GOREVIC PD, 1991, AMYLOID AND AMYLOIDOSIS 1990, P423; GOREVIC PD, 1984, AM J OPHTHALMOL, V98, P216, DOI 10.1016/0002-9394(87)90357-6; HALTIA M, 1990, BIOCHEM BIOPH RES CO, V167, P927, DOI 10.1016/0006-291X(90)90612-Q; HALTIA M, 1990, AM J PATHOL, V136, P1223; HIDA T, 1987, AM J OPHTHALMOL, V104, P249, DOI 10.1016/0002-9394(87)90412-0; HILTUNEN T, 1991, AM J HUM GENET, V49, P522; HUSBY G, 1991, AMYLOID AND AMYLOIDOSIS 1990, P7; IWSNIEWSKI T, 1991, AM J PATHOL, V138, P1077; Jacobson D R, 1991, Adv Hum Genet, V20, P69; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LEVY E, 1990, J EXP MED, V172, P1865, DOI 10.1084/jem.172.6.1865; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MAURY CPJ, 1991, LAB INVEST, V64, P400; MAURY CPJ, 1990, BIOCHIM BIOPHYS ACTA, V1096, P84, DOI 10.1016/0925-4439(90)90016-I; MAURY CPJ, 1990, FEBS LETT, V276, P75, DOI 10.1016/0014-5793(90)80510-P; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MERETOJA J, 1973, CLIN GENET, V4, P173; MERETOJA J, 1969, Annals of Clinical Research, V1, P314; MERETOJA J, 1972, OPHTHALMOLOGICA, V165, P15, DOI 10.1159/000308469; PURCELL JJ, 1983, OPHTHALMOLOGY, V90, P1512; RAFLO GT, 1981, AM J OPHTHALMOL, V92, P221, DOI 10.1016/0002-9394(81)90775-3; RODRIGUES M, 1971, ARCH OPHTHALMOL-CHIC, V85, P277; SACK GH, 1981, JOHNS HOPKINS MED J, V149, P239; SANDGREN O, 1986, OPHTHALMIC RES, V18, P98, DOI 10.1159/000265422; SANDGREN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P790; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARCK T, 1991, OPHTHALMOLOGY, V98, P1197; WARING GO, 1978, SURV OPHTHALMOL, V23, P71, DOI 10.1016/0039-6257(78)90090-5; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; WINKELMAN J E, 1971, Klinische Monatsblaetter fuer Augenheilkunde, V159, P618	41	63	63	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1780	1785		10.1056/NEJM199112193252505	http://dx.doi.org/10.1056/NEJM199112193252505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1658654				2022-12-28	WOS:A1991GV73900005
J	LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE				LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE			ANTIBODY-MEDIATED CLEARANCE OF ALPHAVIRUS INFECTION FROM NEURONS	SCIENCE			English	Article							AGE-DEPENDENT RESISTANCE; CENTRAL NERVOUS-SYSTEM; SINDBIS VIRUS; VIRAL-INFECTION; IMMUNE-RESPONSE; MICE; ENCEPHALITIS; PATHOGENESIS; ENCEPHALOMYELITIS; LYMPHOCYTES	Humoral immunity is important for protection against viral infection and neutralization of extracellular virus, but clearance of virus from infected tissues is thought to be mediated solely by cellular immunity. However, in a SCID mouse model of persistent alphavirus encephalomyelitis, adoptive transfer of hyperimmune serum resulted in clearance of infectious virus and viral RNA from the nervous system, whereas adoptive transfer of sensitized T lymphocytes had no effect on viral replication. Three monoclonal antibodies to two different epitopes on the E2 envelope glycoprotein mediated viral clearance. Treatment of alphavirus-infected primary cultured rat neurons with these monoclonal antibodies to E2 resulted in decreased viral protein synthesis, followed by gradual termination of mature infectious virion production. Thus, antibody can mediate clearance of alphavirus infection from neurons by restricting viral gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Crawford, Thomas/E-6307-2012	Bollinger, Robert/0000-0002-6798-6834	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029234, T32NS007000] Funding Source: NIH RePORTER; NINDS NIH HHS [T32-NS-07000, NS29234] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLAS ZK, 1986, J IMMUNOL, V137, P2380; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUJINAMI RS, 1989, J VIROL, V63, P2081, DOI 10.1128/JVI.63.5.2081-2087.1989; GRIFFIN DE, 1976, J INFECT DIS, V133, P456, DOI 10.1093/infdis/133.4.456; GRIFFIN DE, 1973, CELL IMMUNOL, V9, P426, DOI 10.1016/0008-8749(73)90057-9; JACKSON AC, 1987, LAB INVEST, V56, P418; JACKSON AC, 1988, LAB INVEST, V58, P503; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; LEVINE B, UNPUB; MAUERHOFF T, 1988, J NEUROIMMUNOL, V18, P271, DOI 10.1016/0165-5728(88)90049-5; MCFARLAND HF, 1974, J IMMUNOL, V113, P173; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; MENDOZA QP, 1988, J GEN VIROL, V70, P3015; MOMBURG F, 1986, EUR J IMMUNOL, V16, P551, DOI 10.1002/eji.1830160516; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; SCHMALJOHN AL, 1982, NATURE, V297, P70, DOI 10.1038/297070a0; SCHMALJOHN AL, 1983, VIROLOGY, V130, P305; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHERMAN LA, 1990, J VIROL, V64, P2041, DOI 10.1128/JVI.64.5.2041-2046.1990; STANLEY J, 1986, J VIROL, V58, P107, DOI 10.1128/JVI.58.1.107-115.1986; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; TYLER KL, 1989, J EXP MED, V170, P887, DOI 10.1084/jem.170.3.887	25	325	329	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					856	860		10.1126/science.1658936	http://dx.doi.org/10.1126/science.1658936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658936				2022-12-28	WOS:A1991GN83300045
J	SORBERA, LA; MORAD, M				SORBERA, LA; MORAD, M			MODULATION OF CARDIAC SODIUM-CHANNELS BY CAMP RECEPTORS ON THE MYOCYTE SURFACE	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; VENTRICULAR MUSCLE; ADENYLATE-CYCLASE; G-PROTEIN; ISOPROTERENOL; PHOSPHORYLATION; SYSTEM	The phosphorylation of the cardiac sodium channel by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase A leads to its inactivation. It was shown that extracellular cAMP can also modulate the sodium channel of rat, guinea pig, and frog ventricular myocytes in a rapid (less than 50 milliseconds), reversible, and dose-dependent manner. The decrease in the sodium current was accompanied by a 10- to 15-millivolt shift in the steady-state availability of the sodium channel toward more negative potentials and was inhibited by guanosine-5'-O-(2-thiodiphosphate) or pertussis toxin, suggesting that the extracellular modulation of the sodium channel by cAMP is mediated by a membrane-delimited mechanism that includes a pertussis toxin-sensitive G protein.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; MT DESERT ISL BIOL LAB, SALSBURY COVE, ME 04672 USA	University of Pennsylvania; Mount Desert Island Biological Laboratory					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HAMILL OP, 1981, PFLUEGERS ARCH, V395, P6; Hille B, 1984, IONIC CHANNELS EXCIT; HISATOME I, 1985, J MOL CELL CARDIOL, V17, P657, DOI 10.1016/S0022-2828(85)80065-1; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JAKOBS KH, 1983, EUR J BIOCHEM, V132, P125, DOI 10.1111/j.1432-1033.1983.tb07336.x; JAKOBS KH, 1983, EUR J BIOCHEM, V130, P605, DOI 10.1111/j.1432-1033.1983.tb07192.x; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MOORMAN JR, 1989, CIRC RES, V65, P1804, DOI 10.1161/01.RES.65.6.1804; ONO K, 1989, AM J PHYSIOL, V256, pC1131, DOI 10.1152/ajpcell.1989.256.6.C1131; SCHOUTEN VJA, 1989, PFLUG ARCH EUR J PHY, V415, P1, DOI 10.1007/BF00373135; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; WINDISCH H, 1982, J MOL CELL CARDIOL, V14, P431, DOI 10.1016/0022-2828(82)90175-4	20	50	51	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1286	1289		10.1126/science.1653970	http://dx.doi.org/10.1126/science.1653970			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1653970				2022-12-28	WOS:A1991GE68900043
J	NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B				NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B			MUTATIONS OF CHROMOSOME-5Q21 GENES IN FAP AND COLORECTAL-CANCER PATIENTS	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; P53 GENE; CELL-LINES; CARCINOMAS; RATES; COLI; TUMORIGENESIS; ANTIONCOGENES; LOCALIZATION; ONCOGENES	Previous studies suggested that one or more genes on chromosome 5q2l are responsible for the inheritance of familial adenomatous polyposis (FAP) and Gardner's syndrome (GS), and contribute to tumor development in patients with noninherited forms of colorectal cancer. Two genes on 5q2l that are tightly linked to FAP (MCC and APC) were found to be somatically altered in tumors from sporadic colorectal cancer patients. One of the genes (APC) was also found to be altered by point mutation in the germ line of FAP and GS patients. These data suggest that more than one gene on chromosome 5q2l may contribute to colorectal neoplasia, and that mutations of the APC gene can cause both FAP and GS. The identification of these genes should aid in understanding the pathogenesis of colorectal neoplasia and in the diagnosis and counseling of patients with inherited predispositions to colorectal cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT SURG 2,NISHINOMIYA,HYOGO 663,JAPAN; HAMAMATSU MED COLL,DEPT SURG 2,SHIZUOKA 43131,JAPAN; ICI PLC,PHARMACEUT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,MOLEC GENET LAB,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH HYG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH PUBL HLTH,BALTIMORE,MD 21218	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hamamatsu University School of Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Horii, Akira/AAW-2839-2021; Bryan, Tracy M/B-8468-2014	Horii, Akira/0000-0002-3967-3291; Nilbert, Mef/0000-0003-2717-1937; Bryan, Tracy/0000-0002-7990-5501	NCI NIH HHS [CA35494, CA06973, CA44688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044688, P30CA006973, R01CA035494, R37CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, IN PRESS ONCOGENE; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELDJORD C, 1988, NUCLEIC ACIDS RES, V16, P4927, DOI 10.1093/nar/16.11.4927; BISHOPJM, 1990, CELL, V64, P235; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BONADIO J, 1990, J BIOL CHEM, V265, P2262; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1989, LANCET, V2, P353; DUNLOP MG, 1989, GENOMICS, V5, P350, DOI 10.1016/0888-7543(89)90068-2; ELMORE E, 1983, CANCER RES, V43, P1650; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GROSS ME, 1991, CANCER RES, V51, P1452; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JOSLYN G, IN PRESS CELL; KADEN D, 1989, CANCER RES, V49, P3374; KENDAL WS, 1986, CANCER RES, V46, P6131; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LOEB LA, 1991, CANCER RES, V51, P3075; MIKI Y, IN PRESS JPN J CANCE; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P4; MYERS RM, 1986, COLD SPRING HARB SYM, V51, P275, DOI 10.1101/SQB.1986.051.01.033; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, UNPUB; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SASAKI M, 1989, CANCER RES, V49, P4402; SESHADRI R, 1987, CANCER RES, V47, P407; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Suqarbaker J, 1985, CANCER PRINCIPLES PR, P800; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WADDELL WR, 1989, AM J SURG, V157, P174; WEINBERG RA, 1989, CANCER RES, V49, P3713	50	1600	1708	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					665	669		10.1126/science.1651563	http://dx.doi.org/10.1126/science.1651563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1651563				2022-12-28	WOS:A1991GA30400039
J	LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H				LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H			FUNCTIONAL-ACTIVITY OF MYOGENIC HLH PROTEINS REQUIRES HETERO-OLIGOMERIZATION WITH E12/E47-LIKE PROTEINS INVIVO	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; LOOP-HELIX PROTEINS; DNA-BINDING; NEGATIVE REGULATOR; 10T1/2 FIBROBLASTS; DETERMINATION GENE; SEX DETERMINATION; MYC HOMOLOGY; MYOD; EXPRESSION	In this report we provide four lines of evidence indicating that E12/E47-like proteins interact in vivo with the myogenic HLH proteins MyoD and myogenin. First, cotransfection of MyoD and E47 in COS cells indicates that these factors synergistically enhance transcription of a reporter gene containing an oligomerized MyoD-binding site. Second, mobility-shift assays of muscle cell nuclear extracts, "double shifted" with specific antisera, have identified complexes binding to the MEF1 site that contain either MyoD or myogenin in association with E12/E47-like proteins. Third, association with E47 alters the phosphorylation state of MyoD. Fourth, C3H10T1/2 cells expressing antisense E2A transcripts contain low levels of E2A gene products and display less terminal muscle differentiation when infected with retroviral MyoD or when challenged to differentiate with 5-azacytidine treatment. In addition we demonstrate that MyoD, in conjunction with E12/E47-like proteins, is functioning as a regulatory nodal point for activation of several other downstream muscle regulators.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104; UNIV TEXAS,SW MED SCH,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Massachusetts Institute of Technology (MIT); Whitehead Institute					NIGMS NIH HHS [GM39458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2827; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HARVEY RP, 1990, DEVELOPMENT, V108, P669; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, IN PRESS GENES DEV; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	57	798	808	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					305	315		10.1016/0092-8674(91)90620-E	http://dx.doi.org/10.1016/0092-8674(91)90620-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649701				2022-12-28	WOS:A1991FY71200011
J	SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF				SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF			STRUCTURE OF THE INSULIN-RECEPTOR SUBSTRATE IRS-1 DEFINES A UNIQUE SIGNAL TRANSDUCTION PROTEIN	NATURE			English	Article							GROWTH FACTOR-I; TYROSINE-PHOSPHORYLATION; PHOSPHATIDYLINOSITOL KINASE; CELLS; ADIPOCYTES; COMMON; PHOSPHOPROTEIN; PURIFICATION; 3-KINASE; BINDING	SINCE the discovery of insulin nearly 70 years ago, there has been no problem more fundamental to diabetes research than understanding how insulin works at the cellular level. Insulin binds to the alpha-subunit of the insulin receptor which activates the tyrosine kinase in the beta-subunit, but the molecular events linking the receptor kinase to insulin-sensitive enzymes and transport processes are unknown 1,2. Our discovery that insulin stimulates tyrosine phosphorylation of a protein of relative molecular mass between 165,000 and 185,000, collectively called pp185, showed that the insulin receptor kinase has specific cellular substrates 3. The pp185 is a minor cytoplasmic phosphoprotein found in most cells and tissues 4-10; its phosphorylation is decreased in cells expressing mutant receptors defective in signalling 6,11. We have now cloned IRS-1, which encodes a component of the pp185 band. IRS-1 contains over ten potential tyrosine phosphorylation sites, six of which are in Tyr-Met-X-Met motifs. During insulin stimulation, the IRS-1 protein undergoes tyrosine phosphorylation and binds phosphatidylinositol 3-kinase, suggesting that IRS-1 acts as a multisite 'docking' protein to bind signal-transducing molecules containing Src-homology 2 and Src-homology-3 domains 12-14. Thus IRS-1 may link the insulin receptor kinase and enzymes regulating cellular growth and metabolism.			SUN, XJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, IN PRESS BIOCHEMISTR; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; ESCOBEDO JA, 1991, CELL, V65; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HJOLLUND E, 1988, ACTA ENDOCRINOL-COP, V118, P59; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LATHE R, 1985, J MOL BIOL, V83, P1; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PINES J, 1990, New Biologist, V2, P389; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEMER J, 1987, J BIOL CHEM, V262, P15476; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	31	1413	1448	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					73	77		10.1038/352073a0	http://dx.doi.org/10.1038/352073a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1648180				2022-12-28	WOS:A1991FV17800074
J	TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD				TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD			HEPATITIS-C VIRUS - EVIDENCE FOR SEXUAL TRANSMISSION	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; NON-A; ANTIBODIES	Objective-To determine the prevalence of hepatitis C virus infection and associated risk factors in patients attending a genitourinary medicine clinic, as evidence for sexual transmission. Design-Seroprevalence estimated by reactivity in an enzyme immunoassay for antibodies to C100 protein with supplementary testing with a recombinant immunoblot assay and an assay for hepatitis C virus RNA. Setting-Outpatient genitourinary medicine clinic in central London. Patients-The panel of 1046 serum samples was from 1074 consecutive patients attending the clinic during November and December 1987 and having blood taken for routine testing for syphilis. Before samples were anonymised demographic and risk factor information was extracted from the clinic notes. Samples had already been tested for antibody to HIV-1 and antibody to hepatitis B core antigen. Main results-Significantly more homosexual subjects than heterosexual subjects were positive for hepatitis C antibody determined by enzyme immunoassay alone (19/275 (6.9%) v 8/771 (1.0%), odds ratio 7.14, p < 0.0001) and also when reactive serum samples were also tested by recombinant immunoblot assay (6/270) (2.2%) v 3/770 (0.4%), odds ratio 5.88, p < 0.02). There were also significant associations in patients positive for hepatitis C antibody with positivity for antibodies to HIV and to hepatitis B core antigen, lifetime number of sexually transmitted diseases (homosexual men only), and age (all groups combined). Most patients whose serum samples contained specific antibodies to hepatitis C virus were viraemic. Conclusions-The study provides strong evidence for the sexual transmission of hepatitis C virus. Assays derived from other gene products are desirable to investigate the specificity and sensitivity of the enzyme immunoassay for C100 antibody as a marker of hepatitis C virus infection.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	TEDDER, RS (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT UROL,LONDON WC1E 6JJ,ENGLAND.		Garson, Jeremy A/C-5357-2008; Kelly, Gabrielle E./A-4147-2015; RIESTRA, SABINO/N-2897-2019	Kelly, Gabrielle E./0000-0003-2769-9555; Tedder, Richard/0000-0002-9672-5721; Garson, Jeremy/0000-0003-0553-0126				ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORTIMER PP, 1989, LANCET, V2, P798	10	132	134	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1299	1302		10.1136/bmj.302.6788.1299	http://dx.doi.org/10.1136/bmj.302.6788.1299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ444	1647826	Bronze, Green Published			2022-12-28	WOS:A1991FQ44400016
J	BENABID, AL; POLLAK, P; GERVASON, C; HOFFMANN, D; GAO, DM; HOMMEL, M; PERRET, JE; DEROUGEMONT, J				BENABID, AL; POLLAK, P; GERVASON, C; HOFFMANN, D; GAO, DM; HOMMEL, M; PERRET, JE; DEROUGEMONT, J			LONG-TERM SUPPRESSION OF TREMOR BY CHRONIC STIMULATION OF THE VENTRAL INTERMEDIATE THALAMIC NUCLEUS	LANCET			English	Article							VIM-THALAMOTOMY; MOVEMENT-DISORDERS; NEURONS	The usefulness of high-frequency stimulation of the ventral intermediate nucleus (Vim) as the first neurosurgical procedure in disabling tremor was assessed in 26 patients with Parkinson's disease and 6 with essential tremor. 7 of these patients had already undergone thalamotomy contralateral to the stimulated side, and 11 others had bilateral Vim stimulation at the same time. Chronic stimulating electrodes connected to a pulse generator were implanted in the Vim. Tremor amplitude at rest, during posture holding, and during action and intention manoeuvres was assessed by means of accelerometry. Of the 43 thalami stimulated, 27 showed complete relief from tremor and 11 major improvement (88%). The improvement was maintained for up to 29 months (mean follow-up 13 [SD 9] months). Adverse effects were mild and could be eradicated by reduction or cessation of stimulation. This reversibility and adaptability, allowing control of side-effects, make thalamic stimulation preferable to thalamotomy, especially when treatment of both sides of the brain is needed.	UNIV GRENOBLE, DEPT CLIN & BIOL NEUROSCI,INSERM,U318, UNITE PRECLIN NEUROBIOL, GRENOBLE, FRANCE; JINZHOU MED COLL, DEPT PHYSIOL, JINZHOU, PEOPLES R CHINA	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Jinzhou Medical University			Benabid, Alim L/Q-3506-2017					ALBEFESSARD D, 1988, CAN J NEUROL SCI, V15, P324, DOI 10.1017/S0317167100027840; Andrew J., 1984, MOVEMENT DISORDERS T, P339; ANDY OJ, 1983, APPL NEUROPHYSIOL, V46, P107; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; BENABID AL, 1989, REV NEUROL, V145, P320; BENABID AL, 1988, CURRENT PROBLEMS NEU, V9, P413; BRICE J, 1980, LANCET, V1, P1221; Cooper I S, 1977, Clin Neurosurg, V24, P367; COOPER IS, 1982, APPL NEUROPHYSIOL, V45, P209; Fahn S, 1988, PARKINSONS DIS MOVEM, P225; HIRAI T, 1983, BRAIN, V106, P1001, DOI 10.1093/brain/106.4.1001; KELLY PJ, 1990, THERAPY PARKINSONS D, P415; LAMARRE Y, 1979, ADV NEUROL, V24, P109; MATSUMOTO K, 1977, APPL NEUROPHYSIOL, V39, P257; MAZARS G, 1974, NEUROCHIRURGIE, V20, P117; NAGASEKI Y, 1986, J NEUROSURG, V65, P296, DOI 10.3171/jns.1986.65.3.0296; NARABAYASHI H, 1989, EUR NEUROL, V29, P29, DOI 10.1159/000116450; OHYE C, 1979, J NEUROSURG, V50, P290, DOI 10.3171/jns.1979.50.3.0290; OHYE C, 1982, APPL NEUROPHYSIOL, V45, P275; TAREN J, 1968, J NEUROSURG, V29, P173, DOI 10.3171/jns.1968.29.2.0173; TASKER R, 1986, REV NEUROL, V142, P316; TASKER RR, 1983, APPL NEUROPHYSIOL, V46, P68; WESTER K, 1990, J NEUROL NEUROSUR PS, V53, P427, DOI 10.1136/jnnp.53.5.427	23	1254	1336	1	81	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	1991	337	8738					403	406		10.1016/0140-6736(91)91175-T	http://dx.doi.org/10.1016/0140-6736(91)91175-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671433				2022-12-28	WOS:A1991EX60500013
J	HANKEY, GJ; WARLOW, CP				HANKEY, GJ; WARLOW, CP			LACUNAR TRANSIENT ISCHEMIC ATTACKS - A CLINICALLY USEFUL CONCEPT	LANCET			English	Article							COMMUNITY STROKE PROJECT; ISCHEMIC ATTACKS; BASAL GANGLIA; INFARCTION; LESIONS; TOMOGRAPHY; OCCLUSION; FEATURES; ARTERY; RISK	Lacunar ischaemic stroke syndromes are clinically, pathophysiologically, and prognostically distinguishable from cortical ischaemic stroke syndromes. Could cerebrovascular transient ischaemic attacks (TIAs) share similar heterogeneity? 130 patients with TIAs were prospectively studied, 71 of whom underwent carotid angiography. Symptoms were associated with a 50% or greater stenosis of the ipsilateral internal carotid artery in 36 (67%) of 54 patients with presumed cortical TIAs, but in only 1 (6%) of 17 patients with presumed lacunar TIAs (p < 0.0001). These findings support the view that cortical TIAs are associated with ipsilateral extracranial internal carotid artery atheromatous disease, whereas patients with lacunar TIAs may have absent or insignificant large-vessel disease, and probably intracranial small-vessel disease. Accurate distinction between lacunar and cortical events may have implications for investigation and treatment of patients with TIAs.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				ADAMS HP, 1983, STROKE, V14, P948, DOI 10.1161/01.STR.14.6.948; ALEKSIC SN, 1973, J NEUROL SCI, V19, P331, DOI 10.1016/0022-510X(73)90096-8; [Anonymous], 1989, Stroke, V20, P1407; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DEBONO DP, 1981, LANCET, V1, P343; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DONNAN GA, 1987, STROKE, V18, P296; DONNAN GA, 1982, NEUROLOGY, V32, P49, DOI 10.1212/WNL.32.1.49; FISHER CM, 1965, ARCH NEUROL-CHICAGO, V13, P30, DOI 10.1001/archneur.1965.00470010034005; FISHER CM, 1969, ACTA NEUROPATHOL, V12, P1, DOI 10.1007/BF00685305; GARDNER MJ, 1989, STATISTICS CONFIDENC; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HUANG CY, 1984, J NEUROL NEUROSUR PS, V47, P84, DOI 10.1136/jnnp.47.1.84; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KASE CS, 1988, HDB CLIN NEUROLOGY, P353; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MORI E, 1985, STROKE, V16, P454, DOI 10.1161/01.STR.16.3.454; NELSON RF, 1980, STROKE, V11, P256, DOI 10.1161/01.STR.11.3.256; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; ROTHROCK JF, 1987, STROKE, V18, P781, DOI 10.1161/01.STR.18.4.781; ROTHROCK JF, 1988, NEUROLOGY, V38, P198, DOI 10.1212/WNL.38.2.198; SANTAMARIA J, 1983, STROKE, V14, P911, DOI 10.1161/01.STR.14.6.911; STILLER J, 1982, ARCH NEUROL-CHICAGO, V39, P660, DOI 10.1001/archneur.1982.00510220058014; WARLOW CP, 1982, TRANSIENT ISCHAEMIC, pR7; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442	34	41	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 9	1991	337	8737					335	338		10.1016/0140-6736(91)90953-M	http://dx.doi.org/10.1016/0140-6736(91)90953-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671240				2022-12-28	WOS:A1991EX36200012
J	WRIGHT, JE				WRIGHT, JE			TRIAL OF INHALED SALBUTAMOL FOR PROCTALGIA FUGAX	LANCET			English	Letter																		WRIGHT JE, 1985, LANCET, V2, P659	1	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					359	359		10.1016/0140-6736(91)90984-W	http://dx.doi.org/10.1016/0140-6736(91)90984-W			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671248				2022-12-28	WOS:A1991EX36200032
J	BROWN, P; GAJDUSEK, DC				BROWN, P; GAJDUSEK, DC			SURVIVAL OF SCRAPIE VIRUS AFTER 3 YEARS INTERNMENT	LANCET			English	Note								Supernatant fluid from a scrapie-infected hamster brain homogenate was mixed with soil, packed into perforated petri dishes that were then embedded within soil-containing pots, and buried in a garden for 3 years. Between 2 and 3 log units of the input infectivity of nearly 5 log units survived this exposure, with little leaching of virus into deeper soil layers. These results have implications for environmental contamination by scrapie and by similar agents, including those of bovine spongiform encephalopathy and Creutzfeldt-Jakob disease.			BROWN, P (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892, USA.							BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1980, Epidemiol Rev, V2, P113; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; TATEISHI J, 1987, PRIONS NOVEL INFECTI, P424; [No title captured]	5	177	179	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					269	270		10.1016/0140-6736(91)90873-N	http://dx.doi.org/10.1016/0140-6736(91)90873-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671114				2022-12-28	WOS:A1991EV71900006
J	BOUNAMEAUX, H; CIRAFICI, P; DEMOERLOOSE, P; SCHNEIDER, PA; SLOSMAN, D; REBER, G; UNGER, PF				BOUNAMEAUX, H; CIRAFICI, P; DEMOERLOOSE, P; SCHNEIDER, PA; SLOSMAN, D; REBER, G; UNGER, PF			MEASUREMENT OF D-DIMER IN PLASMA AS DIAGNOSTIC-AID IN SUSPECTED PULMONARY-EMBOLISM	LANCET			English	Article							FIBRIN DEGRADATION PRODUCTS; DEEP VENOUS THROMBOSIS	The potential of plasma measurement of D-dimer (DD), a specific derivative of crosslinked fibrin, for diagnosis or exclusion of pulmonary embolism was investigated in a prospective series of 171 consecutive patients who attended an emergency department with suspected pulmonary embolism. The diagnosis was made or excluded by means of a clinical decision-making process which included clinical evaluation, ventilation-perfusion (VQ) lung scan, and, as indicated, pulmonary angiography, venography, or non-invasive examination of the leg veins. Pulmonary embolism was diagnosed by this process in 55 (32%) of 170 patients with sufficient data. All but 1 of these 55 patients had a DD concentration of 500-mu-g/l or above. The sensitivity and specificity of this cutoff concentration for the presence of pulmonary embolism were 98% and 39%, respectively, which give positive and negative predictive values of 44% and 98%. Among the 115 patients (68%) who had inconclusive VQ scans, 31 were diagnosed as having pulmonary embolism. 29 of the remaining 84 patients without pulmonary embolism had DD concentrations below 500-mu-g/l, which means that further diagnostic procedures could have been avoided in a quarter of the patients with inconclusive VQ scans. The sensitivity of the plasma measurement of DD remained high even 3 and 7 days after presentation (96% and 93%). Plasma measurement of DD therefore has a definite place in the diagnostic procedure for suspected acute pulmonary embolism in attenders at emergency departments: a concentration below 500-mu-g/l rules out the diagnosis.	UNIV GENEVA,HOP CANTONAL,DEPT MED,HEMOSTASIS UNIT,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,HOP CANTONAL,MED POLICLIN,CTR EMERGENCY,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,HOP CANTONAL,DEPT RADIOL,DIV NUCL MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,HOP CANTONAL,DEPT RADIOL,DIV RADIODIAGNOST,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva	BOUNAMEAUX, H (corresponding author), UNIV GENEVA,HOP CANTONAL,DEPT MED,ANGIOL UNIT,CH-1211 GENEVA 4,SWITZERLAND.							ALDERSON PO, 1987, RADIOLOGY, V164, P297, DOI 10.1148/radiology.164.2.3299482; BOUNAMEAUX H, 1989, AM J CLIN PATHOL, V91, P82, DOI 10.1093/ajcp/91.1.82; Bounameaux H, 1990, Blood Coagul Fibrinolysis, V1, P577, DOI 10.1097/00001721-199010000-00045; BOUNAMEAUX H, 1988, LANCET, V2, P628; BRIDEY F, 1989, LANCET, V1, P791; CELI A, 1989, CHEST, V95, P332, DOI 10.1378/chest.95.2.332; Fleiss JL, 1981, STAT METHODS RATES P; FRANCIS CW, 1987, CIRCULATION, V75, P1170, DOI 10.1161/01.CIR.75.6.1170; GAFFNEY PJ, 1988, BRIT J HAEMATOL, V68, P83, DOI 10.1111/j.1365-2141.1988.tb04183.x; GOLDHABER SZ, 1988, AM HEART J, V116, P505, DOI 10.1016/0002-8703(88)90625-4; GUREWICH V, 1973, CHEST, V64, P585, DOI 10.1378/chest.64.5.585; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEATON DC, 1987, J LAB CLIN MED, V110, P588; HOELLERICH VL, 1986, ARCH INTERN MED, V146, P1699; JUNOD AF, 1989, SCHWEIZ MED WSCHR, V119, P1489; KIPPER MS, 1982, CHEST, V82, P411, DOI 10.1378/chest.82.4.411; NIEUWENHUIZEN W, 1988, Fibrinolysis, V2, P1, DOI 10.1016/0268-9499(88)90058-6; OTT P, 1988, ACTA MED SCAND, V224, P263; ROWBOTHAM BJ, 1987, THROMB HAEMOSTASIS, V57, P59; SULLIVAN PJ, 1908, CHEST, V95, P300; WALD N, 1989, APPROPRIATE INVESTIG, P7; 1990, JAMA-J AM MED ASSOC, V263, P2753	22	284	291	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					196	200		10.1016/0140-6736(91)92158-X	http://dx.doi.org/10.1016/0140-6736(91)92158-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670841				2022-12-28	WOS:A1991EU92400003
J	CORAZZA, GR; ZOLI, G; GINALDI, L; CANCELLIERI, C; PROFETA, V; GASBARRINI, G; QUAGLINO, D				CORAZZA, GR; ZOLI, G; GINALDI, L; CANCELLIERI, C; PROFETA, V; GASBARRINI, G; QUAGLINO, D			TUFTSIN DEFICIENCY IN AIDS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; PHAGOCYTOSIS STIMULATING PEPTIDE; INFECTION; DISEASE; SPLENECTOMY	Tuftsin is an endogenous tetrapeptide that stimulates phagocytosis and is released form the Fc fragment of lgG by a splenic endocarboxypeptidase. Tuftsin activity and splenic function were measured in 21 patients with AIDS, 7 patients with AID-related complex (ARC), 22 patients who had undergone splenectomy, and 37 healthy volunteers. There was a significant inverse correlation between tuftsin activity and splenic function in all subjects. Tuftsin activity was significantly lower in patients with AIDS, ARC, and in those who had undergone splenectomy compared with healthy volunteers. Tuftsin deficiency may contribute to the risk of bacterial infection in symptomatic HIV-positive individuals.	UNIV BOLOGNA,DEPT MED PATHOL,I-40126 BOLOGNA,ITALY; GB MORGAGNI L PIERANTONI HOSP,DEPT INFECT DIS,FORLI,ITALY	University of Bologna	CORAZZA, GR (corresponding author), UNIV LAQUILA,DIPARTIMENTO MED INTERNA & SANITA PUBBL,VIA S SISTO 22E,I-67100 LAQUILA,ITALY.		Corazza, Gino Roberto/K-8500-2016	Corazza, Gino Roberto/0000-0001-9532-0573; Ginaldi, Lia/0000-0003-1841-2807; ZOLI, Giorgio/0000-0002-3244-0663				BARRETTCONNOR E, 1971, MEDICINE, V50, P97, DOI 10.1097/00005792-197103000-00002; BENDER BS, 1985, J INFECT DIS, V152, P409, DOI 10.1093/infdis/152.2.409; CHU DZJ, 1985, SURGERY, V97, P701; CONSTANT.A, 1973, AM J DIS CHILD, V125, P663, DOI 10.1001/archpedi.1973.04160050017004; CORAZZA GR, 1984, BRIT MED J, V289, P861, DOI 10.1136/bmj.289.6449.861; Ganz SS, 1987, RADIOLOGY, V165, P97; HO DD, 1987, NEW ENGL J MED, V317, P278; Justice A C, 1988, Trans Assoc Am Physicians, V101, P18; MARILUS R, 1984, ISRAEL J MED SCI, V20, P249; Mathe G, 1987, Cancer Detect Prev Suppl, V1, P445; NAJJAR VA, 1970, NATURE, V228, P672, DOI 10.1038/228672a0; NAJJAR VA, 1972, J RETICULOENDOTH SOC, V12, P197; NAJJAR VA, 1983, ANN NY ACAD SCI, V419, P1, DOI 10.1111/j.1749-6632.1983.tb37086.x; NISHIOKA K, 1972, BIOCHEM BIOPH RES CO, V47, P172, DOI 10.1016/S0006-291X(72)80025-1; RAVRY M, 1972, ANN INTERN MED, V77, P11, DOI 10.7326/0003-4819-77-1-11; SMITH R, 1985, AM J ROENTGENOL, V145, P1201, DOI 10.2214/ajr.145.6.1201; SPIRER Z, 1980, ARCH DIS CHILD, V55, P566, DOI 10.1136/adc.55.7.566; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1987, MMWR, V36, pS3; [No title captured]	21	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					12	13		10.1016/0140-6736(91)93331-3	http://dx.doi.org/10.1016/0140-6736(91)93331-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670648				2022-12-28	WOS:A1991EQ60400005
J	OKADA, K; SHIMURA, Y				OKADA, K; SHIMURA, Y			ASPECTS OF RECENT DEVELOPMENTS IN MUTATIONAL STUDIES OF PLANT SIGNALING PATHWAYS	CELL			English	Review									KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 606, JAPAN	Kyoto University	OKADA, K (corresponding author), NATL INST BASIC BIOL, DIV GENE EXPRESS & REGULAT 1, OKAZAKI, AICHI 444, JAPAN.							BELL CJ, 1990, MOL GEN GENET, V220, P289, DOI 10.1007/BF00260496; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BULLEN BL, 1990, PLANT PHYSIOL, V93, P525, DOI 10.1104/pp.93.2.525; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; KLEE H, 1991, ANNU REV PLANT PHYS, V42, P529, DOI 10.1146/annurev.pp.42.060191.002525; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; MIRZA JI, 1984, PHYSIOL PLANTARUM, V60, P516, DOI 10.1111/j.1399-3054.1984.tb04920.x; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OKADA K, 1992, IN PRESS AUST J PLAN; PALME K, 1992, INT REV CYTOL, V132, P223, DOI 10.1016/S0074-7696(08)62457-2; SCHIEFELBEIN JW, 1991, PLANT CELL, V3, P1147, DOI 10.1105/tpc.3.11.1147; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843	21	50	51	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					369	372		10.1016/0092-8674(92)90159-A	http://dx.doi.org/10.1016/0092-8674(92)90159-A			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643655				2022-12-28	WOS:A1992JH12400002
J	EVANS, MR; READ, CA				EVANS, MR; READ, CA			32P, 33P AND 35S - SELECTING A LABEL FOR NUCLEIC-ACID ANALYSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DNA; FRAGMENTS; INVITRO				EVANS, MR (corresponding author), AMERSHAM INT PLC,DIV LIFE SCI,WHITE LION RD,AMERSHAM HP7 9NA,BUCKS,ENGLAND.							BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; DURRANT I, 1990, BIOTECHNIQUES, V8, P564; DURRANT I, 1990, NATURE, V346, P297, DOI 10.1038/346297a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RICHARDSON CC, 1981, ENZYMES NUCLEIC AC A, V14, P229; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	10	29	29	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					520	521		10.1038/358520a0	http://dx.doi.org/10.1038/358520a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641043				2022-12-28	WOS:A1992JG73900056
J	KAMM, MA; SENAPATI, A				KAMM, MA; SENAPATI, A			DRUG MANAGEMENT OF ULCERATIVE-COLITIS	BRITISH MEDICAL JOURNAL			English	Article							INFLAMMATORY BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; CONTROLLED TRIAL; AZODISAL SODIUM; PREDNISOLONE; SULFASALAZINE; AZATHIOPRINE; INHIBITION; CORTICOSTEROIDS; PREGNANCY				KAMM, MA (corresponding author), ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND.							ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; BARON J H, 1962, Br Med J, V2, P441; BIRNIE GG, 1981, GUT, V22, P452, DOI 10.1136/gut.22.6.452; CAMPBELL AC, 1976, CLIN EXP IMMUNOL, V24, P249; CAMPBELL AC, 1974, CLIN EXP IMMUNOL, V16, P521; Campieri M, 1989, ITALIAN J GASTROEN S, V21, P15; CHAPMAN RW, 1986, GUT, V27, P1210, DOI 10.1136/gut.27.10.1210; CONNELL WR, 1992, GUT               S1, V33, pS10; DANIELSSON A, 1987, SCAND J GASTROENTERO, V22, P987, DOI 10.3109/00365528708991947; DEVLIN HB, 1980, WORLD J SURG, V4, P133; ELIAKIM R, 1988, GASTROENTEROLOGY, V95, P1167, DOI 10.1016/0016-5085(88)90346-0; FORBES A, 1989, ALIMENT PHARM THERAP, V3, P353; GOERG KJ, 1987, DIGESTION, V37, P79, DOI 10.1159/000199472; HAWKEY CJ, 1983, GUT, V24, P213, DOI 10.1136/gut.24.3.213; HAWTHORNE AB, 1992, BRIT MED J, V305, P20, DOI 10.1136/bmj.305.6844.20; IRELAND A, 1989, EUR J GASTROEN HEPAT, V1, P43; JARNEROT G, 1979, SCAND J GASTROENTERO, V14, P869, DOI 10.3109/00365527909181418; JARNEROT G, 1991, GASTROENTEROL INT, V4, P93; KIRK AP, 1982, BRIT MED J, V284, P1291, DOI 10.1136/bmj.284.6325.1291; KOZAREK R A, 1990, Gastroenterology, V98, pA183; LAURITSEN K, 1986, GASTROENTEROLOGY, V91, P837, DOI 10.1016/0016-5085(86)90684-0; LAURITSEN K, 1987, INFLAMM BOWEL DIS, P89; LAURSEN LS, 1990, GUT, V31, P1271, DOI 10.1136/gut.31.11.1271; LEE DAH, 1980, GUT, V21, P215, DOI 10.1136/gut.21.3.215; LENNARDJONES JE, 1965, LANCET, V1, P188; LENNARDJONES JE, 1990, INFLAMM BOWEL DIS, P373; LICHTIGER S, 1990, LANCET, V336, P16, DOI 10.1016/0140-6736(90)91521-B; MCINTYRE PB, 1985, GUT, V26, P822, DOI 10.1136/gut.26.8.822; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MISIEWICZ JJ, 1965, LANCET, V1, P185; MOGADAM M, 1981, GASTROENTEROLOGY, V80, P72; POWELLTUCK J, 1978, SCAND J GASTROENTERO, V13, P833, DOI 10.3109/00365527809182199; POWELLTUCK J, 1981, DIGESTION, V22, P263, DOI 10.1159/000198667; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RHODES JM, 1981, GUT, V22, P642, DOI 10.1136/gut.22.8.642; ROSENBERG JL, 1975, GASTROENTEROLOGY, V69, P96; SANDBERGGERTZEN H, 1986, GASTROENTEROLOGY, V90, P1024, DOI 10.1016/0016-5085(86)90882-6; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4; TAFFET SL, 1983, DIGEST DIS SCI, V28, P833, DOI 10.1007/BF01296907; TRUELOVE SC, 1978, LANCET, V2, P1086; 1990, CURRENT PROBLEMS DEC; 1992, MONTHLY INDEX ME FEB, P30	44	6	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					35	38		10.1136/bmj.305.6844.35	http://dx.doi.org/10.1136/bmj.305.6844.35			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638200	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JC79900033
J	MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J				MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J			EFFECT OF IODINATED WATER-SOLUBLE CONTRAST-MEDIA ON URINARY PROTEIN ASSAYS	BRITISH MEDICAL JOURNAL			English	Letter							TESTS				MORCOS, SK (corresponding author), NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							DAWSON P, 1985, BRIT J RADIOL, V58, P785, DOI 10.1259/0007-1285-58-692-785-b; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mutzel W, 1989, Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd, V128, P101; SHANAHAN JC, 1985, BRIT J RADIOL, V58, P389, DOI 10.1259/0007-1285-58-688-389-b	4	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29-a	http://dx.doi.org/10.1136/bmj.305.6844.29-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638196	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JC79900029
J	WILKINSON, RG				WILKINSON, RG			FOR DEBATE - INCOME-DISTRIBUTION AND LIFE EXPECTANCY	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; HEALTH; INEQUALITIES				WILKINSON, RG (corresponding author), UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,ENGLAND.							BAKER D, 1909, INT J HLTH SCI, V1, P89; BALARAJAN R, 1990, OPCS SERIES DS, V9, P103; BEALE N, 1988, J ROY COLL GEN PRACT, V38, P200; BISHOP JA, 1989, 26 LUX INC STUD WORK; Blaxter M., 1990, HLTH LIFESTYLES; FOX J, 1990, OPCS SERIES LS, V6, P99; GOLDBLATT P, 1990, OPCS SERIES LS, V6, P163; LEGRAND J, 1987, EUR ECON REV, V31, P182, DOI 10.1016/0014-2921(87)90030-4; MACKENBACH JP, 1990, J EPIDEMIOL COMMUN H, V44, P106, DOI 10.1136/jech.44.2.106; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; MARSH C, 1988, EXPLORING DATA; MOSER K, 1990, OPCS SERIES LS, V6, P81; OHiggins M., 1990, ANAL POVERTY EUROPEA; POWER C, 1990, J R STAT SOC A STAT, V153, P17, DOI 10.2307/2983094; Preston SH, 1976, MORTALITY PATTERNS N; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; Townsend P., 1979, POVERTY UK; Townsend PP., 1988, HLTH DEPRIVATION INE; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1986, CLASS HLTH RES LONGI, P88; WILKINSON RG, 1986, CLASS HLTH, P1; 1990, HOUSEHOLDS AVERAGE I; 1990, STATE PUBLIC HLTH YE; 1991, NATIONAL ACCOUNTS MA, V1; 1990, 1990 WORLD BANK WORL; 1990, WORLD TABLES; 1986, LIVING CONDITIONS OE; [No title captured]; 1990, 1979 90 WORLD BANK W; 1979, WORLD HLTH STATISTIC	30	712	730	1	49	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					165	168		10.1136/bmj.304.6820.165	http://dx.doi.org/10.1136/bmj.304.6820.165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1637372	Green Published, Bronze			2022-12-28	WOS:A1992HA97900025
J	DOMBROSKI, BA; MATHIAS, SL; NANTHAKUMAR, E; SCOTT, AF; KAZAZIAN, HH				DOMBROSKI, BA; MATHIAS, SL; NANTHAKUMAR, E; SCOTT, AF; KAZAZIAN, HH			ISOLATION OF AN ACTIVE HUMAN TRANSPOSABLE ELEMENT	SCIENCE			English	Article							DNA-SEQUENCES; MAMMALIAN LINES; FAMILY; POLYMERASE; GENE; EVOLUTION; PHYLOGENY; PROMOTER; INVITRO; COPY	Two de novo insertions of truncated L1 elements into the factor VIII gene on the X chromosome have been identified that produced hemophilia A. A full-length L1 element that is the likely progenitor of one of these insertions was isolated by its sequence identity to the factor VII insertion. This L1 element contains two open-reading frames and is one of at least four alleles of a locus on chromosome 22 that has been occupied by an L1 element for at least 6 million years.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,CTR MED GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,CTR MED GENET,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	KAZAZIAN, HH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,CTR MED GENET,BALTIMORE,MD 21205, USA.							ADAMS JW, 1980, NUCLEIC ACIDS RES, V8, P6113, DOI 10.1093/nar/8.24.6113; [Anonymous], COMMUNICATION; Berg DE, 1989, MOBILE DNA; BRITTEN RJ, 1986, SCIENCE, V231, P1393, DOI 10.1126/science.3082006; BRITTEN RJ, 1989, P NATL ACAD SCI USA, V86, P3718, DOI 10.1073/pnas.86.10.3718; BUDARF M, IN PRESS CYTOGENET C; DOMBROSKI BA, UNPUB; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FURANO AV, 1988, NUCLEIC ACIDS RES, V16, P9215, DOI 10.1093/nar/16.19.9215; GOODMAN M, 1989, GENOME, V31, P316, DOI 10.1139/g89-050; HOLMQUIST R, 1988, MOL BIOL EVOL, V5, P217; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SINGER M, COMMUNICATION; SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457, DOI 10.1101/SQB.1986.051.01.055; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; WOODSAMUELS P, 1989, GENOMICS, V4, P290, DOI 10.1016/0888-7543(89)90332-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; [No title captured]	30	368	386	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1805	1808		10.1126/science.1662412	http://dx.doi.org/10.1126/science.1662412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1662412				2022-12-28	WOS:A1991GW31600048
J	MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH				MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH			3-DIMENSIONAL STRUCTURES OF THE LIGAND-BINDING DOMAIN OF THE BACTERIAL ASPARTATE RECEPTOR WITH AND WITHOUT A LIGAND	SCIENCE			English	Article							DIRECTED CROSS-LINKING; EPIDERMAL GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; ELECTRON-DENSITY MAP; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; SIGNAL TRANSDUCTION; SECONDARY STRUCTURE; WEISSENBERG CAMERA; TAR CHEMORECEPTOR	The three-dimensional structure of an active, disulfide cross-linked dimer of the ligand-binding domain of the Salmonella typhimurium aspartate receptor and that of an aspartate complex have been determined by x-ray crystallographic methods at 2.4 and 2.0 angstrom (angstrom) resolution, respectively. A single subunit is a four-alpha-helix bundle with two long amino-terminal and carboxyl-terminal helices and two shorter helices that form a cylinder 20 angstrom in diameter and more than 70 angstrom long. The two subunits in the disulfide-bonded dimer are related by a crystallographic twofold axis in the apo structure, but by a noncrystallographic twofold axis in the aspartate complex structure. The latter structure reveals that the ligand binding site is located more than 60 angstrom from the presumed membrane surface and is at the interface of the two subunits. Aspartate binds between two alpha-helices from one subunit and one alpha-helix from the other in a highly charged pocket formed by three arginines. The comparison of the apo and aspartate complex structures shows only small structural changes in the individual subunits, except for one loop region that is disordered, but the subunits appear to change orientation relative to each other. The structures of the two forms of this protein provide a step toward understanding the mechanisms of transmembrane signaling.	UNIV CALIF BERKELEY, DEPT BIOCHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Privé, Gilbert G/A-3039-2008	Prive, Gilbert/0000-0002-0712-4319; Scott, William/0000-0002-9273-3564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30725] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; ARGOS P, 1977, BIOCHEM BIOPH RES CO, V75, P83, DOI 10.1016/0006-291X(77)91292-X; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BIEMANN HP, UNPUB; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1990, XPLOR VERSION 21; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; IMAE Y, 1987, J BACTERIOL, V169, P371, DOI 10.1128/jb.169.1.371-379.1987; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)80198-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LYNCH BA, IN PRESS P NATL ACAD; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, IN PRESS SCIENCE; MILLIGAN DL, UNPUB; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOE GR, 1986, MICROBIAL ENERGY TRA, P163; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WARK KB, 1975, NATURE, V257, P818; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YAMAMOTO T, 1984, CELL, V33, P615; 1979, SERK4 DAR LAB COLL C	47	395	399	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1342	1347		10.1126/science.1660187	http://dx.doi.org/10.1126/science.1660187			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1660187	Green Submitted			2022-12-28	WOS:A1991GR77700045
J	DYCK, PJ; LOW, PA; WINDEBANK, AJ; JARADEH, SS; GOSSELIN, S; BOURQUE, P; SMITH, BE; KRATZ, KM; KARNES, JL; EVANS, BA; PINEDA, AA; OBRIEN, PC; KYLE, RA				DYCK, PJ; LOW, PA; WINDEBANK, AJ; JARADEH, SS; GOSSELIN, S; BOURQUE, P; SMITH, BE; KRATZ, KM; KARNES, JL; EVANS, BA; PINEDA, AA; OBRIEN, PC; KYLE, RA			PLASMA-EXCHANGE IN POLYNEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; PERIPHERAL-NERVE MYELIN; CELL DYSCRASIA; CLINICAL CHARACTERISTICS; NEUROPATHY; IGM; PARAPROTEINEMIA; IMMUNOGLOBULIN; AMYLOIDOSIS	Background. Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) has been treated with plasma exchange, intravenous immune globulin, and chemotherapy, but the effectiveness of these treatments remains uncertain. Methods. We randomly assigned 39 patients with stable or worsening neuropathy and MGUS of the IgG, IgA, or IgM type to receive either plasma exchange twice weekly for three weeks or sham plasma exchange, in a double-blind trial. The patients who initially underwent sham plasma exchange subsequently underwent plasma exchange in an open trial. Results. In the double-blind trial, the average neuropathy disability score improved by 2 points from base line (from 62.5 to 60.5) in the sham-exchange group and by 12 points (from 58.3 to 46.3) in the plasma-exchange group (P = 0.06). A similar difference was observed in the weakness score, a component of the neuropathy disability score (improvement, 1 and 10 points, respectively; P = 0.07). After treatment the summed compound muscle action potentials of motor nerves were 1.2 mV lower (worse) than at base line in the sham-exchange group and 0.4 mV higher (better) in the plasma-exchange group (P = 0.07). The greater degree of improvement with plasma exchange was equal in magnitude to or greater than the difference between not being able to walk on the heels or toes and being able to perform these activities. Changes in the vibratory detection threshold, summed motor-nerve conduction velocity, and sensory-nerve action potentials did not differ significantly between the treatment groups. In the open trial, in which patients who initially underwent sham exchange were treated with plasma exchange, the neuropathy disability score (P = 0.04), weakness score (P = 0.07), and summed compound muscle action potentials (P = 0.07) improved more with plasma exchange than they had with sham exchange. In both the double-blind and the open trial, those with IgG or IgA gammopathy had a better response to plasma exchange than those with IgM gammopathy. Conclusions. Plasma exchange appears to be efficacious in neuropathy associated with MGUS, especially of he IgG or IgA type.	MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,TRANSFUS MED SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV HEMATOL & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN,NEUROL SECT,SCOTTSDALE,AZ	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	DYCK, PJ (corresponding author), MAYO CLIN & MAYO FDN,PERIPHERAL NEUROPATHY RES LABS,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ABRAMS GM, 1982, NEUROLOGY, V32, P821, DOI 10.1212/WNL.32.8.821; BAROHN RJ, 1989, ARCH NEUROL-CHICAGO, V46, P878, DOI 10.1001/archneur.1989.00520440064022; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; COLLINS JA, 1974, SURGERY, V75, P274; CREAM JJ, 1974, J NEUROL NEUROSUR PS, V37, P82, DOI 10.1136/jnnp.37.1.82; DALAKAS MC, 1981, ANN NEUROL, V10, P45, DOI 10.1002/ana.410100109; DALAKAS MC, 1980, ARCH NEUROL-CHICAGO, V37, P637, DOI 10.1001/archneur.1980.00500590061010; DELLAGI K, 1983, BLOOD, V62, P280; DELLAGI K, 1984, PRESSE MED, V13, P1199; DYCK PJ, 1980, ANN NEUROL, V8, P590, DOI 10.1002/ana.410080608; DYCK PJ, 1975, MAYO CLIN PROC, V50, P621; DYCK PJ, 1989, DIABETES CARE, V12, P649, DOI 10.2337/diacare.12.9.649; DYCK PJ, 1986, NEW ENGL J MED, V314, P461, DOI 10.1056/NEJM198602203140801; DYCK PJ, 1990, NEUROLOGY, V40, P1607, DOI 10.1212/WNL.40.10.1607; Dyck PJ, 1984, PERIPHERAL NEUROPATH, VII, P2101; DYCK PJ, 1984, PERIPHERAL NEUROPATH, V1, P1103; FERRI C, 1986, RES CLIN LAB, V16, P403; GOSSELIN S, 1991, ANN NEUROL, V30, P54, DOI 10.1002/ana.410300111; HAFLER DA, 1986, NEUROLOGY, V36, P75, DOI 10.1212/WNL.36.1.75; KELLY JJ, 1979, ANN NEUROL, V6, P1, DOI 10.1002/ana.410060102; KELLY JJ, 1981, NEUROLOGY, V31, P24, DOI 10.1212/WNL.31.1.24; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KELLY JJ, 1981, NEUROLOGY, V31, P1480, DOI 10.1212/WNL.31.11.1480; KYLE RA, 1975, MEDICINE, V54, P271; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; LATOV N, 1981, P NATL ACAD SCI-BIOL, V78, P7139, DOI 10.1073/pnas.78.11.7139; LATOV N, 1980, NEW ENGL J MED, V303, P618, DOI 10.1056/NEJM198009113031105; LATOV N, 1981, NEUROLOGY, V31, P1530, DOI 10.1212/WNL.31.12.1530; LOGOTHETIS J, 1960, ARCH NEUROL-CHICAGO, V3, P564, DOI 10.1001/archneur.1960.00450050084010; LOGOTHETIS J, 1968, ARCH NEUROL-CHICAGO, V19, P389, DOI 10.1001/archneur.1968.00480040055005; MELMED C, 1983, NEUROLOGY, V33, P1397, DOI 10.1212/WNL.33.11.1397; NOBILEORAZIO E, 1986, NEUROLOGY, V36, P305; NUSBACHER J, 1981, P WORKSHOP THERAPEUT, P105; PINEDA AA, 1981, P WORKSHOP THERAPEUT, P1; PRINEAS JW, 1976, J NEUROL SCI, V27, P427, DOI 10.1016/0022-510X(76)90213-6; SHERMAN WH, 1984, J NEUROL NEUROSUR PS, V47, P813, DOI 10.1136/jnnp.47.8.813; SMITH IS, 1983, BRAIN, V106, P169, DOI 10.1093/brain/106.1.169; STECK AJ, 1983, NEUROLOGY, V33, P19, DOI 10.1212/WNL.33.1.19; STECK AJ, 1987, ANN NEUROL, V22, P764, DOI 10.1002/ana.410220614; TAKATSU M, 1985, ANN NEUROL, V18, P173, DOI 10.1002/ana.410180203; TOYKA KV, 1982, MUSCLE NERVE, V5, P479, DOI 10.1002/mus.880050610; VITAL C, 1975, Annales d'Anatomie Pathologique, V20, P93; WALDENSTROM JG, 1978, ACTA MED SCAND, V203, P297; WALSH JC, 1971, ARCH NEUROL-CHICAGO, V25, P404, DOI 10.1001/archneur.1971.00490050038003; WINDEBANK A J, 1987, P100	45	237	237	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1482	1486		10.1056/NEJM199111213252105	http://dx.doi.org/10.1056/NEJM199111213252105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1658648	Bronze			2022-12-28	WOS:A1991GQ40600005
J	HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H				HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H			EDITING OF A CHLOROPLAST MESSENGER-RNA BY CREATION OF AN INITIATION CODON	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; PLANT-MITOCHONDRIA; GENE ORGANIZATION; DNA-SEQUENCE; GENOME; MAIZE; MAP	PRIMARY mRNA transcripts in several systems are edited by single base substitutions, small deletions or insertions to yield functional messenger RNA species 1,2. Mitochondrial mRNAs in particular, including those from plants 3-5, seem to be the subject of extensive editing, unlike mRNAs encoded by chloroplast DNA, for which the prediction of amino-acid sequence from the corresponding gene sequence is generally unambiguous 6-8. Occasionally, however, an ACG codon appears at the 5' terminus of chloroplast genes, where the initiation codon ATG would be expected. Here we present evidence for a C --> U editing that is responsible for the conversion of the ACG codon to an AUG initiation codon in the mRNA transcript from the rpl2 gene of the maize plastome, showing that mRNA editing can also occur in chloroplasts.			HOCH, B (corresponding author), UNIV FREIBURG,INST BIOL 3,SCHANZLE STR 1,W-7800 FREIBURG,GERMANY.		/ABF-9144-2020					ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KAVOUSI M, 1990, NUCLEIC ACIDS RES, V18, P4244, DOI 10.1093/nar/18.14.4244; LARRINUA IM, 1983, PLANT MOL BIOL, V2, P129, DOI 10.1007/BF01578513; LONSDALE DM, 1983, CELL, V34, P1007, DOI 10.1016/0092-8674(83)90558-5; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PRUITT KD, 1991, CURR GENET, V19, P191, DOI 10.1007/BF00336486; SCHUSTER W, 1991, PHYSIOL PLANTARUM, V81, P437, DOI [10.1111/j.1399-3054.1991.tb08754.x, 10.1034/j.1399-3054.1991.810321.x]; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1986, NUCLEIC ACIDS RES, V14, P5651, DOI 10.1093/nar/14.14.5651; [No title captured]	18	263	290	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					178	180		10.1038/353178a0	http://dx.doi.org/10.1038/353178a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653905				2022-12-28	WOS:A1991GE73100057
J	FRIEDMAN, J; WEISSMAN, I				FRIEDMAN, J; WEISSMAN, I			2 CYTOPLASMIC CANDIDATES FOR IMMUNOPHILIN ACTION ARE REVEALED BY AFFINITY FOR A NEW CYCLOPHILIN - ONE IN THE PRESENCE AND ONE IN THE ABSENCE OF CSA	CELL			English	Article							A-BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; T-CELL ACTIVATION; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; GENE; CDNA	We report the cloning and characterization of a new binding protein for the immunosuppressive drug cyclosporin A (CsA). This new cyclophilin, cyclophilin C (cyp C), shows extensive homology with all previously identified cyclophilins. Cyp C mRNA is expressed in a restricted subset of tissues relative to cyclophilins A and B, but is present in those tissues reported to be most affected by CsA therapy. A cyp C fusion protein has peptidyl-prolyl isomerase activity, and CsA inhibits this activity. Using the cyp C fusion protein as an affinity ligand to probe cellular extracts, we find that the cyp C fusion protein binds specifically to a 77 kd protein in the absence of CsA, while in the presence of CsA it instead binds specifically to a 55 kd protein. We propose that the p77 is involved in cyp C native function and that the p55 is involved in signal transduction events blocked by treatment with immunosuppressive levels of CsA.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University	FRIEDMAN, J (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305, USA.				NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DURETTE PL, 1988, TRANSPLANT P, V20, P51; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; KOLETSKY A, 1986, J IMMUNOL, V1307, P1054; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; PROTEUS MH, 1991, IN PRESS MOL BRAIN R; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5643; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES LMA, 1991, CELL, V65, P219; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4	35	389	416	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					799	806		10.1016/0092-8674(91)90123-G	http://dx.doi.org/10.1016/0092-8674(91)90123-G			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652374				2022-12-28	WOS:A1991GC74500018
J	MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM				MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM			A DIRECT REPEAT IN THE CELLULAR RETINOL-BINDING PROTEIN TYPE-II GENE CONFERS DIFFERENTIAL REGULATION BY RXR AND RAR	CELL			English	Article							ACID-RESPONSIVE ELEMENT; THYROID-HORMONE; NUCLEAR RECEPTORS; SMALL-INTESTINE; BETA-GENE; EXPRESSION; IDENTIFICATION; CLONING	The vitamin A derivative retinoic acid exerts its effects on transcription through two distinct classes of nuclear receptors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). We provide evidence that expression of the gene for cellular retinol-binding protein type II (CRBPII), a key protein in the intestinal absorption of vitamin A, is dramatically up-regulated by retinoic acid in the presence of RXR but not RAR. This regulation is conferred through a specific cis element in the CRBPII promoter that contains five nearly perfect tandem repeats of the sequence AGGTCA spaced by a single nucleotide. The discovery of this new RX response element provides a means for distinguishing between the two retinoid receptor systems and suggests that an RXR-mediated pathway exists for modulating vitamin A metabolism.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	MANGELSDORF, DJ (corresponding author), HOWARD HUGHES MED INST,LA JOLLA,CA 92186, USA.		Evans, Ronald/AAF-4001-2019; Borgmeyer, Uwe/D-4662-2012	Evans, Ronald/0000-0002-9986-5965; Borgmeyer, Uwe/0000-0003-3727-4083; Mangelsdorf, David/0000-0002-4355-0796				BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1991, TRANSCRIPTIONAL REGU; ONG DE, 1987, ARCH DERMATOL, V123, P1693, DOI 10.1001/archderm.123.12.1693; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559	29	622	659	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					555	561		10.1016/0092-8674(81)90018-0	http://dx.doi.org/10.1016/0092-8674(81)90018-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651173				2022-12-28	WOS:A1991GA94100016
J	JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC				JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC			REGULATION OF B-CELL ANTIGEN RECEPTOR SIGNAL TRANSDUCTION AND PHOSPHORYLATION BY CD45	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LEUKOCYTE-COMMON ANTIGEN; MURINE LYMPHOCYTES-B; HUMAN T-CELLS; MOLECULAR-COMPONENTS; ACTIVATION; IGM; PHOSPHATASE; ANTIBODIES; T200	CD45 is a member of a family of membrane proteins that possess phosphotyrosine phosphatase activity, and is the source of much of the tyrosine phosphatase activity in lymphocytes. In view of its enzymatic activity and high copy number, it seems likely that CD45 functions in transmembrane signal transduction by lymphocyte receptors that arc coupled to activation of tyrosine kinases. The B cell antigen receptor was found to transduce a Ca2+-mobilizing signal only if cells expressed CD45. Also, both membrane immunoglobulin M (mIgM) and CD45 were lost from the surface of cells treated with antibody to CD45, suggesting a physical interaction between these proteins. Finally, CD45 dephosphorylated a complex of mIg-associated proteins that appears to function in signal transduction by the antigen receptor. These data indicate that CD45 occurs as a component of a complex of proteins associated with the antigen receptor, and that CD45 may regulate signal transduction by modulating the phosphorylation state of the antigen receptor subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X; Justement, Louis/0000-0001-7058-867X	NIAID NIH HHS [AI20519, AI21768] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021768, R01AI020519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRAMEAS S, 1979, J IMMUNOL, V122, P648; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P399; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, IN PRESS P NATL ACAD; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, UNPUB; KIENER PA, 1989, J IMMUNOL, V143, P23; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MIRE AR, 1985, BIOCHIM BIOPHYS ACTA, V847, P159, DOI 10.1016/0167-4889(85)90169-7; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P153; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	35	308	314	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1839	1842		10.1126/science.1648262	http://dx.doi.org/10.1126/science.1648262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648262				2022-12-28	WOS:A1991FU06100037
J	OTOOLE, M				OTOOLE, M			OTOOLE RE-CHALLENGES	NATURE			English	Editorial Material																		EISEN, 1991, NATURE, V351, P343; 1991, NATURE, V351, P180	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					692	693		10.1038/351692a0	http://dx.doi.org/10.1038/351692a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648174				2022-12-28	WOS:A1991FU20100031
J	FEKSI, AT; KAAMUGISHA, J; SANDER, JWAS; GATITI, S; SHORVON, SD				FEKSI, AT; KAAMUGISHA, J; SANDER, JWAS; GATITI, S; SHORVON, SD			COMPREHENSIVE PRIMARY HEALTH-CARE ANTIEPILEPTIC DRUG-TREATMENT PROGRAM IN RURAL AND SEMIURBAN KENYA	LANCET			English	Article							EPILEPSY; PROGNOSIS	A programme of antiepileptic treatment in a rural and semi-urban region in Kenya was assessed. Patients with generalised tonic-clonic seizures were treated according to one of two simple drug protocols. Health workers screened cases reported by key informants in the community. From the 529 patients identified by health workers as having active seizures 302 patients aged 6-65 years were recruited by a psychiatrist for therapy with carbamazepine or phenobarbitone. Treatment was supervised largely by primary health workers, and the programme was monitored by a research team, which assessed the effectiveness of treatment. Of the 249 patients who completed the study, 53% became seizure-free in the second 6 months of therapy, and another 26% had substantially (50% or more reduction) fewer seizures than in the 6 months before therapy. The similarity of these findings to those obtained in newly diagnosed patients in the developed world, the low drop-out rate, the low rate of withdrawal due to adverse effects, and the acceptable compliance with therapy indicate that health workers can monitor therapy adequately. Most patients had had several years of delay before starting therapy for their epilepsy, yet they responded well - a finding that does not support the suggestion that the disorder becomes intractable if not treated early.	INST NEUROL,LONDON WC1N 3BG,ENGLAND; NATL HOSP,CHALFONT CTR EPILEPSY,GERRARDS CROSS,ENGLAND; CIBA GEIGY CORP,REG MED CTR,NAIROBI,KENYA	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	FEKSI, AT (corresponding author), PROV GEN HOSP,RIFT VALLEY PROV,POB 71,NAKURU,KENYA.		Shorvon, Simon D/A-2019-2009; Sander, Josemir W/C-1576-2008	Sander, Josemir W/0000-0001-6041-9661; Shorvon, Simon/0000-0003-0313-2001				ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; FEKSI AT, IN PRESS EPILEPSY RE; KAAMUGISHA J, 1988, NEUROEPIDEMIOLOGY, V7, P115, DOI 10.1159/000110144; MATSON RH, 1985, NEW ENGL J MED, V313, P145; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; SHORVON SD, 1988, EPILEPSIA, V29, pS36, DOI 10.1111/j.1528-1157.1988.tb05790.x; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SHORVON SD, 1982, THESIS U CAMBRIDGE; SHORVON SD, 1987, MORE DILEMMAS MANAGE, P8; SHORVON SD, 1982, BRIT MED J, V285, P1169; WATTS AE, 1989, BRIT MED J, V298, P805, DOI 10.1136/bmj.298.6676.805; 1985, COMMUNITY CONTROL EP	12	147	147	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					406	409		10.1016/0140-6736(91)91176-U	http://dx.doi.org/10.1016/0140-6736(91)91176-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX605	1671434				2022-12-28	WOS:A1991EX60500014
J	REBULLA, P; MODELL, B				REBULLA, P; MODELL, B			TRANSFUSION REQUIREMENTS AND EFFECTS IN PATIENTS WITH THALASSEMIA MAJOR	LANCET			English	Article							THALASSEMIA; MANAGEMENT	Analysis of data available in 1985 on 3468 Italian and Greek patients registered in Cooleycare, an international cooperative programme of quality assessment of treatment delivery in thalassaemia, gave the following picture of treatment requirements and effects. The proportion of patients undergoing splenectomy has progressively decreased, and age at splenectomy has increased with time over the past 20 years. Age at first transfusion exceeds 4 years in a small but important group of patients, which indicates that a milder form of thalassaemia exists in this group. Children receiving modern treatment remain of near-normal stature until age 11 but later tend to e stunted. The mean blood requirement is 35% higher in non-splenectomised than in splenectomised patients. Differences in transfusion interval of 2 to 4 weeks have no measurable effect on measurable effect on blood requirement. Mean blood requirement rises gradually with mean haemoglobin concentration, possibly in a non-linear fashion. The prevalence of red cell alloimmunisation rises with delay in start on transfusion. Transfusion reactions were reported in 1% of transfusions (90% of which were leucocyte-depleted), from 17% of patients.	UNIV COLL & MIDDLESEX SCH MED,CTR PERINATAL,LONDON,ENGLAND	University of London; University College London	REBULLA, P (corresponding author), OSPED POLICLIN,CTR TRASFUS & IMMUNOL TRAPIANTI,VIA FRANCESCO SFORZA 35,I-20122 MILAN,ITALY.		Rebulla, Paolo/I-7684-2015	Rebulla, Paolo/0000-0002-3875-5754				CAO A, 1987, THALASSEMIA TODAY ME, P633; GABUTTI V, 1982, ARCH DIS CHILD, V57, P156, DOI 10.1136/adc.57.2.156; MICHAILMERIANOU V, 1987, VOX SANG, V52, P95, DOI 10.1111/j.1423-0410.1987.tb02999.x; MODELL B, 1977, ARCH DIS CHILD, V52, P489, DOI 10.1136/adc.52.6.489; Modell B., 1984, CLIN APPROACH THALAS; PIGA A, 1982, RIV ITAL PED, V8, P823; PIOMELLI S, 1974, ANN NY ACAD SCI, V232, P186, DOI 10.1111/j.1749-6632.1974.tb20584.x; PROPPER RD, 1980, BLOOD, V55, P55; REBULLA P, 1987, THALASSAEMIA TODAY M, P31; WOLMAN IJ, 1964, ANN NY ACAD SCI, V119, P736; 1987, WHO IPCMCH110 REG OF	11	63	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					277	280		10.1016/0140-6736(91)90881-O	http://dx.doi.org/10.1016/0140-6736(91)90881-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671122				2022-12-28	WOS:A1991EV71900014
J	GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL				GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL			EVALUATION OF NEUROLEPTIC DRUG-USE BY NURSING-HOME ELDERLY UNDER PROPOSED MEDICARE AND MEDICAID REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE MEDICATION; CARE; RESIDENTS; FACILITIES	Federal regulations for use of neuroleptic drugs in Medicare- and Medicaid-certified nursing homes throughout the United States were implemented October 1, 1990. These regulations constitute the first time that prescription drugs are required, by law, to be justified by indications documented in the medical chart. This study used extant data to estimate ineligible neuroleptic use at the individual and nursing home levels had these regulations been in effect in 1976 through 1985. Subjects, randomly sampled admissions (N = 5752) and residents (N = 3191), were followed up for up to 24 months in 60 nursing homes. One half of neuroleptic use in each cohort could be considered ineligible under the regulations; all but one of the nursing homes had one or more individuals who were treated with the ineligible use of neuroleptics. Improvements in documentation and/or prescription of neuroleptic drugs for nursing home elderly will be needed to ensure compliance with these new regulations.	UNIV MINNESOTA,SCH STAT,DEPT APPL STAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL EDUC,DEPT EDUC PSYCHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL PHARM,DEPT PHARM PRACTICE,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,DEPT CLIN PHARM,ST PAUL,MN 55101; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; UNIV WASHINGTON,WASHINGTON INST MENTAL ILLNESS TRAINING & RES,SEATTLE,WA 98195	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	GARRARD, J (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV HLTH SERV RES & POLICY,420 DELAWARE ST SE,BOX 729 MAYO,MINNEAPOLIS,MN 55455, USA.			Zelterman, Daniel/0000-0003-0711-8688	NATIONAL INSTITUTE ON AGING [K01AG000434] Funding Source: NIH RePORTER; NIA NIH HHS [1KO1-AG 000434-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1978, INT CLASSIFICATION D; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BUCK JA, 1989, AM J MENT RETARD, V93, P618; BURNS BJ, 1988, J FAM PRACTICE, V26, P155; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; Goodman L.S., 1980, PHARM BASIS THERAPEU, V6th; HILL BK, 1985, PSYCHOPHARMACOL BULL, V21, P279; Institute of Medicine report, 1986, IMPROVING QUALITY CA; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1989, NURSING HOMES NURSIN, P37; Kepferle L, 1983, J Long Term Care Adm, V11, P54; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; 1976, US DHEW MONOGRAPH, V2; 1988, ADVERSE DRUG REACT, P100; 1989, FED REG         0202, V54, P5316; 1986, DRUG EVALUATIONS	20	82	82	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					463	467		10.1001/jama.265.4.463	http://dx.doi.org/10.1001/jama.265.4.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1670645				2022-12-28	WOS:A1991ET37700023
J	POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V				POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V			MOLECULAR-BASIS OF DIFFERENT FORMS OF METACHROMATIC LEUKODYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARYLSULFATASE-A; PSEUDODEFICIENCY; JUVENILE	Background. Metachromatic leukodystrophy is an autosomal recessive inherited lysosomal storage disorder caused by a deficiency or arylsulfatase A. Three forms of the disease can be distinguished according to severity and the age at onset: late infantile (1 to 2 years), juvenile (3 to 16), and adult (> 16). Methods and Results. To understand the molecular basis of the different forms of the disease, we analyzed arylsulfatase A alleles associated with metachromatic leukodystrophy. Two alleles (termed I and A) were identified and accounted for about half of all arylsulfatase A alleles among 68 patients with metachromatic leukodystrophy whom we examined. Sufficient information was available for 66 of the patients to allow classification of their disease. Of the six instances of homozygosity for allele I, all were associated with the late-infantile form of the disease; of the eight instances of homozygosity for allele A, five were associated with the adult form and three with the juvenile form. When both alleles were present, the juvenile form resulted (seven of seven instances). Heterozygosity for allele I (with the other allele unknown) is usually associated with late-infantile disease, and heterozygosity for allele A with a later onset of the disease. The clinical variability can be explained by the different levels of residual arylsulfatase A activity associated with these genotypes. Conclusions. Like many lysosomal storage disorders, metachromatic leukodystrophy shows clinical heterogeneity that seems to reflect genetic heterogeneity. One of the known alleles (allele I) is associated with earlier and more severe disease than the other (allele A).	UNIV GOTTINGEN,DEPT BIOCHEM 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY	University of Gottingen								CLARKE JTR, 1989, AM J MED GENET, V33, P10, DOI 10.1002/ajmg.1320330104; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GIESELMANN V, IN PRESS HUM GENET; GUSTAVSON KH, 1971, ACTA PAEDIATR SCAND, V60, P585, DOI 10.1111/j.1651-2227.1971.tb06994.x; HERZ B, 1984, HUM GENET, V66, P147, DOI 10.1007/BF00286589; HOHENSCHUTZ C, 1988, AM J MED GENET, V31, P169, DOI 10.1002/ajmg.1320310120; HOHENSCHUTZ C, 1989, HUM GENET, V82, P45, DOI 10.1007/BF00288270; KAPPLER J, IN PRESS HUM GENET; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOLODNY EH, 1989, METABOLIC BASIS INHE, V2, P1721; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; STEIN C, 1989, J BIOL CHEM, V264, P1252; TABOR S, 1987, CURRENT PROTOCOLS MO; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066	15	229	234	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					18	22		10.1056/NEJM199101033240104	http://dx.doi.org/10.1056/NEJM199101033240104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1670590	Bronze			2022-12-28	WOS:A1991EQ50300004
J	FUCHS, VR				FUCHS, VR			THE BEST HEALTH-CARE SYSTEM IN THE WORLD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									STANFORD UNIV,STANFORD,CA 94305	Stanford University	FUCHS, VR (corresponding author), NATL BUR ECON RES,204 JUNIPERO SERRA BLVD,STANFORD,CA 94305, USA.							Ikegami N, 1989, Int J Health Plann Manage, V4, P181, DOI 10.1002/hpm.4740040305; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268	3	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					916	917		10.1001/jama.268.7.916	http://dx.doi.org/10.1001/jama.268.7.916			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640624				2022-12-28	WOS:A1992JH58800046
J	MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H				MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H			TRENDS IN MORTALITY, MORBIDITY, AND RISK FACTOR LEVELS FOR STROKE FROM 1960 THROUGH 1990 - THE MINNESOTA HEART SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROVASCULAR-DISEASE; SURVEY EXPERIENCE; DECLINE; POPULATION; SURVIVAL	Objective.-The Minnesota Heart Survey is a population-based study designed to monitor and explain trends in cardiovascular mortality, morbidity, and risk factors. Design.-Surveillance time-trends study. Methods.-The following trends were examined among men and women aged 25 to 74 years living in Minneapolis-St Paul, Minn: (1) stroke mortality from 1960 through 1990; (2) risk factors in population-based surveys conducted in 1973 through 1974, 1980 through 1982, and 1985 through 1987; and (3) morbidity in a 50% sample of hospitalized discharges for acute-stroke in 1970, 1980, and 1985. Results.-Stroke mortality in Minneapolis-St Paul declined slowly from 1960 through 1972 (average fall, 2.4% per year), dropped sharply from 1972 through 1984 (average fall, 6.5% per year), but exhibited little change thereafter (average fall, 1.5% per year). The average level of cardiovascular disease risk factors fell from 1973-1974 to 1985-1987, with the exception of body mass index. In particular, hypertension diagnosis, treatment, and control levels improved substantially between 1973-1974 and 1980-1982, although there was little improvement after 1980-1982. While discharge rates for hospital-coded acute stroke declined substantially between 1970 and 1985 in both sexes, no clear trend was observed in definite stroke rates as validated using standard clinical criteria. Twenty-eight-day case fatality rates of definite stroke improved significantly from 1970 to 1985. Conclusions.-The substantial decline in stroke mortality of more than 50% from 1960 through 1990 appears to have been attributable to both primary and secondary prevention. These data suggest that the long decline in stroke mortality and morbidity in Minneapolis-St Paul has plateaued, although improved detection of stroke with computed tomography prevents an unequivocal conclusion.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	MCGOVERN, PG (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLER J, 1991, SEMIN NEUROL, V11, P353, DOI 10.1055/s-2008-1041240; Bonita R, 1989, HYPERTENSION S1, V3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; DAWSON DA, 1987, VITAL HLTH STAT, V10, P164; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GILLUM RF, 1986, STROKE, V17, P656, DOI 10.1161/01.STR.17.4.656; GILLUM RF, 1985, J CHRON DIS, V38, P8911; GRAVES EJ, 1984, PHS100 US DEP HLTH H; HOWARD G, 1989, STROKE, V20, P345, DOI 10.1161/01.STR.20.3.345; JACOBS DR, 1980, J CHRON DIS, V33, P395, DOI 10.1016/0021-9681(80)90037-5; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; ROSE G, 1991, CIRCULATION, V84, P1405, DOI 10.1161/01.CIR.84.3.1405; ROTHROCK JF, 1991, ANN INTERN MED, V115, P885, DOI 10.7326/0003-4819-115-11-885; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; TILLINGHAST SJ, 1991, AM J EPIDEMIOL, V134, P851, DOI 10.1093/oxfordjournals.aje.a116160; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; 1976, PHS871232 US DEP HLT, P125; 1967, MANUAL INT STATISTIC; 1957, MANUAL INT STATISTIC; 1990, WORLD HLTH STATISTIC; 1975, INT CLASSIFICATION 2, V66; [No title captured]; 1987, JAMA-J AM MED ASSOC, V257, P937; 1980, MONTHLY VITAL STAT S, V28, P1; 1992, MONTHLY VITAL STA S2, V40, P1; 1989, SAS STAT GUIDE; 1989, MMWR, V38, P194; 1972, PHS861684 US DEP 11	33	128	131	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					753	759						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640576				2022-12-28	WOS:A1992JG66600017
J	CAMERON, D; BISHOP, C				CAMERON, D; BISHOP, C			FARM ACCIDENTS IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article											CAMERON, D (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP,NEWBORN SERV,VANCOUVER V6H 3V4,BC,CANADA.							DOYLE Y, 1989, J R SOC HLTH, V4, P128; MAY JJ, 1990, AM J IND MED, V18, P121, DOI 10.1002/ajim.4700180205; 1989, CENSUS 1989; 1986, AGR BLACK SPOT; 1991, 1990 1991 HLTH SAF C	5	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					25	26		10.1136/bmj.305.6844.25	http://dx.doi.org/10.1136/bmj.305.6844.25			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638193	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JC79900024
J	GRAHAM, HJ; FIRTH, J				GRAHAM, HJ; FIRTH, J			HOME ACCIDENTS IN OLDER-PEOPLE - ROLE OF PRIMARY HEALTH-CARE TEAM	BRITISH MEDICAL JOURNAL			English	Article							FALLS	Objectives-To determine the incidence and nature of unreported and reported home accidents in older people and to investigate associated environmental factors. Design-Postal questionnaire requesting information on home accidents in the preceding month. Setting-Inner London general practice. Subjects-All registered patients aged over 65 years (n=1662), of whom 120 were inappropriately registered and 1293 responded. Main outcome measure-Circumstances and consequences of accidents in the home. Results-108 accidents were recorded in 100 patients, giving a home accident rate of 84/1000 patients, equivalent to an annual rate of 1002/1000. 73 accidents were falls, and 83 were unreported. Of the 25 reported accidents, 19 were reported to general practice and six to accident and emergency departments (5.6% of all events). Rates of home accidents increased with age and were higher in women than men (79/819 v 29/474; chi-2=4.5, df=1, p<0.05). Conclusions-The incidence of home accidents in people aged over 65 years was high but few events were reported to medical services. General practice provided the main contact for patients who reported home accidents, and primary care workers have important opportunities for advising elderly patients on home accident prevention. Improved publicity on home safety targeted at older people and their carers would support the primary health care team in this role.			GRAHAM, HJ (corresponding author), FOREST HILL RD GRP PRACTICE,LONDON SE22 0SQ,ENGLAND.							CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; FINSEN V, 1988, J EPIDEMIOL COMMUN H, V42, P200, DOI 10.1136/jech.42.2.200; GLOAG D, 1987, C STRATEGIES ACCIDEN; Gray Barbara, 1966, HOME ACCIDENTS OLDER; LIVESLEY B, 1984, BRIT MED J, V289, P568, DOI 10.1136/bmj.289.6445.568; LIVESLEY B, 1989, FUNNY TURNS EPISODIC; Swift, 1990, REV RES FALLS ELDERL; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; 1989, SAFETY ELDERLY PEOPL; 1989, HOME LEISURE ACCIDEN; 1990, NATIONAL C WORKSHOPS; 1990, BMJ, V300, P104; 1988, PREVENTION ACCIDENTS; 1983, GENERAL HOUSEHOLD SU, V6, P138; 1987, HOSPITAL IN PATIENT; 1986, HOME LEISURE ACCIDEN	16	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					30	32		10.1136/bmj.305.6844.30	http://dx.doi.org/10.1136/bmj.305.6844.30			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638198	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JC79900031
J	ROJAS, CV; WANG, JZ; SCHWARTZ, LS; HOFFMAN, EP; POWELL, BR; BROWN, RH				ROJAS, CV; WANG, JZ; SCHWARTZ, LS; HOFFMAN, EP; POWELL, BR; BROWN, RH			A MET-TO-VAL MUTATION IN THE SKELETAL-MUSCLE NA+ CHANNEL ALPHA-SUBUNIT IN HYPERKALEMIC PERIODIC PARALYSIS	NATURE			English	Article							SODIUM-CHANNEL; CDNA SEQUENCE; RAT-BRAIN; GENE; EXPRESSION; DROSOPHILA	HYPERKALAEMIC periodic paralysis (HYPP) 1 is an autosomal dominant disease that results in episodic electrical inexcitability and paralysis of skeletal muscle. Electrophysiological data indicate that tetrodotoxin-sensitive sodium channels from muscle cells of HYPP-affected individuals show abnormal inactivation 2,3. Genetic analysis of nine HYPP families has shown tight linkage between the adult skeletal muscle sodium channel alpha-subunit gene on chromosome 17q and the disease (lod score, z = 24; recombination frequency theta = 0) 4-6, strongly suggesting that mutations of the alpha-subunit gene cause HYPP. We sequenced the alpha-subunit coding region isolated from muscle biopsies from affected (familial HYPP) and control individuals by cross-species polymerase chain reaction-mediated complementary DNA cloning. We have identified an A --> G substitution in the patient's messenger RNA that causes a Met --> Val change in a highly conserved region of the alpha-subunit, predicted to be in a transmembrane domain. This same change was found in a sporadic case of HYPP as a new mutation. We have therefore discovered a voltage-gated channel mutation responsible for a human genetic disease.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT HUMAN GENET,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261; OREGON HLTH SCI UNIV,PEDIAT METAB LAB,PORTLAND,OR 97201	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Oregon Health & Science University				Schwartz, Lisa/0000-0003-4981-4948; Hoffman, Eric/0000-0001-6470-5139				CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GAMSTORP I, 1956, ACTA PAEDIATRICA, V45, P657; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOCH MC, 1991, J MED GENET, V28, P583, DOI 10.1136/jmg.28.9.583; KOCH MC, IN PRESS HUM GENET; LEHMANNHORN F, 1991, EUR J PHYSL, V418, P297; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; Sambrook J, 1989, MOL CLONING LABORATO; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	24	311	322	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					387	389		10.1038/354387a0	http://dx.doi.org/10.1038/354387a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1659668				2022-12-28	WOS:A1991GT76100049
J	BRUNELL, PA				BRUNELL, PA			CHICKENPOX - EXAMINING OUR OPTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VARICELLA-ZOSTER VIRUS; ACYCLOVIR				BRUNELL, PA (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.							ASANO Y, 1983, PEDIATRICS, V72, P291; BERGER R, 1985, POSTGRAD MED J, V61, P143; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; FEDER HM, 1990, ARCH INTERN MED, V150, P2061, DOI 10.1001/archinte.150.10.2061; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; MOORE DA, 1991, AM J EPIDEMIOL, V133, P1161, DOI 10.1093/oxfordjournals.aje.a115828; PREBLUD SR, 1986, PEDIATRICS, V78, P728; ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801	9	26	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1577	1579		10.1056/NEJM199111283252209	http://dx.doi.org/10.1056/NEJM199111283252209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1658651				2022-12-28	WOS:A1991GR38000009
J	WALKER, DH; MALLER, JL				WALKER, DH; MALLER, JL			ROLE FOR CYCLIN-A IN THE DEPENDENCE OF MITOSIS ON COMPLETION OF DNA-REPLICATION	NATURE			English	Article							MATURATION-PROMOTING FACTOR; EMBRYONIC-CELL CYCLE; MESSENGER-RNA; XENOPUS OOCYTES; PROTEIN; INITIATION; EGGS; DEGRADATION; EXTRACTS; ENTRY	THE cyclins were first identified by their cell-cycle-dependent synthesis and destruction 1-3 and have a key role in the control of mitosis in Xenopus embryonic cell cycles 4-6. All higher eukaryotes have at least two types of cyclins, the A- and B-type, which can be distinguished by sequence motifs and the timing of their destruction in the cell cycle 2,7-10. The degradation of both cyclins is required for exit from mitosis 11, but the activation and destruction of cyclin A occur earlier in the cell cycle than with the B-type cyclins 9-11. This suggests that cyclin A has a distinct role in cell-cycle progression. We have used an antisense oligodeoxynucleotide directed against cyclin A to investigate this role. Ablation of cyclin A messenger RNA in cytostatic factor/metaphase-arrested extracts of Xenopus eggs, followed by in vitro progression into interphase, resulted in the premature appearance of cyclin B/cdc2-associated H1 kinase activity and premature entry into mitosis. Although cyclin A-ablated extracts could initiate DNA synthesis during interphase, S phase was not completed before entry into mitosis. The effects of cyclin A ablation were reversed by the addition of cyclin A mRNA or cyclin A protein to the extracts.			WALKER, DH (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.							BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; COLMAN A, 1990, J CELL SCI, V97, P399; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GABRIELLI GB, IN PRESS J BIOL CHEM; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1987, NUCLEIC ACIDS RES, V16, P6343; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9	28	204	215	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					314	317		10.1038/354314a0	http://dx.doi.org/10.1038/354314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659666				2022-12-28	WOS:A1991GT20400050
J	LEVINE, N; SHEFTEL, SN; EYTAN, T; DORR, RT; HADLEY, ME; WEINRACH, JC; ERTL, GA; TOTH, K; MCGEE, DL; HRUBY, VJ				LEVINE, N; SHEFTEL, SN; EYTAN, T; DORR, RT; HADLEY, ME; WEINRACH, JC; ERTL, GA; TOTH, K; MCGEE, DL; HRUBY, VJ			INDUCTION OF SKIN TANNING BY SUBCUTANEOUS ADMINISTRATION OF A POTENT SYNTHETIC MELANOTROPIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED MELANOGENESIS; ALPHA-MELANOTROPIN; LONGITUDINAL DATA; MELANOMA-CELLS; QUANTIFICATION; ERYTHEMA; HORMONE; INVITRO; MODELS; MOUSE	Objective. - To determine the efficacy of short-term administration of a synthetic analogue of a-melanotropin, [Nle4D-Phe7 (NDP)-alpha-melanocyte-stimulating hormone (MSH), in darkening (tanning) human skin. Design. - Randomized, placebo-controlled, double-blind clinical trial. Setting. - Clinical research unit of a university medical center. Subjects. - Twenty-eight healthy white men with a history of either poor tanning (skin type I or II) or good tanning (skin type III or IV) recruited from advertisements and paid to participate in the study. Methods. - Each subject received 10 subcutaneous injections of either a purified NDP preparation or saline over 12 days. They were followed up for 7 weeks after therapy was completed. All subjects used a high-potency sunscreen during the the trial. Main Outcome Measure. - Skin darkening was quantified by serial chromaticity measurements prior to, during, and after therapy. Results. - A significant parabolic curve of skin darkening activity was noted in subjects with skin type I or II (P < .001) and with skin type III or IV (P << .001) who were given NDP. No darkening occurred in the subjects who were given a placebo. Peak changes were seen 1 to 3 weeks after therapy was completed. Conclusion.-Human skin darkens as a response to a synthetic melanotropin given by subcutaneous injection. Skin tanning appears possible without potentially harmful exposure to ultraviolet radiation.	UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT ANAT, TUCSON, AZ 85724 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT RADIAT ONCOL, TUCSON, AZ 85724 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT CHEM, TUCSON, AZ 85724 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, CTR CANC, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	LEVINE, N (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT INTERNAL MED, DERMATOL SECT, 1501 N CAMPBELL AVE, TUCSON, AZ 85724 USA.							BOLOGNIA J, 1989, J INVEST DERMATOL, V92, P651, DOI 10.1111/1523-1747.ep12696836; CASTRUCCI AMD, 1984, COMP BIOCHEM PHYS B, V78, P519, DOI 10.1016/0305-0491(84)90090-7; DAWSON BV, 1990, J INVEST DERMATOL, V94, P432, DOI 10.1111/1523-1747.ep12874518; DORR RT, 1988, INVEST NEW DRUG, V6, P251; FRIENKEL RK, 1987, DERMATOLOGY GENERAL, P2063; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GILCHREST BA, 1990, J INVEST DERMATOL, V94, P500, DOI 10.1111/1523-1747.ep12874774; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HADLEY ME, 1988, ENDOCRINOLOGY, P159; HADLEY ME, 1988, PIGMENT CELL RES S1, V1, P69; Hruby V. J. W., 1984, PEPTIDE PROTEIN REV, V3, P1; KING RA, 1988, DERMATOL CLIN, V6, P217, DOI 10.1016/S0733-8635(18)30668-5; LERNER AB, 1964, NEW ENGL J MED, V270, P539, DOI 10.1056/NEJM196403122701101; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LEVINE N, 1987, J INVEST DERMATOL, V89, P269, DOI 10.1111/1523-1747.ep12471337; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MALEK ZAA, 1985, CANCER RES, V45, P4735; MALEK ZAA, 1986, J NATL CANCER I, V76, P857; MCGUIRE JS, 1963, ANN NY ACAD SCI, V100, P622, DOI 10.1111/j.1749-6632.1963.tb42919.x; MULLIGAN TM, 1982, CUTIS, V26, P317; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; PATHAK MA, 1987, DERMATOLOGY GENERAL, P1507; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAWELEK JM, 1990, J INVEST DERMATOL, V94, P499, DOI 10.1111/1523-1747.ep12874716; PORGES SB, 1988, PHOTODERMATOLOGY, V5, P197; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SAWYER TK, 1982, J MED CHEM, V25, P1022, DOI 10.1021/jm00351a004; SAWYER TK, 1983, AM ZOOL, V23, P529; SEITZ JC, 1988, DERMATOLOGICA, V177, P70, DOI 10.1159/000248520; SULLIVAN JD, 1976, MECHANISMS BACTERIAL, P217; SZABO G, 1954, BRIT MED J, V1, P1016, DOI 10.1136/bmj.1.4869.1016; WARE JH, 1985, AM STAT, V39, P95, DOI 10.2307/2682803; WESTERHOF W, 1986, PHOTODERMATOLOGY, V3, P310; WILKES BC, 1983, INT J PEPT PROT RES, V22, P313	35	187	199	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2730	2736		10.1001/jama.266.19.2730	http://dx.doi.org/10.1001/jama.266.19.2730			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1658407				2022-12-28	WOS:A1991GP69100029
J	GUY, HR; DURELL, SR; WARMKE, J; DRYSDALE, R; GANETZKY, B				GUY, HR; DURELL, SR; WARMKE, J; DRYSDALE, R; GANETZKY, B			SIMILARITIES IN AMINO-ACID-SEQUENCES OF DROSOPHILA-EAG AND CYCLIC NUCLEOTIDE-GATED CHANNELS	SCIENCE			English	Article							SODIUM-CHANNEL; ALIGNMENT; TOOL		UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	GUY, HR (corresponding author), NCI, MATH BIOL LAB, BETHESDA, MD 20892 USA.			Drysdale, Rachel/0000-0003-3037-0216				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; FELSENSTEIN J, 1990, PHYLIP 3 3 MANUAL; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, MONOVALENT CATIONS B, P31; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KANEHISA M, 1986, NUCLEIC ACIDS RES, V14, P363; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PUSCH M, 1991, Biophysical Journal, V59, p25A; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STEVENS CF, 1991, NATURE, V349, P657, DOI 10.1038/349657a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	20	107	109	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					730	730		10.1126/science.1658932	http://dx.doi.org/10.1126/science.1658932			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1658932				2022-12-28	WOS:A1991GN47400048
J	JACKSON, CL; KONOPKA, JB; HARTWELL, LH				JACKSON, CL; KONOPKA, JB; HARTWELL, LH			SACCHAROMYCES-CEREVISIAE ALPHA-PHEROMONE RECEPTORS ACTIVATE A NOVEL SIGNAL TRANSDUCTION PATHWAY FOR MATING PARTNER DISCRIMINATION	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; A-FACTOR; ADENYLATE-CYCLASE; NUCLEAR-FUSION; CELL-FUSION; G-PROTEIN; PHOSPHOINOSITIDE TURNOVER; STRUCTURAL GENE; PLASMA-MEMBRANE; GAMMA-SUBUNITS	Wild-type S. cerevisiae cells of both mating types prefer partners producing high levels of pheromone and mate very infrequently to cells producing no pheromone. However, some mutants that are supersensitive to pheromone lack this ability to discriminate. In this study, we provide evidence for a novel role of alpha-pheromone receptors in mating partner discrimination that is independent of the known G protein-mediated signal transduction pathway. Furthermore, in response to pheromone, receptors become localized to the emerging region of morphogenesis that is positioned adjacent to the nucleus, suggesting that receptor localization may be involved in mating partner discrimination. Actin, myosin 2, and clathrin heavy chain are involved in mating partner discrimination, since strains carrying mutations in the genes encoding these proteins result in a small but significant defect in mating partner discrimination.			JACKSON, CL (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.		Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019	Jackson, Catherine/0000-0002-0843-145X; Konopka, James/0000-0001-5989-4086	NIGMS NIH HHS [GM17709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017709, R37GM017709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BABA M, 1989, J CELL SCI, V94, P207; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1989, GENETICS, V121, P463; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CLACK JW, 1988, P NATL ACAD SCI USA, V85, P9806, DOI 10.1073/pnas.85.24.9806; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, GENETICS, V126, P301; DELGADO MA, 1984, MOL GEN GENET, V193, P188, DOI 10.1007/BF00327435; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HASEK J, 1987, J GEN MICROBIOL, V133, P3355; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1985, MOL CELL BIOL, V5, P787, DOI 10.1128/MCB.5.4.787; LEMMON SK, 1987, SCIENCE, V238, P504, DOI 10.1126/science.3116672; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MIYAJIMA I, 1988, GENETICS, V119, P797; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1989, GENETICS, V121, P659; OBRIEN DF, 1977, P NATL ACAD SCI USA, V74, P5222, DOI 10.1073/pnas.74.12.5222; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRAKASH L, 1973, J MOL BIOL, V79, P65, DOI 10.1016/0022-2836(73)90270-2; PRENDERGAST JA, 1990, GENETICS, V124, P81; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TKACZ JS, 1979, J CELL BIOL, V80, P326, DOI 10.1083/jcb.80.2.326; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; WATZELE M, 1988, EMBO J, V7, P1483, DOI 10.1002/j.1460-2075.1988.tb02966.x; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	84	107	110	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					389	402		10.1016/0092-8674(91)90190-A	http://dx.doi.org/10.1016/0092-8674(91)90190-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655282				2022-12-28	WOS:A1991GL47000018
J	YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR				YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR			ACTIVATION OF BPV-1 REPLICATION INVITRO BY THE TRANSCRIPTION FACTOR E2	NATURE			English	Article							SV40 DNA-REPLICATION; SIMIAN VIRUS-40 DNA; T-ANTIGEN; HUMAN-CELLS; PROTEIN; ORIGIN; PHOSPHORYLATION; BINDING; COMPLEX	Soluble extracts from uninfected murine cells supplemented with purified viral E1 and E2 proteins support the replication of exogenously added papilloma virus DNA. The E2 transactivator stimulates the binding of the E1 replication protein to the minimal origin of replication and activates DNA replication. These results support the concept that transcription factors have a direct role in the initiation of DNA replication in eukaryotes by participating in the assembly of a complex at the origin of replication.			YANG, L (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.							BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DODSON M, 1989, J BIOL CHEM, V264, P10719; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HATTON KS, 1988, CANCER CELL, V6, P335; HAUSEN HZ, 1988, PAPILLOMAVIRUSES, P245; HOWLEY PM, 1990, VIROLOGY, P1625; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHAW K, 1990, VIROLOGY, P1652; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WOBBE CR, 1986, P NATL ACAD SCI USA, V83, P4612, DOI 10.1073/pnas.83.13.4612	33	280	286	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					628	632		10.1038/353628a0	http://dx.doi.org/10.1038/353628a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656277				2022-12-28	WOS:A1991GK67200058
J	OLDFIELD, EH; DOPPMAN, JL; NIEMAN, LK; CHROUSOS, GP; MILLER, DL; KATZ, DA; CUTLER, GB; LORIAUX, DL				OLDFIELD, EH; DOPPMAN, JL; NIEMAN, LK; CHROUSOS, GP; MILLER, DL; KATZ, DA; CUTLER, GB; LORIAUX, DL			PETROSAL SINUS SAMPLING WITH AND WITHOUT CORTICOTROPIN-RELEASING HORMONE FOR THE DIFFERENTIAL-DIAGNOSIS OF CUSHINGS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STIMULATION TEST; PITUITARY-GLAND; CLINICAL-APPLICATIONS; COMPUTED-TOMOGRAPHY; ADRENAL-TUMORS; DISEASE; ACTH; CT; DEXAMETHASONE; MICROADENOMAS	Background. Measurement of adrenocorticotropin levels in plasma from the inferior petrosal sinuses of patients with Cushing's syndrome can distinguish adrenocorticotropin-secreting pituitary tumors (Cushing's disease) from other causes of the syndrome, principally ectopic adrenocorticotropin secretion from an occult tumor, However, it is unknown whether such measurement consistently identifies patients with Cushing's disease and whether testing with corticotropin-releasing hormone (CRH) enhances the value of the procedure. Methods. We prospectively studied 281 patients with Cushing's syndrome to evaluate the diagnostic efficacy of the procedure. Bilateral sampling was successfully accomplished in 278 patients, with no major morbidity; 262 of these patients underwent sampling before and after administration of ovine CRH. The adrenocorticotropin levels in the samples were used to calculate the ratio of the concentration in plasma from the inferior petrosal sinuses to the concentration in peripheral-blood plasma (the IPS:P ratio). Results. The diagnosis of 246 patients was confirmed surgically as Cushing's disease in 215, as ectopic adrenocorticotropin syndrome in 20, and as primary adrenal disease in 11. An IPS:P ratio greater-than-or-equal-to 2.0 in basal samples identified 205 of the 215 patients with Cushing's disease (sensitivity, 95 percent), with no false positive results (specificity, 100 percent). A peak IPS:P ratio greater-than-or-equal-to 3.0 after CRH administration identified all 203 of the patients with Cushing's disease who received CRH (sensitivity, 100 percent), with no false positive results (specificity, 100 percent). The sensitivity was much lower when the adrenocorticotropin concentrations in the samples from one sinus were considered alone. In patients with Cushing's disease a difference of greater-than-or-equal-to 1.4-fold between the concentrations in the two sinuses (the adrenocorticotropin gradient) predicted the location of the microadenoma in 68 percent of 104 patients during basal sampling and in 71 percent of 105 patients after CRH administration Conclusions. Simultaneous bilateral sampling of plasma from the inferior petrosal sinuses, with the adjunctive use of CRH, distinguishes patients with Cushing's disease from those with ectopic adrenocorticotropin secretion with high diagnostic accuracy.	NICHHD,CTR CLIN,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	OLDFIELD, EH (corresponding author), NINCDS,SURG NEUROL BRANCH,BLDG 10,RM 5D37,BETHESDA,MD 20892, USA.							BROWN SB, 1983, NEURORADIOLOGY, V24, P259, DOI 10.1007/BF00333177; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; CHAMBERS EF, 1982, RADIOLOGY, V144, P109, DOI 10.1148/radiology.144.1.7089241; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; CHROUSOS GP, 1985, ANN INTERN MED, V102, P344, DOI 10.7326/0003-4819-102-3-344; CORRIGAN DF, 1977, NEW ENGL J MED, V296, P861, DOI 10.1056/NEJM197704142961508; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; DOPPMAN JL, 1989, RADIOLOGY, V172, P415, DOI 10.1148/radiology.172.2.2748822; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; DOPPMAN JL, 1988, RADIOLOGY, V166, P347, DOI 10.1148/radiology.166.2.2827231; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; DOPPMAN JL, 1985, RADIOLOGY, V155, P375, DOI 10.1148/radiology.155.2.2984718; DOPPMAN JL, 1989, RADIOLOGY, V173, P286; DUNNICK NR, 1982, RADIOLOGY, V142, P429, DOI 10.1148/radiology.142.2.7054832; DUNNICK NR, 1979, AM J ROENTGENOL, V132, P43, DOI 10.2214/ajr.132.1.43; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; FINDLING JW, 1981, ANN INTERN MED, V94, P647, DOI 10.7326/0003-4819-94-5-647; GRANT SJB, 1983, MED J AUSTRALIA, V1, P336, DOI 10.5694/j.1326-5377.1983.tb136113.x; HERMUS AR, 1986, LANCET, V2, P540, DOI 10.1016/S0140-6736(86)90113-3; HERMUS ARMM, 1986, J CLIN ENDOCR METAB, V62, P634, DOI 10.1210/jcem-62-4-634; KAO M, 1975, CLIN CHEM, V21, P1644; KLEY HK, 1977, NEW ENGL J MED, V297, P731; LANDOLT AM, 1986, CLIN ENDOCRINOL, V25, P687, DOI 10.1111/j.1365-2265.1986.tb03624.x; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LORIAUX DL, 1986, CLIN ENDOCRINOL, P167; LYTRAS N, 1984, CLIN ENDOCRINOL, V20, P71, DOI 10.1111/j.1365-2265.1984.tb00061.x; MANNI A, 1983, J CLIN ENDOCR METAB, V57, P4070; MARCOVITZ S, 1987, AM J ROENTGENOL, V149, P803, DOI 10.2214/ajr.149.4.803; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MULLER OA, 1986, PSYCHONEUROENDOCRINO, V11, P49, DOI 10.1016/0306-4530(86)90031-4; MULLER OA, 1983, J CLIN ENDOCR METAB, V57, P227; NAKAHARA M, 1983, J CLIN ENDOCR METAB, V57, P963, DOI 10.1210/jcem-57-5-963; NIEMAN LK, 1989, J CLIN ENDOCR METAB, V69, P165, DOI 10.1210/jcem-69-1-165; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; Oldfield E H, 1985, N Engl J Med, V312, P100, DOI 10.1056/NEJM198501103120207; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; ORTH DN, 1982, J CLIN ENDOCR METAB, V55, P1017, DOI 10.1210/jcem-55-5-1017; PARENT AD, 1981, J NEUROSURG, V54, P228, DOI 10.3171/jns.1981.54.2.0228; PECK WW, 1989, AM J ROENTGENOL, V152, P145, DOI 10.2214/ajr.152.1.145; PIETERS GFFM, 1983, J CLIN ENDOCR METAB, V57, P513, DOI 10.1210/jcem-57-3-513; SARIS SC, 1987, RADIOLOGY, V162, P775, DOI 10.1148/radiology.162.3.3809493; SCHAAF M, 1977, NEW ENGL J MED, V297, P730; SCHULTE HM, 1987, DEUT MED WOCHENSCHR, V112, P1767, DOI 10.1055/s-2008-1068326; SNOW RB, 1988, SURG NEUROL, V29, P17, DOI 10.1016/0090-3019(88)90117-6; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; VONWERDER K, 1977, NEW ENGL J MED, V297, P730; 1987, NEW ENGL J MED, V317, P1648	49	633	660	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					897	905		10.1056/NEJM199109263251301	http://dx.doi.org/10.1056/NEJM199109263251301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1652686				2022-12-28	WOS:A1991GF85600001
J	WANG, LY; SALTER, MW; MACDONALD, JF				WANG, LY; SALTER, MW; MACDONALD, JF			REGULATION OF KAINATE RECEPTORS BY CAMP-DEPENDENT PROTEIN-KINASE AND PHOSPHATASES	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID; CHANNELS; QUISQUALATE; MODULATION; CALCIUM; FAMILY	In the mammalian central nervous system, receptors for excitatory amino acid neurotransmitters such as the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate receptor mediate a large fraction of excitatory transmission. Currents induced by activation of the AMPA-kainate receptor were potentiated by agents that specifically stimulate adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase A (PKA) activity or were supported by intracellular application of the catalytic subunit of PKA by itself or in combination with cAMP. Furthermore, depression of these currents by a competitive inhibitor of PKA indicates that AMPA-kainate receptors are regulated by endogenous PKA. Endogenous protein phosphatases also regulate these receptors because an inhibitor of cellular phosphatases enhanced kainate currents. Modulation of PKA and phosphatases may regulate the function of these receptors and thus contribute to synaptic plasticity in hippocampal neurons.	HOSP SICK CHILDREN, DIV NEUROSCI, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	WANG, LY (corresponding author), UNIV TORONTO, DEPT PHYSIOL, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.							BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BRAUMANN T, 1985, J CHROMATOGR, V350, P105, DOI 10.1016/S0021-9673(01)93510-1; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSCHER P, 1985, J GEN PHYSIOL, V85, P743, DOI 10.1085/jgp.85.5.743; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALINOW R, 1991, NEURON, V6, P53; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; YUSTA B, 1988, J NEUROCHEM, V51, P1807, DOI 10.1111/j.1471-4159.1988.tb01162.x	23	387	389	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1132	1135		10.1126/science.1653455	http://dx.doi.org/10.1126/science.1653455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653455				2022-12-28	WOS:A1991GD80800030
J	BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I				BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I			PROGRESSIVE ENCEPHALOPATHY AND MYOPATHY IN TRANSGENIC MICE EXPRESSING HUMAN FOAMY VIRUS GENES	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; TAT GENE; DEGENERATION; NEURONS; CELLS; AIDS	Transgenic mice carrying the bel region of human foamy retrovirus (HFV) under transcriptional control of its own long terminal repeat expressed the transgene in their central nervous systems and in smooth and striated muscle tissues. The animals developed a progressive degenerative disease of the central nervous system and of the striated muscle. Because expression of the transgene was closely correlated with the appearance of structural damage and inflammatory reactions were scanty, the disease is likely to be caused directly by the HFV proteins. These unexpected findings call for a reevaluation of the pathogenic potential of HFV in humans.	UNIV WURZBURG,INST VIROL & IMMUNOBIOL,VERSBACHERSTR 7,W-8700 WURZBURG,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST NEUROL,A-1090 VIENNA,AUSTRIA	University of Wurzburg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Lassmann, Hans/Z-2269-2019	Lassmann, Hans/0000-0001-8617-5052; Aguzzi, Adriano/0000-0002-0344-6708				ACHONG G, 1971, J NATL CANCER I, V42, P299; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AGUZZI A, UNPUB; BOTHE K, UNPUB; CAMERONKR, 1978, LANCET, V2, P796; FLUGEL RM, 1987, EMBO J, V6, P2077, DOI 10.1002/j.1460-2075.1987.tb02473.x; GIANGASPERO F, 1989, ACTA NEUROPATHOL, V78, P662, DOI 10.1007/BF00691293; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; MULLER RH, 1980, J GEN VIROL, V47, P399; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; PICCARDO P, 1988, ANN NEUROL S, V23, P156; RETHWILM A, 1990, VIROLOGY, V175, P568, DOI 10.1016/0042-6822(90)90442-T; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; RETHWILM A, 1990, NUCLEIC ACIDS RES, V18, P733, DOI 10.1093/nar/18.4.733; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEISS RA, 1988, NATURE, V333, P497, DOI 10.1038/333497a0; YOUNG D, 1973, ARCH GES VIRUSFORSCH, V42, P228, DOI 10.1007/BF01265647; [No title captured]	27	98	102	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					555	557		10.1126/science.1650034	http://dx.doi.org/10.1126/science.1650034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1650034	Green Submitted			2022-12-28	WOS:A1991FZ34700036
J	MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J				MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J			GLOBAL SUPPRESSION OF PROTEIN FOLDING DEFECTS AND INCLUSION BODY FORMATION	SCIENCE			English	Article							TAIL-SPIKE PROTEIN; AMINO-ACID SUBSTITUTIONS; P22 TAILSPIKE PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; PHAGE-P22 TAILSPIKE; RAMAN-SPECTROSCOPY; POLYPEPTIDE-CHAIN; GENETIC-ANALYSIS; WILD-TYPE	Amino acid substitutions at a site in the center of the bacteriophage protein P22 tailspike polypeptide chain suppress temperature-sensitive folding mutations at many sites throughout the chain. Characterization of the intracellular folding and chain assembly process reveals that the suppressors act in the folding pathway, inhibiting the aggregation of an early folding intermediate into the kinetically trapped inclusion body state. The suppressors alone increase the folding efficiency of the otherwise wild-type polypeptide chain without altering the stability or activity of the native state. These amino acid substitutions identify an unexpected aspect of the protein folding grammar-sequences within the chain that carry information inhibiting unproductive off-pathway conformations. Such mutations may serve to increase the recovery of protein products of cloned genes.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University	MITRAKI, A (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939	NIGMS NIH HHS [GMS17,980] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FANE B, 1991, GENETICS, V127, P263; FANE B, IN PRESS J BIOL CHEM; FUCHS A, IN PRESS BIOCHEMISTR; GEORGIOU G, 1986, APPL ENVIRON MICROB, V52, P1152; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRINGT.WF, 1970, BIOCHEMISTRY-US, V9, P3714, DOI 10.1021/bi00821a010; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; Lee S. J., COMMUNICATION; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MAURIDES PA, 1990, GENETICS, V125, P673; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MITRAKI A, UNPUB; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDSON J, 1988, SCIENCE, V240, P4859; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SATHER S, UNPUB; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STROUP AN, 1990, BIOCHEMISTRY-US, V29, P9765, DOI 10.1021/bi00494a002; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WETZEL R, IN PRESS BIOTECHNOLO; WETZEL R, 1990, PROTEIN DESIGN DEV N, P79; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	57	186	201	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					54	58		10.1126/science.1648264	http://dx.doi.org/10.1126/science.1648264			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648264				2022-12-28	WOS:A1991FV17700031
J	KAPPELLE, LJ; VANLATUM, JC; KOUDSTAAL, PJ; VANGIJN, J				KAPPELLE, LJ; VANLATUM, JC; KOUDSTAAL, PJ; VANGIJN, J			TRANSIENT ISCHEMIC ATTACKS AND SMALL-VESSEL DISEASE	LANCET			English	Article							COMPUTED-TOMOGRAPHY; LACUNAR INFARCTION; ISCHEMIC ATTACKS; STROKE REGISTRY; DIAGNOSIS; FEATURES	Histories and computed tomograms of 606 patients with transient cerebral ischaemia were studied. All symptoms and signs had completely resolved within 24 hours, and any episodes suggestive or posterior fossa ischaemia were excluded. Computed tomography, done after the clinical features had resolved, showed 79 relevant infarcts: 46 were small, deep, lacunar infarcts (58%, 95% confidence interval [CI] 47-69%), and 33 were larger cortical infarcts. The histories and the type of infarct in these 79 patients were compared to see whether lacunar infarcts were preceded by a history of unilateral motor or sensory symptoms without features usually attributed to the cerebral cortex. The positive predictive value of such lacunar symptoms was 0.74, with a negative predictive value of 0.61. 11 patients had a cortical infarct despite a history of lacunar TIAs, but only one occurred in the left hemisphere and speech was not affected. Of 527 patients with transient ischaemic attacks without a relevant infarct visible on computed tomography. 335 (64%) had a history suggestive of lacunar ischaemia, whereas in several other studies 20-25% of patients with ischaemic stroke have evidence of lacunar infarcts. Lacunar TIAs may therefore have a better prognosis than cortical TIAs or may often precede cortical infarcts; alternatively, many cortical infarcts may occur without warning.	UNIV HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS; STATE UNIV UTRECHT,DEPT NEUROL,UTRECHT,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Utrecht University			van Gijn, Jan/A-9444-2008					[Anonymous], 1988, Stroke, V19, P512; AWAD I, 1986, STROKE, V17, P399, DOI 10.1161/01.STR.17.3.399; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; DENNIS M, 1990, J NEUROL, V237, P257, DOI 10.1007/BF00314630; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KAPPELLE LJ, 1989, NEURORADIOLOGY, V31, P316, DOI 10.1007/BF00344174; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KOUDSTAAL PJ, 1989, STROKE, V20, P300, DOI 10.1161/01.STR.20.2.300; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MOHR JP, 1986, STROKE PATHOPHYSIOLO, P475; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; TUSZYNSKI MH, 1989, STROKE, V20, P990, DOI 10.1161/01.STR.20.8.990	18	40	40	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					339	341		10.1016/0140-6736(91)90955-O	http://dx.doi.org/10.1016/0140-6736(91)90955-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671241				2022-12-28	WOS:A1991EX36200013
J	BARROS, A; SILVA, J; MAIA, J				BARROS, A; SILVA, J; MAIA, J			SPONTANEOUS-ABORTIONS AFTER INTRAPERITONEAL OR INTRAUTERINE INSEMINATION	LANCET			English	Letter									UNIV PORTO, FAC MED, DEPT HYG & EPIDEMIOL, P-4200 OPORTO, PORTUGAL	Universidade do Porto	BARROS, A (corresponding author), UNIV PORTO, FAC MED, DEPT MED GENET, P-4200 OPORTO, PORTUGAL.		Barros, Alberto/L-3094-2013	Barros, Alberto/0000-0002-8700-3698				FORRLER A, 1986, LANCET, V1, P916; FORRLER A, 1986, LANCET, V2, P1468	2	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					302	302		10.1016/0140-6736(91)90913-A	http://dx.doi.org/10.1016/0140-6736(91)90913-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671138				2022-12-28	WOS:A1991EV71900043
J	CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM				CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM			SEROLOGICAL IDENTIFICATION OF ESCHERICHIA-COLI O157-H7 INFECTION IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Article							HEMOLYTIC UREMIC SYNDROME; CYTOTOXIN-PRODUCING STRAINS; POLYACRYLAMIDE GELS; ANTIBODIES; PROTEINS; PROBES	To test the value of serological tests as an adjunct to bacteriological methods and toxin testing in haemolytic uraemic syndrome (HUS), 60 patients with the disorder were examined for evidence of faecal Escherichia coli producing verocytotoxin (VTEC), particularly of serogroup O157. They were also tested for serum antibodies reacting with the lipopolysaccharide of E coli O157 by means of an enzyme-linked immunosorbent assay (ELISA) and immunoblotting; for faecal VTEC by means of DNA probes hybridising with the genes encoding verocytotoxins VT1 and VT2; and for "free" faecal VT. Strains of E coli serotype O157:H7 were isolated from 9 patients, and faecal VT2 was detected in 3 of them. Strains of E coli of serotypes O5:H -, O55:H10, O105ac:H18, and O163:H19 were isolated from 4 patients, but faecal VT was not detected. Faecal VT2 was present in 1 patient from whom VTEC were not isolated. Antibodies to the lipopolysaccharide of E coli O157 were detected in serum samples from 44 patients. The 9 patients with faecal O157:H7 all had high titres of these antibodies, but serum samples from 16 healthy control children were negative. Serological testing of patients with HUS for antibodies to the lipopolysaccharide of E coli O157 provides evidence of infection with E coli O157 when faecal bacteria or VT cannot be detected.	CHILDRENS HOSP,DEPT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND		CHART, H (corresponding author), CENT PUBL HLTH LAB,DIV ENTER PATHOGENS,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							CHART H, 1989, J CLIN MICROBIOL, V27, P285, DOI 10.1128/JCM.27.2.285-290.1989; CHART H, 1989, J CLIN PATHOL, V42, P973, DOI 10.1136/jcp.42.9.973; Gross R. J., 1985, SPECIAL PUBLICATION, V13, P345; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KLEANTHOUS H, 1988, EPIDEMIOL INFECT, V101, P327, DOI 10.1017/S0950268800054261; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722, DOI 10.1136/adc.65.7.722; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; SCOTLAND SM, 1987, EPIDEMIOL INFECT, V99, P613, DOI 10.1017/S0950268800066462; SCOTLAND SM, 1985, LANCET, V2, P885; SCOTLAND SM, 1988, J MED MICROBIOL, V25, P237, DOI 10.1099/00222615-25-4-237; SMITH HR, 1984, LANCET, V1, P1242; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Von Gasser C, 1955, SCHWEIZ MED WOCHENSC, V85, P905; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLSHAW GA, 1987, J GEN MICROBIOL, V133, P1309; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	19	136	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					138	140		10.1016/0140-6736(91)90801-U	http://dx.doi.org/10.1016/0140-6736(91)90801-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670788				2022-12-28	WOS:A1991ET67900004
J	AMABILECUEVAS, CF; CHICUREL, ME				AMABILECUEVAS, CF; CHICUREL, ME			BACTERIAL PLASMIDS AND GENE FLUX	CELL			English	Review							PRE-ANTIBIOTIC ERA; ESCHERICHIA-COLI; TI-PLASMID; AGROBACTERIUM-TUMEFACIENS; CONJUGATIVE PLASMIDS; RESISTANCE ELEMENT; DNA TRANSFER; VIRULENCE; PROTEIN; PLANTS		HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Amábile-Cuevas, Carlos/HDO-1753-2022	Amábile-Cuevas, Carlos/0000-0001-6806-544X				AMABILECUEVAS CF, 1991, MUTAT RES, V264, P119, DOI 10.1016/0165-7992(91)90128-Q; ASHRAF MM, 1991, CAN J MICROBIOL, V37, P59, DOI 10.1139/m91-009; BARONDESS JJ, 1990, NATURE, V346, P871, DOI 10.1038/346871a0; BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; BIBB MJ, 1986, ANTIBIOTIC RESISTANC, P323; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; BOUMA JE, 1988, NATURE, V335, P351, DOI 10.1038/335351a0; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; CARLSON TA, 1986, NATURE, V322, P568, DOI 10.1038/322568a0; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CLEWELL DB, 1986, ANNU REV MICROBIOL, V40, P635, DOI 10.1146/annurev.mi.40.100186.003223; CLEWELL DB, 1986, ANTIBIOTIC RESISTANC, P131; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; CUNDLIFFE E, 1984, BRIT MED BULL, V40, P61, DOI 10.1093/oxfordjournals.bmb.a071949; DELVER EP, 1991, J BACTERIOL, V173, P5887, DOI 10.1128/jb.173.18.5887-5892.1991; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DERBYSHIRE KM, 1987, MOL GEN GENET, V206, P161, DOI 10.1007/BF00326552; DESSAUX Y, 1989, J BACTERIOL, V171, P6363, DOI 10.1128/jb.171.11.6363-6366.1989; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DYER DW, 1984, J BACTERIOL, V158, P689, DOI 10.1128/JB.158.2.689-695.1984; FOSTER TJ, 1983, MICROBIOL REV, V47, P361, DOI 10.1128/MMBR.47.3.361-409.1983; GERDES K, 1986, P NATL ACAD SCI USA, V83, P3116, DOI 10.1073/pnas.83.10.3116; GHEYSEN G, 1991, GENE DEV, V5, P287, DOI 10.1101/gad.5.2.287; GORMLEY EP, 1991, J BACTERIOL, V173, P6705, DOI 10.1128/jb.173.21.6705-6708.1991; GRINSTED J, 1990, PLASMID, V24, P163, DOI 10.1016/0147-619X(90)90001-S; GYLES CL, 1977, SCIENCE, V198, P198, DOI 10.1126/science.333581; HAHN FE, 1976, ANTIBIOT CHEMOTHER, V20, P196; HALL BG, 1991, P NATL ACAD SCI USA, V88, P5882, DOI 10.1073/pnas.88.13.5882; HALL RM, 1991, MOL MICROBIOL, V5, P1941, DOI 10.1111/j.1365-2958.1991.tb00817.x; HARRINGTON LC, 1990, J BACTERIOL, V172, P7263, DOI 10.1128/jb.172.12.7263-7264.1990; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HEINEMANN JA, 1991, METHOD ENZYMOL, V194, P187; HENDERSON DJ, 1989, MOL MICROBIOL, V3, P1307, DOI 10.1111/j.1365-2958.1989.tb00112.x; HERRERAESTRELLA A, 1990, P NATL ACAD SCI USA, V87, P9534, DOI 10.1073/pnas.87.24.9534; HINNEBUSCH J, 1991, J BACTERIOL, V173, P7233, DOI 10.1128/jb.173.22.7233-7239.1991; HOPKINS JD, 1991, ANTIMICROB AGENTS CH, V35, P1605, DOI 10.1128/AAC.35.8.1605; HORN N, 1991, MOL GEN GENET, V228, P129, DOI 10.1007/BF00282457; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; INOUYE S, 1991, SCIENCE, V252, P969, DOI 10.1126/science.1709758; JACOBS HT, 1991, J MOL EVOL, V32, P333, DOI 10.1007/BF02102192; KLECKNER N, 1989, MOBILE DNA, P163; LABES G, 1990, PLASMID, V24, P235, DOI 10.1016/0147-619X(90)90007-Y; Levy SB, 1986, ANTIBIOTIC RESISTANC, P17; LIM D, 1991, MOL MICROBIOL, V5, P1863, DOI 10.1111/j.1365-2958.1991.tb00810.x; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LOPEZ J, 1991, J GEN MICROBIOL, V137, P1093, DOI 10.1099/00221287-137-5-1093; LORENZ MG, 1991, ARCH MICROBIOL, V156, P319, DOI 10.1007/BF00263005; MANNING PA, 1981, P NATL ACAD SCI-BIOL, V78, P7487, DOI 10.1073/pnas.78.12.7487; MARTIN C, 1990, NATURE, V345, P739, DOI 10.1038/345739a0; MARUYAMA K, 1991, J MOL EVOL, V33, P514, DOI 10.1007/BF02102804; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MAYERHOFER R, 1991, EMBO J, V10, P697, DOI 10.1002/j.1460-2075.1991.tb07999.x; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; MAZODIER P, 1991, ANNU REV GENET, V25, P147, DOI 10.1146/annurev.ge.25.120191.001051; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; NOVICK RP, 1984, MOL GEN GENET, V195, P374, DOI 10.1007/BF00332777; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; Paraense WL, 1986, ANTIBIOTIC RESISTANC, V1, P117; PAUL JH, 1991, APPL ENVIRON MICROB, V57, P1509, DOI 10.1128/AEM.57.5.1509-1515.1991; PERALTA EG, 1986, EMBO J, V5, P1137, DOI 10.1002/j.1460-2075.1986.tb04338.x; PROJAN SJ, 1991, PLASMID, V25, P241; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REYNAUD A, 1991, INFECT IMMUN, V59, P1888, DOI 10.1128/IAI.59.6.1888-1892.1991; ROMANOWSKI G, 1991, APPL ENVIRON MICROB, V57, P1057, DOI 10.1128/AEM.57.4.1057-1061.1991; ROSNER JL, 1991, J BACTERIOL, V173, P5631, DOI 10.1128/jb.173.18.5631-5638.1991; SAYRE P, 1991, PLASMID, V26, P151, DOI 10.1016/0147-619X(91)90040-4; SCHAFER A, 1990, J BACTERIOL, V172, P1663, DOI 10.1128/jb.172.3.1663-1666.1990; SCOTT JR, 1986, ANTIBIOTIC RESISTANC, P153; SEDGWICK SG, 1989, MOL GEN GENET, V218, P323, DOI 10.1007/BF00331285; SHEN P, 1986, GENETICS, V112, P441; SHOEMAKER NB, 1988, J BACTERIOL, V170, P1651, DOI 10.1128/jb.170.4.1651-1657.1988; Singer M., 1991, GENES GENOMES; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; Sonea S., 1991, SYMBIOSIS SOURCE EVO, P95; STECK TR, 1990, J BACTERIOL, V172, P2191, DOI 10.1128/jb.172.4.2191-2193.1990; STEVENS AM, 1990, J BACTERIOL, V172, P4271, DOI 10.1128/jb.172.8.4271-4279.1990; STEWART GJ, 1986, ANNU REV MICROBIOL, V40, P211, DOI 10.1146/annurev.micro.40.1.211; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; SUKUPOLVI S, 1990, MICROBIOL REV, V54, P331, DOI 10.1128/MMBR.54.4.331-341.1990; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; TOP E, 1991, PLASMID, V25, P238; TRIEUCUOT P, 1987, FEMS MICROBIOL LETT, V48, P289, DOI 10.1111/j.1574-6968.1987.tb02558.x; TRIEUCUOT P, 1986, J ANTIMICROB CHEMOTH, V18, P93, DOI 10.1093/jac/18.Supplement_C.93; VILJANEN P, 1991, FEMS MICROBIOL LETT, V88, P43, DOI 10.1016/0378-1097(91)90695-7; WARD JE, 1988, J BIOL CHEM, V263, P5804; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WILKINS BM, 1991, PLASMID, V25, P227; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1	93	115	118	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					189	199		10.1016/0092-8674(92)90095-T	http://dx.doi.org/10.1016/0092-8674(92)90095-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638628				2022-12-28	WOS:A1992JE75700004
J	STUBBINGS, J; SHEEHANDARE, R; WALTON, S				STUBBINGS, J; SHEEHANDARE, R; WALTON, S			CUTANEOUS VASCULITIS DUE TO CIPROFLOXACIN	BRITISH MEDICAL JOURNAL			English	Letter											STUBBINGS, J (corresponding author), GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							CHOE U, 1989, NEW ENGL J MED, V320, P257; KANUGA J, 1991, Annals of Allergy, V66, P76; PACE JL, 1989, BRIT MED J, V299, P658, DOI 10.1136/bmj.299.6700.658; 1987, DRUG THER B, V25, P69	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29-b	http://dx.doi.org/10.1136/bmj.305.6844.29-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638195	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JC79900030
J	CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW				CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW			HEALTH-CARE WORKERS WITH AIDS - NATIONAL SURVEILLANCE UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VIRUS; OCCUPATIONAL RISK; TRANSMISSION; INFECTION; HIV	Objectives. - To characterize health care workers with the acquired immunodeficiency syndrome (AIDS) in the United States and to evaluate the role of occupational transmission of the human immunodeficiency virus (HIV). Data Source. - National AIDS surveillance data. Methods. - Health care workers with AIDS are reported to the Centers for Disease Control by state and local health departments. Health care workers who do not report a nonoccupational risk for HIV infection are termed undetermined risk cases and are investigated by health departments using a standard protocol. Results. - Through June 30, 1990, there were 5425 cases of AIDS in healthcare workers reported in the United States. Three of these workers developed AIDS following well-documented occupational exposure to HIV-infected blood. Of the 539 health care workers initially reported without a nonoccupational risk, follow-up investigations were completed for 303. Nonoccupational risk factors were established for 237 (78.2%) of the 303 investigated health care workers; 66 workers (21.8%) remained in the undetermined category. Follow-up information was incomplete for 236 health care workers who also remained in the undetermined category, resulting in 5120 health care workers (94.4%) with AIDS with nonoccupational risks for HIV infection. Overall, health care workers were more likely than non-health care workers with AIDS to have an undetermined risk for HIV infection (5.6% vs 2.8%; P < .001). While many of the 66 investigated health care workers had jobs involving contact with patients and/or potential contact with blood, none reported percutaneous, mucous membrane, or cutaneous exposures to blood or body fluids known to be infected with HIV. Conclusion. - Surveillance data suggest that most health care workers with AIDS acquired their HIV infection through a nonoccupational route.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; US PHS,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; United States Public Health Service	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,MAIL STOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED S3B, V91; BUEHLER J, 1989, 5 INT C AIDS MONTR, P124; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control reports include, 1988, MMWR, V37, P229; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; HADLER SC, 1985, INFECT CONT HOSP EP, V6, P24, DOI 10.1017/S0195941700062457; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCORMICK RD, 1981, AM J MED, V70, P928, DOI 10.1016/0002-9343(81)90558-1; Miller J W, 1989, Conn Med, V53, P457; TURNER SB, 1989, AM J PUBLIC HEALTH, V79, P1425, DOI 10.2105/AJPH.79.10.1425; 1991, MMWR, V40, P309; 1987, MMWR, V36, pS1; 1989, EMPLOY EARN, V36, P13; 1991, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P239; 1989, FED REG         0530, V54, P23042; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	24	36	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3459	3462		10.1001/jama.266.24.3459	http://dx.doi.org/10.1001/jama.266.24.3459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1660544				2022-12-28	WOS:A1991GV87800032
J	LO, YJ; POO, MM				LO, YJ; POO, MM			ACTIVITY-DEPENDENT SYNAPTIC COMPETITION INVITRO - HETEROSYNAPTIC SUPPRESSION OF DEVELOPING SYNAPSES	SCIENCE			English	Article							MOTOR UNIT SIZE; SKELETAL-MUSCLE; POLYNEURONAL INNERVATION; RAT MUSCLE; NEUROMUSCULAR-JUNCTIONS; EMBRYONIC NEURON; NEWBORN RATS; ELIMINATION; ACETYLCHOLINE; MECHANISMS	The development and stability of synaptic connections in the nervous system are influenced by the pattern of electrical activity and the competitive interaction between the adjacent nerve terminals. To investigate this influence, a culture system of nerve and muscle cells has been developed in which a single embryonic muscle cell is coinnervated by two spinal neurons. The effect of electrical activity on the synaptic efficacy was examined after repetitive electrical stimulation was applied to one or both neurons. Brief tetanic stimulation of one neuron resulted in immediate functional suppression of the synapse made by the unstimulated neuron innervating the same muscle cell. This heterosynaptic suppression was largely absent when the tetanic stimulation was applied concurrently to both neurons. This result demonstrates that activity-dependent synaptic competition can be studied in vitro at a cellular level.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University					NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1989, J PHYSIOL-LONDON, V417, P25; BROW H, 1990, ANN REV NEUROSCI, V13, P475; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; BUCHANAN J, 1989, J NEUROSCI, V9, P1544; CALLAWAY EM, 1987, NATURE, V328, P357; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DECKER ER, 1990, J NEUROSCI, V10, P3413; DUNIA R, MOTONEURONAL PLASTIC; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hebb DO, 1949, ORG BEHAVIOR, P62; HERRERA AA, 1990, J NEUROBIOL, V21, P73, DOI 10.1002/neu.480210106; HERRERA AA, 1990, J NEUROBIOL, V21, P21; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; KUFFLER D, 1977, BRAIN RES, V138, P353, DOI 10.1016/0006-8993(77)90752-1; LOMO T, 1980, TRENDS NEUROSCI, V3, P126, DOI 10.1016/0166-2236(80)90047-8; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAGCHIELSE T, 1986, DEV BRAIN RES, V25, P211, DOI 10.1016/0165-3806(86)90210-5; NELSON PG, 1989, SCIENCE, V244, P585, DOI 10.1126/science.2717942; NELSON PG, 1990, J NEUROBIOL, V21, P138, DOI 10.1002/neu.480210110; OBRIEN RAD, 1978, J PHYSIOL-LONDON, V282, P571, DOI 10.1113/jphysiol.1978.sp012482; POO M, 1989, J NEUROBIOL, V21, P157; PURVES D, 1990, PRINCIPLES NEURAL DE, V5, P745; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1983, J PHYSIOL-LONDON, V344, P89, DOI 10.1113/jphysiol.1983.sp014926; RIBCHESTER RR, 1984, J PHYSIOL-LONDON, V347, P497, DOI 10.1113/jphysiol.1984.sp015078; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANESSEN DC, 1990, J NEUROBIOL, V21, P223, DOI 10.1002/neu.480210115; VANESSEN DC, 1982, NEURONAL DEV, P333; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	39	137	139	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1019	1022		10.1126/science.1658939	http://dx.doi.org/10.1126/science.1658939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658939				2022-12-28	WOS:A1991GP88300049
J	MOHR, G; LAMBOWITZ, AM				MOHR, G; LAMBOWITZ, AM			INTEGRATION OF A GROUP-I INTRON INTO A RIBOSOMAL-RNA SEQUENCE PROMOTED BY A TYROSYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							NEUROSPORA MITOCHONDRIA; INVOLVEMENT; INVITRO	GROUP I and II introns are mobile elements that propagate by insertion into different genes 1. Some introns of both types self-splice in vitro by transesterification reactions catalysed by the intron RNA 2. These transesterifications are reversible 3-5, and it has been suggested that reverse splicing followed by reverse transcription and recombination with genomic DNA may be a mechanism for intron transposition 6-7. In vivo the splicing of many, if not all, group I and II introns requires protein factors, which may facilitate correct folding of the intron RNAs 8. Here we show that the Neurospora mitochondrial large rRNA intron, a group I intron that is not self-splicing in vitro 9, undergoes reverse splicing in a reaction promoted by the CYT-18 protein, the Neurospora mitochondrial tyrosyl-tRNA synthetase, which is required for splicing the intron in vivo 10. In contrast to known RNA-catalysed reverse splicing reactions, this protein-assisted reverse splicing is sufficiently rapid to compete with forward splicing at low RNA concentrations under physiologically relevant conditions, including high GTP and low Mg2+ concentrations. Our results indicate that proteins that promote splicing could contribute to intron mobility by promoting reverse splicing in vivo.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BARTEL DP, 1991, MOL CELL BIOL, V11, P3390, DOI 10.1128/MCB.11.6.3390; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1985, INT REV CYTOL, V3, P3; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; KITTLE JD, 1991, GENE DEV, V5, P109; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	17	23	26	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					164	167		10.1038/354164a0	http://dx.doi.org/10.1038/354164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1658660				2022-12-28	WOS:A1991GP88000065
J	RANDAZZO, PA; NORTHUP, JK; KAHN, RA				RANDAZZO, PA; NORTHUP, JK; KAHN, RA			ACTIVATION OF A SMALL GTP-BINDING PROTEIN BY NUCLEOSIDE DIPHOSPHATE KINASE	SCIENCE			English	Article							ADENYLATE-CYCLASE; NUCLEOTIDE BINDING; ADP-RIBOSYLATION; ESCHERICHIA-COLI; GS-ALPHA; TUMOR-METASTASIS; CHOLERA-TOXIN; 2 FORMS; EXPRESSION; NM23	Genes that encode nucleoside diphosphate kinases (NDKs) have been implicated as regulators of mammalian tumor metastasis and development in Drosophila melanogaster. However, the cellular pathways through which NDKs function am not known. One potential mechanism of regulation is phosphorylation of guanosine diphosphate (GDP) bound to regulatory guanosine triphosphate (GTP) binding proteins. NDK-catalyzed phosphorylation of bound GDP was investigated for the adenosine diphosphate ribosylation factor (ARF), a 21-kilodalton GTP-binding protein that functions in the protein secretion pathway. Bovine liver NDK, recombinant human NDK, and the protein product of the mouse gene nm23-1, which suppresses the metastatic potential of certain tumor cells, used ARF-GDP as a substrate, thereby allowing rapid and efficient production of activated ARF (ARF-GTP) in the absence of nucleotide exchange. These data are consistent with the proposed function of NDK as an activator of a small GTP-binding protein and provide a mechanism of activation for a regulatory GTP-binding protein that is independent of nucleotide exchange.	NCI,DIV CENT RES,BIOL CHEM LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06514	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yale University			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHENG YC, 1971, BIOCHEMISTRY-US, V10, P2139; COLOMB MG, 1969, BIOCHEMISTRY-US, V8, P1926, DOI 10.1021/bi00833a024; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1983, J BIOL CHEM, V258, P2278; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOURAD N, 1966, J BIOL CHEM, V241, P271; OHTSUKI K, 1985, BIOCHEM INT, V11, P719; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; RANDAZZO PA, UNPUB; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; RULKA C, UNPUB; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SEDMARK J, 1971, J BIOL CHEM, V246, P53; SERAFINI T, IN PRESS CELL; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; UESAKA H, 1987, BIOCHEM BIOPH RES CO, V143, P552, DOI 10.1016/0006-291X(87)91389-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILDMAN D, UNPUB	35	77	78	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					850	853		10.1126/science.1658935	http://dx.doi.org/10.1126/science.1658935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658935				2022-12-28	WOS:A1991GN83300043
J	LI, JD; CARROLL, J; ELLAR, DJ				LI, JD; CARROLL, J; ELLAR, DJ			CRYSTAL-STRUCTURE OF INSECTICIDAL DELTA-ENDOTOXIN FROM BACILLUS-THURINGIENSIS AT 2.5-A RESOLUTION	NATURE			English	Article							BRUSH-BORDER MEMBRANE; VAR TENEBRIONIS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN-STRUCTURE; SPECIFICITY; GENE; BINDING; PURIFICATION; COLEOPTERA; MECHANISM	The structure of the delta-endotoxin from Bacillus thuringiensis subsp. tenebrionis that is specifically toxic to Coleoptera insects (beetle toxin) has been determined at 2.5 angstrom resolution. It comprises three domains which are, from the N- to C-termini, a seven-helix bundle, a three-sheet domain, and a beta-sandwich. The core of the molecule encompassing all the domain interfaces is built from conserved sequence segments of the active delta-endotoxins. Therefore the structure represents the general fold of this family of insecticidal proteins. The bundle of long, hydrophobic and amphipathic helices is equipped for pore formation in the insect membrane, and regions of the three-sheet domain are probably responsible for receptor binding.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge	LI, JD (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; AHMAD W, 1990, FEMS MICROBIOL LETT, V68, P97, DOI 10.1111/j.1574-6968.1990.tb04130.x; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BARTON KA, 1987, PLANT PHYSIOL, V85, P1103, DOI 10.1104/pp.85.4.1103; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARROLL J, 1989, BIOCHEM J, V261, P99, DOI 10.1042/bj2610099; CHOMA CT, 1990, BIOCHEMISTRY-US, V29, P10971, DOI 10.1021/bi00501a015; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHUNGJATUPORNCHAI W, 1988, EUR J BIOCHEM, V173, P9, DOI 10.1111/j.1432-1033.1988.tb13960.x; ELLAR DJ, 1985, MOL BIOL MICROBIAL D, P230; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; HAIDER MZ, 1987, BIOCHEM J, V248, P197, DOI 10.1042/bj2480197; Hodgman T. C, 1990, J DNA SEQU MAPPING, V1, P97; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1986, EUR J BIOCHEM, V161, P273, DOI 10.1111/j.1432-1033.1986.tb10443.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HOFTE H, 1987, NUCLEIC ACIDS RES, V15, P7183, DOI 10.1093/nar/15.17.7183; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KNOWLES BH, 1986, J CELL SCI, V83, P89; KNOWLES BH, 1984, FEBS LETT, V168, P197, DOI 10.1016/0014-5793(84)80245-8; KRAULIS P, IN PRESS J APPL CRYS; KRIEG A, 1983, Z ANGEW ENTOMOL, V96, P500; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LI J, 1988, J MOL BIOL, V199, P543, DOI 10.1016/0022-2836(88)90625-0; MACINTOSH SC, 1990, BIOCHEM BIOPH RES CO, V170, P665, DOI 10.1016/0006-291X(90)92143-N; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NICHOLLS CN, 1989, J BACTERIOL, V171, P5141, DOI 10.1128/jb.171.9.5141-5147.1989; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PERLAK FJ, 1991, P NATL ACAD SCI USA, V88, P3324, DOI 10.1073/pnas.88.8.3324; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHNEPF HE, 1985, J BIOL CHEM, V260, P6273; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SEKAR V, 1987, P NATL ACAD SCI USA, V84, P7036, DOI 10.1073/pnas.84.20.7036; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; VAECK M, 1987, NATURE, V328, P33, DOI 10.1038/328033a0; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; VISSER B, 1990, J BACTERIOL, V172, P6783, DOI 10.1128/jb.172.12.6783-6788.1990; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIDNER WR, 1990, J BACTERIOL, V172, P2826, DOI 10.1128/jb.172.6.2826-2832.1990; Wilcox D. R., 1986, PROTEIN ENG APPLICAT, P395	47	614	690	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					815	821		10.1038/353815a0	http://dx.doi.org/10.1038/353815a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1658659				2022-12-28	WOS:A1991GM73200050
J	WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR				WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR			HEPATITIS-C VIRUS NOT FOUND IN FULMINANT NON-A, NON-B HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Note							FAILURE		DEPT VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA; US FDA, HEPATITIS RES LAB, SAN FRANCISCO, CA 94102 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, STANFORD, CA 94305 USA	US Food & Drug Administration (FDA); University of California System; University of California San Francisco; Stanford University	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR, GASTROENTEROL UNIT, 111B, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.			greenberg, harry/0000-0002-2128-9080; Lake, John/0000-0002-4332-0528	NIDDK NIH HHS [DK-26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; CRISTIANO K, IN PRES HEPATOLOGY; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MUTO Y, 1990, Gastroenterologia Japonica, V25, P32; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	7	131	132	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					111	112		10.7326/0003-4819-115-2-111	http://dx.doi.org/10.7326/0003-4819-115-2-111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	1647717				2022-12-28	WOS:A1991FW09100006
J	WILLIAMS, GT				WILLIAMS, GT			PROGRAMMED CELL-DEATH - APOPTOSIS AND ONCOGENESIS	CELL			English	Review							ANTIGEN-DRIVEN SELECTION; GERMINAL-CENTERS; B-CELLS; BCL-2; SURVIVAL; GROWTH; TRANSLOCATION; EXPRESSION; MECHANISM; CLONING				WILLIAMS, GT (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930				BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DIVE C, 1991, IN PRESS BR J CANCER; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P367; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, IN PRESS EUR J IMMUN; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186	21	899	954	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1097	1098		10.1016/0092-8674(91)90002-G	http://dx.doi.org/10.1016/0092-8674(91)90002-G			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648446				2022-12-28	WOS:A1991FU89900002
J	SKERRITT, JH; HILL, AS				SKERRITT, JH; HILL, AS			SELF-MANAGEMENT OF DIETARY COMPLIANCE IN CELIAC-DISEASE BY MEANS OF ELISA HOME TEST TO DETECT GLUTEN	LANCET			English	Article							CELIAC-DISEASE	To improve compliance with a gluten-free diet in coeliac disease a simple prototype test kit was developed to detect gluten in foods for use at home. The test is based on monoclonal antibodies to heat-stable gluten proteins which crossreact appropriately with barley and rye proteins. It is suitable for use with a wide range of raw or cooked foods. The food is extracted with dilute hydrochloric acid and 1 drop of the extract transferred to an antibody-coated tube; enzyme-labelled gluten detection antibody is added and after 3 min the tube is washed and colour developer is added. The reaction is stopped after 2 min, stabilising the blue color. The home kit was compared with a quantitative laboratory kit, and the qualitative agreement was very good. The kit could distinguish foods with trace gluten contents (acceptable for a "gluten-free" diet) from those with a slightly higher but unacceptable gluten content. In a trial of the prototype kit by 47 coeliac disease patients of diverse ages and educational backgrounds, 93% of tests correctly identified foods as acceptable or unacceptable.			SKERRITT, JH (corresponding author), CSIRO,DIV PLANT IND,WHEAT RES UNIT,POB 7,N RYDE,NSW 2113,AUSTRALIA.							ANAND BS, 1978, Q J MED, V47, P101; BELL L, 1981, J CAN DIET ASSOC, V42, P143; Bos E S, 1981, J Immunoassay, V2, P187, DOI 10.1080/15321818108056977; CAMPBELL JA, 1987, WORLD REV NUTR DIET, V51, P198; CHALLEN RG, 1986, MED J AUSTRALIA, V146, P91; CICLITIRA PJ, 1984, BRIT MED J, V289, P83, DOI 10.1136/bmj.289.6437.83; Cooke WT, 1984, COELIAC DIS; DAVIDSON AGF, 1987, CLIN CHIM ACTA, V163, P1, DOI 10.1016/0009-8981(87)90031-3; DISSANAYAKE AS, 1974, BMJ-BRIT MED J, V4, P189, DOI 10.1136/bmj.4.5938.189; HOMES GKT, 1989, GUT, V30, P333; JONES A, 1978, LANCET, V2, P1047; LEE JW, 1968, J SCI FOOD AGR, V19, P153, DOI 10.1002/jsfa.2740190308; MCNICHOLL B, 1979, GUT, V20, P126, DOI 10.1136/gut.20.2.126; MEREDITH P, 1965, CEREAL CHEM, V42, P64; ODONOGHUE DP, 1979, GASTROENTEROLOGY, V76, P1211; SKERRITT JH, 1990, J AGR FOOD CHEM, V38, P1771, DOI 10.1021/jf00098a029; SKERRITT JH, 1985, J SCI FOOD AGR, V36, P980, DOI 10.1002/jsfa.2740361013; SKERRITT JH, 1987, MED J AUSTRALIA, V147, P262, DOI 10.5694/j.1326-5377.1987.tb133442.x; SKERRITT JH, IN PRESS J ASS OFF A; SKERRITT JH, 1990, DEV APPLICATION IMMU, P88; SWINSON CM, 1980, BRIT MED J, V281, P1258, DOI 10.1136/bmj.281.6250.1258; WALKERSMITH JA, 1979, ARCH DIS CHILD, V54, P783	22	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					379	382		10.1016/0140-6736(91)91163-O	http://dx.doi.org/10.1016/0140-6736(91)91163-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671421				2022-12-28	WOS:A1991EX60500001
J	TURNER, JA; ERSEK, M; HERRON, L; HASELKORN, J; KENT, D; CIOL, MA; DEYO, R				TURNER, JA; ERSEK, M; HERRON, L; HASELKORN, J; KENT, D; CIOL, MA; DEYO, R			PATIENT OUTCOMES AFTER LUMBAR SPINAL FUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; POSTEROLATERAL FUSION; ROD INSTRUMENTATION; SURGICAL-TREATMENT; SPONDYLOLISTHESIS; DISTRACTION; DISK; FIXATION; STABILITY; STENOSIS	Objectives.-To determine success and complication rates for lumbar spinal fusion surgery, predictors of good outcomes, and whether fusion improves success rates of laminectomy for specific low back disorders. Data Sources.-English-language journal articles published from 1966 through April 1991, identified through MEDLINE searching (spinal fusion plus limiting terms), bibliography review, and expert consultation. Study Selection.-Articles were selected only if they reported at least 1 year of follow-up data enabling the classification of clinical outcomes as satisfactory or unsatisfactory for at least 30 patients. Data Extraction.-Two reviewers independently extracted data on patient characteristics, surgical methods, patient outcomes, and quality of study methods. Data Synthesis.-Of 47 articles, there were no randomized trials. Four nonrandomized studies compared surgery with and without fusion for herniated disks; three found no advantage for fusion. On average, 68% of patients had a satisfactory outcome after fusion, but the range was wide (16% to 95%), and the satisfactory outcome rate was lower in prospective than in retrospective studies. The most frequently reported complications were pseudarthrosis (14%) and chronic pain at the bone graft donor site (9%). Clinical outcomes did not differ by diagnosis or fusion technique, but were worse in studies with a greater number of previously operated patients. Conclusions.-For several low back disorders no advantage has been demonstrated for fusion over surgery without fusion, and complications of fusions are common. Randomized controlled trials are needed to compare fusion, surgery without fusion, and nonsurgical treatments in rigorously defined patient groups.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; CENT COAST SPINE INST,SAN LUIS OBISPO,CA; VET AFFAIRS MED CTR,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	TURNER, JA (corresponding author), UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,BACK PAIN OUTCOME ASSESSMENT TEAM,RP-10,SEATTLE,WA 98195, USA.			Ersek, Mary/0000-0002-0520-311X; Ciol, Marcia/0000-0001-6406-4706	AHRQ HHS [HS-06344] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDREW TA, 1986, CLIN ORTHOP RELAT R, V203, P113; ATTENBOROUGH CG, 1975, J BONE JOINT SURG BR, V57, P283, DOI 10.1302/0301-620X.57B3.283; BARR JS, 1967, SURG GYNECOL OBSTET, V38, P306; Blume H.G., 1981, J NEUROLOGICAL ORTHO, V2, P171; BRANCH CL, 1987, SURG NEUROL, V27, P449, DOI 10.1016/0090-3019(87)90252-7; BRODSKY AE, 1991, SPINE, V16, pS261, DOI 10.1097/00007632-199106001-00017; CHOW SP, 1980, SPINE, V5, P452, DOI 10.1097/00007632-198009000-00010; CLOWARD RB, 1981, CLIN ORTHOP RELAT R, P74; Cotler JM, 1990, INSPINAL FUSION, P361; CROCK HV, 1982, CLIN ORTHOP RELAT R, V165, P157; DePalma A F, 1966, Clin Orthop Relat Res, V47, P165; DePalma A F, 1968, Clin Orthop Relat Res, V59, P113; DEYO R, 1991, CLIN RES, V39, pA315; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DUNSKER SB, 1988, CLIN NEUROSURG, V36, P147; EIE N, 1978, ACTA NEUROCHIR, V41, P107, DOI 10.1007/BF01809141; FARFAN HF, 1981, CLIN ORTHOP RELAT R, V158, P198; FLATLEY TJ, 1985, CLIN ORTHOPAEDICS, V196, P273; FLYNN JC, 1970, J BONE JOINT SURG AM, V61, P1143; FORBES DB, 1975, CAN J SURG, V18, P546; FREEBODY D, 1971, Journal of Bone and Joint Surgery British Volume, V53, P617; FRYMOYER J W, 1978, Spine, V3, P1, DOI 10.1097/00007632-197803000-00001; FUJIYA M, 1990, SPINE, V15, P1216, DOI 10.1097/00007632-199011010-00023; GARTLAND JJ, 1990, SPINAL FUSION SCI TE, P391; Goldner J L, 1971, Orthop Clin North Am, V2, P543; GRAHAM CE, 1979, CLIN ORTHOPAEDICS, V140, P72; HANLEY EN, 1989, SPINE, V14, P48, DOI 10.1097/00007632-198901000-00009; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002; HERRON LD, 1983, SPINE, V8, P86, DOI 10.1097/00007632-198301000-00015; HERRON LD, 1991, J SPINAL DISORD, V4, P26; HOROWITCH A, 1989, SPINE, V14, P461, DOI 10.1097/00007632-198904000-00025; HUTTER CG, 1983, CLIN ORTHOP RELAT R, V179, P86; JACKSON RK, 1985, SPINE, V10, P828, DOI 10.1097/00007632-198511000-00009; JACOBS RR, 1974, SOUTH MED J, V67, P177, DOI 10.1097/00007611-197402000-00013; JOHNSON LP, 1988, SPINE, V13, P93, DOI 10.1097/00007632-198801000-00022; KANEDA K, 1985, SPINE, V10, P383, DOI 10.1097/00007632-198505000-00016; KANEDA K, 1986, CLIN ORTHOP RELAT R, V203, P159; KIM SS, 1990, SPINE, V15, P979, DOI 10.1097/00007632-199009000-00026; KOSTUIK JP, 1990, SPINE, V15, P318, DOI 10.1097/00007632-199004000-00013; KOZAK JA, 1990, SPINE, V15, P322, DOI 10.1097/00007632-199004000-00014; Lettin A W, 1967, J Bone Joint Surg Br, V49, P520; LOUIS R, 1986, CLIN ORTHOP RELAT R, V203, P18; NACHEMSON AL, 1985, ACTA ORTHOP SCAND, V56, P285, DOI 10.3109/17453678508993015; NACHLAS IW, 1952, J BONE JOINT SURG AM, V34-A, P981, DOI 10.2106/00004623-195234040-00025; NASCA RJ, 1990, SPINE, V15, P1356, DOI 10.1097/00007632-199012000-00022; NASCA RJ, 1989, SPINE, V14, P451, DOI 10.1097/00007632-198904000-00023; Peek R. D, 1990, SPINAL FUSION SCI TE, P3; PROLO DJ, 1986, SPINE, V11, P601, DOI 10.1097/00007632-198607000-00012; RAUGSTAD TS, 1982, ACTA ORTHOP SCAND, V53, P561, DOI 10.3109/17453678208992258; ROMBOLD C, 1966, J BONE JOINT SURG AM, VA 48, P1282, DOI 10.2106/00004623-196648070-00003; Savini R, 1984, Ital J Orthop Traumatol, V10, P449; SAVINI R, 1980, ITAL J ORTHOP TRA S2, V6, P151; SORENSEN KH, 1978, ACTA ORTHOP SCAND, V49, P269, DOI 10.3109/17453677809005764; Spear C V, 1978, Va Med, V105, P859; SPENGLER DM, 1987, J BONE JOINT SURG AM, V69A, P305, DOI 10.2106/00004623-198769020-00027; STAUFFER RN, 1972, J BONE JOINT SURG AM, VA 54, P756, DOI 10.2106/00004623-197254040-00006; STAUFFER RN, 1972, J BONE JOINT SURG AM, V54, P1195, DOI 10.2106/00004623-197254060-00006; THOMPSON WA, 1974, J BONE JOINT SURG AM, VA 56, P1643, DOI 10.2106/00004623-197456080-00014; TUNTURI T, 1979, ARCH ORTHOP TRAUM SU, V93, P103, DOI 10.1007/BF00389680; URIST MR, 1981, CLIN ORTHOP RELAT R, V154, P97; VAUGHAN PA, 1988, SPINE, V13, P690; WADDELL G, 1979, J BONE JOINT SURG AM, V61, P201, DOI 10.2106/00004623-197961020-00007; WHITE AH, 1983, SPINE, V8, P434, DOI 10.1097/00007632-198305000-00015; WHITE AH, 1987, SPINE, V12, P305, DOI 10.1097/00007632-198704000-00021; Young H, 1959, AM ACAD ORTHOP SURG, V16, P213; ZUCHERMAN J, 1988, SPINE, V13, P570, DOI 10.1097/00007632-198805000-00024	66	363	387	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					907	911		10.1001/jama.268.7.907	http://dx.doi.org/10.1001/jama.268.7.907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640622				2022-12-28	WOS:A1992JH58800044
J	FRAMPTON, MW				FRAMPTON, MW			AN OUTBREAK OF TUBERCULOSIS AMONG HOSPITAL PERSONNEL CARING FOR A PATIENT WITH A SKIN ULCER	ANNALS OF INTERNAL MEDICINE			English	Note						TUBERCULOSIS; HEALTH PERSONNEL; TUBERCULIN TEST; CROSS INFECTION; SKIN ULCER		Extrapulmonary tuberculosis is rarely considered contagious. However, any situation in which organism, can he aerosolized represents a risk for hospital personnel. An 84-year-old woman was admitted to a community hospital with skin ulcer on her thigh and deep venous thrombosis of the leg, Frequent dressing changes and debridement of the ulcer were required. The patient died after 31 days in the hospital. and autopsy showed the ulcer to be a granulomatous lesion containing numerous acid fast bacilli. Subsequent contact investigation showed that of the 59 staff members involved in the patient's care who were previously tuberculin nonreactive, 11 (19%) became tuberculin reactive Ten of these 11 tuberculin-reactive employees recalled being in the patient's room during debridement or dressing changes. Two of the three nurses who did not receive isoniazid prophylaxis developed pleural tuberculosis. Skin lesions can result in nosocomial spread of tuberculosis, probably through aerosolization of infected material.			FRAMPTON, MW (corresponding author), UNIV ROCHESTER, MED CTR, PULM UNIT, BOX 692, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.							HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; WEIR MR, 1985, AM J MED, V79, P467, DOI 10.1016/0002-9343(85)90034-8	3	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					312	313		10.7326/0003-4819-117-4-312	http://dx.doi.org/10.7326/0003-4819-117-4-312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637027				2022-12-28	WOS:A1992JH46400008
J	BORLAND, R; PIERCE, JP; BURNS, DM; GILPIN, E; JOHNSON, M; BAL, D				BORLAND, R; PIERCE, JP; BURNS, DM; GILPIN, E; JOHNSON, M; BAL, D			PROTECTION FROM ENVIRONMENTAL TOBACCO-SMOKE IN CALIFORNIA - THE CASE FOR A SMOKE-FREE WORKPLACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ATTITUDES; WORKSITE; BANS; PREVALENCE; INDUSTRY; POLICY	Objective.-To determine the extent of exposure of nonsmoking indoor workers to environmental tobacco smoke (ETS) according to type of work-site smoking policy, work area, workplace size, and demographic characteristics. Design and Participants.-Participants included 7162 adult, nonsmoking, indoor workers who were interviewed as part of the 1990 California Tobacco Survey. Respondents were asked whether anyone had smoked in their work area within the past 2 weeks. Results.-An estimated 2.2 million California nonsmokers were exposed to tobacco smoke at indoor work sites in 1990. Nonsmoker exposure to ETS was 9.3% for those working in a smoke-free worksite, 23.2% for those working where there was only a work-area restriction, 46.7% for those working where there was a policy that did not include the work area, and 51.4% for those working where there was no work-site smoking policy. After adjustment for type of work area (eg, office, open area), workplace size, and demographic factors, it was determined that nonsmokers working where there was only a work-area ban were 2.8 times more likely to be exposed to ETS than those working in a smoke-free work site. In workplaces with no policy or a policy not covering the work area, nonsmokers were over eight times more likely to be exposed to ETS than those who worked in a smoke-free work site. Nonsmokers who were 18 to 24 years of age, male, or Hispanic, and those with less than a high school education had more exposure to ETS. Conclusion.-These results indicate that adequate protection of nonsmokers from ETS exposure requires a smoke-free work site.	UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; VICTORIAN ANTICANC COUNCIL,CTR BEHAV RES CANC,MELBOURNE,VIC,AUSTRALIA; CALIF DEPT HLTH SERV,TOBACCO CONTROL SECT,SACRAMENTO,CA; UNIV CALIF SAN DIEGO,DIV PULM & CRIT CARE MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego; California Department of Health Care Services; University of California System; University of California San Diego				Borland, Ron/0000-0003-0059-178X; Pierce, John/0000-0002-0075-7471				[Anonymous], 1982, JACKKNIFE BOOTSTRAP; [Anonymous], 1986, ENV TOBACCO SMOKE ME; BEINER L, 1989, AM J PUBLIC HEALTH, V79, P192; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; BORLAND R, 1990, PREV MED, V19, P314, DOI 10.1016/0091-7435(90)90031-E; BROWN ER, 1988, J OCCUP ENVIRON MED, V30, P312; Burton D J, 1987, Occup Health Saf, V56, P105; ERIKSEN MP, 1986, ADV HLTH ED PROMOTIO, V1, P65; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HILL D, 1991, PUBLIC HEALTH REP, V106, P181; HOCKING B, 1991, J OCCUP ENVIRON MED, V33, P163; HUDZINSKI LG, 1990, CHEST, V97, P1198, DOI 10.1378/chest.97.5.1198; MARCUS AC, 1989, J NATL CANCER I, V81, P409, DOI 10.1093/jnci/81.6.409; MARTIN MJ, 1986, NEW ENGL J MED, V315, P647; MILLAR WJ, 1988, CAN J PUBLIC HEALTH, V79, P379; PERTSCHUK M, 1989, NIH PHS90479 US DEP; PETERSEN LR, 1988, PUBLIC HEALTH REP, V103, P115; PIERCE JP, 1991, J NATL CANCER I, V83, P1009, DOI 10.1093/jnci/83.14.1009; PIERCE JP, 1987, CDC878396 US DEP HLT; PIERCE JP, 1992, TECHNICAL REPORT ANA; SORENSEN G, 1986, AM J PUBLIC HEALTH, V76, P544, DOI 10.2105/AJPH.76.5.544; SORENSEN G, 1991, AM J PUBLIC HEALTH, V81, P202; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; 1989, PHS CDC898411 US DEP; 1990, SAS P200 SAS I TECHN, P175; 1987, NATIONAL SURVEY WORK; 1991, MMWR, V40, P1; 1990, EPA6006900006A PUBL; 1987, CURRENT ESTIMATES 10; 1989, 89615512 CTR DIS CON, P1049; 1986, PHS878398 US DEP HLT	32	63	63	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					749	752		10.1001/jama.268.6.749	http://dx.doi.org/10.1001/jama.268.6.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JG666	1640575				2022-12-28	WOS:A1992JG66600016
J	GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH				GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH			HUMAN INFECTION BY GENETICALLY DIVERSE SIVSM-RELATED HIV-2 IN WEST AFRICA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; GENOMIC DIVERGENCE; SOOTY MANGABEY; MONKEYS; AIDS; VARIABILITY; ISOLATE	OUR understanding of the biology and origins of human immunodeficiency virus type 2 (HIV-2) derives from studies of cultured isolates from urban populations experiencing epidemic infection and disease1-8. To test the hypothesis that such isolates might represent only a subset of a larger, genetically more diverse group of viruses, we used nested polymerase chain reactions to characterize HIV-2 sequences in uncultured mononuclear blood cells of two healthy Liberian agricultural workers, from whom virus isolation was repeatedly unsuccessful, and from a culture-positive symptomatic urban dweller. Analysis of pol, env and long terminal repeat regions revealed the presence of three highly divergent HIV-2 strains, one of which (from one of the healthy subjects) was significantly more closely related to simian immunodeficiency viruses infecting sooty mangabeys and rhesus macaques (SIV(SM)/SIV(MAC)) than to any virus of human derivation. This subject also harboured multiply defective viral genotypes that resulted from hypermutation of G to A bases. Our results indicate that HIV-2, SIV(SM) and SIV(MAC) comprise a single, highly diverse group of lentiviruses which cannot be separated into distinct phylogenetic lineages according to species of origin.	UNIV ALABAMA,DIV GEOG MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; LIBERIAN INST BIOMED RES,ROBERTSFIELD,LIBERIA; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Trinity College Dublin	GAO, F (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.		Sharp, Paul/Y-3787-2019; Sharp, Paul M/GPX-1497-2022; Sharp, Paul M/F-5783-2010	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DIETRICH U, 1989, NATURE, V342, P948, DOI 10.1038/342948a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIENNES TW, 1978, ZOONOSES ORIGINS ECO; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FRANCHINI G, 1989, P NATL ACAD SCI USA, V86, P2433, DOI 10.1073/pnas.86.7.2433; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; GILKS C, 1991, NATURE, V354, P262, DOI 10.1038/354262a0; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEGAWA A, 1989, AIDS RES HUM RETROV, V5, P593, DOI 10.1089/aid.1989.5.593; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KHAN AS, 1991, J VIROL, V65, P7061, DOI 10.1128/JVI.65.12.7061-7065.1991; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KIRCHHOFF F, 1990, AIDS, V4, P847, DOI 10.1097/00002030-199009000-00003; KUMAR P, 1990, J VIROL, V64, P890, DOI 10.1128/JVI.64.2.890-901.1990; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1991, HUMAN RETROVIRUSES A; NOVEMBRE FJ, 1992, VIROLOGY, V186, P783, DOI 10.1016/0042-6822(92)90047-S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULZ TF, 1990, J VIROL, V64, P5177, DOI 10.1128/JVI.64.10.5177-5182.1990; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941	30	356	363	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					495	499		10.1038/358495a0	http://dx.doi.org/10.1038/358495a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641038				2022-12-28	WOS:A1992JG73900047
J	GARTON, MJ; TORGERSON, DJ; DONALDSON, C; RUSSELL, IT; REID, DM				GARTON, MJ; TORGERSON, DJ; DONALDSON, C; RUSSELL, IT; REID, DM			RECRUITMENT METHODS FOR SCREENING PROGRAMS - TRIAL OF A NEW METHOD WITHIN A REGIONAL OSTEOPOROSIS STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; CALL; INVITATION; RECALL	Objective-To estimate the response rates and operating costs of three recruitment methods within a regional osteoporosis screening programme. Design-Randomised trial of three types of invitation letter: one offering fixed appointments with option to change time, one offering fixed appointments but requiring telephoned confirmation of intention to attend, and one inviting recipient to telephone to make an appointment. Setting-Osteoporosis screening unit, Aberdeen. Subjects-1200 women aged 45-49 years living within 32 km of Aberdeen and randomly selected from the community health index. 400 women were randomised to each appointment method. Main outcome measures-Numbers attending for screening; default rate among women who confirmed appointments; social class of attenders; cost per appointment slot and per completed scan. Results-299 (75%), 277 (69%), and 217 (54%) women were scanned after fixed, confirmable, and open invitations respectively. Women who attended were given a questionnaire, and 694 (87.5%) returned it. No significant differences were found in the social class of attenders among the three methods. Of the 514 women who made or confirmed appointments, 494 attended for a scan. Total costs per scan were 25.00 Pounds, 21.40 Pounds, and 21.00 Pounds for fixed, confirmable, and open invitations respectively. Conclusions-The offer of a fixed appointment requiring telephoned confirmation has the potential to reduce the costs of scanning without exaggerating any social bias or significantly reducing response rates provided that empty appointments can be rebooked at short notice.	UNIV ABERDEEN, HLTH ECON RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND; UNIV ABERDEEN, HLTH SERV RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen; University of Aberdeen	GARTON, MJ (corresponding author), CITY HOSP, DEPT RHEUMATOL, ABERDEEN AB9 8AU, SCOTLAND.		Russell, Ian T/H-1181-2012; Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Donaldson, Cam/0000-0003-4670-5340				[Anonymous], 1980, CLASSIFICATION OCCUP; GARDNER MJ, 1990, STATISTICS CONFIDENC, P28; GEORGE WD, 1976, BRIT MED J, V2, P858, DOI 10.1136/bmj.2.6040.858; HOBBS P, 1990, BRIT MED J, V301, P1314, DOI 10.1136/bmj.301.6764.1314; HOBBS P, 1980, J EPIDEMIOL COMMUN H, V34, P19, DOI 10.1136/jech.34.1.19; HOUGHTONBA, 1968, MED OFFICER, V120, P334; IRWIG L, 1990, COMMUNITY HEALTH ST, V14, P357; MOSER CA, 1971, SURVEY METHODS SOCIA, P85; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; RIDSDALE LL, 1987, J ROY COLL GEN PRACT, V37, P257; ROBERTSON AJ, 1989, BRIT MED J, V299, P163, DOI 10.1136/bmj.299.6692.163; ROWORTH MA, 1988, COMMUNITY MED, V10, P327; SPENSER JT, 1967, PRACTITIONER, V198, P274; TURNBULL D, 1991, AUST J PUBLIC HEALTH, V15, P33; WILLIAMS EMI, 1989, BMJ-BRIT MED J, V299, P158, DOI 10.1136/bmj.299.6692.158; WILSON A, 1987, BRIT MED J, V295, P181, DOI 10.1136/bmj.295.6591.181-a; [No title captured]; 1981, POPULATION CENSUS SM; 1990, CONSOLIDATED GUIDANC, P7	19	46	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	1992	305	6845					82	84		10.1136/bmj.305.6845.82	http://dx.doi.org/10.1136/bmj.305.6845.82			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638251	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JD85000020
J	MERCER, AR; EMPTAGE, NJ; CAREW, TJ				MERCER, AR; EMPTAGE, NJ; CAREW, TJ			PHARMACOLOGICAL DISSOCIATION OF MODULATORY EFFECTS OF SEROTONIN IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; PRESYNAPTIC FACILITATION; INNERVATING TAIL; DISHABITUATION; MEMORY; LONG; SENSITIZATION; CAMP	In the mollusk Aplysia the neurotransmitter serotonin (5HT) has a fundamental modulatory role in several forms of learning and memory that involve an increase in the efficacy of synaptic transmission between tail sensory neurons (SNs) and motor neurons. The classical 5HT antagonist cyproheptadine (CYP) permits dissociation of three forms of serotonergic modulation in these SNs: (i) CYP reversibly blocks spike-broadening induced either by exogenous application of 5HT or by sensitizing stimulation of a tail nerve. (ii) CYP does not block 5HT-induced or tail input-induced increases in SN somatic excitability. (iii) Concomitant with its block of spike-broadening, CYP reversibly blocks 5HT-induced facilitation of synaptic transmission from SNs. These results suggest that endogenously released 5HT may act at different receptor subtypes that are coupled to different forms of neuromodulation in tail SNs of Aplysia.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520; UNIV OTAGO,DEPT ZOOL,DUNEDIN,NEW ZEALAND	Yale University; University of Otago	CAREW, TJ (corresponding author), YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520, USA.			Mercer, Alison/0000-0001-8110-4247	NIMH NIH HHS [MH 141083] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDSMITH BA, 1991, P NATL ACAD SCI USA, V88, P9021, DOI 10.1073/pnas.88.20.9021; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAWKINS RD, 1987, HDB PHYSL 1, V6, P25; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; OCCOR KA, 1985, NEUROSCI LETT, V55, P65; OCCOR KA, 1986, BRAIN RES, V371, P190; PEROUTKA SJ, 1981, SCIENCE, V212, P827, DOI 10.1126/science.7221567; POLLOCK JD, 1985, J NEUROSCI, V5, P1862; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SUGITA S, 1991, Society for Neuroscience Abstracts, V17, P1590; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	24	100	100	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1811	1813		10.1126/science.1662413	http://dx.doi.org/10.1126/science.1662413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1662413				2022-12-28	WOS:A1991GW31600050
J	KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM				KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM			REGULATION OF PHAGOCYTE OXYGEN RADICAL PRODUCTION BY THE GTP-BINDING PROTEIN RAC-2	SCIENCE			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL NADPH OXIDASE; GUANINE-NUCLEOTIDES; CYTOSOLIC FACTOR; PLASMA-MEMBRANE; ACTIVATION; IDENTIFICATION; ASSOCIATION	A major action of the microbicidal system of human neutrophils is the formation of superoxide anion (O2-) by a multicomponent oxidase that transfers electrons from the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to molecular oxygen. The mechanism of assembly and activation of the oxidase from its cytosolic and membrane-bound components is unknown, but may require the activity of a guanosine 5'-triphosphate (GTP)-binding component A cytosolic GTP-binding protein (G(ox)) that regulates the NADPH oxidase of neutrophils was identified. G(ox) was purified and shown to augment the rate of O2- production in a cell-free oxidase activation system. Sequence analysis of peptide fragments from G(ox) identified it as Rac 2, a member of the Ras superfamily of GTP-binding proteins. Antibody to a peptide derived from the COOH-terminus of Rac 2 inhibited O2- generation in a concentration-dependent manner. These results suggest that Rac 2 is a regulatory component of the human neutrophil NADPH oxidase, and provide new insights into the mechanism by which this oxygen radical-generating system is regulated.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; GENENTECH INC, DEPT CELL BIOL, S SAN FRANCISCO, CA 94080 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Roche Holding; Genentech; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BOKOCH GM, IN PRESS J CLIN INVE; BOKOCH GM, IN PRESS SCIENCE; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; KNAUS UG, UNPUB; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; PEVERI P, 1989, BLOOD, V74, pA107; PEVERI P, UNPUB; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SMITH RM, 1991, BLOOD, V77, P673	31	608	621	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1512	1515		10.1126/science.1660188	http://dx.doi.org/10.1126/science.1660188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1660188				2022-12-28	WOS:A1991GT90300042
J	THUN, MJ; NAMBOODIRI, MM; HEATH, CW				THUN, MJ; NAMBOODIRI, MM; HEATH, CW			ASPIRIN USE AND REDUCED RISK OF FATAL COLON CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; AUTOCHTHONOUS INTESTINAL TUMORS; PROSTAGLANDIN SYNTHESIS; INDOMETHACIN TREATMENT; RATS; INHIBITION; CARCINOGENESIS; PIROXICAM; POLYPOSIS; SULINDAC	Background and Methods. Experiments in animals and two epidemiologic studies in humans suggest that aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) may be protective against colon cancer. We tested this hypothesis in a prospective mortality study of 662,424 adults who provided information in 1982 on the frequency and duration of their aspirin use. Death rates from colon cancer were measured through 1988. The possible influence of other risk factors for colon cancer was examined in multivariate analyses for 598 case patients and 3058 matched control subjects drawn from the cohort. Results. Death rates from colon cancer decreased with more frequent aspirin use in both men and women. The relative risk among persons who used aspirin 16 or more times per month for at least one year was 0.60 in men (95 percent confidence interval, 0.40 to 0.89) and 0.58 in women (95 percent confidence interval, 0.37 to 0.90). The risk estimates were unaffected when we excluded persons who reported at entry into the study that they had cancer, heart disease, stroke, or another condition that might influence both their aspirin use and their mortality. Adjustment for dietary factors, obesity, physical activity, and family history did not alter the findings significantly. No association was found between the use of acetaminophen and the risk of colon cancer. Conclusions. Regular aspirin use at low doses may reduce the risk of fatal colon cancer. Whether this is due to a direct effect of aspirin, perhaps mediated by the inhibition of prostaglandin synthesis, or to other factors indirectly associated with aspirin use is unclear.			THUN, MJ (corresponding author), AMER CANC SOC, DEPT EPIDEMIOL & STAT, 1599 CLIFTON RD, ATLANTA, GA 30329 USA.							[Anonymous], 1988, BRIT MED J, V296, P320; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; FLANDERS WD, 1984, J CHRON DIS, V37, P449, DOI 10.1016/0021-9681(84)90028-6; FURUTA Y, 1988, CANCER RES, V48, P3002; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P433; KUDO T, 1980, GANN, V71, P260; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; Moorghen M, 1990, Acta Histochem Suppl, V39, P195; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; NARISAWA T, 1981, CANCER RES, V41, P1954; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PAGANINIHILL A, 1991, J NATL CANCER I, V83, P1182, DOI 10.1093/jnci/83.16.1182-a; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PLESCIA OJ, 1975, P NATL ACAD SCI USA, V72, P1848, DOI 10.1073/pnas.72.5.1848; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POLLARD M, 1983, J NATL CANCER I, V70, P1103; POLLARD M, 1981, P SOC EXP BIOL MED, V167, P161; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; ROSENBERG L, 1991, J NATL CANCER I, V83, P1183, DOI 10.1093/jnci/83.16.1183; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P230; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	35	1538	1593	4	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1593	1596		10.1056/NEJM199112053252301	http://dx.doi.org/10.1056/NEJM199112053252301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1669840				2022-12-28	WOS:A1991GR77000001
J	WEINBERG, RA				WEINBERG, RA			TUMOR SUPPRESSOR GENES	SCIENCE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE-T-ANTIGEN; NEUROFIBROMATOSIS TYPE-1 GENE; VIRUS-40 LARGE-T; AVIAN ERYTHROBLASTOSIS VIRUS; NORMAL HUMAN CHROMOSOME-11; GTPASE-ACTIVATING PROTEIN; THYROID-HORMONE RECEPTOR; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS	For the past decade, cellular oncogenes have attracted the attention of biologists intent on understanding the molecular origins of cancer. As the present decade unfolds, oncogenes are yielding their place at center stage to a second group of actors, the tumor suppressor genes, which promise to teach us equally important lessons about the molecular mechanisms of cancer pathogenesis.	MIT, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WEINBERG, RA (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [5R35-CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P84; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BENEDICT WF, 1984, CANCER RES, V44, P3471; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE WK, 1989, CC MOL BIOL, P67; CAVENEE WK, 1983, NATURE, V304, P179; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHENG J, 1990, BLOOD, V75, P730; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHO K, COMMUNICATION; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CRAWFORD LV, 1982, I J CANCER, V30, P185; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P24201; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVILEE P, 1991, ONCOGENE, V6, P311; DILLER L, 1990, MOL CELL BIOL, V10, P772; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EGAN C, 1989, ONCOGENE, V4, P383; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HANSEN MF, 1987, CANCER RES, V47, P5518; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, UNPUB; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENSEN RD, 1971, NEW ENGL J MED, V285, P7; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAELBLING M, 1986, CYTOGENET CELL GENET, V41, P65, DOI 10.1159/000132206; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Klein G, 1990, TUMOR SUPPRESSOR GEN, P273; KLINGER HP, CYTOGENET CELL GENET; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS PA, 1990, TUMOR SUPPRESSOR GEN, P201; MARX JL, 1989, SCIENCE, V244, P147, DOI 10.1126/science.2704994; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METHA PP, 1986, CELL, V44, P187; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, ACCOMPLISHMENTS CANC, P197; MONTENARH M, 1989, ONCOGENE, V4, P379; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, COMMUNICATION; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAIN B, 1990, New Biologist, V2, P284; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAUL J, 1987, 1986 P INT C CANC RE, P145; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROBBINS PD, 1991, NATURE, V351, P419, DOI 10.1038/351419a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROULEAU GA, 1987, NATURE, V329, P5419; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; RYGAARD K, 1990, CANCER RES, V50, P5312; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SPORN MB, 1990, ANN REV CELL BIOL, V6, P597; SPORN MB, 1987, J CELL BIOL, V105, P10039; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STENGER JE, IN PRESS MOL CARCINO; Stoker M, 1967, Curr Top Dev Biol, V2, P107; STOKER MGP, 1967, J CELL SCI, V2, P293; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TROSKO JE, 1984, MECHANISMS TUMOR PRO, P120; TSAI YC, 1990, CANCER RES, V50, P40; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, COMMUNICATION; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIENER F, 1974, J CELL SCI, V15, P177; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU HJ, 1989, ONCOGENE, V4, P807; YAMASAKI H, 1988, THEORIES CARCINOGENE, P143; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, ONCOGENE, V4, P471; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	237	1498	1590	0	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1138	1146		10.1126/science.1659741	http://dx.doi.org/10.1126/science.1659741			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1659741				2022-12-28	WOS:A1991GQ83400032
J	GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM				GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM			INDUCTION OF TYPE-I DIABETES BY KILHAM RAT VIRUS IN DIABETES-RESISTANT BB/WOR RATS	SCIENCE			English	Article							MELLITUS	Type I diabetes mellitus is an autoimmune disease resulting from the interaction of genetic and environmental factors. A virus that was identified serologically as Kilham's rat virus (KRV) was isolated from a spontaneously diabetic rat and reproducibly induced diabetes in naive diabetes-resistant (DR) BB/Wor rats. Viral antigen was not identified in pancreatic islet cells, and beta-cell cytolysis was not observed until after the appearance of lymphocytic insulitis. KRV did not induce diabetes in major histocompatibility complex-concordant and discordant non-BB rats and did not accelerate diabetes in diabetes-prone BB/Wor rats unless the rats had been reconstituted with DR spleen cells. This model of diabetes may provide insight regarding the interagation of viruses and autoimmune disease.	UNIV MASSACHUSETTS, MED CTR, DEPT PATHOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CHARLES RIVER LAB, WILMINGTON, MA 01887 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019155, N01DK072287, T32DK007302, R37DK019155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19155, DK7-2287, DK07302] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER L, 1988, FRONTIERS DIABETES R, V2, P74; CERRA MA, 1991, LAB ROBOTICS AUTOMAT, V2, P119; COLLE E, 1986, DIABETES, V35, P454, DOI 10.2337/diabetes.35.4.454; FORREST IM, 1969, PEDIATRICS, V44, P445; GAMBLE DR, 1969, BRIT MED J, V3, P627, DOI 10.1136/bmj.3.5671.627; GUBERSKI DL, UNPUB; JACOBY RO, 1987, ARCH VIROL, V95, P251, DOI 10.1007/BF01310784; LEITER EH, 1988, PATHOLOGY ENDOCRINE, P85; LIKE AA, 1991, DIABETES, V40, P259, DOI 10.2337/diabetes.40.2.259; LIKE AA, 1990, AM J PATHOL, V136, P565; LIKE AA, 1986, J IMMUNOL, V136, P3254; LIKE AA, 1985, J IMMUNOL, V134, P1583; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; SIMPSON RW, 1984, SCIENCE, V223, P1425, DOI 10.1126/science.6701529; THOMAS VA, 1991, DIABETES, V40, P255, DOI 10.2337/diabetes.40.2.255; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; YOON JW, 1991, CURR TOP MICROBIOL I, V160, P95	20	160	162	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1010	1013		10.1126/science.1658938	http://dx.doi.org/10.1126/science.1658938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658938				2022-12-28	WOS:A1991GP88300046
J	CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM				CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM			NATURAL-HISTORY OF THE EOSINOPHILIA-MYALGIA-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						EOSINOPHILIA; MUSCULAR DISEASES; TRYPTOPHAN; FATIGUE; PREDNISONE	TOXIC OIL SYNDROME; TRYPTOPHAN; SCLERODERMA; INGESTION; FASCIITIS; FEATURES	Objective: To describe the natural history and disease progression of the eosinophilia-myalgia syndrome and to assess the therapeutic effects of orally administered steroids on the disorder as of October 1990. Design: Case-series analysis. A cohort of 45 patients with the eosinophilia-myalgia syndrome was followed prospectively by periodic telephone interviews and medical examinations for an average of 14 months after onset of illness. Setting: Washington state. Patients: The cases of 47 patients were reported to the Washington State Department of Health from 1 July to 12 December 1989. Two patients were unavailable for follow-up, and the remaining 45 completed the study. Main Results: Patients were predominantly non-Hispanic white women (87%) with an average age of 49 years. Symptoms typically progressed from early onset of myalgia and fatigue to later development of neurologic and scleroderma-like skin changes. Six (13%) patients recovered completely within 2 to 5 months of symptom onset. After 14 months of illness, over half of the patients who initially presented with myalgia, fatigue, or scleroderma-like skin changes remained symptomatic. The average severity of each major symptom was measured using interviews and patient self-reports and has improved subjectively by at least 40%. Statistical analyses showed no significant difference in long-term symptom duration or severity between patients treated and those not treated with prednisone. Conclusions: The eosinophilia-myalgia syndrome is a long-term illness characterized by progressive improvement during the first 25 weeks after symptom onset, followed by a protracted phase of symptom resolution. We could not show a clear-cut benefit of prednisone in reducing the long-term severity or duration of the disease.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA; MADIGAN ARMY MED CTR, TACOMA, WA 98431 USA; MINOR & JAMES MED CLIN, SEATTLE, WA 98104 USA; WASHINGTON STATE DEPT HLTH, SEATTLE, WA 98155 USA	University of Washington; University of Washington Seattle; Madigan Army Medical Center								ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CALLAHAN LF, 1987, ARTHRITIS RHEUM, V30, P630, DOI 10.1002/art.1780300605; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; FLANNERY MT, 1990, ANN INTERN MED, V112, P300, DOI 10.7326/0003-4819-112-4-300; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1990, ANN INTERN MED, V112, P85, DOI 10.7326/0003-4819-112-2-85; KILBOURNE EM, 1988, AM J EPIDEMIOL, V127, P1210, DOI 10.1093/oxfordjournals.aje.a114914; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MEDSGER TA, 1990, NEW ENGL J MED, V322, P926, DOI 10.1056/NEJM199003293221309; MINDEL A, 1982, LANCET, V1, P697; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; STERNBERG EM, 1980, NEW ENGL J MED, V303, P782, DOI 10.1056/NEJM198010023031403; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; VARGA J, 1990, ANN INTERN MED, V112, P344, DOI 10.7326/0003-4819-112-5-344; 1990, SPSS REFERENCE GUIDE, P687; 1990, MMWR, V39, P89; 1990, MMWR, V39, P14; 1990, MMWR, V38, P327; 1989, MMWR, V38, P785; 1989, MMWR, V38, P765	25	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					437	442		10.7326/0003-4819-115-6-437	http://dx.doi.org/10.7326/0003-4819-115-6-437			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651673				2022-12-28	WOS:A1991GE81000004
J	BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y				BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y			REDOX REGULATION OF A PROTEIN TYROSINE KINASE IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							REDUCTION SENSITIVE INTERACTION; BETA-N-ACETYLGLUCOSAMINIDASE; CELLULAR 50-KDA PROTEIN; 5' NONCODING REGION; OXIDATION-REDUCTION; DISULFIDE ISOMERASE; INSULIN-RECEPTOR; TRANSMEMBRANE PROTEINS; SECRETORY PROTEINS; DNA FRAGMENTATION	The subcellular localization of the mouse Ltk transmembrane protein tyrosine kinase was studied in transfected COS cells, a mature B lymphocyte line, and a low expressing transfected lymphocyte clone. Indirect immunofluorescence and immunogold staining of COS transfectants and endoglycosidase analysis of both COS transfectants and lymphocytes indicate the unusual localization of Ltk to the endoplasmic reticulum (ER). Ltk resembles a receptor tyrosine kinase; it has a short, glycosylated, and cysteine-rich N-terminal domain. Yet, it appears to function in a ligand-independent mechanism: its in vivo catalytic activity is markedly enhanced by alkylating and thiol-oxidizing agents, and the active fraction of the protein occurs as disulfide-linked multimers. The catalytic activity of Ltk in the ER may be regulated via changes in the cellular redox potential, a novel mechanism for regulating protein tyrosine kinases. The ability to respond to redox changes in the cell may, however, be shared with certain receptor kinases during their passage through the ER.			BAUSKIN, AR (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GERONIMO J, 1983, P NATL ACAD SCI USA, V80, P6848; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P363; HEDO JA, 1983, J BIOL CHEM, V258, P20; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUYE S, 1988, SYNTHESIS APPLICATIO; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARU Y, 1990, ONCOGENE RES, V5, P199; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER S, 1986, ONCOGENES GROWTH CON, P70; PORUCHYNSKY MS, 1985, J CELL BIOL, V101, P2199, DOI 10.1083/jcb.101.6.2199; RICE GC, 1986, CANCER RES, V46, P6105; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; ROWE GT, 1984, J MOL CELL CARDIOL, V16, P1075, DOI 10.1016/S0022-2828(84)80020-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; SITIA R, 1987, EMBO J, V6, P3939; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKAHASHI S, 1989, EUR J IMMUNOL, V19, P1911, DOI 10.1002/eji.1830191023; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	77	249	251	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					685	696		10.1016/0092-8674(91)90114-E	http://dx.doi.org/10.1016/0092-8674(91)90114-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652370				2022-12-28	WOS:A1991GC74500009
J	KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG				KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG			VARIABLE EFFECTS OF PHOSPHORYLATION OF PIT-1 DICTATED BY THE DNA RESPONSE ELEMENTS	SCIENCE			English	Article							POU-SPECIFIC DOMAIN; GROWTH-HORMONE; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING; ACTIVATION; PROTEIN; OCT-1; PROMOTERS; SEQUENCE	Pit-1, a tissue-specific POU domain transcription factor, is required for the activation of the prolactin, growth hormone, and Pit-1 promoters that confer regulation by epidermal growth factor, adenosine 3',5'-monophosphate (cAMP), and phorbol esters. Pit-1 is phosphorylated in pituitary cells at two distinct sites in response to phorbol esters and cAMP. Phosphorylation of Pit-1 modifies its conformation on DNA recognition elements and results in increased binding at certain sites and decreased binding at other sites, dependent on DNA sequences adjacent to the core Pit-1 binding motif. One residue (Thr220), located in the POU homeodomain within a sequence conserved throughout the POU-domain family, confers these responses.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	KAPILOFF, MS (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.			Kapiloff, Michael/0000-0002-7005-6953; Wegner, Michael/0000-0002-4586-3294	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAPILOFF MS, UNPUB; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MOHR IJ, 1989, P NATL ACAD SCI USA, V86, P6479, DOI 10.1073/pnas.86.17.6479; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VOSS J, IN PRESS GNEES DEV; VOSS J, IN PRESS J BIOL CHEM	33	196	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					786	789		10.1126/science.1652153	http://dx.doi.org/10.1126/science.1652153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1652153				2022-12-28	WOS:A1991GB29500037
J	CALVI, BR; HONG, TJ; FINDLEY, SD; GELBART, WM				CALVI, BR; HONG, TJ; FINDLEY, SD; GELBART, WM			EVIDENCE FOR A COMMON EVOLUTIONARY ORIGIN OF INVERTED REPEAT TRANSPOSONS IN DROSOPHILA AND PLANTS - HOBO, ACTIVATOR, AND TAM3	CELL			English	Article							M HYBRID DYSGENESIS; ZEA-MAYS-L; ELEMENT-AC; P-ELEMENT; MOLECULAR-BASIS; GENE; SEQUENCE; DNA; INSERTION; EXCISION	We have sequenced HFL1 from D. melanogaster, the only cloned hobo element shown to have transposase activity. The 2959 bp HFL1 sequence predicts a 2.0 kb open reading frame (ORF1) with substantial amino acid similarity to the transposases of Activator (Ac) from maize (Zea mays) and Tam3 from snapdragon (Antirrhinum majus). Mutational analysis of a C-terminal region of ORF1 conserved with Ac and Tam3 indicates that it is essential for hobo transposase activity. This is an example of extensive amino acid sequence identity between short inverted repeat elements in different kingdoms. We discuss the possibility that the conservation of hobo, Ac, and Tam3 transposases represents an example of horizontal transmission of genetic information between plants and animals.			CALVI, BR (corresponding author), HARVARD UNIV, DEPT CELLULAR & DEV BIOL, 16 DIVINITY AVE, CAMBRIDGE, MA 02138 USA.							BEHRENS U, 1984, MOL GEN GENET, V194, P346, DOI 10.1007/BF00383540; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; Blackman R.K., 1989, MOBILE DNA, P523; BLACKMAN RK, 1989, EMBO J, V8, P211, DOI 10.1002/j.1460-2075.1989.tb03366.x; COUPLAND G, 1988, EMBO J, V7, P3653, DOI 10.1002/j.1460-2075.1988.tb03246.x; DANIELS SB, 1990, MOL BIOL EVOL, V7, P589; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEDOROFF N, 1983, CELL, V35, P235, DOI 10.1016/0092-8674(83)90226-X; FUSSWINKEL H, 1991, MOL GEN GENET, V225, P186, DOI 10.1007/BF00269846; HEHL R, 1991, PLANT MOL BIOL, V16, P369, DOI 10.1007/BF00020572; HERRMANN A, 1988, MOL GEN GENET, V212, P93, DOI 10.1007/BF00322449; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KAY BK, 1983, J MOL BIOL, V170, P583, DOI 10.1016/S0022-2836(83)80122-3; KUNZE R, 1987, EMBO J, V6, P1555, DOI 10.1002/j.1460-2075.1987.tb02400.x; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LI MG, 1990, P NATL ACAD SCI USA, V87, P6044, DOI 10.1073/pnas.87.16.6044; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MCCLINTOCK B, 1948, CARNEGIE I WASH, V47, P155; MCGINNIS W, 1983, CELL, V34, P75, DOI 10.1016/0092-8674(83)90137-X; MISMER D, 1987, GENETICS, V116, P565; MULLERNEUMANN M, 1984, MOL GEN GENET, V198, P19, DOI 10.1007/BF00328695; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; POHLMAN RF, 1984, CELL, V37, P635, DOI 10.1016/0092-8674(84)90395-7; PUSTELL J, 1984, NUCLEIC ACIDS RES, V12, P643, DOI 10.1093/nar/12.1Part2.643; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER H, 1985, MOL GEN GENET, V199, P225, DOI 10.1007/BF00330263; SOMMER H, 1988, PLANT TRANSPOSABLE E, P227; STRECK RD, 1986, EMBO J, V5, P3615, DOI 10.1002/j.1460-2075.1986.tb04690.x	38	249	256	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					465	471		10.1016/0092-8674(81)90010-6	http://dx.doi.org/10.1016/0092-8674(81)90010-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651170				2022-12-28	WOS:A1991GA94100008
J	AMAYA, E; MUSCI, TJ; KIRSCHNER, MW				AMAYA, E; MUSCI, TJ; KIRSCHNER, MW			EXPRESSION OF A DOMINANT NEGATIVE MUTANT OF THE FGF RECEPTOR DISRUPTS MESODERM FORMATION IN XENOPUS EMBRYOS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA; SIGNAL TRANSDUCTION; CELL-LINE; TGF-BETA; INDUCTION; GENES; INVITRO; LAEVIS; IDENTIFICATION	Peptide growth factors may play a role in patterning of the early embryo, particularly in the induction of mesoderm. We have explored the role of fibroblast growth factor (FGF) in early Xenopus development by expressing a dominant negative mutant form of the FGF receptor. Using a functional assay in frog oocytes, we found that a truncated form of the receptor effectively abolished wild-type receptor function. Explants from embryos expressing this dominant negative mutant failed to induce mesoderm in response to FGF. In whole embryos the mutant receptor caused specific defects in gastrulation and in posterior development, and overexpression of a wild-type receptor could rescue these developmental defects. These results demonstrate that the FGF signaling pathway plays an important role in early embryogenesis, particularly in the formation of the posterior and lateral mesoderm.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	AMAYA, E (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Holtfreter J., 1955, ANAL DEV, P230; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; PATERNO GD, 1989, DEVELOPMENT, V106, P79; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WOODLAND HR, 1989, CELL, V59, P767, DOI 10.1016/0092-8674(89)90596-5	52	1026	1043	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					257	270		10.1016/0092-8674(91)90616-7	http://dx.doi.org/10.1016/0092-8674(91)90616-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649700				2022-12-28	WOS:A1991FY71200007
J	DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD			THE RECEPTOR FOR CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CELL EXPRESSION SYSTEM; MOLECULAR-CLONING; CHOLINERGIC DIFFERENTIATION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; BETA-CHAIN; INTERLEUKIN-6; PURIFICATION; FAMILY	Although neurotrophic factors were originally isolated on the basis of their ability to support the survival of neurons, these molecules are now thought to influence many aspects of the development and maintenance of the nervous system. Identifying the receptors for these neurotrophic factors should aid in identifying the cells on which these factors act and in understanding their precise mechanisms of action. A "tagged-ligand panning" procedure was used to clone a receptor for ciliary neurotrophic factor (CNTF). This receptor is expressed exclusively within the nervous system and skeletal muscle. The CNTF receptor has a structure unrelated to the receptors utilized by the nerve growth factor family of neurotrophic molecules, but instead is most homologous to the receptor for a cytokine, interleukin-6. This similarity suggests that the CNTF receptor, like the interleukin-6 receptor, requires a second, signal-transducing component. In contrast to all known receptors, the CNTF receptor is anchored to cell membranes by a glycosyl-phosphatidylinositol linkage.			DAVIS, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							ADLER JE, 1989, P NATL ACAD SCI USA, V86, P1080, DOI 10.1073/pnas.86.3.1080; ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BAZAN JF, IN PRESS NEURON; BOULTON TG, IN PRESS CELL; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; Davis S.M, UNPUB; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANDL J, UNPUB; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FUKUDA K, 1985, P NATL ACAD SCI USA, V82, P8795; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD D, 1991, NATURE, V350, P678; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LOW MG, 1987, BIOCHEM J, V244, P1; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1989, NERVE GROWTH FACTORS, P31; MANTHORPE M, 1984, GROWTH MATURATION FA; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, IN PRESS P NATL ACAD; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RAO MS, 1990, DEV BIOL, V139, P654; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SENDTNER M, 1989, NATURE, V345, P920; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; SQUINTO SP, IN PRESS CELL; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WEBER MJ, 1985, J NEUROCHEM, V45, P1541, DOI 10.1111/j.1471-4159.1985.tb07225.x; WONG V, 1987, P NATL ACAD SCI USA, V84, P8726, DOI 10.1073/pnas.84.23.8726; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	56	603	628	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					59	63		10.1126/science.1648265	http://dx.doi.org/10.1126/science.1648265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648265				2022-12-28	WOS:A1991FV17700032
J	IGARASHI, K; ISHIHAMA, A				IGARASHI, K; ISHIHAMA, A			BIPARTITE FUNCTIONAL MAP OF THE ESCHERICHIA-COLI RNA POLYMERASE-ALPHA SUBUNIT - INVOLVEMENT OF THE C-TERMINAL REGION IN TRANSCRIPTION ACTIVATION BY CAMP-CRP	CELL			English	Article							AMP RECEPTOR PROTEIN; TEMPERATURE-SENSITIVE MUTATIONS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PROMOTER STRENGTH; SIGMA-FACTOR; GENE; EXPRESSION; OPERON; LACTOSE	The alpha-subunit of Escherichia coli RNA polymerase plays a major role in the subunit assembly. Carboxy-terminal deletion derivatives lacking 73 or 94 amino acid residues were assembled in vitro into enzyme molecules. Core enzymes consisting of these C-terminal-truncated alpha-subunits were as active in RNA synthesis as native core enzyme. By the addition of sigma-70 subunit, these mutant enzymes initiated transcription from certain promoters. The mutant RNA polymerases, however, did not show cAMP-CRP activated transcription. These results demonstrate that the N-terminal region of the alpha-subunit is involved in the formation of active enzyme molecule, while the C-terminal region plays an essential role in response to transcription activation by cAMP-CRP.			IGARASHI, K (corresponding author), NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN.			Igarashi, Kazuhiko/0000-0002-2470-2475				ADHYA S, 1990, J BIOL CHEM, V265, P10797; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BLANCO C, 1986, MOL GEN GENET, V202, P112, DOI 10.1007/BF00330526; DALE EC, 1986, J MOL BIOL, V192, P793, DOI 10.1016/0022-2836(86)90029-X; DONNELLY CE, 1987, J BACTERIOL, V169, P1812, DOI 10.1128/jb.169.5.1812-1817.1987; FUJIKI H, 1976, MOL GEN GENET, V145, P19, DOI 10.1007/BF00331552; FUKUDA R, 1974, J MOL BIOL, V83, P353, DOI 10.1016/0022-2836(74)90284-8; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V2, P93; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HALLING C, 1990, J BACTERIOL, V172, P3541, DOI 10.1128/jb.172.7.3541-3548.1990; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HUGOUVIEUXCOTTEPATTAT N, 1983, J GEN MICROBIOL, V129, P3345; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; ISHIHAMA A, 1980, J MOL BIOL, V137, P137, DOI 10.1016/0022-2836(80)90321-6; Ishihama A, 1981, Adv Biophys, V14, P1; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KAJITANI M, 1980, MOL GEN GENET, V179, P489, DOI 10.1007/BF00271738; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; NAKAMURA Y, 1980, MOL GEN GENET, V178, P487, DOI 10.1007/BF00337853; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROWLAND GC, 1985, J BACTERIOL, V164, P972, DOI 10.1128/JB.164.2.972-975.1985; SAITOH T, 1976, J MOL BIOL, V206, P591; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; VENEZIA ND, 1990, J BIOL CHEM, V265, P8122; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	40	304	314	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1015	1022		10.1016/0092-8674(91)90553-B	http://dx.doi.org/10.1016/0092-8674(91)90553-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646077				2022-12-28	WOS:A1991FR04700012
J	PORRECO, RP; BARTON, SM; HAVERKAMP, AD				PORRECO, RP; BARTON, SM; HAVERKAMP, AD			OCCLUSION OF UMBILICAL ARTERY IN ACARDIAC, ACEPHALIC TWIN	LANCET			English	Note								In the acardiac, acephalic twin malformation the normal co-twin is put at risk because of the extra cardiac work-load. Surgical procedures may be hazardous to the mother. We describe a novel approach - the insertion of a helical metal coil to induce thrombosis in the umbilical artery of the acardiac twin - which immediately interrupted flow. The co-twin was delivered at 39 weeks and his neonatal course has been normal.	COLORADO PERMANENTE MED GRP PC,DENVER,CO; UNIV COLORADO,HLTH SERV CTR,DEPT OBSTET & GYNECOL,DENVER,CO 80203	Permanente Medical Groups; University of Colorado System; University of Colorado Denver	PORRECO, RP (corresponding author), UNIV COLORADO,HLTH SERV CTR,AMI ST LUKES PERINATAL PROGRAM,DENVER,CO 80203, USA.							ROBIE GF, 1989, NEW ENGL J MED, V320, P512, DOI 10.1056/NEJM198902233200808; VANALLEN MI, 1983, SEMIN PERINATOL, V7, P285	2	85	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					326	327		10.1016/0140-6736(91)90946-M	http://dx.doi.org/10.1016/0140-6736(91)90946-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671233				2022-12-28	WOS:A1991EX36200005
J	CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C				CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C			ASSOCIATION OF ESCHERICHIA-COLI HEP-2 ADHERENCE PATTERNS WITH TYPE AND DURATION OF DIARRHEA	LANCET			English	Article							DIFFUSE ADHERENCE; CELL ADHERENCE; ADHESION; PATHOGENS; CHILDREN; STRAINS; CULTURE; ASSAY	373 (59%) out of 636 faecal specimens obtained during the first 2 years of life of 72 Mexican children yielded adherent Escherichia coli (HEp-2 cells). Strains with localised adherence were significantly associated with acute non-bloody diarrhoea, whereas strains with aggregative adherence were significantly associated with persistent diarrhoea. Half the strains with localised adherence were not enteropathogenic E coli serotypes nor did they hybridise with an enteropathogenic E coli adherence factor DNA probe. All strains with localised adherence gave a positive fluorescent actin staining (FAS) assay, irrespective of serotype. One-third of children colonised by aggregative strains had bloody diarrhoea. Isolation of strains with diffuse adherence was not related to type or duration of diarrhoea but was generally associated with isolation of another pathogenic organism.			CRAVIOTO, A (corresponding author), INST NACL SALUD PUBL, CTR RES INFECT DIS, APARTADO POSTAL 16-116, MEXICO CITY 02000, DF, MEXICO.		Navarro, Armando/AAE-3832-2022; NAVARRO, ARMANDO/AAO-7368-2020	NAVARRO, ARMANDO/0000-0002-6693-7168				BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; BENZ I, 1989, INFECT IMMUN, V57, P1506, DOI 10.1128/IAI.57.5.1506-1511.1989; BHAN MK, 1989, PEDIATR INFECT DIS J, V8, P499, DOI 10.1097/00006454-198908000-00005; BHAN MK, 1989, J INFECT DIS, V158, P70; BILGE SS, 1989, J BACTERIOL, V171, P4281, DOI 10.1128/JB.171.8.4281-4289.1989; CHATKAEOMORAKOT A, 1987, J INFECT DIS, V156, P669, DOI 10.1093/infdis/156.4.669; COBELJIC M, 1989, EPIDEMIOL INFECT, V103, P53, DOI 10.1017/S0950268800030351; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; CRAVIOTO A, 1990, AM J EPIDEMIOL, V131, P886, DOI 10.1093/oxfordjournals.aje.a115579; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; FLEISS JL, 1973, STATISTICAL METHODS, P155; GOMES TAT, 1989, J CLIN MICROBIOL, V27, P266, DOI 10.1128/JCM.27.2.266-269.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P78, DOI 10.1128/IAI.55.1.78-85.1987; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; LEVINE MM, 1988, J INFECT DIS, V158, P224, DOI 10.1093/infdis/158.1.224; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MATHEWSON JJ, 1989, J INFECT DIS, V159, P1057, DOI 10.1093/infdis/159.6.1057; NATARO JP, 1985, J INFECT DIS, V152, P560, DOI 10.1093/infdis/152.3.560; ORSKOV F, 1975, AMPIS B, V83, P565; SAVARINO SJ, 1990, 90TH ANN M AM SOC MI, P45; SCOTLAND SM, 1989, J INFECTION, V19, P237, DOI 10.1016/S0163-4453(89)90729-9; VIAL PA, 1987, J INFECT DIS, V155, P377	23	262	266	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	1991	337	8736					262	264		10.1016/0140-6736(91)90868-P	http://dx.doi.org/10.1016/0140-6736(91)90868-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671111				2022-12-28	WOS:A1991EV71900003
J	VERNON, CC; HARRISON, M				VERNON, CC; HARRISON, M			HYPERTHERMIA WITH LOW-DOSE RADIOTHERAPY FOR RECURRENT BREAST-CARCINOMA	LANCET			English	Letter									HAMMERSMITH HOSP,DEPT RADIOTHERAPY & ONCOL,LONDON W12 0HS,ENGLAND	Imperial College London	VERNON, CC (corresponding author), HAMMERSMITH HOSP,CYCLOTRON UNIT,MRC,HYPERTHERMIA CLIN,LONDON W12 0HS,ENGLAND.							DUNLOP P R C, 1986, International Journal of Hyperthermia, V2, P39, DOI 10.3109/02656738609019992; Egawa S., 1989, J JPN SOC THER RADIO, V1, P135; GONZALEZ DG, 1988, RADIOTHER ONCOL, V12, P95, DOI 10.1016/0167-8140(88)90163-6; LINDHOLM CE, 1987, INT J HYPERTHER, V3, P393, DOI 10.3109/02656738709140410; NOVELL, 1990, LANCET, V336, P1383; PEREZ CA, IN PRESS AM J CLIN O; VANDERZEE J, 1988, INT J RADIAT ONCOL, V15, P1407, DOI 10.1016/0360-3016(88)90237-4	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					59	59		10.1016/0140-6736(91)93384-L	http://dx.doi.org/10.1016/0140-6736(91)93384-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670685				2022-12-28	WOS:A1991EQ60400062
J	WINKLER, E; LEVERTOWSKY, D; SHVORON, A; CHAYEN, D; GOODMAN, RM; TSUR, H				WINKLER, E; LEVERTOWSKY, D; SHVORON, A; CHAYEN, D; GOODMAN, RM; TSUR, H			FAMILIAL LEG ULCERS OF JUVENILE ONSET	LANCET			English	Note								Chronic ulceration of the legs was found in the propositus and in ten male relatives in a family of Iraqi Jews. All eleven males had juvenile onset of symptoms. Venous lesions with ulceration were found in two of the propositus' brothers and without ulceration in his three sisters. The findings suggest an autosomal dominant sex-limited genetic defect.	CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT VASC SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,INST GENET,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	WINKLER, E (corresponding author), CHAIM SHEBA MED CTR,DEPT PLAST SURG,IL-52621 TEL HASHOMER,ISRAEL.							ADAR R, 1983, NEW ENGL J MED, V308, P1113, DOI 10.1056/NEJM198305123081901; Dale J J, 1983, Health Bull (Edinb), V41, P310; GANOR S, 1976, BRIT J DERMATOL, V95, P203, DOI 10.1111/j.1365-2133.1976.tb00829.x; GOODMAN RM, 1979, GENETIC DISORDERS JE, P124; SHIONOYA S, 1989, VASCULAR SURG, P207; THOMPSON JS, 1986, GENETICS MED, P73	6	3	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					15	16		10.1016/0140-6736(91)93333-5	http://dx.doi.org/10.1016/0140-6736(91)93333-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670650				2022-12-28	WOS:A1991EQ60400007
J	METLAY, LA				METLAY, LA			PROPHYLACTIC FLUCONAZOLE AND MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											METLAY, LA (corresponding author), UNIV ROCHESTER,MED CTR,ROCHESTER,NY 14642, USA.			Denning, David/0000-0001-5626-2251				GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					644	644						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640962				2022-12-28	WOS:A1992JK20400018
J	SCHOLTEN, SL; NETTLEMAN, MD; SARRAZIN, EF				SCHOLTEN, SL; NETTLEMAN, MD; SARRAZIN, EF			PROPHYLACTIC FLUCONAZOLE AND MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											SCHOLTEN, SL (corresponding author), UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242, USA.							GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; 1992, MED LETT DRUGS THER, V34, P14	3	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					644	645						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640963				2022-12-28	WOS:A1992JK20400019
J	STEINMEYER, K; ORTLAND, C; JENTSCH, TJ				STEINMEYER, K; ORTLAND, C; JENTSCH, TJ			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A DEVELOPMENTALLY REGULATED SKELETAL-MUSCLE CHLORIDE CHANNEL	NATURE			English	Article							SODIUM-CHANNEL; ACETYLCHOLINE-RECEPTOR; TORPEDO ELECTROPLAX; SELECTIVE CHANNELS; MESSENGER-RNAS; RAT MUSCLE; CONDUCTANCE	SKELETAL muscle is unusual in that 70-85% of resting membrane conductance is carried by chloride ions 1. This conductance is essential for membrane-potential stability, as its block by 9-anthracene-carboxylic acid and other drugs causes myotonia 2,3. Fish electric organs are developmentally derived from skeletal muscle, suggesting that mammalian muscle may express a homologue of the Torpedo mamorata electroplax chloride channel 4,5. We have now cloned the complementary DNA encoding a rat skeletal muscle chloride channel by homology screening to the Cl- channel from Torpedo 4 (Fig. 1a). It encodes a 994-amino-acid protein which is about 54% identical to the Torpedo channel and is predominantly expressed in skeletal muscle. Messenger RNA amounts in that tissue increase steeply in the first 3-4 weeks after birth, in parallel with the increase in muscle Cl- conductance 6. Expression from cRNA in Xenopus oocytes leads to 9-anthracene-carboxylic acid-sensitive currents with time and voltage dependence typical for macroscopic muscle Cl- conductance. This and the functional destruction of this channel in mouse myotonia 7 suggests that we have cloned the major skeletal muscle chloride channel.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, IN PRESS P NATN ACAD; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BLATZ AL, 1985, BIOPHYS J, V47, P119, DOI 10.1016/S0006-3495(85)83884-4; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; CAMERINO DC, 1989, PFLUG ARCH EUR J PHY, V413, P568, DOI 10.1007/BF00594192; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COOPERMAN SS, 1987, P NATL ACAD SCI USA, V84, P8721, DOI 10.1073/pnas.84.23.8721; Higuchi R., 1989, PCR TECHNOLOGY, P61; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TRIMMER JS, 1990, DEV BIOL, V142, P360, DOI 10.1016/0012-1606(90)90356-N; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9	24	382	388	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					301	304		10.1038/354301a0	http://dx.doi.org/10.1038/354301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659664				2022-12-28	WOS:A1991GT20400046
J	YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W				YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W			2 DROSOPHILA RECEPTOR-LIKE TYROSINE PHOSPHATASE GENES ARE EXPRESSED IN A SUBSET OF DEVELOPING AXONS AND PIONEER NEURONS IN THE EMBRYONIC CNS	CELL			English	Article							HOMOPHILIC ADHESION MOLECULE; LEUKOCYTE-COMMON ANTIGEN; PROTO-ONCOGENE HOMOLOG; FASCICLIN-I; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHORYLATION; GRASSHOPPER; SEQUENCE	Two Drosophila receptor-like tyrosine phosphatase genes, DPTP99A and DPTP10D, were characterized. Protein products of these genes show distinct expression patterns specific to subsets of developing CNS axons. DPTP99A expression coincides with the onset of axonogenesis and is expressed in several pioneer neurons, including aCC and RP2, which pioneer the intersegmental nerve; its proteins are transiently expressed in the intersegmental and segmental nerves, arguing for a role in the establishment of these nerves. Both genes produce complex sets of transcripts, owing to the alternative utilization of exons and polyadenylation sites. Each gene produces alternative protein forms, which differ in their C-terminal tails. The deduced proteins possess extracellular FN-III repeats and intracellular PTPase domain(s). We discuss the implications of these results and the role of protein tyrosine dephosphorylation in axon outgrowth and guidance.			YANG, XH (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, DROSOPHILA NEUROBIOL LAB, SINGAPORE 0511, SINGAPORE.							ALEXANDER D R, 1990, New Biologist, V2, P1049; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HSU S, 1988, NEUROSCI LETT, V85, P169; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANESS PF, 1990, CIBA F SYMP, V150, P57; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SAMBROOK J, 1989, MOL CLONNING LABORAT; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	174	181	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					661	673		10.1016/0092-8674(91)90062-4	http://dx.doi.org/10.1016/0092-8674(91)90062-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657401				2022-12-28	WOS:A1991GQ40700004
J	DUNPHY, WG; KUMAGAI, A				DUNPHY, WG; KUMAGAI, A			THE CDC25 PROTEIN CONTAINS AN INTRINSIC PHOSPHATASE-ACTIVITY	CELL			English	Article							FISSION YEAST CDC25; CELL-CYCLE; TYROSINE-PHOSPHATASES; M-PHASE; MITOTIC INDUCER; HUMAN-PLACENTA; KINASE; ACTIVATION; MITOSIS; DIVISION	Genetic and biochemical studies have indicated that the cdc25 protein controls the entry into mitosis by triggering tyrosine dephosphorylation of the cdc2 protein kinase. We show that the isolated cdc25 protein can catalyze dephosphorylation of several model phosphatase substrates, including p-nitrophenyl phosphate and two distinct tyrosine-phosphorylated peptides. The cdc25-dependent cleavage reaction closely resembles dephosphorylation by known tyrosine phosphatases: the reaction requires a reducing agent, shows high sensitivity to sodium vanadate, and proceeds efficiently in the presence of metal chelators. Moreover, the phosphatase activity of the cdc25 protein is eliminated by treatment with N-ethylmaleimide or by alteration of a single conserved cysteine residue by site-directed mutagenesis. These observations indicate that the cdc25 protein can function as a tyrosine phosphatase in the absence of any other protein.			DUNPHY, WG (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORIA AO, 1989, CELL, V58, P193; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722	43	539	553	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					189	196		10.1016/0092-8674(91)90582-J	http://dx.doi.org/10.1016/0092-8674(91)90582-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655274				2022-12-28	WOS:A1991GJ32000017
J	ASHLEY, R; CENT, A; MAGGS, V; NAHMIAS, A; COREY, L				ASHLEY, R; CENT, A; MAGGS, V; NAHMIAS, A; COREY, L			INABILITY OF ENZYME IMMUNOASSAYS TO DISCRIMINATE BETWEEN INFECTIONS WITH HERPES-SIMPLEX VIRUS TYPE-1 AND TYPE-2	ANNALS OF INTERNAL MEDICINE			English	Article						IMMUNOENZYME TECHNIQUES; HERPESVIRUS-HOMINIS; HERPES-GENITALIS; ANTIBODIES, VIRAL; BLOTTING, WESTERN	LINKED IMMUNOSORBENT-ASSAY; GENITAL HERPES; GLYCOPROTEIN-G; HUMAN-SERA; ANTIBODY-RESPONSE; WOMEN; RISK; TRANSMISSION; ACQUISITION; FREQUENCY	Objective: To determine the accuracy of three commercial enzyme immunoassays in detecting and subtyping antibodies to herpes simplex virus type 1 or 2. Design: Cross-sectional. Setting: Referral medical center. Patients: Ninety patients with culture-positive lesions caused by infection with herpes simplex virus type 1 or 2. The results of Western blot and glycoprotein G immunodot enzyme assays showed that an additional 53 patients had subclinical herpes simplex virus type 2 infection, that another 20 patients had subclinical herpes simplex virus type 1 infection, and that 23 patients were seronegative. Measurements: Three commercial enzyme immunoassays were used to determine herpes simplex virus antibody subtypes. Main Results: All three commercial assays performed poorly in all patient groups (except in patients who were seronegative for herpes simplex virus). Among the 40 patients with a first episode of genital herpes, seroconversion to the appropriate viral type was shown by the three assay in only 33%, 55%, and 75% of cases. Among patients with recurrent genital herpes, the three commercial assays identified more than 90% of patients with only herpes simplex virus type 2 antibodies but failed to identify herpes simplex virus type 2 infections in 58% to 76% of patients with antibodies to both virus subtypes. The three assays correctly identified only 55%, 75%, and 85% of the 53 "silent carriers" of herpes simplex virus type 2. Overall, the three enzyme immunoassays detected herpes simplex virus type 2 antibodies in 60%, 62%, and 93% of patients with subtype 2 infections and falsely detected type 2 antibodies in 8%, 27%, and 49% of patients with type 1 infections. Conclusion: Currently licensed enzyme immunoassays give inaccurate or misleading results about the correct herpes simplex virus infecting subtype.	EMORY UNIV, GRADY MEM HOSP, DIV PEDIAT INFECT DIS, ATLANTA, GA 30333 USA	Emory University	ASHLEY, R (corresponding author), UNIV WASHINGTON, CHILDRENS HOSP MED CTR, DEPT LAB MED, DIV VIROL, POB C-5371, SEATTLE, WA 98105 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BECKER TM, 1985, JAMA-J AM MED ASSOC, V253, P1601, DOI 10.1001/jama.253.11.1601; BERNSTEIN DI, 1985, J MED VIROL, V15, P251, DOI 10.1002/jmv.1890150306; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; GILMAN SC, 1977, J INFECT DIS, V136, pS286, DOI 10.1093/infdis/136.Supplement_2.S286; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JORDAN J, 1981, AM J CLIN PATHOL, V76, P467; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MCCLUNG H, 1976, AM J EPIDEMIOL, V104, P192, DOI 10.1093/oxfordjournals.aje.a112289; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MOORE DE, 1989, JAMA-J AM MED ASSOC, V261, P3441, DOI 10.1001/jama.261.23.3441; MORAHAN PS, 1981, INFECT IMMUN, V32, P180, DOI 10.1128/IAI.32.1.180-187.1981; OZAKI Y, 1983, J MED VIROL, V12, P103, DOI 10.1002/jmv.1890120204; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; YEAGER AS, 1984, PEDIATRICS, V73, P188	30	135	137	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					520	526		10.7326/0003-4819-115-7-520	http://dx.doi.org/10.7326/0003-4819-115-7-520			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1652909				2022-12-28	WOS:A1991GG28300003
J	KINZLER, KW; NILBERT, MC; SU, LK; VOGELSTEIN, B; BRYAN, TM; LEVY, DB; SMITH, KJ; PREISINGER, AC; HEDGE, P; MCKECHNIE, D; FINNIEAR, R; MARKHAM, A; GROFFEN, J; BOGUSKI, MS; ALTSCHUL, SF; HORII, A; ANDO, H; MIYOSHI, Y; MIKI, Y; NISHISHO, I; NAKAMURA, Y				KINZLER, KW; NILBERT, MC; SU, LK; VOGELSTEIN, B; BRYAN, TM; LEVY, DB; SMITH, KJ; PREISINGER, AC; HEDGE, P; MCKECHNIE, D; FINNIEAR, R; MARKHAM, A; GROFFEN, J; BOGUSKI, MS; ALTSCHUL, SF; HORII, A; ANDO, H; MIYOSHI, Y; MIKI, Y; NISHISHO, I; NAKAMURA, Y			IDENTIFICATION OF FAP LOCUS GENES FROM CHROMOSOME-5Q21	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL TUMORIGENESIS; PROTEIN; TUMORS; COLI; LOCALIZATION; CARCINOMA; SEQUENCE; PRODUCT; CANCER	Recent studies suggest that one or more genes on chromosome 5q2l are important for the development of colorectal cancers, particularly those associated with familial adenomatous polyposis (F"). To facilitate the identification of genes from this locus, a portion of the region that is tightly linked to FAP was cloned. Six contiguous stretches of sequence (contigs) containing approximately 5.5 Mb of DNA were isolated. Subclones from these contigs were used to identify and position six genes, all of which were expressed in normal colonic mucosa. Two of these genes (APC and MCC) are likely to contribute to colorectal tumorigenesis. The MCC gene had previously been identified by virtue of its mutation in human colorectal tumors. The APC gene was identified in a contig initiated from the MCC gene and was found to encode an unusually large protein. These two closely spaced genes encode proteins predicted to contain coiled-coil regions. Both genes were also expressed in a wide variety of tissues. Further studies of MCC and APC and their potential interaction should prove useful for understanding colorectal neoplasia.	JOHNS HOPKINS UNIV, SCH MED, MOLEC GENET LAB, BALTIMORE, MD 21231 USA; ICI PLC, PHARMACEUT, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA; NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA; JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOKYO 170, JAPAN	Johns Hopkins University; Children's Hospital Los Angeles; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Japanese Foundation for Cancer Research			Altschul, Stephen/R-4000-2019; Heisterkamp, Nora/C-1698-2012; Horii, Akira/AAW-2839-2021; Bryan, Tracy M/B-8468-2014	Heisterkamp, Nora/0000-0003-2769-2273; Horii, Akira/0000-0002-3967-3291; Bryan, Tracy/0000-0002-7990-5501; Nilbert, Mef/0000-0003-2717-1937	NCI NIH HHS [CA35494, CA06973, CA44688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494, R01CA044688, P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1990, CANCER RES, V50, P7717; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CARTER PW, 1990, MOL GEN GENET, V221, P72, DOI 10.1007/BF00280370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Dayhoff M., 1978, ATLAS PROTEIN SEQUEN; DELATTRE O, 1989, LANCET, V2, P353; DUNLOP MG, 1989, GENOMICS, V5, P350, DOI 10.1016/0888-7543(89)90068-2; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUKUI Y, 1989, MOL CELL BIOL, V9, P5617, DOI 10.1128/MCB.9.12.5617; GROSS ME, 1991, CANCER RES, V51, P1452; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, IN PRESS CELL; KINZLER KD, UNPUB; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEERA P, 1989, HUM GENET, V79, P183; MONOCO AP, 1986, NATURE, V323, P646; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P4; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NOONAN E, 1988, NUCLEIC ACIDS RES, V162, P10366; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SASAKI M, 1989, CANCER RES, V49, P4402; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TABATA ST, 1989, SCIENCE, V245, P967; TU G, 1990, CELL, V63, P835; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WU SQ, 1991, CANCER RES, V51, P3323	59	1993	2089	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					661	665		10.1126/science.1651562	http://dx.doi.org/10.1126/science.1651562			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1651562				2022-12-28	WOS:A1991GA30400038
J	GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R				GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R			BOVINE PAPILLOMAVIRUS-E5 ONCOPROTEIN BINDS TO THE 16K COMPONENT OF VACUOLAR H+-ATPASES	NATURE			English	Article							OPEN READING FRAME; TRANSFORMING ACTIVITY; GAP-JUNCTIONS; E5; PROTEIN; GENE; LOCALIZATION; POLYPEPTIDE; MEMBRANES; ENCODES	THE major transforming protein of bovine papillomavirus type 1, E5 (refs 1-4), is mainly associated with endomembranes 5,6, specifically binding to a cellular protein of relative molecular mass 16,000 (16K) (ref. 7). At the same time as transformation, E5 causes the phosphorylation of tyrosine residues in epidermal and platelet-derived growth factor receptors 8,9. We show here that the 16K protein associated with E5 is the 16K component of vacuolar ATPases. This protein is known to be an integral membrane protein in endosomes, bovine chromaffin granules, synaptic vesicles, fungal and plant vacuoles and clathrin-coated vesicles 10-16, as well as a component of gap-junction-like membrane complexes 17. Because proton pumps are critical for the function of cellular compartments that process growth-factor receptors, the interaction of E5 with the 16K protein could explain the pleiomorphic features of cells transformed by E5.	BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	Beatson Institute	GOLDSTEIN, DJ (corresponding author), GEORGETOWN UNIV,DEPT PATHOL,WASHINGTON,DC 20007, USA.							ARAI H, 1987, J BIOL CHEM, V262, P11006; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BUULTJENS TEJ, 1988, CELL TISSUE RES, V251, P571, DOI 10.1007/BF00214005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P22; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	26	172	177	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					347	349		10.1038/352347a0	http://dx.doi.org/10.1038/352347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1649407				2022-12-28	WOS:A1991FY28900075
J	GOODWIN, FK				GOODWIN, FK			DESIPRAMINE HYDROCHLORIDE FOR PANIC DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, J AFFECTIVE DISO MAY	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					323	323						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1647468				2022-12-28	WOS:A1991FV96000005
J	CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P				CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P			PARENTAL-SPECIFIC METHYLATION OF AN IMPRINTED TRANSGENE IS ESTABLISHED DURING GAMETOGENESIS AND PROGRESSIVELY CHANGES DURING EMBRYOGENESIS	CELL			English	Article							DNA METHYLATION; DETERMINES METHYLATION; PATERNAL GENOMES; MOUSE; EXPRESSION; MICE; REGION; CELLS	Genomic imprinting is a regulatory process that requires a cell to recognize the parental origin of alleles. To understand how these alleles are distinguished, we have assessed changes in the DNA methylation of an imprinted transgene as it switches from one inheritance pattern to another while moving through gametogenesis and embryogenesis. We find that both maternally and paternally inherited methylation patterns are erased in primordial germ cells and that distinctive patterns emerge during germ cell maturation. In the case of the maternal allele, the methylation pattern is fully acquired during oogenesis. In the case of the paternal allele, the methylation pattern found in sperm undergoes further modification during embryogenesis. Thus, the distinction between "erased" maternal and paternal alleles is first established during their residence in different germ cells and then may be maintained by the recognition of the distinctive patterns that each allele displays in the zygote.			CHAILLET, JR (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HEATH JK, 1978, DEV MAMMALS, V3; HOGAN B, 1986, MANIPULATING MOUSE E; KIRSCH IR, 1981, NATURE, V293, P585, DOI 10.1038/293585a0; MCGOWAN R, 1989, GENE DEV, V3, P1669, DOI 10.1101/gad.3.11.1669; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MONK M, 1987, DEVELOPMENT, V99, P371; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PEDERSEN RA, 1988, PHYSL REPRODUCTION; QUINN P, 1982, J REPROD FERTIL, V66, P161; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SOLTER D, 1988, ANNU REV GENET, V22, P127; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MAH, 1986, CELL, V45, P127, DOI 10.1016/0092-8674(86)90544-1; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WASSERMAN PM, 1988, PHYSL REPRODUCTION; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176	34	214	221	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					77	83		10.1016/0092-8674(91)90140-T	http://dx.doi.org/10.1016/0092-8674(91)90140-T			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649008				2022-12-28	WOS:A1991FW91300010
J	BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW				BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW			ACTIVATION OF CA2+ ENTRY INTO ACINAR-CELLS BY A NON-PHOSPHORYLATABLE INOSITOL TRISPHOSPHATE	NATURE			English	Article							RAT-LIVER CELLS; 1,4,5-TRISPHOSPHATE 3-KINASE; INTRACELLULAR CA-2+; CALCIUM RELEASE; 1,3,4,5-TETRAKISPHOSPHATE; PHOSPHATES; RECEPTOR; MEMBRANE; THAPSIGARGIN; PURIFICATION	IN many cell types, receptor activation of phosphoinositidase C results in an initial release of intracellular Ca2+ stores followed by sustained Ca2+ entry across the plasma membrane. Inositol 1,4,5-trisphosphate is the mediator of the initial Ca2+ release 1, although its role in the mechanism underlying Ca2+ entry remains controversial 2-6. We have now used two techniques to introduce inositol phosphates into mouse lacrimal acinar cells and measure their effects on Ca2+ entry: microinjection into cells loaded with Fura-2, a fluorescent dye which allows the measurement of intracellular free calcium concentration by microspectrofluorimetry, and perfusion of patch clamp pipettes in the whole-cell configuration while monitoring the activity of Ca2+-activated K+ channels as an indicator of intracellular Ca2+. We report here that inositol 1,4,5-trisphosphate serves as a signal that is both necessary and sufficient for receptor activation of Ca2+ entry across the plasma membrane in these cells.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, RES TRIANGLE PK, NC 27709 USA.		Shears, Stephen B/C-6335-2019; Rossier, Michel/AAW-2895-2021; Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Shears, Stephen B/0000-0001-7309-8916; Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS GM, IN PRESS J BIOL CHEM; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; IRVINE RF, 1989, BIOCHEM SOC T, V17, P6, DOI 10.1042/bst0170006; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KENNEDY ED, 1989, J NEUROCHEM, V53, P1652, DOI 10.1111/j.1471-4159.1989.tb08566.x; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAROD RJ, 1978, J PHYSIOL-LONDON, V281, P371, DOI 10.1113/jphysiol.1978.sp012428; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; YAMAGUCHI K, 1988, BIOCHEM J, V251, P129, DOI 10.1042/bj2510129	32	175	177	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1991	352	6331					162	165		10.1038/352162a0	http://dx.doi.org/10.1038/352162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1648669				2022-12-28	WOS:A1991FW09700059
J	BAKER, TA; MIZUUCHI, M; MIZUUCHI, K				BAKER, TA; MIZUUCHI, M; MIZUUCHI, K			MUB PROTEIN ALLOSTERICALLY ACTIVATES STRAND TRANSFER BY THE TRANSPOSASE OF PHAGE-MU	CELL			English	Article							BACTERIOPHAGE-MU; B-PROTEIN; TARGET IMMUNITY; DNA; MECHANISM; ENDS; PURIFICATION; INTEGRATION; INVITRO; TN10	The MuA and MuB proteins collaborate to mediate efficient transposition of the phage Mu genome into many DNA target sites. MuA (the transposase) carries out all the DNA cleavage and joining steps. MuB stimulates strand transfer by activating the MuA-donor DNA complex through direct protein-protein contact. The C-terminal domain of MuA is required for this MuA-MuB interaction. Activation of strand transfer occurs irrespective of whether MuB is bound to target DNA. When high levels of MuA generate a pool of free MuB (not bound to DNA) or when chemical modification of MuB impairs its ability to bind DNA, MuB still stimulates strand transfer. However, under these conditions, intramolecular target sites are used exclusively because of their close proximity to the MuA-MuB-donor DNA complex.			BAKER, TA (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAINTON R, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1985, CELL, V41, P857, DOI 10.1016/S0092-8674(85)80066-0; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DARZINS A, 1988, P NATL ACAD SCI USA, V85, P6826, DOI 10.1073/pnas.85.18.6826; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; SHERRATT D, 1989, MOBILE DNA, P163; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; Symonds N., 1987, PHAGE MU; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; [No title captured]	30	99	101	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1003	1013		10.1016/0092-8674(91)90552-A	http://dx.doi.org/10.1016/0092-8674(91)90552-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646076				2022-12-28	WOS:A1991FR04700011
J	WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA				WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA			SPONTANEOUS LYMPHOCYTE-PROLIFERATION IN HTLV-II INFECTION	LANCET			English	Note								We measured lymphocyte proliferation in the absence of antigenic stimulation in 45 HTLV-II infected, 9 HTLV-I infected, and 19 HTLV-I seronegative intravenous drug users (IVDU). Lymphocyte proliferation was higher in IVDUs infected with HTLV-II than in seronegative IVDUs but lower than among those infected with HTLV-I. Higher rates of proliferation were also associated with needle sharing, CD4+ and IL2R+ lymphocyte counts, and HTLV-I antibody titres.	NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; DESIRE NARCOT REHABIL CTR,NEW ORLEANS,LA; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103; UNIV ALABAMA,SCH MED,DEPT MED,BIRMINGHAM,AL 35233	National Institutes of Health (NIH) - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham	WIKTOR, SZ (corresponding author), NCI,VIRAL EPIDEMIOL SECT,6130 EXECUT BLVD,EPN 434,ROCKVILLE,MD 20852, USA.		Reuben, Jayne/GWQ-6664-2022	Weiss, Stanley/0000-0002-5485-551X				BLATTNER WA, 1989, VIRAL INFECTIONS HUM, P545; GRIFFIN DE, 1989, NEW ENGL J MED, V320, P1667, DOI 10.1056/NEJM198906223202506; JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LILLEHOJ EP, IN PRESS J CLIN MICR; SOOP M, 1988, SCAND J IMMUNOL, V28, P659, DOI 10.1111/j.1365-3083.1988.tb01499.x	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					327	328		10.1016/0140-6736(91)90947-N	http://dx.doi.org/10.1016/0140-6736(91)90947-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671234				2022-12-28	WOS:A1991EX36200006
J	KRAGBALLE, K; GJERTSEN, BT; DEHOOP, D; KARLSMARK, T; VANDEKERKHOF, PCM; LARKO, O; NIEBOER, C; ROEDPETERSEN, J; STRAND, A; TIKJOB, G				KRAGBALLE, K; GJERTSEN, BT; DEHOOP, D; KARLSMARK, T; VANDEKERKHOF, PCM; LARKO, O; NIEBOER, C; ROEDPETERSEN, J; STRAND, A; TIKJOB, G			DOUBLE-BLIND, RIGHT LEFT COMPARISON OF CALCIPOTRIOL AND BETAMETHASONE VALERATE IN TREATMENT OF PSORIASIS-VULGARIS	LANCET			English	Article							ANALOG MC-903; 1,25-DIHYDROXYVITAMIN-D3; DIFFERENTIATION; KERATINOCYTES; THERAPY; INVITRO; INVIVO; CELLS	The therapeutic efficacy and tolerability of calcipotriol ointment and betamethasone valerate ointment in psoriasis were compared in a multicentre, prospective, randomised, double-blind, right/left trial. 345 inpatients and outpatients with psoriasis vulgaris of symmetrical distribution were treated twice daily for 6 weeks with calcipotriol ointment 50 mu-g/g and betamethasone ointment 0.1% randomly assigned to opposite sides of the body. The main outcome measures-the psoriasis area and severity index (PASI), the investigators' assessments of erythema, thickness, and scaling, and the patients' own assessments of the overall response to treatment-were sought at weeks 2, 4, and 6. Both treatments significantly reduced the PASI scores and the investigator's assessment scores, but at each visit the PASI score was significantly (p < 0.001) lower with calcipotriol than with betamethasone. At 6 weeks the mean PASI reduction was 68.8% with calcipotriol and 61.4% with betamethasone (95% confidence interval for difference 5.1-9.8, p < 0.001). The scores for erythema, thickness, and scaling were significantly (p < 0.001) lower with calcipotriol than with betamethasone at the end of treatment. The patients considered that 82.1% of calcipotriol-treated sides and 69.3% of betamethasone-treated sides had improved greatly or cleared up by the end of treatment (p < 0.001). 57 adverse events were reported by 52 patients (15.1%). The most common adverse event, lesional/perilesional skin irritation, was slightly but not significantly (p = 0.12) more common with calcipotriol treatment. 15 (4.3%) patients were withdrawn from the study, 3 because of local adverse events. There were no changes in serum calcium during the study. Thus, calcipotriol ointment was superior to betamethasone valerate ointment in psoriasis vulgaris. Though long-term results are not yet available, calcipotriol holds great promise as an antipsoriatic agent.	ZIEKENHUIS GELDERSE VALLEC,BENNEKOIN EDE,NETHERLANDS; FYLKESSYKEHUSET,DEPT MED,FLORO,NORWAY; KLINIEK HUIDZIEKTEN,NIJMEGEN,NETHERLANDS; KOBENHAVNS AMTS SYGEHUS GENTOFTE,DEPT DERMATOL,HELLERUP,DENMARK; RIGSHOSP,DEPT DERMATOL,DK-2100 COPENHAGEN,DENMARK; SAHLGRENS UNIV HOSP,DEPT DERMATOL,S-41345 GOTHENBURG,SWEDEN; FREE UNIV AMSTERDAM,ACAD ZIEKENHUIS,DEPT DERMATOL,1007 MC AMSTERDAM,NETHERLANDS; ACAD HOSP UPPSALA,DEPT DERMATOL,S-75014 UPPSALA,SWEDEN; BISPEBJERG HOSP,DEPT DERMATOL,DK-2400 COPENHAGEN,DENMARK	Gelderse Vallei Hospital; Rigshospitalet; University of Copenhagen; Sahlgrenska University Hospital; Vrije Universiteit Amsterdam; University of Copenhagen; Bispebjerg Hospital	KRAGBALLE, K (corresponding author), MARSELISBORG HOSP,DEPT DERMATOL,DK-8000 AARHUS C,DENMARK.		Gjertsen, Bjorn T/O-1542-2015; van de Kerkhof, P.C.M./H-8059-2014	Gjertsen, Bjorn T/0000-0001-9358-9704; 				[Anonymous], PSORIASIS; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; CALVERLEY MJ, 1987, TETRAHEDRON, V43, P4609, DOI 10.1016/S0040-4020(01)86903-9; CHRISTOPHERS E, 1987, DERMATOLOGY GENERAL, P461; CLEMENS TL, 1983, J CLIN ENDOCR METAB, V56, P824, DOI 10.1210/jcem-56-4-824; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; HENDERSON CA, 1989, BRIT J DERMATOL, V121, P493, DOI 10.1111/j.1365-2133.1989.tb15517.x; HOLICK MF, 1989, J INVEST DERMATOL, V92, P446; KOEFFLER HP, 1985, CANCER TREAT REP, V69, P1399; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KRAGBALLE K, 1988, BRIT J DERMATOL, V119, P223, DOI 10.1111/j.1365-2133.1988.tb03204.x; KRAGBALLE K, 1990, ARCH DERMATOL RES, V282, P164, DOI 10.1007/BF00372616; MERKE J, 1987, ACTA ENDOCRINOL-COP, V114, P94; MORIMOTO S, 1986, BRIT J DERMATOL, V115, P421, DOI 10.1111/j.1365-2133.1986.tb06236.x; SMITH EL, 1988, J AM ACAD DERMATOL, V19, P516, DOI 10.1016/S0190-9622(88)70207-8; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; STABERG B, 1989, ACTA DERM-VENEREOL, V69, P147; VANDEKERKHOF PCM, 1989, BRIT J DERMATOL, V120, P661	19	298	304	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					193	196		10.1016/0140-6736(91)92157-W	http://dx.doi.org/10.1016/0140-6736(91)92157-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670840				2022-12-28	WOS:A1991EU92400002
J	YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC				YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC			AUTOMATIC END-EXPIRATORY AIR SAMPLING DEVICE FOR BREATH HYDROGEN TEST IN INFANTS	LANCET			English	Article							BOWEL TRANSIT-TIME; LACTOSE-MALABSORPTION; PREMATURE-INFANTS; H2 MEASUREMENTS; ABSORPTION; CHILDREN; H-2; EXCRETION; PRETERM	An automatic electronically operated end-expiratory air sampler has been developed for use in small infants. Upon expiration, which is detected by a hot-wire sensor, a small portion of the end-expiratory air is automatically collected into a syringe mounted on a syringe driver. The sampler obtained 87% of the end-expiratory air sample. Additionally, highly reproducible and consistent results were obtained for the respiratory gases (O2, N2, CO2). The sampler has been applied for studying breath hydrogen excretion to detect lactose malabsorption. It may also be applicable to study other expiratory gases in infants.	UNIV HONG KONG,ELECTR SERV UNIT,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT CHEM,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	YEUNG, CY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PAEDIAT,HONG KONG,HONG KONG.							BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; BOND JH, 1972, J CLIN INVEST, V51, P1219, DOI 10.1172/JCI106916; BOND JH, 1977, J LAB CLIN MED, V90, P30; BOND JH, 1975, J LAB CLIN MED, V85, P546; DOUWES AC, 1978, ARCH DIS CHILD, V53, P939, DOI 10.1136/adc.53.12.939; DUBOWSKI KM, 1974, CLIN CHEM, V20, P966; FERNANDES J, 1978, AM J CLIN NUTR, V31, P597, DOI 10.1093/ajcn/31.4.597; HOPPER AO, 1983, J PEDIATR GASTR NUTR, V2, P659, DOI 10.1097/00005176-198311000-00015; KIEN CL, 1987, J PEDIATR GASTR NUTR, V6, P286, DOI 10.1097/00005176-198703000-00022; KOCH G, 1968, BIOL NEONATORUM, V12, P136; LEVITT MD, 1970, J LAB CLIN MED, V75, P937; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; LIFSCHITZ CH, 1983, J PEDIATR GASTR NUTR, V2, P478, DOI 10.1097/00005176-198302030-00014; MACLEAN WC, 1980, J PEDIATR-US, V97, P383, DOI 10.1016/S0022-3476(80)80186-7; NIU HC, 1979, J LAB CLIN MED, V94, P755; NOSE O, 1979, ARCH DIS CHILD, V54, P436, DOI 10.1136/adc.54.6.436; OSTRANDER CR, 1983, J PEDIATR GASTR NUTR, V2, P525, DOI 10.1097/00005176-198302030-00022; ROGGERO P, 1986, J PEDIATR GASTR NUTR, V5, P214, DOI 10.1097/00005176-198605020-00009; Smith CA, 1976, PHYSL NEWBORN INFANT; STEVENSON DK, 1982, J PEDIATR GASTR NUTR, V1, P233, DOI 10.1097/00005176-198201020-00014; STEVENSON DK, 1982, J PEDIATR-US, V101, P607, DOI 10.1016/S0022-3476(82)80720-8; TADESSE K, 1986, HONG KONG J PEDIATR, V1, P75; VANDERKLEIVANMOORSEL JM, 1984, EUR J PEDIATR, V141, P221, DOI 10.1007/BF00572764; WILSON HK, 1986, SCAND J WORK ENV HEA, V12, P174, DOI 10.5271/sjweh.2159	24	4	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					90	93		10.1016/0140-6736(91)90746-C	http://dx.doi.org/10.1016/0140-6736(91)90746-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670735				2022-12-28	WOS:A1991ER47700013
J	RIEMERSMA, RA; WOOD, DA; MACINTYRE, CCA; ELTON, RA; GEY, KF; OLIVER, MF				RIEMERSMA, RA; WOOD, DA; MACINTYRE, CCA; ELTON, RA; GEY, KF; OLIVER, MF			RISK OF ANGINA-PECTORIS AND PLASMA-CONCENTRATIONS OF VITAMIN-A, VITAMIN-C, AND VITAMIN-E AND CAROTENE	LANCET			English	Article							CORONARY HEART-DISEASE; LOW-DENSITY LIPOPROTEIN; FATTY-ACIDS; CIGARETTE-SMOKING; ALPHA-TOCOPHEROL; ADIPOSE-TISSUE; ARTERY DISEASE; SERUM SELENIUM; BETA-CAROTENE; ASCORBIC-ACID	The relation between risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene was examined in a population case-control study of 110 cases of angina, identified by the Chest Pain Questionnaire, and 394 controls selected from a sample of 6000 men aged 35-54. Plasma concentrations of vitamins C and E and carotene were significantly inversely related to the risk of angina. There was no significant relation with vitamin A. Smoking was a confounding factor. The inverse relation between angina and low plasma carotene disappeared and that with plasma vitamin C was substantially reduced after adjustment for smoking. Vitamin E remained independently and inversely related to the risk of angina after adjustment for age, smoking habit, blood pressure, lipids, and relative weight. The adjusted odds ratio for angina between the lowest and highest quintiles of vitamin E concentrations was 2.68 (95% confidence interval 1.07-6.70; p = 0.02). These findings suggest that some populations with a high incidence of coronary heart disease may benefit from eating diets rich in natural antioxidants, particularly vitamin E.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,SCOTLAND; UNIV BERN,INST BIOCHEM & MOLEC BIOL,VITAMIN UNIT,CH-3000 BERN,SWITZERLAND	University of Edinburgh; University of Bern	RIEMERSMA, RA (corresponding author), UNIV EDINBURGH,DEPT CARDIOL & MED RIE,CARDIOVASC RES UNIT,GEORGE SQ,EDINBURGH EH8 9XF,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHESON RM, 1983, LANCET, V1, P1191; BELL D, 1990, BRIT HEART J, V63, P82; BERNIER M, 1986, CIRC RES, V58, P331, DOI 10.1161/01.RES.58.3.331; BRUBACHER G, 1974, CLIN BIOCH PRINCIPLE, V2, P989; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; ELLIS N, 1984, J CLIN PATHOL, V37, P200, DOI 10.1136/jcp.37.2.200; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FULTON M, 1988, EUR J CLIN NUTR, V42, P797; GINTER E, 1979, AM J CLIN NUTR, V32, P511, DOI 10.1093/ajcn/32.3.511; GUARNIERI C, 1978, J MOL CELL CARDIOL, V10, P893, DOI 10.1016/0022-2828(78)90336-X; HORNSTRA G, 1975, ROLE FATS HUMAN NUTR, P303; HORWITT MK, 1972, ANN NY ACAD SCI, V203, P223, DOI 10.1111/j.1749-6632.1972.tb27878.x; KALLNER AB, 1981, AM J CLIN NUTR, V34, P1347, DOI 10.1093/ajcn/34.7.1347; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KNOX EG, 1973, LANCET, V1, P1465; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; RIEMERSMA RA, 1990, EUR J CLIN NUTR, V44, P143; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SAHA N, 1988, BRIT J NUTR, V60, P407, DOI 10.1079/BJN19880112; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; THOMSON M, 1985, HUM NUTR-APPL NUTR, V39A, P443; Townsend PP., 1988, HLTH DEPRIVATION INE; VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265; WOOD DA, 1987, LANCET, V1, P177; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4	34	633	637	1	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					1	5		10.1016/0140-6736(91)93327-6	http://dx.doi.org/10.1016/0140-6736(91)93327-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670647				2022-12-28	WOS:A1991EQ60400001
J	GROOPMAN, JE; MOLINA, JM				GROOPMAN, JE; MOLINA, JM			NUCLEOSIDE THERAPY FOR HIV-INFECTION - SOME ANSWERS, MANY QUESTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AIDS-RELATED COMPLEX; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; ZIDOVUDINE; PROFILE		HOP ST LOUIS,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	GROOPMAN, JE (corresponding author), NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215, USA.							BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LANE HC, 1992, 8 INT C AIDS AMST; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1992, 8 INT C AIDS AMST	10	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					639	641		10.1056/NEJM199208273270912	http://dx.doi.org/10.1056/NEJM199208273270912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640958				2022-12-28	WOS:A1992JK20400012
J	FERRIS, DG; FISCHER, PM				FERRIS, DG; FISCHER, PM			ELEMENTARY-SCHOOL STUDENTS PERFORMANCE WITH 2 ELISA TEST SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS OFFICES; RELIABILITY	Objective.-To examine analytic performance by previously untrained and inexperienced subjects using enzyme-linked immunosorbent assay (ELISA) tests developed for decentralized laboratories. Performance variability between tests assigned to the "simple" and "moderately complex" Health Care Financing Administration laboratory levels was evaluated. Design.-A nonrandomized trial of the Surecell Strep-A chorionic gonadotropin ELISA tests. Each subject processed nine unknown specimens (three negative, three weakly positive, and three strongly positive) for each ELISA test. Subjects were blinded to expected test results. Setting.-An elementary school. Subjects.-A convenience sample of 52 students enrolled in the sixth and seventh grades. This age group was chosen because of their ability to generally comprehend instructions and remain attentive to the testing task. Interventions.-Subjects were either self-trained by reading package insert directions or trained by a manufacturer's sales representative. Main Outcome Measures.-Performance was measured as the percentage of correct test results for the unknown specimens. The sensitivity and specificity for each test by operator group were calculated. Results.-Subjects demonstrated an overall sensitivity of 97.1% and specificity of 94.7% for human chorionic gonadotropin unknown specimens and a 95.9% sensitivity and 96.8% specificity for group A steptococcus unknown specimens. No significant differences between the self-trained group and the representative-trained group were observed for either group A streptococcus or human chorionic gonadotropin tests. Performance was so high with the first specimen that improvement over time (ie, a "learning curve") could not be demonstrated. Conclusion.-These ELISA test systems are able to achieve high levels of performance by subjects with no formal laboratory background, no previous method specific experience, and limited self-training.			FERRIS, DG (corresponding author), MED COLL GEORGIA,DEPT FAMILY MED,AUGUSTA,GA 30912, USA.							BELSEY R, 1987, JAMA-J AM MED ASSOC, V258, P353; BELSEY R, 1987, JAMA-J AM MED ASSOC, V258, P357, DOI 10.1001/jama.258.3.357; FERRIS DG, 1990, J FAM PRACTICE, V31, P597; FISCHER PM, 1988, J FAM PRACTICE, V27, P497; FISCHER PM, 1986, JAMA-J AM MED ASSOC, V55, P1464; FLEISS JL, 1981, STATISTICAL METHODS, P126; HICKS JM, 1989, NEW ENGL J MED, V320, P320; NANJI AA, 1988, AM J CLIN PATHOL, V89, P797, DOI 10.1093/ajcp/89.6.797; ZAR JH, 1984, BIOSTAT ANAL, P378; 1987, SURVEYS EXCEL CAP PR; 1985, SURVEYS EXCEL CAP PR; 1990, SURVEYS EXCEL CAP PR	12	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					766	770						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640577				2022-12-28	WOS:A1992JG66600019
J	CAMERON, D; BISHOP, C; SIBERT, JR				CAMERON, D; BISHOP, C; SIBERT, JR			FARM ACCIDENTS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INJURIES	Objective-To examine the problem of accidental injury to children on farms. Design-Prospective county based study of children presenting to accident and emergency departments over 12 months with injuries sustained in a farm setting and nationwide review of fatal childhood farm accidents over the four years April 1986 to March 1990. Setting-Accident and emergency departments in Aberystwyth, Carmarthen, Haverfordwest, and Llanelli and fatal accidents in England, Scotland, and Wales notified to the Health and Safety Executive register. Subjects-Children aged under 16. Main outcome measure-Death or injury after farm related accidents. Results-65 accidents were recorded, including 18 fractures. Nine accidents necessitated admission to hospital for a mean of two (range one to four) days. 13 incidents were related to tractors and other machinery; 24 were due to falls. None of these incidents were reported under the statutory notification scheme. 33 deaths were notified, eight related to tractors and allied machinery and 10 related to falling objects. Conclusions-Although safety is improving, the farm remains a dangerous environment for children. Enforcement of existing safety legislation with significant penalties and targeting of safety education will help reduce accident rates further.	UNIV WALES COLL CARDIFF,LANDSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY HLTH UNIT,CARDIFF CF1 8UL,WALES; UNIV WALES COLL MED,DEPT CHILD HLTH,CARDIFF CF4 4XN,S GLAM,WALES; HLTH & SAFETY EXECUT,EMPLOYMENT MED ADVISORY SERV,CARDIFF,WALES	Cardiff University; Cardiff University								COGBILL TH, 1985, PEDIATRICS, V76, P562; DOYLE Y, 1989, J SOC OCCUP MED, V39, P35; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; RIVARA FP, 1985, PEDIATRICS, V76, P567; SALMI LR, 1989, PEDIATRICS, V83, P267; SWANSON JA, 1987, AM J DIS CHILD, V141, P1276, DOI 10.1001/archpedi.1987.04460120038029; 1986, LABOUR FORCE REPORT; 1986, AGR BLACK SPOT; 1988, PREVENTING ACCIDENTS; 1988, AGR SAFETY LISTINGS	10	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					23	25		10.1136/bmj.305.6844.23	http://dx.doi.org/10.1136/bmj.305.6844.23			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638192	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JC79900023
J	MOLLA, A; PAUL, AV; WIMMER, E				MOLLA, A; PAUL, AV; WIMMER, E			CELL-FREE, DENOVO SYNTHESIS OF POLIOVIRUS	SCIENCE			English	Article							TRANSLATION SYSTEM; INITIATION SITES; RNA-POLYMERASE; POLYPEPTIDE 2C; MESSENGER-RNA; HELA-CELLS; INVITRO; CLEAVAGE; MORPHOGENESIS; INTERMEDIATE	Cell-free translation of poliovirus RNA in an extract of uninfected human (HeLa) cells yielded viral proteins through proteolysis of the polyprotein. In the extract, newly synthesized proteins catalyzed poliovirus-specific RNA synthesis, and formed infectious poliovirus de novo. Newly formed virions were neutralized by type-specific antiserum, and infection of human cells with them was prevented by poliovirus receptor-specific antibodies. Poliovirus synthesis was increased nearly 70-fold when nucleoside triphosphates were added, but it was abolished in the presence of inhibitors of translation or viral genome replication. The ability to conduct cell-free synthesis of poliovirus will aid in the study of picornavirus proliferation and in the search for the control of picornaviral disease.			MOLLA, A (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1181, DOI 10.1128/JVI.12.5.1181-1183.1973; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1122, DOI 10.1128/JVI.12.5.1122-1130.1973; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GRUBMAN MJ, 1985, J VIROL, V56, P120, DOI 10.1128/JVI.56.1.120-126.1985; HARBER JJ, 1991, J VIROL, V65, P326, DOI 10.1128/JVI.65.1.326-334.1991; HARRISON SC, 1990, VIROLOGY, P37; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOCH G, 1973, CURR TOP MICROBIOL I, V2, P89; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LURIA SE, 1967, GENERAL VIROLOGY, P5; MENDELSOHN C, 1986, P NATL ACAD SCI USA, V83, P7845, DOI 10.1073/pnas.83.20.7845; MOLLA A, UNPUB; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; NOVAK JE, 1991, J VIROL, V65, P3384, DOI 10.1128/JVI.65.6.3384-3387.1991; PALMENBERG AC, 1982, J VIROL, V44, P900, DOI 10.1128/JVI.44.3.900-906.1982; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PEREZBERCOFF R, 1980, PROTEIN BIOSYNTHESIS; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; PINCUS SE, 1987, MOL BIOL RNA NEW PER, P175; PUTNAK JR, 1981, MICROBIOL REV, V45, P287, DOI 10.1128/MMBR.45.2.287-315.1981; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROTHBERG PG, 1981, THESIS STATE U NEW Y; RUECKERT RR, 1990, VIROLOGY, P507; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SEMLER BL, 1988, RNA GENETICS, V1, P23; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WALKER AI, 1985, THESIS U CAMBRIDGE; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YPMAWONG MF, 1987, NUCLEIC ACIDS RES, V15, P2069, DOI 10.1093/nar/15.5.2069; YPMAWONG MF, 1987, J VIROL, V61, P3181, DOI 10.1128/JVI.61.10.3181-3189.1987	44	309	326	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1647	1651		10.1126/science.1661029	http://dx.doi.org/10.1126/science.1661029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661029				2022-12-28	WOS:A1991GV07300046
J	ORTEGABARRIA, E; PEREIRA, MEA				ORTEGABARRIA, E; PEREIRA, MEA			A NOVEL TRYPANOSOMA-CRUZI HEPARIN-BINDING PROTEIN PROMOTES FIBROBLAST ADHESION AND PENETRATION OF ENGINEERED BACTERIA AND TRYPANOSOMES INTO MAMMALIAN-CELLS	CELL			English	Article							ENHANCE INFECTION; HIGH-DENSITY; BIOLOGY; INVITRO; NEURAMINIDASE; INHIBITION; INVASION; PEPTIDES	T. cruzi invades mammalian cells in various organs after migrating through the ECM. These activities appear to be mediated by a unique 60 kd protein exposed on the T. cruzi surface, which promotes selective adhesion of trypomastigotes to three ECM components: heparin, heparan sulfate, and collagen. The affinity-purified protein binds to host fibroblasts in a saturable and glycosaminoglycan- and collagen-inhibitable manner. When adsorbed to plastic, it promotes adhesion and spreading of fibroblasts, as does the recombinant protein expressed in E. coli. The endogenous protein, and reactive ECM proteins, are very effective in preventing T. cruzi invasion of culture cells. The recombinant protein localizes on the E. coli surface and induces the bacteria that express it to adhere to and penetrate nonphagocytic Vero cells in a proteoglycan-and collagen-inhibitable manner. Therefore, the protein, named penetrin, could play a critical role in T. cruzi binding to the ECM and to cells, and in host cell invasion.			ORTEGABARRIA, E (corresponding author), TUFTS UNIV,DEPT MED,DIV GEOG MED & INFECT DIS,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B, 1989, MOL BIOL CELL, P802; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; COUGHLIN SR, 1988, J BIOL CHEM, V263, P928; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LEWIN B, 1990, GENES, V4, P451; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LU GY, 1991, MOL BIOCHEM PARASIT, V44, P109; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PRIOLI RP, 1987, P NATL ACAD SCI USA, V84, P3097, DOI 10.1073/pnas.84.10.3097; PRIOLI RP, 1990, MOL BIOCHEM PARASIT, V38, P191, DOI 10.1016/0166-6851(90)90022-E; PRIOLI RP, 1988, MOL BIOCHEM PARASIT, V28, P257, DOI 10.1016/0166-6851(88)90010-2; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PUGSLEY AP, 1987, PROTEIN TRANSFER ORG, P607; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAATZ WD, 1991, J BIOL CHEM, V266, P7366; VELGE P, 1988, PARASITOLOGY, V97, P255, DOI 10.1017/S0031182000058467; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; 1990, WEEKLY EPIDEMIOL RES, V65, P257	35	192	197	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					411	421		10.1016/0092-8674(91)90192-2	http://dx.doi.org/10.1016/0092-8674(91)90192-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655283				2022-12-28	WOS:A1991GL47000020
J	SADEGHNASSERI, S; GERMAIN, RN				SADEGHNASSERI, S; GERMAIN, RN			A ROLE FOR PEPTIDE IN DETERMINING MHC CLASS-II STRUCTURE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SEPARATE ALPHA-CHAINS; IMMUNOGENIC PEPTIDES; ANTIGENIC PEPTIDES; LYMPHOCYTE-T; BETA-CHAINS; MOLECULES; BINDING; IA; RECOGNITION	T LYMPHOCYTES recognize antigen-derived peptides associated with major histocompatibility complex (MHC) class I or class II proteins 1,2. Peptide is critical in class I heavy folding and/or stable association with beta-2-Microglobulin 3-6. Although data exist suggesting a relationship between class II structure and peptide association 7-9, no equivalent positive contribution of peptide to the folding state or stability of class II dimers has yet been demonstrated. We report here that most purified E-alpha(k)E-beta-k molecules leaving low pH in the absence of specific peptide lack a compact, stable dimeric structure. Brief exposure to the appropriate peptide just before and during neutralization promotes this specific conformation in proportion to stably bound peptide, indicating that peptide is important in determining class II MHC structure. Our results also indicate that efficient generation of long-lived peptide-class II complexes involves two stages: initial peptide binding in an acidic environment, which enhances the ability of class II to enter a conformation, from which stabilization upon neutralization results in high-affinity binding of previously associated peptide.			SADEGHNASSERI, S (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; OZATO K, 1980, J IMMUNOL, V124, P533; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VIGUIER M, 1990, P NATL ACAD SCI USA, V87, P7170, DOI 10.1073/pnas.87.18.7170; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	26	290	297	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					167	170		10.1038/353167a0	http://dx.doi.org/10.1038/353167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653903				2022-12-28	WOS:A1991GE73100054
J	FANG, F; NEWPORT, JW				FANG, F; NEWPORT, JW			EVIDENCE THAT THE G1-S AND G2-M TRANSITIONS ARE CONTROLLED BY DIFFERENT CDC2 PROTEINS IN HIGHER EUKARYOTES	CELL			English	Article							CELL-CYCLE CONTROL; MATURATION-PROMOTING FACTOR; YEAST SCHIZOSACCHAROMYCES-POMBE; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; DNA-REPLICATION; M-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE	Xenopus eggs contain two distinct cdc2 homologs of 34 and 32 kd. We show that the 32 kd cdc2 protein, like the 34 kd protein, is a kinase. However, unlike the 34 kd homolog, the 32 kd cdc2 kinase activity does not decrease dramatically at the end of mitosis. The 32 kd protein does not associate with mitotic cyclins B1 and B2 but does associate with cyclin A and a novel doublet of proteins of 54 kd that may regulate its activity. We also show that depletion of the 32 kd cdc2 homolog from a Xenopus extract blocks DNA replication, but does not inhibit entry into mitosis. By contrast, depletion of the 34 kd cdc2 homolog or absence of mitotic cyclins from an extract does not inhibit replication, but does block entry into mitosis. Our results indicate that in higher eukaryotes, DNA replication (G1-S) and mitosis (G2-M) may be controlled by distinctly different cdc2 proteins.			FANG, F (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0322, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRILL SJS, 1990, GENE DEV, V4, P968; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MIAKELYE R, 1983, J CELL BIOL, V97, P81, DOI 10.1083/jcb.97.1.81; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	52	501	518	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1991	66	4					731	742		10.1016/0092-8674(91)90117-H	http://dx.doi.org/10.1016/0092-8674(91)90117-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652371				2022-12-28	WOS:A1991GC74500012
J	MORTIMER, PP				MORTIMER, PP			THE FALLIBILITY OF HIV WESTERN-BLOT	LANCET			English	Editorial Material							RETROVIRUSES HTLV-III; AIDS				MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,VIRUS REFERENCE LAB,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							BENENSON AS, 1989, JAMA-J AM MED ASSOC, V262, P3435; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; EPSTEIN J, 1990, DIAGN CLIN TEST, V28, P50; GENESCA J, 1989, LANCET, V2, P1023; JORGENSEN A, 1990, SCAND J INFECT DIS, V22, P283, DOI 10.3109/00365549009027049; LEPINE DG, 1990, J CLIN MICROBIOL, V28, P1169, DOI 10.1128/JCM.28.6.1169-1171.1990; MORTIMER PP, 1985, LANCET, V2, P873; PARRY JV, 1990, STD9027 DEP HLTH; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SPIELBERG S, 1990, J CLIN MICROBIOL, V28, P303; 1990, MMWR, V39, P380; 1990, WEEK EPIDEMIOL REC; 1989, MMWR, V38, pS7	14	52	55	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					286	287						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671125				2022-12-28	WOS:A1991EV71900017
J	TROUNCE, JQ; LOWE, J; LLOYD, BW; JOHNSTON, DI				TROUNCE, JQ; LOWE, J; LLOYD, BW; JOHNSTON, DI			HEMORRHAGIC-SHOCK ENCEPHALOPATHY AND SUDDEN INFANT DEATH	LANCET			English	Note							HEMORRHAGIC-SHOCK; CHILDREN	In 2 pairs of non-identical twins, haemorrhagic-shock encephalopathy syndrome developed in 1 co-twin while the other died of sudden infant death syndrome. The twin pairs were aged 3 and 4 months, respectively, and no cause was identified. We suggest that stress protein deficiency may underlie both syndromes.	UNIV NOTTINGHAM HOSP,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND; N MIDDLESEX HOSP,DEPT PAEDIAT,LONDON N18 1QX,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PAEDIAT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	TROUNCE, JQ (corresponding author), ROYAL ALEXANDRA HOSP SICK CHILDREN,DYKE RD,BRIGHTON BN1 3JN,E SUSSEX,ENGLAND.			Lowe, James/0000-0002-9856-1599				EMERY JL, 1988, LANCET, V2, P29; LEVIN M, 1983, LANCET, V2, P64; LEVIN M, 1989, J PEDIATR-US, V114, P194, DOI 10.1016/S0022-3476(89)80783-8; ROE CR, 1986, J PEDIATR-US, V108, P13, DOI 10.1016/S0022-3476(86)80762-4; SHANNON DC, 1982, NEW ENGL J MED, V306, P959, DOI 10.1056/NEJM198204223061604; SOFER S, 1986, AM J DIS CHILD, V140, P1252, DOI 10.1001/archpedi.1986.02140260054024; STANTON AN, 1984, LANCET, V2, P1199; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1; 1989, LANCET, V2, P1191; 1985, BRIT MED J, V290, P1578	10	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					202	203		10.1016/0140-6736(91)92160-4	http://dx.doi.org/10.1016/0140-6736(91)92160-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670843				2022-12-28	WOS:A1991EU92400005
J	MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ				MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ			TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1 WILMS-TUMOR GENE-PRODUCT	SCIENCE			English	Article							FINGER POLYPEPTIDE GENE; MAMMALIAN-CELLS; SEQUENCE; ACTIVATION; BINDING; LOCUS; EXPRESSION; PROTEIN; SITE; FOS	The wt1 gene, a putative tumor suppressor gene located at the Wilms tumor (WT) locus on chromosome 11p13, encodes a zinc finger-containing protein that binds to the same DNA sequence as EGR-1, a mitogen-inducible immediate-early gene product that activates transcription. The transcriptional regulatory potential of WT1 has not been demonstrated. In transient transfection assays, the WT1 protein functioned as a repressor of transcription when bound to the EGR-1 site. The repression function was mapped to the glutamine- and proline-rich NH2-terminus of WT1; fusion of this domain to the zinc finger region of EGR-1 converted EGR-1 into a transcriptional repressor.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	The Wistar Institute; Howard Hughes Medical Institute			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [P01CA052009, R01CA023413] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52009, CA-23413, CA-0917-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COOK DM, UNPUB; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COWELL JK, 1991, ONCOGENE, V6, P595; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUFF V, 1991, AM J HUM GENET, V48, P997; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADDEN SL, UNPUB; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, IN PRESS ONCOGENE; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H	31	497	515	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1550	1553		10.1126/science.1654597	http://dx.doi.org/10.1126/science.1654597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1654597				2022-12-28	WOS:A1991GG65100044
J	KURODA, MI; KERNAN, MJ; KREBER, R; GANETZKY, B; BAKER, BS				KURODA, MI; KERNAN, MJ; KREBER, R; GANETZKY, B; BAKER, BS			THE MALELESS PROTEIN ASSOCIATES WITH THE X-CHROMOSOME TO REGULATE DOSAGE COMPENSATION IN DROSOPHILA	CELL			English	Article							SEX-SPECIFIC LETHALS; HELIX-DESTABILIZING PROTEIN; RNA HELICASE ACTIVITY; INITIATION FACTOR-4A; DEPENDENT ATPASE; ESCHERICHIA-COLI; PRP2 PROTEIN; SPLICE SITE; MELANOGASTER; GENE	The maleless (mle) gene is one of four known regulatory loci required for increased transcription (dosage compensation) of X-linked genes in D. melanogaster males. A predicted mle protein (MLE) contains seven short segments that define a superfamily of known and putative RNA and DNA helicases. MLE, while present in the nuclei of both male and female cells, differs in its association with polytene X chromosomes in the two sexes. MLE is associated with hundreds of discrete sites along the length of the X chromosome in males and not in females. The predominant localization of MLE to the X chromosome in males makes it a strong candidate to be a direct regulator of dosage compensation.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	Stanford University; University of Wisconsin System; University of Wisconsin Madison				Kernan, Maurice/0000-0002-1546-6159	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; BACHILLER D, 1986, DEV BIOL, V118, P379, DOI 10.1016/0012-1606(86)90007-2; BAKER BS, 1973, DEV BIOL, V33, P429, DOI 10.1016/0012-1606(73)90148-6; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BIRCHLER JA, 1982, GENETICS, V102, P525; BREEN TR, 1986, GENETICS, V112, P483; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIBENEDETTO AJ, 1987, DEV BIOL, V119, P242, DOI 10.1016/0012-1606(87)90225-9; DOBZHANSKY T, 1957, CHROMOSOMA, V8, P691; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FUKUNAGA A, 1975, GENETICS, V81, P135; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GANGULY R, 1985, GENE, V35, P91, DOI 10.1016/0378-1119(85)90161-1; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KING DS, 1990, NUCLEIC ACIDS RES, V18, P6559, DOI 10.1093/nar/18.22.6559; KORGE G, 1975, P NATL ACAD SCI USA, V72, P4550, DOI 10.1073/pnas.72.11.4550; LAIN S, 1989, GENE, V82, P357, DOI 10.1016/0378-1119(89)90063-2; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWRENCE CB, 1989, EUGENE SOFTWARE PACK; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOVERRE A, 1980, DROS INF SERV, V55, P88; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MARONI G, 1973, CHROMOSOMA, V40, P361, DOI 10.1007/BF00399428; MISMER D, 1987, GENETICS, V116, P565; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; MUKHERJEE AS, 1966, NUCLEUS CALCUTTA, V9, P83; Muller H.J, 1932, P 6 INT C GEN, V1, P213; MULLER HJ, 1948, HARVEY LECT, V43, P165; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Offermann CA, 1936, J GENET, V32, P103, DOI 10.1007/BF02982505; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLNICK SB, 1983, CELL, V34, P37, DOI 10.1016/0092-8674(83)90134-4; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; STERN M, 1990, GENETICS, V124, P133; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANAKA A, 1976, GENETICS, V84, P257; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	77	256	262	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					935	947		10.1016/0092-8674(91)90439-6	http://dx.doi.org/10.1016/0092-8674(91)90439-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653648				2022-12-28	WOS:A1991GE46000012
J	GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L				GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L			CUBAN PROGRAM FOR PREVENTION OF SICKLE-CELL DISEASE	LANCET			English	Article							DNA ANALYSIS; HEMOGLOBIN; DIAGNOSIS; ANEMIA	The percentage of carriers of the sickle cell gene in Cuba ranges from 3 to 7% in different regions. In 1983 the National Medical Genetics Centre initiated a programme for the control of sickle cell disease, which was started in Havana and later extended nationwide. The programme is based on mass education, screening and supportive genetic counselling, care of affected individuals, and availability of prenatal diagnosis. 806 935 pregnant women had been screened by the end of 1989: 29 913 (3.7%) were heterozygous, homozygous or doubly heterozygous for abnormal haemoglobin. 19 686 fathers (67%) were also tested: 1268 at-risk couples were detected. 531 elected to have prenatal diagnosis; 404 results were obtained and 98 affected fetuses (SS or SC) found. In 72 cases the pregnancy was terminated.	S PAEDIAT HOSP, DEPT PROV GENET, Santiago De Cuba, CUBA; MINIST PUBL HLTH CUBA, NATL INST HAEMATOL & IMMUNOL, HAVANA, CUBA; GYNECO OBSTET HOSP RAMON GONZALEZ CORO, PROV DEPT PRENATAL DIAG, HAVANA, CUBA; PAEDIAT HOSP GUANTANAMO, DEPT PROV GENET, GUANTANAMO, CUBA		GRANDA, H (corresponding author), NATL CTR MED GENET, HIGHER INST MED SCI,DEPT BIOCHEM,31 AVE,3102, PLAYA 16, HAVANA, CUBA.							BASSET P, 1978, BLOOD, V51, P971; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; GRANDA-I H, 1987, American Journal of Human Genetics, V41, pA276; HEREDERO L, 1974, HUMANGENETIK, V21, P167, DOI 10.1007/BF00281035; HEREDERO L, 1976, CLIN CHIM ACTA, V71, P515; HEREDERO L, 1974, REV CUB PEDIATRIA, V46; KAN YW, 1978, LANCET, V2, P910; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631	9	31	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	1991	337	8734					152	153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670797				2022-12-28	WOS:A1991ET67900013
J	RIGGS, BL; MELTON, LJ				RIGGS, BL; MELTON, LJ			DRUG-THERAPY - THE PREVENTION AND TREATMENT OF OSTEOPOROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSTMENOPAUSAL BONE LOSS; ESTROGEN REPLACEMENT THERAPY; QUANTITATIVE COMPUTED-TOMOGRAPHY; CALCIUM SUPPLEMENTATION; VITAMIN-D; BREAST-CANCER; TRABECULAR BONE; FRACTURE RATE; INVOLUTIONAL OSTEOPOROSIS; VERTEBRAL FRACTURES		MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic	RIGGS, BL (corresponding author), MAYO CLIN & MAYO FDN, DIV ENDOCRINOL METAB & INTERNAL MED, N 6 PLUMMER, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-27065] Funding Source: Medline; NIA NIH HHS [AG-04875] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE J, 1988, VITAMIN D MOL CELLUL, P310; ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; BARAN D, 1990, J CLIN ENDOCR METAB, V70, P264, DOI 10.1210/jcem-70-1-264; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERG RL, 1990, 2ND 50 YEARS PROMOTI, P76; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BISHOP CW, 1990, J BONE MINER RES S2, V5, pS196; BULLAMORE JR, 1970, LANCET, V2, P535; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CARTER D R, 1990, Journal of Bone and Mineral Research, V5, pS177; CHAPUY MC, 1987, AM J CLIN NUTR, V46, P324, DOI 10.1093/ajcn/46.2.324; CIVITELLI R, 1988, J CLIN INVEST, V82, P1268, DOI 10.1172/JCI113725; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; CUMMINGS SR, 1990, CLIN ORTHOP RELAT R, P163; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DELMAS P D, 1990, Journal of Bone and Mineral Research, V5, pS143; DEMPSTER DW, 1986, J BONE MINER RES, V1, P15; DHUPER S, 1990, J CLIN ENDOCR METAB, V71, P1083, DOI 10.1210/jcem-71-5-1083; DRINKWATER BL, 1990, JAMA-J AM MED ASSOC, V263, P545, DOI 10.1001/jama.263.4.545; DUDA RJ, 1988, J CLIN ENDOCR METAB, V66, P951, DOI 10.1210/jcem-66-5-951; EASTELL R, 1991, J BONE MINER RES, V6, P125; ELDERS PJM, 1991, J CLIN ENDOCR METAB, V73, P533, DOI 10.1210/jcem-73-3-533; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GALLAGHER JC, 1990, METABOLISM, V39, P30, DOI 10.1016/0026-0495(90)90269-I; GALLAGHER JC, 1987, J BONE MINER RES, V2, P491; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GEORGIOU E, 1989, ACTA ORTHOP SCAND, V60, P192, DOI 10.3109/17453678909149252; GIBBONS WE, 1991, 38TH P ANN M SOC GYN, P343; HAARBO J, 1991, AM J MED, V90, P584, DOI 10.1016/S0002-9343(05)80009-9; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; HAYES WC, 1991, RADIOL CLIN N AM, V29, P1; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HEANEY RP, 1991, AM J MED, V91, pS23, DOI 10.1016/0002-9343(91)90243-Q; HENDERSON BE, 1989, AM J OBSTET GYNECOL, V161, P1859, DOI 10.1016/S0002-9378(89)80007-9; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; JOHNSTON CC, 1987, OSTEOPOROSIS 1987, V1, P317; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LOBO RA, 1990, OBSTET GYNECOL, V75, pS18; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LYRITIS GP, 1991, CALCIFIED TISSUE INT, V49, P369, DOI 10.1007/BF02555844; MAMELLE N, 1990, LANCET, V336, P243, DOI 10.1016/0140-6736(90)91764-2; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; Muff R, 1991, Osteoporos Int, V1, P72, DOI 10.1007/BF01880446; NEED AG, 1989, ARCH INTERN MED, V149, P57, DOI 10.1001/archinte.149.1.57; NEER R, 1990, OSTEOPOROSIS 1990, V3, P1314; NORDIN BEC, 1992, J CLIN ENDOCR METAB, V74, P20, DOI 10.1210/jc.74.1.20; NORDIN BEC, 1990, BMJ-BRIT MED J, V300, P1056, DOI 10.1136/bmj.300.6731.1056; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; PAK CYC, 1989, J CLIN ENDOCR METAB, V68, P150, DOI 10.1210/jcem-68-1-150; Parfitt A.M., 1988, OSTEOPOROSIS ETIOLOG, P45; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RAY WA, 1991, ANN INTERN MED, V115, P64, DOI 10.7326/0003-4819-115-1-64; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REGINSTER JY, 1991, AM J MED, V91, pS19, DOI 10.1016/0002-9343(91)90242-P; REGINSTER JY, 1987, LANCET, V2, P1481; REGINSTER JY, 1989, LANCET, V2, P1469; REID IR, 1988, LANCET, V1, P143; RIGGS BL, 1985, J CLIN ENDOCR METAB, V61, P457, DOI 10.1210/jcem-61-3-457; RIGGS BL, 1976, J CLIN ENDOCR METAB, V42, P1139, DOI 10.1210/jcem-42-6-1139; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; SIMKIN A, 1987, CALCIFIED TISSUE INT, V40, P59, DOI 10.1007/BF02555706; SLEMENDA C, 1990, OSTEOPOROSIS 1990, V2, P948; SLOVIK DM, 1981, J CLIN INVEST, V68, P1261, DOI 10.1172/JCI110372; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; UEBELHART D, 1990, BONE MINER, V8, P87, DOI 10.1016/0169-6009(91)90143-N; VALKEMA R, 1987, OSTEOPOROSIS 1987, V2, P836; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1989, RECOMMENDED DIETARY	102	647	673	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					620	627						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640955				2022-12-28	WOS:A1992JK20400008
J	SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B				SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B			RETROGRADE TRANSPORT OF ENDOCYTOSED SHIGA TOXIN TO THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							INTERNALIZED RICIN; PSEUDOMONAS EXOTOXIN; SHIGELLA TOXIN; GOLGI NETWORK; CELLS; SEQUENCE; PROTEIN	SHIGA toxin and some other protein toxins that act on targets in the cytosol have previously been shown to enter the trans-Golgi network1-9. Transport by this route may be necessary for translocation of the toxin to the cytosol and for intoxication5-9, but it is not known whether the enzymatically active part of the toxins actually enters the cytosol from the trans-Golgi network. It has been suggested that such toxins are transported in a retrograde manner to the endoplasmic reticulum and that translocation occurs in this organelle10, but retrograde transport of endocytosed material beyond the trans-Golgi network has never been demonstrated. Here we show that in butyric acid-treated A431 cells endocytosed Shiga toxin is not only transported to the trans-Golgi network, but also to all Golgi stacks, to the endoplasmic reticulum and to the nuclear envelope. Furthermore, butyric acid sensitizes the cells to Shiga toxin, which is consistent with the possibility that retrograde transport is required for translocation of the toxin to the cytosol.	WA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, USSR; UNIV COPENHAGEN, PANUM INST, DEPT ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN, DENMARK	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Copenhagen	SANDVIG, K (corresponding author), NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO 3, NORWAY.			Hansen, Steen/0000-0002-9408-4676				CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; HANSEN SH, 1989, EXP CELL RES, V185, P373, DOI 10.1016/0014-4827(89)90307-8; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; OLSNES S, 1988, IMMUNOTOXINS, V1, P39; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	18	381	394	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1992	358	6386					510	512		10.1038/358510a0	http://dx.doi.org/10.1038/358510a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641040				2022-12-28	WOS:A1992JG73900052
J	METCALFE, D				METCALFE, D			MANAGING CHANGE IN PRIMARY CARE - THE CHAINS OF EDUCATION, EXPERIENCE, AND CULTURE	BRITISH MEDICAL JOURNAL			English	Article											METCALFE, D (corresponding author), UNIV MANCHESTER,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					33	34		10.1136/bmj.305.6844.33	http://dx.doi.org/10.1136/bmj.305.6844.33			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC799	1638199	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JC79900032
J	PTACEK, LJ; GEORGE, AL; GRIGGS, RC; TAWIL, R; KALLEN, RG; BARCHI, RL; ROBERTSON, M; LEPPERT, MF				PTACEK, LJ; GEORGE, AL; GRIGGS, RC; TAWIL, R; KALLEN, RG; BARCHI, RL; ROBERTSON, M; LEPPERT, MF			IDENTIFICATION OF A MUTATION IN THE GENE CAUSING HYPERKALEMIC PERIODIC PARALYSIS	CELL			English	Article							DEPENDENT SODIUM-CHANNEL; POINT MUTATIONS; MOLECULAR-STRUCTURE; ADYNAMIA EPISODICA; CDNA SEQUENCE; HUMAN DNA; INACTIVATION; MYOTONIA; MUSCLE; POLYMORPHISMS	DNA from seven unrelated patients with hyperkalemic periodic paralysis (HYPP) was examined for mutations in the adult skeletal muscle sodium channel gene (SCN4A) known to be genetically linked to the disorder. Single-strand conformation Polymorphism analysis revealed aberrant bands that were unique to three of these seven patients. All three had prominent fixed muscle weakness, while the remaining four did not. Sequencing the aberrant bands demonstrated the same C to T transition in all three unrelated patients, predicting substitution of a highly conserved threonine residue with a methionine in a membrane-spanning segment of this sodium channel protein. The observation of a distinct mutation that cosegregates with HYPP in two families and appears as a de novo mutation in a third establishes SCN4A as the HYPP gene. Furthermore, this mutation is associated with a form of HYPP in which fixed muscle weakness is seen.	UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; UNIV PENN, SCH MED, DAVID MAHONEY INST NEUROL SCI, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT NEUROL, PHILADELPHIA, PA 19104 USA; UNIV ROCHESTER, SCH MED, DEPT NEUROL, ROCHESTER, NY 14642 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Rochester	PTACEK, LJ (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT NEUROL, SALT LAKE CITY, UT 84132 USA.			Griggs, Robert/0000-0001-7988-4854	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD000940] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001862] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00367] Funding Source: Medline; NIAMS NIH HHS [AR-01862] Funding Source: Medline; NICHD NIH HHS [1 K11 HD00940] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BRADLEY WG, 1990, ARCH NEUROL-CHICAGO, V47, P1013, DOI 10.1001/archneur.1990.00530090091018; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GEORGE AL, 1992, IN PRESS ANN NEUROL; Griggs R C, 1977, Adv Neurol, V17, P143; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; LEHMANNHORN F, 1981, MUSCLE NERVE, V4, P396, DOI 10.1002/mus.880040508; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LEONARD JP, 1982, EXP NEUROL, V76, P121, DOI 10.1016/0014-4886(82)90106-6; LEWIS ED, 1979, NEUROLOGY, V29, P1131, DOI 10.1212/WNL.29.8.1131; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMA S, 1986, ANN NY ACAD SCI, V479, P338, DOI 10.1111/j.1749-6632.1986.tb15580.x; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; PTACEK LJ, 1992, IN PRESS NEUROLOGY; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; RUDEL R, 1989, MUSCLE NERVE, V12, P281; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, ANNU REV PHYSIOL, V51, P401, DOI 10.1146/annurev.physiol.51.1.401; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TYLER FH, 1951, J CLIN INVEST, V30, P492, DOI 10.1172/JCI102465; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WROGEMANN K, 1976, LANCET, V1, P672	42	351	367	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					1021	1027						7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1659948				2022-12-28	WOS:A1991GT75500020
J	SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM				SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM			HUD, A PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN, CONTAINS RNA-BINDING DOMAINS AND IS HOMOLOGOUS TO ELAV AND SEX-LETHAL	CELL			English	Article							GENE-PRODUCT; LUNG-CANCER; DROSOPHILA; PROTEINS; ANTIBODY; NEURONS	A neuronal antigen (HuD) recognized by the sera of patients with antibody-associated paraneoplastic encephalomyelitis has been isolated by screening a lambda cerebellar expression library. The recombinant antigen provides an unambiguous assay for this rare condition associated with small cell lung cancer. The recombinant antigen has been used to identify specific infiltrating lymphocytes in tumors and affected brain tissues of patients with antibody-associated paraneoplastic encephalomyelitis and sensory neuronopathy. HuD mRNA is uniquely expressed in brain tissue. The HuD protein shows a remarkable homology to the Drosophila proteins Elav and Sex-lethal and is likely to play a role in neuron-specific RNA processing.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	SZABO, A (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC NEUROONCOL LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			furneaux, henry/0000-0003-2212-1017; Dalmau, Josep/0000-0001-5856-2813; Rosenfeld, Myrna/0000-0001-5095-2534	NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09512, CA 095-12-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BRAIN WR, 1965, BRAIN, V88, P465; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1991, IN PRESS NEUROLOGY; DENNYBROWN D, 1948, J NEUROL NEUROSUR PS, V11, P73, DOI 10.1136/jnnp.11.2.73; FURNEAUX H, 1990, RES PUBL ASSOC RES N, V68, P187; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; GRAUS F, 1985, NEUROLOGY, V35, P538, DOI 10.1212/WNL.35.4.538; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; ONEILL JH, 1988, BRAIN, V111, P577, DOI 10.1093/brain/111.3.577; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X	22	526	541	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					325	333		10.1016/0092-8674(91)90184-Z	http://dx.doi.org/10.1016/0092-8674(91)90184-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655278				2022-12-28	WOS:A1991GL47000012
J	NUMANN, R; CATTERALL, WA; SCHEUER, T				NUMANN, R; CATTERALL, WA; SCHEUER, T			FUNCTIONAL MODULATION OF BRAIN SODIUM-CHANNELS BY PROTEIN-KINASE-C PHOSPHORYLATION	SCIENCE			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; CLONED CDNA; EXPRESSION; NA+; ACTIVATION; INHIBITION; CELLS	Voltage-gated sodium channels, which are responsible for the generation of action potentials in the brain, are phosphorylated by protein kinase C (PKC) in purified form. Activation of PKC decreases peak sodium current up to 80 percent and slows its inactivation for sodium channels in rat brain neurons and for rat brain type IIA sodium channel alpha-subunits heterologously expressed in Chinese hamster ovary cells. These effects are specific for PKC because they can be blocked by specific peptide inhibitors of PKC and can be reproduced by direct application of PKC to the cytoplasmic surface of sodium channels in excised inside-out membrane patches. Modulation of brain sodium channels by PKC is likely to have important effects on signal transduction and synaptic transmission in the central nervous system.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; WESTENBROEK RE, UNPUB; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	28	284	287	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					115	118		10.1126/science.1656525	http://dx.doi.org/10.1126/science.1656525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656525				2022-12-28	WOS:A1991GH60500042
J	TSAI, LH; HARLOW, E; MEYERSON, M				TSAI, LH; HARLOW, E; MEYERSON, M			ISOLATION OF THE HUMAN CDK2 GENE THAT ENCODES THE CYCLIN-A-ASSOCIATED AND ADENOVIRUS-E1A-ASSOCIATED P-33 KINASE	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; CELL-CYCLE; FISSION YEAST; M-PHASE; CDC2; HOMOLOG; MITOSIS; DNA; PHOSPHORYLATION	CYCLINS are regulatory subunits which associate with kinases to form complexes that control many of the important steps in cell-cycle progression. The best characterized of the cyclin-containing complexes is the association of cyclin B with the p34cdc2 kinase. The p34cdc2/cyclin B complex is required for the G2 to M transition (see refs 1-4 for review), but the physiological role of other cyclin complexes is unclear. Human cyclin A binds independently to two kinases, associating with either p34cdc2 or a related protein, p33 (refs 5-7). In adenovirus-transformed cells, the viral E1A oncoprotein seems to associate with p33/cyclin A but not with p34cdc2/cyclin A (B. Faha, M.M., L-H.T. and E.H., manuscript submitted). To isolate the gene for p33, we have cloned several novel human cdc2-related genes. The protein product of one of these genes, cdk2 (cyclin-dependent kinase 2), shares 65% sequence identity with p34cdc2 (ref. 8) and 89% identity with the Xenopus Eg-1 gene product 9. Immunochemical characterization and partial proteolytic mapping show that the cdk2 gene product is the cyclin A-associated p33. Immunoprecipitations of the p33cdk2 protein suggest that it can act as a protein kinase in vitro. As p33cdk2 is bound to cyclin A and is targeted by the viral E1A protein, we suggest that the p33cdk2/cyclin A complex has a unique role in cell-cycle regulation of vertebrate cells.			TSAI, LH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Meyerson, Matthew L/E-7123-2012					ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, IN PRESS SCIENCE; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERMANN CH, IN PRESS J VIROL; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LANE DP, 1978, VIROLOGY, V87, P182, DOI 10.1016/0042-6822(78)90170-8; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NINOMIYATSUJI J, IN PRESS P NATN ACAD; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	490	520	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					174	177		10.1038/353174a0	http://dx.doi.org/10.1038/353174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653904				2022-12-28	WOS:A1991GE73100056
J	COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N				COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N			HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. Patients with cirhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprotein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetaprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.	UNIV MILAN, SAN RAFFAELE HOSP, DEPT SURG, I-20122 MILAN, ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	COLOMBO, M (corresponding author), POLICLIN HOSP MILAN, CTR A MIGLIAVACCA, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.		Piemonti, Lorenzo/P-7605-2017; Donato, Maria francesca/AAC-2372-2019	Piemonti, Lorenzo/0000-0002-2172-2198; sangiovanni, angelo/0000-0002-9996-9385				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1990, ANN SURG, V211, P277; BENEDETTI J, 1983, BMDP STATISTICAL SOF, P557; COLOMBO M, 1985, LIVER, V5, P336; COTTONE M, 1988, HEPATO-GASTROENTEROL, V35, P101; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GIBSON JB, 1978, INT HISTOLOGICAL CLA, V20, P12; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KOBAYASHI K, 1985, HEPATOLOGY, V5, P1100, DOI 10.1002/hep.1840050607; KONDO F, 1990, HEPATOLOGY, V12, P592, DOI 10.1002/hep.1840120324; KUBO Y, 1978, GASTROENTEROLOGY, V74, P578; LIAW YF, 1986, GASTROENTEROLOGY, V90, P263, DOI 10.1016/0016-5085(86)90919-4; MARINGHINI A, 1988, DIGEST DIS SCI, V33, P47, DOI 10.1007/BF01536630; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; OKAZAKI N, 1989, CANCER, V63, P2207, DOI 10.1002/1097-0142(19890601)63:11<2207::AID-CNCR2820631124>3.0.CO;2-C; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F; TANAKA R, 1987, LIVER, V7, P316; TANG Z-Y, 1986, Seminars in Surgical Oncology, V2, P103, DOI 10.1002/ssu.2980020207; ZAMAN SN, 1985, LANCET, V1, P1357; [No title captured]	28	751	770	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					675	680		10.1056/NEJM199109053251002	http://dx.doi.org/10.1056/NEJM199109053251002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1651452				2022-12-28	WOS:A1991GD49700002
J	ARNOLD, FH; HAYMORE, BL				ARNOLD, FH; HAYMORE, BL			ENGINEERED METAL-BINDING PROTEINS - PURIFICATION TO PROTEIN FOLDING	SCIENCE			English	Editorial Material							RECOMBINANT PROTEINS; DENOVO DESIGN; PEPTIDES		MONSANTO CO,DEPT CHEM SCI,CENT RES LABS,ST LOUIS,MO 63167	Monsanto	ARNOLD, FH (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.			Arnold, Frances H./0000-0002-4027-364X				ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BREWER SJ, 1991, PURIFICATION ANAL RE, P239; GHADIRI MR, 1990, J AM CHEM SOC, V112, P1630, DOI 10.1021/ja00160a054; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HAYMORE BL, UNPUB; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; KELLIS JT, UNPUB; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUH SS, 1991, PROTEIN ENG, V4, P301, DOI 10.1093/protein/4.3.301; TODD RJ, 1991, PROTEINS, V10, P156, DOI 10.1002/prot.340100209	13	204	215	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1796	1797		10.1126/science.1648261	http://dx.doi.org/10.1126/science.1648261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648261				2022-12-28	WOS:A1991FU06100027
J	BERATAN, DN; BETTS, JN; ONUCHIC, JN				BERATAN, DN; BETTS, JN; ONUCHIC, JN			PROTEIN ELECTRON-TRANSFER RATES SET BY THE BRIDGING SECONDARY AND TERTIARY STRUCTURE	SCIENCE			English	Article							TUNNELING PATHWAYS; CYTOCHROME-C; MOLECULES	The rate of long-distance electron transfer in proteins rapidly decreases with distance, which is indicative of an electron tunneling process. Calculations predict that the distance dependence of electron transfer in native proteins is controlled by the protein's structural motif. The helix and sheet content of a protein and the tertiary arrangement of these secondary structural units define the distance dependence of electronic coupling in that protein. The calculations use a tunneling pathway model applied previously with success to ruthenated proteins. The analysis ranks the average distance decay constant for electronic coupling in electron transfer proteins and identifies the amino acids that are coupled to the charge localization site more strongly or weakly than average for their distance.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA	California Institute of Technology; University of California System; University of California San Diego	BERATAN, DN (corresponding author), CALTECH, JET PROP LAB, PASADENA, CA 91109 USA.		Beratan, David N/C-5098-2011	Beratan, David N/0000-0003-4758-8676				BALAJI V, 1987, J AM CHEM SOC, V109, P6957, DOI 10.1021/ja00257a010; BERATAN DN, 1984, J AM CHEM SOC, V106, P1584, DOI 10.1021/ja00318a008; BERATAN DN, 1987, J CHEM PHYS, V86, P4488, DOI 10.1063/1.452723; BERATAN DN, 1990, J AM CHEM SOC, V112, P7915, DOI 10.1021/ja00178a011; BERATAN DN, 1985, J CHEM PHYS, V83, P5325, DOI 10.1063/1.449694; BERATAN DN, 1989, PHOTOSYNTH RES, V22, P173, DOI 10.1007/BF00048296; BERATAN DN, 1991, MET IONS BIOL SYST, V27, P97; BOWLER BE, 1989, J AM CHEM SOC, V111, P8757, DOI 10.1021/ja00205a049; Broo A., 1989, INT J QUANTUM CHEM, V16, P185; CONRAD DW, 1989, J AM CHEM SOC, V111, P3461, DOI 10.1021/ja00191a070; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1984, QUANTUM MECHANICAL T; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; FARVER O, 1989, FEBS LETT, V244, P379, DOI 10.1016/0014-5793(89)80567-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JACKMAN MP, 1988, J AM CHEM SOC, V110, P5880, DOI 10.1021/ja00225a046; JACOBS BA, IN PRESS J AM CHEM S; JORTNER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P193, DOI 10.1016/0304-4173(80)90001-4; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1991, PHYS REV A, V43, P4500; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054	24	684	690	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1285	1288		10.1126/science.1656523	http://dx.doi.org/10.1126/science.1656523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1656523				2022-12-28	WOS:A1991FN85700032
J	KAWABE, Y; OCHI, A				KAWABE, Y; OCHI, A			PROGRAMMED CELL-DEATH AND EXTRATHYMIC REDUCTION OF V-BETA-8+ CD4+ T-CELLS IN MICE TOLERANT TO STAPHYLOCOCCUS-AUREUS ENTEROTOXIN-B	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSGENIC MICE; CLONAL-DELETION; NEGATIVE SELECTION; ANTIGEN RECEPTOR; SELF-TOLERANCE; MECHANISM; ANTIBODY	CLONAL deletion and functional inactivation of self-reactive cells have been invoked as mechanisms underlying intrathymic development of T-cell tolerance 1-10. The relative importance of these mechanisms in the development of tolerance of more mature, peripheral T cells either to self or to exogenous antigens is unclear, although recent data relate the development of T-cell tolerance in the periphery to clonal anergy 11. We have now investigated the induction of extrathymic tolerance using BALB/c mice that were made tolerant to Staphylococcus aureus enterotoxin B (ref. 12), a superantigen which specifically interacts in such mice with T cells bearing V-beta-8 antigen receptors 13-16. Both euthymic and athymic mice made tolerant to S. aureus enterotoxin B had a markedly reduced number of V-beta-8.1,2+ CD4+ peripheral T cells. This reduction was accompanied by genomic DNA fragmentation that is associated with cell death. These results indicate that a deletional mechanism can contribute to the induction of T-cell tolerance in peripheral lymphoid cells.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV NEUROBIOL & MOLEC IMMUNOL,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	KAWABE, Y (corresponding author), UNIV TORONTO,DEPT IMMUNOL & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA.							ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BLACKMAN AM, 1990, NATURE, V345, P540; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; JENKINS KM, 1909, J IMMUNOL, V144, P16; JEROME B, 1989, J EXP MED, V169, P1405; KANAGAWA O, 1989, J EXP MED, V170, P1513, DOI 10.1084/jem.170.5.1513; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	26	729	760	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					245	248		10.1038/349245a0	http://dx.doi.org/10.1038/349245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1670963				2022-12-28	WOS:A1991ET51900058
J	ZHONG, Y; WU, CF				ZHONG, Y; WU, CF			ALTERED SYNAPTIC PLASTICITY IN DROSOPHILA MEMORY MUTANTS WITH A DEFECTIVE CYCLIC-AMP CASCADE	SCIENCE			English	Article							ADENYLATE-CYCLASE; SHORT-TERM; POTASSIUM CURRENTS; POTENTIATION; MELANOGASTER; CALCIUM; FACILITATION; HIPPOCAMPUS; DISSECTION; DEFICIENT	Synaptic transmission was examined in Drosophila mutants deficient in memory function. These mutants, dunce and rutabaga, are defective in different steps of the cyclic adenosine 3',5'-monophosphate (cAMP) cascade. In both dunce and rutabaga larvae, voltage-clamp analysis of neuromuscular transmission revealed impaired synaptic facilitation and post-tetanic potentiation as well as abnormal responses to direct application of dibutyryl cAMP. In addition, the calcium dependence of transmitter release was shifted in dunce. The results suggest that the cAMP cascade plays a role in synaptic facilitation and potentiation and indicate that synaptic plasticity is altered in Drosophila memory mutants.			ZHONG, Y (corresponding author), UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242, USA.			Wu, Chun-Fang/0000-0002-4973-2021; Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976				ANDERSON MS, 1988, J NEUROSCI, V8, P242; ATWOOD HL, UNPUB; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; CORFAS G, 1990, J NEUROSCI, V10, P491; DAVIS RL, 1986, MOL CELL BIOL, V6, P1464, DOI 10.1128/MCB.6.5.1464; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DEVAY P, 1987, J NEUROGENET, V4, P275; DIXON D, 1989, J NEUROSCI, V9, P4266; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUDAI Y, 1983, NEUROSCI LETT, V42, P207, DOI 10.1016/0304-3940(83)90408-1; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAUGLAND FN, 1990, J NEUROSCI, V10, P1357; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JOHANSEN J, 1989, J NEUROSCI, V9, P710; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kim Y, UNPUB; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; NELSON TJ, 1989, BIOESSAYS, V10, P75, DOI 10.1002/bies.950100209; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STANLEY EF, 1986, J NEUROSCI, V6, P782; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1984, BEHAV GENET, V14, P527, DOI 10.1007/BF01065446; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1989, Society for Neuroscience Abstracts, V15, P1141; ZHONG Y, UNPUB; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	38	245	256	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					198	201		10.1126/science.1670967	http://dx.doi.org/10.1126/science.1670967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1670967				2022-12-28	WOS:A1991ET17300041
J	JOHNSON, E				JOHNSON, E			ALCOHOLS IMPACT ON FETAL CNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, ALCOHOLISM CLIN EXPT, V16, P295	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-28	WOS:A1992JH58800010
J	JANOFF, EN; BREIMAN, RF; DALEY, CL; HOPEWELL, PC				JANOFF, EN; BREIMAN, RF; DALEY, CL; HOPEWELL, PC			PNEUMOCOCCAL DISEASE DURING HIV-INFECTION - EPIDEMIOLOGIC, CLINICAL, AND IMMUNOLOGICAL PERSPECTIVES	ANNALS OF INTERNAL MEDICINE			English	Review						HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; PNEUMONIA; BACTEREMIA; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; PERSISTENT GENERALIZED LYMPHADENOPATHY; INTRAVENOUS-DRUG-USERS; PERIPHERAL-BLOOD LYMPHOCYTES; ABNORMAL ANTIBODY-RESPONSES; PREDOMINANT IGA2 RESPONSE; CELL-WALL POLYSACCHARIDE; PERSONS 6 YEARS	Objective: To characterize the epidemiology, clinical manifestations, and immunologic risk factors for infections with Streptococcus pneumoniae among persons infected with human immunodeficiency virus (HIV); and to delineate a practical approach for diagnosis, treatment, and prevention of these infections. Data Sources: English-language articles from Index Medicus and their references as well as abstracts from conference proceedings that compared rates as well as clinical and microbiologic features of S. pneumoniae infections in HIV-infected patients. Study Selection: All human studies that included denominators, appropriate control groups, or sufficient clinical descriptions and animal studies with key immunologic observations were cited. Data Extraction: We compared epidemiologic and clinical responses to pneumococcal disease in HIV-infected patients and control subjects and correlated clinical and experimental data on immunologic defects associated with HIV infection with those on regulation of pneumococcal infections. Data Synthesis: Among patients with HIV infection, the incidence of invasive pneumococcal disease is high, bacteremia is a common complication of pneumonia, and relapses occur frequently. However, the clinical presentation, response to therapy, and serotypes isolated are similar to those in persons without HIV infection, and mortality is similar or lower. Specific local and systemic defects in host defense, particularly humoral immunity, may contribute to the high incidence of invasive pneumococcal disease. Conclusions: Streptococcus pneumoniae is the leading cause of invasive bacterial respiratory disease in adults and children with HIV infection. Prompt diagnosis and antimicrobial therapy are associated with a favorable clinical outcome. Characterizing the specific immunologic defects associated with invasive pneumococcal disease in HIV-infected patients may facilitate development of successful, cost-effective strategies for prophylaxis.	UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; CTR DIS CONTROL, RESP DIS BRANCH, ATLANTA, GA 30333 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of Minnesota System; University of Minnesota Twin Cities; Centers for Disease Control & Prevention - USA; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	JANOFF, EN (corresponding author), DEPT VET AFFAIRS MED CTR, INFECT DIS SECT 111F, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Daley, Charles L./AAC-3231-2021		NIAID NIH HHS [AI31373] Funding Source: Medline; PHS HHS [U64/CCU903297] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031373] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; [Anonymous], 1969, Lancet, V1, P163; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; AUSTRIAN R, 1986, CHEST, V90, P738, DOI 10.1378/chest.90.5.738; BALLET JJ, 1987, CLIN EXP IMMUNOL, V68, P479; BARRADAS MCR, 1992, CLIN INFECT DIS, V14, P192, DOI 10.1093/clinids/14.1.192; BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127; BENDER BS, 1985, J INFECT DIS, V152, P409, DOI 10.1093/infdis/152.2.409; BENDER BS, 1987, J CLIN INVEST, V79, P715, DOI 10.1172/JCI112876; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLUMBERG HM, 1989, J INFECT DIS, V160, P725, DOI 10.1093/infdis/160.4.725; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRILES DE, 1989, INFECT IMMUN, V57, P1457, DOI 10.1128/IAI.57.5.1457-1464.1989; BRILES DE, 1980, J EXP MED, V152, P151, DOI 10.1084/jem.152.1.151; BROWN EJ, 1983, INFECT IMMUN, V39, P403, DOI 10.1128/IAI.39.1.403-409.1983; BROWN EJ, 1982, J CLIN INVEST, V69, P85, DOI 10.1172/JCI110444; BROWN EJ, 1983, REV INFECT DIS, V5, pS797; BUNCH C, 1988, NEW ENGL J MED, V319, P902; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CHUDWIN DS, 1985, INFECT IMMUN, V50, P213, DOI 10.1128/IAI.50.1.213-217.1985; DALMASSO AP, 1986, CRC CR REV CL LAB SC, V24, P123, DOI 10.3109/10408368609110272; DAVIDSON M, 1976, JAMA-J AM MED ASSOC, V235, P158, DOI 10.1001/jama.235.2.158; DRUCKER E, 1989, INT J EPIDEMIOL, V18, P926, DOI 10.1093/ije/18.4.926; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FINE DP, 1975, INFECT IMMUN, V12, P772, DOI 10.1128/IAI.12.4.772-778.1975; FINE DP, 1988, J LAB CLIN MED, V112, P487; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GERBERDING JL, 1986, 26TH INT C ANT AG CH; GILLESPIE SH, 1989, J MED MICROBIOL, V28, P237, DOI 10.1099/00222615-28-4-237; GLASER JB, 1985, ANN INTERN MED, V102, P189, DOI 10.7326/0003-4819-102-2-189; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; GORDON DL, 1986, J INFECT DIS, V154, P619, DOI 10.1093/infdis/154.4.619; HILL HR, 1986, PEDIATR INFECT DIS J, V5, P395, DOI 10.1097/00006454-198607000-00003; HODGES RG, 1946, AM J HYG, V44, P207, DOI 10.1093/oxfordjournals.aje.a119090; HOF DG, 1981, AM REV RESPIR DIS, V124, P193; HOGE C, 1990, 30TH ANN INT C ANT A; HOSTETTER MK, 1984, J INFECT DIS, V150, P653, DOI 10.1093/infdis/150.5.653; HOSTETTER MK, 1986, J INFECT DIS, V153, P682, DOI 10.1093/infdis/153.4.682; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; HUMMELL DS, 1981, J IMMUNOL, V127, P1287; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; JANOFF EN, 1991, J IMMUNOL, V147, P2130; JANOFF EN, 1988, J INFECT DIS, V157, P798, DOI 10.1093/infdis/157.4.798; JANOFF EN, 1991, 31ST ANN INT C ANT A; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; JONSSON S, 1986, AM REV RESPIR DIS, V133, P136, DOI 10.1164/arrd.1986.133.1.136; JOUVIN MH, 1987, AIDS, V1, P89; KILIAN M, 1988, MICROBIOL REV, V52, P296, DOI 10.1128/MMBR.52.2.296-303.1988; KLEIN RS, 1989, J INFECT DIS, V160, P826, DOI 10.1093/infdis/160.5.826; KOTLER DP, 1987, DIGEST DIS SCI, V32, P129, DOI 10.1007/BF01297100; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KRASINSKI K, 1988, PEDIATR INFECT DIS J, V7, P323, DOI 10.1097/00006454-198805000-00006; KRUMHOLZ HM, 1989, AM J MED, V86, P776, DOI 10.1016/0002-9343(89)90472-5; LEONI MEG, 1990, 30TH ANN INT C ANT A; LIN RY, 1988, INT ARCH ALLER A IMM, V87, P40, DOI 10.1159/000234646; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LOWELL GH, 1980, J EXP MED, V152, P452, DOI 10.1084/jem.152.2.452; LUE C, 1988, J IMMUNOL, V140, P3793; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MANDELL W, 1988, 4 INT C AIDS STOCKH; MCDANIEL LS, 1991, INFECT IMMUN, V59, P222, DOI 10.1128/IAI.59.1.222-228.1991; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; MULLER F, 1989, CLIN EXP IMMUNOL, V78, P153; MULLER F, 1991, CLIN EXP IMMUNOL, V83, P203, DOI 10.1111/j.1365-2249.1991.tb05615.x; MURATA G H, 1984, AIDS Research, V1, P379; MURPHY PM, 1988, J INFECT DIS, V158, P627, DOI 10.1093/infdis/158.3.627; MURRAY HW, 1985, J IMMUNOL, V135, P2374; MUSHER D, 1986, J INFECT DIS, V154, P935, DOI 10.1093/infdis/154.6.935; MUSHER DM, 1986, J INFECT DIS, V154, P245, DOI 10.1093/infdis/154.2.245; MUSHER DM, 1990, J INFECT DIS, V161, P736, DOI 10.1093/infdis/161.4.736; MUSHER DM, 1990, INFECT IMMUN, V58, P3871, DOI 10.1128/IAI.58.12.3871-3876.1990; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; MUSTAFA M M, 1989, Pediatric Infectious Disease Journal, V8, P907, DOI 10.1097/00006454-198912000-00037; NAHASS RG, 1990, J INFECT DIS, V162, P967, DOI 10.1093/infdis/162.4.967; OCHS HD, 1988, J CLIN IMMUNOL, V8, P57, DOI 10.1007/BF00915157; PERLMAN DM, 1988, ANN INTERN MED, V108, P540, DOI 10.7326/0003-4819-108-4-540; PERRICONE R, 1987, CLIN EXP IMMUNOL, V70, P500; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; PUPPO F, 1991, J LAB CLIN MED, V117, P91; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; REIMER CB, 1988, MONOGR ALLERGY, V23, P83; RIESENFELDORN I, 1989, INFECT IMMUN, V57, P1890, DOI 10.1128/IAI.57.7.1890-1893.1989; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SCHRAGER L, 1987, 3RD INT C AIDS WASH; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SESTINI P, 1988, AM REV RESPIR DIS, V137, P138, DOI 10.1164/ajrccm/137.1.138; SHAH TP, 1987, J INFECT DIS, V155, P594, DOI 10.1093/infdis/155.3.594; SHANSON DC, 1990, T ROY SOC TROP MED H, V84, P14, DOI 10.1016/0035-9203(90)90449-O; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; SLIM J, 1988, 4 INT C AIDS STOCKH; SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; TAGLIABUE A, 1988, J IMMUNOL, V141, P2607; TAGLIABUE A, 1985, J IMMUNOL, V135, P4178; TAGLIABUE A, 1984, J IMMUNOL, V133, P988; TAUSK FA, 1986, J CLIN INVEST, V78, P977, DOI 10.1172/JCI112688; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415; Tilghman RC, 1937, ARCH INTERN MED, V59, P602, DOI 10.1001/archinte.1937.00170200044004; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WARA DW, 1981, REV INFECT DIS, V3, P299; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WHITE S, 1985, CHEST, V87, P486, DOI 10.1378/chest.87.4.486; WINKELSTEIN JA, 1984, CRC CR REV MICROBIOL, V11, P187, DOI 10.3109/10408418409105903; WINKELSTEIN JA, 1978, J IMMUNOL, V120, P174; WINKELSTEIN JA, 1976, J IMMUNOL, V116, P367; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; WOOD CC, 1987, PEDIATR INFECT DIS J, V6, P564, DOI 10.1097/00006454-198706000-00015; YAMAGUCHI EP, 1990, WORLD C LUNG HTL BOS; 1990, GUIDE ADULT IMMUNIZA; 1988, MMWR MORB MORTAL WKL, V37, P593; 1989, MMWR MORB MORTAL WKL, V38, P64	124	280	286	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					314	324		10.7326/0003-4819-117-4-314	http://dx.doi.org/10.7326/0003-4819-117-4-314			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637028				2022-12-28	WOS:A1992JH46400009
J	MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA				MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA			VARIABLE MORTALITY-RATES AMONG DIALYSIS TREATMENT CENTERS	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; DIALYSIS; AGE FACTORS; DIABETIC NEPHROPATHY	STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; SURVIVAL; HEMODIALYSIS; PATIENT; RISK	Objective: To examine the variation in the risk for mortality among patients treated at renal dialysis facilities within a defined geographic area. Setting: All free-standing and hospital-based dialysis facilities in a single southeastern state reported to the registry. Design: Cohort of dialysis patients followed for 1 year by an end-stage renal disease registry. Patients: Patients (n = 3612) aged 20 years and older receiving treatment at the dialysis facilities reporting to the registry during 1987. Measurements: Demographic, comorbid, and severity of illness indicators were abstracted from patient records. Facility-specific risk estimates were derived from a Cox proportional hazards model. Results: Facility-specific mortality rates ranged between 2.0 and 10.5 deaths per 10 000 patient days. Mortality rates were higher among older persons; whites; those with a history of diabetic nephropathy, angina, or congestive heart failure; and patients with either nutritional or functional status impairment. Facility-specific prevalence of each mortality risk factor varied widely. The unadjusted risk for death in a facility at the 75th percentile of risk was 1.3 times that of a facility at the median, whereas at the 25th percentile, it was 0.68 times as likely-a twofold range of risk. Controlling for differences in the prevalence of patient characteristics did not change the interquartile range in risks, and a facility's adjusted risk estimate showed a strong correlation with its unadjusted estimate (R2, 0.566; P < 0.0001). Conclusions: Patient attributes associated with increased risk for mortality vary widely among dialysis facilities. Adjustment for these differences did not, however, substantially change either the degree of variation in mortality risks or the relative ranking of a facility's mortality.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; DURHAM REG HOSP, DURHAM, NC USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA	Emory University; Emory University; Duke University	MCCLELLAN, WM (corresponding author), CLARK HOLDER CLIN, 303 SMITH ST, LA GRANGE, GA 30240 USA.							Acchiardo S R, 1983, Kidney Int Suppl, V16, pS199; BURTON BT, 1971, J AMER MED ASSOC, V218, P718, DOI 10.1001/jama.218.5.718; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; GROSS JB, 1973, ANN INTERN MED, V78, P341, DOI 10.7326/0003-4819-78-3-341; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELLERSTEDT WL, 1984, MAYO CLIN PROC, V59, P776, DOI 10.1016/S0025-6196(12)65589-X; HUSEBYE DG, 1987, ARCH INTERN MED, V147, P1921, DOI 10.1001/archinte.147.11.1921; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; HUTCHINSON TA, 1984, KIDNEY INT, V26, P44, DOI 10.1038/ki.1984.132; LEWIS EJ, 1969, ANN INTERN MED, V70, P311, DOI 10.7326/0003-4819-70-2-311; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAIORCA R, 1988, KIDNEY INT, V34, P518, DOI 10.1038/ki.1988.212; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; RADECKI SE, 1988, AM J KIDNEY DIS, V11, P7, DOI 10.1016/S0272-6386(88)80167-7; ROBERTS JL, 1976, KIDNEY INT, V9, P363, DOI 10.1038/ki.1976.43; UMEN AJ, 1986, STAT MED, V5, P637, DOI 10.1002/sim.4780050611; WALKER JV, 1988, AM J NEPHROL, V8, P40, DOI 10.1159/000167551; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; 1991, USRDS1991  NAT I DIA; 1985, EGRET MANUAL STATIST; 1991, USRDS1991 NAT I DIAB	25	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					332	336		10.7326/0003-4819-117-4-332	http://dx.doi.org/10.7326/0003-4819-117-4-332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637029				2022-12-28	WOS:A1992JH46400011
J	SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H				SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H			CILIARY NEUROTROPHIC FACTOR PREVENTS DEGENERATION OF MOTOR NEURONS IN MOUSE MUTANT PROGRESSIVE MOTOR NEURONOPATHY	NATURE			English	Article							NERVE GROWTH-FACTOR; SPINAL-CORD; FACTOR CNTF; EXPRESSION; SURVIVAL; RAT; SEQUENCE; CULTURE; CLONING	CILIARY neurotrophic factor (CNTF) supports the survival of embryonic motor neurons in vitro1,2 and in vivo3, and prevents lesion-mediated degeneration of rat motor neurons during early post-natal stages4. Here we report that CNTF greatly reduces all the functional and morphological changes in pmn/pmn mice5, an autosomal recessive mutant leading to progressive caudo-cranial motor neuron degeneration. The first manifestations of progressive motor neuronopathy in homozygous pmn/pmn mice become apparent in the hind limbs at the end of the third post-natal week, and all the mice die up to 6 or 7 weeks after birth from respiratory paralysis. Treatment with CNTF prolongs survival and greatly improves motor function of these mice. Moreover, morphological manifestations, such as loss of motor axons in the phrenic nerve and degeneration of facial motor neurons, were greatly reduced by CNTF, although the treatment did not start until the first symptoms of the disease had already become apparent and substantial degenerative changes were already present. The protective and restorative effects of CNTF in this mouse mutant give new perspectives for the treatment of human degenerative motor neuron diseases with CNTF.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,W-8033 MARTINSRIED,GERMANY; UNIV COPENHAGEN,PANUM INST,INST NEUROPHYSIOL,DK-2200 COPENHAGEN,DENMARK	Max Planck Society; University of Copenhagen	SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY.		Sendtner, Michael/J-1542-2012; Carroll, Patrick/AAL-7773-2021; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MESSER A, 1986, J NEUROGENET, V3, P345, DOI 10.3109/01677068609106858; OPPENHEIM RW, 1986, J COMP NEUROL, V246, P281, DOI 10.1002/cne.902460211; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, IN PRESS J CELL BIOL; SENDTNER M, 1991, J CELL SCI S, V15, P103; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0	21	541	553	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					502	504		10.1038/358502a0	http://dx.doi.org/10.1038/358502a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641039	Green Submitted			2022-12-28	WOS:A1992JG73900049
J	CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH				CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH			AGRIN MEDIATES CELL CONTACT INDUCED ACETYLCHOLINE-RECEPTOR CLUSTERING	CELL			English	Article							TORPEDO ELECTRIC ORGAN; CULTURED MUSCLE-CELLS; GENE-RELATED PEPTIDE; MESSENGER-RNA LEVELS; NEUROMUSCULAR-JUNCTION; BASAL LAMINA; AGGREGATING FACTOR; ALPHA-SUBUNIT; MOTOR NEURONS; PROTEIN	One of the important events in synapse formation is the accumulation of neurotransmitter receptors beneath the presynaptic nerve terminal. Agrin is a component of the synaptic basal lamina that induces the clustering of acetylcholine receptors when bath-applied to muscle fibers in culture. When a cDNA encoding a putative agrin protein is transfected into cells, the molecule is secreted and concentrated on the extracellular surface. Coculture of transfected cells with muscle fibers induces the formation of receptor patches at contact sites. These results demonstrate that expression of a single gene encoding agrin confers receptor clustering that is restricted to specific sites of cell-muscle contact.			CAMPANELLI, JT (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BEVAN S, 1977, J PHYSIOL-LONDON, V267, P195, DOI 10.1113/jphysiol.1977.sp011808; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; FALLON JR, 1985, NATURE, V315, P571, DOI 10.1038/315571a0; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GETHING MJ, 1989, METHOD CELL BIOL, V32, P185; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; NITKIN RM, 1990, J CELL BIOL, V111, P1161, DOI 10.1083/jcb.111.3.1161; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PENG HB, 1991, NEURON, V6, P237; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; WEINBERG CB, 1981, DEV BIOL, V84, P255, DOI 10.1016/0012-1606(81)90393-6	39	114	114	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					909	916		10.1016/0092-8674(91)90364-5	http://dx.doi.org/10.1016/0092-8674(91)90364-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1659950				2022-12-28	WOS:A1991GT75500010
J	SHI, Y; SETO, E; CHANG, LS; SHENK, T				SHI, Y; SETO, E; CHANG, LS; SHENK, T			TRANSCRIPTIONAL REPRESSION BY YY1, A HUMAN GLI-KRUPPEL-RELATED PROTEIN, AND RELIEF OF REPRESSION BY ADENOVIRUS E1A PROTEIN	CELL			English	Article							MAMMALIAN-CELLS; RNA-POLYMERASE; DNA; EXPRESSION; GENE; ACTIVATION; PROMOTER; ELEMENT; PURIFICATION; DROSOPHILA	A sequence within the transcription control region of the adeno-associated virus P5 promoter has been shown to mediate transcriptional activation by the adenovirus E1A protein. We report here that this same element mediates transcriptional repression in the absence of E1A. Two cellular proteins have been found to bind to overlapping regions within this sequence element. One of these proteins, YY1, is responsible for the repression. E1A relieves repression exerted by YY1 and further activates transcription through its binding site. A YY1-specific cDNA has been isolated. Its sequence reveals YY1 to be a zinc finger protein that belongs to the GLI-Kruppel gene family. The product of the cDNA binds to YY1 sites. When fused to the GAL4 DNA-binding domain, it is capable of repressing transcription directed by a promoter that contains GAL4-binding sites, and E1A proteins can relieve the repression and activate transcription through the fusion protein.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Princeton University; Howard Hughes Medical Institute; Princeton University			Chang, Long-sheng/E-2871-2011		NATIONAL CANCER INSTITUTE [R01CA038965, R37CA038965] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38965] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TAN S, 1988, EMBO J, V6, P2711; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	47	891	916	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					377	388		10.1016/0092-8674(91)90189-6	http://dx.doi.org/10.1016/0092-8674(91)90189-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655281				2022-12-28	WOS:A1991GL47000017
J	HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM				HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM			CHROMOSOMAL MAPPING OF 2 GENETIC-LOCI ASSOCIATED WITH BLOOD-PRESSURE REGULATION IN HEREDITARY HYPERTENSIVE RATS	NATURE			English	Article							RECOMBINANT INBRED STRAINS; INVITRO AMPLIFICATION; ANGIOTENSIN-I; RENIN GENE; DNA; HYBRIDIZATION; PROBES	The spontaneously hypertensive rat and the stroke-prone spontaneously hypertensive rat are useful models for human hypertension. In these strains hypertension is a polygenic trait, in which both autosomal and sex-linked genes can influence blood pressure 1-7. Linkage studies in crosses between the stroke-prone spontaneously hypertensive rat and the normotensive control strain Wistar-Kyoto have led to the localization of two genes, BP/SP-1 and BP/SP-2, that contribute significantly to blood pressure variation in the F2 population. BP/SP-1 and BP/SP-2 were assigned to rat chromosomes 10 and X, respectively. Comparison of the human and rat genetic maps indicates that BP/SP-1 could reside on human chromosome 17q in a region that also contains the angiotensin I-converting enzyme gene (ACE) 8. This encodes a key enzyme of the renin-angiotensin system 9, and is therefore a candidate gene in primary hypertension. A rat microsatellite marker of ACE was mapped to rat chromosome 10 within the region containing BP/SP-1.	CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; CTR MOLEC MED,W-1115 BERLIN,GERMANY; INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,B-1070 BRUSSELS,BELGIUM; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; UNIV HEIDELBERG,GERMAN INST HIGH BLOOD PRESSURE,W-6900 HEIDELBERG,GERMANY; COLL FRANCE,MED EXPTL LAB,INSERM,U36,F-75231 PARIS 05,FRANCE; UNIV CLAUDE BERNARD,PHYSIOL LAB,F-69373 LYONS,FRANCE; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; GENMARK INC,SALT LAKE CITY,UT 84108; UNIV HEIDELBERG,DEPT PHARMACOL,W-6900 HEIDELBERG,GERMANY; KYOTO UNIV,FAC MED,INST LAB ANIM,KYOTO 606,JAPAN	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Kyoto University			Beckmann, Jacques S/A-9772-2008; JULIER, Cécile/M-9824-2017	Beckmann, Jacques S/0000-0002-9741-1900; JULIER, Cécile/0000-0002-1538-0240				AOKI K, 1972, JPN CIRCULATION J, V36, P539, DOI 10.1253/jcj.36.539; BIOLLAZ J, 1986, HYPERTENSION, V8, P117, DOI 10.1161/01.HYP.8.2.117; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DANNERBERG AL, 1987, HYPERTENSION, V10, P266; DIETZ R, 1984, J CARDIOVASC PHARM, V6, pS230, DOI 10.1097/00005344-198400061-00036; DIETZ R, 1982, HYPERTENSION, V4, P773, DOI 10.1161/01.HYP.4.6.773; DIXON WJ, 1988, BMDP STATISTICAL SOF; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; GEORGES M, 1988, CYTOGENET CELL GENET, V47, P127, DOI 10.1159/000132529; GRADIN K, 1987, ACTA PHYSIOL SCAND, V131, P273, DOI 10.1111/j.1748-1716.1987.tb08237.x; Guyton AC, 1980, ARTERIAL PRESSURE HY; HALL JE, 1986, AM J PHYSIOL, V250, pR960, DOI 10.1152/ajpregu.1986.250.6.R960; HARRAP SB, 1986, HYPERTENSION, V8, P572, DOI 10.1161/01.HYP.8.7.572; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JULIER C, 1990, P NATL ACAD SCI USA, V87, P4585, DOI 10.1073/pnas.87.12.4585; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LEVAN G, IN PRESS GENOMCIS; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LITT M, 1989, AM J HUM GENET, V44, P397; LOUIS WJ, 1969, LANCET, V1, P1035; LUFT FC, 1988, J CLI SCI, V74, P577; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; PICKERING G, 1972, AM J MED, V52, P570, DOI 10.1016/0002-9343(72)90049-6; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; PRAVENEC M, 1989, J HYPERTENS, V7, P217; PRAVENEC M, 1991, GENOMICS, V9, P466, DOI 10.1016/0888-7543(91)90412-8; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RAPP JP, 1982, HYPERTENSION, V4, P459, DOI 10.1161/01.HYP.4.4.459; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SOLOMON E, 1989, CYTOGENET CELL GENET, V51, P319, DOI 10.1159/000132797; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; TANASE H, 1987, JAP CIRC J, V51, P1184; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VANDEVEN CJM, 1983, PFLUG ARCH EUR J PHY, V399, P74, DOI 10.1007/BF00652525; WARD R, 1990, PATHOPHYSIOLOGY DIAG, P81; WEBER JL, 1989, AM J HUM GENET, V44, P388; YAMORI Y, 1970, LAB INVEST, V22, P206; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YASUE Y, IN PRESS CYTOGENET C; YEN TT, 1974, HEREDITY, V33, P309, DOI 10.1038/hdy.1974.97	43	591	608	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					521	529		10.1038/353521a0	http://dx.doi.org/10.1038/353521a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656270				2022-12-28	WOS:A1991GJ64300056
J	HANN, BC; WALTER, P				HANN, BC; WALTER, P			THE SIGNAL RECOGNITION PARTICLE IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST ENDOPLASMIC-RETICULUM; PREPRO-ALPHA-FACTOR; SECRETORY PROTEIN TRANSLOCATION; COLI 4.5S RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; HEAT-SHOCK; MICROSOMAL MEMBRANE; PLASMA-MEMBRANE	We have identified the Saccharomyces cerevisiae homolog of the signal recognition particle (SRP) and characterized its function in vivo. S. cerevisiae SRP is a 16S particle that includes a homolog of the signal sequence-binding protein subunit of SRP (SRP54p) and a small cytoplasmic RNA (scR1). Surprisingly, the genes encoding scR1 and SRP54p are not essential for growth, though SRP-deficient cells grow poorly, suggesting that SRP function can be partially bypassed in vivo. Protein translocation across the ER membrane is impaired in SRP-deficient cells, indicating that yeast SRP, like its mammalian counterpart, functions in this process. Unexpectedly, the degree of the translocation defect varies for different proteins. The ability of some proteins to be efficiently targeted in SRP-deficient cells may explain why previous genetic and biochemical analyses in yeast and bacteria did not reveal components of the SRP-dependent protein targeting pathway.			HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; Davis R W, 1980, Methods Enzymol, V65, P404; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HE F, 1989, CURR GENET, V16, P347, DOI 10.1007/BF00340713; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Maniatis T., 1982, MOL CLONING; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUB K, 1991, IN PRESS MOL CELL BI; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x	60	264	265	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					131	144		10.1016/0092-8674(91)90577-L	http://dx.doi.org/10.1016/0092-8674(91)90577-L			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655273				2022-12-28	WOS:A1991GJ32000012
J	TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG				TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG			REPEAT-I OF THE DIHYDROPYRIDINE RECEPTOR IS CRITICAL IN DETERMINING CALCIUM-CHANNEL ACTIVATION KINETICS	NATURE			English	Article							SODIUM-CHANNEL; SKELETAL-MUSCLE; POTASSIUM CHANNELS; EXPRESSION; MEMBRANE; CDNA	MEMBRANE depolarization causes many kinds of ion channels to open, a process termed activation 1. For both Na+ channels 2-4 and Ca2+ channels 5,6, kinetic analysis of current has suggested that during activation the channel undergoes several conformational changes before reaching the open state. Structurally, these channels share a common motif 7: the central element is a large polypeptide with four repeating units of homology (repeats I-IV), each containing a voltage-sensing region, the S4 segment 8-11. This suggests that the distinct conformational transitions inferred from kinetic analysis may be equated with conformational changes of the individual structural repeats 8. To investigate the molecular basis of channel activation, we constructed complementary DNAs encoding chimaeric Ca2+ channels in which one or more of the four repeats of the skeletal muscle dihydropyridine receptor are replaced by the corresponding repeats derived from the cardiac dihydropyridine receptor. We report here that repeat I determines whether the chimaeric Ca2+ channel shows slow (skeletal muscle-like) 12 or rapid (cardiac-like) 13 activation.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; COLORADO STATE UNIV, COLL VET MED & BIOMED SCI, DEPT PHYSIOL, FT COLLINS, CO 80523 USA	Kyoto University; Kyoto University; Colorado State University			Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KEYNES RD, 1990, PROC R SOC SER B-BIO, V240, P411, DOI 10.1098/rspb.1990.0045; KOSTYUK PG, 1981, J PHYSIOL-LONDON, V310, P403, DOI 10.1113/jphysiol.1981.sp013557; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMA S, 1989, HARVEY LECT, V83, P121; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	27	121	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1991	352	6338					800	803		10.1038/352800a0	http://dx.doi.org/10.1038/352800a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1652692				2022-12-28	WOS:A1991GC96400059
J	NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG				NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG			THE ORIENTATION AND SPACING OF CORE DNA-BINDING MOTIFS DICTATE SELECTIVE TRANSCRIPTIONAL RESPONSES TO 3 NUCLEAR RECEPTORS	CELL			English	Article							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RETINOIC ACID RECEPTORS; SUBUNIT GENE PROMOTER; 5' FLANKING REGION; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATION; PITUITARY-CELLS; AMINO-ACIDS	Characterization of several thyroid hormone (T3), retinoic acid, and estrogen response elements has led to the identification of conserved DNA half-sites (core binding motifs). We present evidence that differences in both the relative orientation and spacing of these motifs within hormone response elements determine the distinct transcriptional responses of three members of the nuclear receptor superfamily. When separated by 3 bp, direct repeat, palindromic, and inverted palindromic arrangements of these motifs impart selective transcriptional responses to retinoic acid, estrogen, and T3 receptors, respectively. Varying the spacing between core motifs alters the specificity. Without spacing, a direct repeat of the core motif paradoxically configures the T3 receptor to confer transactivation in the absence of T3 and repression in its presence. Such an element occurs naturally in the mouse beta-thyrotropin promoter, physiologically under negative regulation by T3. The orientation and spacing of core binding motifs may thus function in concert as a code that accounts for the selective patterns of transcriptional responses of hormonally regulated promoters.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOLEC PATHOL GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,NEUROSCI GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	NAAR, AM (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093, USA.		Yu, Victor/A-7899-2015; Glass, Christopher/AAI-3933-2021	Yu, Victor/0000-0003-3270-4734; Glass, Christopher/0000-0003-4344-3592				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1987, J BIOL CHEM, V262, P981; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JONAT G, 1990, CELL, V62, P1189; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MORITA S, 1990, J ENDOCRINOL, V125, P251, DOI 10.1677/joe.0.1250251; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHUPNIK MA, 1987, ENDOCRINOLOGY, V121, P619, DOI 10.1210/endo-121-2-619; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	53	573	578	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1267	1279		10.1016/0092-8674(91)90021-P	http://dx.doi.org/10.1016/0092-8674(91)90021-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648451				2022-12-28	WOS:A1991FU89900018
J	SHENG, M; THOMPSON, MA; GREENBERG, ME				SHENG, M; THOMPSON, MA; GREENBERG, ME			CREB - A CA2+-REGULATED TRANSCRIPTION FACTOR PHOSPHORYLATED BY CALMODULIN-DEPENDENT KINASES	SCIENCE			English	Article							AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; PROTEIN-KINASE; CYCLIC-AMP; LEUCINE ZIPPER; C-FOS; SOMATOSTATIN GENE; BINDING-PROTEIN; PYRUVATE-KINASE; NERVOUS-SYSTEM	The mechanism by which Ca2+ mediates gene induction in response to membrane depolarization was investigated. The adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB) was shown to function as a Ca2+-regulated transcription factor and as a substrate for depolarization-activated Ca2+-calmodulin-dependent protein kinases (CaM kinases) I and II. CREB residue Ser133 was the major site of phosphorylation by the CaM kinases in vitro and of phosphorylation after membrane depolarization in vivo. Mutation of Ser133 impaired the ability of CREB to respond to Ca2+. These results suggest that CaM kinases may transduce electrical signals to the nucleus and that CREB functions to integrate Ca2+ and cAMP signals.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Sheng, Morgan/0000-0002-8703-5366	NCI NIH HHS [R01 CA 43855] Funding Source: Medline; NINDS NIH HHS [R01 NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, IN PRESS P NATL ACAD; DOSKELAND AP, 1984, EUR J BIOCHEM, V145, P31, DOI 10.1111/j.1432-1033.1984.tb08518.x; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SCHWORER CM, 1985, J BIOL CHEM, V260, P3018; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SODERLING TR, 1986, BIOCHEM BIOPH RES CO, V139, P1017, DOI 10.1016/S0006-291X(86)80279-0; THOMPSON M, UNPUB; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZHU Z, 1989, J BIOL CHEM, V264, P6550	30	1364	1387	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1427	1430		10.1126/science.1646483	http://dx.doi.org/10.1126/science.1646483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1646483				2022-12-28	WOS:A1991FP86800035
J	BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M				BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M			LIVER-CELL DYSPLASIA AND RISK OF HEPATOCELLULAR-CARCINOMA IN CIRRHOSIS - A PRELIMINARY-REPORT	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; ALCOHOL		FATEBENEFRATELLI HOSP,DEPT PATHOL,I-20129 MILAN,ITALY; PREDABISSI HOSP,DEPT MED 1,MELEGNANO,ITALY; CASTELLANA GROTTE HOSP,DEPT MED,BARI,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT MED 1,I-20122 MILAN,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT PATHOL 2,I-20122 MILAN,ITALY; BOLOGNINI HOSP,DEPT MED,SERIATE,ITALY	University of Milan; University of Milan	BORZIO, M (corresponding author), FATEBENEFRATELLI HOSP,DEPT MED 1,I-20129 MILAN,ITALY.			Roncalli, Massimo/0000-0002-7901-8910; Leandro, Gioacchino/0000-0001-6624-4532; Bruno, Savino/0000-0002-3887-864X				ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217; FARBER E, 1976, CANCER RES, V36, P2532; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RONCALLI M, 1986, CANCER, V57, P1515, DOI 10.1002/1097-0142(19860415)57:8<1515::AID-CNCR2820570813>3.0.CO;2-J; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0	5	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1312	1312		10.1136/bmj.302.6788.1312	http://dx.doi.org/10.1136/bmj.302.6788.1312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1647827	Green Published, Bronze			2022-12-28	WOS:A1991FQ44400020
J	DUNLOP, MG; WYLLIE, AH; STEEL, CM; PIRIS, J; EVANS, HJ				DUNLOP, MG; WYLLIE, AH; STEEL, CM; PIRIS, J; EVANS, HJ			LINKED DNA MARKERS FOR PRESYMPTOMATIC DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS	LANCET			English	Article							LONG ARM; CHROMOSOME-5; LOCALIZATION; GENE; COLI; MAPS	41 symptom-free individuals aged 0-39 years who were at risk of familial adenomatous polyposis (FAP) were genotyped with six linked DNA probes. 28 individuals were informative for probes flanking the gene and 14 people assigned a probe-derived risk of over 0.93 were subsequently shown to be affected by clinical screening. 4 individuals who had been discharged from follow-up were designated high risk by this method. In those screened negative, risk was calculated from genotypic, colonic, and CHRPE finding and 89% of subjects had a risk below 0.003. An integrated risk analysis may have an important place in screening programmes for FAP.	CANC RES CAMPAIGN,EDINBURGH,SCOTLAND; UNIV EDINBURGH,DEPT CLIN SURG,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	DUNLOP, MG (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1987, DAN MED BULL, V34, P1; CHAPMAN PD, 1989, BRIT MED J, V298, P353, DOI 10.1136/bmj.298.6670.353; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; EMERY AEH, 1986, METHODOLOGY MED GENE; IWAMA T, 1990, BRIT J SURG, V77, P273, DOI 10.1002/bjs.1800770312; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MURDAY V, 1989, CANCER SURV, V8, P139; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; POLKINGHORNE PJ, 1990, EYE, V4, P216, DOI 10.1038/eye.1990.29; STEWART GD, 1987, NUCLEIC ACIDS RES, V15, P3939, DOI 10.1093/nar/15.9.3939; TOPS CMJ, 1989, LANCET, V2, P1361; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118	16	51	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					313	316		10.1016/0140-6736(91)90940-Q	http://dx.doi.org/10.1016/0140-6736(91)90940-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671230				2022-12-28	WOS:A1991EX36200001
J	SPICKETT, GP; MISBAH, SA; CHAPEL, HM				SPICKETT, GP; MISBAH, SA; CHAPEL, HM			PRIMARY ANTIBODY DEFICIENCY IN ADULTS	LANCET			English	Review							PRIMARY IMMUNODEFICIENCY DISORDERS; INTRAVENOUS IMMUNOGLOBULIN; PRIMARY HYPOGAMMAGLOBULINEMIA; DIAGNOSIS; HOME				SPICKETT, GP (corresponding author), JOHN RADCLIFFE HOSP,DEPT IMMUNOL,OXFORD OX3 9DU,ENGLAND.							AGUILAR FP, 1987, AM J GASTROENTEROL, V682, P472; [Anonymous], DIAGNOSIS TREATMENT; BJORKANDER J, 1984, EUR J RESPIR DIS, V65, P529; BLORE J, 1989, BRIT MED J, V298, P516, DOI 10.1136/bmj.298.6672.516; BUCKLEY RH, 1986, CLIN IMMUNOL IMMUNOP, V40, P13, DOI 10.1016/0090-1229(86)90065-6; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; CUNNINGHAMRUNDL.C, 1981, ROYAL SOC MED INT C, P61; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; Eibl M M, 1989, Immunodefic Rev, V1 Suppl, P1; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; HENIN Y, 1988, VOX SANG, V54, P78, DOI 10.1111/j.1423-0410.1988.tb01621.x; KINLEN LJ, 1985, LANCET, V1, P263; KUMARARATNE DS, 1991, ROY SOC MED INT CONG, V173, P132; LAU YL, 1988, ARCH DIS CHILD-FETAL, V63, P758, DOI 10.1136/adc.63.7_Spec_No.758; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Leen C L, 1985, Sarcoidosis, V2, P91; LEEN CLS, 1986, J INFECTION, V12, P241, DOI 10.1016/S0163-4453(86)94216-7; McCluskey DR, 1989, P R COLL PHYSICIANS, V19, P191; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; OCHS HD, 1986, LANCET, V1, P610; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; ROIFMAN CM, 1987, LANCET, V1, P1075; SPICKETT G P, 1990, Immunodeficiency Reviews, V2, P199; STIEHM ER, 1986, CLIN IMMUNOL IMMUNOP, V40, P69, DOI 10.1016/0090-1229(86)90070-X; TAYLORROBINSON D, 1985, GENITOURIN MED, V61, P404; WEBSTER ADB, 1987, BAILLIERE CLIN GASTR, V1, P547, DOI 10.1016/0950-3528(87)90047-9; WEBSTER ADB, 1981, J CLIN IMMUNOL, V1, P113, DOI 10.1007/BF00915388; WILLIAMS PE, 1989, VOX SANG, V57, P15, DOI 10.1111/j.1423-0410.1989.tb04977.x; 1989, IMMUNODEF REV, V1, P173	29	77	77	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					281	284		10.1016/0140-6736(91)90882-P	http://dx.doi.org/10.1016/0140-6736(91)90882-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671123				2022-12-28	WOS:A1991EV71900015
J	HANES, SD; BRENT, R				HANES, SD; BRENT, R			A GENETIC MODEL FOR INTERACTION OF THE HOMEODOMAIN RECOGNITION HELIX WITH DNA	SCIENCE			English	Article							DROSOPHILA EMBRYO; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; BINDING-SPECIFICITY; ANTERIOR PATTERN; LAMBDA-REPRESSOR; BICOID PROTEIN; AMINO-ACID; SEQUENCE; OPERATOR	The Bicoid homeodomain protein controls anterior development in the Drosophila embryo by binding to DNA and regulating gene expression. With the use of genetic assays in yeast, the interaction between the Bicoid homeodomain and a series of mutated DNA sites was studied. These experiments defined important features of homeodomain binding sites, identified specific amino acid-base pair contacts, and suggested a model for interaction of the recognition alpha-helices of Bicoid and Antennapedia-class homeodomain proteins with DNA. The model is in general agreement with results of crystallographic and magnetic resonance studies, but differs in important details. It is likely that genetic studies of protein-DNA interaction will continue to complement conventional structural approaches.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	HANES, SD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HANES SD, UNPUB; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P538; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1990, NATURE, V9, P615; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAMSON ML, 1989, CELL, V57, P1145; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TREISMAN J, 1989, CELL, V59, P553; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0	41	201	206	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					426	430		10.1126/science.1671176	http://dx.doi.org/10.1126/science.1671176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1671176				2022-12-28	WOS:A1991EU50400040
J	MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M				MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M			IDENTIFICATION OF PATHOLOGICAL MINERAL-DEPOSITS BY RAMAN MICROSCOPY	LANCET			English	Note							CRYSTAL DEPOSITION	Raman microscopy-the analysis of scattered photons after excitation-is well established in non-biological sciences for the identification of crystals. It shows promise in biological (clinical) specimens also, as demonstrated here in studies of synovial fluid, and gouty tophus, selected for their known content of sodium urate and calcium pyrophosphate crystals.	NEWCASTLE POLYTECH,DEPT CHEM & LIFE SCI,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	Northumbria University; Bristol Royal Infirmary								ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303; BOWDEN M, 1990, 12TH P INT C RAM SPE, P844; DIEPPE P, 1988, RHEUM DIS CLIN N AM, V14, P415; DIEPPE P, 1985, CLIN RHEUM DIS, V11, P367; ETZ ES, 1986, MICROBEAM ANAL, V21, P39; Gardiner D., 1989, PRACTICAL RAMAN SPEC; GARDINER DJ, 1986, PHILOS T R SOC A, V320, P295, DOI 10.1098/rsta.1986.0118; HARRIES JE, 1983, ANN RHEUM DIS, V42, P100, DOI 10.1136/ard.42.Suppl_1.100	8	27	27	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					77	78		10.1016/0140-6736(91)90738-B	http://dx.doi.org/10.1016/0140-6736(91)90738-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670728				2022-12-28	WOS:A1991ER47700006
J	HUGHES, EF; WILSON, J				HUGHES, EF; WILSON, J			RESPONSE TO TREATMENT WITH ANTIHISTAMINES IN A FAMILY WITH MYOTONIA CONGENITA	LANCET			English	Article								In a family in which myotonia congenita was found in five generations, both great-grandparents of the index case were affected. In subsequent generations mild and severely affected cases were clearly segregated down parallel lines of this family. The grandmother of the index case had noted improvement with an antihistamine. When the index case was prescribed trimeprazine, she showed a striking reduction in severity of symptoms. Antihistamines seem to deserve further evaluation as a safe and effective treatment for myotonia congenita.	HOSP SICK CHILDREN,DEPT NEUROL,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								ADRIAN RH, 1976, J PHYSIOL-LONDON, V258, P125, DOI 10.1113/jphysiol.1976.sp011410; BECKER PE, 1973, NEW DEV ELECTROMYOGR, V1, P407; BRYANT SH, 1973, NEW DEVELOPMENTS ELE, V1, P420; COOK J D, 1984, Neurology, V34, P193; DURRELLI L, 1983, J NEUROL SCI, V59, P167; GERST JW, 1984, J NEUROL NEUROSUR PS, V47, P1044, DOI 10.1136/jnnp.47.9.1044-a; GRANT R, 1987, J NEUROL NEUROSUR PS, V50, P199, DOI 10.1136/jnnp.50.2.199; KUHN E, 1973, NEW DEV ELECTROMYOGR, V1, P413; LIPICKY RJ, 1973, J CLIN INVEST, V50, P2091; MUNSAT TL, 1967, NEUROLOGY, V17, P359, DOI 10.1212/WNL.17.4.359; PETER JB, 1975, EXP NEUROL, V49, P115, DOI 10.1016/0014-4886(75)90198-3; Rowland L. P., 1985, PRINCIPLES NEURAL SC, P196; STREIB EW, 1986, ANN NEUROL, V19, P501, DOI 10.1002/ana.410190515	13	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					28	30		10.1016/0140-6736(91)93342-7	http://dx.doi.org/10.1016/0140-6736(91)93342-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670657				2022-12-28	WOS:A1991EQ60400016
J	FRANKEL, SR; EARDLEY, A; LAUWERS, G; WEISS, M; WARRELL, RP				FRANKEL, SR; EARDLEY, A; LAUWERS, G; WEISS, M; WARRELL, RP			THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, PROMYELOCYTIC, ACUTE; TRETINOIN; DYSPNEA; DEXAMETHASONE	NITRIC-OXIDE; DIFFERENTIATION THERAPY; TRANSLOCATION; INTERLEUKIN-2; DEXAMETHASONE; BREAKPOINT; INDUCTION; PULMONARY; TOXICITY; LOCUS	Objective: To describe a novel complication of therapy with all-trans retinoic acid in patients with acute promyelocytic leukemia. Design: Case series. Setting. Comprehensive cancer center. Patients: Consecutive patients with a morphologic diagnosis of acute promyelocytic leukemia who underwent remission induction treatment with all-trans retinoic acid, 45 mg/m2 body surface area per day. Measurements and Results: Nine of 35 patients (26%; 95% Cl, 9% to 52%) with acute promyelocytic leukemia who were treated with all-trans retinoic acid developed a syndrome consisting primarily of fever and respiratory distress. Additional prominent signs and symptoms included weight gain, lower-extremity edema, pleural or pericardial effusions, and episodic hypotension. The onset of this symptom complex occurred from 2 to 21 days after starting treatment. Three deaths occurred; post-mortem examinations in two patients showed pulmonary interstitial infiltration with maturing myeloid cells. Six other patients survived, each achieving complete remission (five patients with all-trans retinoic acid only; 1 patient with chemotherapy). In six of the nine cases, the onset of the syndrome was preceded by an increase in peripheral blood leukocytes to a level of at least 20 x 10(9) cells/L. Certain therapeutic interventions, including leukapheresis, temporary cessation of therapy with all-trans retinoic acid, and cytotoxic chemotherapy in moderate doses were not useful after respiratory distress was established. However, the administration of high-dose corticosteroid therapy (dexamethasone, 10 mg IV intravenously every 12 hours for 3 or more days) early in the course of the syndrome resulted in prompt symptomatic improvement and full recovery in three of four patients. Conclusions: The use of all-trans retinoic acid to induce hematologic remission in patients with acute promyelocytic leukemia is associated in some patients with the development of a potentially lethal syndrome that is not uniformly accompanied by peripheral blood leukocytosis. Early recognition of the symptom complex of fever and dyspnea, combined with prompt corticosteroid treatment, may decrease morbidity and mortality associated with this syndrome.	MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castaigne S, 1990, BLOOD S, V76, p260a; CHANG KS, 1992, BLOOD, V79, P554; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; FELDMAN EJ, 1989, ACTA HAEMATOL-BASEL, V82, P117; FENAUX P, 1991, LEUKEMIA RES, V15, P655, DOI 10.1016/0145-2126(91)90067-4; FENAUX P, 1991, BLOOD S, V78, pA79; Frankel S, 1991, BLOOD S, V78, p380a; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; HIBBS JR, 1991, 2ND P INT C BIOL NIT; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUMPHRIES JE, 1990, SOUTH MED J, V83, P1157, DOI 10.1097/00007611-199010000-00010; JONES ME, 1978, AM J MED, V65, P673, DOI 10.1016/0002-9343(78)90856-2; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LESTER TJ, 1985, AM J MED, V79, P43, DOI 10.1016/0002-9343(85)90544-3; LOCOCO F, 1991, BLOOD, V77, P1657; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; MIER JW, 1990, BLOOD, V76, P1933; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MONCADA S, 1991, PHARMACOL REV, V43, P109; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; RODEGHIERO F, 1990, BLOOD, V75, P2112; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TALLMAN MS, 1992, BLOOD, V79, P543; VERNANT JP, 1979, CANCER, V44, P264, DOI 10.1002/1097-0142(197907)44:1<264::AID-CNCR2820440144>3.0.CO;2-G; VETTO JT, 1987, J CLIN ONCOL, V5, P496, DOI 10.1200/JCO.1987.5.3.496; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZGORDON M, 1991, P AN M AM SOC CLIN, V10, P225	36	578	608	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					292	296		10.7326/0003-4819-117-4-292	http://dx.doi.org/10.7326/0003-4819-117-4-292			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637024				2022-12-28	WOS:A1992JH46400004
J	HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD				HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD			INCREASED INCIDENCE OF HODGKIN DISEASE IN HOMOSEXUAL MEN WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HODGKINS DISEASE; HOMOSEXUALITY; ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKIN LYMPHOMA	HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; COHORT; AIDS	Objective: To evaluate the incidence of Hodgkin disease and non-Hodgkin lymphoma among homosexual men infected with human immunodeficiency virus (HIV). Design: Cohort study with computer-matched identification of participants with the Northern California Cancer Center registry. Population rate comparisons were made with data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Participants: The 6704 homosexual men in the San Francisco City Clinic Cohort study. Measurements: Incidence of Hodgkin disease, non-Hodgkin lymphoma, HIV infection, and the acquired immunodeficiency syndrome (AIDS); calculation of sex and age-adjusted standardized morbidity ratios and attributable risk. Results: Eight cases of Hodgkin disease and 90 cases of non-Hodgkin lymphoma were identified through computer matching among cohort members residing in the San Francisco Bay area from 1978 through 1989. Among the HIV-infected men, the age-adjusted standardized morbidity ratio was 5.0 (95% Cl, 2.0 to 10.3) for Hodgkin disease and 37.7 (Cl, 30.3 to 46.7) for non-Hodgkin lymphoma. The excess risk attributable to HIV infection was 19.3 cases of Hodgkin disease per 100 000 person-years and 224.9 cases of non-Hodgkin lymphoma per 100 000 person-years. Conclusion: An excess incidence of Hodgkin disease was found in HIV-infected homosexual men. Additional well-designed epidemiologic studies are needed to determine whether Hodgkin disease should be considered an HIV-related malignancy.	SAN FRANCISCO DEPT PUBL HLTH, SAN FRANCISCO, CA USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30333 USA	San Francisco Department of Public Health; Centers for Disease Control & Prevention - USA					PHS HHS [U64/CCU900523-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUCHBINDER S, 1991, 7 INT C AIDS FLOR, P33; BYERS RH, 1988, AIDS, V2, P207; GARNIER G, 1991, ANN INTERN MED, V115, P233, DOI 10.7326/0003-4819-115-3-233_1; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; MONFARDINI S, 1988, JNCI-J NATL CANCER I, V80, P855, DOI 10.1093/jnci/80.11.855; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1992, JAMA-J AM MED ASSOC, V267, P1090, DOI 10.1001/jama.267.8.1090; ROITHMANN S, 1990, NEW ENGL J MED, V323, P275; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1988, ANN INTERN MED, V108, P309, DOI 10.7326/0003-4819-108-2-309_2; 1987, MMWR, V36, pS1; 1990, SEER CANCER REGISTRY	14	138	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					309	311		10.7326/0003-4819-117-4-309	http://dx.doi.org/10.7326/0003-4819-117-4-309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637026				2022-12-28	WOS:A1992JH46400007
J	GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB				GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB			SPECIFIC SEQUENCES AND A HAIRPIN STRUCTURE IN THE TEMPLATE STRAND ARE REQUIRED FOR N4-VIRION RNA-POLYMERASE PROMOTER RECOGNITION	CELL			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION INITIATION; OPEN COMPLEX; IDENTIFICATION; PURIFICATION; MECHANISM; KINETICS; INTERACT; ELEMENTS; LOOP	Coliphage N4 virion-encapsidated, DNA-dependent RNA polymerase (vRNAP) is inactive on double-stranded N4 DNA; however, denatured promoter-containing templates are accurately transcribed. We report that all determinants of vRNAP promoter recognition exist in the template strand, indicating that this enzyme is a site-specific, single-stranded DNA-binding protein. We show that conserved sequences and the integrity of inverted repeats present at the promoters are essential for activity, suggesting the necessity for specific secondary structure. Evidence for such a structure is presented. We propose a model for in vivo utilization of vRNAP promoters in which template negative supercoiling yields single-strandedness at the promoter to reveal the determinants of vRNAP binding. This structure is stabilized by the binding of E. coli single-stranded DNA-binding protein to yield an "activated promoter."	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NIAID NIH HHS [AI 07099, AI 12575] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07183] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Chamberlin M., 1982, ENZYMES, V15, P87; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRICK F, 1971, NATURE, V234, P25, DOI 10.1038/234025a0; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P3220, DOI 10.1073/pnas.75.7.3220; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FEAVERS IM, 1989, J BIOL CHEM, V264, P9114; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GERMANN MW, 1990, NUCLEIC ACIDS RES, V18, P1489, DOI 10.1093/nar/18.6.1489; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; GUINTA D, 1986, VIROLOGY, V150, P33, DOI 10.1016/0042-6822(86)90263-1; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; KIINO DR, 1988, BACTERIOPHAGES, V2, P457; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; Maniatis T., 1982, MOL CLONING; MARKIEWICZ P, 1988, NUCLEIC ACIDS RES, V16, P1011, DOI 10.1093/nar/16.3.1011; MARKIEWICZ P, 1992, IN PRESS GENES DEV; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; TAKASE H, 1991, BIOCHEM BIOPH RES CO, V176, P1593, DOI 10.1016/0006-291X(91)90470-R; VANDERLAAN K, 1977, VIROLOGY, V76, P596, DOI 10.1016/0042-6822(77)90241-0; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZEHRING WA, 1983, J BIOL CHEM, V258, P8074; ZIVIN R, 1981, J MOL BIOL, V152, P335, DOI 10.1016/0022-2836(81)90246-1	49	74	76	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					491	500		10.1016/0092-8674(92)90173-A	http://dx.doi.org/10.1016/0092-8674(92)90173-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643660				2022-12-28	WOS:A1992JH12400014
J	SAUNDERS, WS; HOYT, MA				SAUNDERS, WS; HOYT, MA			KINESIN-RELATED PROTEINS REQUIRED FOR STRUCTURAL INTEGRITY OF THE MITOTIC SPINDLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MICROBEAM IRRADIATIONS; GENE; DROSOPHILA; MOTOR; MICROTUBULES; SEGREGATION	For S. cerevisiae cells, the assembly of a bipolar mitotic spindle requires the action of either Cin8p or Kip1p, gene products related to the mechanochemical enzyme kinesin. In this paper we demonstrate that the activity of either one of these proteins is also required following spindle assembly. When their function was eliminated, preanaphase bipolar spindles rapidly collapsed, with previously separated poles being drawn together. In contrast, anaphase spindles were apparently resistant to collapse. Deletion of kinesin-related KAR3 partially suppressed the phenotypes associated with loss of Cin8p/Kip1p function. Our findings suggest that the structure of the preanaphase bipolar spindle is maintained by counteracting forces produced by kinesin-related proteins.			SAUNDERS, WS (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HOGAN CJ, 1990, CELL MOTIL CYTOSKEL, V16, P99, DOI 10.1002/cm.970160203; HOYT MA, 1992, IN PRESS J CELL BIOL; HYAMS JS, 1989, MITOSIS MOL MECHANIS; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LAFOUNTAIN JR, 1972, J CELL SCI, V10, P79; LESLIE RJ, 1983, J CELL BIOL, V96, P548, DOI 10.1083/jcb.96.2.548; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; McDonald K., 1989, MITOSIS MOL MECHANIS, P1; MCDONALD KL, 1979, J CELL BIOL, V83, P443, DOI 10.1083/jcb.83.2.443; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROOF DM, 1992, IN PRESS J CELL BIOL; ROSE MD, 1992, IN PRESS GUIDEBOOK C; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sherman F., 1983, METHODS YEAST GENETI; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; SPURCK TP, 1990, J CELL BIOL, V111, P1505, DOI 10.1083/jcb.111.4.1505; STEARNS T, 1990, GENETICS, V124, P251; TAYLOR EW, 1960, ANN NY ACAD SCI, V90, P430, DOI 10.1111/j.1749-6632.1960.tb23261.x; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108	31	330	335	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					451	458		10.1016/0092-8674(92)90169-D	http://dx.doi.org/10.1016/0092-8674(92)90169-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643659				2022-12-28	WOS:A1992JH12400010
J	SCHNEEWIND, O; MODEL, P; FISCHETTI, VA				SCHNEEWIND, O; MODEL, P; FISCHETTI, VA			SORTING OF PROTEIN-A TO THE STAPHYLOCOCCAL CELL-WALL	CELL			English	Article							ESCHERICHIA-COLI K-12; MEMBRANE-PROTEIN; OUTER-MEMBRANE; ENDOPLASMIC-RETICULUM; BACILLUS-SUBTILIS; TRANSMEMBRANE PROTEINS; ALKALINE-PHOSPHATASE; CYTOPLASMIC DOMAIN; LEADER PEPTIDASE; BINDING PROTEIN	The cell wall of gram-positive bacteria can be thought of as representing a unique cell compartment, which contains anchored surface proteins that require specific sorting signals. Some biologically important products are anchored in this way, including protein A and fibronectin binding protein of Staphylococcus aureus and streptococcal M protein. Studies of staphylococcal protein A and Escherichia coli alkaline phosphatase show that the signal both necessary and sufficient for cell wall anchoring consists of an LPXTGX motif, a C-terminal hydrophobic domain, and a charged tail. These sequence elements are conserved in many surface proteins from different gram-positive bacteria. We propose the existence of a hitherto undescribed sorting mechanism that positions proteins on the surface of gram-positive bacteria.			SCHNEEWIND, O (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011822, R01AI011822] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11822] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1970, BIOCHEMISTRY-US, V9, P5041, DOI 10.1021/bi00828a001; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BRISSETTE JL, 1990, J MOL BIOL, V211, P565, DOI 10.1016/0022-2836(90)90266-O; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOMI H, 1990, J IMMUNOL, V144, P4046; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSEFSSON LG, 1981, J BIOL CHEM, V256, P2504; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOEWY ZG, 1987, GENE DEV, V1, P626, DOI 10.1101/gad.1.6.626; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MODEL P, 1990, CELL, V61, P739, DOI 10.1016/0092-8674(90)90180-M; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MURPHY E, 1981, PLASMID, V5, P292, DOI 10.1016/0147-619X(81)90006-8; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; Novick R.P., 1990, MOL BIOL STAPHYLOCOC; NOVICK RP, 1979, PLASMID, V2, P109, DOI 10.1016/0147-619X(79)90010-6; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PATEE PA, 1961, CAN J MICROBIOL, V82, P875; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PROJAN SJ, 1987, J BACTERIOL, V169, P5131, DOI 10.1128/jb.169.11.5131-5139.1987; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1986, METHOD ENZYMOL, V125, P129; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1990, J BACTERIOL, V172, P3310, DOI 10.1128/jb.172.6.3310-3317.1990; SHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501, DOI 10.1146/annurev.mi.37.100183.002441; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TWETEN RK, 1983, J BACTERIOL, V153, P297, DOI 10.1128/JB.153.1.297-303.1983; UHLEN M, 1984, J BACTERIOL, V159, P713; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WU CH, 1971, INFECT IMMUN, V3, P784, DOI 10.1128/IAI.3.6.784-792.1971; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1984, J BIOL CHEM, V259, P6013	93	446	468	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					267	281		10.1016/0092-8674(92)90101-H	http://dx.doi.org/10.1016/0092-8674(92)90101-H			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638631				2022-12-28	WOS:A1992JE75700010
J	MILLIGAN, DL; KOSHLAND, DE				MILLIGAN, DL; KOSHLAND, DE			INTRASUBUNIT SIGNAL TRANSDUCTION BY THE ASPARTATE CHEMORECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; DIRECTED CROSS-LINKING; HUMAN INSULIN-RECEPTOR; ESCHERICHIA-COLI; PROTEIN METHYLATION; PHOSPHORYLATION; DIMERIZATION; ADAPTATION; ACTIVATION; FAMILY	Receptors that transmit signals across cell membranes are typically composed of multiple subunits. To test whether subunit interactions are required for transmembrane signaling by the bacterial aspartate receptor, dimers were constructed with (i) two full-length subunits, (ii) one full-length subunit and one subunit lacking the cytoplasmic domain, or (iii) one full-length subunit and one subunit lacking both the cytoplasmic and the transmembrane domains. Methylation of the cytoplasmic domain of all three receptor constructs was stimulated by the binding of aspartate. These findings demonstrate that transmembrane signaling does not require interactions between cytoplasmic or transmembrane domains of adjacent subunits and suggest that signaling occurs via conformational changes transduced through a single subunit.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	MILLIGAN, DL (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK 09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, UNPUB; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; PESSIN JE, 1985, MOL BASIS INSULIN AC, P3; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	25	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1651	1654		10.1126/science.1661030	http://dx.doi.org/10.1126/science.1661030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661030				2022-12-28	WOS:A1991GV07300047
J	GOODRICH, JM; MORI, M; GLEAVES, CA; DUMOND, C; CAYS, M; EBELING, DF; BUHLES, WC; DEARMOND, B; MEYERS, JD				GOODRICH, JM; MORI, M; GLEAVES, CA; DUMOND, C; CAYS, M; EBELING, DF; BUHLES, WC; DEARMOND, B; MEYERS, JD			EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-LEUKOCYTE INTERFERON; INTRAVENOUS IMMUNE GLOBULIN; PLACEBO-CONTROLLED TRIAL; HIGH-DOSE ACYCLOVIR; VIRUS INFECTION; INTERSTITIAL PNEUMONIA; RECIPIENTS; IMMUNOGLOBULIN; COMBINATION; EFFICACY	Background. Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir for the early treatment of CMV infection in asymptomatic recipients of bone marrow transplants whose surveillance cultures for CMV became positive. Methods. Bone marrow-allograft recipients who were seropositive for CMV antibodies or who received seropositive marrow were screened for CMV excretion by culture of throat swabs, blood, urine, or bronchoalveolar-lavage fluid. In this double-blind trial, 72 patients who had marrow engraftment and were excreting virus were randomly assigned to receive either placebo or ganciclovir (5 mg per kilogram of body weight twice a day for one week, followed by 5 mg per kilogram per day) for the first 100 days after transplantation. Patients were followed for the development of biopsy-confirmed CMV disease, ganciclovir-related toxicity, and survival. Results. Between assignment to the study drug and day 100 after transplantation, CMV disease developed in only 1 of the 37 patients assigned to receive ganciclovir (3 percent), but in 15 of the 35 patients assigned to receive placebo (43 percent, P < 0.00001). The ganciclovir recipients had rapid suppression of virus excretion; 85 percent had negative cultures after one week of treatment, as compared with 44 percent of the placebo group (P = 0.001). The principal toxic reaction was neutropenia; 11 ganciclovir recipients had an absolute neutrophil count below 0.75 x 10(9) per liter, as compared with 3 placebo recipients (P = 0.052). Treatment was discontinued in 11 ganciclovir recipients and 1 placebo recipient because of neutropenia (P = 0.003). After treatment was stopped, the neutrophil count recovered in all patients. Overall survival was significantly greater in the ganciclovir group than in the placebo group both 100 days and 180 days after transplantation (P = 0.041 and 0.027, respectively). Conclusions. Early treatment with ganciclovir in patients with positive surveillance cultures reduces the incidence of CMV disease and improves survival after allogeneic bone marrow transplantation.	UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; SYNTEX INC, INST CLIN MED, PALO ALTO, CA 94304 USA	University of Washington; University of Washington Seattle; Syntex Corporation	GOODRICH, JM (corresponding author), FRED HUTCHINSON CANC RES CTR, PROGRAM INFECT DIS, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NCI NIH HHS [CA-15704, CA-18029] Funding Source: Medline; NHLBI NIH HHS [HL-36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1987, TRANSFUSION, V27, P478, DOI 10.1046/j.1537-2995.1987.27688071699.x; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; COX DR, 1972, J R STAT SOC B, V34, P187; DIETERICH DT, 1988, REV INFECT DIS, V10, pS532; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FRANK I, 1988, ANN INTERN MED, V109, P769, DOI 10.7326/0003-4819-109-10-769; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; KAPLAN CS, 1989, ARCH INTERN MED, V149, P2095, DOI 10.1001/archinte.149.9.2095; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEAY S, 1988, REV INFECT DIS, V10, pS563; KRAEMER KG, 1978, TRANSPLANT P, V10, P237; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEYERS JD, 1982, J INFECT DIS, V146, P80, DOI 10.1093/infdis/146.1.80; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1980, J INFECT DIS, V141, P555, DOI 10.1093/infdis/141.5.555; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1987, ANN INTERN MED, V107, P809, DOI 10.7326/0003-4819-107-6-809; MEYERS JD, 1989, REV INFECT DIS    S7, V11, pS1691; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REED EC, 1986, ANN INTERN MED, V105, P214, DOI 10.7326/0003-4819-105-2-214; REED EC, 1987, J INFECT DIS, V156, P641, DOI 10.1093/infdis/156.4.641; REED EC, 1990, ANN INTERN MED, V112, P505, DOI 10.7326/0003-4819-112-7-505; REUSSER P, 1991, BLOOD, V78, P1373; RUBIN RH, 1990, REV INFECT DIS, V12, pS754; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368; SYNDMAN DR, 1988, REV INFECT DIS S3, V10, pS554; WADE JC, 1984, J INFECT DIS, V149, P750, DOI 10.1093/infdis/149.5.750; WADE JC, 1983, J INFECT DIS, V148, P557, DOI 10.1093/infdis/148.3.557; WADE JC, 1982, AM J MED, V73, P249, DOI 10.1016/0002-9343(82)90100-0; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12	37	543	554	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1601	1607		10.1056/NEJM199112053252303	http://dx.doi.org/10.1056/NEJM199112053252303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1658652	Bronze			2022-12-28	WOS:A1991GR77000003
J	JUPPNER, H; ABOUSAMRA, AB; FREEMAN, M; KONG, XF; SCHIPANI, E; RICHARDS, J; KOLAKOWSKI, LF; HOCK, J; POTTS, JT; KRONENBERG, HM; SEGRE, GV				JUPPNER, H; ABOUSAMRA, AB; FREEMAN, M; KONG, XF; SCHIPANI, E; RICHARDS, J; KOLAKOWSKI, LF; HOCK, J; POTTS, JT; KRONENBERG, HM; SEGRE, GV			A G-PROTEIN LINKED RECEPTOR FOR PARATHYROID-HORMONE AND PARATHYROID-HORMONE RELATED PEPTIDE	SCIENCE			English	Article							CANINE RENAL CORTEX; OSTEO-SARCOMA CELLS; HUMORAL HYPERCALCEMIA; PLASMA-MEMBRANE; OK CELLS; CLONING; STIMULATION; EXPRESSION; MALIGNANCY; SEQUENCE	The complementary DNA encoding a 585-amino acid parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor with seven potential membrane-spanning domains was cloned by COS-7 expression using an opossum kidney cell complementary DNA (cDNA) library. The expressed receptor binds PTH and PTHrP with equal affinity, and both ligands equivalently stimulate adenylate cyclase. Striking homology with the calcitonin receptor and lack of homology with other G protein-linked receptors indicate that receptors for these calcium-regulating hormones are related and represent a new family.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; VET ADM OUTPATIENT CLIN,BOSTON,MA 02108; TUFTS UNIV,SCH DENT MED,BOSTON,MA 02111	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Tufts University			Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142; Hock, Janet/0000-0001-8873-2545	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BRINGHURST FR, COMMUNICATION; CHASE LR, 1968, SCIENCE, V159, P545, DOI 10.1126/science.159.3814.545; COLE JA, 1989, AM J PHYSIOL, V256, pF672, DOI 10.1152/ajprenal.1989.256.4.F672; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOKALKOWSKI LF, UJNPUB; HRUSKA KA, 1987, J CLIN INVEST, V79, P230, DOI 10.1172/JCI112788; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KARPF DB, 1991, J BONE MINER RES, V6, P173; KARPF DB, 1987, BIOCHEMISTRY-US, V26, P7825, DOI 10.1021/bi00398a044; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIN H, 1991, SCIENCE, V254, P1021; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485; NISSENSON RA, 1987, BIOCHEMISTRY-US, V26, P1874, DOI 10.1021/bi00381a013; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NISSENSON RA, 1986, ENDOCRINOLOGY, V118, P932, DOI 10.1210/endo-118-3-932; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; ROSENBLATT M, 1989, ENDOCRINOLOGY, P848; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; SHIGENO C, 1988, J BIOL CHEM, V263, P18369; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TEITELBAUM AP, 1984, ENDOCRINOLOGY, V114, P980, DOI 10.1210/endo-114-3-980; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711	32	1107	1156	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1024	1026		10.1126/science.1658941	http://dx.doi.org/10.1126/science.1658941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658941				2022-12-28	WOS:A1991GP88300051
J	AACH, RD; STEVENS, CE; HOLLINGER, FB; MOSLEY, JW; PETERSON, DA; TAYLOR, PE; JOHNSON, RG; BARBOSA, LH; NEMO, GJ				AACH, RD; STEVENS, CE; HOLLINGER, FB; MOSLEY, JW; PETERSON, DA; TAYLOR, PE; JOHNSON, RG; BARBOSA, LH; NEMO, GJ			HEPATITIS-C VIRUS-INFECTION IN POSTTRANSFUSION HEPATITIS - AN ANALYSIS WITH 1ST-GENERATION AND 2ND-GENERATION ASSAYS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; TRANSMITTED VIRUSES; CORE ANTIGEN; ANTIBODY; BLOOD; RECIPIENTS; DONORS	Background. The causes of post-transfusion non-A, non-B hepatitis are still not fully defined, nor is it clear how accurate the tests are that are used to screen blood donors for hepatitis C virus (HCV) and to diagnose post-transfusion hepatitis caused by infected blood. Methods. We used two first-generation enzyme-linked immunoassays (EIAs) and one second-generation immunoassay to test for anti-HCV antibodies in serum samples collected between 1976 and 1979 in the Transfusion-Transmitted Viruses Study (from 1247 patients who underwent transfusion and 1235 matched control subjects who did not receive transfusions). We tested serum collected before and after infection from the patients in whom non-A, non-B hepatitis developed, serum from their blood donors, and serum from 41 of the control subjects who had hepatitis unrelated to transfusion. Results. Of the 115 patients in whom post-transfusion non-A, non-B hepatitis developed, the initial serum samples of 111 were anti-HCV-negative; after hepatitis developed in these 111 patients, the first-generation EIAs detected anti-HCV in 51 (46 percent), and the second-generation assay detected anti-HCV in an additional 16 (14 percent), for a total of 60 percent. Of 40 controls, 37 were anti-HCV-negative initially, and none seroconverted after hepatitis developed. If the 3 percent rate of non-A, non-B, non-C hepatitis among the controls (37 of 1235) was applied to the 1247 transfusion recipients, only 74 of the 111 cases of hepatitis were attributable to the transfusion. Thus, 91 percent (67 of 74) of the cases of post-transfusion hepatitis were caused by HCV. Of the 99 donors, 60 were HCV-positive (9 on second-generation tests only) and 39 were not. Conclusions. Nearly all cases of non-A, non-B post-transfusion hepatitis are caused by HCV. Screening with a second-generation assay improves the rate of detection of HCV infection in patients with post-transfusion hepatitis and in blood donors. The use of this test showed a 3.6 percent risk of non-A, non-B, non-C hepatitis, which was not significantly different from the rate in the controls (3.0 percent).	NHLBI,DIV BLOOD DIS & RESOURCES,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; NEW YORK BLOOD CTR,NEW YORK,NY 10021; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; BAYLOR COLL MED,HOUSTON,TX 77030; ABBOTT LABS,N CHICAGO,IL 60064	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Case Western Reserve University; New York Blood Center; University of Southern California; Baylor College of Medicine; Abbott Laboratories	AACH, RD (corresponding author), MT SINAI MED CTR,1 MT SINAI DR,CLEVELAND,OH 44106, USA.		Hollinger, F Blaine/AAY-3323-2021		NHLBI NIH HHS [N01-HB-42972] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; Alter HJ, 1978, VIRAL HEPATITIS, P359; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAWSON GJ, 1991, J CLIN MICROBIOL, V29, P551, DOI 10.1128/JCM.29.3.551-556.1991; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; HOLLINGER FB, 1982, VIRAL HEPATITIS, P361; HOLLINGER FB, 1984, VIRAL HEPATITIS LIVE, P319; HOLLINGER FB, 1978, INTERVIROLOGY, V18, P60; KNODELL RG, 1976, LANCET, V1, P557; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; MOSLEY JW, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P402; PRINCE AM, 1974, LANCET, V2, P241; RAKELA J, 1980, GASTROENTEROLOGY, V78, P1318; SEEFF LB, 1978, VIRAL HEPATITIS, P371; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q	22	513	517	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1325	1329		10.1056/NEJM199111073251901	http://dx.doi.org/10.1056/NEJM199111073251901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1656258				2022-12-28	WOS:A1991GN47000001
J	HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE				HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE			MEDICAL EVALUATION OF INTERNATIONALLY ADOPTED-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYTOMEGALO-VIRUS INFECTION; HEPATITIS-B VIRUS; DAY-CARE; TRANSMISSION; TUBERCULOSIS; EPIDEMIOLOGY; PHYSICIANS; PREVALENCE; COUNTRIES; RISKS	Background. Despite many reports of medical illness in children adopted from abroad, there are currently no accepted guidelines for medical evaluation of this population. Methods. Two hundred ninety-three children adopted from 15 countries (mean age, 14.0 months; 55 percent girls) were evaluated by history taking, physical examination, and screening tests for hepatitis B virus (HBV), human immunodeficiency virus type 1, tuberculin reactivity, intestinal parasites, syphilis, excretion of cytomegalovirus, renal disease, and anemia. All but four were seen within one month of their arrival in the United States. Results. Fifty-seven percent of the children (168 of 293) were found to have at least one important medical condition. Eighty-one percent of the diagnoses were established by screening test, rather than by history taking or physical examination. Infectious diseases made up the majority of the medical conditions (73 percent). Serologic testing for hepatitis B surface antigen was positive in 5 percent of the children. Characteristics associated with the acquisition of HBV infection included arrival within the first three years of the study (P = 0.017), Asian origin (P = 0.011), and receipt of a blood transfusion abroad (P = 0.008). Ten children (3 percent) had positive Mantoux skin tests, and four of these had active pulmonary tuberculosis. Tuberculin reactivity was significantly associated with older age (P < 0.001) and lower weight (P = 0.037). Intestinal parasites were isolated from 14 percent of the international adoptees. Non-Korean adoptees were 16 times more likely to be harboring at least one intestinal parasite than were Korean adoptees (P = 0.005). Conclusions. Directed screening tests should be a routine component of the medical evaluation of all children adopted from abroad, regardless of age, sex, or country of origin.	UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	HOSTETTER, MK (corresponding author), UNIV MINNESOTA, DEPT PEDIAT, INT ADOPT CLIN, UMHC BOX 296, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.							AACH RD, 1987, TXB PEDIATRIC INFECT, V1, P718; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; BASS JL, IN PRESS PEDIATRICS; BLACK RE, 1977, PEDIATRICS, V60, P486; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P1011, DOI 10.1097/00006454-198706110-00001; CHRISTENSON B, 1986, SCAND J INFECT DIS, V18, P105, DOI 10.3109/00365548609032315; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; GREENBLATT M, 1985, NEW ENGL J MED, V312, P1639; HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002; HOSTETTER M, 1989, AM J DIS CHILD, V143, P325, DOI 10.1001/archpedi.1989.02150150079022; HOSTETTER MK, 1989, PEDIATRICS, V83, P559; HOSTETTER MK, 1989, PEDIATRICS, V84, P936; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JENISTA JA, 1987, AM J DIS CHILD, V141, P298, DOI 10.1001/archpedi.1987.04460030076029; KAUNITZ AM, 1987, JAMA-J AM MED ASSOC, V258, P3537, DOI 10.1001/jama.258.24.3537; LANGE WR, 1989, PEDIATR INFECT DIS J, V8, P625, DOI 10.1097/00006454-198909000-00012; LANGE WR, 1987, PEDIATR INFECT DIS J, V6, P447, DOI 10.1097/00006454-198705000-00006; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; NORDENFELT E, 1978, SCAND J INFECT DIS, V10, P161, DOI 10.3109/inf.1978.10.issue-3.01; PASS RF, 1987, NEW ENGL J MED, V316, P1366, DOI 10.1056/NEJM198705283162203; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHULZER M, 1987, INT J EPIDEMIOL, V16, P584, DOI 10.1093/ije/16.4.584; Smith-Garcia T, 1989, J Community Health, V14, P227, DOI 10.1007/BF01338874; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; VERNON TM, 1976, JAMA-J AM MED ASSOC, V235, P2829, DOI 10.1001/jama.235.26.2829; WALPOLE RE, 1982, INTRO STATISTICS, P40; WESSEL MA, 1960, NEW ENGL J MED, V262, P446, DOI 10.1056/NEJM196003032620906; WHITE NH, 1989, J INFECT DIS, V159, P1013, DOI 10.1093/infdis/159.6.1013; 1985, MMWR, V34, P313; 1985, ADOPTION FACTBOOK, P126; 1990, STATISTICAL ABSTRACT, P835; 1985, MMWR, V34, P329; 1988, PEDIATRICS, V82, P941; 1983, MEASURING CHANGE NUT, P75; 1990, MMWR, V39, P1	35	119	120	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					479	485		10.1056/NEJM199108153250706	http://dx.doi.org/10.1056/NEJM199108153250706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649404				2022-12-28	WOS:A1991GA76300006
J	PARDUE, ML				PARDUE, ML			DYNAMIC INSTABILITY OF CHROMOSOMES AND GENOMES	CELL			English	Editorial Material							GENE AMPLIFICATION; HET DNA; HETEROCHROMATIN; KINETOCHORE; DROSOPHILA; MOVEMENT; SEQUENCE; RECOMBINATION; CENTROMERES; ANTIBODIES				PARDUE, ML (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.ge.19.120185.000333; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GORBSKY GJ, 1988, J CELL BIOL, V106, P1185, DOI 10.1083/jcb.106.4.1185; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LOWENHAUPT KY, 1989, MOL CELL BIOL, V9, P1173, DOI 10.1128/MCB.9.3.1173; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PARDUE ML, 1990, CHROMOSOMA, V100, P3, DOI 10.1007/BF00337597; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STEUER ER, 1990, NATURE, V345, P260; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091; [No title captured]	34	34	34	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					427	431		10.1016/0092-8674(81)90007-6	http://dx.doi.org/10.1016/0092-8674(81)90007-6			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651168				2022-12-28	WOS:A1991GA94100005
J	VORTKAMP, A; GESSLER, M; GRZESCHIK, KH				VORTKAMP, A; GESSLER, M; GRZESCHIK, KH			GLI3 ZINC-FINGER GENE INTERRUPTED BY TRANSLOCATIONS IN GREIG SYNDROME FAMILIES	NATURE			English	Article							CEPHALOPOLYSYNDACTYLY SYNDROME; LOCALIZATION; CHROMOSOME-7	THE Greig cephalopolysyndactyly syndrome (GCPS) is an autosomal dominant disorder affecting limb and craniofacial development in humans 1,2. GCPS-affected individuals are characterized by postaxial polysyndactyly of hands, preaxial polysyndactyly of feet, macroephaly, a broad base of the nose with mild hypertelorism and a prominent forehead. The genetic locus has been pinpointed to chromosome 7p13 by three balanced translocations associated with GCPS in different families 3,4,19. This assignment is corroborated by the detection of two sporadic GCPS cases carrying overlapping deletions in 7p13 (ref. 7), as well as by tight linkage of GCPS to the epidermal growth factor receptor gene in 7p12-13 (ref. 8). Of the genes that map to this region, those encoding T cell receptor-gamma, interferon-beta-2, epidermal growth factor receptor, and Hox1.4, a potential candidate gene for GCPS, have been excluded from the region in which the deletions overlap 7,9. Here we show that two of the three translocations interrupt the GLI3 gene, a zinc-finger gene of the GLI-Kruppel family already localized to 7p13 (refs 5, 6). The breakpoints are within the first third of the coding sequence. In the third translocation, chromosome 7 is broken at about 10 kilobases downstream of the 3' end of GLI3. Our results indicate that mutations disturbing normal GLI3 expression may have a causative role in GCPS.			VORTKAMP, A (corresponding author), UNIV MARBURG,INST HUMANGENET,BAHNHOFSTR 7A,W-3550 MARBURG,GERMANY.			Gessler, Manfred/0000-0002-7915-6045				BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BRUETON L, 1988, AM J MED GENET, V31, P799, DOI 10.1002/ajmg.1320310412; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRABKIN H, 1989, GENOMICS, V4, P518, DOI 10.1016/0888-7543(89)90275-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOLLOP TR, 1985, AM J MED GENET, V22, P59, DOI 10.1002/ajmg.1320220106; GREIG DAVID M., 1926, EDINBURGH MED JOUR, V33, P189; JOBS A, 1990, HUM GENET, V84, P147; KRUGER G, 1989, AM J MED GENET, V32, P411, DOI 10.1002/ajmg.1320320329; Maniatis T., 1982, MOL CLONING; POHL TM, 1990, DEVELOPMENT, V110, P1153; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; TOMMERUP N, 1983, AM J MED GENET, V16, P313, DOI 10.1002/ajmg.1320160304; VORTKAMP A, IN PRESS GENOMICS; WAGNER K, 1990, GENOMICS, V8, P487, DOI 10.1016/0888-7543(90)90035-S; WINTER RM, 1988, AM J MED GENET, V31, P793, DOI 10.1002/ajmg.1320310411	19	473	487	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					539	540		10.1038/352539a0	http://dx.doi.org/10.1038/352539a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650914	Green Submitted			2022-12-28	WOS:A1991GA22600066
J	EKBOM, K				EKBOM, K			TREATMENT OF ACUTE CLUSTER HEADACHE WITH SUMATRIPTAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALATION; MIGRAINE; GR43175	Background. Attacks of cluster headache are difficult to treat. Sumatriptan, an agonist of 5-hydroxytryptamine1-like receptors, has proved effective in the treatment of migraine. The clinical similarities between migraine and cluster headache and positive results from an open pilot study in patients with cluster headache indicated that sumatriptan should be evaluated more rigorously in the treatment of this condition. Methods. We conducted a randomized, double-blind, placebo-controlled crossover study to assess the efficacy and tolerability of sumatriptan in 49 patients with cluster headache. The patients received, in random order, a subcutaneous injection of 6 mg of sumatriptan for one cluster-headache attack and placebo for another attack. The results for the two attacks could be fully evaluated for 39 patients. A response to treatment was defined as complete or almost complete relief of headache (no pain or mild pain) within 15 minutes after the injection. Results. In the 39 patients, the severity of headache decreased in 74 percent of the attacks within 15 minutes of treatment with sumatriptan, as compared with 26 percent of the attacks for which placebo was given (P < 0.001). Thirty-six percent of the patients were free of pain within 10 minutes after the administration of sumatriptan, as compared with 3 percent after placebo (P < 0.001); by 15 minutes these numbers had increased to 46 percent and 10 percent, respectively (P < 0.001). Thirteen percent of the patients required oxygen as an additional treatment 15 minutes after receiving sumatriptan, as compared with 49 percent of those who received placebo. The severity of functional disability and the incidence of ipsilateral conjunctival injection also decreased more in response to sumatriptan than placebo. Sumatriptan was well tolerated, and there were no serious adverse events. Conclusions. Sumatriptan is an effective and well-tolerated treatment for acute attacks of cluster headache.			EKBOM, K (corresponding author), SODER HOSP,DEPT NEUROL,S-11883 STOCKHOLM,SWEDEN.							BARRE F, 1982, HEADACHE, V22, P69, DOI 10.1111/j.1526-4610.1982.hed2202069.x; BELLVILLE JW, 1968, CLIN PHARMACOL THER, V9, P290; EKBOM K, 1990, HEADACHE Q CURR TREA, V1, P65; EKBOM K, 1987, MIGRAINE CLIN THERAP, P223; FERRARI M, 1989, CEPHALALGIA S10, V9, P348; FOGAN L, 1985, ARCH NEUROL-CHICAGO, V42, P362, DOI 10.1001/archneur.1985.04060040072015; Gutterman DL, 1989, CEPHALALGIA S10, V9, P412; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HUMPHREY PPA, 1989, CEPHALALGIA, V9, P23; KENWARD MG, 1987, APPL STAT-J ROY ST C, V36, P192, DOI 10.2307/2347551; KITTRELLE JP, 1985, ARCH NEUROL-CHICAGO, V42, P496, DOI 10.1001/archneur.1985.04060050098017; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KRABBE A, 1989, CEPHALALGIA S10, V9, P406; KUDROW L, 1981, HEADACHE, V21, P1, DOI 10.1111/j.1526-4610.1981.hed2101001.x; LANCE JW, 1989, CEPHALALGIA, V9, P7; LASAGNA L, 1960, ANN NY ACAD SCI, V86, P28, DOI 10.1111/j.1749-6632.1960.tb42788.x; MULLERSCHWEINITZER E, 1977, AGENTS ACTIONS, V7, P383; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; 1991, NEW ENGL J MED, V325, P316	19	260	270	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1991	325	5					322	326		10.1056/nejm199108013250505	http://dx.doi.org/10.1056/nejm199108013250505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY715	1647496				2022-12-28	WOS:A1991FY71500005
J	KENDELL, RE				KENDELL, RE			CHRONIC FATIGUE, VIRUSES, AND DEPRESSION	LANCET			English	Editorial Material							POSTVIRAL FATIGUE; MAGNETIC-RESONANCE; MUSCLE; INFECTION; SYMPTOMS; PATIENT				KENDELL, RE (corresponding author), UNIV EDINBURGH,ROYAL EDINBURGH HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,SCOTLAND.							ANDREASEN NC, 1986, ARCH GEN PSYCHIAT, V43, P246; [Anonymous], 1989, ANN REPORT; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; Beard GM, 1869, BOSTON MED SURG J, V80, P217; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHURCH AJ, 1980, MED J AUSTRALIA, V1, P307, DOI 10.5694/j.1326-5377.1980.tb134875.x; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P961; KENDELL RE, 1983, HDB PSYCHIATRY, V4, P232; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; MANU P, 1988, ANN INTERN MED, V109, P554, DOI 10.7326/0003-4819-109-7-554; SCHLEIFER SJ, 1983, JAMA-J AM MED ASSOC, V250, P374, DOI 10.1001/jama.250.3.374; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; YONGE RP, 1988, J ROY SOC MED, V81, P322, DOI 10.1177/014107688808100607; YOUSEF GE, 1988, LANCET, V1, P146; 1987, HLTH LIFESTYLE SURVE; 1989, WHO ICD10 DIV MENT H, pCH5	25	44	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					160	162						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET679	1670800				2022-12-28	WOS:A1991ET67900016
J	KORN, EL; BAUMRIND, S				KORN, EL; BAUMRIND, S			RANDOMIZED CLINICAL-TRIALS WITH CLINICIAN-PREFERRED TREATMENT	LANCET			English	Article							CANCER	The standard design for randomised clinical trials may be inappropriate when the clinician believes that one of the treatments being tested is superior for the patient, or when the clinician has a preference for one of the treatments. For such instances the suggestion is that the patient is randomly allocated to treatment only when there is clinical disagreement about treatment of choice for that patient, and then the patient is assigned to a clinician who had thought that the regimen allocated is the one most appropriate for that patient.	UNIV CALIF SAN FRANCISCO, SCH DENT, DEPT GROWTH & DEV, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	KORN, EL (corresponding author), NCI, BIOMETR RES BRANCH, EXECUT PLAZA N, ROOM 739, BETHESDA, MD 20892 USA.							ANGELL M, 1984, NEW ENGL J MED, V310, P1385, DOI 10.1056/NEJM198405243102111; BAUM M, 1989, BRIT MED J, V299, P251, DOI 10.1136/bmj.299.6693.251; BEGG CB, 1989, STAT SCI, V4, P320; Berry DA., 1989, STAT SCI, V4, P306, DOI [10.1214/ss/1177012385, DOI 10.1214/SS/1177012385]; ELLENBERG SS, 1984, NEW ENGL J MED, V310, P1404, DOI 10.1056/NEJM198405243102141; Hellman S., 1979, CANCER CLIN TRIALS, V2, P189; LEVINE RJ, 1979, CLIN PHARMACOL THER, V25, P728; MACKILLOP WJ, 1986, BRIT J CANCER, V54, P661, DOI 10.1038/bjc.1986.224; MOORE MJ, 1988, J CLIN ONCOL, V6, P1736, DOI 10.1200/JCO.1988.6.11.1736; OROURKE PP, 1989, PEDIATRICS, V84, P957; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Royall R., 1989, STAT SCI, V4, P318, DOI [10.1214/ss/1177012387, DOI 10.1214/SS/1177012387]; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; Ware JH, 1989, STAT SCI, V4, P298, DOI DOI 10.1214/ss/1177012384; 1983, BRIT MED J, V286, P1117	18	39	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	1991	337	8734					149	152		10.1016/0140-6736(91)90809-4	http://dx.doi.org/10.1016/0140-6736(91)90809-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670796				2022-12-28	WOS:A1991ET67900012
J	HATTORI, T; ASOU, N; SUZUSHIMA, H; TAKATSUKI, K; TANAKA, K; NAITO, K; NATORI, H; OIZUMI, K				HATTORI, T; ASOU, N; SUZUSHIMA, H; TAKATSUKI, K; TANAKA, K; NAITO, K; NATORI, H; OIZUMI, K			LEUKEMIA OF NOVEL GASTROINTESTINAL LYMPHOCYTE-T POPULATION INFECTED WITH HTLV-I	LANCET			English	Note							CELL RECEPTOR; BETA-CHAINS; GENE; REARRANGEMENTS; LEUKEMIA	In a 72-year-old man with watery diarrhoea and leukocytosis the proliferation of abnormal cells was studied in specimens obtained by endoscopic biopsy of the gastrointestinal tract. Flow cytometry of leukaemia cells revealed a monoclonal expansion of "double-negative" (CD4-, CD8-) cells bearing T-cell receptor (TCR alpha-beta products. Southern blotting confirmed monoclonal integration of HTLV-1. A novel T-cell subset of double-negative TCR alpha-beta cells in the gastrointestinal tract in adult man may be a target for HTLV-1 infection.	KURUME UNIV, SCH MED, DEPT INTERNAL MED 1, KURUME, FUKUOKA 830, JAPAN	Kurume University	HATTORI, T (corresponding author), KUMAMOTO UNIV, SCH MED, DEPT INTERNAL MED 2, KUMAMOTO 860, JAPAN.		Hattori, Toshio/AAI-4599-2020	Hattori, Toshio/0000-0003-0947-7625				ASOU N, 1989, BLOOD, V74, P2707; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; GROH V, 1989, P NATL ACAD SCI USA, V86, P5059, DOI 10.1073/pnas.86.13.5059; HATTORI T, 1981, BLOOD, V58, P645; LONDEI M, 1989, P NATL ACAD SCI USA, V86, P8502, DOI 10.1073/pnas.86.21.8502; MATSUOKA M, 1988, LEUKEMIA, V2, P84; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; SHIRONO K, 1989, BLOOD, V73, P1664; SPENCER J, 1988, AM J PATHOL, V132, P1	9	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	1991	337	8733					76	77		10.1016/0140-6736(91)90737-A	http://dx.doi.org/10.1016/0140-6736(91)90737-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670727				2022-12-28	WOS:A1991ER47700005
J	GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z				GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z			PREGNANCY AFTER EMBRYO BIOPSY AND COAMPLIFICATION OF DNA FROM X-CHROMOSOME AND Y-CHROMOSOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN PREIMPLANTATION EMBRYOS; AMPLIFICATION; FERTILIZATION		YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510	Yale University	GRIFO, JA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CTR REPROD MED & INFERTIL,DEPT OBSTET & GYNECOL,505 E 70TH ST,NEW YORK,NY 10021, USA.			Grifo, James/0000-0003-0439-2374				COHEN J, 1992, MICROMANIPULATION HU; GORDON JW, 1986, J EXP ZOOL, V239, P347, DOI 10.1002/jez.1402390306; GRIFO JA, 1991, 30TH ANN M SOC GYN I; GRIFO JA, 1990, J IN VITRO FERTIL EM, V1, P92; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; PIETERS MHEC, 1992, J ASSIST REPROD GEN, V9, P68, DOI 10.1007/BF01204118; PLACHOT M, 1988, HUM REPROD, V3, P125, DOI 10.1093/oxfordjournals.humrep.a136644; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731	10	92	93	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					727	729		10.1001/jama.268.6.727	http://dx.doi.org/10.1001/jama.268.6.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640572				2022-12-28	WOS:A1992JG66600012
J	HUNTER, T; KARIN, M				HUNTER, T; KARIN, M			THE REGULATION OF TRANSCRIPTION BY PHOSPHORYLATION	CELL			English	Review							NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; RNA POLYMERASE-II; EPIDERMAL GROWTH-FACTOR; CELL-SPECIFIC INHIBITOR; SERUM RESPONSE FACTOR; C-FOS TRANSCRIPTION; REL-ASSOCIATED PP40; NUCLEAR FACTOR CREB		UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	HUNTER, T (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186, USA.							ABATE C, 1991, ONCOGENE, V6, P2179; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEGROOT R, 1992, IN PRESS ONCOGENE; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P1; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIN A, 1992, IN PRESS CELL, V70; LINK E, 1992, J BIOL CHEM, V267, P239; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LU H, 1992, IN PRESS NATURE; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PULVERER B, 1992, IN PRESS ONCOGENE; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHINDLER C, 1992, IN PRESS SCIENCE; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ JL, 1991, TRENDS CELL BIOL, V1, P130; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, IN PRESS MOL CELL BI; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	133	1288	1325	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					375	387		10.1016/0092-8674(92)90162-6	http://dx.doi.org/10.1016/0092-8674(92)90162-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643656	Bronze			2022-12-28	WOS:A1992JH12400003
J	PETERSON, HB; WALKER, CK; KAHN, JG; WASHINGTON, AE; ESCHENBACH, DA; FARO, S				PETERSON, HB; WALKER, CK; KAHN, JG; WASHINGTON, AE; ESCHENBACH, DA; FARO, S			PELVIC INFLAMMATORY DISEASE - KEY TREATMENT ISSUES AND OPTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLAMYDIA-TRACHOMATIS; CLINDAMYCIN-GENTAMICIN; GYNECOLOGIC INFECTIONS; SULBACTAM AMPICILLIN; DOXYCYCLINE; THERAPY; WOMEN; CIPROFLOXACIN; METRONIDAZOLE; SALPINGITIS	Objective. - To examine available data regarding optimal antimicrobial therapy for pelvic inflammatory disease (PID) and to address selected treatment issues confronting clinicians caring for women with PID. Data Sources. - Studies evaluated to help establish the Centers for Disease Control's 1989 Sexually Transmitted Diseases Treatment Guidelines and other reports published since 1985. A MEDLINE search of English-language literature was conducted using the indexing terms ''pelvic inflammatory disease'' or ''pelvic infections'' or ''salpingitis'' and ''treatment.'' In addition, abstracts and bibliographies of articles and books were reviewed. Study Selection. - Studies were selected for detailed review if they evaluated the effectiveness of an antimicrobial regimen for treatment of PID. Data Extraction. - All studies were evaluated to determine the numbers of women treated and the percentage with clinical or microbiologic evidence of cure. Data Synthesis. - A variety of combination antimicrobial regimens are highly effective in providing clinical and microbiologic evidence of cure; few data are available to assess optimal therapy for prevention of late sequelae. Because PID is polymicrobial in cause, recommended antimicrobial regimens are broad-spectrum in coverage. Conclusions. - No single agent that provides sufficient coverage is currently available. Several combination regimens appear highly effective clinically even among women with tubo-ovarian abscess formation. Uncertainties regarding the effectiveness of antimicrobial therapy for prevention of late sequelae complicate decisions regarding the choice among regimens and the appropriateness of ambulatory treatment of women with PID. Pending better data, hospitalization should be strongly considered, where feasible, particularly for those women with PID desiring further childbearing. Sex partners of all women with PID should be treated.	BAYLOR COLL MED,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195	Baylor College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	PETERSON, HB (corresponding author), CTR DIS CONTROL,DIV REPROD HLTH,WOMENS HLTH & FERTIL BRANCH,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024768] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24768] Funding Source: Medline; PHS HHS [282-88-0018] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APUZZIO JJ, 1989, AM J MED, V87, pS148, DOI 10.1016/0002-9343(89)90046-6; BRIHMER C, 1988, SCAND J INFECT DIS S, V53, P65; BROOK I, 1987, ARCH GYNECOL OBSTET, V241, P133, DOI 10.1007/BF00931309; BRUHAT MA, 1989, INT J GYNAECOL OBS S, V2, P41; BRUMSTED JR, 1988, FERTIL STERIL, V50, P667; BRUNHAM RC, 1984, AM J OBSTET GYNECOL, V148, P235, DOI 10.1016/S0002-9378(84)80061-7; BRUNHAM RC, 1988, J INFECT DIS, V158, P510, DOI 10.1093/infdis/158.3.510; CAMPBELL WF, 1990, AM J OBSTET GYNECOL, V162, P343, DOI 10.1016/0002-9378(90)90382-H; COVINO JM, 1990, ANTIMICROB AGENTS CH, V34, P148, DOI 10.1128/AAC.34.1.148; CROMBLEHOLME W, 1986, DRUGS, V31, P11, DOI 10.2165/00003495-198600312-00003; CROMBLEHOLME WR, 1990, OBSTET GYNECOL, V75, P752; CROMBLEHOLME WR, 1989, AM J MED, V87, pS142, DOI 10.1016/0002-9343(89)90045-4; DODSON MG, 1986, OBSTET GYNECOL, V67, P657, DOI 10.1097/00006250-198605000-00010; FARO S, 1988, CURR THER RES CLIN E, V43, P349; GALL SA, 1990, OBSTET GYNECOL, V75, P282; GUNNING J, 1986, DRUGS, V31, P14, DOI 10.2165/00003495-198600312-00004; HEINONEN PK, 1986, GENITOURIN MED, V62, P235; HEINONEN PK, 1989, AM J MED, V87, pS152, DOI 10.1016/0002-9343(89)90047-8; HEINONEN PK, 1989, SCAND J INFECT DIS S, V60, P66; HEMSELL DL, 1987, SURG GYNECOL OBSTET, V165, P223; HEMSELL DL, 1988, DRUGS, V35, P39, DOI 10.2165/00003495-198800357-00010; HEMSELL DL, 1988, AM J OBSTET GYNECOL, V158, P722, DOI 10.1016/S0002-9378(16)44535-7; HEMSELL DL, 1988, J REPROD MED, V33, P799; HENRYSUCHET J, 1986, CHLAMYDIAL INFECTION, P201; JONES RN, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90098-1; LANDERS DV, 1991, AM J OBSTET GYNECOL, V164, P849, DOI 10.1016/0002-9378(91)90528-Y; LARSEN JW, 1987, CLIN THER, V9, P77; MCGREGGOR JA, 1988, J REPROD MED S6, V33, P595; OBWEGESER J, 1989, J ANTIMICROB CHEMOTH, V24, P165, DOI 10.1093/jac/24.suppl_B.165; ORIEL JD, 1989, REV INFECT DIS, V11, pS1273; PAAVONEN J, 1987, BRIT J OBSTET GYNAEC, V94, P454, DOI 10.1111/j.1471-0528.1987.tb03125.x; PASTOREK JG, 1985, AM J MED, V78, P47, DOI 10.1016/0002-9343(85)90204-9; PATTON DL, 1989, OBSTET GYNECOL, V73, P622; PEARLMAN MD, 1990, ANTIMICROB AGENTS CH, V34, P1399, DOI 10.1128/AAC.34.7.1399; POINDEXTER AN, 1988, AM J OBSTET GYNECOL, V158, P717, DOI 10.1016/S0002-9378(16)44534-5; POULY J L, 1985, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V14, P989; SELLORS JW, 1988, FERTIL STERIL, V49, P451; SHEPARD MK, 1989, FERTIL STERIL, V52, P232; SOPER DE, 1988, OBSTET GYNECOL, V72, P7; SOPER DE, 1990, OCT ANN M INF DIS SO; SWEET RL, 1983, JAMA-J AM MED ASSOC, V250, P2641, DOI 10.1001/jama.250.19.2641; SWEET RL, 1988, AM J OBSTET GYNECOL, V158, P736, DOI 10.1016/S0002-9378(16)44537-0; SWEET RL, 1985, 1985 INT C ANT AG CH; SWEET RL, 1989, INT J GYNAECOL OBS S, V2, P13; SWENSON CE, 1985, SEX TRANSM DIS, V13, P40; TEISALA K, 1989, ANN MED, V21, P63, DOI 10.3109/07853898909149184; TOOMEY KE, 1990, REV INFECT DIS, V12, P5645; WALTERS MD, 1990, OBSTET GYNECOL, V75, P867; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WASSERHEIT JN, 1986, ANN INTERN MED, V104, P187, DOI 10.7326/0003-4819-104-2-187; WENDEL GD, 1989, REV INFECT DIS, V11, pS1314; WESTROM L, 1987, CONTRACEPTION, V36, P111, DOI 10.1016/0010-7824(87)90064-3; WOLNERHANSSEN P, 1988, AM J OBSTET GYNECOL, V158, P577, DOI 10.1016/0002-9378(88)90030-0; WOLNERHANSSEN P, 1988, OBSTET GYNECOL, V71, P595; 1986, PRECIS 3 UPDATE OBST, P17; 1989, MMWR-MORBID MORTAL W, V38, P31; 1985, MMWR-MORBID MORTAL W, V34, P19	58	19	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2605	2611		10.1001/jama.266.18.2605	http://dx.doi.org/10.1001/jama.266.18.2605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1658404				2022-12-28	WOS:A1991GN66000038
J	CROOK, T; TIDY, JA; VOUSDEN, KH				CROOK, T; TIDY, JA; VOUSDEN, KH			DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FORESKIN KERATINOCYTES; RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; OPEN READING FRAME; CERVICAL-CARCINOMA; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; TRANSFORMING GENE; E7 ONCOPROTEIN	Human papillomavirus (HPV) types 16 and 18 appear to play a role in the development of ano-genital malignancies, whereas HPV 6 and 11 are usually associated with benign lesions. One HPV16 oncoprotein, E6, complexes with and promotes degradation of the cellular tumor suppressor p53. Here we show that E6 proteins of both oncogenic and benign HPV types associate in vitro with p53, but binding by E6 proteins of benign HPV types cannot target p53 for degradation. A C-terminal region of E6 conserved among all HPV types is important for p53 binding. However, N-terminal sequences of E6 conserved only between oncogenic HPV types are necessary to direct p53 degradation. p53 binding by E6 appears necessary but not sufficient for this activity. All E6 proteins tested showed comparable transcriptional trans-activating activity, a property that does not require the ability to bind or direct degradation of p53.	SAMARITAN HOSP WOMEN, DEPT GYNECOL ONCOL, LONDON NW1 5YE, ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, IN PRESS ONCOGENE; DANOS O, 1987, CANCER CELL, V5, P145; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL CV, 1983, J BIOL CHEM, V258, P14120; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, IN PRESS P NATL ACAD; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1983, EMBO J, V2, P2341, DOI 10.1002/j.1460-2075.1983.tb01744.x; SEDMAN SA, 1991, IN PRESS J VIROL; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	53	486	521	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					547	556		10.1016/0092-8674(91)90529-8	http://dx.doi.org/10.1016/0092-8674(91)90529-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657399				2022-12-28	WOS:A1991GN66400011
J	LI, H; BINGHAM, PM				LI, H; BINGHAM, PM			ARGININE SERINE-RICH DOMAINS OF THE SU(WA) AND TRA RNA PROCESSING REGULATORS TARGET PROTEINS TO A SUBNUCLEAR COMPARTMENT IMPLICATED IN SPLICING	CELL			English	Article							DROSOPHILA-MELANOGASTER; NUCLEOLAR LOCALIZATION; BINDING PROTEINS; MESSENGER-RNA; GENE; SEX; SEQUENCES; SIMILARITY; EXPRESSION; ENCODES	Two unrelated pre-mRNA splicing regulators-suppressor-of-white-apricot (su(w(a))) and transformer (tra)-contain distinctive, approximately 120 amino acid arginine/serine (RS)-rich domains. Deletion of the su(w(a)) RS domain eliminates function. Replacement with the tra RS domain restores su(w(a)) function to nearly wild-type levels. Replacement with a 10 amino acid simple nuclear entry signal allows partial, inefficient function. Thus, the su(w(a)) RS domain apparently serves a generic function(s) subsuming nuclear entry. Moreover, immunocytochemical studies demonstrate that both RS domains specifically direct localization of a fused reporter protein to a punctate subnuclear compartment shown previously to be enriched in several constitutive splicing components. We propose that RS domains are a new class of targeting signals directing concentration of proteins in a subnuclear compartment implicated in splicing metabolism.			LI, H (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794, USA.				PHS HHS [32003] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1991, IN PRESS CELL; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KRAINER AR, 1991, IN PRESS CELL; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH HC, 1985, J CELL BIOL, V101, P560, DOI 10.1083/jcb.101.2.560; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; ZACHAR Z, 1987, MOL CELL BIOL, V7, P2498, DOI 10.1128/MCB.7.7.2498; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	29	201	204	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					335	342		10.1016/0092-8674(91)90185-2	http://dx.doi.org/10.1016/0092-8674(91)90185-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655279				2022-12-28	WOS:A1991GL47000013
J	ORTH, DN				ORTH, DN			DIFFERENTIAL-DIAGNOSIS OF CUSHINGS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORTICOTROPIN-RELEASING FACTOR; DISEASE; PLASMA				ORTH, DN (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232, USA.							BURCH W, 1983, NEW ENGL J MED, V308, P103; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; CHROUSOS GP, 1985, ANN INTERN MED, V102, P344, DOI 10.7326/0003-4819-102-3-344; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; MEIKLE AW, 1982, CLIN ENDOCRINOL, V16, P401, DOI 10.1111/j.1365-2265.1982.tb00733.x; MILLER DL, 1991, RADIOLOGY, V178, P281, DOI 10.1148/radiology.178.1.1843445; MILLER DL, 1991, RADIOLOGY, V178, P37, DOI 10.1148/radiology.178.1.1845785; NICHOLSON WE, 1984, CLIN CHEM, V30, P259; Oldfield E H, 1985, N Engl J Med, V312, P100, DOI 10.1056/NEJM198501103120207; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301	10	36	38	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					957	959		10.1056/NEJM199109263251309	http://dx.doi.org/10.1056/NEJM199109263251309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1652688				2022-12-28	WOS:A1991GF85600009
J	LIPSON, SJ; OCONNELL, JX; ROSENTHAL, DI; SCULLY, RE; SEIDEN, MV; PITCHER, JD; SCHMID, HOE				LIPSON, SJ; OCONNELL, JX; ROSENTHAL, DI; SCULLY, RE; SEIDEN, MV; PITCHER, JD; SCHMID, HOE			A 47-YEAR-OLD WOMAN WITH BACK PAIN AND A LESION IN A VERTEBRAL BODY - HYDROXYAPATITE-CRYSTAL DEPOSITION DISEASE, WITH EROSION INTO ADJACENT VERTEBRAL BODY	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							DISK DISEASE; MR; MARROW		HARVARD UNIV, SCH MED, ORTHOPAED SURG, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LIPSON, SJ (corresponding author), BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA.							AMOR B, 1977, J RHEUMATOL, V4, P101; BULLOUGH PG, 1988, ATLAS SPINAL DISEASE; DEROOS A, 1987, AM J ROENTGENOL, V149, P531, DOI 10.2214/ajr.149.3.531; DIEPPE P, 1985, CLIN RHEUM DIS, V11, P367; FEUERMAN T, 1986, J NEUROSURG, V65, P404, DOI 10.3171/jns.1986.65.3.0404; GRAVANIS MB, 1983, AM J SURG PATHOL, V7, P357, DOI 10.1097/00000478-198306000-00007; HAJEK PC, 1987, RADIOLOGY, V162, P245, DOI 10.1148/radiology.162.1.3786770; HAYES CW, 1987, AM J ROENTGENOL, V149, P967, DOI 10.2214/ajr.149.5.967; KELLER PJ, 1987, RADIOLOGY, V164, P539, DOI 10.1148/radiology.164.2.3602398; MCCARTY DJ, 1981, ARTHRITIS RHEUM, V24, P464, DOI 10.1002/art.1780240303; MODIC MT, 1985, RADIOLOGY, V157, P157, DOI 10.1148/radiology.157.1.3875878; MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678; MODIC MT, 1989, MAGNETIC RESONANCE I, P75; MOHAN V, 1980, CLIN RADIOL, V31, P575, DOI 10.1016/S0009-9260(80)80055-9; MUNDY GR, 1987, BONE, V8, pS9; PINALS RS, 1966, ARTHRITIS RHEUM, V9, P566, DOI 10.1002/art.1780090403; RAMOS A, 1985, RADIOLOGY, V157, P615, DOI 10.1148/radiology.157.3.4059548; UHTHOFF HK, 1976, CLIN ORTHOP RELAT R, V118, P164; WILNER D, 1982, RADIOLOGY BONE TUMOR	19	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					794	799						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1651457				2022-12-28	WOS:A1991GE45600007
J	HOPKINS, CR				HOPKINS, CR			POLARITY SIGNALS	CELL			English	Review							CYTOPLASMIC DOMAIN; CELL-SURFACE; EPITHELIAL-CELLS; MEMBRANE DOMAINS; RECEPTOR; PROTEINS; ENDOCYTOSIS; SECRETION; TRANSPORT; GLYCOPROTEINS				HOPKINS, CR (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND.							BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRANDLI AW, 1990, J CELL BIOL, V111, P2902; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLAWN JF, 1991, IN PRESS EMBO J; CUTLER DF, 1988, J CELL SCI, V91, P1; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUGHSON EJ, 1989, J CELL SCI, V94, P327; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KOK JW, 1991, J CELL BIOL, V114, P231, DOI 10.1083/jcb.114.2.231; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; TROWBRIDGE IS, 1991, IN PRESS CURR OPIN C; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	30	53	53	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					827	829		10.1016/0092-8674(91)90427-Z	http://dx.doi.org/10.1016/0092-8674(91)90427-Z			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653646				2022-12-28	WOS:A1991GE46000002
J	LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM				LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM			NORMALIZATION OF CURRENT KINETICS BY INTERACTION BETWEEN THE ALPHA-1-SUBUNIT AND BETA-SUBUNIT OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE-SENSITIVE CA2+ CHANNEL	NATURE			English	Article							CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GAMMA-SUBUNIT; CA-2+ CHANNEL; RECEPTOR; SEQUENCE; PROTEIN; CELLS; CDNA	PURIFICATION of skeletal muscle dihydropyridine binding sites has enabled protein complexes to be isolated from which Ca2+ currents have been reconstituted. Complementary DNAs encoding the five subunits of the dihydropyridine receptor, alpha-1, beta, gamma, alpha-2 and delta (ref. 1), have been cloned 2-6 and it is now recognized that alpha-2 and delta are derived from a common precursor 7,8. The alpha-1 subunit can itself produce Ca2+ currents, as was demonstrated using mouse L cells lacking alpha-2-delta (refs 9, 10), beta (ref. 10) and gamma (our unpublished results). In L cells, stable expression of skeletal muscle-alpha-1 alone was sufficient to generate voltage-sensitive, high-threshold L-type Ca2+ channel currents which were dihydropyridine-sensitive and blocked by Cd2+, but the activation kinetics were about 100 times slower than expected for skeletal muscle Ca2+ channel currents. This could have been due to the cell type in which alpha-1 was being expressed or to the lack of a regulatory component particularly one of the subunits that copurifies with alpha-1. We show here that coexpression of skeletal muscle-beta with skeletal muscle-alpha-1 generates cell lines expressing Ca2+ channel currents with normal activation kinetics as evidence for the participation of the dihydropyridine-receptor beta-subunits in the generation of skeletal muscle Ca2+ channel currents.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DIV NEUROSCI,HOUSTON,TX 77030; UNIV SAARLAND,FAC MED,INST PHYSIOL CHEM,W-6650 HOMBURG,GERMANY	Baylor University; Baylor University; Saarland University	LACERDA, AE (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.							BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1983, J PHYSIOL-LONDON, V344, P549, DOI 10.1113/jphysiol.1983.sp014956; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COGNARD C, 1986, PFLUG ARCH EUR J PHY, V407, P677, DOI 10.1007/BF00582651; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; LACERDA AE, 1989, J GEN PHYSIOL, V93, P1243, DOI 10.1085/jgp.93.6.1243; LIAO CF, 1989, J BIOL CHEM, V264, P7328; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	21	268	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					527	530		10.1038/352527a0	http://dx.doi.org/10.1038/352527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650913				2022-12-28	WOS:A1991GA22600062
J	MATTHEWS, W; JORDAN, CT; WIEGAND, GW; PARDOLL, D; LEMISCHKA, IR				MATTHEWS, W; JORDAN, CT; WIEGAND, GW; PARDOLL, D; LEMISCHKA, IR			A RECEPTOR TYROSINE KINASE SPECIFIC TO HEMATOPOIETIC STEM AND PROGENITOR CELL-ENRICHED POPULATIONS	CELL			English	Article							MONOCLONAL-ANTIBODIES; CDNA LIBRARIES; PROTO-ONCOGENE; GROWTH-FACTOR; FETAL LIVER; W-LOCUS; CFU-S; DIFFERENTIATION; FAMILY; PURIFICATION	To elucidate the molecular biology of the hematopoietic stem cell, we have begun to isolate genes from murine cell populations enriched in stem cell activity. One such cDNA encodes a novel receptor tyrosine kinase, designated fetal liver kinase-2 or flk-2, which is related to the W locus gene product c-kit. Expression analyses suggest an extremely restricted distribution of flk-2. It is expressed in populations enriched for stem cells and primitive uncommitted progenitors, and is absent in populations containing more mature cells. Therefore, this receptor may be a key signal transducing component in the totipotent hematopoietic stem cell and its immediate self-renewing progeny.	JOHNS HOPKINS UNIV, DEPT MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	MATTHEWS, W (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.		jordan, craig/D-7666-2014	jordan, craig/0000-0003-0869-3465	NCI NIH HHS [CA45339] Funding Source: Medline; NIDDK NIH HHS [DK42989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042989, R37DK042989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIHARA Y, 1986, EUR J IMMUNOL, V16, P1391, DOI 10.1002/eji.1830161113; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BOGGS DR, 1982, J CLIN INVEST, V70, P242, DOI 10.1172/JCI110611; BUTCHER EC, 1989, LYMPHOID TISSUES ORG; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOHNSON GR, 1984, J CELL PHYSIOL, V118, P45, DOI 10.1002/jcp.1041180110; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; Maniatis T., 1982, MOL CLONING; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; METCALF D, 1984, HEMOPOIETIC COLONIES; MEVITSKY HI, 1991, J IMMUNOL, V146, P1113; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1983, BLOOD, V61, P823; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PHARR PN, 1988, EXP HEMATOL, V16, P748; PIERRES A, 1984, J IMMUNOL, V132, P2775; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; SZILVASSY SJ, 1989, BLOOD, V74, P930; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; VISSER JWM, 1984, J EXP MED, V159, P1576, DOI 10.1084/jem.159.6.1576; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	53	548	588	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1143	1152		10.1016/0092-8674(91)90010-V	http://dx.doi.org/10.1016/0092-8674(91)90010-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648448				2022-12-28	WOS:A1991FU89900007
J	GOODWIN, FK				GOODWIN, FK			COCAINE ANALOGS AND BRAIN IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							KUHAR MJ, 1991, EUR J PHARMACOL, V194, P133; 1991, MOL PHARMACOL, V39, P339; IN PRESS PHARM EXP T	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-28	WOS:A1991FR83500006
J	WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G				WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G			CRYSTAL-STRUCTURE OF AN N-TERMINAL FRAGMENT OF THE DNA GYRASE B-PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; A-PROTEIN; GYRB GENE; RESOLUTION; TOPOISOMERASES; REFINEMENT; COMPLEX; SITE	The crystal structure of an N-terminal fragment of the Escherichia coli DNA gyrase B protein, complexed with a nonhydrolysable ATP analogue, has been solved at 2.5 angstrom resolution. It consists of two domains, both containing novel protein folds. The protein fragment forms a dimer, whose N-terminal domains are responsible for ATP binding and hydrolysis. The C-terminal domains form the sides of a 20 angstrom hole through the protein dimer which may play a role in DNA strand passage during the supercoiling reaction.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,ENGLAND	University of Leicester	WIGLEY, DB (corresponding author), YORK UNIV,DEPT CHEM,YORK YO1 5DD,ENGLAND.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Maxwell, Anthony/0000-0002-5756-6430	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MORRISON A, 1980, J BIOL CHEM, V255, P2211; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1990, J MOL BIOL, V215, P493, DOI 10.1016/S0022-2836(05)80162-7; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RICE DW, 1981, ACTA CRYSTALLOGR A, V37, P491, DOI 10.1107/S0567739481001186; SUBRAMANIAN E, 1977, P NATL ACAD SCI USA, V74, P556, DOI 10.1073/pnas.74.2.556; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012	26	491	495	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					624	629		10.1038/351624a0	http://dx.doi.org/10.1038/351624a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646964				2022-12-28	WOS:A1991FT11200055
J	BOTHWELL, M				BOTHWELL, M			KEEPING TRACK OF NEUROTROPHIN RECEPTORS	CELL			English	Review							GROWTH-FACTOR RECEPTORS; GENE-TRANSFER; EXPRESSION; CELLS; GANGLIA; BINDING				BOTHWELL, M (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							GREEN SH, 1986, J BIOL CHEM, V261, P5316; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOSANG M, 1985, J BIOL CHEM, V260, P655; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1991, IN PRESS P NATL ACAD; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RADEKE MJ, 1991, IN PRESS NEURON, V7; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTTER A, 1979, J BIOL CHEM, V254, P5972; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	27	304	324	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					915	918		10.1016/0092-8674(91)90540-F	http://dx.doi.org/10.1016/0092-8674(91)90540-F			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646079				2022-12-28	WOS:A1991FR04700001
J	MATHEWS, LS; VALE, WW				MATHEWS, LS; VALE, WW			EXPRESSION CLONING OF AN ACTIVIN RECEPTOR, A PREDICTED TRANSMEMBRANE SERINE KINASE	CELL			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; GROWTH FACTOR-BETA; COLONY-STIMULATING FACTOR; OVARIAN FOLLICULAR-FLUID; FSH-RELEASING PROTEIN; BINDING-PROTEIN; COMPLEMENTARY-DNA; CELL; INHIBIN; PURIFICATION	Activins are involved in the regulation of multiple biological events, ranging from early development to pituitary function. To characterize the cellular mechanisms involved in these processes, cDNAs coding for an activin receptor were cloned from AtT20 mouse corticotropic cells by screening COS cell transfectants for binding of I-125-activin A. The cDNAs code for a protein of 494 amino acids comprising a ligand-binding extracellular domain, a single membrane-spanning domain, and an intracellular kinase domain with predicted serine/ threonine specificity. I-125-activin A binds to transfected COS cells with an affinity of 180 pM and can be competed by activin A, activin B, and inhibin A, but not by transforming growth factor beta-1. The kinase domain, but not the extracellular sequence, of the activin receptor is most closely related to the C. elegans daf-1 gene product, a putative transmembrane serine/threonine-specific protein kinase for which the ligand is not known.			MATHEWS, LS (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13527-12, HD-07343-01] Funding Source: Medline; NIDDK NIH HHS [DK-26741-11] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, IN PRESS CURR OPIN S, V1; HANSK SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; HINO M, 1989, J BIOL CHEM, V264, P10309; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUNTER T, 1991, Current Biology, V1, P15, DOI 10.1016/0960-9822(91)90113-B; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAPOLT PS, 1989, MOL ENDOCRINOL, V3, P1666, DOI 10.1210/mend-3-10-1666; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Maniatis T., 1982, MOL CLONING; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, IN PRESS P ENDOCRINE, V73; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MINE T, 1989, ENDOCRINOLOGY, V125, P586, DOI 10.1210/endo-125-2-586; MOSELY B, 1989, CELL, V59, P335; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUGINO H, 1988, J BIOL CHEM, V263, P15249; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	59	704	784	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					973	982		10.1016/0092-8674(91)90549-E	http://dx.doi.org/10.1016/0092-8674(91)90549-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646080				2022-12-28	WOS:A1991FR04700008
J	MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG				MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG			AEROSOL ALPHA-1-ANTITRYPSIN TREATMENT FOR CYSTIC-FIBROSIS	LANCET			English	Note							HUMAN NEUTROPHIL ELASTASE	In cystic fibrosis neutrophil-dominated inflammation on the respiratory epithelial surface results in a chronic epithelial burden of the destructive enzyme, neutrophil elastase. Alpha-1-antitrypsin (alpha-1AT), the main inhibitor of neutrophil elastase in lung, was given in aerosol form to 12 cystic fibrosis patients. It suppressed neutrophil elastase in the respiratory epithelial lining fluid (ELF) and restored the ELF anti-neutrophil elastase capacity when ELF alpha-1AT reached 8-mu-mol/l. This treatment also reversed the inhibitory effect of cystic fibrosis ELF on pseudomonas killing by neutrophils, which suggests that it may augment host defence in cystic fibrosis.	NHLBI,PULM BRANCH,BLDG 10,ROOM 6DO3,BETHESDA,MD 20892; NIDDKD,PEDIAT METAB BRANCH,BETHESDA,MD; NIAID,CLIN INVEST LAB,BETHESDA,MD 20892; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL & CYST FIBROSIS,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			McElvaney, Noel/A-6809-2010	mcelvaney, Noel/0000-0002-0152-4370				BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREUER R, 1989, AM REV RESPIR DIS, V139, P779, DOI 10.1164/ajrccm/139.3.779; FICK RB, 1984, J CLIN INVEST, V74, P236, DOI 10.1172/JCI111407; LUCEY EC, 1988, EXP LUNG RES, V14, P671, DOI 10.3109/01902148809087836; SUTER S, 1989, PSEUDOMONAS AERUGINO, P158; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	7	297	307	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					392	394		10.1016/0140-6736(91)91167-S	http://dx.doi.org/10.1016/0140-6736(91)91167-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671425				2022-12-28	WOS:A1991EX60500005
J	BUTLER, KM; HUSSON, RN; BALIS, FM; BROUWERS, P; EDDY, J; ELAMIN, D; GRESS, J; HAWKINS, M; JAROSINSKI, P; MOSS, H; POPLACK, D; SANTACROCE, S; VENZON, D; WIENER, L; WOLTERS, P; PIZZO, PA				BUTLER, KM; HUSSON, RN; BALIS, FM; BROUWERS, P; EDDY, J; ELAMIN, D; GRESS, J; HAWKINS, M; JAROSINSKI, P; MOSS, H; POPLACK, D; SANTACROCE, S; VENZON, D; WIENER, L; WOLTERS, P; PIZZO, PA			DIDEOXYINOSINE IN CHILDREN WITH SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; AZIDOTHYMIDINE AZT; ZIDOVUDINE THERAPY; DOUBLE-BLIND; PHARMACOLOGY; TOXICITY; HIV	Background. 2',3'-Dideoxyinosine (ddl) is a dideoxynucleoside with potent activity in vitro against the human immunodeficiency virus (HIV). In initial clinical trials in adults, ddl showed evidence of antiretroviral activity with little hematologic toxicity. Methods. We conducted a phase I-II study in 43 children with symptomatic (CDC class P-2) HIV infection. Of these children, 16 (median age, 10 years) had previously received zidovudine, and 27 (median age, 2.6 years) had not. ddl was administered orally in three divided doses totalling 60, 120, 180, 360, or 540 mg per square meter of body-surface area per day for 24 weeks. Eight of the 43 patients did not complete 24 weeks of ddl: Eight of the 43 patients did not complete 24 weeks of ddl: 6 died, 1 was withdrawn because of progressive disease, and the other because of toxicity. Results. After oral administration, ddl was rapidly absorbed, although its bioavailability varied greatly among patients. Pancreatitis developed in two children, one receiving ddl at each of the two highest doses. The median CD4 cell count in 38 patients with paired counts increased from 0.218 x 10(9) per liter (218 per cubic millimeter) at base line to 0.327 x 10(9) per liter (327 per cubic millimeter) after 20 to 24 weeks (P = 0.01). Those with CD4 cell counts above 01. x 10(9) per liter (100 per cubic millimeter) at base line were significantly more likely to improve in this respect. The median levels of p24 antigen (in 27 patients with detectable levels at entry) declined from 272 pg per milliliter at 20 to 24 weeks (P = 0.005). The plasma concentration of ddl correlated significantly with both the degree of decline in the p24 antigen and the degree of improvement in IQ score. Improvement in clinical and immunologic measures occurred in both the previously untreated patients and in those who had been treated with zidovudine. Conclusions. Dideoxyinosine was well tolerated and showed promising antiretroviral activity in HIV-infected children. The correlation between the clinical response and the plasma concentration of ddl indicates that bioavailability is an important consideration in the use of ddl to treat HIV infection and that individualized pharmacokinetic monitoring and dose adjustment may be important for optimal activity.	NCI,PEDIAT BRANCH,BLDG 10,RM 13N240,BETHESDA,MD 20892; NCI,BIOSTAT & DATA MANAGEMENT SECT,CLIN ONCOL PROGRAM,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT PHARM,BETHESDA,MD 20892; MED ILLNESS COUNSELING,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)			Husson, Robert/Y-7288-2019; Venzon, David J/B-3078-2008; Wiener, Lori/Q-8448-2016	Balis, Frank/0000-0002-8117-6926; Wiener, Lori/0000-0002-9573-8870				BLANCHE S, 1988, AM J MED, V85, P203; BROUWERS P, 1990, J PEDIATR-US, V117, P980, DOI 10.1016/S0022-3476(05)80150-7; CARPEN ME, 1990, J CHROMATOGR-BIOMED, V526, P69, DOI 10.1016/S0378-4347(00)82484-6; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COONEY DA, 1987, BIOCHEM PHARMACOL, V36, P1765, DOI 10.1016/0006-2952(87)90235-8; DOURNON E, 1988, LANCET, V2, P1297; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HART CC, 1989, ANN INTERN MED, V111, P691, DOI 10.7326/0003-4819-111-8-691_1; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MURPHY RL, 1990, AM J MED, V88, pN53; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; 1987, MMWR, V36, P225	20	209	211	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					137	144		10.1056/NEJM199101173240301	http://dx.doi.org/10.1056/NEJM199101173240301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1670591				2022-12-28	WOS:A1991ER47100001
J	SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC				SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC			LONG-TERM BONE LOSS IN MEN - EFFECTS OF GENETIC AND ENVIRONMENTAL-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; TWINS; ALCOHOL DRINKING; SMOKING	NHLBI TWIN; CIGARETTE-SMOKING; RISK-FACTORS; MASS; FRACTURES; OSTEOPOROSIS; WOMEN; HIP; AGE; HERITABILITY	Objective: To identity environmental factors associated with bone loss in adult male twins and to determine the extent to which shared environmental characteristics affect estimates of the genetic influence on bone loss. Design: A 16-year cohort study. Setting: A midwestern university hospital. Participants:One hundred and eleven male veterans of World War II or the Korean conflict, born between 1916 and 1927. All were twins, with the sample comprising 48 pairs and 15 persons whose twin brothers were deceased or seriously ill. Measurements: Bone mass and environmental characteristics (cigarette smoking, alcohol consumption, physical activity, dietary calcium intake, use of thiazide diuretics) measured at baseline and 16 years later. Results: Rates of radial bone loss averaged 0.45% per year. Those who both smoked and used alcohol at levels greater than the median for the population had a rate of bone loss (10% in 16 years) twice the rate of those who were below the median level for both variables (5% bone loss, P = 0.003). Rates of bone loss were correlated within twin pairs, and these correlations were diminished 25% to 35% by adjustments for environmental influences on bone loss. However, statistically significant within-pair correlations remained (r congruent-to 0.4), which did not differ between monozygotic and dizygotic twin pairs after adjustments for smoking, alcohol use, dietary calcium intake, and exercise. Conclusions: Bone loss in men during mid-life is determined, at least in part, by environmental factors, including smoking, alcohol intake, and, possibly, physical activity. Rates of bone loss were similar within twin pairs, apparently because of a shared environment.			SLEMENDA, CW (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV BIOSTAT, 702 BARNHILL DR, INDIANAPOLIS, IN 46202 USA.			Williams, Christopher/0000-0001-6346-8100	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055027] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR750] Funding Source: Medline; NHLBI NIH HHS [HC 55027] Funding Source: Medline; NIA NIH HHS [AG 05793] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON WE, 1989, AM J PUBLIC HEALTH, V79, P1556, DOI 10.2105/AJPH.79.11.1556; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; CHRISTIAN JC, 1974, AM J HUM GENET, V26, P154; CHRISTIANSEN C, 1987, LANCET, V1, P1106; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, V179, P107; FABSITZ R, 1985, J CHRON DIS, V38, P165, DOI 10.1016/0021-9681(85)90089-X; FABSITZ RR, 1988, ACTA GENET MED GEMEL, V37, P217, DOI 10.1017/S0001566000003822; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KRALL EA, 1991, J BONE MINER RES, V6, P331; MEIER DE, 1984, ANN INTERN MED, V101, P605, DOI 10.7326/0003-4819-101-5-605; NILSSON BE, 1970, ACTA CHIR SCAND, V136, P383; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PEDERSEN N, 1981, TWIN RES G, V3, P37; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SUZUKI DT, 1981, INTRO GENETIC ANAL; Swan G E, 1990, J Subst Abuse, V2, P39; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1989, REDUCING HLTH CONSEQ	32	181	188	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					286	291		10.7326/0003-4819-117-4-286	http://dx.doi.org/10.7326/0003-4819-117-4-286			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637023				2022-12-28	WOS:A1992JH46400003
J	PERKINS, LA; LARSEN, I; PERRIMON, N				PERKINS, LA; LARSEN, I; PERRIMON, N			CORKSCREW ENCODES A PUTATIVE PROTEIN TYROSINE PHOSPHATASE THAT FUNCTIONS TO TRANSDUCE THE TERMINAL SIGNAL FROM THE RECEPTOR TYROSINE KINASE TORSO	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYO; POSTERIOR PATTERN; BICOID PROTEIN; X-CHROMOSOME; BODY PATTERN; MELANOGASTER; MUTATIONS; REQUIREMENT; SYSTEM	We describe the characterization of the Drosophila gene, corkscrew (csw), which is maternally required for normal determination of cell fates at the termini of the embryo. Determination of terminal cell fates is mediated by a signal transduction pathway that involves a receptor tyrosine kinase, torso, a serine/threonine kinase, D-raf, and the transcription factors, tailless and huckebein. Double mutant and cellular analyses between csw, torso, D-raf, and tailless indicate that csw acts downstream of torso and in concert with D-raf to positively transduce the torso signal via tailless, to downstream terminal genes. The csw gene encodes a putative nonreceptor protein tyrosine phosphatase covalently linked to two N-terminal SH2 domains, which is similar to the mammalian PTP1C protein.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	PERKINS, LA (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSSON D, 1983, GENETICS, V105, P309; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, IN PRESS GENETICS; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V89, P1123; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; Klingler M, 1990, Semin Cell Biol, V1, P151; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Maniatis T., 1982, MOL CLONING; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MLODZIK M, 1987, GENE DEV, V1, P603, DOI 10.1101/gad.1.6.603; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1985, GENETICS, V111, P23; PERRIMON N, 1986, GENETICS, V113, P695; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROBERTSON HM, 1988, GENETICS, V118, P461; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	83	374	379	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					225	236		10.1016/0092-8674(92)90098-W	http://dx.doi.org/10.1016/0092-8674(92)90098-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638629				2022-12-28	WOS:A1992JE75700007
J	MORTON, RF; JETT, JR; MCGINNIS, WL; EARLE, JD; THERNEAU, TM; KROOK, JE; ELLIOTT, TE; MAILLIARD, JA; NELIMARK, RA; MAKSYMIUK, AW; DRUMMOND, RG; LAURIE, JA; KUGLER, JW; ANDERSON, RT				MORTON, RF; JETT, JR; MCGINNIS, WL; EARLE, JD; THERNEAU, TM; KROOK, JE; ELLIOTT, TE; MAILLIARD, JA; NELIMARK, RA; MAKSYMIUK, AW; DRUMMOND, RG; LAURIE, JA; KUGLER, JW; ANDERSON, RT			THORACIC RADIATION-THERAPY ALONE COMPARED WITH COMBINED CHEMORADIOTHERAPY FOR LOCALLY UNRESECTABLE NON-SMALL CELL LUNG-CANCER - A RANDOMIZED, PHASE-III TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							COMBINATION CHEMOTHERAPY; BRONCHOGENIC-CARCINOMA; ONCOLOGY GROUP; RADIOTHERAPY; PATTERNS; SURVIVAL	Objective: To compare the survival of patients with medically inoperable or unresectable stage III non-small cell lung cancer treated with thoracic radiotherapy alone or in combination with chemotherapy. Design: Randomized, prospective phase III trial. Setting: Multi-institutional cooperative oncology group. Patients: A total of 121 patients were enrolled in the study, of whom 7 (5.8%) were ineligible. All patients were ambulatory and had measurable or evaluable disease. Before they were randomized, patients were stratified by ECOG performance score, histologic type, maximum tumor diameter, and NCCTG institution. Interventions: Radiotherapy consisted of a total of 5000 cGy in 5 weeks with a 1000 cGy boost in 5 fractions to a small tumor field. Combined modality therapy was MACC which is intravenous methotrexate, intravenous doxorubicin, intravenous cyclophosphamide, and oral lomustine (CCNU), on day 1 and 28. Chemotherapy was followed by identical thoracic radiotherapy 4 weeks after the second cycle of chemotherapy. Four weeks after thoracic radiotherapy was completed, patients received another two cycles of identical chemotherapy. Patients who had progression of disease after chest irradiation only were treated with MACC chemotherapy. Main Results: Major clinical responses were observed in 31 of 56 (55%; 95% CI, 42% to 68%) patients treated with combination therapy and 37 of 58 (64%; CI, 51% to 76%) treated with radiation only (P > 0.2). The median time to progression was 192 days with radiotherapy only compared with 199 days for combined modality therapy (P > 0.2). The median survival time was 313 days compared with 317 days, respectively (P > 0.2). The 1-, 2-, and 5-year survival rates after thoracic radiation only were 45% (CI, 32% to 58%), 16% (CI, 6% to 25%), and 7%. With chemoradiotherapy, the survival rates were 46% (CI, 33% to 60%), 21% (CI, 11% to 32%), and 5%, respectively. Myelosuppression was significantly greater for the combined modality therapy arm (P = 0.002). Conclusion: Chemotherapy with MACC, in combination with thoracic radiotherapy, did not result in significant survival advantage compared with radiation alone (P > 0.2) in patients with medically inoperable or unresectable stage III non-small cell lung cancer.	MAYO CLIN & MAYO FDN, DIV MED ONCOL, ROCHESTER, MN 55905 USA	Mayo Clinic				Elliott, Thomas/0000-0002-8570-4933	NCI NIH HHS [CA-35101, CA-35103, CA-25224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA035101, U10CA025224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAIN K, 1990, P AN M AM SOC CLIN, V9, P227; CARR DT, 1972, CANCER, V29, P375, DOI 10.1002/1097-0142(197202)29:2<375::AID-CNCR2820290218>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; COX JD, 1990, J CLIN ONCOL, V8, P1543, DOI 10.1200/JCO.1990.8.9.1543; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DILLMAN RO, 1988, P AN M AM SOC CLIN, V7, P195; EAGAN RT, 1981, CANCER CLIN TRIALS, V4, P381; EAGAN RT, 1979, CANCER, V44, P1125, DOI 10.1002/1097-0142(197909)44:3<1125::AID-CNCR2820440348>3.0.CO;2-4; JETT J, 1989, P AN M AM SOC CLIN, V8, P223; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRIS MG, 1985, CANCER TREAT REP, V69, P387; KROOK JE, 1984, CANCER TREAT REP, V68, P493; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MATTSON K, 1988, EUR J CANCER CLIN ON, V24, P477, DOI 10.1016/S0277-5379(98)90020-7; MORTON RF, 1988, P AN M AM SOC CLIN, V7, P200; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; PEREZ CA, 1980, INT J RADIAT ONCOL, V6, P987, DOI 10.1016/0360-3016(80)90106-6; ROBINOW JS, 1989, INT J RADIAT ONCOL, V17, P1203, DOI 10.1016/0360-3016(89)90527-0; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; SEALY R, 1982, CANCER, V49, P1338, DOI 10.1002/1097-0142(19820401)49:7<1338::AID-CNCR2820490705>3.0.CO;2-Y; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; TROVO MG, 1990, CANCER, V65, P400, DOI 10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H; UMSAWASDI T, 1988, INT J RADIAT ONCOL, V14, P43, DOI 10.1016/0360-3016(88)90049-1; 1977, MANUAL STAGING CANCE	26	183	184	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					681	686		10.7326/0003-4819-115-9-681	http://dx.doi.org/10.7326/0003-4819-115-9-681			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1656827				2022-12-28	WOS:A1991GL69700003
J	GOODWIN, FK				GOODWIN, FK			TRICYCLICS AND HEART-TRANSPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							SHAPIRO PA, 1991, AM J PSYCHIAT, V148, P371; DIAGNOSTIC STATISTIC	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-28	WOS:A1991FR83500005
J	KAWAMOTO, F				KAWAMOTO, F			RAPID DIAGNOSIS OF MALARIA BY FLUORESCENCE MICROSCOPY WITH LIGHT-MICROSCOPE AND INTERFERENCE FILTER	LANCET			English	Article							PARASITES; PROBES	Fluorochrome staining to detect malaria parasites in bloodfilms is more sensitive, is easier to do, and is less time-consuming than Giemsa staining. However, standard epi-illuminated, mercury vapour, fluorescence microscopes are expensive, especially for tropical countries where malaria is endemic. Fluorescence microscopy with a standard light microscope and a new interference filter specially designed for the fluorochrome stain, acridine orange, was used to detect malaria parasites in thick and thin bloodfilms. In this system two fluorescence colours, green (nuclei) and red (cytoplasm), were emitted from stained parasites. Thick and thin bloodfilms from patients with malaria were examined with this system. Bloodfilms had been fixed and stored for 1-5 years. Rapid scanning of both thick and thin bloodfilms was possible at a magnification of x 200 with standard lenses, indicating that this may be a useful economic system for rapid diagnosis of malarias.			KAWAMOTO, F (corresponding author), NAGOYA UNIV,SCH MED,DEPT MED ZOOL,NAGOYA,AICHI 466,JAPAN.							BARKER RH, 1986, SCIENCE, V231, P1434, DOI 10.1126/science.3513309; BRUCECHWATT LJ, 1987, LANCET, V2, P1509; KAWAMOTO F, 1987, PARASITOL TODAY, V3, P284, DOI 10.1016/0169-4758(87)90110-4; KAWAMOTO F, 1987, JPN J MED SCI BIOL, V40, P35, DOI 10.7883/yoken1952.40.35; RICKMAN LS, 1989, LANCET, V1, P68; ROST FWD, 1980, HISTOCHEMISTRY THEOR, V1, P346; RYGAARD J, 1969, ACTA PATHOL MIC SC, V76, P146; SPIELMAN A, 1988, AM J TROP MED HYG, V39, P337, DOI 10.4269/ajtmh.1988.39.337; VOLLER A, 1982, BRIT MED BULL, V38, P173, DOI 10.1093/oxfordjournals.bmb.a071755; 1977, FLUORESCENT ANTIBODY, P95	10	98	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					200	202		10.1016/0140-6736(91)92159-Y	http://dx.doi.org/10.1016/0140-6736(91)92159-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670842				2022-12-28	WOS:A1991EU92400004
J	HSIA, DC; AHERN, CA; RITCHIE, BP; MOSCOE, LM; KRUSHAT, WM				HSIA, DC; AHERN, CA; RITCHIE, BP; MOSCOE, LM; KRUSHAT, WM			MEDICARE REIMBURSEMENT ACCURACY UNDER THE PROSPECTIVE PAYMENT SYSTEM, 1985 TO 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRG CREEP; INDEX	Background.-Hospital reimbursement by Medicare's prospective payment system depends on accurate identification and coding of inpatients' diagnoses and procedures using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). A previous study showed that 20.8%+/-0.5% (mean+/-SE) of hospital bills for 1985 contained error's that changed their diagnosis related group (DRG) and that a significant 61.6%+/-1.3% of errors overreimbursed the hospitals. This DRG "creep" improperly increased net reimbursement by 1.9%, $308 million when projected nationally. The present study updated our previous study with 1988 data. Methods.-The Office of Inspector General, US Department of Health and Human Services, obtained a simple random sample of 2451 hospital charts for Medicare discharges from 1988. The American Medical Record Association reabstracted the ICD-9-CM codes on a blinded basis, grouped them to DRGs, and determined the reasons for discrepancies. Results.-Coding errors declined to 14.7%+/-0.7% in 1988, and a nonsignificant 50.7%+/-2.6% of DRG errors overreimbursed the hospitals. Projected nationally, hospitals did not receive a significant overreimbursement. Physician misspecification of the narrative diagnoses underreimbursed the hospitals, while billing department resequencing overreimbursed them. Conclusions.-The attestation requirement may have deterred DRG creep due to attending physician upcoding, but the peer review organizations' sentinel effect and educational activities have not eliminated hospital resequencing.			HSIA, DC (corresponding author), US DEPT HHS,OFF INSPECTOR GEN,OM 1-D-16,6340 SECUR BLVD,BALTIMORE,MD 21207, USA.							BOGDANICH W, 1991, GREAT WHITE LIE, P129; CAMPBELL PM, 1980, RELIABILITY NATIONAL; Carter G.M., 1985, R3292HCFA RAND CORP; CARTER GM, 1990, J HEALTH ECON, V9, P411, DOI 10.1016/0167-6296(90)90003-L; CAVANAGH DP, 1990, OEI120900660 US DEP; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DELANEY AM, 1987, 1985 NATIONAL DRG VA; DEMLO LK, 1977, RELIABILITY HOSPITAL; FOX LA, 1985, HOSPITALS, V59, P92; GLANTZ SA, 1981, RPIMER BIOSTATISTICS, P172; HEXTER AC, 1990, PUBLIC HEALTH REP, V105, P296; Hodges J T, 1985, Healthc Financ Manage, V39, P70; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; HSIA DC, IN PRESS J AM HLTH I; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P221; KNIGHT JW, 1992, OEI129000190 US DEP; KNIGHT JW, 1992, OEI12900191 US DEP H; Kusserow R P, 1989, Consultant, V29, P93; MAKLAN CW, 1991, OM910517 AG HLTH CAR; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; SPIEGAL AD, 1986, COST CONTAINDMENT DR, P36; STONE DS, 1989, OAI128801180 US DEP; Young W W, 1986, J Am Med Rec Assoc, V57, P29; 1983, FED REG         0901, V48, P39752; 1980, PHS801260 US DEP HLT; 1991, BACKGROUND FUTURE DI, P6; 1989, 03294 HLTH CAR FIN A, P16; 1991, REPORT RECOMMENDATIO, P20; 1991, STATISTICAL ABSTRACT, P6	29	135	136	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					896	899		10.1001/jama.268.7.896	http://dx.doi.org/10.1001/jama.268.7.896			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640619				2022-12-28	WOS:A1992JH58800041
J	YARED, A				YARED, A			DIAGNOSIS - V65.5	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					796	796						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640588				2022-12-28	WOS:A1992JG66600039
J	DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA				DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA			POLYPEPTIDES CONTAINING HIGHLY CONSERVED REGIONS OF TRANSCRIPTION INITIATION-FACTOR SIGMA-70 EXHIBIT SPECIFICITY OF BINDING TO PROMOTER DNA	CELL			English	Article								The sigma-70 subunit of E. coli RNA polymerase is required for sequence-specific recognition of promoter DNA. Genetic studies and sequence analysis have indicated that sigma-70 contains two specific DNA-binding domains that recognize the two conserved portions of the prokaryotic promoter. However, intact sigma-70 does not bind to DNA. Using C-terminal and internal polypeptides of sigma-70, carrying one or both putative DNA-binding domains, we demonstrate that sigma-70 does contain two DNA-binding domains, but that N-terminal sequences inhibit the ability of intact sigma-70 to bind to DNA. Thus, we propose that sigma-70 is a sequence-specific DNA-binding protein that normally functions through an allosteric interaction with the core subunits of RNA polymerase.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	DOMBROSKI, AJ (corresponding author), UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA.				NIAID NIH HHS [AI19635] Funding Source: Medline; NIGMS NIH HHS [GM23467] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023467, R01GM023467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1990, ANNU REV BIOCHEM, V53, P293; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CHENCHICK A, 1981, FEBS LETT, V128, P46, DOI 10.1016/0014-5793(81)81076-9; CHENCHIK AA, 1982, MOL BIOL+, V16, P26; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GROSS CA, 1992, IN PRESS TRANSCRIPTI; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HILTON MD, 1985, J BIOL CHEM, V260, P8121; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HU JC, 1988, J MOL BIOL, V203, P15, DOI 10.1016/0022-2836(88)90087-3; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUDO T, 1981, MOL GEN GENET, V181, P63, DOI 10.1007/BF00339006; KUDO T, 1981, J BIOL CHEM, V256, P9778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LEDERER H, 1991, J MOL BIOL, V219, P747, DOI 10.1016/0022-2836(91)90669-W; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3516, DOI 10.1021/bi00556a016; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Maniatis T., 1982, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; RAMESH U, 1989, BIOCHEM BIOPH RES CO, V160, P121, DOI 10.1016/0006-291X(89)91629-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SHANER SL, 1982, COLD SPRING HARB SYM, V47, P463; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; STRAGIER P, 1989, SCIENCE, V243, P507, DOI 10.1126/science.2536191; STRAUSS HS, 1980, BIOCHEMISTRY-US, V19, P3504, DOI 10.1021/bi00556a015; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TREMPY JE, 1985, MOL BIOL MICROBIAL D, P162; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WELLMAN A, 1991, BIOCHEM BIOPH RES CO, V177, P140, DOI 10.1016/0006-291X(91)91959-G; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU CW, 1975, P NATL ACAD SCI USA, V72, P3019, DOI 10.1073/pnas.72.8.3019; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	65	296	302	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					501	512		10.1016/0092-8674(92)90174-B	http://dx.doi.org/10.1016/0092-8674(92)90174-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643661	Bronze			2022-12-28	WOS:A1992JH12400015
J	TIAN, SS; TSOULFAS, P; ZINN, K				TIAN, SS; TSOULFAS, P; ZINN, K			3 RECEPTOR-LINKED PROTEIN-TYROSINE PHOSPHATASES ARE SELECTIVELY EXPRESSED ON CENTRAL-NERVOUS-SYSTEM AXONS IN THE DROSOPHILA EMBRYO	CELL			English	Article							IMMUNOGLOBULIN SUPERFAMILY; FASCICLIN-I; SRC GENE; C-SRC; DOMAINS; KINASE; LOCALIZATION; RECOGNITION; SEQUENCE; DNA	We describe the isolation of seven different protein-tyrosine phosphatase (PTPase) cDNAs from Drosophila embryos, three of which are primarily expressed in the central nervous system (CNS). The CNS-specific PTPases include the previously sequenced DLAR, as well as two novel PTPases (denoted DPTP10D and DPTP99A), which have extracellular domains consisting of multiple fibronectin type III repeats. Each of the Drosophila sequences is most closely related to a different human PTPase. The three PTPase mRNAs are expressed in different patterns of cells in the ventral nerve cord, and all three proteins are restricted to axons. DLAR and DPTP99A are apparently expressed on most or all axons, while DPTP10D is primarily localized to the anterior commissure and its junctions with the longitudinal tracts.			TIAN, SS (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.		Tsoulfas, Pantelis/GNH-1922-2022	Tsoulfas, Pantelis/0000-0003-1974-6366	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28182] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; KLABT C, 1991, CELL, V64, P801; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TONKS NK, 1989, ADV PROTEIN PHOSPHAT, V5, P149; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	33	194	200	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					675	685		10.1016/0092-8674(91)90063-5	http://dx.doi.org/10.1016/0092-8674(91)90063-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657402				2022-12-28	WOS:A1991GQ40700005
J	MARU, Y; WITTE, ON				MARU, Y; WITTE, ON			THE BCR GENE ENCODES A NOVEL SERINE THREONINE KINASE-ACTIVITY WITHIN A SINGLE EXON	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MUSCLE PYRUVATE-KINASE; ACUTE LYMPHOCYTIC-LEUKEMIA; C-ABL PROTEIN; PHILADELPHIA-CHROMOSOME; FUSED TRANSCRIPT; TYROSINE; PRODUCT; REGION	Sequences encoded by the first exon of BCR that bind to the ABL SH2 domain are essential for the activation of the ABL tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene. The normal cellular BCR gene encodes a 160,000 dalton phosphoprotein associated with a serine/threonine kinase activity, but it shows only weak dispersed homologies to protein kinases. p160c-BCR Was purified to apparent homogeneity as an oligomer of > 600,000 daltons that contains autophosphorylation activity and transphosphorylation activity for several protein substrates. A region containing paired cysteine residues within the 426 amino acids encoded by the first exon of BCR is essential for its novel phosphotransferase activity, which overlaps with the strong SH2-binding regions. The recent demonstration of a GTPase-activating function within the C-terminal portion of BCR suggests that the protein kinase and SH2-binding domains may work in concert with other regions of the molecule in intracellular signaling processes.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	MARU, Y (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R35CA053867, R01CA027507] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53867, R01 CA27507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSON RB, 1989, ONCOGENE, V4, P243; ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCH FS, 1978, J BIOL CHEM, V253, P6100; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; RON D, 1991, NEW BIOL, V3, P372; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Summers MD, 1987, TEXAS AGR EXPT STATI; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIMMONS MS, 1989, ONCOGENE, V4, P559; TOGASHI CT, 1982, J BIOL CHEM, V257, P112; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2	59	227	237	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					459	468		10.1016/0092-8674(91)90521-Y	http://dx.doi.org/10.1016/0092-8674(91)90521-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657398				2022-12-28	WOS:A1991GN66400003
J	RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA				RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA			ON THE COMPLEXITY OF SELF	NATURE			English	Article							ANTIGEN	SELF peptides bound to self major histocompatibility complex (MHC) molecules have been implicated both in positive 1,2 and in negative 3,4 selection of T cells during intrathymic development. We report here that the novel MHC-restricted monoclonal antibody Y-Ae (ref. 5) detects the MHC class II bound form of a major self peptide 6. Y-Ae binds approximately 12% of the relevant MHC class II molecules on self antigen presenting cells. The peptide detected by Y-Ae is one of several major peptides eluted from the MHC molecule 6. These data suggest that self peptides presented by self MHC class II molecules at densities sufficient to signal a CD4 T cell are of very limited complexity. Furthermore, as Y-Ae stains antigen presenting cells that mediate negative selection but not thymic cortical epithelial cells 5 that drive positive selection 3, differential expression of self peptide:self MHC class II complexes may be a key feature of intrathymic selection.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute								BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; RUDENSKY AY, NATURE, V353, P622; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61	11	252	255	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					660	662		10.1038/353660a0	http://dx.doi.org/10.1038/353660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656278				2022-12-28	WOS:A1991GK67200070
J	LEYVRAZ, PF; BACHMANN, F; HOEK, J; BULLER, HR; POSTEL, M; SAMAMA, M; VANDENBROEK, MD				LEYVRAZ, PF; BACHMANN, F; HOEK, J; BULLER, HR; POSTEL, M; SAMAMA, M; VANDENBROEK, MD			PREVENTION OF DEEP-VEIN THROMBOSIS AFTER HIP-REPLACEMENT - RANDOMIZED COMPARISON BETWEEN UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN	BRITISH MEDICAL JOURNAL			English	Article							LOW-DOSE HEPARIN; VENOUS THROMBOSIS; PULMONARY-EMBOLISM; SUBCUTANEOUS HEPARIN; ARTHROPLASTY; THROMBOEMBOLISM; PROPHYLAXIS; TRIAL; DIHYDROERGOTAMINE; EFFICACY	Objective - To evaluate the efficacy and safety of two subcutaneous prophylactic regimens for postoperative deep vein thrombosis after total hip replacement. Design - Prospective open randomised multi-centre trial. Setting - 28 European departments of orthopaedic surgery. Intervention - All patients had bilateral phlebography 10 days after surgery. 31 patients receiving low molecular weight heparin and 29 receiving unfractionated heparin were excluded from the efficacy analysis for various reasons. Patients - 349 patients undergoing total hip replacement between September 1988 and May 1989. 174 patients received subcutaneously a low molecular weight heparin (Fraxiparine) with anti-factor Xa activity of 41 IU/kg/day for three days, then 62 IU/kg/day from day 4 to day 10. 175 patients received subcutaneous unfractionated heparin at intervals of eight hours; doses were adjusted to maintain the activated thromboplastin time at two to five seconds above control values. Main outcome measure - Total incidence of deep vein thrombosis and incidence of proximal deep vein thrombosis on bilateral phlebography. Results - The total incidence of deep vein thrombosis was 16% in patients receiving unfractionated heparin and 12.6% in patients receiving low molecular weight heparin (p = 0.45), and the incidence of thrombosis of the proximal veins was 13.1% and 2.9% respectively (p < 0.001). Four patients receiving unfractionated heparin and one receiving low molecular weight heparin developed pulmonary embolism. The incidence of bleeding complications was low and comparable in the two groups. Conclusion - Low molecular weight heparin is at least as effective as unfractionated heparin in preventing deep vein thrombosis and is more effective at preventing thrombosis of the proximal veins in patients undergoing hip replacement. Low molecular weight heparin is not more likely to cause bleeding complications and is simpler to give than unfractionated heparin.	UNIV AMSTERDAM,ACAD MED CTR,CTR HAEMOSTASIS THROMBOSIS ARTERIOSCLEROSIS & INFLAMMAT RES,1105 AZ AMSTERDAM,NETHERLANDS; SANOFI RES,F-94256 GENTILLY,FRANCE; HOP COCHIN,ORTHOPAED SURG,F-75674 PARIS 14,FRANCE; HOP HOTEL DIEU,CENT LAB,F-75181 PARIS,FRANCE	University of Amsterdam; Academic Medical Center Amsterdam; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	LEYVRAZ, PF (corresponding author), VAUDOIS UNIV HOSP,CH-1011 LAUSANNE,SWITZERLAND.		Hoek, Janet/A-5186-2010	Hoek, Janet/0000-0003-4362-1539				AIACH M, 1988, ANN BIOL CLIN-PARIS, V46, P715; BARROWCLIFFE TW, 1988, THROMB HAEMOSTASIS, V60, P1; BEISAW NE, 1988, J BONE JOINT SURG AM, V70A, P2, DOI 10.2106/00004623-198870010-00002; BERGQVIST D, 1976, ACTA ORTHOP SCAND, V47, P549, DOI 10.3109/17453677608988736; Bergqvist D., 1983, POSTOPERATIVE THROMB, P32; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CONSTANT G, 1983, THROMB RES, V31, P365; DECHAVANNE M, 1989, HAEMOSTASIS, V1, P5; DELACAFFINIERE JY, 1981, REV CHIR ORTHOP, V67, P47; DORFMAN GS, 1987, AM J ROENTGENOL, V148, P263, DOI 10.2214/ajr.148.2.263; ESTROPPEY D, 1989, THROMB HAEMOSTASIS, V62, P1107; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; Fleiss JL, 1981, STAT METHODS RATES P; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; GENT M, 1986, CHEST, V89, P3965; HAMPSON WGJ, 1974, LANCET, V2, P795; HARRIS WH, 1985, J BONE JOINT SURG AM, V67A, P57, DOI 10.2106/00004623-198567010-00008; HOEK J, 1989, THROMB HAEMOST S, V62, P1637; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HURLEY PB, 1986, T ORTHOP RES SOC, V11, P303; HYERS TM, 1989, CHEST S, V95, P37; KAKKAR VV, 1979, JAMA-J AM MED ASSOC, V241, P39, DOI 10.1001/jama.241.1.39; KELTON JG, 1984, J LAB CLIN MED, V103, P606; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; Leyvraz P, 1988, J Arthroplasty, V3, P81, DOI 10.1016/S0883-5403(88)80056-1; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; LORMEAU JC, 1988, PATHOL BIOL, V36, P335; MERLI GJ, 1987, MED CLIN N AM, V71, P377, DOI 10.1016/S0025-7125(16)30847-1; MORRIS GK, 1974, LANCET, V2, P797; MOSKOVITZ PA, 1978, J BONE JOINT SURG AM, V60, P1065, DOI 10.2106/00004623-197860080-00008; NILLIUS AS, 1979, BRIT J SURG, V66, P324, DOI 10.1002/bjs.1800660508; PAIEMENT GD, 1987, CLIN ORTHOP RELAT R, V223, P188; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PLANES A, 1991, J BONE JOINT SURG BR, V73, P418, DOI 10.1302/0301-620X.73B3.1670442; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; ROBERTS HR, 1986, JAMA-J AM MED ASSOC, V256, P744; SAGAR S, 1976, LANCET, V1, P1151; SALZMAN EM, 1987, HEMOSTASIS THROMBOSI, P1252; SALZMAN EW, 1986, NEW ENGL J MED, V315, P957, DOI 10.1056/NEJM198610093151509; SALZMAN EW, 1976, J BONE JOINT SURG AM, V58, P903, DOI 10.2106/00004623-197658070-00001; SIKORSKI JM, 1981, J BONE JOINT SURG BR, V63, P171, DOI 10.1302/0301-620X.63B2.7217137; SIMON P, 1990, J CHIR-PARIS, V127, P252; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; TORHOLM C, 1991, J BONE JOINT SURG BR, V73, P434, DOI 10.1302/0301-620X.73B3.1670445; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VANDENBERG E, 1982, LANCET, V2, P268; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; 1975, BRIT J SURG, V62, P348	49	217	221	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					543	548		10.1136/bmj.303.6802.543	http://dx.doi.org/10.1136/bmj.303.6802.543			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1655136	Bronze, Green Published			2022-12-28	WOS:A1991GE94800020
J	HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A				HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A			INDUCTION OF BCL-2 EXPRESSION BY EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 PROTECTS INFECTED B-CELLS FROM PROGRAMMED CELL-DEATH	CELL			English	Article							POSITIVE BURKITTS-LYMPHOMA; ANTIGEN-DRIVEN SELECTION; ENDONUCLEASE ACTIVATION; FOLLICULAR LYMPHOMA; DEREGULATED BCL2; TRANSGENIC MICE; GENE-EXPRESSION; GROWTH; TRANSLOCATION; APOPTOSIS	Epstein-Barr virus (EBV) not only induces growth transformation in human B lymphocytes, but has more recently been shown to enhance B cell survival under suboptimal conditions where growth is inhibited; both effects are mediated through the coordinate action of eight virus-coded latent proteins. The effect upon cell survival is best recognized in EBV-positive Burkitt's lymphoma cell lines where activation of full virus latent gene expression protects the cells from programmed cell death (apoptosis). Here we show by DNA transfection into human B cells that protection from apoptosis is conferred through expression of a single EBV latent protein, the latent membrane protein LMP 1. Furthermore, we demonstrate that LMP 1 mediates this effect by up-regulating expression of the cellular oncogene bcl-2. The interplay between EBV infection and expression of this cellular oncogene has important implications for virus persistence and for the pathogenesis of virus-associated malignant disease.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	HENDERSON, S (corresponding author), UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326; Hope, Sheila/0000-0002-3608-4379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], EPSTEIN BARR VIRUS; BAKHSHI A, 1985, CELL, V41, P889; CHEAH MSC, 1986, NATURE, V319, P239; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFF E, 1990, VIROLOGY, P1889; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1989, ONCOGENE, V4, P1123; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; ROWE M, 1986, INT J CANCER, V37, P363; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	50	1129	1155	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1107	1115		10.1016/0092-8674(91)90007-L	http://dx.doi.org/10.1016/0092-8674(91)90007-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648447				2022-12-28	WOS:A1991FU89900004
J	BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE				BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE			BELL-SHAPED CALCIUM-RESPONSE CURVES OF INS(1,4,5)P3-GATED AND CALCIUM-GATED CHANNELS FROM ENDOPLASMIC-RETICULUM OF CEREBELLUM	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; MUSCLE SARCOPLASMIC-RETICULUM; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; SINGLE CHANNEL; ADENINE-NUCLEOTIDES; RELEASE CHANNEL; SKELETAL-MUSCLE; CA-2+ RELEASE	RELEASE of calcium from intracellular stores occurs by two pathways, an inositol 1,4,5-trisphosphate (InsP3)-gated channel 1-3 and a calcium-gated channel (ryanodine receptor) 4-6. Using specific antibodies, both receptors were found in Purkinje cells of cerebellum 7,8. We have now Compared the functional properties of the channels corresponding to the two receptors by incorporating endoplasmic reticulum vesicles from canine cerebellum into planar bilayers. InsP3-gated channels were observed most frequently. Another channel type was activated by adenine nucleotides or caffeine, inhibited by ruthenium red, and modified by ryanodine, characteristics of the ryanodine receptor/channel 6. The open probability of both channel types displayed a bell-shaped curve for dependence on calcium. For the InsP3-gated channel, the maximum probability of opening occurred at 0.2-mu-M free calcium, with sharp decreases on either side of the maximum. Maximum activity for the ryanodine receptor/channel was maintained between 1 and 100-mu-M calcium. Thus, within the physiological range of cytoplasmic calcium, the InsP3-gated channel itself allows positive feedback and then negative feedback for calcium release, whereas the ryanodine receptor/channel behaves solely as a calcium-activated channel. The existence in the same cell of two channels with different responses to calcium and different ligand sensitivities provides a basis for complex patterns of intracellular calcium regulation.	UNIV CONNECTICUT, CTR HLTH, DEPT MED, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06032 USA; ACAD SCI USSR, INST CYTOL, LENINGRAD 194064, USSR	University of Connecticut; University of Connecticut; Russian Academy of Sciences			/AAX-8408-2021; Oka, Yoshitaka/C-9670-2010	/0000-0001-9657-9704; Oka, Yoshitaka/0000-0002-3482-3051				AIREY JA, 1990, J BIOL CHEM, V265, P14187; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HARTOONIAN AT, 1991, SCIENCE, V251, P75; HERRMANNFRANK A, 1990, BIOPHYS J, V57, pA156; HINGORANI S R, 1990, Society for Neuroscience Abstracts, V16, P1018; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8; WATRAS J, IN PRESS J NEUROSCI; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	35	1538	1561	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	1991	351	6329					751	754		10.1038/351751a0	http://dx.doi.org/10.1038/351751a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648178				2022-12-28	WOS:A1991FU20100066
J	HENEGHAN, C				HENEGHAN, C			CONSENT TO MEDICAL-TREATMENT	LANCET			English	Editorial Material											HENEGHAN, C (corresponding author), EALING GEN HOSP,SOUTHALL UB1 3HW,ENGLAND.							GUIDE CONSENT EXAMIN; PATIENT CONSENT EXAM	2	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					421	421		10.1016/0140-6736(91)91185-W	http://dx.doi.org/10.1016/0140-6736(91)91185-W			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671437				2022-12-28	WOS:A1991EX60500018
J	JAMES, MR; MARSHALL, H; CAREWMCCOLL, M				JAMES, MR; MARSHALL, H; CAREWMCCOLL, M			PULSE OXIMETRY DURING APPARENT TONIC-CLONIC SEIZURES	LANCET			English	Note								A pulse oximeter was used to monitor arterial oxygen saturations in 11 patients during apparent tonic-clonic seizures. 8 had a clinical diagnosis of genuine fits, 6 of whom showed striking falls in oxygen saturation during the seizures. 3 had a clinical diagnosis of pseudoseizures, none of whom had hypoxia during these episodes. Pulse oximetry during apparent tonic-clonic seizures may help to identify patients with low arterial oxygen tension who need immediate intervention.	HOPE HOSP,DEPT ACCID & EMERGENCY,SALFORD M6 8HD,LANCS,ENGLAND		JAMES, MR (corresponding author), ROYAL PRESTON HOSP,DEPT ACCID & EMERGENCY,PRESTON PR2 4HT,ENGLAND.							SADEH M, 1983, J NEUROL NEUROSUR PS, V46, P566, DOI 10.1136/jnnp.46.6.566	1	29	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					394	395						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671426				2022-12-28	WOS:A1991EX60500006
J	HERXHEIMER, A				HERXHEIMER, A			HOW MUCH DRUG IN THE TABLET	LANCET			English	Editorial Material								Many recommended drug doses are higher than necessary, for two reasons. Drugs are often introduced at a dose that will be effective in around 90% of the target population, because this helps market penetration. Doses are also partly determined by an irrational preference for round numbers. The dose excess due to such digit preference may be as much as 70% of the correct dose and on average is probably 25%. Needlessly high doses are bound to cause avoidable unwanted effects in a proportion of patients. Rigorous methods must be used to determine the doses recommended and the amount of drug to be put into a tablet or other dosage form.			HERXHEIMER, A (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON W6 8RF,ENGLAND.							ALEXANDER GR, 1989, AM J PUBLIC HEALTH, V79, P600, DOI 10.2105/AJPH.79.5.600; HERXHEIMER A, 1987, LANCET, V1, P32; ROSE GA, 1964, LANCET, V1, P296; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P71	5	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					346	348		10.1016/0140-6736(91)90958-R	http://dx.doi.org/10.1016/0140-6736(91)90958-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX362	1671244				2022-12-28	WOS:A1991EX36200016
J	SEATON, A; LEGGE, JS; HENDERSON, J; KERR, KM				SEATON, A; LEGGE, JS; HENDERSON, J; KERR, KM			ACCELERATED SILICOSIS IN SCOTTISH STONEMASONS	LANCET			English	Article							MINERS; PNEUMOCONIOSIS; SANDBLASTERS	A small group of stonemasons working with sandstone was exposed to levels of respirable quartz up to 130 times the workplace standard over a period of up to 6 years. Two died of accelerated silicosis, a disease that caused serious diagnostic difficulties and was initially not recognised by the doctors of the then Department of Health and Social Security Medical Boarding Centre (respiratory diseases). Previous descriptions of this disease in the UK date back to the years of the industrial revolution (late 18th century). One other mason on the site proved to have an earlier stage of accelerated silicosis and two had radiographic changes of early classic silicosis. Regulations intended to prevent silicosis have been in place in the UK for many decades and were strengthened by the Health and Safety at Work Act in 1974. Although the workers had been aware of a health risk from quartz, they had not been able to persuade management to take effective preventive action until serious illness had occurred. Current pressures on management to cut overheads and to achieve maximum productivity could, as in this instance, lead to neglect of health and safety standards.	CITY HOSP,DEPT RESP MED,ABERDEEN,SCOTLAND; CIVIL SERV OCCUPAT HLTH SERV,EDINBURGH,SCOTLAND; UNIV ABERDEEN,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND	University of Edinburgh; University of Aberdeen	SEATON, A (corresponding author), UNIV ABERDEEN,SCH MED,DEPT ENVIRONM & OCCUPAT MED,FORESTERHILL,ABERDEEN AB9 2ZD,SCOTLAND.							BAILEY WC, 1974, AM REV RESPIR DIS, V110, P115; BUECHNER HA, 1969, DIS CHEST, V55, P274, DOI 10.1378/chest.55.4.274; GREENHOW EH, 1866, T PATHOL SOC LOND, V17, P36; JOHNSTONE J, 1799, MEM MED SOC LOND, V5, P89; SAIYED HN, 1985, AM J IND MED, V8, P135, DOI 10.1002/ajim.4700080208; SEATON A, 1981, LANCET, V2, P1272; SEATON A, 1981, THORAX, V36, P412, DOI 10.1136/thx.36.6.412; SEATON A, 1986, THORAX, V41, P591, DOI 10.1136/thx.41.8.591; SEATON A, 1989, BRIT MED J, V298, P846, DOI 10.1136/bmj.298.6677.846; Seaton A., 1989, CROFTON DOUGLASS RES, P808; SURATT PM, 1977, AM REV RESPIR DIS, V115, P521; WARRELL DA, 1975, THORAX, V30, P389, DOI 10.1136/thx.30.4.389; 1988, ARCH PATHOL LAB MED, V112, P673	13	24	26	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					341	344		10.1016/0140-6736(91)90956-P	http://dx.doi.org/10.1016/0140-6736(91)90956-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671242				2022-12-28	WOS:A1991EX36200014
J	VANGEET, C; VANDENBOSSCHE, L; EGGERMONT, E; DEVLIEGER, H; VERMYLEN, J; JAEKEN, J				VANGEET, C; VANDENBOSSCHE, L; EGGERMONT, E; DEVLIEGER, H; VERMYLEN, J; JAEKEN, J			POSSIBLE PLATELET CONTRIBUTION TO PATHOGENESIS OF TRANSIENT NEONATAL HYPERAMMONEMIA SYNDROME	LANCET			English	Article							BETA-THROMBOGLOBULIN; HYPER-AMMONEMIA; 11-DEHYDROTHROMBOXANE-B2; THROMBOXANE-B2; CIRCULATION; THROMBOSIS; CLEARANCE; PROTEINS; RELEASE	The pathogenesis of the transient neonatal hyperammonaemia syndrome is largely unknown. The role of platelet activation was investigated in three preterm infants with this syndrome by non-invasive methods. In all three infants, urinary concentrations of beta-thromboglobulin and 11-dehydrothromboxane B2 levels were much higher during the hyperammonaemia than those in ten control preterm infants. It is possible that transient platelet activation occurs in the portal system of these infants, thereby causing the hyperammonaemia.	CATHOLIC UNIV LEUVEN,HOSP GASTHUISBERG,DEPT PEDIAT,B-3000 LOUVAIN,BELGIUM	KU Leuven	VANGEET, C (corresponding author), CATHOLIC UNIV LEUVEN,HOSP GASTHUISBERG,CTR THROMBOSIS & VASC RES,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							BALLARD RA, 1978, NEW ENGL J MED, V299, P920, DOI 10.1056/NEJM197810262991704; BASTL CP, 1981, BLOOD, V57, P233; BOLTON AE, 1980, THROMB RES, V19, P249, DOI 10.1016/0049-3848(80)90423-5; CATELLA F, 1986, P NATL ACAD SCI USA, V83, P5861, DOI 10.1073/pnas.83.16.5861; CATHELINEAU L, 1979, ARCH FR PEDIATR, V36, P724; CIABATTONI G, 1989, BIOCHIM BIOPHYS ACTA, V992, P66, DOI 10.1016/0304-4165(89)90051-2; DAFONSEC.F, 1973, Z KLIN CHEM KLIN BIO, V11, P426; DAWES J, 1978, THROMB RES, V12, P851, DOI 10.1016/0049-3848(78)90279-7; DEPPERMANN D, 1980, THROMB RES, V17, P63, DOI 10.1016/0049-3848(80)90294-7; EGGERMONT E, 1980, ACTA PAEDIATR BELG, V33, P163; GOLDBERG RN, 1979, PEDIATRICS, V64, P336; JAEKEN J, 1982, NEUROLOGY, V32, P1070, DOI 10.1212/WNL.32.9.1070-a; KAPLAN KL, 1979, BLOOD, V53, P604; LUDLAM CA, 1979, BRIT J HAEMATOL, V41, P271, DOI 10.1111/j.1365-2141.1979.tb05855.x; POLLACK L, 1978, PEDIATR RES, V12, P532, DOI 10.1203/00006450-197804001-01018; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; TADA K, 1979, EUR J PEDIATR, V130, P105, DOI 10.1007/BF00442347; VANGEET C, 1990, EICOSANOIDS, V3, P39; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; WALSER M, 1983, METABOLIC BASIS INHE, P402	20	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					73	75		10.1016/0140-6736(91)90736-9	http://dx.doi.org/10.1016/0140-6736(91)90736-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670726				2022-12-28	WOS:A1991ER47700004
J	CALLAHAN, CM				CALLAHAN, CM			MARY-GO-ROUND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					843	843						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640591				2022-12-28	WOS:A1992JH58800002
J	SCHLUNEGGER, MP; GRUTTER, MG				SCHLUNEGGER, MP; GRUTTER, MG			AN UNUSUAL FEATURE REVEALED BY THE CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2	NATURE			English	Article							FACTOR-BETA; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEINS; REFINEMENT; COMPLEX; PATTERN; PROGRAM; MEMBER	TRANSFORMING growth factor type-beta-2 (TGF-beta-2)1 is a member of an expanding family of growth factors that regulate proliferation and differentiation of many different cell types2,3. TGF-beta-2 binds to various receptors4, one of which was shown to be a serine/threonine kinase5. TGF-beta-2 is involved in wound healing6, bone formation7 and modulation of immune functions8. We report here the crystal structure of TGF-beta-2 at 2.2 angstrom resolution, which reveals a novel monomer fold and dimer association. The monomer consists of two antiparallel pairs of beta-strands forming a flat curved surface and a separate, long alpha-helix. The disulphide-rich core has one disulphide bond pointing through a ring formed by the sequence motifs Cys-Ala-Gly-Ala-Cys and Cys-Lys-Cys, which are themselves connected through the cysteines. Two monomers are connected through a single disulphide bridge and associate such that the helix of one subunit interacts with the concave beta-sheet surface of the other. Four exposed loop regions might determine receptor specificity. The structure provides a suitable model for the TGF-beta-s and other members of the super-family9-11 and is the basis for the analysis of the TGF-beta-2 interactions with the receptor.			SCHLUNEGGER, MP (corresponding author), CIBA GEIGY AG,DIV PHARMACEUT,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND.							BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; COX DA, 1992, ANGIOGENESIS KEY PRI, P287; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; Massague J., 1990, REV CELL BIOL, V6, P597; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REES DC, 1980, P NATL ACAD SCI-BIOL, V77, P4633, DOI 10.1073/pnas.77.8.4633; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	25	306	338	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					430	434		10.1038/358430a0	http://dx.doi.org/10.1038/358430a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641027				2022-12-28	WOS:A1992JF85300061
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - LOWER GASTROINTESTINAL HEMORRHAGE	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					107	110		10.1136/bmj.305.6845.107	http://dx.doi.org/10.1136/bmj.305.6845.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638226	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JD85000032
J	STONELAKE, PS; BAKER, PR; BAKER, PG; MORRISON, JM; SPOONER, D				STONELAKE, PS; BAKER, PR; BAKER, PG; MORRISON, JM; SPOONER, D			STEROID-RECEPTORS IN EARLY BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Letter									UNIV BIRMINGHAM,DEPT SURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,W MIDLANDS BREAST CANC GRP,CLIN TRIALS UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham	STONELAKE, PS (corresponding author), DUDLEY RD GEN HOSP,DEPT SURG,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							CHEVALLIER B, 1990, BRIT J CANCER, V61, P436, DOI 10.1038/bjc.1990.96; CLARK GM, 1989, P ROY SOC EDINB, V958, P145; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; RUBENS RD, 1992, BRIT MED J, V304, P1361, DOI 10.1136/bmj.304.6838.1361; THORPE SM, 1987, CANCER RES, V47, P6126; 1992, LANCET, V339, P71	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					51	51		10.1136/bmj.305.6844.51-b	http://dx.doi.org/10.1136/bmj.305.6844.51-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638210	Green Published			2022-12-28	WOS:A1992JC79900054
J	FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU				FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU			A HEPATIC RETICULOENDOTHELIAL CELL-RECEPTOR SPECIFIC FOR SO4-4GAINAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA THAT MEDIATES RAPID CLEARANCE OF LUTROPIN	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; LIVER ENDOTHELIAL-CELLS; RAT-LIVER; HYALURONIC-ACID; SIALYLATED OLIGOSACCHARIDES; BOVINE LUTROPIN; STRUCTURAL ELUCIDATION; ENDOCYTOSIS; HEPATOCYTES	We have identified a receptor in hepatic endothelial and Kupffer cells that binds oligosaccharides terminating with the sequence SO4-4GalNAc-beta-1,4GlcNAc-beta-1,2-Man-alpha (S4GGnM). This receptor can account for the rapid removal of the glycoprotein hormone lutropin, which bears unique Asn-linked oligosaccharides terminating in S4GGnM, from the circulation. Hepatic endothelial cells express 579,000 S4GGnM receptors at their surface and bind lutropin with an apparent K(d) of 1.63 x 10(-7) M. Bound ligand is rapidly internalized. Binding does not require divalent cations, is reversed by incubation at pH 5.0 or below, and is inhibited by fucoidin but not by hyaluronate, heparin, chondroitin sulfate, or dextran sulfate. We propose that the S4GGnM-specific receptor represents a major mechanism for clearance of certain sulfated glycoproteins from the blood, including members of the glycoprotein hormone family.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta	FIETE, D (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.		Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [R37-CA-21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK-41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1991, IN PRESS P NATL ACAD; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; DAMM JBL, 1990, EUR J BIOCHEM, V189, P175, DOI 10.1111/j.1432-1033.1990.tb15474.x; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; HINDSGAUL V, 1987, CAN J CHEM, V65, P1645; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KNOOK DL, 1977, EXP CELL RES, V109, P317, DOI 10.1016/0014-4827(77)90011-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V174, P940, DOI 10.1016/0006-291X(91)91509-B; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MIAN AJ, 1973, CARBOHYD RES, V304, P449; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; PARSONS TF, 1980, P NATL ACAD SCI-BIOL, V77, P7089, DOI 10.1073/pnas.77.12.7089; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SMEDSROD B, 1985, J LEUKOCYTE BIOL, V38, P213, DOI 10.1002/jlb.38.2.213; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SMITH PL, 1991, IN PRESS P NATL ACAD	30	264	270	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1103	1110		10.1016/0092-8674(91)90287-9	http://dx.doi.org/10.1016/0092-8674(91)90287-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662117				2022-12-28	WOS:A1991GX16400009
J	DEMPLE, B; AMABILECUEVAS, CF				DEMPLE, B; AMABILECUEVAS, CF			REDOX REDUX - THE CONTROL OF OXIDATIVE STRESS RESPONSES	CELL			English	Review							ESCHERICHIA-COLI; POSITIVE CONTROL; CYCLING AGENTS; REGULON; ACTIVATION; PROTEINS				DEMPLE, B (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115, USA.		Amábile-Cuevas, Carlos/HDO-1753-2022	Amábile-Cuevas, Carlos/0000-0001-6806-544X				AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ANDERSEN J, 1990, BIOCHEMISTRY-US, V29, P9249, DOI 10.1021/bi00491a020; BOLKER M, 1989, EMBO J, V8, P2403, DOI 10.1002/j.1460-2075.1989.tb08370.x; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; GREENBERG JT, 1988, EMBO J, V7, P2611, DOI 10.1002/j.1460-2075.1988.tb03111.x; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8921; TAO K, 1991, J BIOCHEM-TOKYO, V109, P262; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TARTAGLIA LA, 1991, IN PRESS J BIOL CHEM; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	21	210	211	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					837	839		10.1016/0092-8674(91)90355-3	http://dx.doi.org/10.1016/0092-8674(91)90355-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1659949				2022-12-28	WOS:A1991GT75500002
J	HARDY, I; GERSHON, AA; STEINBERG, SP; LARUSSA, P				HARDY, I; GERSHON, AA; STEINBERG, SP; LARUSSA, P			THE INCIDENCE OF ZOSTER AFTER IMMUNIZATION WITH LIVE ATTENUATED VARICELLA VACCINE - A STUDY IN CHILDREN WITH LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ACUTE LYMPHOCYTIC-LEUKEMIA; HERPES-ZOSTER; HEALTHY-CHILDREN; FOLLOW-UP; VIRUS; IMMUNITY; INFECTIONS; ADULTS; PROTECTION	Background. The Oka strain of live attenuated varicella vaccine is immunogenic and highly protective, but there has been concern about the risk of zoster after immunization. Methods. We examined the incidence of zoster, risk factors for it, and measures of immune response in children with leukemia who received the vaccine and in appropriate controls. Results. After a mean follow-up of 4.1 years, zoster was documented in 13 of the 548 vaccinated children with leukemia (2.4 percent). In a subgroup of 96 vaccinated children matched prospectively with 96 children with leukemia who had had natural varicella infections, there were 4 cases of zoster among the vaccinated children and 15 among the controls, for crude incidence rates of 0.80 and 2.46 cases per 100 person-years, respectively (P = 0.01). Of the total of 13 vaccinated children who had zoster, 11 had a skin rash due to varicella-zoster virus, either from the vaccine itself or from breakthrough varicella after household exposure in the period between immunization and the documentation of zoster. In the 268 children who had any type of rash caused by varicella-zoster virus after vaccination, as compared with those who did not have a rash, the relative risk of subsequent zoster was 5.75. For the 21 vaccinated children who received bone marrow transplants, as compared with those who did not, the relative risk of zoster was 7.5. Cell-mediated immunity as assessed by lymphocyte stimulation was lower in 4 children in whom zoster later developed than in 29 controls who had been vaccinated but who did not have zoster (mean stimulation index, 5.1 vs. 23.8; P = 0.0001). Conclusions. In children with leukemia who receive the live attenuated varicella vaccine, the subsequent incidence of zoster is lower than in children who have natural varicella infections.	COLUMBIA UNIV,DEPT PEDIAT,650 W 168TH ST,NEW YORK,NY 10027	Columbia University				Dennehy, Penelope/0000-0002-2259-5370	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062529, R21AI024021, R01AI024021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 62529, AI 24021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBETER AM, 1986, PEDIATRICS, V78, P748; ARBETER AM, 1984, AM J DIS CHILD, V138, P434, DOI 10.1001/archpedi.1984.02140430012004; ARBETER AM, 1990, PEDIATRICS, V85, P338; ARBETER AM, 1986, PEDIATRICS, V78, P742; ARVIN AM, 1978, J INFECT DIS, V137, P531, DOI 10.1093/infdis/137.5.531; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; ARVIN AM, 1980, J CLIN INVEST, V65, P869, DOI 10.1172/JCI109739; ASANO Y, 1985, PEDIATRICS, V75, P667; ASANO Y, 1977, PEDIATRICS, V59, P3; ASANO Y, 1983, PEDIATRICS, V72, P291; BRUNELL PA, 1982, LANCET, V2, P1069; BRUNELL PA, 1987, PEDIATRICS, V79, P922; BRUNELL PA, 1988, PEDIATRICS, V81, P779; BRUNELL PA, 1986, PEDIATRICS, V77, P53; FELDMAN S, 1973, AM J DIS CHILD, V126, P178, DOI 10.1001/archpedi.1973.02110190156009; GELB LD, 1987, J INFECT DIS, V155, P633, DOI 10.1093/infdis/155.4.633; GERSHON AA, 1984, JAMA-J AM MED ASSOC, V252, P355, DOI 10.1001/jama.252.3.355; GERSHON AA, 1990, J INFECT DIS, V161, P661, DOI 10.1093/infdis/161.4.661; GERSHON AA, 1989, NEW ENGL J MED, V320, P892, DOI 10.1056/NEJM198904063201403; HAMMERSCHLAG MR, 1989, J INFECT DIS, V160, P535, DOI 10.1093/infdis/160.3.535; HAMMERSCHLAG MR, 1989, J INFECT DIS, V160, P1095; KATZ J, 1987, W J MED, P179; LAWRENCE R, 1988, NEW ENGL J MED, V318, P543, DOI 10.1056/NEJM198803033180904; LEVENTHAL BG, 1974, ISRAEL J MED SCI, V10, P867; LJUNGMAN P, 1986, J INFECT DIS, V153, P840, DOI 10.1093/infdis/153.5.840; LOCKSLEY RM, 1985, J INFECT DIS, V152, P1172, DOI 10.1093/infdis/152.6.1172; NOVELLI MM, 1988, AM J DIS CHILD, V142, P71; RAND KH, 1977, NEW ENGL J MED, V296, P1372, DOI 10.1056/NEJM197706162962402; RUCKDESCHEL JC, 1977, AM J MED, V62, P77, DOI 10.1016/0002-9343(77)90352-7; SAKURAI N, 1982, INT C SERIES, V571, P87; SCHUCHTER LM, 1989, BLOOD, V74, P1424; Stern ES, 1937, BRIT J DERMATOL SYPH, V49, P263, DOI 10.1111/j.1365-2133.1937.tb10402.x; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; TSOLIA M, 1990, J PEDIATR-US, V116, P184, DOI 10.1016/S0022-3476(05)82872-0; WACKER P, 1989, BONE MARROW TRANSPL, V4, P191; WILLIAMS DL, 1985, J PEDIATR-US, V106, P259, DOI 10.1016/S0022-3476(85)80301-2; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669	37	331	341	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1545	1550		10.1056/NEJM199111283252204	http://dx.doi.org/10.1056/NEJM199111283252204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1658650				2022-12-28	WOS:A1991GR38000004
J	STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ				STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ			INACTIVATION OF MUSCLE CHLORIDE CHANNEL BY TRANSPOSON INSERTION IN MYOTONIC MICE	NATURE			English	Article							RECESSIVE GENERALIZED MYOTONIA; MOUSE MUTANT ADR; SEQUENCE; ETN; CONDUCTANCE; EXPRESSION; PROTEIN; RAT	MYOTONIA (stiffness and impaired relaxation of skeletal muscle) is a symptom of several diseases caused by repetitive firing of action potentials in muscle membranes 1. Purely myotonic human diseases are dominant myotonia congenita (Thomsen) and recessive generalized myotonia (Becker), whereas myotonic dystrophy is a systemic disease. Muscle hyperexcitability was attributed to defects in sodium channels 2,3 and/or to a decrease in chloride conductance (in Becker's myotonia 4 and in genetic animal models 5-10). Experimental blockage of Cl- conductance (normally 70-85% of resting conductance in muscle") in fact elicits myotonia 1,9. ADR (ref. 12) mice are a realistic animal model 5-7,12-18 for recessive autosomal myotonia. In addition to Cl- conductance 5, many other parameters 6,12,16 are changed in muscles of homozygous animals. We have now cloned the major mammalian skeletal muscle chloride channel (ClC-1) 19. Here we report that in ADR mice a transposon of the ETn family 20-23 has inserted into the corresponding gene, destroying its coding potential for several membrane-spanning domains. Together with the lack of recombination between the Clc-1 gene and the adr locus, this strongly suggests a lack of functional chloride channels as the primary cause of mouse myotonia.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY	University of Hamburg; University of Bielefeld			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553				ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRINKMEIER H, 1987, BIOCHEM BIOPH RES CO, V148, P1383, DOI 10.1016/S0006-291X(87)80285-1; BRULET P, 1985, P NATL ACAD SCI USA, V82, P2054, DOI 10.1073/pnas.82.7.2054; BRULET P, 1983, P NATL ACAD SCI-BIOL, V80, P5641, DOI 10.1073/pnas.80.18.5641; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; BUCAN M, 1986, EMBO J, V5, P2899, DOI 10.1002/j.1460-2075.1986.tb04585.x; CAMERINO DC, 1989, PFLUG ARCH EUR J PHY, V413, P568, DOI 10.1007/BF00594192; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; FRANKE C, 1991, MUSCLE NERVE, V14, P762, DOI 10.1002/mus.880140811; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; FUCHTBAUER EM, 1988, P NATL ACAD SCI USA, V85, P3880, DOI 10.1073/pnas.85.11.3880; HELLER AH, 1982, J NEUROSCI, V2, P924; Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOCKUSCH H, 1988, EUR J BIOCHEM, V171, P101, DOI 10.1111/j.1432-1033.1988.tb13764.x; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; JOCKUSCH H, 1990, MOUSE GENOME, V86, P216; KOLTGEN D, 1991, MUSCLE NERVE, V14, P775, DOI 10.1002/mus.880140813; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; LIPICKY RJ, 1966, J GEN PHYSIOL, V50, P89, DOI 10.1085/jgp.50.1.89; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MEYERS JC, 1981, P NATL ACAD SCI USA, V78, P3516; NEUMANN P, 1989, MOUSE NEWS LETT, V83, P157; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; RUDEL R, 1990, TRENDS NEUROSCI, V13, P1, DOI 10.1016/0166-2236(90)90049-G; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SHELL B, 1987, MOL CELL BIOL, V7, P1364, DOI 10.1128/MCB.7.4.1364; SONIGO P, 1987, P NATL ACAD SCI USA, V84, P3768, DOI 10.1073/pnas.84.11.3768; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; WATKINS WJ, 1984, LAB ANIM, V18, P1, DOI 10.1258/002367784780865036; WILKE TM, 1987, MOL CELL BIOL, V57, P1646; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	35	319	325	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					304	308		10.1038/354304a0	http://dx.doi.org/10.1038/354304a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659665				2022-12-28	WOS:A1991GT20400047
J	ODELL, TJ; KANDEL, ER; GRANT, SGN				ODELL, TJ; KANDEL, ER; GRANT, SGN			LONG-TERM POTENTIATION IN THE HIPPOCAMPUS IS BLOCKED BY TYROSINE KINASE INHIBITORS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SRC GENE-PRODUCT; RAT-BRAIN; PHORBOL ESTERS; PHOSPHORYLATION; RECEPTOR; SLICES; CELLS	LONG-TERM potentiation (LTP) in the hippocampus is thought to contribute to memory formation. In the Ca1 region, LTP requires the NMDA (N-methyl-D-aspartate) receptor-dependent influx of Ca2+ and activation of serine and threonine protein kinases. Because of the high amount of protein tyrosine kinases in hippocampus and cerebellum 1,2, two regions implicated in learning and memory, we examined the possible additional requirement of tyrosine kinase activity in LTP. We first examined the specificity in brain of five inhibitors of tyrosine kinase 3-5 (Table 1) and found that two of them, lavendustin A and genistein, showed substantially greater specificity for tyrosine kinase from hippocampus 6 than for three serine-threonine kinases: protein kinase A, protein kinase C, and Ca2+/calmodulin kinase II. Lavendustin A and genistein selectively blocked the induction of LTP when applied in the bath or injected into the postsynaptic cell. By contrast, the inhibitors had no effect on the established LTP, on normal synaptic transmission, or on the neurotransmitter actions attributable to the actions of protein kinase A or protein kinase C. These data suggest that tyrosine kinase activity could be required postsynaptically for long-term synaptic plasticity in the hippocampus. As Ca2+ calmodulin kinase II or protein kinase C seem also to be required 7,8, the tyrosine kinases could participate postsynaptically in a kinase network together with serine and threonine kinases.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	ODELL, TJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.			Grant, Seth/0000-0001-8732-8735				AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AURICCHIO F, 1987, METHOD ENZYMOL, V139, P731; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MALENKA RC, 1986, J NEUROSCI, V6, P475; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NICOLL RA, 1988, NEURON, V1, P7; ODELL TJ, IN PRESS P NATN ACAD; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TERLAU H, 1990, EUR J NEUROSCI, V2, P973, DOI 10.1111/j.1460-9568.1990.tb00009.x; TERLAU H, 1989, BRAIN RES, V484, P352, DOI 10.1016/0006-8993(89)90380-6; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7	29	510	523	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					558	560		10.1038/353558a0	http://dx.doi.org/10.1038/353558a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656271				2022-12-28	WOS:A1991GJ64300067
J	YAMAMOTO, LJ; TEDDER, DG; ASHLEY, R; LEVIN, MJ				YAMAMOTO, LJ; TEDDER, DG; ASHLEY, R; LEVIN, MJ			HERPES-SIMPLEX VIRUS TYPE-1 DNA IN CEREBROSPINAL-FLUID OF A PATIENT WITH MOLLARETS MENINGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							RECURRENT ASEPTIC-MENINGITIS; GENITAL HERPES; EPIDERMOID CYST; ORAL ACYCLOVIR; GENE; SUPPRESSION; SECONDARY; GANGLIONS; ETIOLOGY; SEQUENCE		ST JOSEPHS HOSP,DEPT INTERNAL MED,DENVER,CO; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT PEDIAT,PEDIAT INFECT DIS SECT,DENVER,CO 80202; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG007347] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20381] Funding Source: Medline; NIA NIH HHS [P01 AGO7347-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHARD JM, 1990, AM J MED, V89, P807, DOI 10.1016/0002-9343(90)90226-4; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARINGER JR, 1973, NEW ENGL J MED, V288, P648, DOI 10.1056/NEJM197303292881303; BECKER WJ, 1984, CAN J NEUROL SCI, V11, P387, DOI 10.1017/S0317167100045777; BERGSTROM T, 1990, J INFECT DIS, V162, P322, DOI 10.1093/infdis/162.2.322; BERGSTROM T, 1990, SCAND J INFECT DIS, V22, P239, DOI 10.3109/00365549009037909; BRUYN GW, 1962, NEUROLOGY, V12, P745, DOI 10.1212/WNL.12.11.745; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; CROSSLEY GH, 1990, AM J MED, V89, P805, DOI 10.1016/0002-9343(90)90225-3; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; GORDON YJ, 1988, J VIROL, V62, P1832, DOI 10.1128/JVI.62.5.1832-1835.1988; GRAMAN PS, 1987, ARCH NEUROL-CHICAGO, V44, P1204, DOI 10.1001/archneur.1987.00520230084023; HAYNES BF, 1976, JAMA-J AM MED ASSOC, V236, P1967, DOI 10.1001/jama.236.17.1967; HERMANS PE, 1972, AM J MED, V52, P128, DOI 10.1016/0002-9343(72)90014-9; IIVANAINEN M, 1973, ACTA NEUROL SCAND, V49, P133; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KINNMAN J, 1979, J NEUROL SCI, V43, P265, DOI 10.1016/0022-510X(79)90120-5; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MINDEL A, 1988, LANCET, V1, P926; MOLLARET P, 1944, REV NEUROL, V76, P57; NORDBRING F, 1971, Scandinavian Journal of Infectious Diseases, V3, P75; STEEL JG, 1982, ANN NEUROL, V11, P17, DOI 10.1002/ana.410110104; STOPPE G, 1987, J NEUROL, V234, P103, DOI 10.1007/BF00314112; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; SZABO M, 1983, ACTA NEUROPATHOL, V59, P115, DOI 10.1007/BF00691596; TSURUMI T, 1987, GENE, V52, P129; WARREN KG, 1978, NEW ENGL J MED, V298, P1068, DOI 10.1056/NEJM197805112981907	30	92	95	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1082	1085		10.1056/NEJM199110103251507	http://dx.doi.org/10.1056/NEJM199110103251507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1653900				2022-12-28	WOS:A1991GJ10800007
J	PELLETIER, J; BRUENING, W; LI, FP; HABER, DA; GLASER, T; HOUSMAN, DE				PELLETIER, J; BRUENING, W; LI, FP; HABER, DA; GLASER, T; HOUSMAN, DE			WT1 MUTATIONS CONTRIBUTE TO ABNORMAL GENITAL SYSTEM-DEVELOPMENT AND HEREDITARY WILMS-TUMOR	NATURE			English	Article							SEX-DETERMINING REGION; GENE; DNA; CHROMOSOME-11; DELETION	WILMS' tumour (WT), aniridia, genitourinary abnormalities and mental retardation form a symptom group (WAGR syndrome) associated with hemizygous deletions of DNA in chromosome band 11p13 (refs 1, 2). However, it has not been clear whether hemizygosity at a single locus contributes to more than one phenotype. The tumour suppressor gene for Wilms' tumour, WT1, has been characterized 3,4: it is expressed at high levels in the glomeruli of the kidney 5, as well as the gonadal ridge of the developing gonad 5, the Sertoli cells of the testis 6 and the epithelial and granulosa cells of the ovary 6, suggesting a developmental role in the genital system in addition to the kidney. We now report constitutional mutations within the WT1 genes of two individuals with a combination of WT and genital abnormalities as evidence of a role for a recessive oncogene in mammalian development.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA; NCI,DIV CANC ETIOL,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; HARVARD UNIV,BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	PELLETIER, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1989, CANCER CELLS MOL DIA, P253; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ CE, IN PRESS GENOMICS; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	16	410	414	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					431	434		10.1038/353431a0	http://dx.doi.org/10.1038/353431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1654525				2022-12-28	WOS:A1991GH60600057
J	SHARIEF, MK; HENTGES, R; CIARDI, M				SHARIEF, MK; HENTGES, R; CIARDI, M			INTRATHECAL IMMUNE-RESPONSE IN PATIENTS WITH THE POSTPOLIO SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL NERVOUS-SYSTEM; SUBACUTE SCLEROSING PANENCEPHALITIS; SOLUBLE INTERLEUKIN-2 RECEPTORS; AMYOTROPHIC LATERAL SCLEROSIS; VIRUS-SPECIFIC IGG; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; NEUROMUSCULAR SYMPTOMS; ENTEROVIRUS INFECTION; IMMUNODEFICIENT CHILD	Background. The syndrome of progressive muscular atrophy decades after acute paralytic poliomyelitis (post-polio syndrome) is not well understood. The theory that physiologic changes and aging cause the new weakness does not explain the immunologic abnormalities reported in some patients. An alternative explanation is persistent or recurrent poliovirus infection. Methods. We assessed the intrathecal antibody response to poliovirus and intrathecal production of interleukin-2 and soluble interleukin-2 receptors in 36 patients with the post-polio syndrome and 67 controls (including 13 who had had poliomyelitis but had no new symptoms and 18 with amyotrophic lateral sclerosis). Intrathecal antibody responses to measles, mumps, herpes simplex, and varicella-zoster viruses were also determined. Results. Oligoclonal IgM bands specific to poliovirus were detected in the cerebrospinal fluid of 21 of the 36 patients with the post-polio syndrome (58 percent) but in none of the control group (P < 0.0001). In quantitative studies there was evidence of increased intrathecal synthesis of IgM antibodies to poliovirus only among the patients with the post-polio syndrome; there was no increased synthesis of IgM to measles, mumps, herpes simplex, or varicella-zoster viruses. The patients with post-polio syndrome had significantly higher mean (+/- SD) cerebrospinal fluid levels of interleukin-2 and soluble interleukin-2 receptors than the controls (8.1 +/- 5.3 vs. 1.4 +/- 0.8 U per milliliter and 159.6 +/- 102.9 vs. 10.7 +/- 6.2 U per milliliter, respectively). The intrathecal synthesis of IgM antibodies to poliovirus correlated with the cerebrospinal fluid concentrations of interleukin-2 (P < 0.0005) and soluble interleukin-2 receptors (P < 0.001). Conclusions. An intrathecal immune response against poliovirus is present in many patients with the post-polio syndrome. In some of these patients the recrudescence of muscle weakness may be caused by persistent or recurrent infection of neural cells with the poliovirus.	UCL NATL HOSP NEUROL & NEUROSURG, DEPT CLIN NEUROCHEM, LONDON, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT MED MICROBIOL, LONDON, ENGLAND; FREE UNIV BRUSSELS, DEPT NEUROPSYCHIAT, B-1050 BRUSSELS, BELGIUM	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Universite Libre de Bruxelles; Vrije Universiteit Brussel				ciardi, maria rosa/0000-0002-0894-6496				BOOSS J, 1986, VIRAL ENCEPHALITIS P; BOUTIN B, 1987, ANN NEUROL, V22, P658, DOI 10.1002/ana.410220518; CHIODI F, 1986, J MED VIROL, V18, P149, DOI 10.1002/jmv.1890180207; CHIODI F, 1988, J NEUROL SCI, V87, P37, DOI 10.1016/0022-510X(88)90052-4; CORTAN RS, 1988, J IMMUNOL, V139, P1883; DALAKAS MC, 1984, REV INFECT DIS, V6, pS562; DALAKAS MC, 1986, NEW ENGL J MED, V314, P959, DOI 10.1056/NEJM198604103141505; DALAKAS MC, 1986, EUR NEUROL, V25, P381, DOI 10.1159/000116038; DALAKAS MC, 1986, ARCH NEUROL-CHICAGO, V43, P933, DOI 10.1001/archneur.1986.00520090061018; DALAKAS MC, 1988, ADV CONT NEUROLOGY, V29, P51; DALAKAS MC, 1987, RES CLIN ASPECTS LAT, P241; DALAKAS MC, 1985, LATE EFFECTS POLIOMY, P73; DAVIS LE, 1977, NEW ENGL J MED, V297, P241, DOI 10.1056/NEJM197708042970503; DEFREITAS EC, 1986, P NATL ACAD SCI USA, V83, P2637, DOI 10.1073/pnas.83.8.2637; DORRIES R, 1984, J NEUROIMMUNOL, V7, P77, DOI 10.1016/S0165-5728(84)80008-9; ENGEL WK, 1970, ARCH NEUROL-CHICAGO, V22, P97, DOI 10.1001/archneur.1970.00480200003001; FEIGIN RD, 1971, J PEDIATR-US, V79, P642, DOI 10.1016/S0022-3476(71)80313-X; FLETCHER M, 1987, LYMPHOKINE RES, V6, P45; FORSBERG P, 1986, ACTA NEUROL SCAND, V73, P372, DOI 10.1111/j.1600-0404.1986.tb03292.x; FRYDEN A, 1978, INFECT IMMUN, V21, P852, DOI 10.1128/IAI.21.3.852-861.1978; GALLO P, 1988, ANN NEUROL, V24, P795, DOI 10.1002/ana.410240618; GINSBERG AH, 1989, ARCH NEUROL-CHICAGO, V46, P497, DOI 10.1001/archneur.1989.00520410031018; GLASBERG MR, 1978, NEUROLOGY, V28, P387; GONZALEZSCARANO F, 1987, ANN NEUROL, V22, P565, DOI 10.1002/ana.410220502; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; GRIFFIN DE, 1989, NEW ENGL J MED, V320, P1667, DOI 10.1056/NEJM198906223202506; GUILLEMINAULT C, 1978, SLEEP APNEA SYNDROME, V11, P309; HAYWOOD AM, 1986, NEW ENGL J MED, V315, P939, DOI 10.1056/NEJM198610093151506; JOHNSON RT, 1981, ANN NEUROL, V9, P616, DOI 10.1002/ana.410090619; JOHNSON RT, 1984, REV INFECT DIS, V6, pS568; JOHNSON RT, 1982, VIRAL INFECTIONS NER, P61; JUBELT B, 1989, J INFECT DIS, V159, P866, DOI 10.1093/infdis/159.5.866; JUBELT B, 1980, J NEUROPATH EXP NEUR, V39, P138, DOI 10.1097/00005072-198003000-00003; KAISER R, 1989, J NEUROL, V236, P395, DOI 10.1007/BF00314897; KITTUR SD, 1990, ANN NEUROL, V28, P168, DOI 10.1002/ana.410280209; Kostulas V K, 1985, Acta Neurol Scand Suppl, V103, P1; KURENT JE, 1979, ARCH NEUROL-CHICAGO, V36, P269, DOI 10.1001/archneur.1979.00500410047006; LANE DJ, 1974, Q J MED, V43, P551; LANG JM, 1988, IMMUNOL LETT, V19, P99, DOI 10.1016/0165-2478(88)90126-5; LANGE DJ, 1989, ARCH NEUROL-CHICAGO, V46, P502, DOI 10.1001/archneur.1989.00520410036019; LIPKIN WI, 1988, TRENDS NEUROSCI, V11, P43, DOI 10.1016/0166-2236(88)90160-9; LIPTON HL, 1975, INFECT IMMUN, V11, P1147, DOI 10.1128/IAI.11.5.1147-1155.1975; LOHLER J, 1988, J NEUROIMMUNOL, V20, P181, DOI 10.1016/0165-5728(88)90159-2; MATSUMURA K, 1988, J NEUROL NEUROSUR PS, V51, P313, DOI 10.1136/jnnp.51.2.313; MILLER JR, 1981, ANN NEUROL, V9, P590, DOI 10.1002/ana.410090613; Raymond M, 1875, GAZETTE MED PARIS, V4, P225; REES RC, 1990, IMMUNOL TODAY, V11, P36; SALAZARGRUESO EF, 1989, ANN NEUROL, V26, P709, DOI 10.1002/ana.410260604; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SCHADLICH HJ, 1985, KLIN WOCHENSCHR, V63, P505, DOI 10.1007/BF01747980; SHARIEF MK, 1990, J IMMUNOL METHODS, V130, P19, DOI 10.1016/0022-1759(90)90294-6; SHARIEF MK, 1989, J NEUROIMMUNOL, V23, P149, DOI 10.1016/0165-5728(89)90034-9; SHARIEF MK, 1989, J NEUROL NEUROSUR PS, V52, P949, DOI 10.1136/jnnp.52.8.949; SHARIEF MK, 1991, ANN NEUROL, V29, P147, DOI 10.1002/ana.410290206; SHARIEF MK, 1991, BRAIN, V114, P181; SHARIEF MK, 1990, J NEUROL SCI, V96, P131, DOI 10.1016/0022-510X(90)90126-8; SHARIEF MK, 1991, J NEUROIMMUNOL, V32, P43, DOI 10.1016/0165-5728(91)90070-N; SHARIEF MK, IN PRESS NEUROLOGY; Shi Q., 1990, GEL ELECTROPHORESIS; SKOLDENBERG B, 1981, ACTA NEUROL SCAND, V63, P273; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; TOMLINSON BE, 1977, J NEUROL SCI, V34, P213, DOI 10.1016/0022-510X(77)90069-7; UKKONEN P, 1986, J CLIN MICROBIOL, V24, P954, DOI 10.1128/JCM.24.6.954-958.1986; VANDVIK B, 1982, J NEUROL, V228, P25, DOI 10.1007/BF00313407; VANDVIK B, 1976, SCAND J IMMUNOL, V5, P979, DOI 10.1111/j.1365-3083.1976.tb03050.x; WIECHERS DO, 1981, MUSCLE NERVE, V4, P524, DOI 10.1002/mus.880040610; ZUCCHELLI GC, 1989, CLIN CHEM, V35, P1155; 1875, GAZ MED PARIS, V4, P127	69	101	102	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					749	755		10.1056/NEJM199109123251101	http://dx.doi.org/10.1056/NEJM199109123251101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1651456	Bronze			2022-12-28	WOS:A1991GE45600001
J	MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K				MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K			THE ROLE OF PHOSPHORYLATION AND THE CDC28 PROTEIN-KINASE IN CELL-CYCLE REGULATED NUCLEAR IMPORT OF THE SACCHAROMYCES-CEREVISIAE TRANSCRIPTION FACTOR-SWI5	CELL			English	Article							HO GENE; C-MYB; B-MYB; YEAST; DNA; SACCHAROMYCES; BINDING; IDENTIFICATION; NUCLEOPLASMIN; TRANSLOCATION	The intracellular localization of the S. cerevisiae transcription factor SWI5 is cell cycle dependent. The protein is nuclear in G1 cells but cytoplasmic in S, G2, and M phase cells. We have identified SWI5's nuclear localization signal (NLS) and show that it can confer cell cycle-dependent nuclear entry to a heterologous protein. Located within or close to the NLS are three serine residues, mutation of which results in constitutive nuclear entry. These residues are phosphorylated in a cell cycle-dependent manner in vivo, being phosphorylated when SWI5 is in the cytoplasm and dephosphorylated when it is in the nucleus. As all three serines are phosphorylated by purified CDC28-dependent H1 kinase activity in vitro, we propose a model in which the CDC28 kinase acts directly to control nuclear entry of SWI5.			MOLL, T (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Surana, Uttam/H-1142-2011	Tebb, Graham/0000-0002-1294-2025; Surana, Uttam/0000-0002-4785-6514; Nasmyth, Kim/0000-0001-7030-4403				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HICKS JB, 1976, GENETICS, V83, P245; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1980, GENETICS, V95, P561; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Rubin G M, 1975, Methods Cell Biol, V12, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V	47	459	463	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					743	758		10.1016/0092-8674(91)90118-I	http://dx.doi.org/10.1016/0092-8674(91)90118-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652372				2022-12-28	WOS:A1991GC74500013
J	KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM				KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM			TRANSPORT OF CATIONIC AMINO-ACIDS BY THE MOUSE ECOTROPIC RETROVIRUS RECEPTOR	NATURE			English	Article							CULTURED ANIMAL-CELLS; GLUCOSE TRANSPORTER; MAMMALIAN-CELLS; RAT-LIVER; GENE; MEMBRANE; PROTEIN; SYSTEM; HISTIDINE; PROMOTER	SUSCEPTIBILITY of rodent cells to infection by ecotropic murine leukaemia viruses (MuLV) is determined by binding of the virus envelope to a membrane receptor that has multiple membrane-spanning domains 1. Cells infected by ecotropic MuLV synthesize envelope protein, gp70, which binds to this receptor, thereby preventing additional infections. The consequences of envelope-MuLV receptor binding for the infected host cell have not been directly determined, partly because the cellular function of the MuLV receptor protein is unknown. Here we report a coincidence in the positions of the first eight putative membrane-spanning domains found in the virus receptor 1 and in two related proteins 2, the arginine 2-4 and histidine 2,3,5 permeases of Saccharomyces cerevisiae (Fig. 1), but not in any other proteins identified by computer-based sequence comparison of the GenBank data base 1. Xenopus oocytes injected with receptor-encoding messenger RNA show increased uptake of L-arginine, L-lysine and L-ornithine. The transport properties and the expression pattern of the virus receptor behave in ways previously attributed to y+ (refs 6, 7), the principal transporter of cationic L-amino acids in mammalian cells.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ARONSON DL, 1981, BIOCHEMISTRY-US, V20, P7064, DOI 10.1021/bi00528a002; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CHRISTENSEN HN, 1967, J BIOL CHEM, V238, P3686; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DESJEUX JF, 1987, PEDIATR RES, V21, P477, DOI 10.1203/00006450-198705000-00011; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PARDRIDGE WM, 1975, AM J PHYSIOL, V228, P1155; ROSENBERG LE, 1962, J BIOL CHEM, V237, P2265; SAMARZIJA I, 1982, PFLUG ARCH EUR J PHY, V393, P199, DOI 10.1007/BF00584070; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VADGAMA JV, 1987, J BIOL CHEM, V262, P13273; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; WEBER E, 1988, J MOL EVOL, V27, P342; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1983, J BIOL CHEM, V258, P8028	29	492	507	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					725	728		10.1038/352725a0	http://dx.doi.org/10.1038/352725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652100				2022-12-28	WOS:A1991GC06400062
J	NATSOULIS, G; BOEKE, JD				NATSOULIS, G; BOEKE, JD			NEW ANTIVIRAL STRATEGY USING CAPSID NUCLEASE FUSION PROTEINS	NATURE			English	Article							VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; STAPHYLOCOCCAL NUCLEASE; ELEMENT TRANSPOSITION; REVERSE-TRANSCRIPTASE; TY1 TRANSPOSITION; YEAST; GENE; RIBONUCLEASE; EXPRESSION	OVEREXPRESSION of dominant-negative mutants of various viral proteins can result in 'intracellular immunization' (refs 1, 2). Here we describe a new approach to interfering with viral replication in which a nuclease is fused to a capsid component so that the nuclease is encapsidated inside the virion where it can inactivate viral nucleic acid. We used Ty1, a yeast retrotransposon whose transposition closely parallels retroviral replication mechanisms and serves as an easily manipulated model for the retroviral infection process 3. We constructed fusion genes consisting of the region encoding the N-terminal portion of the TYA/TYB open reading frames of retrotransposon Ty1 and either of two different nuclease genes. Ty1-nuclease fusion proteins are targeted to Ty1 virus-like particles, and are active in degrading nucleic acids. A Ty1-barnase fusion protein causes 98-99% reduction in the efficiency of Ty1 transposition in vivo, presumably by degrading encapsidated Ty1 RNA. This strategy, referred to as capsid-targeted viral inactivation, may be useful for interfering with the replication of retroviruses and other viruses.			NATSOULIS, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1988, MOL CELL BIOL, V8, P1432, DOI 10.1128/MCB.8.4.1432; BOEKE JD, 1989, MOBILE DNA, P335; BRIERLEY C, 1990, NUCLEIC ACIDS RES, V18, P2947, DOI 10.1093/nar/18.10.2947; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIKORSKI RS, 1989, GENETICS, V122, P19; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WELDON RA, 1990, J VIROL, V64, P4169, DOI 10.1128/JVI.64.9.4169-4179.1990; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618; YOSHIOKA K, 1990, EMBO J, V9, P535, DOI 10.1002/j.1460-2075.1990.tb08140.x; YOUNGREN SD, 1988, J MOL CELL BIOL, V8, P1421	29	62	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	635		10.1038/352632a0	http://dx.doi.org/10.1038/352632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650915				2022-12-28	WOS:A1991GB21100059
J	ROSENDAAL, FR; HEIJBOER, H; BRIET, E; BULLER, HR; BRANDJES, DPM; DEBRUIN, K; HOMMES, DW; VANDENBROUCKE, JP				ROSENDAAL, FR; HEIJBOER, H; BRIET, E; BULLER, HR; BRANDJES, DPM; DEBRUIN, K; HOMMES, DW; VANDENBROUCKE, JP			MORTALITY IN HEREDITARY ANTITHROMBIN-III DEFICIENCY - 1830 TO 1989	LANCET			English	Article								To determine whether antithrombin-III (AT-III) deficiency leads to an excess mortality, we studied 171 individuals from ten families with a proven hereditary deficiency. 73 were classified as certainly deficient either by direct measurement of AT-III concentration or by mendelian inheritance patterns. 98 individuals had a high probability (0.5) of deficiency. The 64 deaths recorded did not exceed those expected for the general population adjusted for age, sex, and calendar period. We suggest that a policy of prophylactic anticoagulation for patients with AT-III deficiency cannot be recommended.	UNIV HOSP LEIDEN,DEPT HAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CTR THROMBOSIS HAEMOSTASIS & ATHEROSCLEROSIS RES,1105 AZ AMSTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); University of Amsterdam; Academic Medical Center Amsterdam	ROSENDAAL, FR (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,BLDG 1 C0-P,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				COSGRIFF TM, 1983, MEDICINE, V62, P209, DOI 10.1097/00005792-198307000-00002; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; HALAL F, 1983, AM J MED GENET, V14, P737, DOI 10.1002/ajmg.1320140415; LEVINE MN, 1989, CHEST, V95, pS26, DOI 10.1378/chest.95.2.26S; MICHIELS JJ, 1984, NETH J MED, V27, P226; THALER E, 1981, CLIN HAEMATOL, V10, P369; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; 1983, LANCET, V1, P1021	8	71	71	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					260	262		10.1016/0140-6736(91)90867-O	http://dx.doi.org/10.1016/0140-6736(91)90867-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671110	Green Submitted			2022-12-28	WOS:A1991EV71900002
J	MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR				MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR			ANTIMICROBIAL RESISTANCE OF PNEUMOCOCCI IN CHILDREN WITH ACUTE LOWER RESPIRATORY-TRACT INFECTION IN PAKISTAN	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; CO-TRIMOXAZOLE; DEVELOPING-COUNTRIES; NEW-GUINEA; ETIOLOGY; VACCINE; PENICILLIN; SEROTYPES	87 strains of Streptococcus pneumoniae isolated during three winter seasons (1986-89) from the blood of children with acute lower respiratory tract infection (ALRI) in Pakistan were serotyped and tested for susceptibility to a range of antimicrobial agents. 97% of isolates were resistant to at least one antimicrobial drug. 62% had decreased susceptibility to co-trimoxazole (trimethoprim/sulphamethoxazole) (31% were fully resistant) and 39% were resistant to chloramphenicol. All isolates were susceptible to erythromycin, cefaclor, cephalothin, ceftriaxone, cefuroxime, rifampicin, vancomycin, and clindamycin. 29% of isolates were neither vaccine types nor vaccine-related types. Serotype distribution and antimicrobial susceptibility varied significantly during the three winter seasons. No single serotype was found in all three winters. The findings highlight the need for surveillance of antimicrobial resistance and serotype distribution of S pneumoniae in developing countries as a guide both to the choice of agent for treatment of pneumococcal infections, especially ALRI, and to the formulation of new pneumococcal conjugate vaccines for use in young children.	NATL INST HLTH,ISLAMABAD,PAKISTAN; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110; CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,ANTIMICROB INVEST BRANCH,ATLANTA,GA 30333	Washington University (WUSTL); Centers for Disease Control & Prevention - USA	MASTRO, TD (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV BACTERIAL DIS,RESP DIS BRANCH,MAILSTOP C-09,ATLANTA,GA 30333, USA.		Anwar, Farooq/K-8137-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024332] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAMPBELL H, 1988, LANCET, V2, P1182; CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; ELMOUZAN MI, 1988, TROP GEOGR MED, V40, P213; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GREENWOOD BM, 1970, LANCET, V1, P360; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LINARES J, 1983, EUR J CLIN MICROBIOL, V2, P473, DOI 10.1007/BF02013907; LINARES J, 1984, J ANTIMICROB CHEMOTH, V13, P353, DOI 10.1093/jac/13.4.353; MONTO AS, 1989, REV INFECT DIS, V11, P498; ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8; OTIN CL, 1988, J ANTIMICROB CHEMOTH, V22, P659, DOI 10.1093/jac/22.5.659; PALLARES R, 1988, NEW ENGL J MED, V318, P124; RILEY ID, 1981, ARCH DIS CHILD, V56, P354, DOI 10.1136/adc.56.5.354; RILEY ID, 1986, LANCET, V2, P877; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, LANCET, V2, P537; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WARD J, 1981, REV INFECT DIS, V3, P254; WEINBERG GA, 1990, B WORLD HEALTH ORGAN, V68, P179; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; 1986, WHORSD85; 1986, B WORLD HEALTH ORGAN, V64, P929; 1988, WHOARI893; 1985, LANCET, V2, P699; 1988, LANCET, V1, P1142; 1986, WHORSD8626; 1988, METHODS DILUTION ANT	34	110	110	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					156	159		10.1016/0140-6736(91)90813-5	http://dx.doi.org/10.1016/0140-6736(91)90813-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670799				2022-12-28	WOS:A1991ET67900015
J	SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW				SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW			ABNORMALITIES OF THE LEFT TEMPORAL-LOBE AND THOUGHT-DISORDER IN SCHIZOPHRENIA - A QUANTITATIVE MAGNETIC-RESONANCE-IMAGING STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTORHINAL CORTEX; PARAHIPPOCAMPAL GYRUS; CEREBRAL ASYMMETRY; VENTRICULAR VOLUME; PLANUM TEMPORALE; MR IMAGES; BRAIN; MONKEY; SYMPTOMS; SYSTEM	Background. Data from postmortem, CT, and magnetic resonance imaging (MRI) studies indicate that patients with schizophrenia may have anatomical abnormalities of the left temporal lobe, but it is unclear whether these abnormalities are related to the thought disorder characteristic of schizophrenia. Methods. We used new MRI neuroimaging techniques to derive (without knowledge of the diagnosis) volume measurements and three-dimensional reconstructions of temporal-lobe structures in vivo in 15 right-handed men with chronic schizophrenia and 15 matched controls. Results. As compared with the controls, the patients had significant reductions in the volume of gray matter in the left anterior hippocampus-amygdala (by 19 percent [95 percent confidence interval, 3 to 36 percent]), the left parahippocampal gyrus (by 13 percent [95 percent confidence interval, 3 to 23 percent], vs. 8 percent on the right), and the left superior temporal gyrus (by 15 percent [95 percent confidence interval, 5 to 25 percent]). The volume of the left posterior superior temporal gyrus correlated with the score on the thought-disorder index in the 13 patients evaluated (r = -0.81, P = 0.001). None of these regional volume decreases were accompanied by a decrease in the volume of the overall brain or temporal lobe. The volume of gray matter in a control region (the superior frontal gyrus) was essentially the same in the patients and controls. Conclusions. Schizophrenia involves localized reductions in the gray matter of the left temporal lobe. The degree of thought disorder is related to the size of the reduction in volume of the left posterior superior temporal gyrus.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; BROCKTON VET AFFAIRS MED CTR,BROCKTON,MA; BRIGHAM & WOMENS HOSP,MAGNET RESONANCE IMAGING CTR,BOSTON,MA 02115; MASSACHUSETTS MENTAL HLTH CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Shenton, Martha/V-8780-2019; Pollak, Seth D/G-2345-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH000746, R01MH040799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001083] Funding Source: NIH RePORTER; NIMH NIH HHS [K01-MH-00746-04, R01 MH040799] Funding Source: Medline; NINDS NIH HHS [K04-NS-01083] Funding Source: Medline; PHS HHS [40,799] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARAL DG, 1983, BRAIN RES, V275, P263, DOI 10.1016/0006-8993(83)90987-3; Andreasen N., 1984, SCALE ASSESSMENT POS; Andreasen N.C, 1981, SCALE ASSESSMENT NEG; ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BLEULER E, 1950, MONOGRAPH SERIES SCH, V1; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOGERTS B, 1984, FORTSCHR NEUROL PSYC, V52, P428, DOI 10.1055/s-2007-1002212; Boyd E, 1962, BIOL HDB, P346; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLINE HE, 1987, MAGN RESON IMAGING, V5, P345, DOI 10.1016/0730-725X(87)90124-X; CLINE HE, 1991, J COMPUT ASSIST TOMO, V15, P344, DOI 10.1097/00004728-199103000-00035; CLINE HE, 1988, MED PHYS, V15, P320, DOI 10.1118/1.596225; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; COLTER N, 1987, ARCH GEN PSYCHIAT, V44, P1023; CROW TJ, 1990, BRIT J PSYCHIAT, V156, P788, DOI 10.1192/bjp.156.6.788; CROW TJ, 1990, SCHIZOPHRENIA BULL, V16, P433, DOI 10.1093/schbul/16.3.433; CROW TJ, 1989, ARCH GEN PSYCHIAT, V46, P1145; Daniels DL, 1987, CRANIAL SPINAL MAGNE; DEGREEF G, 1991, INT C SCHIZOPHRENIA; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, BIOL PSYCHIAT, V25, P835, DOI 10.1016/0006-3223(89)90263-1; DELISI LE, 1991, BIOL PSYCHIAT, V29, P519; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FALKAI P, 1988, BIOL PSYCHIAT, V24, P515, DOI 10.1016/0006-3223(88)90162-X; FAUX SF, 1990, ELECTROEN CLIN NEURO, V75, P378, DOI 10.1016/0013-4694(90)90083-V; FILIPEK PA, 1989, ANN NEUROL, V25, P61, DOI 10.1002/ana.410250110; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GALABURDA AM, 1984, CEREBRAL DOMINANCE B, P11; GERIG G, 1990, BIWIITR124 ETH EIDG; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; Holzman, 1979, ASSESSING SCHIZOPHRE; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; JOHNSTONE EC, 1989, J NEUROL NEUROSUR PS, V52, P736, DOI 10.1136/jnnp.52.6.736; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KIKINIS R, 1990, NATO ADV SCI I F-COM, V60, P441; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; MCCARLEY RW, 1991, SCHIZOPHR RES, V4, P209, DOI 10.1016/0920-9964(91)90034-O; MCCARLEY RW, 1989, ARCH GEN PSYCHIAT, V46, P698; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OJEMANN GA, 1988, BRAIN, V111, P1383, DOI 10.1093/brain/111.6.1383; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PERONA P, 1987, 1987 P IEEE WORKSH C, P16; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; POSNER MI, 1988, ARCH GEN PSYCHIAT, V45, P814; Rosene D. L., 1987, CEREB CORTEX, V6, P345, DOI DOI 10.1007/978-1-4615-6616-8_9; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; SANGHERA MK, 1979, EXP NEUROL, V63, P610, DOI 10.1016/0014-4886(79)90175-4; SAUNDERS RC, 1988, J COMP NEUROL, V271, P185, DOI 10.1002/cne.902710203; SCHWARZKOPF SB, 1991, SCHIZOPHR RES, V4, P412, DOI 10.1016/0920-9964(91)90367-Z; SHELTON RC, 1986, HDB SCHIZOPHRENIA, V1, P207; SHENTON ME, 1989, BIOL PSYCHIAT, V25, P710, DOI 10.1016/0006-3223(89)90242-4; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SHENTON ME, 1987, ARCH GEN PSYCHIAT, V44, P21; SHENTON ME, 1990, 145TH AM PSYCH ASS A; SOLOVAY MR, 1986, SCHIZOPHRENIA BULL, V12, P483; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WEINBERGER DR, 1986, HDB SCHIZOPHRENIA, V1, P397; Wernicke C., 1874, APHASISCHE SYMPTOMEN; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P628, DOI 10.1111/j.1600-0447.1987.tb02933.x; WITTER MP, 1991, J COMP NEUROL, V307, P437, DOI 10.1002/cne.903070308; WYPER DJ, 1979, J NEUROL NEUROSUR PS, V42, P345, DOI 10.1136/jnnp.42.4.345; YOUNG AH, 1991, BRIT J PSYCHIAT, V158, P158, DOI 10.1192/bjp.158.2.158; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	78	1002	1010	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					604	612		10.1056/NEJM199208273270905	http://dx.doi.org/10.1056/NEJM199208273270905			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK204	1640954	Green Published			2022-12-28	WOS:A1992JK20400005
J	NICHOLAS, R; OMEARA, PD; CALONGE, N				NICHOLAS, R; OMEARA, PD; CALONGE, N			IS SYNCOPE RELATED TO MODERATE ALTITUDE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BLOOD-PRESSURE; CIRCULATORY ADJUSTMENTS; DIAGNOSTIC EVALUATION; FOLLOW-UP; HYPOXIA	Study Objective.-To investigate factors related to syncope occurring on recent ascent to moderate altitude. Design.-A 1-year retrospective case-control study, using local acclimatized residents as a control group. Setting.-The two main ambulance destinations for Summit County, Colorado (elevation, 2770 m). Patients.-All patients with a diagnosis of syncope, near-syncope, or fainting whose medical records were available for review. Results.-There was a significant relationship (P<.05) between syncope of unknown origin and recent arrival at altitude (<24 hours), and a significant inverse relationship (P<.05) between syncope of unknown origin and arterial oxygen saturation as measured by pulse oximetry. Conclusions.-Short-term exposure to moderate altitude may be related to otherwise unexplained syncope in healthy young adults. We suggest the name high-altitude syncope for this entity and encourage further research in this area.	UNIV COLORADO,HLTH SCI CTR,DEPT FAMILY MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,AF WILLIAMS FAMILY MED RESIDENCY,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NICHOLAS, R (corresponding author), SNAKE RIVER HLTH SERV,COLORADO ALTITUDE RES INST,POB 38,KEYSTONE,CO 80435, USA.							ABBOUD FM, 1989, NEW ENGL J MED, V320, P390, DOI 10.1056/NEJM198902093200609; APPLETON F, 1967, CIRCULATION S, V36, P55; BRINCHMANNHANSEN O, 1989, AVIAT SPACE ENVIR MD, V60, P970; CLEGG EJ, 1970, P R SOC LOND, V194, P83; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DOHERTY JU, 1985, AM J CARDIOL, V55, P703, DOI 10.1016/0002-9149(85)90140-7; HEISTAD DD, 1980, CIRCULATION, V61, P463, DOI 10.1161/01.CIR.61.3.463; HOUSTON CS, 1980, GOING HIGHER; KAPOOR W, 1984, ANN INTERN MED, V100, P755, DOI 10.7326/0003-4819-100-5-755; KAPOOR W, 1986, AM J MED, V80, P419, DOI 10.1016/0002-9343(86)90716-3; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARTICOR.E, 1969, AM J CARDIOL, V23, P364, DOI 10.1016/0002-9149(69)90516-5; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; PALATINI P, 1989, AM J CARDIOL, V64, P1379, DOI 10.1016/0002-9149(89)90587-0; PIERCE EC, 1962, J APPL PHYSIOL, V17, P899, DOI 10.1152/jappl.1962.17.6.899; STULTS BM, 1986, WESTERN J MED, V144, P234; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; WEITZ CA, 1982, SOC SCI MED, V16, P223, DOI 10.1016/0277-9536(82)90026-0; 1988, SUMMIT COUNTY STATIS	20	35	36	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					904	906		10.1001/jama.268.7.904	http://dx.doi.org/10.1001/jama.268.7.904			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640621				2022-12-28	WOS:A1992JH58800043
J	BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB				BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB			NEW PHANTOM DINOFLAGELLATE IS THE CAUSATIVE AGENT OF MAJOR ESTUARINE FISH KILLS	NATURE			English	Article							TOXINS	A WORLDWIDE increase in toxic phytoplankton blooms over the past 20 years1,2 has coincided with increasing reports of fish diseases and deaths of unknown cause3. Among estuaries that have been repeatedly associated with unexplained fish kills on the western Atlantic Coast are the Pamlico and Neuse Estuaries of the southeastern United States4. Here we describe a new toxic dinoflagellate with 'phantom-like' behaviour that has been identified as the causative agent of a significant portion of the fish kills in these estuaries, and which may also be active in other geographic regions. The alga requires live finfish or their fresh excreta for excystment and release of a potent toxin. Low cell densities cause neurotoxic signs and fish death, followed by rapid algal encystment and dormancy unless live fish are added. This dinoflagellate was abundant in the water during major fish kills in local estuaries, but only while fish were dying; within several hours of death where carcasses were still present, the flagellated vegetative algal population had encysted and settled back to the sediments. Isolates from each event were highly lethal to finfish and shellfish in laboratory bioassays. Given its broad temperature and salinity tolerance, and its stimulation by phosphate enrichment, this toxic phytoplankter may be a widespread but undetected source of fish mortality in nutrient-enriched estuaries.	N CAROLINA STATE UNIV,DEPT COMPAN ANIM & SPECIAL SPECIES MED,RALEIGH,NC 27606	University of North Carolina; North Carolina State University	BURKHOLDER, JM (corresponding author), N CAROLINA STATE UNIV,DEPT BOT,BOX 7612,RALEIGH,NC 27695, USA.							Gaines G, 1987, BIOL DINOFLAGELLATES; HALLEGRAEFF GM, 1988, J PLANKTON RES, V10, P533, DOI 10.1093/plankt/10.3.533; LAGLER KF, 1962, ICHTHYOLOGY, P268; MILLER KH, 1990, PAMLICO ENV RESPONSE; PALENIK B, 1988, Biological Oceanography, V6, P347; ROBERTS RJ, 1983, J MAR BIOL ASSOC UK, V63, P741, DOI 10.1017/S0025315400071186; ROBINEAU B, 1991, MAR BIOL, V108, P293, DOI 10.1007/BF01344344; RUDEK J, 1991, MAR ECOL PROG SER, V75, P133, DOI 10.3354/meps075133; RYTHER JH, 1954, ECOLOGY, V35, P522, DOI 10.2307/1931041; SHUMWAY S E, 1990, Journal of the World Aquaculture Society, V21, P65, DOI 10.1111/j.1749-7345.1990.tb00529.x; SMAYDA TJ, 1989, NOVEL PHYTOPLANKTON, P449; SMITH SA, 1988, 3RD P INT C PATH MAR, P167; Sokal R. R, 1981, BIOMETRY; SPERO HJ, 1982, J PHYCOL, V18, P357; STANLEY DH, 1988, S COASTAL WATER RESO, P155; Taylor FJR, 1987, BIOL DINOFLAGELLATES, P24; THORP JH, 1991, ECOLOGY CLASSIFICATI, P77; WHITE AW, 1981, MAR BIOL, V65, P255, DOI 10.1007/BF00397119; WHITE AW, 1988, 1987 P INT C IMP TOX, P9; 1987, 1986 N CAR DEP ENV H; 1990, 1990 N CAR DEP ENV H; 1988, 1987 N CAR DEP ENV H; 1989, 1988 N CAR DEP ENV H	23	290	300	1	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					407	410		10.1038/358407a0	http://dx.doi.org/10.1038/358407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641022				2022-12-28	WOS:A1992JF85300053
J	KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR				KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR			RETINOBLASTOMA GENE-PRODUCT ACTIVATES EXPRESSION OF THE HUMAN TGF-BETA-2 GENE THROUGH TRANSCRIPTION FACTOR ATF-2	NATURE			English	Article							PROTEIN; BINDING; GROWTH; FAMILY; BETA	THE retinoblastoma susceptibility gene product (pRb) plays an important role in constraining cellular proliferation and in regulating the cell cycle1,2. The pRb inhibits transcription of genes involved in growth control (reviewed in ref. 3) and can regulate transforming growth factor beta-1 (TGF-beta-1) gene expression4,5. TGF-beta isoforms also down-regulate cellular proliferation6,7. To determine whether pRb also regulates expression of other TGF-beta isoforms, we examined the effect of pRb on the expression of the human TGF-beta-2 gene. The human TGF-beta-2 promoter contains multiple elements including an ATF site, which is essential for basal promoter activity8. Here we report that pRb activates transcription of the human TGF-beta-2 gene. The promoter element responsible for pRb-mediated transcriptional regulation is a binding site for ATF proteins, an extensive transcription factor family9. We provide evidence that implicates ATF-2 in pRb-responsiveness. First, the ATF promoter element in the TGF-beta-2 gene is a high-affinity ATF-2-binding site. Second, a GAL4-ATF2 fusion protein can support pRb-mediated transcriptional activation of a promoter containing GAL4-binding sites. Third, ATF-2 in nuclear extracts can interact with pRb. Our results reveal a new mechanism by which pRb constrains cellular proliferation: by activating ex ression of the inhibitory growth factor, TGF-beta-2.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0	22	253	257	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					331	334		10.1038/358331a0	http://dx.doi.org/10.1038/358331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641004				2022-12-28	WOS:A1992JE68400064
J	RADFORD, SE; DOBSON, CM; EVANS, PA				RADFORD, SE; DOBSON, CM; EVANS, PA			THE FOLDING OF HEN LYSOZYME INVOLVES PARTIALLY STRUCTURED INTERMEDIATES AND MULTIPLE PATHWAYS	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; EGG-WHITE LYSOZYME; RIBONUCLEASE-A; ALPHA-LACTALBUMIN; CIRCULAR-DICHROISM; PROTEIN; NMR; EXCHANGE; KINETICS	Analysis of the folding of hen lysozyme shows that the protein does not become organized in a single cooperative event but that different parts of the structure become stabilized with very different kinetics. In particular, in most molecules the alpha-helical domain folds faster than the beta-sheet domain. Furthermore, different populations of molecules fold by kinetically distinct pathways. Thus, folding is not a simple sequential assembly process but involves parallel alternative pathways, some of which may involve substantial reorganization steps.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Oxford; University of Cambridge; University of Cambridge	RADFORD, SE (corresponding author), UNIV OXFORD,OXFORD CTR MOLEC SCI,S PARKS RD,OXFORD OX1 3QR,ENGLAND.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ELOVE GA, 1991, ACS SYM SER, V470, P50; ELOVE GA, IN PRESS BIOCHEMISTR; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GOUX WJ, 1980, BIOPOLYMERS, V19, P2191, DOI 10.1002/bip.1980.360191205; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JONG MF, 1990, BIOCHEMISTRY-US, V29, P10433; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; KLEMM JD, 1991, BIOCHEMISTRY-US, V30, P589, DOI 10.1021/bi00216a038; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PEDERSEN TG, 1991, J MOL BIOL, V218, P413, DOI 10.1016/0022-2836(91)90722-I; RADFORD SE, IN PRESS PROTEINS ST; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEDIN RE, 1982, BIOCHEMISTRY-US, V21, P1098, DOI 10.1021/bi00534a042; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; [No title captured]	45	747	751	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					302	307		10.1038/358302a0	http://dx.doi.org/10.1038/358302a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641003				2022-12-28	WOS:A1992JE68400055
J	CLACK, GB; BEVAN, G; PETERS, TJ; EDDLESTON, ALWF				CLACK, GB; BEVAN, G; PETERS, TJ; EDDLESTON, ALWF			KINGS MODEL FOR ALLOCATING SERVICE INCREMENT FOR TEACHING AND RESEARCH (SIFTR)	BRITISH MEDICAL JOURNAL			English	Article											CLACK, GB (corresponding author), KINGS COLL SCH MED & DENT,FAC CLIN MED,LONDON SE5 9PJ,ENGLAND.							PERRIN J, 1987, FINANCIAL ACCOUNTABI, V3, P209; 1990, 2ND REP STEER GROUP; 1991, ALLOCATING MED SIFTR; 1991, UNIVERSITY STRATEGY; 1991, HLTH DATABASE 1991	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					95	96		10.1136/bmj.305.6845.95	http://dx.doi.org/10.1136/bmj.305.6845.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638254	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JD85000027
J	HAWTHORNE, AB; LOGAN, RFA; HAWKEY, CJ; FOSTER, PN; AXON, ATR; SWARBRICK, ET; SCOTT, BB; LENNARDJONES, JE				HAWTHORNE, AB; LOGAN, RFA; HAWKEY, CJ; FOSTER, PN; AXON, ATR; SWARBRICK, ET; SCOTT, BB; LENNARDJONES, JE			RANDOMIZED CONTROLLED TRIAL OF AZATHIOPRINE WITHDRAWAL IN ULCERATIVE-COLITIS	BRITISH MEDICAL JOURNAL			English	Article							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; 6-MERCAPTOPURINE; EFFICACY	Objective-To determine whether azathioprine can prevent relapse in ulcerative colitis. Design-One year placebo controlled double blind trial of withdrawal or continuation of azathioprine. Setting-Outpatient clinics of five hospitals. Subjects-79-patients with ulcerative colitis who had been taking azathioprine for six months or more. Patients in full remission for two months or more (67), and patients with chronic low grade or corticosteroid dependent disease (12) were randomised separately. 33 patients in remission received azathioprine and 34 placebo; five patients with chronic stable disease received azathioprine and seven placebo. Main outcome measure-Rate of relapse. Relapse was defined as worsening of symptoms or sigmoidoscopic appearance. Results-For the remission group the one year rate of relapse was 36% (12/33) for patients continuing azathioprine and 590/o (20/34) for those taking placebo (hazard rate ratio 0,5, 95% confidence interval 0.25 to 1.0). For the subgroup of 54 patients in long term remission (greater than six months before entry to trial) benefit was still evident, with a 31% (8/26) rate of relapse with azathioprine and 61% (17/28) with placebo (p<0.01). For the small group of patients with chronic stable colitis (six were corticosteroid dependent and six had low grade symptoms) no benefit was found from continued azathioprine therapy. Adverse events were minimal. Conclusions-Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug. Demonstration of the relapse preventing properties of azathioprine has implications for a large number of patients with troublesome ulcerative colitis, who may benefit from treatment with azathioprine.	UNIV NOTTINGHAM HOSP,DEPT THERAPEUT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND; GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; NEW CROSS HOSP,WOLVERHAMPTON WV10 0QP,ENGLAND; LINCOLN CTY HOSP,LINCOLN,ENGLAND; ST MARKS HOSP,GASTROENTEROL,LONDON EC1V,ENGLAND	University of Nottingham; Leeds General Infirmary; New Cross Hospital								ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BEAN RHD, 1962, MED J AUSTRALIA, V2, P592, DOI 10.5694/j.1326-5377.1962.tb20590.x; COX JA, 1989, GUT, V29, P686; HAWTHORNE A B, 1989, Gastroenterology, V96, pA201; HAWTHORNE AB, 1989, DRUGS, V38, P267, DOI 10.2165/00003495-198938020-00007; JEWELL DP, 1974, BMJ-BRIT MED J, V4, P627, DOI 10.1136/bmj.4.5945.627; KIRK AP, 1982, BRIT MED J, V284, P1291, DOI 10.1136/bmj.284.6325.1291; LOBO AJ, 1990, DIS COLON RECTUM, V33, P182; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; ODONOGHUE DP, 1978, LANCET, V2, P955, DOI 10.1016/S0140-6736(78)92524-2; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; ROSENBERG JL, 1975, AM J DIG DIS, V20, P721, DOI 10.1007/BF01070829; ROSENBERG JL, 1975, GASTROENTEROLOGY, V69, P96; VERHAVE M, 1990, J PEDIATR-US, V117, P809, DOI 10.1016/S0022-3476(05)83349-9; WILLOUGHBY JM, 1971, LANCET, V2, P944; WILLOUGHBY JMT, 1990, GUT, V31, pA1193	17	388	402	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					20	22		10.1136/bmj.305.6844.20	http://dx.doi.org/10.1136/bmj.305.6844.20			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638191	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JC79900022
J	MAHOWALD, M; DOUGLAS, R				MAHOWALD, M; DOUGLAS, R			A SILICON NEURON	NATURE			English	Article								BY combining neurophysiological principles with silicon engineering, we have produced an analog integrated circuit with the functional characteristics of real nerve cells. Because the physics underlying the conductivity of silicon devices and biological membranes is similar, the 'silicon neuron' is able to emulate efficiently the ion currents that cause nerve impulses and control the dynamics of their discharge. It operates in real-time and consumes little power, and many 'neurons' can be fabricated on a single silicon chip. The silicon neuron represents a step towards constructing artificial nervous systems that use more realistic principles of neural computation than do existing electronic neural networks.	UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; CALTECH,COMPUTAT & NEURAL SYST LAB,PASADENA,CA 91125; UNIV CAPE TOWN,DEPT PHYSIOL,CAPE TOWN 7925,SOUTH AFRICA	University of Oxford; California Institute of Technology; University of Cape Town								HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hopfield JJ, 1990, NETWORK-COMP NEURAL, V1, P27, DOI 10.1088/0954-898X/1/1/003; LINARES-BARRANCO B, 1991, IEEE J SOLID-ST CIRC, V26, P956, DOI 10.1109/4.92015; MAHOWALD MA, 1991, SCI AM, V264, P76, DOI 10.1038/scientificamerican0591-76; MCCORMICK DA, 1990, SYNAPTIC ORG BRAIN, P220; Mead C.A., 1989, ANALOG VLSI NEURAL S; MURRAY AF, 1987, ELECTRON LETT, V23, P642, DOI 10.1049/el:19870459	7	294	300	3	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					515	518		10.1038/354515a0	http://dx.doi.org/10.1038/354515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1661852				2022-12-28	WOS:A1991GW75100011
J	PALESTINE, AG; POLIS, MA; DESMET, MD; BAIRD, BF; FALLOON, J; KOVACS, JA; DAVEY, RT; ZURLO, JJ; ZUNICH, KM; DAVIS, M; HUBBARD, L; BROTHERS, R; FERRIS, FL; CHEW, E; DAVIS, JL; RUBIN, BI; MELLOW, SD; METCALF, JA; MANISCHEWITZ, J; MINOR, JR; NUSSENBLATT, RB; MASUR, H; LANE, HC				PALESTINE, AG; POLIS, MA; DESMET, MD; BAIRD, BF; FALLOON, J; KOVACS, JA; DAVEY, RT; ZURLO, JJ; ZUNICH, KM; DAVIS, M; HUBBARD, L; BROTHERS, R; FERRIS, FL; CHEW, E; DAVIS, JL; RUBIN, BI; MELLOW, SD; METCALF, JA; MANISCHEWITZ, J; MINOR, JR; NUSSENBLATT, RB; MASUR, H; LANE, HC			A RANDOMIZED, CONTROLLED TRIAL OF FOSCARNET IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; VIRUS RETINITIS; PHOSPHONOFORMATE FOSCARNET; REPLICATION INVITRO; GANCICLOVIR; DISEASE; INHIBITION; INFECTIONS; ZIDOVUDINE	Objective: To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS. Patients: Twenty-four previously untreated persons with AIDS and cytomegalovirus retinitis who were at low risk for loss of their visual acuity. Intervention: Patients were randomly assigned to receive either no therapy (delayed treatment, control group) or immediate treatment with intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks (induction regimen) followed by a maintenance regimen of 90 mg/kg once a day. Measurements: Patients were examined weekly until they reached the primary clinical end point, defined as progression of their retinitis border by 750-mu-m or the development of a new retinal lesion due to cytomegalovirus. Progression was evaluated using retinal photographs by masked readers. Secondary evaluations included changes in visual acuity, cytomegalovirus shedding in the blood and urine, serum levels of human immunodeficiency virus type 1 (HIV-1) p24 antigen, and total CD4 T lymphocyte counts. Results: The mean time to progression of retinitis was 3.2 weeks in the control group (n = 11) compared with 13.3 weeks in the treatment group (n = 13) (P < 0.001). Nine of 13 patients in the treatment group had positive blood cultures for cytomegalovirus at entry and all nine cleared their blood of cytomegalovirus by the end of the induction period (P = 0.004) compared with one of six patients in the control group. No reductions in p24 levels were seen in the control patients compared with a reduction of more than 50% in p24 levels for all four patients on treatment for whom follow-up levels were available. The main adverse effects of foscarnet treatment were seizures (2 of 13 patients), hypomagnesemia (9 of 13), hypocalcemia (11 of 13), and elevations in serum creatinine above 176.8-mu-mol/L (2.0 mg/dL) (3 of 13). The control patients received an average of 0.2 units of blood per week compared with an average of 0.6 units of blood per week for the patients on treatment. Conclusions: The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS. Its judicious use is likely to prevent loss of vision in these patients. In this study, however, there was little change in visual acuity in patients in either the immediate or delayed treatment group because only patients with non-sight-threatening disease were selected.	NIAID, BLDG 10, ROOM 11B-13, BETHESDA, MD 20892 USA; US FDA, BETHESDA, MD 20014 USA; UNIV WISCONSIN, MADISON, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA); University of Wisconsin System; University of Wisconsin Madison			De Smet, Marc D./E-2451-2013; Kovacs, Joseph/AAU-6105-2021; Davis, Janet L/GPC-8037-2022	De Smet, Marc D./0000-0002-9217-5603; Kovacs, Joseph/0000-0002-5191-9880; Davis, Janet L/0000-0001-6395-5881; Polis, Michael/0000-0002-9151-2268				BACH MC, 1985, ANN INTERN MED, V103, P381, DOI 10.7326/0003-4819-103-3-381; BERGDAHL S, 1988, LANCET, V1, P1052; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; DERAY G, 1989, AM J NEPHROL, V9, P316, DOI 10.1159/000167987; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; FANNING MM, 1990, J ACQ IMMUN DEF SYND, V3, P472; FARTHING CF, 1987, AIDS, V1, P21; FELSENSTEIN D, 1985, ANN INTERN MED, V103, P377, DOI 10.7326/0003-4819-103-3-377; FREITAS VR, 1989, ANTIVIR RES, V12, P205, DOI 10.1016/0166-3542(89)90030-2; GAUB J, 1987, AIDS, V1, P27; GROSSBERG HS, 1989, NEW ENGL J MED, V320, P1560; GUARDA LA, 1984, AM J CLIN PATHOL, V81, P549, DOI 10.1093/ajcp/81.5.549; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1988, J INFECT DIS, V158, P862, DOI 10.1093/infdis/158.4.859; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KORETZ SH, 1986, NEW ENGL J MED, V314, P801, DOI 10.1056/NEJM198603273141301; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LEHOANG P, 1989, OPHTHALMOLOGY, V96, P865; MANISCHEWITZ JF, 1990, ANTIMICROB AGENTS CH, V34, P373, DOI 10.1128/AAC.34.2.373; MASUR H, 1986, ANN INTERN MED, V104, P41, DOI 10.7326/0003-4819-104-1-41; MOSKOWITZ L, 1985, ARCH PATHOL LAB MED, V109, P735; OBERG B, 1982, PHARMACOL THERAPEUT, V19, P387, DOI 10.1016/0163-7258(82)90074-2; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; SANDSTROM EG, 1985, LANCET, V1, P1480; SARIN PS, 1985, BIOCHEM PHARMACOL, V34, P4075, DOI 10.1016/0006-2952(85)90392-2; WAHREN B, 1980, INTERVIROLOGY, V14, P7, DOI 10.1159/000149156; WALMSLEY SL, 1988, J INFECT DIS, V157, P569, DOI 10.1093/infdis/157.3.569	31	281	286	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					665	673		10.7326/0003-4819-115-9-665	http://dx.doi.org/10.7326/0003-4819-115-9-665			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1656826				2022-12-28	WOS:A1991GL69700001
J	JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES				JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES			GENETIC-MAPPING OF A GENE CAUSING HYPERTENSION IN THE STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT	CELL			English	Article							ANGIOTENSIN-CONVERTING ENZYME; FRAGMENT LENGTH POLYMORPHISMS; QUANTITATIVE-TRAIT LOCI; BLOOD-PRESSURE; GROWTH-HORMONE; MENDELIAN FACTORS; LINKAGE MAP; DNA; IDENTIFICATION; CHROMOSOME-17	The stroke-prone spontaneously hypertensive rat (SHRSP) is a well-characterized model for primary hypertension in humans. High blood pressure in SHRSP shows polygenic inheritance, but none of the loci responsible have previously been identified. To locate genes controlling this quantitative trait, we mapped a large collection of DNA polymorphisms in a cross between SHRSP and the normotensive WKY strain. Here we report strong genetic evidence that a gene, Bp1, having a major effect on blood pressure maps to rat chromosome 10 with a LOD score of 5.10 and is closely linked to the rat gene encoding angiotensin-converting enzyme (ACE), an enzyme that plays a major role in blood pressure homeostasis and is an important target of anti-hypertensive drugs. We also find significant, albeit weaker, linkage to a locus, Bp2, on chromosome 18. We discuss the implications of genetic dissection of quantitative disease-related phenotypes in mammals.	UNIV HEIDELBERG, GERMAN INST HIGH BLOOD PRESSURE RES, W-6900 HEIDELBERG, GERMANY; CTR MOLEC MED, BERLIN, GERMANY; STANFORD UNIV, MED CTR, DIV CARDIOL, STANFORD, CA 94305 USA; UNIV HEIDELBERG, DEPT PHARMACOL, W-6900 HEIDELBERG, GERMANY; HARVARD UNIV, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, DIV CARDIOL, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Ruprecht Karls University Heidelberg; Stanford University; Ruprecht Karls University Heidelberg; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	JACOB, HJ (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012	Kusumi, Kenro/0000-0002-1458-4540	NHGRI NIH HHS [HG00198] Funding Source: Medline; NHLBI NIH HHS [HL35610, HL42663] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R01HL042663, R37HL035610] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R37HG000198, R01HG000198] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BIANCH G, 1990, HYPERTENSION PATHOPH, pCH78; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; Dollery CT., 1985, CECIL TXB MED, V17th, P266; DZAU VJ, 1988, CIRCULATION, V77, P4; East EM, 1916, GENETICS, V1, P164; EDWARDS MD, 1987, GENETICS, V116, P113; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; HABER E, 1986, SCI AM MED CARDIOLOG; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER ME, 1982, AM J HUM GENET, V34, P227; HAVLIK RJ, 1979, AM J EPIDEMIOL, V110, P304, DOI 10.1093/oxfordjournals.aje.a112815; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LEVAN G, 1990, GENETIC MAPS LOCUS M; LEVINE RS, 1982, AM J EPIDEMIOL, V116, P759, DOI 10.1093/oxfordjournals.aje.a113465; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; MUELLER SM, 1985, ARTERY, V12, P337; NAKATA K, 1987, J CARDIOVASC PHARM, V9, P305, DOI 10.1097/00005344-198703000-00007; NEUMANN PE, 1991, P NATL ACAD SCI USA, V88, P5408, DOI 10.1073/pnas.88.12.5408; Nilsson-Ehle H, 1909, LUNDS U AARSKR, V5, P1; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PAGE RCL, 1995, DIABETIC MED, V12, P209, DOI 10.1111/j.1464-5491.1995.tb00460.x; PATERSON AH, 1991, GENETICS, V127, P181; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PATERSON AH, 1990, GENETICS, V124, P735; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; RAPP JP, 1982, HYPERTENSION, P582; RIORDAN JR, 1989, SCIENCE, V245, P1066; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROBINSON R, 1972, GENE MAPPING LABOR B; ROBINSON R, 1979, LABORATORY RAT, V1, P38; Sambrook J, 1989, MOL CLONING LABORATO; SCHLAGER G, 1967, GENETICS, V55, P497; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; THODAY JM, 1961, NATURE, V191, P368, DOI 10.1038/191368a0; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wright S., 1968, EVOLUTION GENETICS P, P373; YAMORI Y, 1982, HYPERTENSION, P556	54	685	699	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					213	224		10.1016/0092-8674(91)90584-L	http://dx.doi.org/10.1016/0092-8674(91)90584-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655275				2022-12-28	WOS:A1991GJ32000019
J	COOK, PR				COOK, PR			THE NUCLEOSKELETON AND THE TOPOLOGY OF REPLICATION	CELL			English	Review							DNA TOPOISOMERASE-II; INTERTWINED CATENATED DIMERS; CELL-FREE-EXTRACT; NUCLEAR MATRIX; SACCHAROMYCES-CEREVISIAE; POLYMERASE-ALPHA; MITOTIC CHROMOSOMES; XENOPUS EGGS; SV40 ORIGIN; INTACT DNA				COOK, PR (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, S PARKS RD, OXFORD OX1 3RE, ENGLAND.			Cook, Peter/0000-0002-6639-188X				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALBERTS BM, 1990, NATURE, V346, P514, DOI 10.1038/346514a0; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CALLAN HG, 1982, PROC R SOC SER B-BIO, V214, P417, DOI 10.1098/rspb.1982.0020; COOK PR, 1988, J CELL SCI, V90, P1; COOK PR, 1989, EUR J BIOCHEM, V185, P487, DOI 10.1111/j.1432-1033.1989.tb15141.x; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DINGMAN CW, 1974, J THEOR BIOL, V43, P187, DOI 10.1016/S0022-5193(74)80052-4; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; GALLOWAY J, 1990, NATURE, V343, P513, DOI 10.1038/343513a0; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GOLLIN SM, 1984, J CELL SCI, P203; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACKSON DA, 1988, J CELL SCI, V90, P365; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JACKSON DA, 1986, J MOL BIOL, V192, P77, DOI 10.1016/0022-2836(86)90465-1; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JACKSON DA, 1986, J MOL BIOL, V192, P65, DOI 10.1016/0022-2836(86)90464-X; JACKSON DA, 1990, BIOESSAYS, V12, P87, DOI 10.1002/bies.950120207; JACKSON DA, 1985, EMBO J, V4, P913, DOI 10.1002/j.1460-2075.1985.tb03718.x; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KORNBERG A, 1987, J CELL SCI, P1; Kornberg Arthur, 1974, DNA SYNTHESIS; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MANTON I, 1945, NATURE, V155, P471, DOI 10.1038/155471a0; MANTON I, 1950, BIOL REV, V25, P486, DOI 10.1111/j.1469-185X.1950.tb00770.x; MARILLEY M, 1989, EXP CELL RES, V180, P475, DOI 10.1016/0014-4827(89)90074-8; MARTELLI AM, 1990, EXP CELL RES, V190, P227, DOI 10.1016/0014-4827(90)90190-L; MCCREADY SJ, 1980, J CELL SCI, V46, P365; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; RAO P N, 1974, P785; RICHTER A, 1987, NUCLEIC ACIDS RES, V15, P3455, DOI 10.1093/nar/15.8.3455; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TUBO RA, 1987, J BIOL CHEM, V262, P5857; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VERHEIJEN R, 1988, J CELL SCI, V90, P11; WANG X, 1991, J CELL SCI, V98, P107; WHITE JH, 1988, SCIENCE, V241, P323, DOI 10.1126/science.3388041; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WONG C, 1989, P NATL ACAD SCI USA, V86, P1914, DOI 10.1073/pnas.86.6.1914; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	72	198	198	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1991	66	4					627	635		10.1016/0092-8674(91)90109-C	http://dx.doi.org/10.1016/0092-8674(91)90109-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652367				2022-12-28	WOS:A1991GC74500004
J	PARKER, CN; HALFORD, SE				PARKER, CN; HALFORD, SE			DYNAMICS OF LONG-RANGE INTERACTIONS ON DNA - THE SPEED OF SYNAPSIS DURING SITE-SPECIFIC RECOMBINATION BY RESOLVASE	CELL			English	Article							LAMBDA INTEGRATIVE RECOMBINATION; TN3 RESOLVASE; TN21 RESOLVASE; RECOGNITION FUNCTIONS; BACTERIOPHAGE-LAMBDA; LAC REPRESSOR; BINDING-SITES; RES SITES; PROTEIN; PRODUCTS	A noninvasive method for monitoring communications on DNA was developed from the specificity of resolvase for the arrangement of its recombinational sites. Constraints in DNA structure, caused by interactions between distant sites, can be detected by resolvase as they arise. The method was used to follow the formation and decay of synaptic intermediates during site-specific recombination by resolvase. Synaptic complexes were formed very rapidly, at a rate limited by the initial association of the protein with DNA rather than the physical motion of DNA segments. The recombinational sites seem to encounter each other by an ordered motion, perhaps dictated by DNA super-coiling instead of random collisions, so that the first encounter produces the active complex.	UNIV BRISTOL,CTR MOLEC RECOGNIT,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; ACKROYD AJ, 1990, J MOL BIOL, V216, P633, DOI 10.1016/0022-2836(90)90388-3; AVILA P, 1990, J MOL BIOL, V216, P645, DOI 10.1016/0022-2836(90)90389-4; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BELLOMY GR, 1990, PROG NUCL ACIDS RES, V30, P81; BENJAMIN HA, 1989, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Berg O, 1981, BIOCHEMISTRY-US, V20, P6926; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; CASTELL SE, 1989, NUCLEIC ACIDS RES, V17, P7045, DOI 10.1093/nar/17.17.7045; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; CASTELL SE, 1988, THESIS U BRISTOL BRI; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DIVER WP, 1983, MOL GEN GENET, V191, P189, DOI 10.1007/BF00334812; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; HAGERMAN P, 1908, ANNU REV BIOPHYS BIO, V17, P165; HALFORD SE, 1985, MOL GEN GENET, V200, P169, DOI 10.1007/BF00383331; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HATFULL GF, 1988, GENETIC RECOMBINATIO, P3257; KLEIN J, 1990, SCIENCE, V250, P640, DOI 10.1126/science.250.4981.640; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Luke P A, 1987, Gene Amplif Anal, V5, P185; Maniatis T., 1982, MOL CLONING; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; ROGOWSKY P, 1985, EMBO J, V4, P2135, DOI 10.1002/j.1460-2075.1985.tb03904.x; SALDANHA R, 1987, J MOL BIOL, V196, P505, DOI 10.1016/0022-2836(87)90028-3; SALVO JJ, 1988, STRUCTURE EXPRESSION, V3, P105; SHERRATT D, 1989, MOBILE DNA, P163; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	47	58	58	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					781	791		10.1016/0092-8674(91)90121-E	http://dx.doi.org/10.1016/0092-8674(91)90121-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652373				2022-12-28	WOS:A1991GC74500016
J	HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR				HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR			ASTROVIRUSES AS A CAUSE OF GASTROENTERITIS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN-DETECTION; SEROTYPES; DIAGNOSIS; VIRUSES	Background. Infection with astroviruses has been associated with gastroenteritis in children, and serologic surveys indicate that this infection may be frequent. The importance of astroviruses as agents of gastroenteritis has not been shown in a controlled study, however. Methods. We used monoclonal antibody-based enzyme immunoassays to detect astroviruses, enteric adenoviruses, and rotaviruses in stool samples obtained from age-matched children with and children without gastroenteritis. The samples were obtained in two studies, three years apart, among patients attending an outpatient clinic in Bangkok, Thailand. Results. In the first study, astroviruses were detected in 8.6 percent (96 of 1111) of the children with gastroenteritis and in 2.0 percent (19 of 947) of the children without gastroenteritis. In the second study the rates were 8.6 percent (50 of 580) and 2.1 percent (11 of 512), respectively. For both studies combined, enteric adenoviruses were detected in 2.6 percent of those with gastroenteritis and in 0.5 percent of the controls, whereas rotaviruses were detected in 19 percent of those with gastroenteritis and in 1.0 percent of the controls. The clinical findings associated with astrovirus infection were similar to those associated with rotavirus infection, except for a trend toward greater dehydration in the children infected with rotaviruses. Conclusions. These two controlled studies involving a total of 3150 Thai children provide evidence that astroviruses are a common cause of viral gastroenteritis. Astroviruses were found in association with gastroenteritis more frequently than were enteric adenoviruses, and with nearly half the frequency of rotaviruses.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	HERRMANN, JE (corresponding author), UNIV MASSACHUSETTS,SCH MED,DIV INFECT DIS & IMMUNOL,WORCESTER,MA 01655, USA.							ASHLEY CR, 1978, J CLIN PATHOL, V31, P939, DOI 10.1136/jcp.31.10.939; CEPKO CL, 1983, J CLIN MICROBIOL, V17, P360, DOI 10.1128/JCM.17.2.360-364.1983; CUKOR G, 1984, J CLIN MICROBIOL, V19, P888, DOI 10.1128/JCM.19.6.888-892.1984; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ELLIS ME, 1984, ARCH DIS CHILD, V59, P848, DOI 10.1136/adc.59.9.848; GRAY JJ, 1987, J MED VIROL, V23, P377, DOI 10.1002/jmv.1890230410; HERRMANN JE, 1990, ARCH VIROL, V110, P213, DOI 10.1007/BF01311289; HERRMANN JE, 1987, LANCET, V2, P743; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HERRMANN JE, 1988, J INFECT DIS, V158, P182, DOI 10.1093/infdis/158.1.182; KONNO T, 1982, J MED VIROL, V9, P11, DOI 10.1002/jmv.1890090103; KOTLOFF KL, 1975, LANCET, V2, P451; KURTZ J, 1978, MED MICROBIOL IMMUN, V166, P227, DOI 10.1007/BF02121154; KURTZ JB, 1987, CIBA F SYMP, V128, P92; KURTZ JB, 1984, LANCET, V2, P1405; KURTZ JB, 1977, J CLIN PATHOL, V30, P948, DOI 10.1136/jcp.30.10.948; KURTZ JB, 1979, J MED VIROL, V3, P221, DOI 10.1002/jmv.1890030308; LEE TW, 1981, J GEN VIROL, V57, P421, DOI 10.1099/0022-1317-57-2-421; MADELEY CR, 1977, J HYG-CAMBRIDGE, V78, P261, DOI 10.1017/S0022172400056151; MADELEY CR, 1975, LANCET, V2, P124; MADELEY CR, 1978, J HYG LOND, V82, P285; MIDDLETON PJ, 1982, VIRUS INFECTIONS GAS, P211; NAZER H, 1982, J PEDIATR GASTR NUTR, V1, P555, DOI 10.1097/00005176-198212000-00018; RIEPENHOFFTALTY M, 1983, J CLIN MICROBIOL, V17, P352, DOI 10.1128/JCM.17.2.352-356.1983; TAYLOR DN, 1986, J INFECT DIS, V153, P1132, DOI 10.1093/infdis/153.6.1132	26	159	164	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1757	1760		10.1056/NEJM199106203242501	http://dx.doi.org/10.1056/NEJM199106203242501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1645459				2022-12-28	WOS:A1991FR68100001
J	BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C				BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C			WILD-TYPE BUT NOT MUTANT P53 IMMUNOPURIFIED PROTEINS BIND TO SEQUENCES ADJACENT TO THE SV40 ORIGIN OF REPLICATION	CELL			English	Article							LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; MONKEY CELLS; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; DNA-REPLICATION; MOUSE P53; GENE; TRANSCRIPTION	The DNA from a wide variety of human tumors has sustained mutations within the conserved p53 coding regions. We have purified wild-type and tumor-derived mutant p53 proteins expressed from baculovirus vectors and examined their interactions with SV40 DNA. Using DNAase I footprinting assays, we observed that both human and murine wild-type p53 proteins bind specifically to sequences adjacent to the late border of the viral replication origin. By contrast, mutant p53 proteins failed to bind specifically to these sequences. SV40 T antigen prevented wild-type p53 from interacting with this region. These data show that normal but not oncogenic forms of p53 are capable of sequence-specific interactions with viral DNA. Furthermore, they provide insights into the mechanisms by which viral proteins might regulate the control of viral growth and cell division.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	BARGONETTI, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA43460, CA33620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460, P01CA033620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DILLER L, 1990, MOL CELL BIOL, V10, P5775; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, IN PRESS SCIENCE; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, IN PRESS SCIENCE; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; OROURKE RW, 1986, NATURE, V320, P182; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	65	395	407	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1083	1091		10.1016/0092-8674(91)90560-L	http://dx.doi.org/10.1016/0092-8674(91)90560-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646078	hybrid			2022-12-28	WOS:A1991FR04700019
J	GAVISH, D; BRESLOW, JL				GAVISH, D; BRESLOW, JL			LIPOPROTEIN(A) REDUCTION BY N-ACETYLCYSTEINE	LANCET			English	Note							LP(A)	Lipoprotein(a), a complex of low-density lipoprotein linked by disulphide bridges with apo(a), is associated with atherosclerotic disease when present at very high plasma concentrations. In vitro, N-acetylcysteine (NAC) dissociates this complex. In two patients with high Lp(a) levels NAC lowered plasma Lp(a) from 58 to 20 mg/dl and from 59 to 18 mg/dl: reductions of this order have not hitherto been achieved either by drugs or by diet.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Rockefeller University			Breslow, Jan L/B-7544-2008					DURRINGTON PN, 1988, LANCET, V1, P1070; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1990, J LIPID RES, V31, P909; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GAVISH D, 1990, CLIN RES, pA250; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; PRESCOTT LF, 1983, ANN REV PHARM TOXICO, V23, P83; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540	9	87	90	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					203	204		10.1016/0140-6736(91)92161-T	http://dx.doi.org/10.1016/0140-6736(91)92161-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670844				2022-12-28	WOS:A1991EU92400006
J	BRAUDE, S; GRAHAM, A; MITCHELL, D				BRAUDE, S; GRAHAM, A; MITCHELL, D			LYMPHEDEMA HYPERCALCEMIA SYNDROME MEDIATED BY PARATHYROID-HORMONE-RELATED PROTEIN	LANCET			English	Note								A 24-year-old woman presented with a crypotogenic, hypercalcaemic syndrome with metastatic pulmonary calcification and leg and massive breast enlargement and bilateral chylous pleural effusions compatible with a generalised lymphatic abnormality. The patient's serum parathyroid hormone-related protein concentration was very high at a time when she was significantly hypercalcaemic, implying that the hypercalcaemia was mediated by this protein.	ROYAL BROMPTON & NATL HEART HOSP,LONDON SW3 6HP,ENGLAND	Imperial College London								DOCHERTY HM, 1989, J MOL ENDOCRINOL, V2, P11, DOI 10.1677/jme.0.0020011; KHOSLA S, 1990, NEW ENGL J MED, V322, P1157; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; RATCLIFFE WA, 1988, ANN CLIN BIOCHEM, V25, P171	4	26	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					140	141		10.1016/0140-6736(91)90802-V	http://dx.doi.org/10.1016/0140-6736(91)90802-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670789				2022-12-28	WOS:A1991ET67900005
J	PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM				PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM			MIGRATION STIMULATING ACTIVITY IN SERUM OF BREAST-CANCER PATIENTS	LANCET			English	Article							FIBROBLAST PHENOTYPE; SKIN FIBROBLASTS; SCATTER FACTOR; FETAL; COLLAGEN; PURIFICATION; CELLS	An assay to measure the ability to stimulate migration of fibroblasts into collagen gel was carried out on serum from treated and untreated breast cancer patients and from healthy controls. Migration stimulating activity was found in the serum of 10 (83%) of 12 untreated breast cancer patients immediately before surgical resection of the primary tumour and in 9 (75%) of them 4 days after resection; in 13 (93%) of 14 patients 1-13 years after tumour resection who had received adjuvant treatment; and in 2 (10%) of 20 healthy women matched for age. The migration stimulating activity in cancer patients' serum was indistinguishable from the migration stimulating factor produced in vitro by fetal and cancer patient skin fibroblasts in its behaviour in various biochemical fractionation procedures. The presence of this activity in the serum of treated breast cancer patients clearly distinguishes it from other oncofetal proteins, which all seem to be produced by tumours.	UNIV MANCHESTER,DEPT CELL & STRUCT BIOL,COUPLAND 3 BLDG,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Manchester; Christie NHS Foundation Trust; Christie Hospital				Howell, Anthony/0000-0002-6233-719X				AZZARONE B, 1984, INT J CANCER, V33, P759, DOI 10.1002/ijc.2910330608; DECKER M, 1989, CANCER RES, V49, P3499; DURNING P, 1984, LANCET, V1, P890; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE J, 1987, LANCET, V1, P1477; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTTMAN R, 1983, LANCET, V2, P556; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SCHOR SL, 1985, J CELL SCI, V73, P235; SCHOR SL, 1979, J CELL SCI, V38, P267; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1988, J CELL SCI, V90, P391; SCHOR SL, 1980, J CELL SCI, V41, P159; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606; SCHOR SL, 1987, BREAST CANCER SCI CL, P142; SCHOR SL, 1988, IN VITRO CELL DEV, V25, P137; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WARN RM, 1989, NATURE, V340, P186, DOI 10.1038/340186a0	20	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					130	133		10.1016/0140-6736(91)90798-T	http://dx.doi.org/10.1016/0140-6736(91)90798-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670786				2022-12-28	WOS:A1991ET67900002
J	LAPORTE, JR; CARNE, X; VIDAL, X; MORENO, V; JUAN, J				LAPORTE, JR; CARNE, X; VIDAL, X; MORENO, V; JUAN, J			UPPER GASTROINTESTINAL-BLEEDING IN RELATION TO PREVIOUS USE OF ANALGESICS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Article							SPONTANEOUSLY REPORTED DATA; NON-NARCOTIC ANALGESICS; PEPTIC-ULCER; ASPIRIN; HEMORRHAGE; ULCEROGENICITY; PIROXICAM	To assess the risk of upper gastrointestinal bleeding associated with the use of individual non-narcotic analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), a multicentre study of 875 cases of upper gastrointestinal bleeding and 2682 hospital controls was done. With control for confounding factors, the overall odds ratio estimate for aspirin taken at least once during the week before the first symptom was 7.2 (95% confidence interval 5.4-9.6). Non-aspirin NSAIDs associated with upper gastrointestinal bleeding were diclofenac (7.9 ]4.3-14.6[), indomethacin (4.9 ]2.0-12.2[), naproxen (6.5 ]2.2-19.6[), and piroxicam (19.1 [8.2-44.3]). Paracetamol, propyphenazone, and dipyrone did not increase the risk. A previous history of gastrointestinal bleeding or peptic ulcer did not greatly affect odds ratio estimates, which differed according to sex and were higher for younger than for older patients. However, the incidence of upper gastrointestinal bleeding was higher among the elderly.			LAPORTE, JR (corresponding author), UNIV AUTONOMA BARCELONA,DEPT PHARMACOL,CLIN PHARMACOL UNIT,CS VALL DHEBRON,E-08035 BARCELONA,SPAIN.		Laporte, Joan-Ramon/A-1302-2011; Figueras, Albert/H-7743-2012; Figueras, Albert/I-7421-2013; Vidal, Xavier/I-5958-2019; Moreno, Victor/A-1697-2010	Figueras, Albert/0000-0002-2740-2013; Figueras, Albert/0000-0002-2740-2013; Vidal, Xavier/0000-0001-6705-4298; Moreno, Victor/0000-0002-2818-5487				ALLIBONE A, 1958, LANCET, V2, P179; ALVAREZ AS, 1958, LANCET, V1, P920; ARMSTRONG CP, 1987, BRIT MED J, V294, P772, DOI 10.1136/bmj.294.6574.772-a; BARTLE WR, 1986, ARCH INTERN MED, V146, P2365, DOI 10.1001/archinte.146.12.2365; BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BELCON MC, 1985, J CHRON DIS, V38, P101, DOI 10.1016/0021-9681(85)90013-X; BROGDEN RN, 1986, DRUGS, V32, P60, DOI 10.2165/00003495-198600324-00006; CARSON J L, 1988, Journal of Clinical Pharmacology, V28, P554; CHARLET N, 1985, J CLIN PHARMACOL, V25, P564, DOI 10.1002/j.1552-4604.1985.tb02880.x; COGGON D, 1982, GUT, V23, P340, DOI 10.1136/gut.23.4.340; DUGGAN JM, 1986, GUT, V27, P929, DOI 10.1136/gut.27.8.929; FAULKNER G, 1988, BRIT MED J, V297, P1311, DOI 10.1136/bmj.297.6659.1311; FRESTON JW, 1988, TOXICOL PATHOL, V16, P260, DOI 10.1177/019262338801600219; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; IVEY KJ, 1986, DRUGS, V32, P71, DOI 10.2165/00003495-198600324-00007; JICK H, 1978, LANCET, V2, P87; JICK H, 1981, ARCH INTERN MED, V141, P316, DOI 10.1001/archinte.141.3.316; KELLY JJ, 1956, AM J MED SCI, V232, P119, DOI 10.1097/00000441-195608000-00001; Langman M J, 1986, Med Toxicol, V1 Suppl 1, P34; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LANGMAN MJS, 1983, AM J MED, V74, P79, DOI 10.1016/0002-9343(83)90533-8; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; LEVY M, 1974, NEW ENGL J MED, V290, P1158, DOI 10.1056/NEJM197405232902102; MATTHEWSON K, 1988, GUT, V29, P70, DOI 10.1136/gut.29.1.70; MCGUIGAN JE, 1987, HARRISONS PRINCIPLES, P1239; MIESCHER PA, 1986, DRUGS, V32, P90, DOI 10.2165/00003495-198600324-00008; MOEBIUS UM, 1986, LANCET, V1, P383; MUIR A, 1959, LANCET, V1, P539; PIPER DW, 1981, GASTROENTEROLOGY, V80, P427; RAINSFORD KD, 1981, BRIT J PHARMACOL, V73, pP226; ROSSI AC, 1987, BRIT MED J, V294, P147, DOI 10.1136/bmj.294.6565.147; SIMON LS, 1980, NEW ENGL J MED, V302, P1179; SIMON LS, 1980, NEW ENGL J MED, V302, P1237; SOMERVILLE K, 1986, LANCET, V1, P462; STODOLNIK E, 1990, EUR J CLIN PHARMACOL, V38, P31, DOI 10.1007/BF00314799; SZABO S, 1989, MED TOXICOL ADV DRUG, V4, P77, DOI 10.1007/BF03259905; VALMAN HB, 1968, BMJ-BRIT MED J, V4, P661, DOI 10.1136/bmj.4.5632.661; [No title captured]	40	280	293	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					85	89		10.1016/0140-6736(91)90744-A	http://dx.doi.org/10.1016/0140-6736(91)90744-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670734				2022-12-28	WOS:A1991ER47700012
J	RIDLEY, AJ; HALL, A				RIDLEY, AJ; HALL, A			THE SMALL GTP-BINDING PROTEIN RHO REGULATES THE ASSEMBLY OF FOCAL ADHESIONS AND ACTIN STRESS FIBERS IN RESPONSE TO GROWTH-FACTORS	CELL			English	Article							LYSOPHOSPHATIDIC ACID; CLOSTRIDIUM-BOTULINUM; ACTIVATING PROTEIN; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE-PRODUCT; R-RAS; CELLS; IDENTIFICATION	Actin stress fibers are one of the major cytoskeletal structures in fibroblasts and are linked to the plasma membrane at focal adhesions. rho, a ras-related GTP-binding protein, rapidly stimulated stress fiber and focal adhesion formation when microinjected into serum-starved Swiss 3T3 cells. Readdition of serum produced a similar response, detectable within 2 min. This activity was due to a lysophospholipid, most likely lysophosphatidic acid, bound to serum albumin. Other growth factors including PDGF induced actin reorganization initially to form membrane ruff les, and later, after 5 to 10 min, stress fibers. For all growth factors tested the stimulation of focal adhesion and stress fiber assembly was inhibited when endogenous rho function was blocked, whereas membrane ruffling was unaffected. These data imply that rho is essential specifically for the coordinated assembly of focal adhesions and stress fibers induced by growth factors.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST,INST CANC RES,FULHAM RD,LONDON SW3 6JB,ENGLAND.			Ridley, Anne/0000-0001-8186-5708				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BENTON AM, 1982, BLOOD, V60, P642; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1352; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GERRARD JM, 1984, BIOCHIM BIOPHYS ACTA, V795, P487, DOI 10.1016/0005-2760(84)90177-2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JALINK K, 1990, J BIOL CHEM, V265, P12232; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1981, NATURE, V292, P373; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHAAFI RI, 1986, J CELL BIOL, V102, P1459, DOI 10.1083/jcb.102.4.1459; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; Small J V, 1988, Electron Microsc Rev, V1, P155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SWITZER S, 1965, J LIPID RES, V6, P506; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478	53	3921	3998	5	169	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					389	399		10.1016/0092-8674(92)90163-7	http://dx.doi.org/10.1016/0092-8674(92)90163-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643657				2022-12-28	WOS:A1992JH12400004
J	BUCK, M; CANNON, W				BUCK, M; CANNON, W			SPECIFIC BINDING OF THE TRANSCRIPTION FACTOR SIGMA-54 TO PROMOTER DNA	NATURE			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN NTRC; ACTIVATION; INITIATION; MECHANISM; ENHANCERS; INVIVO; GENES	A CENTRAL event in transcription is the assembly on DNA of specific complexes near the initiation sites for RNA synthesis. Activation of transcription by one class of enhancer-binding proteins requires an RNA polymerase holoenzyme1 containing the specialized transcription factor, sigma-54 (sigma-54). We report here that sigma-54 alone specifically binds to promoter DNA and is responsible for many of the close contacts between RNA polymerase holoenzyme and promoter DNA, a property proposed for the major sigma-70 protein family. Binding of simga-54 to promoter DNA is not equivalent to that of holoenzyme suggesting that there is a constraint on sigma-54 conformation when bound with core RNA polymerase. Footprints indicate sigma-54 is at the leading edge of DNA-bound holoenzyme. Like the holoenzyme1-4, sigma-54-binding to promoter DNA does not result in DNA strand separation. Instead the specific DNA-binding activity of sigma-54 assists assembly of a closed promoter complex. This complex can be isomerized to the open (DNA melted) complex by activator protein5,6, but promoter-bound sigma-54 alone cannot be induced to melt DNA. The pathway leading to productive transcription is similar to that proposed for eukaryotic RNA polymerase II systems.			BUCK, M (corresponding author), UNIV SUSSEX,AFRC,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND.							AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V6, P2219; BMORETT E, 1988, P NATL ACAD SCI USA, V8, P9401; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, IN PRESS MOL MICROBI; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1986, REGULATION GENE EXPR, P139; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	22	133	133	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					422	424		10.1038/358422a0	http://dx.doi.org/10.1038/358422a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641025	Bronze			2022-12-28	WOS:A1992JF85300058
J	RAVNSKOV, U				RAVNSKOV, U			CHOLESTEROL LOWERING TRIALS IN CORONARY HEART-DISEASE - FREQUENCY OF CITATION AND OUTCOME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; PRIMARY-PREVENTION; RANDOMIZED TRIALS; MORTALITY; DIET; RISK; REDUCTION	Objective-To see if the claim that lowering cholesterol values prevents coronary heart disease is true or if it is based on citation of supportive trials only. Design-Comparison of frequency of citation with outcome of all controlled cholesterol lowering trials using coronary heart disease or death, or both, as end point. Subjects-22 controlled cholesterol lowering trials. Results-Trials considered by their directors as supportive of the contention were cited almost six times more often than others, according to Science Citation Index. Apart from trials discontinued because of alleged side effects of treatment, unsupportive trials were not cited after 1970, although their number almost equalled the number considered supportive. In three supportive reviews the outcome of the selected trials was more favourable than the outcome of the excluded and ignored trials. In the 22 controlled cholesterol lowering trials studied total and coronary heart disease mortality was not changed significantly either overall or in any subgroup. A statistically significant 0-32% reduction in non-fatal coronary heart disease seemed to be due to bias as event frequencies were unrelated to trial length and to mean net reduction in cholesterol value; individual changes in cholesterol values were unsystematically or not related to outcome; and after correction for a small but significant increase in non-medical deaths in the intervention groups total mortality remained unchanged (odds ratio 1.02). Conclusion-Lowering serum cholesterol concentrations does not reduce mortality and is unlikely to prevent coronary heart disease. Claims of the opposite are based on preferential citation of supportive trials.										[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEADY JA, 1980, LANCET, V2, P379; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEREN P, 1966, ACTA MED SCAND, V446, P1; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCORMICK J, 1988, LANCET, V2, P839; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1961, LANCET, V2, P499; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE G, 1986, LANCET, V1, P869; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Smith RL, 1989, AM CLIN LAB, P26; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; STEHBENS WE, 1989, NUTR REV, V47, P1, DOI 10.1111/j.1753-4887.1989.tb02743.x; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZARLING EJ, 1983, JAMA-J AM MED ASSOC, V250, P1177; 1971, BMJ, V4, P775; 1971, BMJ, V4, P767; 1972, JAMA-J AM MED ASSOC, V220, P996; 1970, JAMA-J AM MED ASSOC, V214, P1303	40	253	252	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1992	305	6844					15	19		10.1136/bmj.305.6844.15	http://dx.doi.org/10.1136/bmj.305.6844.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638188	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JC79900021
J	RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM				RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM			EFFECTS OF LONG-TERM SULINDAC THERAPY ON COLONIC POLYPOSIS	ANNALS OF INTERNAL MEDICINE			English	Note									BARCELONA UNIV, HOSP CLIN, DEPT GASTROENTEROL, VILLARROEL 170, E-08036 BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL BADALONA, DEPT GASTROENTEROL, BADALONA, SPAIN; HOSP GEN GRANOLLERS, DEPT MED, GRANOLLERS, SPAIN; HOSP GEN GRANOLLERS, DEPT SURG, GRANOLLERS, SPAIN	University of Barcelona; Hospital Germans Trias i Pujol								BENGOECHEA O, 1987, AM J SURG PATHOL, V11, P323, DOI 10.1097/00000478-198704000-00010; CAPPELL MS, 1989, DIS COLON RECTUM, V32, P641, DOI 10.1007/BF02555767; GONZAGA RAF, 1985, LANCET, V1, P751; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICHOLSON ML, 1991, GUT, V32, P413, DOI 10.1136/gut.32.4.413; SAPERAS E, 1990, AM J GASTROENTEROL, V85, P138; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	10	210	218	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					952	954		10.7326/0003-4819-115-12-952	http://dx.doi.org/10.7326/0003-4819-115-12-952			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1659272				2022-12-28	WOS:A1991GU41700007
J	OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I				OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I			IDENTIFICATION OF A GS ACTIVATOR REGION OF THE BETA-2-ADRENERGIC RECEPTOR THAT IS AUTOREGULATED VIA PROTEIN KINASE-A-DEPENDENT PHOSPHORYLATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; GTP-BINDING PROTEINS; GROWTH FACTOR-II; ADENYLATE-CYCLASE; PHOSPHOLIPID-VESICLES; DISTINCT PATHWAYS; PERTUSSIS-TOXIN; LYMPHOMA-CELLS; BASIC RESIDUES	We have localized a G protein activator region of the human beta-2-adrenergic receptor to region beta-III-2 (from Arg259 to Lys273). The synthetic beta-III-2, corresponding to the C-terminal end of the third cytoplasmic loop, activates G(s) at nanomolar concentrations and weakly activates G(i). Beta-III-2 activates adenylyl cyclase at nanomolar concentrations in wild-type S49 lymphoma membranes, but not in membranes of unc mutant S49 cells, in which G(s) is uncoupled from beta-adrenergic stimulation. Phosphorylation of beta-III-2 by cAMP-dependent protein kinase A, which is involved in the desensitization of the beta-adrenergic receptor from G(s), drastically reduces the effect of beta-III-2 on G(s) while potentiating its action on G(i), resulting in a total loss of adenylyl cyclase-stimulating activity. These findings indicate that this receptor sequence is a multipotential G protein activator whose G protein specificity is regulated by protein kinase A.	SUNTORY BIOMED CTR,TOKYO,GUMMA 37005,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Suntory Holdings Ltd; Aichi Cancer Center	OKAMOTO, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,BUNKYO KU,TOKYO 113,JAPAN.		Inagaki, Masaki/B-9920-2016					ABRAMSON SN, 1985, J BIOL CHEM, V260, P4580; ASANO T, 1984, J BIOL CHEM, V259, P9351; Beavo J A, 1974, Methods Enzymol, V38, P299; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CLARK RB, 1986, BIOCHEM J, V235, P399, DOI 10.1042/bj2350399; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HOUSE C, 1987, J BIOL CHEM, V262, P772; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MORISHITA R, 1990, BIOCHEM BIOPH RES CO, V172, P249, DOI 10.1016/S0006-291X(05)80201-3; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; ROSS EM, 1977, P NATL ACAD SCI USA, V74, P3715, DOI 10.1073/pnas.74.9.3715; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219	38	256	266	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					723	730		10.1016/0092-8674(91)90067-9	http://dx.doi.org/10.1016/0092-8674(91)90067-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657404				2022-12-28	WOS:A1991GQ40700009
J	REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S				REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S			SPECIFIC EGF REPEATS OF NOTCH MEDIATE INTERACTIONS WITH DELTA AND SERRATE - IMPLICATIONS FOR NOTCH AS A MULTIFUNCTIONAL RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; NEURONAL PRECURSOR CELLS; NEUROGENIC LOCUS NOTCH; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; NEGATIVE COMPLEMENTATION; GENETIC INTERACTIONS; LDL RECEPTOR; FACTOR-IX	The neurogenic loci Notch and Delta, which both encode EGF-homologous transmembrane proteins, appear to function together in mediating cell-cell communication and have been shown to interact at the cell surface in vitro. To examine the role of the EGF repeats in this interaction, we performed an extensive deletion mutagenesis of the extracellular domain of Notch. We find that of the 36 EGF repeats of Notch, only two, 11 and 12, are both necessary and sufficient to mediate interactions with Delta. Furthermore, this Delta binding ability is conserved in the corresponding two repeats from the Xenopus Notch homolog. We report a novel molecular interaction between Notch and Serrate, another EGF-homologous transmembrane protein containing a region of striking similarity to Delta, and show that the same two EGF repeats of Notch also constitute a Serrate binding domain. These results suggest that Notch may act as a multifunctional receptor whose 36 EGF repeats form a tandem array of discrete ligand-binding units, each of which may potentially interact with several different proteins during development.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; INDIANA UNIV,DEPT BIOL,PROGRAM MOLEC CELLULAR & DEV BIOL,BLOOMINGTON,IN 47405	Yale University; Indiana University System; Indiana University Bloomington	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511, USA.				NIGMS NIH HHS [GM20093, GM37813] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTON AK, 1989, DEV GENET, V10, P261, DOI 10.1002/dvg.1020100315; APPELLA E, 1987, J BIOL CHEM, V262, P4437; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARTAVANISTSAKON.S, 1991, IN PRESS, V7, P427; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIS LD, 1991, IN PRESS J BIOL CHEM; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FOSTER GG, 1975, GENETICS, V81, P99; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HANDFORD PA, 1990, EMBO J, V9, P479; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY PL, 1968, PUBLICATION NUMBER C, V627; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T, 1989, DECONTAMINATION DILU; MARKOPOULOU K, 1989, J NEUROGENET, V6, P11, DOI 10.3109/01677068909107097; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MORITA T, 1984, J BIOL CHEM, V259, P5698; MOSS RE, 1985, THESIS HARVARD U; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PORTIN P, 1975, GENETICS, V81, P121; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SHEPARD SB, 1989, GENETICS, V122, P429; SUGO T, 1984, J BIOL CHEM, V259, P5705; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	655	710	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					687	699		10.1016/0092-8674(91)90064-6	http://dx.doi.org/10.1016/0092-8674(91)90064-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657403				2022-12-28	WOS:A1991GQ40700006
J	LAMBALLE, F; KLEIN, R; BARBACID, M				LAMBALLE, F; KLEIN, R; BARBACID, M			TRKC, A NEW MEMBER OF THE TRK FAMILY OF TYROSINE PROTEIN-KINASES, IS A RECEPTOR FOR NEUROTROPHIN-3	CELL			English	Article							NERVE GROWTH-FACTOR; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; GENE-TRANSFER; BRAIN; EXPRESSION; SEQUENCES; DELETION; CELLS; IDENTIFICATION	We report the isolation and molecular characterization of trkC, a new member of the trk family of tyrosine protein kinase genes. trkC is preferentially expressed in the brain. In situ hybridization studies revealed trkC transcripts in the hippocampus, cerebral cortex, and the granular cell layer of the cerebellum. The product of the trkC gene has been identified as a glycoprotein of 145,000 daltons, gp145trkC, which is equally related to the previously characterized gp140trk and gp145trkB tyrosine kinases. gp145trkC is a functional receptor for neurotrophin-3 (NT-3). However, gp145trkC does not bind the highly related neurotrophic factors NGF or BDNF. In proliferating cells, the interaction between gp145trkC and NT-3 elicits a more efficient biological response than when NT-3 binds to its other receptors gp140trk and gp145trkB. These results indicate that gp145trkC may play an important role in mediating the neurotrophic effects of NT-3.			LAMBALLE, F (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Lamballe, Fabienne/P-4293-2017; Klein, Ruediger/C-6147-2008; Lamballe, Fabienne/GLT-0820-2022	Klein, Ruediger/0000-0002-3109-0163; Lamballe, Fabienne/0000-0001-7631-942X				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARBACID M, 1991, IN PRESS BIOCH BIOPH; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOGAN B, 1986, MANIPULATING MOUSE E; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NEBREDA AR, 1991, SCIENCE, V252, P568; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SNYDER SH, 1991, NATURE, V350, P195, DOI 10.1038/350195a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	53	985	1039	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					967	979		10.1016/0092-8674(91)90442-2	http://dx.doi.org/10.1016/0092-8674(91)90442-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653651				2022-12-28	WOS:A1991GE46000015
J	KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM				KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM			CHROMOSOMAL TRANSLOCATION T(15-17) IN HUMAN ACUTE PROMYELOCYTIC LEUKEMIA FUSES RAR-ALPHA WITH A NOVEL PUTATIVE TRANSCRIPTION FACTOR, PML	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; ZINC FINGER; GLUCOCORTICOID RECEPTOR; INSITU HYBRIDIZATION; RESPONSIVE ELEMENT; GENE-EXPRESSION; VIRUS TYPE-1; BETA-GENE; PROTEIN	A unique mRNA produced in leukemic cells from a t(15; 17) acute promyelocytic leukemia (APL) patient encodes a fusion protein between the retinoic acid receptor-alpha (RAR-alpha) and a myeloid gene product called PML. PML contains a cysteine-rich region present in a new family of apparent DNA-binding proteins that includes a regulator of the interleukin-2 receptor gene (Rpt-1) and the recombination-activating gene product (RAG-1). Accordingly, PML may represent a novel transcription factor or recombinase. The aberrant PML-RAR fusion product, while typically retinoic acid responsive, displays both cell type- and promoter-specific differences from the wild-type RAR-alpha. Because patients with APL can be induced into remission with high dose RA therapy, we propose that the nonliganded PML-RAR protein is a new class of dominant negative oncogene product. Treatment with RA would not only relieve this inhibition, but the activated PML-RAR protein may actually promote myelocyte differentiation.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; MEM SLOAN KETTERING CANC CTR,LEUKEMIA & DEV CHEMOTHERAPY SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	KAKIZUKA, A (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, CELL, V66; DOOLITTLE RF, 1987, URFS ORFS PRIMER HOW; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1988, CATALOG CHROMOSOME A; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROWLEY JD, 1977, LANCET, V1, P549; ROWLEY JD, 1977, INT J CANCER, V20, P860; SALVATO MS, 1989, VIROLOGY, V173, P1, DOI 10.1016/0042-6822(89)90216-X; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UMEX RM, 1991, SCIENCE, V251, P288; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	65	1353	1378	1	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					663	674		10.1016/0092-8674(91)90112-C	http://dx.doi.org/10.1016/0092-8674(91)90112-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652368	Green Published			2022-12-28	WOS:A1991GC74500007
J	BAKER, D; KLEIN, R				BAKER, D; KLEIN, R			EXPLAINING OUTPUTS OF PRIMARY HEALTH-CARE - POPULATION AND PRACTICE FACTORS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine whether variations in the activities of general practice among family health service authorities can be explained by the populations characteristics and the organisation and resourcing of general practice. Design - The family health services authorities were treated as discrete primary health care systems. Nineteen performance indicators reflecting the size, distribution, and characteristics of the population served; the organisation of general practice (inputs); and the activities generated by general practitioners and their staff (output) were analysed by stepwise regression. Setting - 90 family health services authorities in England. Main outcome measures - Rates of cervical smear testing, immunisation, prescribing, and night visiting. Results - 53% of the variation in uptake of cervical cytology was accounted for by Jarman score (t = -3.3), list inflation (-0.41), the proportion of practitioners over 65 (-0.64), the number of ancillary staff per practitioner (2.5), and 70% of the variation in immunisation rates by standardised mortality ratios (-6.6), the proportion of practitioners aged over 65 (-4.8), and the number of practice nurses per practitioner (3.5). Standardised mortality ratios (8.4), the number of practitioners (2.3), and the proportion over 65 (2.2), and the number of ancillary staff per practitioner (-3.1) accounted for 69% of variation in prescribing rates. 54% of the variation in night visiting was explained by standardised mortality ratios (7.1), the proportion of practitioners with lists sizes below 1000 (-2.2), the proportion aged over 65 (-0.4), and the number of practice nurses per practitioner (-2.5). Conclusions - Family health services authorities are appropriate systems for studying output of general practice. Their performance indicators need to be refined and to be linked to other relevant factors, notably the performance of hospital, community, and social services.			BAKER, D (corresponding author), UNIV BATH,SCH SOCIAL SCI,CTR ANAL SOCIAL POLICY,BATH BA2 7AY,AVON,ENGLAND.							BOSANQUET N, 1989, FAMILY DOCTORS INCEN; BUTLER JR, 1987, TOO MANY PATIENTS; BUTLER JR, 1980, HOW MANY PATIENTS; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; ILLSLEY R, 1986, Q J SOC AFF, V2, P151; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; KLEIN R, 1982, PUBLIC ADMIN, V60, P385, DOI 10.1111/j.1467-9299.1982.tb00490.x; MECHANIC D, 1979, J HEALTH SOC BEHAV, V20, P387, DOI 10.2307/2955413; SENIOR ML, IN PRESS ENV PLANN C; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; Townsend P., 1988, INEQUALITIES HLTH; WILKIN D, 1987, ANATOMY URBAN GENERA; 1990, FAMILY PRACTICE SERV; 1989, TERMS SERVICE DOCTOR; 1989, WORKING PATIENTS; 1986, INSTAT INTERACTIVE S; [No title captured]	18	50	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					225	229		10.1136/bmj.303.6796.225	http://dx.doi.org/10.1136/bmj.303.6796.225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ563	1653065	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300025
J	FISCHER, EH; CHARBONNEAU, H; TONKS, NK				FISCHER, EH; CHARBONNEAU, H; TONKS, NK			PROTEIN TYROSINE PHOSPHATASES - A DIVERSE FAMILY OF INTRACELLULAR AND TRANSMEMBRANE ENZYMES	SCIENCE			English	Article							LEUKOCYTE-COMMON ANTIGEN; EPIDERMAL GROWTH-FACTOR; SERINE-THREONINE KINASE; RABBIT SKELETAL-MUSCLE; CELL-CYCLE CONTROL; CHICKEN-EMBRYO FIBROBLASTS; XENOPUS-LAEVIS OOCYTES; ROUS-SARCOMA VIRUS; PHOSPHOTYROSYL-PROTEIN; HUMAN-PLACENTA	Protein tyrosine phosphatases (PTPs) represent a diverse family of enzymes that exist as integral membrane and nonreceptor forms. The PTPs, with specific activities in vitro 10 to 1000 times greater than those of the protein tyrosine kinases would be expected to effectively control the amount of phosphotyrosine in the cell. They dephosphorylate tyrosyl residues in vivo and take part in signal transduction and cell cycle regulation. Most of the transmembrane forms, such as the leukocyte common antigen (CD45), contain two conserved intracellular catalytic domains; but their external segments are highly variable. The structural features of the transmembrane forms suggest that these receptor-linked PTPs are capable of transducing external signals; however, the ligands remain unidentified. A hypothesis is proposed explaining how phosphatases might act synergistically with the kinases to elicit a full physiological response, without regard to the state of phosphorylation of the target proteins.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory	FISCHER, EH (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM15731, GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALEXANDER D R, 1990, New Biologist, V2, P1049; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDREASSEN P, UNPUB; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; BALLOU LM, 1986, ENZYMES, V17, P311; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BRAUTIGAN DL, 1981, J BIOL CHEM, V256, P6519; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUYON JP, 1990, J IMMUNOL, V144, P191; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHERNOFF J, 1983, ARCH BIOCHEM BIOPHYS, V226, P517, DOI 10.1016/0003-9861(83)90321-1; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHOCK PB, 1978, CURR TOP CELL REGUL, V13, P53; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOL DE, UNPUB; COPPER JA, 1985, MOL CELL BIOL, V5, P3304; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DePaoli-Roach A A, 1985, FEBS Lett, V183, P423; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1989, ADV PROTEIN PHOSPHAT, V5, P479; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Fischer E. H., 1971, CURR TOP CELL REGUL, V4, P211; FISCHER EH, 1983, B I PASTEUR, V81, P7; FOULKES JG, 1983, J BIOL CHEM, V258, P431; FRIEDEN C, 1978, ANN REV BIOCH, V20, P124; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HORLEIN D, 1982, BIOCHEMISTRY-US, V21, P5577; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWELL BW, 1991, MOL CELL BIOL, V11, P5658; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEBE M, 1990, J BIOL CHEM, V265, P17607; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7754; JENO P, 1989, J BIOL CHEM, V264, P1293; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JONES SW, 1989, J BIOL CHEM, V264, P7747; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; Krebs E G, 1981, Curr Top Cell Regul, V18, P401; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1991, IMMUNOGENETICS, V33, P33; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NAKAMURA KD, 1983, MOL CELL BIOL, V3, P380, DOI 10.1128/MCB.3.3.380; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PINES J, 1990, New Biologist, V2, P389; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHACHTERNOIMAN E, 1983, PHILOS T R SOC LON B, V202, P157; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHENOLIKAR S, 1990, ADV SEC MESS PHOSPH, V23, P1; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2761, DOI 10.1073/pnas.74.7.2761; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2766; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STURGILL TW, 1988, NATURE, V334, P1715; SUCHARD SJ, 1987, BIOCHIM BIOPHYS ACTA, V896, P35, DOI 10.1016/0005-2736(87)90353-1; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1985, CELL, V41, P83, DOI 10.1016/0092-8674(85)90063-7; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; TONKS NK, 1989, ADV PROTEIN PHOSPHAT, V5, P149; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VANDENHEEDE JR, 1985, J BIOL CHEM, V260, P512; VANDENHEEDE JR, 1981, FEBS LETT, V127, P1, DOI 10.1016/0014-5793(81)80326-2; VANDENHEEDE JR, 1987, FEBS LETT, V216, P291, DOI 10.1016/0014-5793(87)80708-1; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; YANG Q, UNPUB; YANG SD, 1980, J BIOL CHEM, V255, P1759; YANG SD, 1980, J BIOL CHEM, V255, P10231; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	175	936	992	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					401	406		10.1126/science.1650499	http://dx.doi.org/10.1126/science.1650499			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1650499				2022-12-28	WOS:A1991FY28800029
J	MCKEIGUE, PM; SHAH, B; MARMOT, MG				MCKEIGUE, PM; SHAH, B; MARMOT, MG			RELATION OF CENTRAL OBESITY AND INSULIN RESISTANCE WITH HIGH DIABETES PREVALENCE AND CARDIOVASCULAR RISK IN SOUTH ASIANS	LANCET			English	Article							CORONARY HEART-DISEASE; FAT DISTRIBUTION; NORTHWEST LONDON; ADIPOSE-TISSUE; SERUM-LIPIDS; MORTALITY; MEN; ADULTS; WOMEN; DIET	The hypothesis that the high mortality from coronary heart disease (CHD) in South Asians settled overseas compared with other populations is due to metabolic disturbances related to insulin resistance was tested in a population survey of 3193 men and 561 women aged 40-69 years in London, UK. The sample was assembled from industrial workforces and general practitioners' lists. In comparison with the European group, the South Asian group had a higher prevalence of diabetes (19% vs 4%), higher blood pressures, higher fasting and post-glucose serum insulin concentrations, higher plasma triglyceride, and lower HDL cholesterol concentrations. Mean waist-hip girth ratios and trunk skinfolds were higher in the South Asian than in the European group. Within each ethnic group waist-hip ratio was correlated with glucose intolerance, insulin, blood pressure, and triglyceride. These results confirm the existence of an insulin resistance syndrome, prevalent in South Asian populations and associated with a pronounced tendency to central obesity in this group. Control of obesity and greater physical activity offer the best chances for prevention of diabetes and CHD in South Asian people.	UNIV COLL & MIDDLESEX SCH MED,DEPT COMMUNITY MED,LONDON,ENGLAND	University of London; University College London			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1985, WHO TECH REP SER, V727, P1; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BOLINDER J, 1983, DIABETES, V32, P117, DOI 10.2337/diabetes.32.2.117; DONAHUE RP, 1987, LANCET, V1, P821; DUCIMETIERE P, 1986, INT J OBESITY, V10, P229; Duncan I.W., 1982, PROCEDURE PROPOSED C; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MORRISON JA, 1981, JAMA-J AM MED ASSOC, V245, P939, DOI 10.1001/jama.245.9.939; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; PEEPLES LH, 1989, METABOLISM, V38, P1029, DOI 10.1016/0026-0495(89)90017-6; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SEIDELL JC, 1988, EUR J CLIN INVEST, V18, P243, DOI 10.1111/j.1365-2362.1988.tb01253.x; SLACK J, 1977, BRIT MED J, V2, P353, DOI 10.1136/bmj.2.6083.353; STERN MP, 1981, AM J EPIDEMIOL, V113, P546, DOI 10.1093/oxfordjournals.aje.a113131; YKIJARVINEN H, 1988, DIABETES, V37, P1271, DOI 10.2337/diabetes.37.9.1271; ZIMMET P, 1977, DIABETOLOGIA, V13, P111, DOI 10.1007/BF00745137; 1989, LANCET, V1, P589; 1990, MORTALITY GEOGRAP DS	30	1184	1190	3	56	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					382	386		10.1016/0140-6736(91)91164-P	http://dx.doi.org/10.1016/0140-6736(91)91164-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671422				2022-12-28	WOS:A1991EX60500002
J	TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M				TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME-5 OR CHROMOSOME-18	NATURE			English	Article							FAMILIAL POLYPOSIS COLI; COLORECTAL CARCINOMAS; CONSTITUTIONAL HETEROZYGOSITY; GENE; ASSIGNMENT; TUMORS; ARM	DEVELOPMENT of colon carcinomas can be associated with allelic deletions on several chromosomes, including 5q and 18q (refs 1-10). The APC gene11-13 on 5q and the DCC gene14 on 18q have been identified as potential tumor suppressor genes, whose suppression contributes to colon carcinogenesis. To investigate the role of genes in these deleted regions, we have now introduced a single normal human chromosome into a human colon carcinoma cell line, COKFu, through microcell hybridization15-20. Several clones of hybrid cells containing normal chromosome 5, and others containing normal chromosome 18, were obtained. The morphology of the hybrid cells was markedly altered: the hybrids with chromosome 5 exhibited a closely packed polygonal morphology, and the hybrid cells with chromosome 18 were flattened. The cloning efficiency of the hybrid cells in soft agar was reduced from 0.46 to 0% of that of the parental carcinoma cells, and the tumorigenicity of these hybrid cells in athymic nude mice was completely suppressed. The growth properties of the hybrid cells with chromosome 11 were not substantially changed. These results strongly suggest that the genes on normal chromosome 5 and 18 function as tumor suppressors in colon carcinogenesis.	TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tottori University	TANAKA, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.							ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DIETZSCH E, 1986, NUCLEIC ACIDS RES, V14, P1923, DOI 10.1093/nar/14.4.1923; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, CARCINOGENESIS, V2, P12; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYAKI M, 1990, CANCER RES, V50, P7166; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; SASAKI M, 1989, CANCER RES, V49, P4402; SAXSON PJ, 1986, EMBO J, V5, P3461; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	25	184	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					340	342		10.1038/349340a0	http://dx.doi.org/10.1038/349340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1670965				2022-12-28	WOS:A1991EU50100056
J	[Anonymous]				[Anonymous]			SURGEONS AND HIV	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					169	169						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670803				2022-12-28	WOS:A1991ET67900021
J	MILLER, E; ASHWORTH, LAE; ROBINSON, A; WAIGHT, PA; IRONS, LI				MILLER, E; ASHWORTH, LAE; ROBINSON, A; WAIGHT, PA; IRONS, LI			PHASE-II TRIAL OF WHOLE-CELL PERTUSSIS-VACCINE VS AN ACELLULAR VACCINE CONTAINING AGGLUTINOGENS	LANCET			English	Article							BORDETELLA-PERTUSSIS	An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.	PUBL HLTH LAB SERV,SALISBURY,ENGLAND		MILLER, E (corresponding author), COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,COMMUNICABLE DIS SURVEILLANCE UNIT,LONDON NW9 5EQ,ENGLAND.							[Anonymous], 1988, LANCET, Vi, P955; KURONEN T, 1979, INT S PERTUSSIS, P34; MOXON ER, 1990, LANCET, V335, P1324, DOI 10.1016/0140-6736(90)91200-T; POLLOCK TM, 1984, LANCET, V2, P146, DOI 10.1016/S0140-6736(84)91057-2; PRESTON NW, 1976, J HYG-CAMBRIDGE, V77, P85, DOI 10.1017/S0022172400055546; ROBINSON A, 1989, VACCINE, V7, P491, DOI 10.1016/0264-410X(89)90270-3; ROBINSON A, 1989, VACCINE, V7, P321, DOI 10.1016/0264-410X(89)90193-X; RUTTER DA, 1988, VACCINE, V6, P29, DOI 10.1016/0264-410X(88)90010-2; STORSAETER J, 1990, VACCINE, V8, P457, DOI 10.1016/0264-410X(90)90246-I; 1989, IMMUNISATION INFECTI; 1979, WHO TECH REP SER, V638, P60	11	41	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					70	73		10.1016/0140-6736(91)90735-8	http://dx.doi.org/10.1016/0140-6736(91)90735-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670725				2022-12-28	WOS:A1991ER47700003
J	DOTTI, CG; PARTON, RG; SIMONS, K				DOTTI, CG; PARTON, RG; SIMONS, K			POLARIZED SORTING OF GLYPIATED PROTEINS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							CELLS; CULTURE	Our recent studies suggested that neurons and epithelial cells sort viral glycoproteins in a similar manner. The apical influenza virus haemagglutinin was preferentially delivered to the axon of hippocampal neurons in culture, whereas the basolateral vesicular stomatitis virus glycoprotein was sorted to the dendrites. 1 To investigate whether other membrane proteins showed similar sorting in neurons and epithelial cells, we have analysed the localization of a glypiated (glycosylphosphatidylinositol-anchored) protein, Thy-1, in hippocampal neurons in culture. In MDCk and other epithelial cells, endogenous glycosylphosphatidylinositol (GPI)-anchored proteins, as well as mutated exogenous proteins containing the GPI-attachment signal, undergo preferential delivery to the apical surface 2-4. This polarized sorting of GPI-anchored proteins has been been proposed to occur by the same mechanisms as the sorting of glycolipids to the apical surface 5,6. We report here that the neuronal GPI-protein Thy-1 is present in hippocampal neurons in culture and is exclusively located on the axonal surface. This finding further strengthens our hypothesis that the mechanisms of sorting of surface components may be similar in neurons and epithelial cells.			DOTTI, CG (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Dotti, Carlos G/I-5533-2015; Parton, Robert G/C-5673-2009	Dotti, Carlos G/0000-0003-4052-1719; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				BANKER GA, 1988, INTRINSIC DETERMINAN, P61; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; LAEMMLI V, 1979, NATURE, V257, P418; LISANTI M, 1989, J CELL BIOL, V109, P2140; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MASON D, 1980, BIOCHEM J, V147, P1; MORRIS RJ, 1985, J NEUROCYTOL, V14, P427, DOI 10.1007/BF01217754; ROTHMAN S, 1981, J COMP NEUROL, V195, P141, DOI 10.1002/cne.901950108; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON JM, 1990, J CELL SCI, V96, P143	20	218	220	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					158	160		10.1038/349158a0	http://dx.doi.org/10.1038/349158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670898				2022-12-28	WOS:A1991ER41800059
J	RUBEN, B; BAND, JD; WONG, P; COLVILLE, J				RUBEN, B; BAND, JD; WONG, P; COLVILLE, J			PERSON-TO-PERSON TRANSMISSION OF BRUCELLA-MELITENSIS	LANCET			English	Note								Human brucellosis is primarily an occupational hazard in the USA; in the Middle East and Africa ingestion of contaminated diary products is an important route of infection. Whether human beings can become infected via person-to-person spread is uncertain. During an investigation of a common-source, laboratory-associated outbreak due to Brucella melitensis, biotype 3, the wife of a microbiologist with serologically proven brucellosis became infected. Her blood isolate was indistinguishable from the epidemic strain. In the absence of other risk factors, we suggest that sexual intercourse is a possible means of transmission.	WILLIAM BEAUMONT HOSP,DIV INFECT DIS,ROYAL OAK,MI 48073; WILLIAM BEAUMONT HOSP,DEPT MICROBIOL,ROYAL OAK,MI 48073	Beaumont Health; Beaumont Health								BRUCELLOSIS, 1990, CONTROL COMMUNICABLE, P66; BRUCELLOSIS, 1988, REPORT COMMITTEE INF, P140; FORBES K A, 1954, Urol Surv, V4, P391; FOX MD, 1977, J INFECT DIS, V136, P312, DOI 10.1093/infdis/136.2.312; GOOSSENS H, 1983, LANCET, V1, P773; Kaufmann A F, 1980, Ann N Y Acad Sci, V353, P105, DOI 10.1111/j.1749-6632.1980.tb18912.x; LUBANI MM, 1988, EUR J PEDIATR, V147, P520, DOI 10.1007/BF00441980; NAPARSTEK E, 1982, LANCET, V1, P574; STANTICPAVLINIC M, 1983, INFECTION, V11, P313, DOI 10.1007/BF01641354; YOUNG EJ, 1975, ARCH INTERN MED, V135, P240, DOI 10.1001/archinte.135.2.240	10	58	64	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					14	15		10.1016/0140-6736(91)93332-4	http://dx.doi.org/10.1016/0140-6736(91)93332-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670649				2022-12-28	WOS:A1991EQ60400006
J	DENNING, DW				DENNING, DW			PROPHYLACTIC FLUCONAZOLE AND MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											DENNING, DW (corresponding author), MONSALL HOSP,MANCHESTER M10 8WR,ENGLAND.		Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251				WINSTON DJ, 1991, 31ST INT C ANT AG CH	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					645	645						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640964				2022-12-28	WOS:A1992JK20400020
J	PONTICELLI, C; ZUCCHELLI, P; PASSERINI, P; CESANA, B				PONTICELLI, C; ZUCCHELLI, P; PASSERINI, P; CESANA, B			METHYLPREDNISOLONE PLUS CHLORAMBUCIL AS COMPARED WITH METHYLPREDNISOLONE ALONE FOR THE TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; NATURAL-HISTORY; NEPHROTIC SYNDROME; RENAL-FUNCTION; GLOMERULONEPHRITIS; PREDNISONE; IMMUNOSUPPRESSION; CYCLOPHOSPHAMIDE; NEOPLASIA	Background and Methods. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). Results. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). Conclusions. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.	OSPED MAGGIORE MILANO,IST SCI,DIV NEPHROL & DIAL,MILAN,ITALY; OSPED MALPIGHI BOLOGNA,BOLOGNA,ITALY; OSPED MAGGIORE MILANO,EPIDEMIOL LAB,DIREZ SCI,MILAN,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna								ABE S, 1989, AM J NEPHROL, V9, P30, DOI 10.1159/000167931; ALPERS CE, 1986, KIDNEY INT, V30, P465, DOI 10.1038/ki.1986.209; ARMITAGE P, 1987, STATISTICAL METHODS; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; CADMAN EC, 1991, HARRISONS PRINCIPLES, P1587; CAMERON JS, 1990, Q J MED, V74, P1313; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1988, NEPHROLOGY, P695; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; EAGEN JW, 1977, KIDNEY INT, V11, P297, DOI 10.1038/ki.1977.47; EHRENREICH T, 1976, NEW ENGL J MED, V295, P741, DOI 10.1056/NEJM197609302951401; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GEISSER S, 1958, ANN MATH STAT, V29, P885, DOI 10.1214/aoms/1177706545; HOPPER J, 1989, NEW ENGL J MED, V321, P260; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNT LP, 1988, KIDNEY INT, V34, P382, DOI 10.1038/ki.1988.192; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; LAGRUE G, 1975, J UROL NEPHROL, V81, P655; MACTIER R, 1986, Q J MED, V60, P793; MATHIESON PW, 1988, LANCET, V2, P869; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; PONTICELLI C, 1991, NEPHROL DIAL TRANSPL, V6, P381, DOI 10.1093/ndt/6.6.381; RAMZY MH, 1981, CLIN NEPHROL, V16, P13; SUKI WN, 1981, AM J NEPHROL, V1, P11, DOI 10.1159/000166481; TILLER DJ, 1981, 8TH P INT C NEPHR, P345; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247; WILLIAMS PS, 1989, NEPHROL DIAL TRANSPL, V4, P181, DOI 10.1093/oxfordjournals.ndt.a091853; Zucchelli P, 1987, Nephrol Dial Transplant, V2, P73	32	146	152	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					599	603		10.1056/NEJM199208273270904	http://dx.doi.org/10.1056/NEJM199208273270904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640953	Bronze			2022-12-28	WOS:A1992JK20400004
J	DINERMAN, H; STEERE, AC				DINERMAN, H; STEERE, AC			LYME-DISEASE ASSOCIATED WITH FIBROMYALGIA	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; FIBROMYALGIA; FATIGUE; HEADACHE; SLEEP DISORDERS	NEUROLOGIC MANIFESTATIONS; BORRELIOSIS; PENICILLIN; FIBROSITIS; ARTHRITIS; DIAGNOSIS; ASSAY	Objective: To describe the clinical and laboratory findings as well as results of treatment in patients with Lyme disease associated with fibromyalgia. Design: Observational cohort study. The mean duration of observation was 2.5 years (range, 1 to 4 years). Setting. Diagnostic Lyme disease clinic in a university hospital. Patients: Of 287 patients seen with Lyme disease during a 3.5-year period, 22 (8%) had fibromyalgia associated with this illness, and 15 (5%) participated in the observational study. Measurements: Symptoms and signs of fibromyalgia, immunodiagnostic tests for Lyme disease, and tests of neurologic function. Results: Of the 15 patients, 9 developed widespread musculoskeletal pain, tender points, dysesthesias, memory difficulties, and debilitating fatigue a mean duration of 1.7 months after early Lyme disease; the remaining six patients developed those symptoms during the course of Lyme arthritis. At the time of our evaluation, late in the course of their illness, 11 patients had positive immunoglobulin (Ig) G antibody responses to Borrelia burgdorferi by enzyme-linked immunosorbent assay (ELISA), one had a positive Western blot, and the three seronegative patients had positive cellular immune responses to borrelial antigens. Four patients had abnormal cerebrospinal fluid analyses that showed an elevated protein level, a slight pleocytosis, or intrathecal antibody production to the spirochete. The signs of Lyme disease resolved with antibiotic therapy, usually intravenous ceftriaxone, 2 g/d for 2 to 4 weeks, except in one patient with persistent knee swelling. However, 14 of the 15 patients continued to have symptoms of fibromyalgia. Currently, only one patient is completely asymptomatic. Conclusions: Lyme disease may trigger fibromyalgia, but antibiotics do not seem to be effective in the treatment of the fibromyalgia.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	DINERMAN, H (corresponding author), NEW ENGLAND MED CTR, BOX 406, 750 WASHINGTON ST, BOSTON, MA 02111 USA.			Steere, Allen/0000-0002-5268-9853	NIAMS NIH HHS [AR-20358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENGTSSON A, 1986, ARTHRITIS RHEUM, V29, P817, DOI 10.1002/art.1780290701; CAPUTO GM, 1991, JAMA-J AM MED ASSOC, V266, P359, DOI 10.1001/jama.1991.03470030059010; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; IMBODEN JB, 1959, ARCH INTERN MED, V103, P406, DOI 10.1001/archinte.1959.00270030037004; KAPLAN RE, 1992, IN PRESS NEUROLOGY, P42; KRUEGER J M, 1989, Journal of Rheumatology, V16, P52; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; MOLDOFSKY H, 1975, PSYCHOSOM MED, V37, P341, DOI 10.1097/00006842-197507000-00008; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; REILLY P A, 1990, Current Opinion in Rheumatology, V2, P282; RUSSELL IJ, 1989, RHEUM DIS CLIN N AM, V15, P149; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIMMS RW, 1988, J RHEUMATOL, V15, P1271; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WOLFE F, 1985, J RHEUMATOL, V12, P1159; YOUNG EJ, 1982, J INFECT DIS, V146, P606, DOI 10.1093/infdis/146.5.606; 1991, MMWR, V40, P417	33	177	182	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					281	285		10.7326/0003-4819-117-4-281	http://dx.doi.org/10.7326/0003-4819-117-4-281			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637022				2022-12-28	WOS:A1992JH46400002
J	DAVIES, K				DAVIES, K			MOVING STRAIGHT TO THE TARGET	NATURE			English	Article							GENE											ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; VERMA IM, 1990, SCI AM, V263, P68, DOI 10.1038/scientificamerican1190-68; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	9	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					519	519		10.1038/358519a0	http://dx.doi.org/10.1038/358519a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641042	Bronze			2022-12-28	WOS:A1992JG73900055
J	FU, XY				FU, XY			A TRANSCRIPTION FACTOR WITH SH2 AND SH3 DOMAINS IS DIRECTLY ACTIVATED BY AN INTERFERON-ALPHA-INDUCED CYTOPLASMIC PROTEIN TYROSINE KINASE(S)	CELL			English	Article							GENE REGULATORY ELEMENTS; INDUCED NUCLEAR FACTORS; PHOSPHOLIPASE-C-GAMMA; CLASS-I GENES; SIGNAL TRANSDUCTION; STIMULATED TRANSCRIPTION; BINDING PROTEIN; PDGF RECEPTOR; CONSENSUS SEQUENCE; ENHANCER ELEMENT	Interferon-stimulated gene factor 3 (ISGF3), the primary transcription factor induced by interferon-alpha, is a complex of four (113, 91, 84, and 48 kd) proteins. This paper reports that the 113, 91, and 84 kd (ISGF3-alpha) proteins of ISGF3 contain conserved SH2 and SH3 domains. A specific interferon alpha-induced cytoplasmic protein tyrosine kinase(s) can form a transient complex with ISGF3-alpha proteins. These ISGF3-alpha proteins can be immunoprecipitated by anti-phosphotyrosine antibodies only after interferon-alpha treatment. Phosphoamino acid analyses of P-32-labeled ISGF3-alpha proteins confirm that ISGF3-alpha proteins are directly tyrosine phosphorylated both in vitro and in vivo in response to interferon-alpha, and this tyrosine phosphorylation can be inhibited by staurosporine and genistein. Phosphatase treatment of these ISGF3-alpha proteins results in inhibition of ISGF3 complex formation in vitro. These observations indicate that interferon alpha-induced direct tyrosine phosphorylation of ISGF3-alpha proteins is necessary for activation of the transcription factor ISGF3.			FU, XY (corresponding author), CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEMAEYER E, 1989, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EISEMAN E, 1992, NATURE, V355, P78; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, IN PRESS P NATL ACAD; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; HANNIGAN GE, 1991, J BIOL CHEM, V266, P8765; HARLOW E, 1988, ANTIBODIES LABORATOR; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVY D, 1990, New Biologist, V2, P923; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou G, 1989, CURR OPIN CELL BIOL, V1, P167, DOI 10.1016/0955-0674(89)90082-3; PAWSON T, 1988, ONCOGENE, V3, P491; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHINDLER C, 1992, IN PRESS SCIENCE; SCHINDLER C, 1992, IN PRESS P NATL ACAD; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, IN PRESS MOL CELL BI; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WATERFIELD MD, 1991, METHOD ENZYMOL, V200, P627; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; [No title captured]; [No title captured]	125	379	400	2	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					323	335		10.1016/0092-8674(92)90106-M	http://dx.doi.org/10.1016/0092-8674(92)90106-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638633				2022-12-28	WOS:A1992JE75700015
J	HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A				HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A			A CDNA-ENCODING A PRB-BINDING PROTEIN WITH PROPERTIES OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; SV40 LARGE-T; CELL-CYCLE; DNA-BINDING; RB GENE; REGULATORY SEQUENCES; TRANS-ACTIVATION	The retinoblastoma protein (PRB) plays an important role in the control of cell proliferation, apparently by binding to and regulating cellular transcription factors such as E2F. Here we describe the characterization of a cDNA clone that encodes a protein with properties of E2F. This clone, RBP3, was identified by the ability of its gene product to interact with pRB. RBP3 bound to pRB both in vitro and in vivo, and this binding was competed by viral proteins known to disrupt pRB-E2F association. RBP3 bound to E2F recognition sequences in a sequence-specific manner. Furthermore, transient expression of RBP3 caused a 10-fold transactivation of the adenovirus E2 promoter, and this transactivation was dependent on the E2F recognition sequences. These properties suggest that RBP3 encodes E2F, or an E2F-like protein.			HELIN, K (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02129 USA.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; 				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	79	651	685	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					337	350		10.1016/0092-8674(92)90107-N	http://dx.doi.org/10.1016/0092-8674(92)90107-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638634				2022-12-28	WOS:A1992JE75700016
J	CARDE, P				CARDE, P			CURRENT ISSUES IN CANCER .10. HODGKINS-DISEASE .1. IDENTIFICATION AND CLASSIFICATION	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL STAGE-I; PROGNOSTIC FACTORS; THERAPY; IRRADIATION; PREDICTOR; CELLS				CARDE, P (corresponding author), INST GUSTAVE ROUSSY,SERV MED,CS AXEL UNIT,F-94805 VILLEJUIF,FRANCE.							BERGSAGEL DE, 1982, CANCER TREAT REP, V66, P717; BRADA M, 1986, RADIOTHER ONCOL, V5, P15, DOI 10.1016/S0167-8140(86)80004-4; Carde P, 1989, Recent Results Cancer Res, V117, P101; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; CARDE P, 1988, NATL CANCER I MONOGR, V6, P303; CARDE P, 1992, IN PRESS CLIN STAGIN; CULINE S, 1989, EUR J CANCER CLIN ON, V25, P551, DOI 10.1016/0277-5379(89)90269-1; DIEHL V, 1990, SEMIN ONCOL, V17, P660; FOBAIR P, 1986, J CLIN ONCOL, V4, P805, DOI 10.1200/JCO.1986.4.5.805; FRIEDMAN S, 1988, J CLIN ONCOL, V6, P596, DOI 10.1200/JCO.1988.6.4.596; GAUSE A, 1991, BLOOD, V77, P1983; GLATSTEIN E, 1969, CANCER-AM CANCER SOC, V24, P709, DOI 10.1002/1097-0142(196910)24:4<709::AID-CNCR2820240408>3.0.CO;2-E; HAGEMEISTER FB, 1990, CANCER, V65, P1090, DOI 10.1002/1097-0142(19900301)65:5<1090::AID-CNCR2820650509>3.0.CO;2-#; HAYBITTLE JL, 1985, LANCET, V1, P967; HENRYAMAR M, 1990, INT J RADIAT ONCOL, V19, P1155, DOI 10.1016/0360-3016(90)90221-5; HENRYAMAR M, 1990, SEMIN ONCOL, V17, P758; HENRYAMAR M, 1991, ANN INTERN MED, V114, P361, DOI 10.7326/0003-4819-114-5-361; HOHL RJ, 1989, HEMATOL ONCOL CLIN N, V3, P331, DOI 10.1016/S0889-8588(18)30560-4; JUCKER M, 1991, BLOOD, V77, P2413; KADIN ME, 1990, AM J PATHOL, V136, P1209; Kaplan H.S., 1980, HODGKINS DISEASE; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; MANSFIELD CM, 1990, CANCER, V66, P2295, DOI 10.1002/1097-0142(19901201)66:11<2295::AID-CNCR2820661107>3.0.CO;2-S; MAUCH P, 1988, J CLIN ONCOL, V6, P1576, DOI 10.1200/JCO.1988.6.10.1576; MCLENNAN KA, 1989, CANCER, V64, P1686; MUELLER N, 1991, ANN ONCOL, V2, P23, DOI 10.1093/annonc/2.suppl_2.23; RADFORD JA, 1988, J CLIN ONCOL, V6, P940, DOI 10.1200/JCO.1988.6.6.940; REE HJ, 1987, CANCER, V59, P1717, DOI 10.1002/1097-0142(19870515)59:10<1717::AID-CNCR2820591007>3.0.CO;2-U; SAMOSZUK M, 1990, BLOOD, V75, P13; SMITH SR, 1991, ANN ONCOL, V2, P39, DOI 10.1093/annonc/2.suppl_2.39; SOMERS R, 1990, C INSERM, V196; SOMERS R, 1988, P AM SOC CLIN ONCOL, V914, P236; SPECHT L, 1991, CANCER TREAT REV, V18, P21, DOI 10.1016/0305-7372(91)90003-I; STEIN H, 1991, ANN ONCOL, V2, P33, DOI 10.1093/annonc/2.suppl_2.33; TUBIANA M, 1985, INT J RADIAT ONCOL, V11, P23, DOI 10.1016/0360-3016(85)90358-X; TUBIANA M, 1989, BLOOD, V73, P47; TUBIANA M, 1981, EUR J CANCER, V17, P355, DOI 10.1016/0014-2964(81)90128-6; TUBIANA M, 1979, INT J RADIAT ONCOL, V15, P645; URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006	39	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					99	102		10.1136/bmj.305.6845.99	http://dx.doi.org/10.1136/bmj.305.6845.99			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1638255	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JD85000029
J	YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG				YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG			RXR-BETA - A COREGULATOR THAT ENHANCES BINDING OF RETINOIC ACID, THYROID-HORMONE, AND VITAMIN-D RECEPTORS TO THEIR COGNATE RESPONSE ELEMENTS	CELL			English	Article							HUMAN OSTEOCALCIN GENE; DNA-BINDING; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; MOLECULAR-CLONING; MAMMALIAN-CELLS; SEQUENCE; PROTEINS; IDENTIFICATION; TRANSCRIPTION	The retinoic acid receptor (RAR) requires coregulators to bind effectively to response elements in target genes. A strategy of sequential screening of expression libraries with a retinoic acid response element and RAR identified a cDNA encoding a coregulator highly related to RXR-alpha. This protein, termed RXR-beta, forms heterodimers with RAR, preferentially increasing its DNA binding and transcriptional activity on promoters containing retinoic acid, but not thyroid hormone or vitamin D, response elements. Remarkably, RXR-beta also heterodimerizes with the thyroid hormone and vitamin D receptors, increasing both DNA binding and transcriptional function on their respective response elements. RXR-alpha also forms heterodimers with these receptors. These observations suggest that retinoid X receptors meet the criteria for biochemically characterized cellular coregulators and serve to selectively target the high affinity binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate DNA response elements.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,MOLEC PATHOL GRP,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	YU, VC (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Yu, Victor/A-7899-2015; Glass, Christopher/AAI-3933-2021	Yu, Victor/0000-0003-3270-4734; Glass, Christopher/0000-0003-4344-3592				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P299; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HE X, 1989, NATURE, V343, P38; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1095, P63; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9781; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIPKIN SM, 1991, IN PRESS P NATL ACAD; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPORN MB, 1983, CANCER RES, V43, P3034; STUDIER FW, 1986, J MOL BIOL, V189, P13; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	78	1237	1264	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1251	1266		10.1016/0092-8674(91)90301-E	http://dx.doi.org/10.1016/0092-8674(91)90301-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662118				2022-12-28	WOS:A1991GX16400023
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOOD LABELING REFORM INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-28	WOS:A1991GU96400003
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			INJECTED XWNT-8 RNA ACTS EARLY IN XENOPUS EMBRYOS TO PROMOTE FORMATION OF A VEGETAL DORSALIZING CENTER	CELL			English	Article							MESODERM-INDUCING FACTOR; MESSENGER-RNA; CELL LINEAGE; AMPHIBIAN DEVELOPMENT; LAEVIS EMBRYOS; GROWTH-FACTOR; INDUCTION; EXPRESSION; AXIS; PATTERN	Expression cloning from a pool of gastrula cDNAs identified the Wnt family member Xwnt-8 as having dorsal axis-inducing activity in Xenopus embryos. Microinjected Xwnt-8 mRNA was able to rescue the development of a dorsally complete anterior-posterior axis in embryos ventralized by exposure to UV light. Axis induction was observed in embryos injected in either marginal or vegetal blastomeres at the 32-cell stage. Vegetal blastomeres receiving Xwnt-8 mRNA contributed progeny not to the induced dorsal axis, but to the endoderm, a result consistent with Xwnt-8 causing cells to act as a Nieuwkoop center (the vegetal-inducing component of normal dorsal axis formation), rather than as a Spemann organizer (the induced dorsal marginal zone component that directly forms the dorsal mesoderm). Xwnt-8, which is normally expressed ventrally in midgastrula and neurula embryos, appears to mimic, when injected, maternally encoded dorsal mesoderm-inducing factors that act early in development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; COOKE J, 1987, DEVELOPMENT, V99, P197; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1987, DEVELOPMENT, V99, P527; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; FRANK D, 1991, IN PRESS DEVELOPMENT; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; Gerhart J, 1980, BIOL REGULATION DEV, V2; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1991, IN PRESS METH CELL B, V36; HAUSEN P, 1991, EARLY DEV XENOPUS; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1991, ADV DEV BIOL, V1, P31; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1973, ADV MORPHOGEN, V10, P2; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P361; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	59	544	558	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					753	765		10.1016/0092-8674(91)90070-F	http://dx.doi.org/10.1016/0092-8674(91)90070-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657405				2022-12-28	WOS:A1991GQ40700012
J	WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R				WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R			INCREASE IN CANDIDA-KRUSEI INFECTION AMONG PATIENTS WITH BONE-MARROW TRANSPLANTATION AND NEUTROPENIA TREATED PROPHYLACTICALLY WITH FLUCONAZOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TORULOPSIS-GLABRATA; FUNGEMIA; FREQUENCY; CANCER; FEVER; COLONIZATION; THERAPY	Background. In early 1990 fluconazole was introduced as a prophylactic antifungal agent after bone marrow transplantation. During the same year Candida krusei emerged as the chief candida pathogen among patients with bone marrow transplants. Methods. To determine whether there was a correlation between the introduction of fluconazole and the increased incidence of C. krusei, we conducted a retrospective study based on the medical, mycologic, and autopsy records of all adult inpatients who had undergone bone marrow transplantation (n = 296) or who had leukemia (n = 167) at the study center during 1989 and 1990. Results. The 84 patients who received antifungal prophylaxis with fluconazole had a sevenfold greater frequency of C. krusei infection than the 335 patients who did not receive fluconazole (8.3 percent vs. 1.2 percent, P = 0.002), despite having a lower frequency of disseminated C. albicans and C. tropicalis infections (0 vs. 6.0 percent, P = 0.02). Ten of the 11 C. krusei infections were controlled by a combination of amphotericin B and flucytosine. Colonization by C. krusei was found in 40.5 percent of the patients who received fluconazole but in only 16.7 percent of those who did not receive it (P < 0.0001). Colonization was independently associated with the prophylactic use of both fluconazole (odds ratio, 3.50; P < 0.001) and norfloxacin (odds ratio, 2.53; P = 0.04). C. krusei was not susceptible to fluconazole in vitro. Conclusions. In patients at high risk for disseminated candida infections, suppression of bacterial flora and the more common candida pathogens may permit some less pathogenic, but natively resistant candida species, such as C. krusei, to emerge as systemic pathogens.	JOHNS HOPKINS MED INST,DEPT LAB MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,CTR ONCOL,BALTIMORE,MD 21205; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; NCI,OFF DIRECTOR,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WINGARD, JR (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BONE MARROW TRANSPLANT PROGRAM,ATLANTA,GA 30322, USA.			Wingard, John/0000-0001-7478-5398	NCI NIH HHS [CA15396, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, P01CA015396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISNER J, 1976, AM J MED, V61, P23, DOI 10.1016/0002-9343(76)90026-7; CALDERONE RA, 1987, REV INFECT DIS, V9, pS400; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; HARVEY RL, 1987, ARCH INTERN MED, V147, P2117, DOI 10.1001/archinte.147.12.2117; HORN R, 1985, REV INFECT DIS, V7, P646; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KARP JE, 1991, REV INFECT DIS, V13, P592; KING RD, 1980, INFECT IMMUN, V27, P667, DOI 10.1128/IAI.27.2.667-674.1980; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; MCILROY MA, 1991, J INFECT DIS, V163, P420, DOI 10.1093/infdis/163.2.420; MERZ WG, 1984, J CLIN MICROBIOL, V20, P1194, DOI 10.1128/JCM.20.6.1194-1195.1984; MERZ WG, 1986, J CLIN MICROBIOL, V24, P581, DOI 10.1128/JCM.24.4.581-584.1986; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; Rinaldi M. G., 1988, DIAGNOSTIC PROCEDURE, P325; SANDFORD GR, 1980, J INFECT DIS, V142, P503, DOI 10.1093/infdis/142.4.503; WILEY JM, 1990, J CLIN ONCOL, V8, P280, DOI 10.1200/JCO.1990.8.2.280; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1979, ANN INTERN MED, V91, P539, DOI 10.7326/0003-4819-91-4-539; 1989, AM J MED, V86, P668	21	813	830	1	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1274	1277		10.1056/NEJM199110313251803	http://dx.doi.org/10.1056/NEJM199110313251803			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1669837				2022-12-28	WOS:A1991GM04100003
J	TAMPE, R; CLARK, BR; MCCONNELL, HM				TAMPE, R; CLARK, BR; MCCONNELL, HM			ENERGY-TRANSFER BETWEEN 2 PEPTIDES BOUND TO ONE MHC CLASS-II MOLECULE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN; RECOGNITION	The 17-amino acid peptide from chicken ovalbumin, Ova(323-339), was labeled at the amino terminus with fluorescein [FOva(323-339)] and near the carboxyl terminus with Texas Red [AcOva(323-338)KTR]. Fluorescence spectroscopy was carried out on resolved electrophoretic bands on nonreducing polyacrylamide gels derived from incubation mixtures containing major histocompatibility complex (MHC) class II molecules IA(d) and the FOva(323-339)- and AcOva(323-338)KTR-labeled peptides. Energy transfer between fluorescein and Texas Red was observed in the "floppy" alpha-beta heterodimer band, but not in the "compact" alpha-beta heterodimer band. Energy transfer was detected between the truncated peptides FOva(323-328)CONH2 and AcOva(331-338)KTR in both the compact alpha-beta and floppy alpha-beta gel bands. The energy-transfer data suggest that the two binding sites of floppy alpha-beta arise from splitting apart a putative large, single binding site region in compact alpha-beta.	ANERGEN INC,REDWOOD CITY,CA 94063		TAMPE, R (corresponding author), STANFORD UNIV,STAUFFER LAB PHYS CHEM,STANFORD,CA 94305, USA.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160	NIAID NIH HHS [2R37 AI 13587-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013587] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAYANI H, 1989, J EXP MED, V170, P1609, DOI 10.1084/jem.170.5.1609; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; DORMAIR K, 1990, P NATL ACAD SCI USA, V87, P4143; DORNMAIR K, UNPUB; DORNMAIR K, 1990, COLD SPRING HARB SYM, V54, P409; FOSTER T, 1946, NATURWISSENSCHAFTEN, V6, P166; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHNO S, 1991, P NATL ACAD SCI USA, V88, P3065, DOI 10.1073/pnas.88.8.3065; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERUTZ MF, 1972, NATURE, V237, P495, DOI 10.1038/237495a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TAMPE R, UNPUB	17	40	42	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					87	89		10.1126/science.1656526	http://dx.doi.org/10.1126/science.1656526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656526				2022-12-28	WOS:A1991GH60500032
J	HUME, RI; DINGLEDINE, R; HEINEMANN, SF				HUME, RI; DINGLEDINE, R; HEINEMANN, SF			IDENTIFICATION OF A SITE IN GLUTAMATE RECEPTOR SUBUNITS THAT CONTROLS CALCIUM PERMEABILITY	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; CHLORIDE CURRENT; XENOPUS OOCYTES; CHANNELS; NEURONS; FAMILY; INJECTION; CLONING	The neurotransmitter glutamate mediates excitatory synaptic transmission throughout the brain. A family of genes encoding subunits of the non-N-methyl-D-aspartate (non-NMDA) type of glutamate receptor has been cloned. Some combinations of these subunits assemble into receptors with a substantial permeability to calcium, whereas others do not. To investigate the structural features that control ion permeation through these ligand-gated channels, mutant receptors subunits with single-amino acid changes were constructed. Mutation of a certain amino acid that results in a net charge change (from glutamine to arginine or vice versa) alters both the current-voltage relation and the calcium permeability of non-NMDA receptors. A site has thus been identified that regulates the permeation properties of these glutamate receptors.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Salk Institute; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill			, Richard/AAI-5000-2020; dingledine, Ray/F-5173-2011	Dingledine, Ray/0000-0001-7128-4520; Hume, Richard/0000-0001-9807-112X	NINDS NIH HHS [NS25782, NS28709, NS21043] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021043, R01NS025782, R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DINGLEDINE R, UNPUB; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	23	621	634	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1028	1031		10.1126/science.1653450	http://dx.doi.org/10.1126/science.1653450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653450				2022-12-28	WOS:A1991GC98200045
J	GOODWIN, FK				GOODWIN, FK			ALCOHOL, CAFFEINE, AND FETAL CELLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							HENDERSON GI, 1991, ALCOHOL CLIN EXP RES, V15, P175, DOI 10.1111/j.1530-0277.1991.tb01850.x	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1650851				2022-12-28	WOS:A1991GB97500008
J	CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M				CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRK TYROSINE PROTEIN-KINASE MEDIATES THE MITOGENIC PROPERTIES OF NERVE GROWTH-FACTOR AND NEUROTROPHIN-3	CELL			English	Article							FACTOR NGF RECEPTORS; MOLECULAR-CLONING; FACTOR FAMILY; GENE-TRANSFER; HIGH-AFFINITY; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; EXPRESSION; ONCOGENE	The product of the trk proto-oncogene encodes a receptor for nerve growth factor (NGF). Here we show that NGF is a powerful mitogen that can induce resting NIH 3T3 cells to enter S phase, grow in semisolid medium, and become morphologically transformed. These mitogenic effects are absolutely dependent on expression of gp140trk receptors, but do not require the presence of the previously described low affinity NGF receptor. gp140trk also serves as a receptor for the related factor neurotrophin-3 (NT-3), but not for brain-derived neurotrophic factor. Both NGF and NT-3 induce the rapid phosphorylation of gp140trk receptors and the transient expression of c-Fos proteins. However, NT-3 appears to elicit more limited mitogenic responses than NGF. These results indicate that the product of the trk proto-oncogene is sufficient to mediate signal transduction processes induced by NGF and NT-3, at least in proliferating cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,GROWTH REGULAT LAB,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,BIOTECHNOL LAB,PRINCETON,NJ 08543; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; Bristol-Myers Squibb; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CORDONCARDO, C (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,MOLEC ONCOL LAB,POB 4000,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008; Kovary, Karla/E-3979-2013; Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017	Klein, Ruediger/0000-0002-3109-0163; Lamballe, Fabienne/0000-0001-7631-942X; JONES, KEVIN/0000-0002-3802-7562	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016033-190014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; BARBACID M, 1991, IN PRESS ACTA REV CA; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1991, BIOCHEM BIOPH RES CO, V174, P379, DOI 10.1016/0006-291X(91)90531-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1991, IN PRESS CELL, V66; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REPRESA J, 1989, DEV BIOL, V134, P21, DOI 10.1016/0012-1606(89)90074-2; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SUTTER A, 1979, J BIOL CHEM, V254, P5972; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	59	499	513	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					173	183		10.1016/0092-8674(91)90149-S	http://dx.doi.org/10.1016/0092-8674(91)90149-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649007	Green Accepted			2022-12-28	WOS:A1991FW91300019
J	MAASILTA, P; HALME, M; MATTSON, K; CANTELL, K				MAASILTA, P; HALME, M; MATTSON, K; CANTELL, K			PHARMACOKINETICS OF INHALED RECOMBINANT AND NATURAL ALPHA INTERFERON	LANCET			English	Letter									NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	MAASILTA, P (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT PULM MED,SF-00290 HELSINKI,FINLAND.							BOCCI V, 1984, ANTIVIR RES, V4, P211, DOI 10.1016/0166-3542(84)90019-6; KINNULA V, 1989, J INTERFERON RES, V9, P419, DOI 10.1089/jir.1989.9.419	2	24	28	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					371	371		10.1016/0140-6736(91)91009-J	http://dx.doi.org/10.1016/0140-6736(91)91009-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671273				2022-12-28	WOS:A1991EX36200061
J	JACK, A; BRADLEY, D				JACK, A; BRADLEY, D			SCALES MODIFIED FOR DOSE DETERMINATION IN POPULATION-BASED CHEMOTHERAPY	LANCET			English	Article							SCHISTOSOMA-HAEMATOBIUM; GAMBIAN COMMUNITY; TRANSMISSION; INFECTION	Integration of schistosomiasis control into primary health care services in The Gambia required semiliterate health workers to administer praziquantel and metrifonate to the community in doses based on weight. Special scales to weigh people with a direct readout in the form of numbers of tablets obviated the need to read figures or make calculations at the scene. The scales were used with a simple record system. Coverage of up to 97% was achieved with single dose praziguantel; for three doses of metrifonate spread over 2 months, coverage reached 82.4%. The tablet scale was easy to devise and fit to commercial scales.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine								DUKE BOL, 1954, ANN TROP MED PARASIT, V48, P287, DOI 10.1080/00034983.1954.11685626; GOLL PH, 1984, T ROY SOC TROP MED H, V78, P222, DOI 10.1016/0035-9203(84)90282-7; Korte R., 1984, World Health, P22; MCCULLOUGH FS, 1954, ANN TROP MED PARASIT, V48, P277, DOI 10.1080/00034983.1954.11685625; Mott K. E., 1984, World Health Forum, V5, P221; SMITHERS S. R., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P354, DOI 10.1016/0035-9203(56)90044-X; SMITHERS S. R., 1958, ANN TROP MED AND PARASITOL, V52, P315; WILKINS HA, 1986, T ROY SOC TROP MED H, V80, P1009, DOI 10.1016/0035-9203(86)90308-1; WILKINS HA, 1977, ANN TROP MED PARASIT, V71, P53, DOI 10.1080/00034983.1977.11687161; WILSON A, 1984, WORLD HLTH       DEC, P26	10	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 26	1991	337	8735					219	221		10.1016/0140-6736(91)92171-W	http://dx.doi.org/10.1016/0140-6736(91)92171-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670852				2022-12-28	WOS:A1991EU92400015
J	GRAZIANO, JH; BLUM, C				GRAZIANO, JH; BLUM, C			LEAD-EXPOSURE FROM LEAD CRYSTAL	LANCET			English	Note								In a study of the elution of lead (Pb) from crystal decanters and glasses, port containing 89-mu-g Pb/l was placed in decanters and the Pb content of the wine rose steadily to 3518-mu-g/l after 4 months. Wines and spirits stored in crystal decanters for a long time contained Pb at concentrations up to 21 530-mu-g/l. In a short-term experiment white wine eluted small amounts of Pb from crystal glasses within minutes.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University	GRAZIANO, JH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							DELEACY EA, 1987, MED J AUSTRALIA, V147, P622; Elias RW, 1985, DIETARY ENV LEAD HUM, P79; Fernandez F., 1982, ATOM SPECTROSC, V3, P130; Nriagu J.O., 1985, DIETARY ENV LEAD HUM, P1; PLANCHES LTD, 1848, LEAD DISEASES TREATI, P37; 1988, NATURE EXTENT LEAD P, pI28	6	41	41	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					141	142						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670790				2022-12-28	WOS:A1991ET67900006
J	WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J				WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J			FAMILIAL COMBINED HYPERLIPEMIA LINKED TO THE APOLIPOPROTEIN AI-CIII-AIV GENE-CLUSTER ON CHROMOSOME-11Q23-Q24	NATURE			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; CORONARY HEART-DISEASE; DNA POLYMORPHISMS; LINKAGE ANALYSIS; LIPID-LEVELS; DEFICIENCY; HUMANS	Familial combined hyperlipidaemia (FCHL) is a common inherited disorder of lipid metabolism with a prevalence of 0.5-2.0% (refs 1,2). It is estimated to cause 10% of premature coronary heart disease 1,3. The underlying metabolic and genetic defects in FCHL have not been identified, but a population study has suggested an association between FCHL and an XmnI restriction fragment length polymorphism (RFLP) within the apolipoprotein AI-CIII-AIV gene cluster 4. Here we confirm this association and show that it results from linkage disequilibrium between FChl and the 6.6-kilobase (kb) allele of the XmnI RFLP. Subsequent analysis in seven FChl families, ascertained through a proband carrying the 6.6 kb XmnI allele, demonstrated linkage to the AI-CIII-AIV cluster on 11q23-q24, z = 6.86 with no recombinants. This assignment will facilitate the identification of the mutation that causes hyperlipidaemia in these families.	NORTHWICK PK HOSP & CLIN RES CTR,MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; GLASGOW ROYAL INFIRM,INST PATHOL BIOCHEM,GLASGOW G4 0SF,SCOTLAND	Imperial College London; Medical Research Council Clinical Trials Unit; University of Glasgow				Thakker, Rajesh/0000-0002-1438-3220				BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRIFFIN BA, 1990, ATHEROSCLEROSIS, V83, P59, DOI 10.1016/0021-9150(90)90131-2; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; KESSLING AM, 1985, CLIN GENET, V28, P296; LANDER ES, 1988, MAPPING COMPLEX GENE, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAW A, 1986, LANCET, V1, P1301; NIKKILA EA, 1973, LANCET, V1, P954; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; OTT J, 1985, Genetic Epidemiology, V2, P79, DOI 10.1002/gepi.1370020108; ROSE HG, 1973, AM J MED, V54, P148, DOI 10.1016/0002-9343(73)90218-0; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; WILSON TME, IN PRESS NUCLEIC ACI; WINDLER E, 1985, J LIPID RES, V26, P556; 1980, NIH801527 PUBL, V1	24	175	176	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					161	164		10.1038/349161a0	http://dx.doi.org/10.1038/349161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670899				2022-12-28	WOS:A1991ER41800060
J	ADKINSON, NF				ADKINSON, NF			DRUG ALLERGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							HUMAN RECOMBINANT DNA; ACE INHIBITORS; HUMAN INSULIN; ANGIOEDEMA; HISTORY				ADKINSON, NF (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR, CLIN IMMUNOL UNIT, OFF 2, 5501 HOPKINS BAYVIEW CIRCLE, BALTIMORE, MD 21224 USA.							ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; AGOSTONI A, 1991, AM J MED, V90, P278; ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BALSELLS MC, 1991, DIABETES CARE, V14, P423, DOI 10.2337/diacare.14.5.423; FELDMAN JM, 1985, PHARMACOTHERAPY, V5, P43; FIREMAN P, 1982, DIABETES CARE, V5, P119, DOI 10.2337/diacare.5.2.S119; FRANK MM, 1992, CURRENT THERPAY ALLE, P55; GIANNOCCARO PJ, 1989, CAN J CARDIOL, V5, P335; GOMEZ HJ, 1987, J CARDIOVASC PHARM, V9, pS27, DOI 10.1097/00005344-198700003-00008; GRAMMER LC, 1987, J LAB CLIN MED, V109, P141; JICK H, 1982, REV INFECT DIS, V4, P426; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; ORFAN N, 1990, JAMA-J AM MED ASSOC, V264, P1287, DOI 10.1001/jama.264.10.1287; SHAH RR, 1989, ADVERSE DRUG REACT T, V8, P183; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WEISS ME, 1989, PRINCIPLES PRACTICE, P264	17	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					771	773		10.1001/jama.268.6.771	http://dx.doi.org/10.1001/jama.268.6.771			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640578				2022-12-28	WOS:A1992JG66600020
J	LONGMORE, GD; LODISH, HF				LONGMORE, GD; LODISH, HF			AN ACTIVATING MUTATION IN THE MURINE ERYTHROPOIETIN RECEPTOR INDUCES ERYTHROLEUKEMIA IN MICE - A CYTOKINE RECEPTOR SUPERFAMILY ONCOGENE	CELL			English	Article							FOCUS-FORMING VIRUS; LEUKEMIA-VIRUS; MEMBRANE GLYCOPROTEIN; GROWTH-FACTOR; FRIEND-VIRUS; MYELOPROLIFERATIVE SYNDROME; EXPRESSION CLONING; CSF-1 RECEPTOR; POINT MUTATION; MULTI-CSF	A point mutation at codon 129 of the murine erythropoietin receptor (cEpoR) results in constitutive activation. We have generated a recombinant spleen focus-forming retrovirus in which the env gene is replaced by the cEpoR cDNA. Mice infected with this virus (but not by viruses expressing the wild-type EpoR) develop erythrocytosis and splenomegaly. From the spleen of infected animals we have isolated clonal, growth factor-independent, proerythroblast cell lines that express cEpoR, do not express the putative oncogene spi-1, and have rearranged and inactivated expression of the p53 suppressor oncogene. These cells induce erythroleukemia upon injection into mice. This demonstrates that oncogenic point mutations exist in a member of the cytokine receptor superfamily. The activated erythropoietin receptor does not transform cultured fibroblasts, suggesting why oncogenic mutations in other members of this receptor superfamily have not been detected.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	LONGMORE, GD (corresponding author), NINE CAMBRIDGE CTR, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.				NHLBI NIH HHS [HL32262] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1984, J VIROL, V52, P248, DOI 10.1128/JVI.52.1.248-254.1984; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVID YB, 1988, ONCOGENE, V3, P179; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER JK, 1989, EXP HEMATOL, V17, P10; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P140; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRAU GE, 1986, J IMMUNOL, V136, P686; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1980, CELL, V22, P693; HARLOW E, 1988, ANTIBODIES LABORATOR; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KRANTZ SB, 1991, BLOOD, V77, P419; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LI JP, 1986, J VIROL, V57, P534, DOI 10.1128/JVI.57.2.534-538.1986; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LINEMEYER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1401, DOI 10.1073/pnas.78.3.1401; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SRINIVAS RV, 1983, VIROLOGY, V125, P274, DOI 10.1016/0042-6822(83)90201-5; TROXLER DH, 1977, J VIROL, V22, P361, DOI 10.1128/JVI.22.2.361-372.1977; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WOLFF L, 1986, P NATL ACAD SCI USA, V83, P3376, DOI 10.1073/pnas.83.10.3376; WOLFF L, 1982, J VIROL, V43, P472, DOI 10.1128/JVI.43.2.472-481.1982; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	70	135	136	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1089	1102		10.1016/0092-8674(91)90286-8	http://dx.doi.org/10.1016/0092-8674(91)90286-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662116				2022-12-28	WOS:A1991GX16400008
J	HEALY, B				HEALY, B			ORAL-ADMINISTRATION OF ACYCLOVIR APPEARS INEFFECTIVE IN TREATING ACUTE INFECTIOUS-MONONUCLEOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J INFECT DIS, V164, P788	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-28	WOS:A1991GR77500008
J	GARCIABLANCO, MA; CULLEN, BR				GARCIABLANCO, MA; CULLEN, BR			MOLECULAR-BASIS OF LATENCY IN PATHOGENIC HUMAN VIRUSES	SCIENCE			English	Article							EPSTEIN-BARR-VIRUS; HERPES-SIMPLEX VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL; MEMBRANE-PROTEIN; GENE-EXPRESSION; TRIGEMINAL GANGLIA; INSITU HYBRIDIZATION; PERIPHERAL-BLOOD; TYPE-1 MUTANT	Several human viruses are able to latently infect specific target cell populations in vivo. Analysis of the replication cycles of herpes simplex virus, Epstein-Barr virus, and human immunodeficiency virus suggests that the latent infections established by these human pathogens primarily result from a lack of host factors critical for the expression of viral early gene products. The subsequent activation of specific cellular transcription factors in response to extracellular stimuli can induce the expression of these viral regulatory proteins and lead to a burst of lytic viral replication. Latency in these eukaryotic viruses therefore contrasts with latency in bacteriophage, which is maintained primarily by the expression of virally encoded repressors of lytic replication.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, GENET SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028233, R01AI029821] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29821, AI28233] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ACE CI, 1989, J VIROL, V63, P2260, DOI 10.1128/JVI.63.5.2260-2269.1989; Ahmed R., 1990, VIROLOGY, P241; BAICHWAL VR, 1988, CELL, V52, P787, DOI 10.1016/0092-8674(88)90419-9; BLOCK TM, 1990, J VIROL, V64, P3417, DOI 10.1128/JVI.64.7.3417-3426.1990; BLOOM BR, 1976, COLD SPRING HARB SYM, V41, P73, DOI 10.1101/SQB.1977.041.01.011; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHEUNG AK, 1989, J VIROL, V63, P2908, DOI 10.1128/JVI.63.7.2908-2913.1989; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEVIRAO GB, 1991, J VIROL, V65, P2179, DOI 10.1128/JVI.65.5.2179-2190.1991; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FELDMAN LT, 1991, HERPESVIRUS TRANSCRI, P234; FLEMINGTON E, 1990, J VIROL, V64, P4549, DOI 10.1128/JVI.64.9.4549-4552.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FOLKS TM, 1988, J IMMUNOL, V140, P1117; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HARRIS RA, 1989, J VIROL, V63, P3513, DOI 10.1128/JVI.63.8.3513-3515.1989; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HILL JM, 1990, VIROLOGY, V174, P117, DOI 10.1016/0042-6822(90)90060-5; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; KEWP LM, 1990, NEURON, V4, P215; KIEFF E, 1990, VIROLOGY, P1889; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LEIB DA, 1989, J VIROL, V63, P2893, DOI 10.1128/JVI.63.7.2893-2900.1989; LEIB DA, 1989, J VIROL, V63, P759, DOI 10.1128/JVI.63.2.759-768.1989; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MELLERICK DM, 1987, VIROLOGY, V158, P265, DOI 10.1016/0042-6822(87)90198-X; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; MURRAY RJ, 1990, P NATL ACAD SCI USA, V87, P2906, DOI 10.1073/pnas.87.8.2906; NARA PL, 1991, FASEB J, V5, P2437, DOI 10.1096/fasebj.5.10.1712328; NSIAH YA, 1991, INTERVIROLOGY, V32, P101, DOI 10.1159/000150190; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; POMERANTZ R, COMMUNICATION; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROCK DL, 1986, J GEN VIROL, V67, P2515, DOI 10.1099/0022-1317-67-11-2515; ROIZMAN B, 1987, ANNU REV MICROBIOL, V41, P543, DOI 10.1146/annurev.mi.41.100187.002551; ROIZMAN B, 1990, VIROLOGY 1990, P1795; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SEARS AE, 1991, J VIROL, V65, P2929, DOI 10.1128/JVI.65.6.2929-2935.1991; SINCLAIR AJ, 1991, J VIROL, V65, P2237, DOI 10.1128/JVI.65.5.2237-2244.1991; STEINER I, 1989, EMBO J, V8, P505, DOI 10.1002/j.1460-2075.1989.tb03404.x; STEINER I, 1990, J VIROL, V64, P1630, DOI 10.1128/JVI.64.4.1630-1638.1990; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VALYINAGY T, 1991, J VIROL, V65, P4142, DOI 10.1128/JVI.65.8.4142-4152.1991; Wagner E. K., 1991, HERPESVIRUS TRANSCRI, P1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WEINBERG JB, IN PRESS J EXP MED; WHITLEY RJ, 1990, VIROLOGY, P1843; WILCOX CL, 1987, J VIROL, V61, P2311, DOI 10.1128/JVI.61.7.2311-2315.1987; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHU XX, 1990, J VIROL, V64, P4489, DOI 10.1128/JVI.64.9.4489-4498.1990	86	141	149	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1991	254	5033					815	820		10.1126/science.1658933	http://dx.doi.org/10.1126/science.1658933			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658933				2022-12-28	WOS:A1991GN83300033
J	TENG, DHF; ENGELE, CM; VENKATESH, TR				TENG, DHF; ENGELE, CM; VENKATESH, TR			A PRODUCT OF THE PRUNE LOCUS OF DROSOPHILA IS SIMILAR TO MAMMALIAN GTPASE-ACTIVATING PROTEIN	NATURE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; AWD PROTEINS; RAS P21; GAP; GENE; DNA; MELANOGASTER; ELEMENTS; CLONING	THE X-linked prune (pn) eye-colour mutation of Drosophila melanogaster has a highly specific, complementary lethal interaction with the conditional dominant Killer of prune (awd(K-pn)) mutation 1,2. Although awd(K-pn) flies have no apparent phenotype on their own, pn awd(K-pn) double mutants die as second or third larval instars. The awd locus encodes a nucleoside diphosphate kinase 3, an enzyme that catalyses the transfer of high-energy phosphate bonds between nucleoside diphosphates and nucleoside triphosphates 4, which is essential for the normal development of Drosophila. Analysis of the pn locus has suggested that the complementary DNA, TcD37, encodes a putative pn+ product 5. Here we report the nucleotide sequence of TcD37 and the similarity of its deduced protein product to the catalytic domain of mammalian GTPase-activating proteins (GAPs); GAPs stimulate the GTPase activity of Ras (ref. 6), which are plasma membrane-bound proteins involved in the regulation of cell proliferation and differentiation 7. These results suggest that the Drosophila TcD37 protein participates in a biochemical pathway similar to that of Ras and GAPs in mammals and yeast. We propose that the interaction between pn and awd is due to a neomorphic mutation that enhances the ability of Awd(K-pn) nucleoside diphosphate kinase to induce a regulatory GTPase into a GTP-bound 'on' state, whereas Pn modulates the activity of this GTPase either by switching it to a GDP-bound 'off' state or by interfering with its effector function.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN GM, 1985, CHEM BIOCH PTERINS, P115; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; EVANS BA, 1978, BIOCHEM GENET, V16, P13, DOI 10.1007/BF00484381; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MACKAY WJ, 1983, GENETICS, V105, P35; MACLEAN JR, 1990, GENETICS, V126, P1007; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PARKS RW, 1973, ENZYMES, P307; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STURTEVANT AH, 1956, GENETICS, V41, P118; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TENG DHF, 1991, GENETICS, V128, P373; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	35	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					437	440		10.1038/353437a0	http://dx.doi.org/10.1038/353437a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1654526				2022-12-28	WOS:A1991GH60600059
J	SCHULTZ, SC; SHIELDS, GC; STEITZ, TA				SCHULTZ, SC; SHIELDS, GC; STEITZ, TA			CRYSTAL-STRUCTURE OF A CAP-DNA COMPLEX - THE DNA IS BENT BY 90-DEGREES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; AMP RECEPTOR PROTEIN; NUCLEIC-ACID INTERACTION; REPRESSOR OPERATOR COMPLEX; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; CYCLIC-AMP; RNA-POLYMERASE; B-DNA; BINDING DOMAIN	The 3 angstrom resolution crystal structure of the Escherichia coli catabolite gene activator protein (CAP) complexed with a 30-base pair DNA sequence shows that the DNA is bent by 90-degrees. This bend results almost entirely from two 40-degrees kinks that occur between TG/CA base pairs at positions 5 and 6 on each side of the dyad axis of the complex. DNA sequence discrimination by CAP derives both from sequence-dependent distortion of the DNA helix and from direct hydrogen-bonding interactions between three protein side chains and the exposed edges of three base pairs in the major groove of the DNA. The structure of this transcription factor-DNA complex provides insights into possible mechanisms of transcription activation.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	SCHULTZ, SC (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Shields, George C/C-6454-2012; Steitz, Thomas A./C-6559-2009	Shields, George C/0000-0003-1287-8585; 	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BANTZ DA, 1974, ACTA CRYSTALLOGR A, VA 30, P257, DOI 10.1107/S0567739474000520; BECKWITH J, 1972, J MOL BIOL, V69, P155, DOI 10.1016/0022-2836(72)90031-9; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BIENKOWSKA J, 1989, PROGRAM LOLIPLOT; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1989, PROGRAM XPLOR; BRUNGER AT, COMMUNICATION; BUSBY S, 1987, MICROBIOL SCI, V4, P371; CRICK FHC, 1975, NATURE, V255, P530, DOI 10.1038/255530a0; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; DICKERSON RE, COMMUNICATION; DICKSON RC, 1977, J MOL BIOL, V111, P65, DOI 10.1016/S0022-2836(77)80132-0; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; ESCHENLAUER AC, IN PRESS J BACTERIOL; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; FURNISH G, 1989, PROGRAM PLOT; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GENT ME, 1987, BIOCHEM J, V242, P645, DOI 10.1042/bj2420645; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JORDAN SR, 1985, SCIENCE, V230, P1383; KATTI S, COMMUNICATION; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lu P, 1985, Adv Biophys, V20, P153, DOI 10.1016/0065-227X(85)90035-8; MAJORS J, 1977, THESIS HARVARD U CAM; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PASSNER J, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERLO A, PROGRAM SZAZAM VERSI; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; PORSCHKE D, 1984, EMBO J, V3, P2873, DOI 10.1002/j.1460-2075.1984.tb02223.x; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROULD MR, 1990, PROGRAM MAXIMAGE; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SAYRE D, 1982, COMPUTATIONAL CRYSTA, P303; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SHIELDS GC, UNPUB; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SOBELL HM, 1976, P NATL ACAD SCI USA, V73, P3068, DOI 10.1073/pnas.73.9.3068; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STEITZ TA, 1983, J BIOMOL STRUCT DYN, V1, P1023, DOI 10.1080/07391102.1983.10507500; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SUSSMAN JL, 1978, P NATL ACAD SCI USA, V75, P103, DOI 10.1073/pnas.75.1.103; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHURKIN VB, 1979, NUCLEIC ACIDS RES, V6, P1081, DOI 10.1093/nar/6.3.1081; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	91	1038	1050	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1001	1007		10.1126/science.1653449	http://dx.doi.org/10.1126/science.1653449			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653449	Green Submitted			2022-12-28	WOS:A1991GC98200037
J	WALTERS, ET; ALIZADEH, H; CASTRO, GA				WALTERS, ET; ALIZADEH, H; CASTRO, GA			SIMILAR NEURONAL ALTERATIONS INDUCED BY AXONAL INJURY AND LEARNING IN APLYSIA	SCIENCE			English	Article							SENSORY NEURONS; TRANSMITTER RELEASE; PRESYNAPTIC FACILITATION; BEHAVIORAL SENSITIZATION; SYNAPTIC CONNECTIONS; CELLULAR MECHANISM; INNERVATING TAIL; GILL-WITHDRAWAL; MODULATION; SUGGESTS	Learning in the marine mollusk Aplysia has been associated with enhanced sensory function, expressed in mechanosensory neurons as (i) decreases in action potential threshold, accommodation, and afterhyperpolarization, and (ii) increases in action potential duration, afterdischarge, and synaptic transmission. These alterations also occur, with a delay, after sensory axons are injured under conditions in which synaptic transmission is severely reduced. The latency and specificity of injury-induced alterations indicate that induction signals are generated at the site of injury and conveyed centrally by axonal transport. Similarities in neuronal modifications support the hypothesis that some memory mechanisms evolved from mechanisms of injury-induced sensory compensation and repair.			WALTERS, ET (corresponding author), UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77225, USA.			Walters, Edgar/0000-0003-0718-102X	NIAID NIH HHS [AI11361] Funding Source: Medline; NIMH NIH HHS [MH38726] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038726] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALIZADEH H, 1990, Society for Neuroscience Abstracts, V16, P597; BILLY AJ, 1989, J NEUROSCI, V9, P1254; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CROW TJ, 1980, SCIENCE, V209, P412, DOI 10.1126/science.209.4454.412; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; KLEIN M, 1986, P NATL ACAD SCI USA, V83, P7994, DOI 10.1073/pnas.83.20.7994; MACKEY SL, 1989, J NEUROSCI, V9, P4227; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; WALTERS E, UNPUB; WALTERS ET, 1987, J NEUROSCI, V7, P408; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834	22	89	92	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					797	799		10.1126/science.1652154	http://dx.doi.org/10.1126/science.1652154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB295	1652154				2022-12-28	WOS:A1991GB29500041
J	PLUMMER, MR; HESS, P				PLUMMER, MR; HESS, P			REVERSIBLE UNCOUPLING OF INACTIVATION IN N-TYPE CALCIUM CHANNELS	NATURE			English	Article							SINGLE SODIUM-CHANNELS; CHICK SENSORY NEURONS; SYMPATHETIC NEURONS; CA-2+ CHANNELS; CA-CHANNEL; CURRENTS; RELEASE; SENSITIVITY; MODULATION; MEMBRANE	N-TYPE calcium channels are thought to be expressed specifically in neuronal cells 1-3 and to have a dominant role in the control of neurotransmitter release from sympathetic neurons 4, 5. But their unitary properties are poorly understood and the separation of neuronal Ca2+ current into components carried by N-type or L-type Ca2+ channels is controversial 6. Here we show that individual N-type Ca2+ channels in sympathetic neurons can carry two kinetically distinct components of current, one that is rapidly transient and one that is long lasting. The mechanism that gives rise to these two components is unexpected for Ca2+ channels: a test depolarization elicits either a rapidly inactivating, single short burst with an average duration of 40 ms, or sustained, noninactivating channel activity lasting for over 1 s. The switching between inactivating and noninactivating activity is a slow process, the occurrence of each type of unitary kinetic behaviour remaining statistically correlated over several seconds. Variable coupling of inactivation in N-type Ca2+ channels could be an effective mechanism for the modulation of neuronal excitability and synaptic plasticity.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BOLAND LM, 1990, J PHYSIOL-LONDON, V420, P223, DOI 10.1113/jphysiol.1990.sp017909; COOPER E, 1989, J GEN PHYSIOL, V94, P881, DOI 10.1085/jgp.94.5.881; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORN R, 1984, BIOPHYS J, V45, P323, DOI 10.1016/S0006-3495(84)84158-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KONGSAMUT S, 1989, ANN NY ACAD SCI, V560, P312, DOI 10.1111/j.1749-6632.1989.tb24112.x; KOSTYUK PG, 1988, PFLUG ARCH EUR J PHY, V411, P661, DOI 10.1007/BF00580863; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MCMANUS OB, 1987, PFLUG ARCH EUR J PHY, V410, P530, DOI 10.1007/BF00586537; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PATLAK JB, 1989, J GEN PHYSIOL, V94, P279, DOI 10.1085/jgp.94.2.279; PATLAK JB, 1985, J GEN PHYSIOL, V86, P89, DOI 10.1085/jgp.86.1.89; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P1; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; Zar JH., 1999, BIOSTAT ANAL	27	116	118	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					657	659		10.1038/351657a0	http://dx.doi.org/10.1038/351657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646965				2022-12-28	WOS:A1991FT11200068
J	BAINTON, R; GAMAS, P; CRAIG, NL				BAINTON, R; GAMAS, P; CRAIG, NL			TN7 TRANSPOSITION INVITRO PROCEEDS THROUGH AN EXCISED TRANSPOSON INTERMEDIATE GENERATED BY STAGGERED BREAKS IN DNA	CELL			English	Article							ESCHERICHIA-COLI CHROMOSOME; BACTERIOPHAGE-MU; RETROVIRAL DNA; TN10 TRANSPOSITION; TY1 TRANSPOSITION; INTEGRATION; SEQUENCE; IDENTIFICATION; REPLICATION; MECHANISM	We have developed a cell-free system in which the bacterial transposon Tn7 inserts at high frequency into its preferred target site in the Escherichia coli chromosome, attTn7; Tn7 transposition in vitro requires ATP and Tn7-encoded proteins. Tn7 transposes via a cut and paste mechanism in which the element is excised from the donor DNA by staggered double-strand breaks and then inserted into attTn7 by the joining of 3' transposon ends to 5' target ends. Neither recombination intermediates nor products are observed in the absence of any protein component or DNA substrate. Thus, we suggest that Tn7 transposition occurs in a nucleoprotein complex containing several proteins and the substrate DNAs and that recognition of attTn7 within this complex provokes strand cleavages at the Tn7 ends.	UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAINTON, R (corresponding author), UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Gamas, Pascal/0000-0002-6253-4249	NIGMS NIH HHS [GMO 7618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BARTH PT, 1976, J BACTERIOL, V125, P800, DOI 10.1128/JB.125.3.800-810.1976; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg DE, 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHOLS H, 1990, J BIOL CHEM, V265, P14697; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GRINDLEY NDF, 1978, COLD SPRING HARB SYM, V43, P1257; GRINGAUZ E, 1988, J BACTERIOL, V170, P2832, DOI 10.1128/jb.170.6.2832-2840.1988; HANIFORD DB, 1991, CELL, V64, P171; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; KLECKNER N, 1990, ANNU REV CELL BIOL, V6, P297, DOI 10.1146/annurev.cb.06.110190.001501; KUBO K, 1990, J BACTERIOL, V182, P2774; LEE CH, 1983, P NATL ACAD SCI-BIOL, V80, P6765, DOI 10.1073/pnas.80.22.6765; LICHTENSTEIN C, 1982, NATURE, V297, P601, DOI 10.1038/297601a0; MCKOWN RL, 1988, J BACTERIOL, V170, P352, DOI 10.1128/jb.170.1.352-358.1988; MCKOWN RL, 1987, P NATL ACAD SCI USA, V84, P7807, DOI 10.1073/pnas.84.22.7807; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NKLECKNER N, 1989, MOBILE DNA, P227; ORLE KA, 1990, GENE, V96, P1, DOI 10.1016/0378-1119(90)90333-M; Pato ML, 1989, MOBILE DNA, P23; QADRI MI, 1989, J MOL BIOL, V207, P85, DOI 10.1016/0022-2836(89)90442-7; ROBERTS D, 1988, P NATL ACAD SCI USA, V85, P6037, DOI 10.1073/pnas.85.16.6037; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; THOMPSON JF, 1989, MOBILE DNA, P1; VARMUS H, 1989, MOBILE DNA, P53; WADDELL CS, 1989, P NATL ACAD SCI USA, V86, P3958, DOI 10.1073/pnas.86.11.3958; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137	49	127	132	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					805	816		10.1016/0092-8674(91)90388-F	http://dx.doi.org/10.1016/0092-8674(91)90388-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645619				2022-12-28	WOS:A1991FP51600011
J	VANDERPOEL, CL; CUYPERS, HTM; REESINK, HW; WEINER, AJ; QUAN, S; DINELLO, R; VANBOVEN, JJP; WINKEL, I; MULDERFOLKERTS, D; EXELOEHLERS, PJ; SCHAASBERG, W; LEENTVAARKUYPERS, A; POLITO, A; HOUGHTON, M; LELIE, PN				VANDERPOEL, CL; CUYPERS, HTM; REESINK, HW; WEINER, AJ; QUAN, S; DINELLO, R; VANBOVEN, JJP; WINKEL, I; MULDERFOLKERTS, D; EXELOEHLERS, PJ; SCHAASBERG, W; LEENTVAARKUYPERS, A; POLITO, A; HOUGHTON, M; LELIE, PN			CONFIRMATION OF HEPATITIS-C VIRUS-INFECTION BY NEW 4-ANTIGEN RECOMBINANT IMMUNOBLOT ASSAY	LANCET			English	Article							NON-A; ANTIBODIES	A new four-antigen recombinant immunoblot assay (4-RIBA) for confirmation of hepatitis C virus (HCV) C-100 enzyme-linked immunosorbent assay (ELISA) reactivity was tested in stored serum samples (1984-86) of blood donors and recipients and compared with results from polymerase chain reaction (PCR) analysis of fresh (1990) plasma samples of donors and recipients from the original study. Of 37 HCV C-100 ELISA-positive blood products, 8 were 4-RIBA positive, of which 7 were implicated in post-transfusion non-A, non-B hepatitis (PT-NANBH) and/or PCR confirmed recipient HCV infection. Of 9 recipients with PT-NANBH, 8 were reactive in 4-RIBA (6 positive and 2 indeterminate). With fresh plasma samples, 3 donors and 6 recipients who were 4-RIBA positive were also PCR positive. 4 4-RIBA indeterminate and 78 4-RIBA negative samples of donors and recipients were PCR negative. Of 6 4-RIBA positive recipients, 5 were PCR positive four to six years later. 1.6% of the 383 recipients became chronically infected with HCV. The new 4-RIBA represents a candidate confirmation test to discriminate between infective and non-infective HCV c-100 ELISA-positive blood donors.	CHIRON CORP,EMERYVILLE,CA; MUNICIPAL HLTH SERV,DEPT INFECT DIS,AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS	Novartis	VANDERPOEL, CL (corresponding author), RED CROSS BLOOD BANK,POB 9137,1006 AC AMSTERDAM,NETHERLANDS.			Houghton, Michael/0000-0003-3762-6771				CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; REESINK HW, 1988, VIRAL HEPATITIS LIVE, P558; VANDERPOEL CL, 1990, LANCET, V336, P187, DOI 10.1016/0140-6736(90)91718-P; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1989, Patent No. 318216	11	532	554	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					317	319		10.1016/0140-6736(91)90942-I	http://dx.doi.org/10.1016/0140-6736(91)90942-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671231				2022-12-28	WOS:A1991EX36200002
J	GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM				GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM			REQUIREMENT FOR ASSOCIATION OF P56LCK WITH CD4 IN ANTIGEN-SPECIFIC SIGNAL TRANSDUCTION IN T-CELLS	CELL			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHORBOL-MYRISTATE ACETATE; CLASS-I MOLECULES; LYMPHOCYTES-T; TRANSGENIC MICE; GENE-TRANSFER; MOUSE CD4; RECEPTOR; ACTIVATION	The T cell-specific transmembrane glycoprotein CD4 interacts with class II MHC molecules via its external domain and is associated with the tyrosine kinase p56lck via a cysteine motif in its cytoplasmic domain. We have assessed the ability of CD4 to synergize with the antigen-specific T cell receptor (TCR) for induction of transmembrane signals that result in lymphokine production. Mutant CD4 molecules were introduced into T cells that lacked endogenous CD4 but expressed TCRs specific for lysozyme peptides or the superantigen SEA bound to A(b) or A(bm12) class II MHC molecules. With either ligand, T cell activation occurred only when CD4 was associated with p56lck. These results demonstrate that residues within the cytoplasmic domain of CD4 are required for its coreceptor function in TCR-mediated signal transduction and strongly support the notion that the association of CD4 with p56lck is critical in this process.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLAICHENHAUS, N (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; ACRES RB, 1987, J IMMUNOL, V139, P2268; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BIDDISON WE, 1984, J EXP MED, V159, P783, DOI 10.1084/jem.159.3.783; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JANEWAY CA, 1989, TODAY, V10, P234; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MACDONALD HR, 1990, J EXP MED, V171, P1381, DOI 10.1084/jem.171.4.1381; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, ADV IMMUNOL, V44, P265; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RONCHESE F, 1987, J IMMUNOL, V139, P629; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHASTRI N, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P249; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WASSMER P, 1985, J IMMUNOL, V135, P2237; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	53	447	462	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					511	520		10.1016/0092-8674(91)90235-Q	http://dx.doi.org/10.1016/0092-8674(91)90235-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1671341				2022-12-28	WOS:A1991EX36100007
J	PECKHAM, CS				PECKHAM, CS			CHILDREN BORN TO WOMEN WITH HIV-1 INFECTION - NATURAL-HISTORY AND RISK OF TRANSMISSION	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; POLYMERASE CHAIN-REACTION; HTLV-III INFECTION; INFANTS BORN; IMMUNOLOGICAL FEATURES; PERINATAL TRANSMISSION; TYPE-1; PREGNANCY; SPECTRUM; MOTHERS	600 children born to HIV-infected mothers by June 15, 1990, in ten European centres were followed to study the natural history of HIV infection and the vertical transmission rate. They were seen at birth, every 3 months up to 18 months of age, and every 6 months thereafter. At last follow-up, 64 children were judged to be HIV infected and 343 had lost antibody and were presumed uninfected. The initial clinical feature in infected children was usually a combination of persistent lymphadenopathy, splenomegaly, and hepatomegaly, though 30% of children presented with AIDS, or with oral candidosis followed rapidly by AIDS. An estimated 83% of infected children show laboratory or clinical features of HIV infection by 6 months of age. By 12 months, 26% have AIDS and 17% die of HIV-related disease. Subsequently, the disease progresses more slowly and most children remain stable or even improve during the second year. The vertical transmission rate, based on results in 372 children born at least 18 months before the analysis, was 12.9% (95% Cl 9.5-16.3%). Virus has been repeatedly isolated in an additional small proportion of children (2.5%, 95% Cl 0.7-6.3%) who lost maternal antibody and have remained clinically and immunologically normal. Without a definitive virological diagnosis, the monitoring of immunoglobulins, CD4/CD8 ratio, and clinical signs could identify HIV infection in 48% of infected children by 6 months, with a specificity of more than 99%.			PECKHAM, CS (corresponding author), INST CHILD HLTH, DEPT PAEDIAT EPIDEMIOL, 30 GUILFORD ST, LONDON WC1N 1EH, ENGLAND.		De Rossi, A./L-3128-2015	De Rossi, A./0000-0001-6435-7509; GIAQUINTO, CARLO/0000-0001-9365-0413				AIUTI F, 1987, LANCET, V2, P858; AMADORI A, 1990, PEDIATR INFECT DIS J, V9, P26, DOI 10.1097/00006454-199001000-00006; BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BELMAN AL, 1988, AM J DIS CHILD, V142, P29, DOI 10.1001/archpedi.1988.02150010039017; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EPSTEIN LG, 1986, PEDIATRICS, V78, P678; GOEDERT JJ, 1989, LANCET, V2, P1351; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HAGUE RA, 1989, ARCH DIS CHILD, V64, P1146, DOI 10.1136/adc.64.8.1146; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; JOHNSTONE FD, 1988, BRIT MED J, V296, P467, DOI 10.1136/bmj.296.6620.467; JONCKHEER T, 1986, EUR J PEDIATR, V145, P511, DOI 10.1007/BF02429054; KAMANI N, 1988, PEDIATR INFECT DIS J, V7, P383, DOI 10.1097/00006454-198806000-00003; KOCH S, 1989, 5TH SAT C INT C AIDS; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; LAURE F, 1988, LANCET, V2, P538; MOK JQ, 1987, LANCET, V1, P1164; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; PAHWA S, 1986, JAMA-J AM MED ASSOC, V255, P2299, DOI 10.1001/jama.255.17.2299; PARKS WP, 1985, CANCER RES, V45, P4659; PHAROAH P O D, 1990, Archives of Disease in Childhood, V65, P147; ROGERS M, 1990, 6TH INT C AIDS, P145; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RUBINSTEIN A, 1986, CLIN IMMUNOL IMMUNOP, V40, P115, DOI 10.1016/0090-1229(86)90074-7; RUBINSTEIN A, 1986, J PEDIATR, V108, P1498; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAULSBURY FT, 1987, PEDIATR INFECT DIS J, V6, P544, DOI 10.1097/00006454-198706000-00012; SCHAAD UB, 1988, EUR J PEDIATR, V147, P300, DOI 10.1007/BF00442700; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; 1988, LANCET, V2, P1043; 1990, PEDIATR INFECT DIS J, V9, P402; 1988, LANCET, V2, P1039; 1987, MMWR, V15, P225	40	205	207	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	1991	337	8736					253	260						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671109				2022-12-28	WOS:A1991EV71900001
J	IBBERTSON, HK; MANNING, PJ; HOLDAWAY, IM; GAMBLE, G; SYNEK, BJL				IBBERTSON, HK; MANNING, PJ; HOLDAWAY, IM; GAMBLE, G; SYNEK, BJL			THE ACROMEGALIC ROSARY	LANCET			English	Article							GROWTH	Palpable enlargement of the costochondral junctions on the anterolateral chest wall was detected in 26 of 27 patients with acromegaly. In a further study three doctors wearing eyemasks examined a further 13 acromegalic patients and 12 control subjects; costochondral enlargement was detected with a sensitivity of 77% and specificity of 86%. It was not found in normal subjects in the absence of previous chest injury. The presence and extent of costochondral enlargement was unrelated to the duration of active or cured acromegaly, the initial or present growth hormone concentrations, or other clinical features of growth hormone excess. Costochondral enlargement is a common clinical sign in acromegaly and can serve as a biological marker of previous or current growth hormone excess.	UNIV AUCKLAND,SCH MED,DEPT MED,ENDOCRINOL SECT,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT PATHOL,AUCKLAND,NEW ZEALAND	University of Auckland; University of Auckland				Gamble, Greg/0000-0003-0412-3203				GLUCKMAN PD, 1983, CLIN ENDOCRINOL, V19, P405, DOI 10.1111/j.1365-2265.1983.tb00014.x; HIRJI KF, 1990, STAT MED, V9, P835, DOI 10.1002/sim.4780090713; HOLDAWAY IM, 1978, CLIN ENDOCRINOL, V8, P45, DOI 10.1111/j.1365-2265.1978.tb01349.x; JONES DR, 1969, MAYO CLIN PROC, V44, P330; JONES DR, 1969, MAYO CLIN PROC, V44, P324; LIKE AA, 1963, AM J PATHOL, V43, P36; MADSEN K, 1983, NATURE, V304, P545, DOI 10.1038/304545a0; Marie P., 1986, REV MED LIEGE, V6, P297; MARIE P, 1891, ACROMEGALY, P1; ROSS GT, 1960, MAYO CLIN P, V35, P400; 1987, SAS STAT GUIDE PERSO, P189	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					154	156						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670798				2022-12-28	WOS:A1991ET67900014
J	AMOS, A; JACOBSON, B; WHITE, P				AMOS, A; JACOBSON, B; WHITE, P			CIGARETTE ADVERTISING POLICY AND COVERAGE OF SMOKING AND HEALTH IN BRITISH WOMENS MAGAZINES	LANCET			English	Article								A survey of cigarette advertising and coverage of health aspects of smoking in 86 British magazines with a large female readership was done in 1989. The findings were compared with the results of a 1985 survey which had led to the introduction of new voluntary restrictions in 1986 on cigarette advertising in magazines. Although there was a decrease in the proportion of magazines accepting cigarette advertising (64% to 42%), the new restrictions failed to cover the most popular magazines, so that an estimated collective readership of 7 million women aged 15-24 years were still exposed to cigarette advertising. Revenue from cigarette advertising by women's magazines increased by 10% in real terms between 1985 and 1988. There was a small decrease in the coverage given to health aspects of smoking; a third of magazines were willing to use pictures of people smoking in their editorial pages. The findings show that the voluntary restrictions introduced in the UK in 1986 have had a small effect on cigarette advertising and have failed to achieve their aim of protecting young women.	ST LEONARDS HOSP,CITY & HACKNEY HLTH AUTHOR,DEPT PUBL HLTH,LONDON,ENGLAND		AMOS, A (corresponding author), UNIV EDINBURGH,DEPT COMMUNITY MED,TEVIOT PL,EDINBURGH EH8 9AG,SCOTLAND.							AMOS A, IN PRESS 7TH P WORLD; BATE S, 1990, CAMPAIGN        0316, P31; COLE J, 1988, TOBACCO          MAR, P7; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DOUGLAS T, 1988, MARKETING WEEK  0422, P15; JACOBSON B, 1985, SMOKE GETS YOUR EYES; WARNER K, IN PRESS 7TH P WORLD; 1989, DH2982 OFF POP CENS; 1989, NATIONAL LEADERSHIP; 1983, HLTH SMOKING; 1986, GOVERNMENT ANNOUNCE; 1990, IT CAN BE DONE SMOKE; 1988, SMOKE FREE EUROPE 5; 1987, TOBACCO          MAR, P21; 1989, 2ND DEP HLTH COMM MO; 1986, VOLUNTARY AGREEMENT; 1989, TEENAGE GIRLS SMOKIN; 1989, MEDIA EXPENDITURE AN; 1989, 1ST DEP HLTH SOC SEC; C37689 COMM EUR COMM; 1990, GENERAL HOUSEHOLD SU; 1989, HLTH TOBACCO; 1990, OPCS SS902 OFF POP C	23	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					93	96		10.1016/0140-6736(91)90747-D	http://dx.doi.org/10.1016/0140-6736(91)90747-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER477	1670736				2022-12-28	WOS:A1991ER47700014
J	RIVERA, GK; RAIMONDI, SC; HANCOCK, ML; BEHM, FG; PUI, CH; ABROMOWITCH, M; MIRRO, J; OCHS, JS; LOOK, AT; WILLIAMS, DL; MURPHY, SB; DAHL, GV; KALWINSKY, DK; EVANS, WE; KUN, LE; SIMONE, JV; CRIST, WM				RIVERA, GK; RAIMONDI, SC; HANCOCK, ML; BEHM, FG; PUI, CH; ABROMOWITCH, M; MIRRO, J; OCHS, JS; LOOK, AT; WILLIAMS, DL; MURPHY, SB; DAHL, GV; KALWINSKY, DK; EVANS, WE; KUN, LE; SIMONE, JV; CRIST, WM			IMPROVED OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA WITH REINFORCED EARLY TREATMENT AND ROTATIONAL COMBINATION CHEMOTHERAPY	LANCET			English	Article							BIOLOGIC FEATURES; ACUTE-LEUKEMIA; CHILDREN; IMMUNOPHENOTYPE; METHOTREXATE; THERAPY; AGE	To improve outcome in childhood acute lymphoblastic leukaemia (ALL), a stratified, randomised study of extended intensified chemotherapy was done. 358 evaluable patients received remission reinforcement therapy (teniposide, cytarabine, high-dose methotrexate) added to a four-drug induction regimen. Those achieving complete remission were randomised on the basis of risk group assignment to conventional continuation treatment or to four pairs of drugs rotated weekly or every 6 weeks. All patients received intrathecal chemotherapy; higher risk patients also received 1800 cGy cranial irradiation after 1 year of remission. Complete remission was induced in 96% of the patients. At median follow-up of 40 (range 19-73) months, 4-year event-free survival (SE) was 73 (4)% overall, 81 (6)% in the lower-risk group (n = 110), and 69 (5)% in the higher-risk group (n = 248). Outcome within risk groups was not significantly affected by the speed of rotation of drug pairs during continuation treatment. Various high-risk subgroups had apparently improved responses to this treatment. This intensified chemotherapy may cure 69-77% of children with ALL.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT & INFORMAT SYST, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DIV PHARMACEUT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT RADIAT ONCOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	RIVERA, GK (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, POB 318, MEMPHIS, TN 38101 USA.		Evans, William E./C-2069-2012; Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [CA 21765, CA 20180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABROMOWITCH M, 1988, MED PEDIATR ONCOL, V16, P297, DOI 10.1002/mpo.2950160502; BLEYER WA, 1977, CANCER TREAT REP, V61, P1419; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CRIST W, 1986, MED PEDIATR ONCOL, V14, P135, DOI 10.1002/mpo.2950140306; CRIST W, 1989, BLOOD, V74, P1252; CRIST W, 1990, BLOOD, V76, P489; CRIST WM, 1990, BLOOD, V76, P117; DAHL GV, 1987, J CLIN ONCOL, V5, P1015, DOI 10.1200/JCO.1987.5.7.1015; EVANS WE, 1988, BLUT, V56, P241, DOI 10.1007/BF00320282; FREI E, 1965, BLOOD-J HEMATOL, V26, P642, DOI 10.1182/blood.V26.5.642.642; GAGNON GA, 1989, BLOOD, V74, P2088; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; GOLDIN A, 1971, CANCER CHEMOTH REP 1, V55, P309; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; HARNDEN DG, 1985, BIRTH DEFECTS-ORIG, P1; JAKASCHAUB GE, 1988, LEUKEMIA, V2, pS73; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; LANE D M, 1970, Cancer Chemotherapy Reports, V54, P113; LOOK AT, 1988, PEDIATR CLIN N AM, V35, P723; MOE PJ, 1984, EUR PAEDIATR HAEMATO, V1, P113; PASTAN I, 1987, NEW ENGL J MED, V316, P1383; PETO J, 1986, LANCET, V1, P408; PUI CH, 1988, J CLIN ONCOL, V6, P56, DOI 10.1200/JCO.1988.6.1.56; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; Riehm H, 1990, Haematol Blood Transfus, V33, P439; Rivera G K, 1987, Haematol Blood Transfus, V30, P156; RIVERA GK, 1988, NEW ENGL J MED, V318, P1541; RIVERA GK, 1988, MED PADIATR ONCOL, V14, P177; SATHER HN, 1986, MED PEDIATR ONCOL, V14, P166, DOI 10.1002/mpo.2950140311; SHUSTER JJ, 1990, BLOOD, V75, P166; WILLIAMS DL, 1984, CANCER GENET CYTOGEN, V13, P239, DOI 10.1016/0165-4608(84)90046-3	31	366	371	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					61	66		10.1016/0140-6736(91)90733-6	http://dx.doi.org/10.1016/0140-6736(91)90733-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670723				2022-12-28	WOS:A1991ER47700001
J	HEALY, B				HEALY, B			ASPIRIN AND WARFARIN EFFECTIVE IN PREVENTING STROKE AND EMBOLISM IN PATIENTS WITH ATRIAL-FIBRILLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V84, P527	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-28	WOS:A1991GR77500006
J	HEALY, B				HEALY, B			CURRENTLY LICENSED IMMUNOASSAYS DO NOT ACCURATELY DISTINGUISH ANTIBODIES TO HERPES-SIMPLEX VIRUS SUBTYPES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P520	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-28	WOS:A1991GR77500007
